Page 1
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date: Sep. 2024 

# **Drug Master File of** **Finerenone**

#### **DMF-001**



Signature/Stamp: 



Date: 



Place: Changsha City, China 

### **Hinye Pharmaceutical Co., Ltd.**



Finerenone 

Confidential Hinye Pharmaceutical Co., Ltd. 



Page 1 of 542 





Page 2
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date: Sep. 2024 

## **Table of Contents**



**Table of Contents.............................................................................................................................. 2** 



**3.2.S.1 General Information.........................................................................................................4** 



3.2.S.1.1 Nomenclature.......................................................................................................... 4 



3.2.S.1.2 Structure...................................................................................................................5 



**3.2.S.2 Manufacture.........................................................................................................................7** 



3.2.S.2.1 Manufacturer............................................................................................................. 7 



3.2.S.2.2 Description of Manufacturing Process and Process Controls................ 8 



3.2.S.2.3 Control of Materials............................................................................................ 10 



3.2.S.2.6 Manufacturing Process Development...........................................................11 



**3.2.S.3 Characterization............................................................................................................. 13** 



3.2.S.3.1 Elucidation of Structure and other Characteristics................................13 



3.2.S.3.2 Impurities...............................................................................................................86 



**3.2.S.4** **Control of Drug Substance....................................................................................143** 



3.2.S.4.1 Specification.......................................................................................................... 143 



3.2.S.4.2 Analytical Procedures......................................................................................145 



3.2.S.4.3 Validation of Analytical Procedure................................................................ 153 



3.2.S.4.4 Batch Analyses.................................................................................................. 424 



3.2.S.4.5 Justification of Specification.........................................................................430 



**3.2.S.5** **Reference Standards or Materials..................................................................... 433** 



**3.2.S.6** **Container Closure System.................................................................................... 501** 



I. Description of Container Closure System.................................................................. 501 



II. Specification of Packaging Materials.......................................................................... 501 



Finerenone 

Confidential Hinye Pharmaceutical Co., Ltd. 



Page 2 of 542 





Page 3
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date: Sep. 2024 



III. Annexes: COAs..................................................................................................................509 



**3.2.S.7 Stability............................................................................................................................** **510** 



3.2.S.7.1 Stability Summary and Conclusions......................................................... 510 



3.2.S.7.2 Post-approval Stability Protocol and Stability Commitment............. 514 



3.2.S.7.3 Stability Data......................................................................................................518 



Finerenone 

Confidential Hinye Pharmaceutical Co., Ltd. 



Page 3 of 542 





Page 4
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date: Sep. 2024 



**3.2.S.1 General Information** 



**3.2.S.1.1** **Nomenclature** 



**Recommended International Nonproprietary Name (INN)** 



Finerenone 



**European Pharmacopoeia monograph name** 



N/A 



**United States Adopted Name (USAN)** 



Finerenone 



**Chemical name** 



(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6- 



naphthyridine-3-carboxamide 



**Company code** 



YA2304 



**Chemical Abstracts Service (CAS) registry number** 



1050477-31-0 



Finerenone 

Confidential Hinye Pharmaceutical Co., Ltd. 



Page 4 of 542 





Page 5
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date: Sep. 2024 



**3.2.S.1.2** **Structure** 



**Structure formula** 



**Molecular formula** 



C21H22N4O3 



**Relative molecular mass (Mr)** 



378.43 



**Stereochemistry** 



The molecule of Finerenone contains one chiral centers at C-9. The active 



substance has absolute configuration (S) for the C-9 positions. 



Finerenone 

Confidential Hinye Pharmaceutical Co., Ltd. 



Page 5 of 542 





Page 6
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date: Sep. 2024 



**3.2.S.1.3** **General Properties** 



















----------------------------------------------------------------------
|Items           |Characteristics or properties                      |
|----------------|---------------------------------------------------|
|Appearance      |White to yellow powder                             |
|----------------|---------------------------------------------------|
|Melting point   |Approximately 252 ℃                               | 
|----------------|---------------------------------------------------|
|Solubility      |Dissolved in methanol, slightly soluble in ethanol,|
|                |acetonitrile, and acetone, slightly soluble in     |
|                |isopropanol, almost insoluble in water             |
|----------------|---------------------------------------------------|
|Hygroscopicity  |It is non-hygroscopic.                             |
|----------------|---------------------------------------------------|
|hydrate         |This product does not contain crystal water.       |
|----------------|---------------------------------------------------|
|Dissociation    |4.39                                               |
|constant [(pKa)]|                                                   |
|----------------|---------------------------------------------------|
|partition       |Log D（1-Octanol/buffer solution pH 2.4）=0.4 Log  |  
|coefficient     |D（1-Octanol/buffer solution pH 7.4）=2.8          |  
|----------------|---------------------------------------------------|
|BCS             |Class Ⅱ                                           | 
|classification  |                                                   |
----------------------------------------------------------------------

Finerenone 

Confidential Hinye Pharmaceutical Co., Ltd. 



Page 6 of 542 





Page 7
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date: Sep. 2024 



**3.2.S.2 Manufacture** 



**3.2.S.2.1 Manufacturer** 



**Manufacturer** 



Name: Hinye Pharmaceutical Co., Ltd. 



DUNS Number: 526215965 



Address: No.109, Kangtian Road, Changsha National Biological Industrial Base, 



Hunan Province, China 



Telephone Number: +86-731-82728186 



Fax Number: +86-731-82728064 



Post Code: 410331 



**Manufacturing Site** 



Name: Hinye Pharmaceutical Co., Ltd. 



DUNS Number: 526215965 



Address: No.109, Kangtian Road, Changsha National Biological Industrial Base, 



Hunan Province, China 



Telephone Number: +86-731-82728186 



Fax Number: +86-731-82728064 



Post Code: 410331 



**Responsibility of manufacturer** 



Hinye Pharmaceutical Co., Ltd. has the full responsibility of the manufacture, 



packaging and testing of Finerenone. 



Finerenone 

Confidential Hinye Pharmaceutical Co., Ltd. 



Page 7 of 542 





Page 8
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date: Sep. 2024 



**3.2.S.2.2** **Description of Manufacturing Process and Process Controls** 



**3.2.S.2.2.1** **Synthetic Process of the Manufacturing Process** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 8 of 542 





Page 9
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date: Sep. 2024 






















































----------------------------------------------------------------------------
|Materia l |Chemical Name                                        |CAS No.  |
|Code      |                                                     |         |
|----------|-----------------------------------------------------|---------|
|CDI       |N. N-carbonyldiimidazole                             |530-62-1 |
|----------|-----------------------------------------------------|---------|
|DMAP      |4-Dimethylaminopyridine                              |1122-58-3|
|----------|-----------------------------------------------------|---------|
|HMDS      |Hexamethyldisilazane                                 |999-97-3 |
|----------|-----------------------------------------------------|---------|
|YA2304- 1 |4-cyano-2-methoxybenzaldehyde                        |21962-45-|
|          |                                                     |8        |
|----------|-----------------------------------------------------|---------|
|YA2304- 2 |Ethyl 2-cyanoacetoacetate                            |65193-87-|
|          |                                                     |5        |
|----------|-----------------------------------------------------|---------|
|YA2304- 4 |4-amino-5-methyl-2-hydroxypyridine                   |95306-64-|
|          |                                                     |2        |
|----------|-----------------------------------------------------|---------|
|YA2304- 10|D - (+) - Dibenzoyl Tartaric Acid                    |17026-42-|
|          |                                                     |5        |
|----------|-----------------------------------------------------|---------|
|YA2304- 3 |2-cyanoethyl 2- (4-cyano-2-methoxybenzylidene)       |1050477-3|
|          |-3-oxobutyric acid ester                             |9-8      |
|----------|-----------------------------------------------------|---------|
|YA2304- 5 |4- (4-cyano-2-methoxyphenyl)                         |1050477-4|
|          |-2,8-dimethyl-5-oxo-1,4,5,6-tetrahydro-1,6-naphthalen|3-4      |
|          |e-3-carboxylic acid 2-cyanoethyl ester               |         |
|----------|-----------------------------------------------------|---------|
|YA2304- 6 |4- (4-cyano-2-methoxyphenyl)                         |1050477-4|
|          |-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthalene-3-|4-5      |
|          |carboxylic acid 2-cyanoethyl ester                   |         |
|----------|-----------------------------------------------------|---------|
|YA2304- 7 |4- (4-cyano-2-methoxyphenyl)                         |1050477-4|
|          |-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthalene-3-|5-6      |
|          |carboxylic acid                                      |         |
|----------|-----------------------------------------------------|---------|
|YA2304- 8 |4- (4-cyano-2-methoxyphenyl)                         |1050477-2|
|          |-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthalene-3-|7-4      |
|          |carboxamide                                          |         |
|----------|-----------------------------------------------------|---------|
|YA2304- 9 |Non maleketone D - (+) - dibenzoyl tartrate          |N/A      |
|----------|-----------------------------------------------------|---------|
|YA2304- CP|(4S) -4- (4-cyano-2-methoxyphenyl)                   |1050477-3|
|          |-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthalene-3-|1-0      |
|          |carboxamide                                          |         |
|----------|-----------------------------------------------------|---------|
|YA2304    |(4S) -4- (4-cyano-2-methoxyphenyl)                   |1050477-3|
|          |-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthalene-3-|1-0      |
|          |carboxamide                                          |         |
----------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 9 of 542 





Page 10
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.2.3** **Control of Materials** 



**3.2.S.2.3.1** **Materiased in the Manufacturing of the Drug Substance** 



Table 3.2.S.2.3-1 Materials Used in the Manufacturing of the Drug Substance 









---------------------------------------------------------------------
|Materials|Name                                |Grade               |
|---------|------------------------------------|--------------------|
|Starting |4-cyano-2-methoxybenzaldehyde       |Industrial chemicals|
|materials|(YA2304-1)                          |                    |
|         |------------------------------------|--------------------|
|         |Ethyl 2-cyanoacetoacetate (YA2304-2)|Industrial chemicals|
|         |------------------------------------|--------------------|
|         |4-amino-5-methyl-2-hydroxypyridine  |Industrial chemicals|
|         |(YA2304-4)                          |                    |
|---------|------------------------------------|--------------------|
|Reagents |piperidine                          |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Glacial acetic Acid                 |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Concentrated sulfuric acid          |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Triethyl orthoacetate               |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Sodium Hydroxide                    |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Anhydrous sodium acetate            |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Concentrated hydrochloric Acid      |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |N, N-carbonyl diimidazole           |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |4-dimethylaminopyridine             |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Hexamethyldisilazane                |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |D-(+) -dibenzoyltartaric acid       |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Sodium phosphate                    |Industrial chemicals|
|---------|------------------------------------|--------------------|
|Solvents |Isopropyl alcohol                   |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |2-butanol                           |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |N-methylpyrrolidone                 |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |tetrahydrofuran                     |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Toluene                             |Industrial chemicals|
|         |------------------------------------|--------------------|
|         |Anhydrous ethanol                   |Industrial chemicals|
---------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 10 of 542 





Page 11
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.2.6** **Manufacturing Process Development** 



Hinye Pharmaceutical Co., Ltd. began to develop Finerenone on the basis of 



publicly available patent. Three consecutive commercial-scale validation 



batches were manufactured in Dec. 2023 to Feb. 2024. 



Based on the literature (Authorization Notice No. CN101641352A), The patent 



describes that Starting from 4-cyano-2-methoxybenzaldehyde, it undergoes a 



Krebs condensation reaction with ethyl 2-cyanoacetoacetate, followed by a 



cyclization reaction with 4-amino-5-methyl-2-hydroxypyridine. The racemate 



is then obtained through ethylation, hydrolysis, and amidation reactions, and 



finally separated and transformed into the product. 



This route involves 5 chemical reaction steps, 1 splitting step, and 1 



crystallization step, with moderate reaction steps and easy availability of raw 



materials. Compared with other synthetic routes, it avoids the use of 



expensive catalysts, has relatively high yields, is easy to operate, and is 



suitable for commercial production. Therefore, the applicant develops and 



improves the process based on this route, and proposes this route as the 



declared process route. 



The preparation of this product is divided into 7 steps: in the first step, 



YA2304-1 and YA2304-2 are used as raw materials, and pyridine and acetic 



acid are used as catalysts to prepare YA2304-3 through condensation 



reaction; The second step is to prepare intermediate YA2304-5 by cyclization 



reaction between YA2304-3 and raw material YA2304-4. In the third step, 



intermediate YA2304-5 is catalyzed by concentrated sulfuric acid to undergo 



ethylation reaction with triethyl acetate to obtain YA2304-6; Step four, 



YA2304-6 is hydrolyzed under the action of sodium hydroxide to obtain 



YA2304-7; The fifth step is to activate YA2304-7 with CDI and prepare 



intermediate YA2304-8 by ammonification reaction with 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 11 of 542 





Page 12
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



hexamethyldisilazane. Step 6: Intermediate YA2304-8 and YA2304-10 are 



chiral separated to obtain YA2304-9; Step seven, YA2304-9 was prepared 



using sodium phosphate to obtain intermediate YA2304-CP. YA2304 was 



prepared by recrystallization of YA2304-CP with anhydrous ethanol. 



In Apr. Dec. 2023 to Feb. 2024, the manufacturing process of Finerenone had 



been successfully validated by running three consecutive commercial-scale 



batches (Batch No.: 231201, 240101, 240102). The batch size of Commercial 



scale batches and the validation batches were 10 kg/batch. The 



manufacturing site and process of Commercial scale batches and the 



validation batches were same. Refers to 3.2.S.4.4, the analyses resultes show 



that the Commercial scale batches and the validation batches Finerenone 



have the same quality. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 12 of 542 





Page 13
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3 Characterization** 



**3.2.S.3.1** **Elucidation of Structure and other Characteristics** 



**I. Evidences of Chemical Structure** 



The drug substance described in the present dossier is Finerenone which has 



the following structure formula: 



Molecular formula: C21H22N4O3 



Molecular weight: 378.43 g/mol 



Chemical name: (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1, 



4-dihydro-1,6-naphthyridine-3-carboxamide 



The applicant conducted Elemental analysis, 1H nuclear magnetic resonance 



spectroscopy, 13C nuclear magnetic resonance spectroscopy, 2D nuclear 



magnetic resonance, infrared spectroscopy, mass spectrometry, single crystal 



X-ray powder diffraction, thermogravimetric analysis, differential scanning 



calorimetry, and X-ray powder diffraction on the sample of Finerenone (batch 



No. 231101) prepared in commercial batches according to the registration 



process described in 3.2.S.2.2, and confirmed the chemical structure of the 



product as shown in Table 3.2.S.3.1-1. 



The applicant conducted physical and chemical property analysis such as 



Raman spectroscopy, differential thermal analysis, and thermogravimetric 



analysis on commercially produced samples with batch No. 231101, 



confirming that there is no crystallization water or crystallization solvent in 



the homemade Finerenone, and that the crystal form of this product is 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 13 of 542 





Page 14
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



consistent with the crystal form of the active pharmaceutical ingredient used 



in the original manufacturer's formulation. 



Table 3.2.S.3.1-1 Sample Information for Structure Elucidation 









-------------------------------------------------------------------------
|Structure                     |Sample information                      |
|------------------------------|----------------------------------------|
|Molecular formula: C21H22N4O3 |BatchNo.: 231101 Assay: 100.1% Source of|
|Molecular weight: 378.43 g/mol|sample: Hinye Pharmaceutical Co., Ltd.  |
|                              |Test items: LC-MS/MS, IR, NMR, XRD, TGA |
|                              |and DSC.                                |
-------------------------------------------------------------------------

The following investigations were carried out to confirm the chemical 



structure: 



a. liquid chromatography tandem mass spectrometry (LC-MS/MS) 



b. Infrared Absorption Spectroscopy (IR) 



c. Nuclear Magnetic Resonance Spectroscopy (NMR) 



d. Thermogravimetric Analysis (TGA) 



e. Differential Scanning Calorimetry (DSC) 



f. X-ray Powder Diffraction (XRD) 



g. Elemental Analysis 



h. single crystal x-ray diffraction (single crystal XRD) 



Details and data concerning these analyses or tests are presented as follows. 



**Ia. liquid chromatography tandem mass spectrometry (LC-MS/MS)** 



Sample Batch No.: 231101 



Instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Test method: China Pharmacopoeia 2020 Edition four General Rules 0512 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 14 of 542 





Page 15
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



and 0431. 



Test result: 



Table 3.2.S.3.1-2 Mass Spectrum Data of the Substance to be Examined 













--------------------------------------------------------------
|Batch No.|Accurate measured mass|Theoretical|Elemental      |
|         |value                 |value      |composition    |
|---------|----------------------|-----------|---------------|
|231101   |379.18                |378.43     |[C21H22N4O3+H]+|
--------------------------------------------------------------

Interpretation: 



The molecular weight of Finerenone is 378.43. In the positive ion mode, the 



mass-charge ratio of 379.18 peak is detected, which is attributed to the 



molecular ion peak in the positive ion mode, which is consistent with the 



molecular weight of Finerenone. 



The spectrum is provided in: 3.2.S.3.1 _Annex 1_ _Mass spectrum of_ Finerenone 



_(batch No.:_ 231101 _)_ 



**Ib. Infrared Absorption Spectroscopy (IR)** 



Sample Batch No.: 231101 



Instrument: Shimadzu IR Affinity-1s Fourier Transform Infrared Spectrometer 



Sample preparation: KBr pellet pressing method 



Table 3.2.S.3.1-3 Infrared Spectrum Data of the Substance to be Examined 






























-----------------------------------------------------------------
|Absorption peak |Type of   |Possible |Remarks                  |
|posit ion (cm-1)|vibr ation|Gro ups  |                         |
|----------------|----------|---------|-------------------------|
|3475.73         |υNH2     |-CONH2   |Asymmetric stretching    | 
|                |          |         |vibr ation of nitrogen   |
|                |          |         |and hydr ogen            |
|----------------|----------|---------|-------------------------|
|3415.93         |υNH      |-CONH2   |Nitrogen hydrogen symmetr| 
|                |          |         |ic stretching vibration  |
|----------------|----------|---------|-------------------------|
|3365.78         |υNH      |-NH      |Nitrogen hydrogen        | 
|                |          |         |stretchi ng vibration    |
|----------------|----------|---------|-------------------------|
|3115.04, 3079.53|υCH      |Pyridine |Carbon hydrogen stretchin| 
|                |          |rin g,   |g vibration              |
|                |          |benzene r|                         |
|                |          |ing      |                         |
-----------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 15 of 542 





Page 16
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 





































--------------------------------------------------------------------------
|2974.23, 2953.02, 28|υCH        |-CH3,-CH2,-C|Carbon hydrogen stretchin| 
|35.36               |            |H           |g vibration              |
|--------------------|------------|------------|-------------------------|
|2229.71             |υC≡N      |-CN         |Carbon nitrogen triple   |  
|                    |            |            |bon d stretching         |
|                    |            |            |vibration                |
|--------------------|------------|------------|-------------------------|
|1683.86             |υC=O       |-CONH2      |Carbon oxygen double bon | 
|                    |            |            |d stretching vibration   |
|--------------------|------------|------------|-------------------------|
|1660.71             |υC=C       |-C=C        |Carbon carbon double bon | 
|                    |            |            |d stretching vibration   |
|--------------------|------------|------------|-------------------------|
|1606.70, 1573.91, 14|υC=N，υC=C|Pyridine    |Expansion and contraction|   
|89.05               |            |rin g,      |vibrations of carbon     |
|                    |            |benzene r   |nitro gen and carbon     |
|                    |            |ing         |carbon do uble bonds     |
|--------------------|------------|------------|-------------------------|
|1463.97             |δCH        |-CH2        |In-plane shear vibration | 
|--------------------|------------|------------|-------------------------|
|1454.33, 1431.18, 14|δCH        |-CH3        |Out of plane deformation | 
|08.04, 1381.03      |            |            |v ibration               |
|--------------------|------------|------------|-------------------------|
|1267.23, 1257.59    |υ=C-O-C    |-OCH3,-OCH2 |Asymmetric stretching    | 
|                    |            |            |vibr ation of ether bond |
|--------------------|------------|------------|-------------------------|
|1138.00, 1031.92    |υ=C-O-C    |-OCH3,-OCH2 |Symmetric stretching     | 
|                    |            |            |vibrat ion of ether bond |
--------------------------------------------------------------------------

**Analysis and results:** 







IR υ cm [-1] (KBr) : 3475.73cm [-1] , 3415.93cm [-1] are the stretching vibration peaks 



of the primary amide group, 1683.86cm [-1] are the stretching vibration peaks of 



the carbonyl group in the amide, indicating that the compound contains an 



amide structure. 3365.78cm [-1] is the nitrogen and hydrogen expansion 



vibration of secondary amine, indicating that the compound contains a 



secondary amine structure. 3115.04cm [-1] and 3079.53cm [-1] are the 



hydrocarbon stretching vibration of pyridine ring and benzene ring, and 



1606.70cm [-1] , 1573.91cm [-1] and 1489.05cm [-1] are the skeleton vibration of 



pyridine ring and benzene ring, indicating that the compound contains 



pyridine ring and benzene ring. 2229.71cm [-1] is cyanogroup stretching 



vibration, indicating that the compound contains a cyanogroup. 2974.23cm [-1] , 



2953.02cm [-1] , 2835.36cm [-1] and 2964.59cm [-1] are the hydrocarbon stretching 



vibrations of multiple methyl and methylene groups, and 1463.97cm [-1] , 



1454.33cm [-1] , 1431.18, 1408.04 and 1381.03 are bending vibrations. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 16 of 542 





Page 17
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Indicating that the compound contains methylene and multiple methyl groups. 



1267.23cm [-1] and 1257.59cm [-1] are asymmetric stretching vibrations of alkyl 



aromatic ether bonds, and 1138.00cm [-1] and 1031.92cm [-1] are symmetric 



stretching vibrations of ether bonds, indicating that the compound contains 



two alkyl aromatic ether bonds. According to the above IR data, the compound 



contains amide bond, secondary amine, pyridine ring, phenyl ring, 



carbon-carbon double bond, alkyl aromatic ether bond, methylene and several 



methyl groups, which is consistent with the structure of Finerenone. 



The spectrum is provided in: 



_3.2.S.3.1 Annex 2 Infrared (IR) spectrum of_ Finerenone. _(batch No.:_ 231101 _)._ 



**Ic. Nuclear Magnetic Resonance Spectroscopy (NMR)** 



Sample Batch No.: 231101 



Instrument: Bruker Avance AV 400 Superconducting Fourier-Transform NMR 



Spectrometer 



Test conditions: 



 - solvent: DMSO- _d6_ 



 - inner standard: TMS ( [1] H NMR) 



 - resonant frequency for the [1] H NMR: 400MHz 



 - resonant frequency for the [13] C NMR: 100MHz 



The serial number of carbon atoms and hydrogen atoms in the structure (not 



IUPAC nomenclature, only for NMR spectrometry): 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 17 of 542 





Page 18
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.3.1-4 1H NMR Spectrum Data of the Substance to be Examined 













-----------------------------------------------------------
|Peak No.|Chemical   |Multiplicity|Number of|Attributed to|
|        |shift (ppm)|            |protons  |             |
|--------|-----------|------------|---------|-------------|
|1       |1.029-1.064|t           |3H       |27-CH3       |
|--------|-----------|------------|---------|-------------|
|2       |2.118      |s           |3H       |28-CH3       |
|--------|-----------|------------|---------|-------------|
|3       |2.190      |s           |3H       |22-CH3       |
|--------|-----------|------------|---------|-------------|
|4       |3.824      |s           |3H       |24-CH3       |
|--------|-----------|------------|---------|-------------|
|5       |3.986-4.030|m           |2H       |26-CH2       |
|--------|-----------|------------|---------|-------------|
|6       |5.384      |s           |1H       |9-CH         |
|--------|-----------|------------|---------|-------------|
|7       |6.714-6.804|bs          |2H       |20-NH2       |
|--------|-----------|------------|---------|-------------|
|8       |7.144-7.163|d           |1H       |4-CH         |
|--------|-----------|------------|---------|-------------|
|9       |7.274-7.293|d           |1H       |5-CH         |
|--------|-----------|------------|---------|-------------|
|10      |7.376      |s           |1H       |1-CH         |
|--------|-----------|------------|---------|-------------|
|11      |7.551      |s           |1H       |16-CH        |
|--------|-----------|------------|---------|-------------|
|12      |7.711      |s           |1H       |12-NH        |
-----------------------------------------------------------

According to H-H COSY, DEPT135, DEPT90, [13] C- [1] H HSQC [13] , C- [1] H HMBC 



spectrum, the hydrogen spectrum of the tested sample is assigned as follows: 



On [1] H NMR spectra, δ2.500 is the DMSO- _d6_ solvent peak, δ3.383 ppm is the 



water peak, both of which are the solvent peaks in deuterium reagents. 



Peak 1: δ 1.029-1.064, 3H, t, 6.8Hz, CH3, should be coupled with methylene. 



COSY shows correlation with δH3.986 (26-CH2), HSQC shows correlation with 



δC14.353 (27-C). It can be determined as 27-CH3. 



Peak 2: δ2.118, 3H, t, is CH3. COSY shows a weak correlation with 



δH7.551(16-CH), HSQC shows a strong correlation with δC13.846, HMBC 



shows a strong correlation with δC111.538, δC144.271 (16-CH) and a weak 



correlation with δC103.245, δC159.464. It can be determined as 28-CH3. 



Peak 3: δ2.190, 3H, t, is CH3. COSY shows a weak correlation with δH5.384 



(9-CH), HSQC shows a weak correlation with δC18.146, HMBC shows a strong 



correlation with δC105.399, δC138.229 and a weak correlation with δC169.843, 



and a very weak correlation with δC32.442 (9-CH). It can be determined as 



22-CH3. 



Peak 4: δ3.824, 3H, s, is CH3, HSQC shows a correlation with δC56.098, 



HMBC shows a correlation with δC155.720 (3-C) and a weak correlation with 



δC114.63, can be determined as 24-CH3. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 18 of 542 





Page 19
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Peak 5: δ3.986-4.030, 2H, m, 6.8Hz, CH, coincidences with2 δH1.029 (27-CH3). 



COSY shows a correlation with δH1.029 (27-CH3), HSQC shows a correlation 



with δC60.624, and HMBC shows a strong correlation with δC14.353 and 



δC159.464(18-C), which can be determined as 26-CH2. 



Peak 6: δ5.384, 1H, s, COSY shows a weak correlationH with δ2.190, HSQC 



shows a correlation with δC32.442, HMBC shows a correlation with δC103.245, 



δC105.399, δC130.989, δC138.229, δC141.761, δC144.271, δC155.720, 



δC159.464, δC169.843, which can be identified as 9-CH. 



Peak 7: δ6.714-6.804, 2H, bs, HSQC shows no correlation peak and can be 



determined as 20-NH2. 



Peak 8: δ7.144-7.163, 1H, d, 7.6Hz, COSY showed correlation with δH7.274, 



HSQC showed correlation with δC130.989, HMBC showed correlation with 



δC32.442, δC109.596, δC119.057, δC155.720 (3-C). So it can be determined as 



4-CH. 



Peak 9: δ7.274-7.293, 1H, d, 7.6Hz, COSY display is associated with δH7.144, 



HSQC display is associated with δC124.852, HMBC display is associated with 



δC114.182, δC119.057, δC141.761. Can be identified as 5-CH. 



Peak 10: δ7.376, 1H, s, HSQC shows correlation with δC114.182, HMBC 



shows correlation with δC109.596, δC119.057, δC124.852, δC141.761, 



δC155.720. It can be determined as 1-CH. 



Peak 11: δ 7.551, 1H, s, HSQC shows correlation with δC144.271, HMBC 



shows correlation with δC159.464 (18-C) and can be determined as 16-CH. 



Peak 12: δ 7.711, s, 1H, HSQC shows no correlation peak and can be 



determined as 12-NH. 



Based on the above analysis, all the 22 H signals in the structure of the tested 



sample are clearly attributed, which is consistent with its structure. 



Table 3.2.S.3.1-5 13C NMR Spectrum Data of the Substance to be Examined 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 19 of 542 





Page 20
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

---------------------------------------------------------
|Peak No.|Chemical shift (ppm)|Number of C|Attributed to|
|        |                    |atoms      |             |
|--------|--------------------|-----------|-------------|
|1       |13.846              |1          |28-C         |
|--------|--------------------|-----------|-------------|
|2       |14.353              |1          |27-C         |
|--------|--------------------|-----------|-------------|
|3       |18.146              |1          |22-C         |
|--------|--------------------|-----------|-------------|
|4       |32.442              |1          |9-C          |
|--------|--------------------|-----------|-------------|
|5       |56.098              |1          |24-C         |
|--------|--------------------|-----------|-------------|
|6       |60.624              |1          |26-C         |
|--------|--------------------|-----------|-------------|
|7       |103.245             |1          |14-C         |
|--------|--------------------|-----------|-------------|
|8       |105.399             |1          |10-C         |
|--------|--------------------|-----------|-------------|
|9       |109.596             |1          |2-C          |
|--------|--------------------|-----------|-------------|
|10      |111.538             |1          |15-C         |
|--------|--------------------|-----------|-------------|
|11      |114.182             |1          |1-C          |
|--------|--------------------|-----------|-------------|
|12      |119.057             |1          |6-C          |
|--------|--------------------|-----------|-------------|
|13      |124.852             |1          |5-C          |
|--------|--------------------|-----------|-------------|
|14      |130.989             |1          |4-C          |
|--------|--------------------|-----------|-------------|
|15      |138.229             |1          |11-C         |
|--------|--------------------|-----------|-------------|
|16      |141.761             |1          |7-C          |
|--------|--------------------|-----------|-------------|
|17      |144.271             |1          |13-C         |
|--------|--------------------|-----------|-------------|
|18      |144.271             |1          |16-C         |
|--------|--------------------|-----------|-------------|
|19      |155.720             |1          |3-C          |
|--------|--------------------|-----------|-------------|
|20      |159.464             |1          |18-C         |
|--------|--------------------|-----------|-------------|
|21      |169.843             |1          |19-C         |
---------------------------------------------------------



According to DEPT135, DEPT90, [13] C- [1] H HSQC, [13] C- [1] H HMBC spectrum, the 



carbon spectrum of the tested sample is classified as follows: 



δ38.905 ~ 40.121ppm on the [13] C NMR spectra are the multiple peaks of the 



solvent DMSO- _d6_ . 



Peak 1: δ13.846, DEPT135, DEPT90 spectrum shows first order carbon, 



HSQC shows direct correlation with δH2.118 (28-CH3), HMBC shows remote 



correlation with δH7.551 (16-CH). It can be determined as 28-C. 



Peak 2: δ14.353, DEPT135, DEPT90 spectrum shows first order carbon, 



HSQC shows direct correlation with δH1.029 (27-CH3), HMBC shows remote 



correlation with δH3.986 (26-CH2). It can be determined as 27-C. 



Peak 3: δ18.146, DEPT135, DEPT90 spectrum shows first order carbon, 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 20 of 542 





Page 21
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



HSQC shows direct correlation with δH2.190 (22-CH3), HMBC shows remote 



correlation with δH7.711 (12-NH). It can be determined as 22-C. 



Peak 4: δ32.442, DEPT135, DEPT90 spectrum shows tertiary carbon, HSQC 



shows direct correlation with δH5.384 (9-CH), HMBC shows remote correlation 



with δH7.144 (4-CH), δH7.376 (1-CH), δH2.190 (22-CH3). It can be determined 



as 9-C. 



Peak 5: δ56.098, DEPT135, DEPT90 spectrum shows first order carbon, 



HSQC shows direct correlation with δH3.824 (24-CH3), HMBC shows no 



remote correlation. It can be determined as 24-C. 



Peak 6: δ60.624, DEPT135, DEPT90 spectrum shows secondary carbon, 



HSQC shows direct correlation with δH3.986 (26-CH2), HMBC shows remote 



correlation with δH1.029 (27-CH3). It can be determined as 26-C. 



Peak 7: δ103.245, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows no direct correlation, HMBC shows remote correlation with 



δH5.384 (9-CH),H δ7.711 (12-NH),H δ7.551(16-CH),H δ2.118 (28-CH3). It can be 



determined to be 14-C. 



Peak 8: δ105.399, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows no direct correlation, HMBC shows remote correlation with 



δH5.384 (9-CH), δH7.711 (12-NH), δH2.190 (22-CH3). It can be determined as 



10-C. 



Peak 9: δ109.596, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows no direct correlation, HMBC shows remote correlation with 



δH7.144 (4-CH), δH7.376 (1-CH). It can be determined as 2-C. 



Peak 10: δ111.538, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows no direct correlation, HMBC shows remote correlation with 



δH2.118 (28-CH3), δH7.551 (16-CH), δH7.711 (12-NH). It can be determined as 



15-C. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 21 of 542 





Page 22
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Peak 11: δ114.182, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows direct correlation with δH7.376 (1-CH), HMBC shows remote 



correlation with δH7.274 (5-CH), δH3.824 (24-CH3). It can be determined as 



1-C. 



Peak 12: δ119.057, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows no direct correlation, HMBC shows remote correlation with 



δH7.376 (1-CH), δH7.274 (5-CH), δH7.144 (4-CH). It can be determined as 6-C. 



Peak 13: δ124.852, DEPT135, DEPT90 spectrum shows tertiary carbon, 



HSQC shows direct correlation with δH7.274 (5-CH), HMBC shows remote 



correlation with δH7.376 (1-CH), δH7.144 (4-CH). It can be determined as 5-C. 



Peak 14: δ130.989, DEPT135, DEPT90 spectrum shows tertiary carbon, 



HSQC shows direct correlation with δH7.144 (4-CH), HMBC shows remote 



correlation with δH5.384 (9-CH). Can be determined as 4-C. 



Peak 15: δ138.229, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows no direct correlation, HMBC shows remote correlation with 



δH2.190 (22-CH3),H δ5.384 (9-CH),H δ7.711 (12-NH). It can be determined as 



11-C. 



Peak 16: δ141.761, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows no direct correlation, HMBC shows remote correlation with 



δH5.384 (9-CH), δH7.274 (5-CH), δH7.376 (1-CH). It can be determined as 7-C. 



Peak 17: δ144.271, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows direct correlation with δH7.551 (16-CH), And HMBC also shows a 



remote correlation with δH2.118 (28-CH3), δH5.384 (9-CH), δH7.551 (16-CH), 



δH7.711 (12-NH). They can be identified as 13-C and 16-C carbons. 



Peak 18: δ155.720, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HSQC shows no direct correlation, HMBC showed a remote correlation withH 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 22 of 542 





Page 23
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



δ3.824 (24-CH3), δH7.144 (4-CH), δH5.384 (9-CH), δH7.376 (1-CH), δH7.274 



(5-CH). Can be determined as 3-C. 



Peak 19: δ159.464, HSQC shows no direct correlation, HMBC shows 



correlation with δH2.118 (28-CH3), δH3.986-4.030 (26-CH2), δH7.551 (16-CH), 



δH7.711 (12-NH), so it can be determined that the peak is 18-C. 



Peak 20: δ169.843, DEPT135, DEPT90 spectrum shows quaternary carbon, 



HMBC shows a remote correlation with δH5.384 (27-CH3), δH2.118 (28-CH3), 



δH7.711 (12-NH), we can determine that the peak is 19-C. 



According to the above analysis, the carbon spectrum of the tested sample 



shows 20 groups of carbon peaks, a total of 21 carbon atoms, and all of them 



are clearly attributed. 



The NMR data were consistent with the target compounds. 



The spectra are provided in: 



_3.2.S.3.1 Annex 3_ _NMR spectrum of_ Finerenone _(batch No.: 231101)_ 



**Id. Thermogravimetric Analysis (TGA)** 



_Sample Batch No.:_ 231101. 



_Instrument: : TG 209 F1 Thermogravimetric Analyze_ r 



Test conditions: 



- 35-500 ℃, heating rate of 10 ℃/min; 



- nitrogen, flow rate 20ml/min 



Test result: 



Table 3.2.S.3.1-6 TGA Result of the Substance to be Examined 










-------------------------------------
|Lot No.|Endothermic process        |
|       |---------------------------|
|       |Temperature      |Mass loss|
|-------|-----------------|---------|
|231101 |35.0 ℃⁓ 184.2 ℃|0.60%    |  
-------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 23 of 542 





Page 24
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



242.7 ℃ ⁓ 438.8 ℃ 97.30% 



Interpretation: 



TGA shows that the weight loss of the self-made sample is 0.60% at 



35℃⁓ 184.2℃. Combined with DSC detection spectrum, the sample does not 



absorb heat before melting (about 254℃), indicating that the sample does not 



contain crystal water or crystalline solvent. 



The TGA thermogram is provided in: 



_3.2.S.3.1 Annex 4 TGA thermogram report of Finerenone_ (batch No.: 231101 ). 



_3.2.S.3.1 Annex 5 TGA thermogram report of Finerenone_ (batch No.: 231201, 



240101, 240102) 



**Ie. Differential Scanning Calorimetry (DSC)** 



Sample Batch No.: _231101_ . 



Instrument: DSC 25 Differential Scanning Calorimeter 



Test conditions: 



- experimental atmosphere: N2, 50 mL/min. 



- scanning procedure: Heat up from 30 ℃ to 350 ℃ at 20 ℃/min rate. 



Test result: 



The samples submitted for inspection were detected by differential scanning 



calorimetry, and there was a multiple endothermic process within the 



detection temperature range (30-400℃). The peak temperature is shown in 



Table 3.2.S.3.1- _7_ : 



Table 3.2.S.3.1-7 DSC Result of the Substance to be Examined 









------------------------------------------------------
|Batch No|endothermic process                        |
|        |-------------------------------------------|
|        |The initial temperature|Peak temperature/℃| 
|        |of extrapolation/℃    |                   | 
------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 24 of 542 





Page 25
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



231101 254.38 257.04 



Interpretation: 



DSC showed that the self-made sample had an endothermic peak at 254℃, 



without other endothermic peaks, indicating that the endothermic peak was 



the melting point, consistent with the melting point reported in the original 



research patent (about 252℃). 



The DSC pattern is provided in: 



_3.2.S.3.1 Annex 6_ _DSC pattern on Finerenone (batch No.: 231101, 231201,_ 



_240101, 240102)_ 



**If. X-ray Diffraction Pattern (XRD)** 



Sample Batch No.: _231101._ 



Instrument: Japanese Institute of Technology (Smartlab 3kW) X-ray 



diffractometer 



Test method: Light tube voltage 40kW, filament current 15mA, Cu radiation, 



Ni filtering, Hypix 3000 two-dimensional detector. 



Detection and analysis: The sample has the maximum peak value (error range 



is ±0.2°) at 2θ angles of 8.5, 14.1, 17.2, 19.0, 20.5, 25.6 and 26.5, which is 



consistent with the characteristic peak of polycrystalline substance I reported 



in the original research patent. 



The XRD pattern is provided in: 



3.2.S.3.1 Annex 7 XRD pattern on Finerenone (batch No.: 231101) 



3.2.S.3.1 Annex 8 XRD pattern on Finerenone (batch No.: 231201) 



3.2.S.3.1 Annex 9 XRD pattern on Finerenone (batch No.: 240101) 



3.2.S.3.1 Annex 10 XRD pattern on Finerenone (batch No.: 240102) 



**Ig. Elemental Analysis** 



Instrument model: Elementar Vario EL cube element analyzer 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 25 of 542 





Page 26
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Test method: JY/T 0580-2020 element analyzer analysis method general rules 



Table 3.2.S.3.1-8 Elemental analysis data of the tested sample 










-------------------------------------------------------------
|Elements |C      |H      |N      |O                        |
|---------|-------|-------|-------|-------------------------|
|Test     |66.57% |5.95%  |14.96% |12.52% (This value is    |
|results  |       |       |       |calculated from the first|
|         |       |       |       |three test values)       |
|---------|-------|-------|-------|-------------------------|
|Theoretic|66.65% |5.86%  |14.81% |12.68%                   |
|al result|       |       |       |                         |
-------------------------------------------------------------

Analytical results: According to the test results of C, H and N, the mass 



fraction of oxygen element can be calculated as 12.52%. The error between the 



test results of C, H, O and N and the theoretical results is less than 0.3%, 



which can be determined to be consistent with the molecular composition 



C21H22N4O3 of Finerenone. 



The Elemental Analysis report is provided in: 



3.2.S.3.1 Annex 11 Elemental Analysis report on Finerenone (batch No.: 



231101) 



**Ih. Single crystal X-ray diffraction** 



Finerenone contains a chiral center, and the stereoscopic configuration can be 



confirmed by single crystal X-ray diffraction. See the attached single crystal 



test report for details. 



Monocrystalline culture: 160mg of Finerenone and 6ml of anhydrous ethanol 



were heated and dissolved, then filtered with precision. The filtrate was placed 



in a vial and incubated at 25℃ for 3⁓ 4 days to obtain monocrystalline. 



Instrument: D8 Venture 



Testing parameters: 



- Light source: Cu target 



- X-ray: CU-k (= 1.54178 A) 



- Detector: CMOS surface detector 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 26 of 542 





Page 27
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



-Resolution: 0.80Å 



- Current voltage: 50 kV, 1.2mA 



- exposure time: 2 s 



- Face detector to sample distance: 40 mm 



- Test temperature: 150(2)K. 



Structure analysis and finishing process: 



After integral reduction of diffraction data by SAINT program, empirical 



absorption correction of data by SADABS program; SHELXT2014 was used to 



analyze the single crystal structure by direct method, and the structure was 



refined by least square method. The hydrogen atom refining process was 



obtained by isotropic calculation, the hydrogen atom on N was obtained by 



residual electron density, and the hydrogen atom on C-H was obtained by 



calculation and hydrogenation, and it was refined by riding model. The Flack 



constant is -0.01(11), and the chirality of C9 is S configuration. See Figure 



3.2.S.3.1-1 for an ellipsoid diagram of the molecular stereostructure of 



Finerenone. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 27 of 542 





Page 28
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Fig. 3.2.S.3.1-1 Ellipsoid of the three-dimensional structure of Finerenone 



**Comprehensive analysis and conclusion** 



The molecular formula of Finerenone is C21H22N4O3, there is a chiral center, 



and the chiral configuration of C9 is S configuration (the atomic number here 



is the nuclear magnetic structure analysis number). The applicant confirmed 



the chemical plane structure of the product by elemental analysis, mass 



spectrometry, infrared spectroscopy, nuclear magnetic resonance 1H 



spectrum, nuclear magnetic resonance 13C spectrum and two-dimensional 



nuclear magnetism; In order to confirm the three-dimensional configuration of 



Finerenone, the applicant cultured single crystals with 231101 batches of 



samples, commissioned the Research Center for Drug Quality Control and 



Solid State Chemistry, Shanghai Institute of Pharmaceutical Sciences, 



Chinese Academy of Sciences to test them, and confirmed that C9 in the 



molecular structure of the product is the S configuration. TGA proved that 



this product does not contain crystal water and crystalline solvent, and the 



structural formula is as follows: 



The applicant used DSC and XRD methods to identify the crystal shape of the 



self-made Finerenone, and confirmed that the crystal shape of the product is 



consistent with that reported in the original patent. 



**II. Physicochemical Characteristics** 



**IIa. Appearance** 



According to the evaluation report of the original research formulation 



launched by the original manufacturer in the European Union, the 



appearance of the original product is White to yellow crystalline 



non-hygroscopic powder. The applicant conducted a visual inspection on the 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 28 of 542 





Page 29
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



self-made commercial batch of Finerenone, and the test results are shown in 



the table below. 

---------------------------------------------------
|Batch No.            |Appearance                 |
|---------------------|---------------------------|
|EMA Assessment report|White to yellow crystalline|
|                     |non-hygroscopic powder     |
|---------------------|---------------------------|
|231201               |White powder               |
|---------------------|---------------------------|
|240101               |White powder               |
|---------------------|---------------------------|
|240102               |White powder               |
---------------------------------------------------



**IIb. Solubility** 



Referring to the IF document of the original preparation agent listed in Japan, 



it can be seen that the solubility of the original preparation API is "dissolved in 



methanol, slightly soluble in ethanol, acetonitrile and acetone, slightly soluble 



in isopropyl alcohol, and almost insoluble in water". The applicant has studied 



the solubility of three batches of commercially produced finelidone in 



methanol, ethanol, acetonitrile, acetone, isopropyl alcohol and water in 



accordance with the General rules of the Chinese Pharmacopoeia 2020 



Edition. The test results are basically consistent with the description of 



solubility of the original research API. 



Table 3.2.S.3.1-9 Results of Solubility Studies of Finerenone 









----------------------------------------------------------------------------
|Batch No.|Solubility                                                      |
|---------|----------------------------------------------------------------|
|231201   |This product is dissolved in methanol, slightly soluble in      |
|         |ethanol, acetonitrile and acetone, slightly soluble in isopropyl|
|         |alcohol, and almost insoluble in water                          |
|---------|----------------------------------------------------------------|
|240101   |This product is dissolved in methanol, slightly soluble in      |
|         |ethanol, acetonitrile, and acetone, slightly soluble in         |
|         |isopropyl alcohol, and almost insoluble in water                |
|---------|----------------------------------------------------------------|
|240102   |This product is dissolved in methanol, slightly soluble in      |
|         |ethanol, acetonitrile, and acetone, slightly soluble in         |
|         |isopropyl alcohol, and almost insoluble in water                |
----------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 29 of 542 





Page 30
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**IIc. Hygroscopicity** 



Refer to the IF file of the original development agent listed in Japan, it can be 



seen that the original research product has no moisture induction. According 



to the General Rule 9103 of the Fourth Part of the 2020 edition of Chinese 



Pharmacopoeia, the applicant conducted a humidification test on three 



batches of commercial-scale mass-produced Finerenone. The experimental 



conditions were 25±1℃ and the relative humidity was 80%±2%. The test 



results showed that the product had non-hygroscopic, which was consistent 



with that of the original product. 



Table 3.2.S.3.1-10 Results of Hygroscopicity Determination of Finerenone 






















----------------------------------------------------------------------------
|Batch No.|Weight of |Sample (g)|Weight of blank|Mass      |Results        |
|         |blank     |          |vessel and     |increasing|               |
|         |vessel (g)|          |sample(g) after|percentage|               |
|         |          |          |standing for   |(%)       |               |
|         |          |          |24h            |          |               |
|---------|----------|----------|---------------|----------|---------------|
|231201   |20.63545  |1.01424   |21.64979       |0.01%     |non-hygroscopic|
|---------|----------|----------|---------------|----------|---------------|
|240101   |22.77341  |1.02158   |23.79492       |-0.01%    |non-hygroscopic|
|---------|----------|----------|---------------|----------|---------------|
|240102   |20.08668  |1.19142   |21.27804       |-0.01%    |non-hygroscopic|
|---------|----------|----------|---------------|----------|---------------|
|Original formulation IF file   |non-hygroscopic                           |
----------------------------------------------------------------------------

**IId. Melting Point** 



The crystal form of Finerenone was reported in the patent CN106795155 



A applied by the original research manufacturer in China. The crystal for 



m was measured by DSC and melted at about 252℃. The curve diagram 



is as follows: 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 30 of 542 





Page 31
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Fig. 3.2.S.3.1-2 patent CN106795155A reported the DSC map of Fine 



renone crystal type 



The applicant's evaluation of a pilot lot (Batch No.: 231101) and three 



commercial-scale batch production batches of Finerenone (Batch No.: 



Differential scanning calorimetry (DSC) was performed on 231201, 240101 



and 240102. The results showed melting at about 252 ° C, and no other 



absorption and exothermic peaks were observed, indicating that no phase 



changes occurred other than melting. The DSC maps of the four batches of 



samples are consistent with those of the crystal type reported in patent 



CN106795155A. The specific data are shown in below Table. 










------------------------------------------------------
|Batch No.|Endothermic process                       |
|         |------------------------------------------|
|         |Extrapolation starting|Peak temperature/℃| 
|         |temperature/℃        |                   | 
|---------|----------------------|-------------------|
|231101   |254.38                |257.04             |
|---------|----------------------|-------------------|
|231201   |253.88                |256.33             |
|---------|----------------------|-------------------|
|240101   |254.02                |256.74             |
|---------|----------------------|-------------------|
|240102   |255.16                |256.93             |
------------------------------------------------------

The DSC thermogram on Finerenone is provided in: 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 31 of 542 





Page 32
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



_3.2.S.3.1 Annex 6 DSC pattern of_ Finerenone (batch No.: 231101, 231201, 



240101, 240102) 



**IIe. Thermogravimetric Analysis (TGA)** 



Combined with the chemical structure formula and molecular formula of 



Finerenone published in the evaluation report of the original preparation 



agent listed in the EU (see 3.2.S.1.2 for details), it can be seen that the 



Finerenone used in the original research does not contain crystal water or 



crystallization solvent. The applicant conducted thermogravimetric analysis of 



a pilot batch (Batch No.: 231101) and three commercial-scale batches of 



Finerenone (lBatch No.: 231201, 240101 and 240102). The specific data are 



shown in below Table. 



Table 3.2.S.3.1-12 TGA Result of the Substance to be Examined 










-------------------------------------
|Batch No.|Endothermic process      |
|         |-------------------------|
|         |Temperature/C|Mass loss %|
|---------|-------------|-----------|
|231101   |184 ℃       |0.60%      | 
|---------|-------------|-----------|
|231201   |175 ℃       |0.16%      | 
|---------|-------------|-----------|
|240101   |175 ℃       |0.24%      | 
|---------|-------------|-----------|
|240102   |175 ℃       |0.16%      | 
-------------------------------------

See 3.2.S.2.2.3 for the crystalline solvent of this product, it can be seen that 



the crystalline solvent of this product is anhydrous ethanol, which may bring 



a small amount of water, so the crystalline solvent most likely to be contained 



in this product is ethanol and water. From the analysis of the test results, it 



can be seen that there is basically no weight loss when the sample is heated to 



175℃, indicating that the sample does not contain crystal water or crystalline 



solvent. 



The TGA thermogram is provided in: 



_3.2.S.3.1 Annex 4_ _TGA thermogram report of Finerenone_ (batch No.: 231101 _)._ 



_3.2.S.3.1 Annex 5_ _TGA thermogram report of Finerenone_ (batch No.: 231201, 



240101, 240102 _)._ 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 32 of 542 





Page 33
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**IIf. Polymorphism** 



In the patent CN106795155A applied by the original research manufactu 



rer in China, the polycrystalline form I of Finerenone was reported. The 



crystal form by powder X-ray diffraction pattern (that is, XRD pattern) h 



as a peak maximum at the 2θ Angle of 8.5, 14.1, 17.2, 19.0, 20.5, 25.6, 



26.5. The relevant XRD pattern is shown in below Fig. 3.2.S.3.1-3. 



Figure 3.2.S.3.1-3 patent CN106795155A reported the XRD pattern of Fi 



nerenone polycrystalline form I 



Applicant for a pilot lot (Batch No.: 231101) and three commercial-scale 



batches of Finerenone (Batch No.: 231201, 240101 and 240102) were tested 



by XRD. The XRD patterns of the four batches of samples were consistent with 



those of polycrystalline Ⅰ crystal as reported in patent CN106795155A. At the 



same time, combined with the DSC and XRD test results, it can be seen that 



the applicant's self-made Finerenone crystal pattern is consistent with the 



Finerenone polycrystalline pattern I reported in patent CN106795155A, and 



the registration process can ensure that the same crystal pattern of the 



product is consistently produced. 



The XRD pattern is provided in: 



_3.2.S.3.1 Annex 7 XRD pattern of Finerenone (batch No.: 231101)_ 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 33 of 542 





Page 34
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



_3.2.S.3.1 Annex 8 XRD pattern of Finerenone (batch No.: 231201)_ 



_3.2.S.3.1 Annex 9 XRD pattern of Finerenone (batch No.: 240101)_ 



_3.2.S.3.1 Annex 10 XRD pattern of Finerenone (batch No.: 240102)_ 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 34 of 542 





Page 35
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**III. Material Safety Data Sheet** 



**SECTION 1: Identification** 



1.1 Product identifier 



Product name: Finerenone 



1.2 Recommended use of the chemical and restrictions on use 



Identified uses: Industrial and scientific research use. 



1.3 Supplier's details 



Company: Hinye Pharmaceutical Co., Ltd. 



Address: No.109, Kangtian Road, Changsha National Biological Industrial 



Base, Hunan Province 



Telephone: 86-10-69703845 



**SECTION 2: Hazard identification** 



2.1 GHS Classification 



Not a hazardous substance or mixture. 



2.2 GHS Label elements, including precautionary statements 



Not a hazardous substance or mixture. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 35 of 542 





Page 36
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



2.3 Physical and chemical hazards 



Referring to current information, no physical or chemical hazard. 



2.4 Health hazards 



Referring to current information, no health hazard. 



2.5 Environmental hazards 



Referring to current information, no environmental hazard. 



2.6 Other hazards 



Caution: Physiologically highly active, therapeutically usable substance. The 



substance must be handled with the care required for hazardous materials. 



**SECTION 3: Composition/information on ingredients** 

-------------------------------------------------------
|Product name|CAS No.     |Formula   |Molecular weight|
|------------|------------|----------|----------------|
|Finerenone  |1050477-31-0|C21H22N4O3|378.43 g/mol    |
-------------------------------------------------------



**SECTION 4: First-aid measures** 



If inhaled 



After inhalation: fresh air. Consult doctor if feeling unwell. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 36 of 542 





Page 37
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



In case of skin contact 



In case of skin contact: Take off immediately all contaminated clothing. Rinse 



skin with water/ shower. Consult a physician. 



In case of eye contact 



After eye contact: rinse out with plenty of water. Remove contact lenses. 



If swallowed 



After swallowing: immediately make victim drink water (two glasses at most). 



Consult a physician. 



4.2 Most important symptoms/effects, acute and delayed 



The most important known symptoms and effects are described in the 



labelling (refers to section 2.2) and/or in section 11 



4.3 Indication of any immediate medical attention and special treatment 



needed 



no data available 



4.4 Notes to physician 



No data available 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 37 of 542 





Page 38
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**SECTION 5: Firefighting measures** 



5.1 Extinguishing media 



Suitable extinguishing media 



Water Foam Carbon dioxide (CO2) Dry powder 



Unsuitable extinguishing media 



For this substance/mixture no limitations of extinguishing agents are given. 



5.2 Special hazards arising from the substance or mixture 



Carbon oxides 



Nitrogen oxides (NOx) 



Combustible. 



Development of hazardous combustion gases or vapours possible in the event 



of fire. 



5.3 Advice for firefighters 



Stay in danger area only with self-contained breathing apparatus. Prevent 



skin contact by keeping a safe distance or by wearing suitable protective 



clothing. 



Suppress (knock down) gases/vapors/mists with a water spray jet. Prevent 



fire extinguishing water from contaminating surface water or the ground 



water system. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 38 of 542 





Page 39
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**SECTION 6: Accidental release measures** 



6.1 Personal precautions, protective equipment and emergency procedures 



Advice for non-emergency personnel: Avoid inhalation of dusts. Avoid 



substance contact. 



Ensure adequate ventilation. Evacuate the danger area, observe emergency 



procedures,consult an expert. 



For personal protection refers to section 8. 



6.2 Environmental precautions 



Do not let product enter drains. 



6.3 Methods and materials for containment and cleaning up 



Cover drains. Collect, bind, and pump off spills. Observe possible material 



restrictions (refers to sections 7 and 10). Take up dry. Dispose of properly. 



Clean up affected area. Avoid generation of dusts. 



6.4 Reference to other sections 



For disposal refers to section 13. 



**SECTION 7: Handling and storage** 



7.1 Precautions for safe handling 



For precautions refers to section 2.2. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 39 of 542 





Page 40
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



7.2 Conditions for safe storage, including any incompatibilities 



Storage conditions 



Tightly closed. Dry. 



Storage stability 



Recommended storage temperature 



2 - 8 ℃ 



Storage class 



Storage class (TRGS 510): 11: Combustible Solids. 



**SECTION 8: Exposure controls/personal protection** 



8.1Control parameters 



Ingredients with workplace control parameters 



Contains no substances with occupational exposure limit values. 



8.2 Exposure controls 



Appropriate engineering controls 



Change contaminated clothing. Preventive skin protection recommended. 



Wash hands after working with substance. 



Personal protective equipment 



Eye/face protection 



Use equipment for eye protection tested and approved under appropriate 



government standards such as NIOSH (US) or EN 166(EU). Safety glasses 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 40 of 542 





Page 41
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Skin protection 



This recommendation applies only to the product stated in the safety data 



sheet,supplied by us and for the designated use. When dissolving in or mixing 



with other substances and under conditions deviating from those stated in 



EN374 please contact the supplier of CE-approved gloves (e.g. KCL GmbH, 



D-36124 Eichenzell, Internet: www.kcl.de). 



Full contact 



Material: Nitrile rubber 



Minimum layer thickness: 0.11 mm 



Break through time: 480 min 



Material tested:KCL 741 Dermatril® L 



Splash contact 



Material: Nitrile rubber 



Minimum layer thickness: 0.11 mm 



Break through time: 480 min 



Material tested:KCL 741 Dermatril® L 



Body Protection 



protective clothing 



Respiratory protection 



required when dusts are generated. 



Our recommendations on filtering respiratory protection are based on the 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 41 of 542 





Page 42
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



following standards: DIN EN 143, DIN 14387 and other accompanying 



standards relating to the used respiratory protection system. 



Control of environmental exposure 



Do not let product enter drains. 



**SECTION 9: Physical and chemical properties** 



9.1 Information on basic physical and chemical properties 



Appearance 



Form:solid 



Odor 



no data available 



Odor Threshold 



no data available 



pH 



no data available 



Melting point/freezing point 



no data available 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 42 of 542 





Page 43
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Initial boiling point and boiling range 



no data available 



Flash point 



No data available 



Evaporation rate 



No data available 



Flammability (solid,gas) 



no data available 



Upper/lower flammability or explosive limits 



no data available 



Vapor pressure 



no data available 



Vapor density 



no data available 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 43 of 542 





Page 44
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Density 



no data available 



Relative density 



no data available 



Water solubility 



no data available 



Partition coefficient n-octanol/water 



no data available 



Autoignition temperature 



no data available 



Decomposition temperature 



no data available 



Viscosity 



no data available 



Explosive properties 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 44 of 542 





Page 45
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



no data available 



Oxidizing properties 



none 



9.2 Other safety information 



no data available 



**SECTION 10: Stability and reactivity** 



10.1 Chemical stability 



The product is chemically stable under standard ambient conditions (room 



temperature) . 



10.2 Possibility of hazardous reactions 



no data available 



10.3Conditions to avoid 



no information available 



10.4Incompatible materials 



Strong oxidizing agents 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 45 of 542 





Page 46
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



10.5Hazardous decomposition products 



In the event of fire: refers to section 5 



**SECTION 11: Toxicological information** 



11.1 Information on toxicological effects 



Acute toxicity 



Oral: no data available 



Inhalation: no data available 



Dermal: no data available 



Skin corrosion/irritation 



no data available 



Serious eye damage/eye irritation 



No data available 



Respiratory or skin sensitization 



No data available 



Germ cell mutagenicity 



No data available 



Carcinogenicity 



No data available 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 46 of 542 





Page 47
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Reproductive toxicity 



No data available 



Specific target organ toxicity - single exposure 



No data available 



Specific target organ toxicity - repeated exposure 



No data available 



Aspiration hazard 



No data available 



11.2 Additional Information 



To the best of our knowledge, the chemical, physical, and toxicological 



properties have not been thoroughly investigated. 



**SECTION 12: Ecological information** 



12.1Toxicity 



no data available 



12.2 Persistence and degradability 



no data available 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 47 of 542 





Page 48
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



12.3 Bioaccumulative potential 



no data available 



12.4 Mobility in soil 



no data available 



12.5 Results of PBT and vPvB assessment 



no data available 



12.6 Endocrine disrupting properties 



No data available 



12.7 Other adverse effects 



no data available 



**SECTION 13: Disposal considerations** 



13.1 Waste treatment methods 



Product 



Offer surplus and non-recyclable solutions to a licensed disposal company. 



**SECTION 14: Transport information** 



14.1 UN No. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 48 of 542 





Page 49
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



ADR/RID: - IMDG: - IATA-DGR: - 



14.2 UN Proper Shipping Name 



ADR/RID: Not dangerous goods 



IMDG: Not dangerous goods 



IATA: Not dangerous goods 



14.3 Transport hazard class(es) 



ADR/RID: -IMDG:- IATA-DGR: - 



14.4 Packing group 



ADR/RID: -IMDG:- IATA-DGR: - 



14.5 Environmental hazards 



ADR/RID: no IMDG: no IATA: no 



14.6 Special precautions for user 



no data available 



14.7 Incompatible materials 



Strong oxidizing agents 



Further information 



Not classified as dangerous in the meaning of transport regulations. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 49 of 542 





Page 50
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**SECTION 15: Regulatory information** 



15.1 Safety, health and environmental regulations/legislation specific for the 



substance or mixture 



National regulatory information 



Other regulations 



Please pay attention on the waste treatment should also comply with local 



regulations requirement. 



**SECTION 16: Other information** 



Further information 



The above information is believed to be correct but does not purport to be all 



inclusive and shall be used only as a guide. The information in this document 



is based on the present state of our knowledge and is applicable to the product 



with regard to appropriate safety precautions. It does not represent any 



guarantee of the properties of the product. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 50 of 542 





Page 51
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**Annexes to 3.2.S.3.1** 



3.2.S.3.1 Annex 1 Mass spectrum of Finerenone (batch No.: 231101) 



3.2.S.3.1 Annex 2 Infrared (IR) spectrum of Finerenone (batch No.: 231101) 



180301) 



3.2.S.3.1 Annex 3 NMR spectrum of Finerenone (batch No.: 231101) 



3.2.S.3.1 Annex 4 Elemental analysis report of Finerenone (batch No.: 



231101) 



3.2.S.3.1 Annex 5 TGA thermogram report of Finerenone (batch No.: 231101) 



3.2.S.3.1 Annex 6 XRD pattern on Finerenone (batch No.: 231101) 



3.2.S.3.1 Annex 7 DSC pattern of Finerenone (batch No.: 210601) 



3.2.S.3.1 Annex 8 DSC pattern of Finerenone (batch No.: 210602) 



3.2.S.3.1 Annex 9 DSC pattern of Finerenone (batch No.: 210603) 



3.2.S.3.1 Annex 10 XRD pattern of Finerenone (batch No.: 210601) 



3.2.S.3.1 Annex 11 XRD pattern of Finerenone (batch No.: 210602) 



3.2.S.3.1 Annex 12 XRD pattern of Finerenone (batch No.: 210603) 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 51 of 542 





Page 52
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 1 Mass spectrum of Finerenone (batch No.: 231101)** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 52 of 542 





Page 53
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 2 Infrared (IR) spectrum of Finerenone (batch No.:** 



**231101)** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 53 of 542 





Page 54
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 54 of 542 





Page 55
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 55 of 542 





Page 56
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 3 NMR spectrum of Finerenone (batch No.: 231101)** 



1H-NMR 谱 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 56 of 542 





Page 57
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



13C-NMR 谱 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 57 of 542 





Page 58
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



COSY 谱 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 58 of 542 





Page 59
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



DEPT135 谱 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 59 of 542 





Page 60
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



DEPT90 谱 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 60 of 542 





Page 61
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



HSQC 谱 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 61 of 542 





Page 62
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



HMBC 谱 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 62 of 542 





Page 63
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 4 TGA thermogram report of Finerenone (batch No.:** 



**231101)** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 63 of 542 





Page 64
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 64 of 542 





Page 65
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 65 of 542 





Page 66
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 66 of 542 





Page 67
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 5 TGA thermogram report of Finerenone (batch No.:** 



**231201, 240101 and 240102)** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 67 of 542 





Page 68
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 68 of 542 





Page 69
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 69 of 542 





Page 70
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 70 of 542 





Page 71
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 71 of 542 





Page 72
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 6 DSC pattern of Finerenone (batch No.: 231101, 231201, 240101, 240102)** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 72 of 542 





Page 73
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 73 of 542 





Page 74
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 74 of 542 





Page 75
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 75 of 542 





Page 76
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 7 XRD pattern on Finerenone (batch No.: 231101)** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 76 of 542 





Page 77
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 77 of 542 





Page 78
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 8 XRD pattern on Finerenone (batch No.: 231201)** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 78 of 542 





Page 79
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 79 of 542 





Page 80
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 9 XRD pattern on Finerenone (batch No.: 240101)** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 80 of 542 





Page 81
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 81 of 542 





Page 82
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex 10 XRD pattern on Finerenone (batch No.: 240102)** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 82 of 542 





Page 83
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 83 of 542 





Page 84
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.1 Annex** **11 Elemental analysis** **on Finerenone (batch No.:** 



**231101)** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 84 of 542 





Page 85
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 85 of 542 





Page 86
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.2** **Impurities** 



The applicant combined the registration process to analyze the impurity 



spectrum of Finerenone, in which there may be organic impurities, inorganic 



impurities, residual solvents, metal impurities and potential genotoxic 



impurities, five categories of impurities, and the source, destination and 



related control strategies of the above five categories of impurities have been 



analyzed and studied as follows: 



**3.2.S.3.2.1 Organic Impurities** 



The organic impurities in Finerenone mainly come from the starting materials 



and intermediates, side reaction products and degradation products that are 



not completely reacted into the starting materials during the reaction process. 



For the information of the impurities, see Table 3.2.S.3.2.1-1 Organic 



impurities spectrum of Finerenone. Of the impurities, YA2304-23, 



YA2304-24, YA2304-33, YA2304-43, YA2304-38, YA2304-40, YA2304-41, 



YA2304-1, YA2304-4, 4-dimethylamino pyridine, YA2304-47, sulfate 



impurities and nitrosamines impurities With a cautionary structure, the 



applicant does not make a specific analysis in this section, but a separate 



description and analysis in section 3.2.S.3.2.5 of Genotoxic Impurities. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 86 of 542 





Page 87
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.3.2-1 Potential Organic Impurities in Drug Substance Finerenone 






























--------------------------------------------------------------------------------------------
|Names of  |Chemical name   |Chemical structure|Impurity   |Control|Whether to set quality |
|impurities|                |formula           |source     |limits |standards              |
|----------|----------------|------------------|-----------|-------|-----------------------|
|YA2304-23 |4-bromo-2-hydrox|                  |Impurity   |N/A    |no (Including warning  |
|          |ybenzaldehyde   |                  |introduced |       |structure, see         |
|          |                |                  |by starting|       |"3.2.S.3.2.5 Genotoxic |
|          |                |                  |material   |       |Impurities" section for|
|          |                |                  |YA2304-1   |       |relevant control       |
|          |                |                  |           |       |strategies)            |
|----------|----------------|------------------|-----------|-------|-----------------------|
|YA2304-24 |4-bromo-2-metho |                  |Impurity   |N/A    |no (Including warning  |
|          |xybenzaldehyde  |                  |introduced |       |structure, see         |
|          |                |                  |by starting|       |"3.2.S.3.2.5 Genotoxic |
|          |                |                  |material   |       |Impurities" section for|
|          |                |                  |YA2304-1   |       |relevant control       |
|          |                |                  |           |       |strategies)            |
|----------|----------------|------------------|-----------|-------|-----------------------|
|YA2304-33 |4-cyano-2-hydrox|                  |Impurity   |N/A    |no (Including warning  |
|          |ybenzaldehyde   |                  |introduced |       |structure, see         |
|          |                |                  |by starting|       |"3.2.S.3.2.5 Genotoxic |
|          |                |                  |material   |       |Impurities" section for|
|          |                |                  |YA2304-1   |       |relevant control       |
|          |                |                  |           |       |strategies)            |
|----------|----------------|------------------|-----------|-------|-----------------------|
|YA2304-43 |4-aminoformyl-2-|                  |Impurity   |N/A    |no (Including warning  |
|          |methoxybenzalde |                  |introduced |       |structure, the relevant|
|          |hyde            |                  |by starting|       |control strategies are |
|          |                |                  |material   |       |detailed in section    |
|          |                |                  |YA2304-1   |       |                       |
--------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 87 of 542 





Page 88
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-----------------------------------------------------------------------------------
|         |                 |       |           |       |3.2.S.3.2.5 Genotoxic    |
|         |                 |       |           |       |Impurities)              |
|---------|-----------------|-------|-----------|-------|-------------------------|
|YA2304-38|4-methylene-2-ox |       |Impurity   |N/A    |no (Including warning    |
|         |acyclobutanone   |       |introduced |       |structure, see           |
|         |                 |       |by starting|       |"3.2.S.3.2.5 Genotoxic   |
|         |                 |       |material   |       |Impurities" section for  |
|         |                 |       |YA2304-2   |       |relevant control         |
|         |                 |       |           |       |strategies)              |
|---------|-----------------|-------|-----------|-------|-------------------------|
|YA2304-39|3-hydroxypropioni|       |Impurity   |N/A    |no (The impurity has been|
|         |trile            |       |introduced |       |controlled by no more    |
|         |                 |       |by starting|       |than 5.0% in the starting|
|         |                 |       |material   |       |material YA2304-2 and is |
|         |                 |       |YA2304-2   |       |no longer controlled in  |
|         |                 |       |           |       |the finished product)    |
|---------|-----------------|-------|-----------|-------|-------------------------|
|YA2304-57|2-cyanoethyl     |       |Impurity   |N/A    |no (The impurity has been|
|         |acetate          |       |introduced |       |controlled by no more    |
|         |                 |       |by starting|       |than 2.0% in the starting|
|         |                 |       |material   |       |material YA2304-2 and is |
|         |                 |       |YA2304-2   |       |no longer controlled in  |
|         |                 |       |           |       |the finished product)    |
-----------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 88 of 542 





Page 89
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 





















-------------------------------------------------------------------------------------
|YA2304-40|2-chloro-5-methyl |       |Impurities  |NA     |no (Including warning    |
|         |-4-nitropyridine-n|       |introduced  |       |structure, see           |
|         |-oxide            |       |by starting |       |"3.2.S.3.2.5 Genotoxic   |
|         |                  |       |material    |       |Impurities" section for  |
|         |                  |       |YA2304-4    |       |relevant control         |
|         |                  |       |            |       |strategies)              |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-41|2-chloro-4-amino- |       |Impurity    |N/A    |no (Including warning    |
|         |5-methylpyridine  |       |introduced  |       |structure, see           |
|         |                  |       |by starting |       |"3.2.S.3.2.5 Genotoxic   |
|         |                  |       |material    |       |Impurities" section for  |
|         |                  |       |YA2304-4    |       |relevant control         |
|         |                  |       |            |       |strategies)              |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-1 |4-cyano-2-methox  |       |Incompletely|N/A    |no (Including warning    |
|         |ybenzaldehyde     |       |reacted star|       |structure, see           |
|         |                  |       |ting        |       |"3.2.S.3.2.5 Genotoxic   |
|         |                  |       |material in |       |Impurities" section for  |
|         |                  |       |the prep    |       |relevant control         |
|         |                  |       |aration of  |       |strategies)              |
|         |                  |       |in          |       |                         |
|         |                  |       |termediate Y|       |                         |
|         |                  |       |A2304-5     |       |                         |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-2 |2-cyanoacetoaceta |       |Incompletely|N/A    |no (The impurity has been|
|         |te ethyl ester    |       |reacted star|       |controlled not more than |
|         |                  |       |ting        |       |0.5% in the intermediate |
|         |                  |       |material in |       |YA2304-5 and is no longer|
|         |                  |       |the prep    |       |controlled in the        |
|         |                  |       |aration of  |       |finished product)        |
|         |                  |       |in          |       |                         |
|         |                  |       |termediate Y|       |                         |
|         |                  |       |A2304-5     |       |                         |
-------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 89 of 542 





Page 90
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















-----------------------------------------------------------------------------------
|YA2304-3 |2-cyanoethyl     |       |An incomple|N/A    |no (The impurity has been|
|         |2-(4-cyano-2-met |       |te         |       |controlled less than 1.0%|
|         |hoxybenzyl)      |       |intermedi  |       |in the intermediate      |
|         |-3-oxy-butyrate  |       |ate product|       |YA2304-5 and is no longer|
|         |                 |       |i n the    |       |controlled in the        |
|         |                 |       |prepar     |       |finished product)        |
|         |                 |       |ation of   |       |                         |
|         |                 |       |inte       |       |                         |
|         |                 |       |rmediate YA|       |                         |
|         |                 |       |2304-5     |       |                         |
|---------|-----------------|-------|-----------|-------|-------------------------|
|YA2304-4 |4-amino-5-methyl |       |Incomplete |N/A    |no (Including warning    |
|         |-2-hydroxypyridin|       |s tarting  |       |structure, see           |
|         |e                |       |mate rial  |       |"3.2.S.3.2.5 Genotoxic   |
|         |                 |       |for prep   |       |Impurities" section for  |
|         |                 |       |aration of |       |relevant control         |
|         |                 |       |in         |       |strategies)              |
|         |                 |       |termediate |       |                         |
|         |                 |       |Y A2304-5  |       |                         |
|---------|-----------------|-------|-----------|-------|-------------------------|
|YA2304-47|4-amino-5-methyl |       |Derived imp|N/A    |no (Including warning    |
|         |-2-methoxypyridi |       |urity of   |       |structure, see           |
|         |ne               |       |start ing  |       |"3.2.S.3.2.5 Genotoxic   |
|         |                 |       |material   |       |Impurities" section for  |
|         |                 |       |YA2304-4   |       |relevant control         |
|         |                 |       |           |       |strategies)              |
|---------|-----------------|-------|-----------|-------|-------------------------|
|YA2304-5 |4 - (4 - cyano - |       |During the |N/A    |no (The impurity has been|
|         |2 - methoxy      |       |p          |       |controlled not more than |
|         |phenyl) - 2, 8 - |       |reparation |       |0.3% in the intermediate |
|         |dimethyl - 5     |       |of         |       |YA2304-8, and is no      |
|         |-,4,5,6 oxygen   |       |intermediat|       |longer controlled in the |
|         |generation - 1-4 |       |e YA2304-8,|       |finished product)        |
|         |h - 1, 6 -       |       |the interme|       |                         |
|         |nalidixic - 3-2  |       |diate was  |       |                         |
|         |- ethyl cyano    |       |no t       |       |                         |
|         |formate          |       |completely |       |                         |
|         |                 |       |reacted    |       |                         |
-----------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 90 of 542 





Page 91
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















-----------------------------------------------------------------------------------------
|YA2304-6     |4 - (4 - cyano -  |       |Incomplete  |N/A    |no (The impurity has been|
|             |2 - methoxy       |       |i           |       |controlled not more than |
|             |phenyl) - 5 -     |       |ntermediate |       |0.3% in the intermediate |
|             |ethoxy - 2, 8 -   |       |product in  |       |YA2304-8, and is no      |
|             |dimethyl - 1,     |       |t he        |       |longer controlled in the |
|             |4-2 h - 1, 6 -    |       |preparati   |       |finished product)        |
|             |nalidixic - 3-2   |       |on of       |       |                         |
|             |- ethyl cyano     |       |interm      |       |                         |
|             |formate           |       |ediate      |       |                         |
|             |                  |       |YA230 4-8   |       |                         |
|-------------|------------------|-------|------------|-------|-------------------------|
|YA2304-7     |4-(4-cyano-2-met  |       |Incomplete  |N/A    |no (The impurity has been|
|             |hoxyphenyl)       |       |i           |       |controlled not more than |
|             |-5-ethoxy-2,      |       |ntermediate |       |0.15% in the intermediate|
|             |8-dimethyl-1,     |       |product in  |       |YA2304-8, and is no      |
|             |4-dihydro-1,      |       |t he        |       |longer controlled in the |
|             |6-nalididine-3-car|       |preparati   |       |finished product)        |
|             |boxylic acid      |       |on of       |       |                         |
|             |                  |       |interm      |       |                         |
|             |                  |       |ediate      |       |                         |
|             |                  |       |YA230 4-8   |       |                         |
|-------------|------------------|-------|------------|-------|-------------------------|
|YA2304-55    |4 - (4 - cyano -  |       |Incomplete  |N/A    |no (The impurity has been|
|             |2 - methoxy       |       |i           |       |controlled not more than |
|             |phenyl) - 2, 8 -  |       |ntermediate |       |0.20% in the intermediate|
|             |dimethyl - 5      |       |product in  |       |YA2304-8, and is no      |
|             |-,4,5,6 oxygen    |       |t he        |       |longer controlled in the |
|             |generation - 1-4  |       |preparati   |       |finished product)        |
|             |h - 1, 6 -        |       |on of       |       |                         |
|             |nalidixic - 3 -   |       |interm      |       |                         |
|             |carbonyl          |       |ediate      |       |                         |
|             |imidazole         |       |YA230 4-8   |       |                         |
|-------------|------------------|-------|------------|-------|-------------------------|
|4-dimethylami|4-dimethylaminop  |       |Reaction    |N/A    |no (Including warning    |
|nopyridine   |yridine (DMAP)    |       |rea gent in |       |structu re, see          |
|(DMAP)       |                  |       |the         |       |"3.2.S.3.4.2.5 Geno toxic|
|             |                  |       |synthesis   |       |Impurities" section fo r |
|             |                  |       |of          |       |relevant control         |
|             |                  |       |intermediate|       |strategie                |
|             |                  |       |YA2304-8    |       |                         |
-----------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 91 of 542 





Page 92
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 





















-------------------------------------------------------------------------------------
|         |                  |       |            |       |s)                       |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-10|D- (+)            |       |Resolution  |≤0.10%|is (Finished products are| 
|         |-dibenzoyltartaric|       |reagent in  |       |controlled according to  |
|         |acid              |       |the         |       |specific impurities)     |
|         |                  |       |synthesis   |       |                         |
|         |                  |       |of          |       |                         |
|         |                  |       |intermediate|       |                         |
|         |                  |       |YA2304-CP   |       |                         |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-12|4 - (4 - amino    |       |Side        |≤0.10%|is (Controlled by        | 
|         |formyl - 2 -      |       |reaction    |       |non-specific impurities  |
|         |methoxy phenyl)   |       |product in  |       |in finished product)     |
|         |- 5 - ethoxy -    |       |the         |       |                         |
|         |2, 8 - dimethyl   |       |synthesis   |       |                         |
|         |- 1, 4-2 h - 1,   |       |of the      |       |                         |
|         |6 - nalidixic -   |       |intermediate|       |                         |
|         |3 - formamide     |       |YA2304-CP   |       |                         |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-14|4 - (4 - cyano -  |       |Side        |≤0.15%|is (Finished products are| 
|         |2 - methoxy       |       |reaction    |       |controlled by specific   |
|         |phenyl) - 5 -     |       |products    |       |impurities)              |
|         |methoxy - 2, 8 -  |       |            |       |                         |
|         |dimethyl - 1,     |       |            |       |                         |
|         |4-2 h - 1, 6 -    |       |            |       |                         |
|         |nalidixic - 3 -   |       |            |       |                         |
|         |formamide         |       |            |       |                         |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-15|4 - (4 - cyano -  |       |Side        |≤0.15%|is (Finished products are| 
|         |2 - methoxy       |       |reaction    |       |controlled by specific   |
|         |phenyl) - 5-2 -   |       |products    |       |impurities)              |
|         |isopropyl oxygen  |       |            |       |                         |
|         |radicals, 8 -     |       |            |       |                         |
|         |dimethyl - 1,     |       |            |       |                         |
|         |4-2               |       |            |       |                         |
-------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 92 of 542 





Page 93
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 






























-------------------------------------------------------------------------------------
|         |h - 1, 6 -        |       |            |       |                         |
|         |nalidixic - 3 -   |       |            |       |                         |
|         |formamide         |       |            |       |                         |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-16|4-(4-cyano-2-met  |       |Side        |≤0.10%|is (Controlled by        | 
|         |hoxyphenyl)       |       |reaction    |       |non-specific impurities  |
|         |-5-methoxy-2,     |       |products    |       |in finished product)     |
|         |8-dimethyl-1,     |       |            |       |                         |
|         |4-dihydro-1,      |       |            |       |                         |
|         |6-nalididine-3-car|       |            |       |                         |
|         |boxylic acid      |       |            |       |                         |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-17|Benzoic acid      |       |A           |N/A    |no (The impurity is      |
|         |                  |       |by-product  |       |controlled as a specific |
|         |                  |       |in the      |       |impurity in the crude    |
|         |                  |       |synthesis   |       |product, the limit is not|
|         |                  |       |of the      |       |more than 0.15%, and the |
|         |                  |       |intermediate|       |finished product is no   |
|         |                  |       |YA2304-CP   |       |longer controlled)       |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-52|D-(+)-            |       |A           |N/A    |no (Has been in the      |
|         |monobenzoyl       |       |by-product  |       |finished Finerenone      |
|         |tartaric acid     |       |in the      |       |through multiple batches |
|         |                  |       |synthesis   |       |of statistical proof can |
|         |                  |       |of the      |       |be completely removed,   |
|         |                  |       |intermediate|       |the finished product is  |
|         |                  |       |YA2304-CP   |       |no longer controlled)    |
-------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 93 of 542 





Page 94
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 
























-------------------------------------------------------------------------------------
|YA2304-18|4 - (4 - cyano -  |       |Side        |≤0.10%|is (Controlled by        | 
|         |2 - methoxy       |       |reaction    |       |non-specific impurities  |
|         |phenyl) - 5-2 -   |       |products    |       |in finished product)     |
|         |isopropyl oxygen  |       |            |       |                         |
|         |radicals, 8 -     |       |            |       |                         |
|         |dimethyl - 1,     |       |            |       |                         |
|         |4-2 h - 1, 6 -    |       |            |       |                         |
|         |nalidixic - 3 -   |       |            |       |                         |
|         |formic acid       |       |            |       |                         |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-19|4-(4-cyano-2-met  |       |Side        |≤0.15%|is (Finished products are| 
|         |hoxyphenyl)       |       |reaction    |       |controlled by specific   |
|         |-5-ethoxy-2,      |       |products    |       |impurities)              |
|         |8-dimethyl-1,     |       |            |       |                         |
|         |6-nalididine-3-for|       |            |       |                         |
|         |mamide            |       |            |       |                         |
|---------|------------------|-------|------------|-------|-------------------------|
|YA2304-20|4 - (4 - (4 r) -  |       |enantiomers |≤0.15%|is (Finished products are| 
|         |cyano - 2 -       |       |            |       |controlled by specific   |
|         |methoxy phenyl)   |       |            |       |impurities)              |
|         |- 5 - ethoxy -    |       |            |       |                         |
|         |2, 8 - dimethyl   |       |            |       |                         |
|         |- 1, 4-2 h - 1,   |       |            |       |                         |
|         |6 - nalidixic -   |       |            |       |                         |
|         |3 - formamide     |       |            |       |                         |
|---------|------------------|-------|------------|-------|-------------------------|
|imidazole|Imidazole         |       |Reaction    |N/A    |no (has been completely  |
|         |                  |       |byproducts  |       |removed in the finished  |
|         |                  |       |and         |       |fineridone through       |
|         |                  |       |hydrolysates|       |multiple batches of      |
|         |                  |       |of CDI      |       |statistical proof, no    |
|         |                  |       |            |       |longer controlled in the |
|         |                  |       |            |       |finished product)        |
-------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 94 of 542 





Page 95
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 










































------------------------------------------------------------------------------------
|Dimethyl    |Dimethyl sulfate |       |Side    |≤75pp m|is (Including the warning| 
|sulfate     |                 |       |reaction|        |structure, the relevant  |
|            |                 |       |products|        |control strategy is      |
|            |                 |       |        |        |detailed in the section  |
|            |                 |       |        |        |"3.2.S.3.4.2.5 Genotoxic |
|            |                 |       |        |        |Impurities")             |
|------------|-----------------|-------|--------|--------|-------------------------|
|Diethyl     |Diethyl sulfate  |       |Side    |≤75pp m|is (Including the warning| 
|sulfate     |                 |       |reaction|        |structure, the relevant  |
|            |                 |       |products|        |control strategy is      |
|            |                 |       |        |        |detailed in the section  |
|            |                 |       |        |        |"3.2.S.3.4.2.5 Genotoxic |
|            |                 |       |        |        |Impurities")             |
|------------|-----------------|-------|--------|--------|-------------------------|
|Diisopropyl |Diisopropyl      |       |Side    |≤75pp m|is (Including the warning| 
|sulfate     |sulfate          |       |reaction|        |structure, the relevant  |
|            |                 |       |products|        |control strategy is      |
|            |                 |       |        |        |detailed in the section  |
|            |                 |       |        |        |"3.2.S.3.4.2.5 Genotoxic |
|            |                 |       |        |        |Impurities")             |
|------------|-----------------|-------|--------|--------|-------------------------|
|Di-sec-butyl|Di-sec-butyl     |       |Side    |≤75pp m|is (Including the warning| 
|sulfate     |sulfate          |       |reaction|        |structure, the relevant  |
|            |                 |       |products|        |control strategy is      |
|            |                 |       |        |        |detailed in the section  |
|            |                 |       |        |        |"3.2.S.3.4.2.5 Genotoxic |
|            |                 |       |        |        |Impurities")             |
|------------|-----------------|-------|--------|--------|-------------------------|
|NDMA        |N-nitrosodimethyl|N N O  |Side    |N/A     |no (No longer controlled |
|            |amine            |       |reaction|        |in finished fineridone   |
|            |                 |       |product |        |after                    |
------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 95 of 542 





Page 96
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 

































----------------------------------------------------------------------------------
|       |                  |          |        |       |multiple batch statistics|
|       |                  |          |        |       |prove non-existence)     |
|-------|------------------|----------|--------|-------|-------------------------|
|NDEA   |N-nitrosodiethyla |N N O     |Side    |N/A    |no (No longer controlled |
|       |mine              |          |reaction|       |in finished fineridone   |
|       |                  |          |products|       |after multiple batch     |
|       |                  |          |        |       |statistics prove         |
|       |                  |          |        |       |non-existence)           |
|-------|------------------|----------|--------|-------|-------------------------|
|NDIPA  |N-nitrosodiisopro |N N O     |Side    |N/A    |no (No longer controlled |
|       |pylamine          |          |reaction|       |in finished fineridone   |
|       |                  |          |products|       |after multiple batch     |
|       |                  |          |        |       |statistics prove         |
|       |                  |          |        |       |non-existence)           |
|-------|------------------|----------|--------|-------|-------------------------|
|NDBA   |N-nitrosodibutyla |N N O     |Side    |N/A    |no (No longer controlled |
|       |mine              |          |reaction|       |in finished fineridone   |
|       |                  |          |products|       |after multiple batch     |
|       |                  |          |        |       |statistics prove         |
|       |                  |          |        |       |non-existence)           |
|-------|------------------|----------|--------|-------|-------------------------|
|NIEPA  |N-nitrosoethylisop|N N O     |Side    |N/A    |no (No longer controlled |
|       |ropylamine        |          |reaction|       |in finished fineridone   |
|       |                  |          |products|       |after multiple batch     |
|       |                  |          |        |       |statistics prove         |
|       |                  |          |        |       |non-existence)           |
|-------|------------------|----------|--------|-------|-------------------------|
|NMBA   |N-nitroso-methyl- |OH N N O O|Side    |N/A    |no (No longer controlled |
|       |4-aminobutyric    |          |reaction|       |in finished fineridone   |
|       |acid              |          |products|       |after multiple batch     |
|       |                  |          |        |       |statistics prove         |
|       |                  |          |        |       |non-existence)           |
----------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 96 of 542 





Page 97
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 



























------------------------------------------------------------------------------------
|NMPA   |N-nitrosotoluidine|N N O        |Side    |N/A    |no (No longer controlled|
|       |                  |             |reaction|       |in finished fineridone  |
|       |                  |             |products|       |after multiple batch    |
|       |                  |             |        |       |statistics prove        |
|       |                  |             |        |       |non-existence)          |
|-------|------------------|-------------|--------|-------|------------------------|
|NDPA   |N-nitrosodipropyl |H3C N H3C N O|Side    |N/A    |no (No longer controlled|
|       |amine             |             |reaction|       |in finished fineridone  |
|       |                  |             |products|       |after multiple batch    |
|       |                  |             |        |       |statistics prove        |
|       |                  |             |        |       |non-existence)          |
------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 97 of 542 





Page 98
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



（ **1** ） **YA2304-39** 



YA2304-39 is the incomplete raw material in the synthesis of the starting 



material YA2304-2. Its molecular structure formula is as follows: 



The Applicant intends to control YA2304-39 as a specific impurity by no 



more than 5.0% in the starting material YA2304-2 and calculate the impurity 



content by self-comparison method with correction factor. Refer to the 



validation report of YA2304-2 Related Substance Methodology under item 



3.2.2.3.6.1 that YA2304-39 has a correction factor of 0.9 relative to 



YA2304-2. At the same time, the reasonability of the impurity limit in the 



standard of the applicant's design of the impurity experiment is investigated. 



The investigation results show that the removal capacity of the registered 



process for impurity YA2304-39 is NLT 5.0%. The experimental process is 



detailed in section 3.2.S.2.3.5.2. Therefore, impurity YA2304-39 is no longer 



controlled in the finished Finerenone. 



（ **2** ） **YA2304-57** 



YA2304-57 is a by-product in the synthesis of the starting material YA2304-2. 



Its molecular structure formula is as follows: 



The applicant intends to control YA2304-57 as a specific impurity in the 



starting material YA2304-2 by no more than 2.0% and calculate the impurity 



content by self-comparison method with correction factor. Refer to the 



validation report of YA2304-2 Related Substance Methodology under item 



3.2.2.3.6.1 that YA2304-57 has a correction factor of 0.9 relative to 



YA2304-2. At the same time, the applicant designed an experiment to 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 98 of 542 





Page 99
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



investigate the reasonability of the impurity limit in the standard for adding 



impurities, and the investigation results show that the removal capacity of 



the registered process for impurity YA2304-57 is NLT 2.0%. The experimental 



process is detailed in section 3.2.S.2.3.5.2. Therefore, the impurity 



YA2304-57 is no longer controlled in the finished Finerenone. 



**(3) YA2304-2** 



YA2304-2 is the incomplete starting material in Finerenone synthesis. Its 



molecular structure formula is as follows: 



The applicant intends to use YA2304-2 as a specific impurity in the 



intermediate YA2304-5 to control no more than 0.5%, and calculate the 



impurity content by external standard method. At the same time, the 



applicant designed an experiment to investigate the rationality of the 



impurity limit in the standard for adding impurities, and the investigation 



results show that the removal capacity of the registration process for 



impurity YA2304-2 is NLT 0.5%. The experimental process is detailed in 



section 3.2.S.2.4.3.1.1. Therefore, impurity YA2304-2 is no longer controlled 



in the finished Finerenone. 



**(4) YA2304-3** 



YA2304-3 is an intermediate product in the synthesis of the intermediate 



YA2304-5. Its molecular structure formula is as follows: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 99 of 542 





Page 100
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The applicant intends to control YA2304-3 as a specific impurity not 



exceeding 1.0% in the intermediate YA2304-5, and calculate the impurity 



content by self-comparison method with correction factor. Refer to the 



validation report of YA2304-5 on Substance Methodology under item 



3.2.S.2.4.3.1.3.1 that YA2304-3 has a correction factor of 2.4 relative to 



YA2304-5. At the same time, the reasonableness of the impurity limit in the 



test standard for impurity addition designed by the applicant shows that the 



removal ability of the registration process for impurity YA2304-3 is NLT 1.0%. 



The experimental process is detailed in section 3.2.S.2.4.3.1.1. Therefore, 



impurity YA2304-3 is no longer controlled in the finished finalizone. 



**(5) YA2304-5** 



YA2304-5 is an intermediate in Finerenone synthesis. Its molecular 



structure formula is as follows: 



The applicant intends to control YA2304-5 as a specific impurity not 



exceeding 0.3% in the intermediate YA2304-8, and calculate the impurity 



content by self-comparison method with correction factor. Refer to the 



validation report of YA2304-8 on Substance Methodology under item 



3.2.S.2.4.3.2.3. The correction factor of YA2304-5 relative to YA2304-8 is 1.2. 



At the same time, the reasonability of the impurity limit in the test standard 



for impurity addition designed by the applicant shows that the removal 



capacity of the registration process for impurity YA2304-5 is NLT 0.3%, and 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 100 of 542 





Page 101
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



the experimental process is detailed in section 3.2.S.2.4.3.2.1. Therefore, 



impurity YA2304-5 is no longer controlled in the finished Finerenone. 



**(6) YA2304-6** 



YA2304-6 is an intermediate product in the synthesis of the intermediate 



YA2304-8. Its molecular structure formula is as follows: 



The applicant intends to control YA2304-6 as a specific impurity not 



exceeding 0.3% in the intermediate YA2304-8, and calculate the impurity 



content by self-comparison method with correction factor. Refer to the 



validation report of YA2304-8 Related Substance Methodology under item 



3.2.S.2.4.3.2.3, YA2304-6 has a correction factor of 1.1 relative to YA2304-8. 



At the same time, the reasonability of the impurity limit in the test standard 



for impurity addition designed by the applicant shows that the removal 



capacity of the registration process for impurity YA2304-6 is NLT 0.3%, and 



the experimental process is detailed in section 3.2.S.2.4.3.2.1. Therefore, 



impurity YA2304-6 is no longer controlled in the finished Finerenone. 



**(7) YA2304-7** 



YA2304-7 is an intermediate product in the synthesis of the intermediate 



YA2304-8. Its molecular structure formula is as follows: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 101 of 542 





Page 102
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The applicant intends to control YA2304-7 as a specific impurity not 



exceeding 0.15% in the intermediate YA2304-8, and calculate the impurity 



content by self-comparison method with correction factor. Refer to the 



validation report of YA2304-8 Related Substance Methodology under item 



3.2.S.2.4.3.2.3. It can be seen that YA2304-7 has a correction factor of 1.0 



relative to YA2304-8. At the same time, the applicant designed an impurity 



addition experiment to investigate the reasonability of the impurity limit in 



the standard. The experimental process is detailed in section 3.2.S.2.4.3.2.1. 



Therefore, impurity YA2304-7 is no longer controlled in the finished 



Finerenone. 



**(8) YA2304-55** 



YA2304-55 is an intermediate product in the synthesis of the intermediate 



YA2304-8. Its molecular structure formula is as follows: 



The applicant intends to control YA2304-55 as a specific impurity not 



exceeding 0.20% in the intermediate YA2304-8, and calculate the impurity 



content by self-comparison method with correction factor. Refer to the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 102 of 542 





Page 103
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



validation report of YA2304-8 on Substance Methodology under item 



3.2.S.2.4.3.2.3 that YA2304-55 has a correction factor of 1.2 relative to 



YA2304-8. At the same time, the reasonability of the impurity limit in the test 



standard designed by the applicant for adding impurities shows that the 



removal capacity of the registered process for impurity YA2304-55 is NLT 



0.20%, and the impurity limit meets the process requirements. The 



experimental process is detailed in section 3.2.S.2.4.3.2.1. Therefore, 



impurity YA2304-55 is no longer controlled in the finished Finerenone. 



**(9) YA2304-10** 



YA2304-10 is the resolution reagent in the synthesis of intermediate 



YA2304-CP. Its molecular structure formula is as follows: 



The applicant intends to control the impurity YA2304-10 as a specific 



impurity in the finished Finerenonee, with the limit of not exceeding the 



identification threshold of 0.10%, and calculate the peak area according to 



the external standard method. 



**(10) YA2304-12** 



YA2304-12 is a possible by-product in the synthesis of intermediate 



YA2304-CP, and the impurity may be produced by hydrolysis of Finerenone 



under acidic or alkaline conditions. According to the degradation 



experimental data in 3.2.S.4.3.1 Methodology-verification of related 



substances of the finished product, Finerenone did not degrade impurity 



YA2304-12 under weak acid (destruction by 2mL of 0.1mol/l hydrochloric 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 103 of 542 





Page 104
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



acid for 24h). The known impurity YA2304-12 (content 0.07%) was mainly 



produced by the degradation of Finerenone under the condition of weak base 



(destruction of 2mL of 0.1mol/l sodium hydroxide for 24h). Its molecular 



structure formula and chemical reaction process are as follows: 



The Applicant initially controlled impurity YA2304-12 as a specific impurity 



in the finished Finerenonee to a limit of 0.15% above the defined threshold. 



Refer to the Validation report of the Methodology for the Analysis of 



Substances in 3.2.S.4.3.1 that YA2304-12 has a correction factor of 1.2 



relative to Finerenone. The applicant tested three commercial-scale batches 



of Finerenone (batch No. 231201, 240101 and 240102) by the method of 



substance related, and no impurity YA2304-12 was detected in each sample. 



For specific test data, please refer to Table 3.2.S.3.3.2.1 -2. In addition, the 



impurity was also investigated by the applicant in the stability study. See 



3.2.S.7.3 stability data for the above three commercial-scale batch 



Finerenone apis under accelerated stability test conditions (temperature 40 ° 



C ±2 ° C; Humidity 75%±5%) and long-term stability test conditions 



(temperature 30℃±2℃, relative humidity RH65%±5%) for 6 months, the 



impurity YA2304-12 was not detected, indicating that the Finerenone raw 



material will not produce impurity YA2304-12 during stable placement. 



Therefore, the applicant finally controlled the impurity YA2304-12 in the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 104 of 542 





Page 105
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



finished product as a non-specific impurity to not exceed the identification 



threshold of 0.10%. 



**(11) YA2304-14, YA2304-15 and YA2304-16, YA2304-18** 



Impurity formation path and mutual conversion relationship of YA2304-14, 



YA2304-15 and YA2304-16 and YA2304-18 are as follows: 



① Triethyl orthoacetate may contain a small amount of methyl and isopropyl 



substituted impurities, and YA2304-50 and YA2304-51 can be formed by 



alkylation reaction with YA2304-5, and YA2304-16 and YA2304-18 can be 



formed by hydrolysis reaction in the following steps. And then the 



corresponding derivatives YA2304-14 and YA2304-15 are generated by 



ammonolysis. 



② In the presence of methanol and isopropyl alcohol, Finerenone may also 



generate impurities YA2304-14 and YA2304-15 by ether exchange, 



respectively. 



③YA2304-14 and YA2304-15 may be hydrolyzed under acidic conditions to 



produce impurities YA2304-16 and YA2304-18, respectively. 



The molecular structure formula and chemical reaction process of each 



impurity are as follows: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 105 of 542 





Page 106
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Impurities YA2304-14 and YA2304-15 are process impurities that are finally 



converted in the finished product. The original research import registration 



preparation standard JX20220072 controls these two impurities (the code of 



the impurity in the import registration standard is BAY1814286 and 



BAY1814288, respectively) as non-specific impurities shall not exceed 0.2%. 



The applicant intends to more strictly control the impurities YA2304-14 and 



YA2304-15 as specific impurities in the finished Finerenone, which shall not 



exceed the defined threshold of 0.15%. 



The Applicant originally controlled the impurities YA2304-16 and YA2304-18 



as specific impurities in the finished finnalidone to the extent that they both 



did not exceed the defined threshold of 0.15%. Refer to the 3.2.S.4.3.1 



Validation Report on the Methodology of Substance Analysis that YA2304-16 



has a correction factor of 1.0 with respect to Finerenone and YA2304-18 has 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 106 of 542 





Page 107
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



a correction factor of 1.1 with respect to Finerenone. The applicant tested 



three commercial-scale batches of Finerenone (batch No. 231201, 240101 



and 240102) by using the substance related method. Impurities YA2304-16 



and YA2304-18 in each sample were not detected. For specific test data, 



please refer to Table 3.2.S. In addition, the impurity was also investigated by 



the applicant in the stability study. See 3.2.S.7.3 stability data for the above 



three commercial-scale batch Finerenone apis under accelerated stability 



test conditions (temperature 40 ° C ±2 ° C; Humidity 75%±5%) and long-term 



stability test conditions (temperature 30℃±2℃, relative humidity 



RH65%±5%) for 6 months, impurities YA2304-16 and YA2304-18 were not 



detected. It indicated that the impurities YA2304-16 and YA2304-18 would 



not be produced during the stable placement of Finerenone. As a result, the 



applicant ultimately controls the impurities YA2304-16 and YA2304-18 as 



non-specific impurities in the finished product without exceeding the 



identification threshold of 0.10%. 



**(12) YA2304-17 and YA2304-52** 



Impurities YA2304-17 and YA2304-52 are hydrolyzed products of the 



resolution reagent YA2304-10 (D-(+) -dibenzoyltartaric acid), and their 



molecular structure formula and chemical reaction process are as follows: 



The applicant initially controlled the impurity YA2304-17 as a specific 



impurity in the finished Finerenone, with the limit not exceeding the defined 



threshold of 0.15%, and calculated according to the external standard 



method. The Applicant tested three commercial-scale batches of Finerenone 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 107 of 542 





Page 108
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



No. 231201, 240101 and 240102 by the method of substance related, and no 



impurity YA2304-17 was detected in each sample. For specific test data, 



please refer to Table 3.2.S. In addition, the impurity was also investigated by 



the applicant in the stability study. Refer to the stability data of 3.2.S.7.3, it 



can be seen that the above three batches of commercial-scale mass produced 



Finerenone apis were placed under accelerated stability test conditions 



(temperature 40℃±2℃, humidity 75%±5%) and long-term stability test 



conditions (temperature 30℃±2℃, relative humidity RH65%±5%) for 6 



months. Impurity YA2304-17 was also not detected, indicating that the 



impurity YA2304-17 would not be produced during the stable placement of 



the Finerenone bulk drug. In summary, the registered process has a good 



ability to remove impurity YA2304-17 and does not degrade during the 



stability period to produce impurity YA2304-17. The applicant intends to 



eventually use impurity YA2304-17 as a specific impurity in the crude 



product, which shall not exceed the defined threshold of 0.15% and shall not 



control impurity YA2304-17 in the finished product. 



The applicant tested three commercial-scale batches of Finerenone No. 



231201, 240101 and 240102 by using the Substance II method. No impurity 



YA2304-52 was detected in each sample. For specific test data, please refer to 



Table 3.2.S. The test results showed that the registered process had a good 



ability to remove impurity YA2304-52. Therefore, the applicant does not 



control the impurity YA2304-52 in the finished product. 



**(13) YA2304-19** 



YA2304-19 is the oxidative degradation product in the process of preparing 



YA2304-CP. Its molecular structure formula and chemical reaction process 



are as follows: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 108 of 542 





Page 109
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The impurity (the code of the impurity in the import registration standard is 



BAY1040818) shall not be controlled more than 0.5% as a specific impurity 



in the original research import registration preparation standard 



JX20220072, and the applicant intends to use the impurity as a specific 



impurity in the finished Finerenonee to more strictly control that the 



impurity shall not exceed the defined threshold of 0.15%. Refer to the 



validation report of 3.2.S.4.3.1 Related Substance analysis Methodology, 



YA2304-19 has a correction factor of 0.7 relative to Finerenone. 



（ **14** ） **YA2304-20** 



YA2304-20 is the enantiomer impurity of the finished product. The chemical 



structure formula is as follows: 



The impurity was not controlled in JX20220072, the standard for imported 



registered preparations of the original research. The applicant intends to 



control the impurity as a specific impurity not exceeding the defined 



threshold value of 0.15% in the quality standard of Finerenone, and calculate 



the content of the impurity according to the external standard method. 



**(15) Imidazole** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 109 of 542 





Page 110
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Imidazole is the by-product of the reaction and the hydrolyzed product of 



reagent CDI. The applicant tested three commercially-produced batches of 



Finerenone No. 231201, 240101 and 240102 by the method of Substance II. 



No imidazole was detected in each sample. For specific test data, please refer 



to Table 3.2.S. The test results showed that the registered process had a good 



scavenging ability for imidazole. Therefore, the applicant does not control the 



imidazole in the finished product. 



**(16) Unknown degradation impurities** 



Refer to the degradation experimental data in 3.2.S.4.3.1 Methodological 



verification of finished product related substances. Under the condition of 



destruction by weak acid (destruction by 2mL of 0.1mol/l hydrochloric acid 



for 24h), the raw material of Finerenone mainly degraded to produce known 



impurities YA2304-16 (content < 0.05%) and unknown impurities of 



RRT≈0.59 (content 2.02%). The known impurity YA2304-12 (content 0.07%) 



was mainly degraded under the condition of weak base (destruction of 2mL of 



0.1mol/l sodium hydroxide for 24h). The degradation of Finerenone under 



oxidation destruction (2mL destruction of 3% hydrogen peroxide for 24h) 



mainly produced unknown impurities YA2304-19 (content 0.12%) and 



RRT≈0.64 (content 0.43%). The solid samples of Finerenone were destroyed 



by light (4500±500Lux, 90±5μWcm [2] for 30d) degradation mainly produced 5 



known impurities YA2304-14, YA2304-15, YA2304-16, YA2304-17, 



YA2304-19, and unknown impurities with RRT≈1.53 (content of 0.05%). The 



5 known impurities produced by degradation except the impurity YA2304-19 



content of 0.17%, the other known impurities produced by degradation 



content of < 0.05%; Two known impurities, YA2144-16 and YA2144-19, and 



three unknown impurities, RRT≈0.64, RRT≈0.87 and RRT≈0.96, were mainly 



produced by the degradation of fenelidone bulk drug solution by light 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 110 of 542 





Page 111
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



(4500±500Lux, 90±5μWcm [2] destroying the test product solution for 24h). 



The contents of YA2304-16 and YA2304-19 produced by degradation were < 



0.05% and 0.54%, and the contents of RRT≈0.64, RRT≈0.87 and RRT≈0.96 



produced by degradation were 0.06%, 0.06% and 0.08%, respectively. These 



unknown impurities can be effectively separated by the method of related 



substances. Under other conditions, the unknown impurities were not 



degraded in the samples. 



3.S.7.3 Accelerated Stability Test and long-term stability test data showed 



that three commercial-scale batches of Finerenone 231201, 240101 and 



240102 were subjected to accelerated stability test at 6 months (temperature 



40℃±2℃, All impurities during the relative humidity RH75%±5% and the 



6-month long-term stability test (temperature 30℃±2℃, relative humidity 



RH65%±5%) were in line with the internal control standards, and no new 



unknown degradation impurities were produced. 



In accordance with the provisions of ICHQ1A(R2) section 2.1.2: If some 



degradation products of the degradation test have been confirmed to be not 



generated under accelerated or long-term stability test conditions, it is not 



necessary to control the impurity. Therefore, the Applicant shall not control 



the said unknown degradation impurity as a specific impurity in the finished 



product and shall not exceed the identification threshold of 0.10% as a 



non-specific impurity. 



**Detection of potential organic impurities in commercial-scale mass** 



**production of Finerenone** 



The detection of potential organic impurities in three commercial-scale b 



atches of Finerenone with batch NO.s 231201, 240101 and 240102 are 



shown in Table 3.2.S. 4.1-2. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 111 of 542 





Page 112
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.3.2.1-2 Detection of each potential organic impurity in Finer 



















-----------------------------------------------------------------
|Batch No. Impurity name |231201      |240101      |240102      |
|------------------------|------------|------------|------------|
|Related    |YA2304-10   |Not detected|Not detected|Not detected|
|subs tance |            |            |            |            |
|           |------------|------------|------------|------------|
|           |YA2304-12   |Not detected|Not detected|Not detected|
|           |------------|------------|------------|------------|
|           |YA2304-14   |Not detected|Not detected|Not detected|
|           |------------|------------|------------|------------|
|           |YA2304-15   |Not detected|Not detected|< 0.05%     |
|           |------------|------------|------------|------------|
|           |YA2304-16   |Not detected|Not detected|Not detected|
|           |------------|------------|------------|------------|
|           |YA2304-17   |Not detected|Not detected|Not detected|
|           |------------|------------|------------|------------|
|           |YA2304-18   |Not detected|Not detected|Not detected|
|           |------------|------------|------------|------------|
|           |YA2304-19   |< 0.05%     |< 0.05%     |< 0.05%     |
|           |------------|------------|------------|------------|
|           |Other single|< 0.05%     |< 0.05%     |< 0.05%     |
|           |i mpurities |            |            |            |
|           |------------|------------|------------|------------|
|           |Total       |< 0.05%     |< 0.05%     |< 0.05%     |
|           |Miscella    |            |            |            |
|           |neous       |            |            |            |
|-----------|------------|------------|------------|------------|
|Related Sub|YA2304-52   |Not detected|Not detected|Not detected|
|stance II  |            |            |            |            |
|           |------------|------------|------------|------------|
|           |Imidazole   |Not detected|Not detected|Not detected|
|-----------|------------|------------|------------|------------|
|Enantiomer |YA2304-20   |0.03%       |0.03%       |0.02%       |
-----------------------------------------------------------------

**3.2.S.3.2.2 Inorganic Impurities** 



Inorganic impurities in Finerenone may originate from reaction reagents, 



catalysts used in the production process, and inorganic salts used in the 



post-treatment process. For inorganic impurities that may be introduced into 



the starting material, the applicant intends to set up a incandescent residue 



item in each starting material quality standard to control inorganic 



impurities. Therefore, the applicant combined with 3.2.S.2.2.3 process 



description to analyze and study the inorganic impurities in the process of 



Finerenone preparation, and formulated the corresponding control strategy, 



as detailed in Table 3.2.S.3.2.2-1. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 112 of 542 





Page 113
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.3.2.2-1 Analysis and Control Strategies of Inorganic Impurities in 


















---------------------------------------------------------------------------
|Names of  |Impurity source and removal analysis   |Control     |Is the   |
|Impurities|                                       |Limits      |negatio n|
|          |                                       |            |of entry |
|          |                                       |            |criteria |
|----------|---------------------------------------|------------|---------|
|Sodium    |Sodium acetate is the reagent used in  |Incandescent|is       |
|acetate   |step 2. This impurity is soluble in    |residue     |         |
|          |water and can be removed by subsequent |≤0.1%      |         | 
|          |washing and crystallization processes. |            |         |
|          |The applicant intends to control sodium|            |         |
|          |acetate by burning residue.            |            |         |
|----------|---------------------------------------|------------|---------|
|Sulfuric  |Sulfuric acid is the reagent used in   |Incandescent|is       |
|acid      |step 2 and is converted to sodium      |residue     |         |
|          |sulfate. Sodium sulfate dissolves      |≤0.1%      |         | 
|          |easily in water and can be removed by  |            |         |
|          |subsequent washing and crystallization |            |         |
|          |processes. The applicant intends to    |            |         |
|          |control sodium sulfate by burning      |            |         |
|          |residue.                               |            |         |
|----------|---------------------------------------|------------|---------|
|Sodium    |Sodium hydroxide is the reagent used in|Incandescent|is       |
|hydroxide |step 2, which can be converted into    |residue     |         |
|          |sodium chloride. Sodium chloride is    |≤0.1%      |         | 
|          |soluble in water and can be removed by |            |         |
|          |subsequent washing and crystallization |            |         |
|          |processes. The applicant intends to    |            |         |
|          |control sodium chloride by burning     |            |         |
|          |residue.                               |            |         |
|----------|---------------------------------------|------------|---------|
|Hydrochlo |Hydrochloric acid is the reagent used  |Incandescent|is       |
|ric acid  |in step 2 and is converted to sodium   |residue     |         |
|          |chloride. Sodium chloride is soluble in|≤0.1%      |         | 
|          |water and can be removed by subsequent |            |         |
|          |washing and crystallization processes. |            |         |
|          |The applicant intends to control sodium|            |         |
|          |chloride by burning residue.           |            |         |
|----------|---------------------------------------|------------|---------|
|Sodium    |Sodium phosphate is the reagent used in|Burning     |is       |
|phosphate |Step 3 that is partially converted to  |residue     |         |
|          |convert disodium hydrogen phosphate    |≤0.1%      |         | 
|          |after the base is modulated in step 3. |            |         |
|          |The impurities of                      |            |         |
---------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 113 of 542 





Page 114
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



disodium hydrogen phosphate and sodium 



phosphate are soluble in water and can be 



removed by subsequent washing and 



crystallization processes. The applicant 



intends to control disodium hydrogen 



phosphate and sodium phosphate through 



incandescent residue. 



**Chlorides and sulfates** 



Finerenone can remove trace amounts of chloride and sulfate that may 



remain after multiple washing, filtration, and recrystallization processes. The 



applicant has tested the chlorides and sulfates of multiple batches of 



commercial-scale mass-produced Finerenone in accordance with General 



Rules 0801 and 0802 of Part 4 of the 2020 Edition of the Chinese 



Pharmacopoeia. The test results of chloride and sulfate are not more than 



0.02%, and the test results of sulfate are not more than 0.1%, as detailed in 



Table 3.2.S.3.2.2-2. Since the incandescent residue can also control chloride 



and sulfate, the applicant intends not to set up a test item for chloride and 



sulfate in the finished product standard. 



**The detection of various inorganic impurities in commercial-scale batch** 



**production of Finerenone** 



The applicant has tested the burning residue, chloride and sulfate of three 



batches of commercial-scale mass produced Finerenone (batch No. 231201, 



240101 and 240102 respectively), and the test results all meet the 



requirements of the standard. The test results are shown in Table 



3.2.S.3.2.2-2. 



Table 3.2.S.3.2.2-2 Statistics of detection data of inorganic impurities in 



Finerenone 













Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 114 of 542 





Page 115
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 

-------------------------------------------------
|Incandescent residue|conforms|conforms|conforms|
|≤0.1%              |        |        |        | 
|--------------------|--------|--------|--------|
|Chloride ≤0.02%    |conforms|conforms|conforms| 
|--------------------|--------|--------|--------|
|Sulfate ≤0.1%      |conforms|conforms|conforms| 
-------------------------------------------------



**3.2.S.3.2.3 Residual solvents** 



Solvent Control Strategies". It intends to control triethylamine in starting 



material YA2304-2 with reference to ICHQ3C(R9) and the four General Rules 



The residual solvents that may be introduced into starting material 



YA2304-1 are acetone, N, N-dimethylformamide, dichloromethane, ethanol, 



methanol and methyl tert-butyl ether, the residual solvents that may be 



introduced into starting material YA2304-2 are ethyl acetate and 



triethylamine, and the residual solvents that may be introduced into starting 



material YA2304-2 are methanol and ethanol. In the preparation of 



Finerenonee, the applicant used eight dissolution reagents, including 



piperidine, acetic acid, isopropyl alcohol, secondary butanol, 



n-methylpyrrolidone, toluene, tetrahydrofuran and ethanol. The reagent was 



triethyl acetate reaction and hydrolysis to produce ethanol and ethyl acetate, 



and a trace amount of benzene may be introduced into the solvent acetone, 



toluene and ethanol. 



In summary, 16 residual solvents such as acetone, N, N-dimethylformamide, 



dichloromethane, ethanol, methyl tert-butyl ether, ethyl acetate, 



triethylamine, methanol, acetic acid, piperidine, isopropyl alcohol, secondary 



butanol, n-methylpyrrolidone, toluene, tetrahydrofuran and benzene may be 



present in the finished finnalidone. The applicant intends to control 



acetone,N, N-dimethylformamide, dichloromethane, methanol and methyl 



tert-butyl ether in starting material YA2304-1 with reference to ICHQ3C(R9) 



and the Four General Rules 0861 of the 2020 edition of the Chinese 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 115 of 542 





Page 116
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Pharmacopoeia. The relevant control strategies are detailed in section 



3.2.S.2.3.3.2 "Residual0861 of the 2020 edition of the Chinese 



Pharmacopoeia. The relevant control strategies are detailed in section 



3.2.S.2.3.5.2 "Residual Solvent Control Strategy"; It is proposed to control 



methanol in starting material YA2304-4 with reference to ICHQ3C(R9) and 



General Rules 0861 of the fourth part of the 2020 edition of Chinese 



Pharmacopoeia. The relevant control strategies are detailed in section 



3.2.S.2.3.7.2 "Residual Solvent Control Strategy"; Acetic acid is the reagent 



used in step 1, which can be easily removed by dissolving in aqueous 



solution with alkali-forming inorganic salts in subsequent steps, and the 



applicant intends not to conduct research control on it; For the remaining 



residual solvents, the applicant classifies them with reference to ICHQ3C(R9) 



and the fourth General Rule 0861 of the 2020 edition of the Chinese 



Pharmacopoeia, and formulates the corresponding control limits, as detailed 



in Table 3.2.S.3.2.3-1. 



Table 3.2.S.3.2.3-1 Classification and control limits of residual solvents 

























----------------------------------------------------------------
|Name of solvent   |Steps to use              |Solvent|Limits  |
|                  |                          |classif|        |
|                  |                          |ication|        |
|------------------|--------------------------|-------|--------|
|Ethyl acetate     |Starting material YA2304-2|Class 3|≤0.5%  | 
|                  |i s introduced, reagent   |       |        |
|                  |triethyl orthoacetate     |       |        |
|                  |reaction and h ydrolysis  |       |        |
|------------------|--------------------------|-------|--------|
|Isopropyl alcohol |Steps 1                   |Class 3|≤0.5%  | 
|------------------|--------------------------|-------|--------|
|sec-butanol       |Step 1                    |Class 3|≤0.5%  | 
|------------------|--------------------------|-------|--------|
|N-methylpyrrolidon|Step 2                    |Class 2|≤0.053%| 
|e                 |                          |       |        |
|------------------|--------------------------|-------|--------|
|Toluene           |Step 2                    |Class 2|≤0.089%| 
|------------------|--------------------------|-------|--------|
|tetrahydrofuran   |Step 2                    |Class 2|≤0.072%| 
|------------------|--------------------------|-------|--------|
|Ethanol           |Steps 1,3,4               |Class 3|≤0.5%  | 
|------------------|--------------------------|-------|--------|
|Piperidine        |Steps 1                   |Class 4|≤0.1%  | 
----------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 116 of 542 





Page 117
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 




benzene Toluene and ethanol introdu 



ced 




≤0.0002% 




Class 1 




The applicant has developed two sets of GC methods and one set of HP 



LC methods to detect the residual solvent of the finished product, one s 



et of GC methods to detect ethyl acetate, ethanol, isopropyl alcohol, sec 



ondary butanol, tetrahydrofuran, toluene, n-methylpyrrolidone, the other 



set of GC methods to detect benzene, and one set of HPLC methods to 



detect piperidine. At the same time, the applicant has carried out syste 



matic methodological verification on the above three sets of residual sol 



vent methods, and the verification results show that the method is spec 



ific, linear and has a good recovery rate. The quantification limit of etha 



nol is 0.01%, the quantification limit of isopropanol is 0.01%, the quant 



ification limit of ethyl acetate is 0.01% and the quantification limit of se 



condary butanol is 0.008%. The limit of quantification of tetrahydrofura 



n is 0.007%, the limit of quantification of toluene is 0.004%, the limit o 



f quantification of N-methylpyrrolidone is 0.006%, the limit of quantifica 



tion of benzene is 0.000053% and the limit of quantification of piperidin 



e is 0.01%, all of which are far below the standard control limit. See 3. 



2.S.4.3.4, 3.2.S.4.3.5 and 3.2.S.4.3.6 for the relevant methodological vali 



dation. 



**Detection of residual solvents in commercial-scale batch production** 



**of Finerenone** 



The applicant has tested the residual solvent of three batches of comme 



rcial-scale mass produced Finerenone (batch No. 231201, 240101 and 2 



40102 respectively), and the test results all meet the standard requirem 



ents. The detection information is shown in Table 3.2.S.3.2.3-2. 



Table 3.2.S.3.2.3-2 Test data of residual solvent in Finerenone 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 117 of 542 





Page 118
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 







































---------------------------------------------------------------------------------------
|Batch     |Limit s   |10% of     |231201   |240101   |240102   |LOD       |LOQ       |
|          |          |limits     |         |         |         |          |          |
|----------|----------|-----------|---------|---------|---------|----------|----------|
|Ethanol   |≤0. 5%   |≤0.05%    |0.1%     |0.2%     |0.1%     |0.003%    |0.01%     |  
|----------|----------|-----------|---------|---------|---------|----------|----------|
|Isoprop yl|≤0. 5%   |≤0.05%    |Not      |Not      |Not      |0.003%    |0.01%     |  
|alco hol  |          |           |detecte d|detecte d|detecte d|          |          |
|----------|----------|-----------|---------|---------|---------|----------|----------|
|Ethyl a   |≤0. 5%   |≤0.05%    |Not      |Not      |Not      |0.003%    |0.01%     |  
|cetate    |          |           |detecte d|detecte d|detecte d|          |          |
|----------|----------|-----------|---------|---------|---------|----------|----------|
|sec-but   |≤0. 5%   |≤0.05%    |Not      |Not      |Not      |0.002%    |0.008%    |  
|anol      |          |           |detecte d|detecte d|detecte d|          |          |
|----------|----------|-----------|---------|---------|---------|----------|----------|
|tetrahy   |≤0.07 2% |≤0.0072%  |Not      |Not      |Not      |0.002%    |0.007%    |  
|drofura n |          |           |detecte d|detecte d|detecte d|          |          |
|----------|----------|-----------|---------|---------|---------|----------|----------|
|Toluene   |≤0.08 9% |≤0.0089%  |Not      |Not      |Not      |0.001%    |0.004%    |  
|          |          |           |detecte d|detecte d|detecte d|          |          |
|----------|----------|-----------|---------|---------|---------|----------|----------|
|N-meth    |≤0.05 3% |≤0.0053%  |Not      |Not      |Not      |0.002%    |0.006%    |  
|ylpyrrol  |          |           |detecte d|detecte d|detecte d|          |          |
|idone     |          |           |         |         |         |          |          |
|----------|----------|-----------|---------|---------|---------|----------|----------|
|piperidi  |≤0. 1%   |≤0.01%    |Not      |Not      |Not      |0.003%    |0.01%     |  
|ne        |          |           |detecte d|detecte d|detecte d|          |          |
|----------|----------|-----------|---------|---------|---------|----------|----------|
|benzen e  |≤0.00 02%|≤0.00002 %|Not      |Not      |Not      |0.000016 %|0.000053 %|  
|          |          |           |detecte d|detecte d|detecte d|          |          |
---------------------------------------------------------------------------------------

According to the test results of three commercial-scale batches of self-made 



samples for residual solvents, except for ethanol used in the last step of the 



process, the remaining eight residual solvents were not detected (LOD is 



detailed in Table 3.2.S.3.2.3-2), all below 10% of their acceptable limits. 



Therefore, the applicant in the final draft quality standards, the solvent used 



in the last step of the process of ethanol and the second class of solvents 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 118 of 542 





Page 119
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



N-methylpyrrolidone, toluene and tetrahydrofuran set into the quality 



standards for control, the limit of ethanol shall not be 0.5%; 



N-methylpyrrolidone shall not exceed 0.053%; Toluene must not exceed 



0.089%; Tetrahydrofuran shall not exceed 0.072%, and the remaining 



solvents shall not be controlled. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 119 of 542 





Page 120
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.3.2.4 Impurities of Metal Elements** 



With reference to ICH-Q3D (R2), the applicant conducts risk assessment 



of potential metal element impurities in the preparation of finalizone from 



three aspects, including process introduction, material introduction and 



equipment introduction, and includes palladium and highly toxic Class 1 



and 2A metal element impurities as follows: 



**palladium** 



The catalyst palladium acetate was used in the preparation of Finer 



enone starting material YA2304-1, and trace amounts of palladium may 



remain in the finished product. The oral acceptable limit of palladium 



referenced to ICHQ3D(R2) is 10μg/g (i.e. 10 PPM). The Applicant tested 



three commercial-scale batches of Finerenone (lots 231201, 240101 and 



240102), each containing significantly less than 1ppm of palladium (1 



0% of the acceptable limit), as detailed in Table 3.2.S.3.2.4-1. 



Table.2.S.3.2.4-1 Statistics of palladium content in Finerenone 













------------------------------------------------------------
|Batch No.        |231201   |240101   |240102   |10% of the|
|Elemental        |         |         |         |acceptable|
|impurities       |         |         |         |limit     |
|-----------------|---------|---------|---------|----------|
|Palladium content|0.053 ppm|0.084 ppm|0.009 ppm|1ppm      |
------------------------------------------------------------

In summary, the palladium content of Finerenone produced by regis 



tered process was less than 10% (i.e. 1ppm) of the oral acceptable limit 



of palladium in ICH-Q3D (R2). With reference to the "Implementation o 



f policy on elemental impurities in the Certification Procedure" publishe 



d by EDQM, the applicant can see that if the metal element is introduc 



ed before the final synthetic reaction, And if the corresponding metal el 



ement test results in 3 batches of commercial-scale finished products ar 



e all lower than 30% of the acceptable limit, the finished product stand 



ard may not include the impurity in the routine test project, as detailed 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 120 of 542 





Page 121
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



in 3.2.S.4.5. Based on this analysis, the risk of Finerenone introducing 



palladium element is low, and the registered process can control the i 



mpurity below 10% of the acceptable limit. Therefore, the applicant does 



not control it. 



**lead** 



See ICH-Q3D (R2) for an oral PDE of 5μg/ day for lead. The maximum 



daily dose (MDD) of Finerenone is 20mg (much less than 1g), and the 



applicant calculated an oral acceptable limit of 5μg/g (i.e. 5 PPM) for lead 



based on a daily intake of 1g. In order to exclude the possibility of the 



introduction of more toxic Group 1 (lead) metal elements into various 



manufacturing materials and equipment, the Applicant tested three 



commercial-scale batches of Finerenone (Batch No. 231201, 240101 and 



240102). The levels of lead detected in these three batches were all below 



30% of the acceptable oral limits (see Table 3.2.S.3.2.4-2 for details). 



Therefore, the Applicant intends not to control the elemental impurity lead in 



the finished product. 



Table 3.2.S.3.2.4-2 Statistics of lead detection data in Finerenone 













-------------------------------------------------------
|Batch No.   |231201   |240101   |240102   |30% of the|
|Elemental   |         |         |         |acceptable|
|impurities  |         |         |         |limit     |
|------------|---------|---------|---------|----------|
|Lead content|0.380 ppm|0.386 ppm|0.093 ppm|1.5 ppm   |
-------------------------------------------------------

**Other Class 1 and Class 2A elemental impurities** 



See ICH-Q3D (R2) for oral Pdes of 15μg/ day, 5μg/ day, 30μg/ day, 



50μg/ day, 200μg/ day, and 100μg/ day for arsenic, cadmium, mercury, 



cobalt, nickel, and vanadium, respectively. The maximum daily dose (MDD) 



of Finerenone is 20mg (much less than 10g), The applicant calculated the 



oral acceptable limits of arsenic, cadmium, mercury, lead, cobalt, nickel and 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 121 of 542 





Page 122
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



vanadium with a daily intake of 10g as 1.5μg/g (i.e. 1.5ppm), 0.5μg/g (i.e. 



0.5ppm), 3μg/g (i.e. 3 PPM), 5μg/g (i.e.5 PPM), 20μg/g (i.e. 20 PPM), 10μg/g 



(i.e. 20 PPM), respectively. I.e. 10ppm). In order to exclude the possibility of 



the introduction of highly toxic Class 1 (arsenic, cadmium and mercury) and 



Class 2A (cobalt, nickel and vanadium) metal elements into each production 



material and production equipment, the applicant tested three 



commercial-scale batch produced batches of Finerenone (Batch No. 231201, 



240101 and 240102), The levels of lead detected in these three batches were 



all below 30% of the acceptable oral limits (see Table 3.2.4-3 for details). 



Therefore, the Applicant intends not to control the element impurities of 



Class 1 (arsenic, cadmium and mercury) and Class 2A (cobalt, nickel and 



vanadium) in the finished product. 



Table 3.2.S.3.2.4-3 Finerenone Category 1 and 2A element impurity 



inspection status 




-----------------------------------------------------------------------
|Batch No. Elemental|231201   |240101   |240102   |LODs     |30% of a |
|impurities         |         |         |         |         |cceptable|
|                   |         |         |         |         |limits   |
|-------------------|---------|---------|---------|---------|---------|
|Arsenic levels     |Undetecte|Not      |Not      |0.004 ppm|0.45 ppm |
|                   |d        |detected |detected |         |         |
|-------------------|---------|---------|---------|---------|---------|
|Cadmium content    |Undetecte|Not      |Not      |0.001 ppm|0.15 ppm |
|                   |d        |detected |detected |         |         |
|-------------------|---------|---------|---------|---------|---------|
|Mercury content    |Undetecte|Not      |Not      |0.020 ppm|0.9 ppm  |
|                   |d        |detected |detected |         |         |
|-------------------|---------|---------|---------|---------|---------|
|Cobalt content     |0.005 ppm|0.028 ppm|Undetecte|0.001 ppm|1.5 ppm  |
|                   |         |         |d        |         |         |
|-------------------|---------|---------|---------|---------|---------|
|Nickel content     |0.174 ppm|0.351 ppm|0.088 ppm|0.011 ppm|6ppm     |
|-------------------|---------|---------|---------|---------|---------|
|Vanadium content   |Undetecte|0.004 ppm|Undetecte|0.002 ppm|3ppm     |
|                   |d        |         |d        |         |         |
-----------------------------------------------------------------------

**Heavy metal** 






















Metal reaction reagents are not used in the preparation process of Finer 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 122 of 542 





Page 123
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



enone, considering that the materials used and the equipment may intr 



oduce trace heavy metals. Therefore, the applicant proposed a heavy me 



tal test item in Finerenone, and controlled its limit to not exceed 10 pp 



m. At the same time, the applicant tested three commercial-scale batche 



s of Finerenone No. 231201, 240101 and 240102 for heavy metals, and 



the test results did not exceed 10ppm, as detailed in 3.2.S.3.2.4-4. 



Table 3.2.S.3.2.4-4 Statistics of heavy metal detection data in Finere 



none 

--------------------------------------
|Batch No.|231201  |240101  |240102  |
|---------|--------|--------|--------|
|≤10ppm  |conforms|conforms|conforms| 
--------------------------------------



**3.2.S.3.2.5 Potential genotoxic impurities** 



The applicant combined the preparation process of the starting material and 



the preparation process of Finerenonee to conduct genotoxic impurity 



analysis. Among them, the starting material YA2304-1 may introduce 



YA2304-23, YA2304-24, YA2304-33, YA2304-43, dimethyl sulfate and other 



five potential genotoxic impurities. The starting material YA2304-2 may 



introduce one potential genotoxic impurity such as YA2304-38; Two 



potential genotoxic impurities (YA2304-40, YA2304-41) may be introduced 



into starting material YA2304-4. Potential genotoxic impurities such as 



YA2304-1, YA2304-4, YA2304-47, diethyl sulfate, diisopropyl sulfate, 



di-sec-butylsulfate, 4-dimethylaminopyridine and nitrosamines may be 



introduced in the preparation of Finerenone. Specific studies are as follows: 



**(1) YA2304-23** 



YA2304-23 is an incomplete raw material in the synthesis of starting 



material YA2304-1. This impurity has a potential genotoxic warning 



structure and is a potential genotoxic impurity. Its molecular structure 



formula is as follows: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 123 of 542 





Page 124
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The applicant intends to control the impurity YA2304-23 under the relevant 



substances in the starting material YA2304-1, and design the impurity 



removal experiment to investigate the rationality of the impurity limit. The 



results show that when the impurity YA2304-23 content in the starting 



material YA2304-1 is 0.5%, The registration process can effectively ensure 



that the impurity YA2304-23 content in the subsequent production of 



intermediate YA2304-8 is far less than 30% of the maximum acceptable limit 



of genotoxic impurities in the finished product (i.e. 22.5ppm). The 



experimental process is detailed in section 3.2.S.2.3.3.2. At the same time, 



the applicant tested three commercial-scale batches of Finerenone (Batch 



No. 231201, 240101 and 240102), and no impurity YA2304-23 was detected 



in any of the batches (LOD: 6.02ppm), i.e., well below 30% of the acceptable 



limit (i.e. 22.5ppm), as detailed in Table 3.2.S.3.2.5-5. 



According to Method 3 under item 8.1 of ICH-M7, when an impurity standard 



higher than the acceptable limit of the API is proposed in the starting 



material, the appropriate analytical method combined with the knowledge of 



the impurity destination and removal as well as relevant process control is 



adopted to ensure that the impurity level in the API is less than 30% of the 



acceptable limit, and the data of the commercial scale of multiple batches are 



collected. If it is proved that the impurity level is below 30% of the acceptable 



limit, the impurity can no longer be controlled in the subsequent process. 



Therefore, the Applicant intends to control YA2304-23 as a specific impurity 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 124 of 542 





Page 125
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



by no more than 0.5% in the starting material YA2304-1, and this impurity 



will no longer be controlled in the finished product. 



**(2) YA2304-24** 



YA2304-24 is an intermediate in the synthesis of the starting material 



YA2304-1. This impurity has a potential genotoxic warning structure and is a 



potential genotoxic impurity. Its molecular structure formula is as follows: 



The applicant intends to control the impurity YA2304-24 under the relevant 



substances in the starting material YA2304-1, and design the impurity 



removal experiment to investigate the rationality of the impurity limit. The 



results show that when the impurity YA2304-24 content in the starting 



material YA2304-1 is 0.5%, The registration process can effectively ensure 



that the impurity YA2304-24 content in the subsequent production of 



intermediate YA2304-8 is far less than 30% of the maximum acceptable limit 



of genotoxic impurity in the finished product (i.e. 22.5ppm). The 



experimental process is detailed in section 3.2.S.2.3.3.2. At the same time, 



the applicant tested three commercial-scale batches of Finerenone (Batch 



No. 231201, 240101 and 240102), and no impurity YA2304-24 was detected 



in any of the batches (LOD: 6.09ppm), i.e., well below 30% of the acceptable 



limit (i.e. 22.5ppm), as detailed in Table 3.2.S.3.2.5-5. 



Referring to Method 3 under item 8.1 of ICH-M7, the Applicant intends to 



control YA2304-24 as a specific impurity by no more than 0.5% in the 



starting material YA2304-1, which will no longer be controlled in the finished 



product. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 125 of 542 





Page 126
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**(3) YA2304-33** 



YA2304-33 is a by-product in the synthesis of the starting material YA2304-1. 



This impurity has a potential genotoxic warning structure and is a potential 



genotoxic impurity. Its molecular structure formula is as follows: 



The applicant intends to control the impurity YA2304-33 under the relevant 



substances in the starting material YA2304-1, and design the impurity 



removal experiment to investigate the rationality of the impurity limit. The 



results show that when the impurity YA2304-33 content in the starting 



material YA2304-1 is 0.5%, The registration process can effectively ensure 



that the impurity YA2304-33 content in the subsequent production of 



intermediate YA2304-8 is far less than 30% of the maximum acceptable limit 



of genotoxic impurities in the finished product (i.e. 22.5ppm). The 



experimental process is detailed in section 3.2.S.2.3.3.2. At the same time, 



the applicant tested three commercial-scale batches of Finerenone (Batch 



No. 231201, 240101 and 240102), and no impurity YA2304-33 was detected 



in any of the batches (LOD: 5.91ppm), i.e., well below 30% of the acceptable 



limit (i.e. 22.5ppm), as detailed in Table 3.2.S.3.2.5-5. 



Referring to Method 3 under item 8.1 of ICH-M7, the Applicant intends to 



control YA2304-33 as a specific impurity by no more than 0.5% in the 



starting material YA2304-1, which will no longer be controlled in the finished 



product. 



**(4) YA2304-43** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 126 of 542 





Page 127
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-43 is the degradation product of starting material YA2304-1. This 



impurity has a potential genotoxic warning structure and is a potential 



genotoxic impurity. Its molecular structure formula is as follows: 



The applicant intends to control the impurity YA2304-43 under the relevant 



substances in the starting material YA2304-1, and design the impurity 



removal experiment to investigate the rationality of the impurity limit. The 



results show that when the impurity YA2304-43 content in the starting 



material YA2304-1 is 0.5%, The registration process can effectively ensure 



that the impurity YA2304-43 content in the subsequent production of 



intermediate YA2304-8 is far less than 30% of the maximum acceptable limit 



of genotoxic impurity in the finished product (i.e. 22.5ppm). The 



experimental process is detailed in section 3.2.S.2.3.3.2. At the same time, 



the applicant tested three commercial-scale batches of Finerenone (Batch 



No. 231201, 240101 and 240102), and no impurity YA2304-43 was detected 



in any of the batches (LOD: 7.33ppm), i.e., well below 30% of the acceptable 



limit (i.e. 22.5ppm), as detailed in Table 3.2.S.3.2.5-5. 



Referring to Method 3 under item 8.1 of ICH-M7, the Applicant intends to 



control YA2304-43 as a specific impurity by no more than 0.5% in the 



starting material YA2304-1, and this impurity will no longer be controlled in 



the finished product. 



**(5) YA2304-38** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 127 of 542 





Page 128
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-38 is an incomplete raw material in the synthesis of starting 



material YA2304-2. This impurity has a potential genotoxic warning 



structure and is a potential genotoxic impurity. Its molecular structure 



formula is as follows: 



[The applicant queried the microbial mutation test (Ames test) data of the](https://echa.europa.eu/home）可知，2-氯丙烷显示无遗传毒性，结果详见下图) 



compound from the Ministry of Health, Labor and Welfare of Japan 



(Occupational safety website), and it can be seen that the Ames test result of 



4-methylene-2-oxacyclobutanone (YA2304-38) was Negative. The screenshot 



of the query result is as follows: 



According to the requirements of ICH-M7, the impurity can be classified into 



5 categories of potential genotoxic impurities and can be controlled as 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 128 of 542 





Page 129
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



non-mutagenic impurities. The applicant intends to limit impurity 



YA2304-38 to 1.0% under residual solvent in starting material YA2304-2, 



and to design an impurity removal experiment to investigate the rationality of 



the impurity limit. The results show that when the impurity YA2304-38 



content in starting material YA2304-2 is 1.0%, The registration process can 



effectively ensure the removal of impurity YA2304-38 in the subsequent 



production of Finerenonee. The experimental process is detailed in section 



3.2.S.2.3.5.2. At the same time, the applicant tested three commercial-scale 



batches of Finerenone No. 231201, 240101 and 240102, and no impurity 



YA2304-38 (LOD: 0.027%) was detected in each batch of samples. For details, 



see Table 3.2.5-1. Therefore, the applicant intends to control YA2304-38 as a 



specific impurity by no more than 1.0% in the starting material YA2304-2, 



and this impurity will no longer be controlled in the finished product. 



Table 3.2.5-1 Test data for YA2304-38 in Finerenone 

------------------------------------------------
|Batch No.|231201    |240101  |240102  |LOD    |
|---------|----------|--------|--------|-------|
|YA2304-38|Undetected|Not     |Not     |0.027% |
|         |          |detected|detected|       |
------------------------------------------------



**(6) YA2304-40** 



YA2304-40 is an incomplete raw material in the synthesis of starting 



material YA2304-4. This impurity has a potential genotoxic warning 



structure and is a potential genotoxic impurity. Its molecular structure 



formula is as follows: 



The applicant intends to control the impurity YA2304-40 under the relevant 



substances in the starting material YA2304-4, and design the impurity 



removal experiment to investigate the rationality of the impurity limit. The 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 129 of 542 





Page 130
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



results show that when the impurity YA2304-4 content is 0.5%, the impurity 



YA2304-40 should not exceed 0.5%. The registration process can effectively 



ensure that the impurity YA2304-40 content in the subsequent production of 



Finerenonee is far less than 30% of the maximum acceptable limit of 



genotoxic impurity in the finished product (i.e. 22.5ppm). The experimental 



process is detailed in section 3.2.S.2.3.7.2. At the same time, the applicant 



tested three commercial-scale batches of Finerenone (Batch No. 231201, 



240101 and 240102), and no impurity YA2304-40 was detected in any of the 



batches (LOD: 12.59ppm), i.e., well below 30% of the acceptable limit (i.e. 



22.5ppm), as detailed in Table 3.2.S.3.2.5-5. 



Referring to Method 3 under item 8.1 of ICH-M7, the Applicant intends 



to control YA2304-40 as a specific impurity by no more than 0.5% in t 



he starting material YA2304-4, which will no longer be controlled in the 



finished product. 



**(7) YA2304-41** 



YA2304-41 is an intermediate in the synthesis of the starting material 



YA2304-4. This impurity has a potential genotoxic warning structure and is a 



potential genotoxic impurity. Its molecular structure formula is as follows: 



The applicant intends to control the impurity YA2304-41 under the relevant 



substances in the starting material YA2304-4, and design the impurity 



removal experiment to investigate the reasonableness of the impurity limit. 



The results show that when the impurity YA2304-41 content in the starting 



material YA2304-4 is 0.5%, The registration process can effectively ensure 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 130 of 542 





Page 131
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



that the impurity YA2304-41 content in the subsequent production of 



Finerenonee is far less than 30% of the maximum acceptable limit of 



genotoxic impurity in the finished product (i.e. 22.5ppm). The experimental 



process is detailed in section 3.2.S.2.3.7.2. At the same time, the applicant 



tested three commercial-scale batches of Finerenone (Batch No. 231201, 



240101 and 240102), and no impurity YA2304-41 was detected in any of the 



batches (LOD: 7.51ppm), i.e., well below 30% of the acceptable limit (i.e. 



22.5ppm), as detailed in Table 3.2.S.3.2.5-5. 



Referring to Method 3 under Item 8.1 of ICH-M7, the Applicant intends 



to control YA2304-41 as a specific impurity by no more than 0.5% in t 



he starting material YA2304-4, which will no longer be controlled in the 



finished product. 



**(8) YA2304-1** 



YA2304-1 is an incomplete starting material in the synthesis of Finerenonee. 



This impurity has a potential genotoxic warning structure and is a potential 



genotoxic impurity. Its molecular structure formula is as follows: 



The applicant intends to control the impurity YA2304-1 in the intermediate 



YA2304-5 under the relevant substances by 0.5%, and design the impurity 



removal experiment to investigate the rationality of the impurity limit. The 



results show that when the impurity YA2304-1 content in the intermediate 



YA2304-5 is 0.5%, The registration process can effectively ensure that the 



impurity YA2304-1 content in the subsequent production of Finerenonee is 



far less than 30% of the maximum acceptable limit of genotoxic impurity in 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 131 of 542 





Page 132
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



the finished product (i.e. 22.5ppm). The experimental process is detailed in 



section 3.2.S.2.4.3.1.1. At the same time, the applicant tested three 



commercial-scale batches of Finerenone (Batch No. 231201, 240101 and 



240102), and no impurity YA2304-1 was detected in any of the batches (LOD: 



12.86ppm), i.e., well below 30% of the acceptable limit (i.e. 22.5ppm), as 



detailed in Table 3.2.S.3.2.5-5. 



Referring to Method 3 under item 8.1 of ICH-M7, the Applicant intends to 



control YA2304-1 as a specific impurity by no more than 0.5% in the 



intermediate YA2304-5, which will no longer be controlled in the finished 



product. 



**(9) YA2304-4** 



YA2304-4 is an incomplete starting material in Finerenone synthesis. This 



impurity has a potential genotoxic warning structure and is a potential 



genotoxic impurity. Its molecular structure formula is as follows: 



The applicant intends to control the impurity YA2304-5 in the intermediate 



YA2304-5 under the relevant substances under 1.5%, and design the 



impurity removal experiment to investigate the rationality of the impurity 



limit. The results show that when the impurity YA2304-5 content in the 



intermediate YA2304-5 is 1.5%, The registration process can effectively 



ensure that the content of impurity YA2304-4 in the subsequent production 



of Finerenonee is far less than 30% of the maximum acceptable limit of 



genotoxic impurity in the finished product (i.e. 22.5ppm). The experimental 



process is detailed in section 3.2.S.2.4.3.1.1. At the same time, the applicant 



tested three commercial-scale batches of Finerenone (Batch No. 231201, 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 132 of 542 





Page 133
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



240101 and 240102), and no impurity YA2304-4 was detected in any of the 



batches (LOD: 12.41ppm), i.e., well below 30% of the acceptable limit (i.e. 



22.5ppm), as detailed in Table 3.2.S.3.2.5-5. 



Referring to Method 3 under item 8.1 of ICH-M7, the Applicant intends to 



control YA2304-4 as a specific impurity by no more than 1.5% in the 



intermediate YA2304-5, which will no longer be controlled in the finished 



product. 



**(10) YA2304-47** 



YA2304-47 is a derivative impurity of the starting material YA2304-4 



involved in the subsequent reaction. This impurity has a potential genotoxic 



warning structure and is a potential genotoxic impurity. Its molecular 



structure formula is as follows: 



The applicant intends to limit impurity YA2304-4 to 1.5% under related 



substances in the intermediate YA2304-5, and design an impurity removal 



experiment to investigate the reasonableness of the impurity limit. The 



results show that when the impurity YA2304-4 content in the intermediate 



YA2304-5 is 1.5%, The registration process can effectively ensure that the 



impurity YA2304-47 content in the subsequent production of Finerenonee is 



far less than 30% of the maximum acceptable limit of genotoxic impurity in 



the finished product (i.e. 22.5ppm). The experimental process is detailed in 



section 3.2.S.2.4.3.1.1. At the same time, the applicant tested three 



commercial-scale batches of Finerenone (Batch No. 231201, 240101 and 



240102), and no impurity YA2304-47 was detected in any of the batches 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 133 of 542 





Page 134
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



(LOD: 6.37ppm), i.e., well below 30% of the acceptable limit (i.e. 22.5ppm), as 



detailed in Table 3.2.S.3.2.5-5. 



Referring to Method 3 under Item 8.1 of ICH-M7, the Applicant intends to 



control YA2304-4 as a specific impurity by no more than 1.5% in the 



intermediate YA2304-5, and its derived impurity YA2304-47 will no longer be 



controlled in the finished product. 



**(11) Sulfate impurities** 



Dimethyl sulfate is an incomplete reaction reagent in the synthesis of 



starting material YA2304-1. Diethyl sulfate, diisopropyl sulfate and 



disec-butyl sulfate are the by-products that may be formed by the reaction of 



concentrated sulfuric acid with ethanol, isopropyl alcohol and 2-butanol in 



the synthesis of finalizone. Four potential genotoxic impurities are dimethyl 



sulfate, diethyl sulfate, diisopropyl sulfate, and disec-butyl sulfate. Their 



molecular structure formula is as follows: 



With reference to ICH-M7, the acceptable limit of a single genotoxic impurity 



in Finerenone was calculated based on TTC as 75ppm, that is, the maximum 



acceptable limit of dimethyl sulfate, diethyl sulfate, diisopropyl sulfate and 



di-sec-butylsulfate in Finerenone was 75ppm. 



Since NLT 3 impurities containing genotoxic warning structures are 



controlled in the finished fineridone, the applicant calculated the control 



limits of multiple genotoxic impurities in the finished fineridone with 



reference to ICH-M7 (R1) : The maximum daily dose (MDD) of Finerenone is 



20mg, and the maximum daily tolerable dose (TTC) of the sum of the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 134 of 542 





Page 135
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



impurities containing the genotoxic warning structure is 5μg according to 



the following formula: 



Genotoxic impurity limit (ppm) = TTC/MDD 



TTC: Maximum tolerable daily dose, μg/ day, 



MDD: maximum daily dose, g/ day; 



The calculated acceptable limit of the sum of impurities containing genotoxic 



warning structure in finalizone was 250ppm, that is, the maximum 



acceptable limit of the sum of dimethyl sulfate, diethyl sulfate, diisopropyl 



sulfate and di-sec-butyl sulfate in finalizone was 250ppm. 



The applicant tested the contents of the above four sulfate genotoxic 



impurities in three commercial-scale batches of Finerenone No. 231201, 



240101 and 240101. Dimethyl sulfate, diethyl sulfate, diisopropyl sulfate 



and di-sec-butylsulfate were not detected. The specific test results are shown 



in Table 3.2.S.3.2.5-4, and the relevant methodology verification report is 



shown in 3.2.S.4.3.6. 



Referring to Method 1 under ICH-M7 8.1, periodic confirmatory testing may 



be performed if the level of mutagenic impurities in the API is below 30% of 



the acceptable limit in at least 6 consecutive pilot batches or 3 consecutive 



production batches. Therefore, the applicant intends to schedule the 



genotoxic impurities of sulfate as part of the release criteria for finished 



Finerenone with a testing cycle of one batch for every 10 batches. 



**(12) 4-dimethylaminopyridine (abbreviated: DMAP)** 



4-dimethylaminopyridine contains a genotoxicity warning structure, CAS 



number 1122-58-3, the molecular structure formula is as follows: 



CH3 



CH3 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 135 of 542 





Page 136
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The applicant queried Ames test data of the compound through the 



European Chemicals Agency (ECHA) database and found that 



4-dimethylaminopyridine has been detected in Salmonella typhimurium TA 



[1535, TA 1537, TA 98 and TA 100 and Escherichia coli WP2 uvr A reverse](https://echa.europa.eu/home）可知，2-氯丙烷显示无遗传毒性，结果详见下图) 



mutation test (Ames test) did not show mutagenic activity, as shown in the 



screenshot below: 



According to the requirements of ICH-M7, the impurity can be classified 



into 5 potentially genotoxic impurities and can be controlled as non-m 



utagenic impurities, i.e. the acceptable limit of the impurity is 0.10%. 4 



-dimethylaminopyridine is a catalyst added in the ammoniation reaction 



of step 3 of the preparation process of non-nellidone, and the amount 



of feed is very small; The compound is soluble in water and ethanol, an 



d is an organic base, after the subsequent two alcohol water system be 



ating, filtration and a recrystallization of ethanol is easy to be removed, 



and D- (+) -dibenzoyl tartar conversion into water-soluble organic salt i 



s also easy to be removed. The applicant tested three commercial-scale 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 136 of 542 





Page 137
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



batches of Finerenone (batch No. 231201, 240101, 240102), and found 



that 4-dimethylaminopyridine was not detected in each batch of sample 



s, as detailed in Table 3.2.S.3.2.5-2. 



Table 3.2.S.3.2.5-2 Detection data of 4-dimethylaminopyridine in Fineren 



one 









----------------------------------------------------------
|Names of impurities  |231201  |240101  |240102  |LOD    |
|---------------------|--------|--------|--------|-------|
|4-dimethylaminopyridi|Not     |Not     |Not     |0.0005%|
|ne                   |detected|detected|detected|       |
----------------------------------------------------------

See 3.2.S.4.3.2 for the LOD of 4-dimethylaminopyridine (DMAP) in the 



finished product related Substance II analysis method is 0.0005%, which is 



far below the acceptable limit for this impurity. According to this analysis, 



although 4-dimethylaminopyridine (DMAP) was added in the preparation 



process of Finerenonee, the impurity can be effectively removed by the 



registration process. Therefore, the applicant intends not to control 



4-dimethylaminopyridine (DMAP) in the finished product. 



**(13) nitrosamine impurities** 



The applicant intends to conduct the following evaluation and research on 8 



possible nitrosamine impurities such as NDMA, NDEA, NDIPA, NDBA, NIEPA, 



NMBA, NMPA, NDPA: 



The AI values of NDMA, NDEA, NDIPA, NIEPA, NMBA and NMPA are 



announced in the "Control of Nitrosamine Impurities in Human Drugs" 



issued by FDA as follows: 



The AI values of the NDBA published in the Control of Nitrosamine Impurities 



in Human Drugs by the CHMP are as follows: 



The TD50 value of the oral pathway of NDPA (CAS: 621-64-7) rats was 



0.186mg/kg/day published in the CPDB, and the query screenshot is as 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 137 of 542 





Page 138
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



follows: 



Based on the above query results, the applicant calculated the AI of NDPA 



with reference to ICH-M7 (R2) according to the following formula, in which 



the AI of NDPA under oral route is 186ng/ day, the calculation formula is as 



follows: 



Maximum daily intake AI (ng/ day) =TD50×50kg/50000 



The applicant intends to refer to the "Control of Nitrosamine Impurities in 



Human Drugs" issued by CHMP to calculate the impurity limit according to 



TTC method, in which the AI of impurity NDPA is calculated according to 



18ng/ day. The relevant references are described as follows: 



The maximum daily dose (MDD) of Finerenone is 20mg, and the applicant 



calculates the above impurity limit with reference to ICH-M7 (R2) according 



to the following formula, the calculation results are detailed in Table 3.2.5-3. 



Impurity limit (ppm) = AI/MDD 



AI: Maximum daily intake, ng/ day; MDD: maximum daily dose, mg/ day; 



The maximum acceptable limits of NDMA, NDEA, NDIPA, NEIPA, NMBA, 



NMPA, NDBA and NDPA in finalizone were calculated to be 4.8ppm, 1.32ppm, 



1.32ppm, 1.32ppm, 1.32ppm, 4.8ppm, 1.32ppm, 1.32ppm and 0.9ppm, 



respectively . The applicant intends to strictly control the above eight 



nitrosamine impurities in the finished product to not exceed 0.3ppm during 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 138 of 542 





Page 139
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



the research process. 



The applicant intends to develop LC-MS method to detect the above eight 



nitrosamine impurities in combination with the above impurity limits, and 



conducts corresponding methodological research with reference to the 



General Rule 9101 of the 2020 edition of Chinese Pharmacopoeia. The 



verification results show that the method is specific, linear and has a good 



recovery rate, and the LOD of each impurity is about 10% of the impurity 



control limit. For details, see Table 3.2.5-3. At the same time, NDMA, NDEA, 



NDIPA, NDBA, NEIPA, NMBA, NMPA and NDPA were not detected in the 



three commercial-scale batches of Finerenone No. 231201, 240101 and 



240102. In other words, the detected amounts were all less than 10% of the 



impurity control limit, as detailed in Table 3.2.S.3.2.5-4. 



Table 3.2.5-3 Acceptable limits of nitrosamine impurities in finalizone 



















--------------------------------------------------------------------
|Names of  |Impurity|Acceptable limits |More stringent   |LOD (ppm)|
|Impurities|AI (ng/ |based on TTC      |acceptable limits|         |
|          |day)    |calculations (ppm)|(ppm) proposed by|         |
|          |        |                  |the applicant    |         |
|----------|--------|------------------|-----------------|---------|
|NDMA      |96      |4.8               |0.3              |0.0310   |
|----------|--------|------------------|-----------------|---------|
|NDEA      |26.5    |1.32              |0.3              |0.0336   |
|----------|--------|------------------|-----------------|---------|
|NDIPA     |26.5    |1.32              |0.3              |0.0319   |
|----------|--------|------------------|-----------------|---------|
|NEIPA     |26.5    |1.32              |0.3              |0.0303   |
|----------|--------|------------------|-----------------|---------|
|NMBA      |96      |4.8               |0.3              |0.0298   |
|----------|--------|------------------|-----------------|---------|
|NMPA      |26.5    |1.32              |0.3              |0.0327   |
|----------|--------|------------------|-----------------|---------|
|NDBA      |26.5    |1.32              |0.3              |0.0341   |
|----------|--------|------------------|-----------------|---------|
|NDPA      |18      |0.9               |0.3              |0.0354   |
--------------------------------------------------------------------

February 26, 2021, Questions and answers for marketing authorisation 



holders/applicants on the CHMP Opinion for the Article 5(3) of the EMA As 



described in Q&A No. 15 of Regulation (EC) No 726/2004 referral on 



nitrosamine impurities in human medicinal products, When the amount of 



nitrosamine impurities detected is less than 10% of the acceptable limit in 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 139 of 542 





Page 140
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



the finished product calculated by AI, the test may not be carried out, as 



follows: 



The translation of the underlined part in red is as follows: 



Routine testing can only be avoided if the level of nitrosamine is consistently 



below 10% of the acceptable limit for AI-based calculations in the finished 



product. 



In summary, in the three batches of commercial-scale mass production of 



finnalidone, the quality inspection quantity of eight nitrosamine impurities, 



such as NDMA, NDEA, NDIPA, NDBA, NEIPA, NMBA, NMPA and NDPA, is far 



less than 10% of the acceptable limit. The applicant intends not to control the 



above eight nitrosamine impurities in the finished product. 



**The** **detection** **situation** **of** **potential** **genotoxic** **impurities** **in** 



**commercial-scale mass production of Finerenone** 



Table 3.2.S.3.2.5-4 Detection results of nitrosamine impurities in Finerenone 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 140 of 542 





Page 141
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 






























--------------------------------------------------------------------------
|Impurities|231201  |240101  |240102  |LOD       |Acceptable  |More      |
|Batch No. |        |        |        |          |limits      |stringent |
|          |        |        |        |          |based on    |acceptable|
|          |        |        |        |          |TTC         |limits    |
|          |        |        |        |          |calculations|drawn up  |
|          |        |        |        |          |            |by the    |
|          |        |        |        |          |            |applicant |
|----------|--------|--------|--------|----------|------------|----------|
|NDMA      |Not     |Not     |Not     |0.0310 ppm|4.8 ppm     |0.3 ppm   |
|          |detected|detected|detected|          |            |          |
|----------|--------|--------|--------|----------|------------|----------|
|NDEA      |Not     |Not     |Not     |0.0336 ppm|1.32 ppm    |0.3 ppm   |
|          |detected|detected|detected|          |            |          |
|----------|--------|--------|--------|----------|------------|----------|
|NDIPA     |Not     |Not     |Not     |0.0319 ppm|1.32 ppm    |0.3 ppm   |
|          |detected|detected|detected|          |            |          |
|----------|--------|--------|--------|----------|------------|----------|
|NEIPA     |Not     |Not     |Not     |0.0303 ppm|1.32 ppm    |0.3 ppm   |
|          |detected|detected|detected|          |            |          |
|----------|--------|--------|--------|----------|------------|----------|
|NMBA      |Not     |Not     |Not     |0.0298 ppm|4.8 ppm     |0.3 ppm   |
|          |detected|detected|detected|          |            |          |
|----------|--------|--------|--------|----------|------------|----------|
|NMPA      |Not     |Not     |Not     |0.0327 ppm|1.32 ppm    |0.3 ppm   |
|          |detected|detected|detected|          |            |          |
|----------|--------|--------|--------|----------|------------|----------|
|NDBA      |Not     |Not     |Not     |0.0341 ppm|1.32 ppm    |0.3 ppm   |
|          |detected|detected|detected|          |            |          |
|----------|--------|--------|--------|----------|------------|----------|
|NDPA      |Not     |Not     |Not     |0.0354 ppm|0.9 ppm     |0.3 ppm   |
|          |detected|detected|detected|          |            |          |
--------------------------------------------------------------------------

Table 3.2.S.3.2.5-5 Summary of genotoxic impurity detection results in 



commercial-scale batch production of Finerenone 

























------------------------------------------------------------
|Impurities|231201  |240101  |240102  |LOD      |30% of    |
|Batch No. |        |        |        |         |acceptable|
|          |        |        |        |         |limits for|
|          |        |        |        |         |genotoxic |
|          |        |        |        |         |impurities|
|----------|--------|--------|--------|---------|----------|
|YA2304-23 |Not     |Not     |Not     |6.02 ppm |22.5 ppm  |
|          |detected|detected|detected|         |          |
|----------|--------|--------|--------|---------|----------|
|YA2304-24 |Not     |Not     |Not     |6.09 ppm |22.5 ppm  |
|          |detected|detected|detected|         |          |
|----------|--------|--------|--------|---------|----------|
|YA2304-33 |Not     |Not     |Not     |5.91 ppm |22.5 ppm  |
|          |detected|detected|detected|         |          |
|----------|--------|--------|--------|---------|----------|
|YA2304-43 |Not     |Not     |Not     |12.22 ppm|22.5 ppm  |
|          |detected|detected|detected|         |          |
|----------|--------|--------|--------|---------|----------|
|YA2304-40 |Not     |Not     |Not     |12.59 ppm|22.5 ppm  |
------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 141 of 542 





Page 142
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















------------------------------------------------------------
|            |detected|detected|detected|         |        |
|------------|--------|--------|--------|---------|--------|
|YA2304-41   |Not     |Not     |Not     |7.51 ppm |22.5 ppm|
|            |detected|detected|detected|         |        |
|------------|--------|--------|--------|---------|--------|
|YA2304-1    |Not     |Not     |Not     |12.86 ppm|22.5 ppm|
|            |detected|detected|detected|         |        |
|------------|--------|--------|--------|---------|--------|
|YA2304-4    |Not     |Not     |Not     |12.41 ppm|22.5 ppm|
|            |detected|detected|detected|         |        |
|------------|--------|--------|--------|---------|--------|
|YA2304-47   |Not     |Not     |Not     |6.37 ppm |22.5 ppm|
|            |detected|detected|detected|         |        |
|------------|--------|--------|--------|---------|--------|
|Dimethyl    |Not     |Not     |Not     |2.2 ppm  |22.5 ppm|
|sulfate     |detected|detected|detected|         |        |
|------------|--------|--------|--------|---------|--------|
|Diethyl     |Not     |Not     |Not     |2.3 ppm  |22.5 ppm|
|sulfate     |detected|detected|detected|         |        |
|------------|--------|--------|--------|---------|--------|
|Diisopropyl |Not     |Not     |Not     |2.3 ppm  |22.5 ppm|
|sulfate     |detected|detected|detected|         |        |
|------------|--------|--------|--------|---------|--------|
|Di-sec-butyl|Not     |Not     |Not     |2.3 ppm  |22.5 ppm|
|sulfate     |detected|detected|detected|         |        |
------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 142 of 542 





Page 143
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4** **Control of Drug Substance** 



**3.2.S.4.1 Specification** 



Specifications of Finerenone are summarized in the following table. 



Table 3.2.S.4.1-1 Specifications of Finerenone 
















-----------------------------------------------------------------------------
|Test Items              |Acceptance Criteria           |Method             |
|------------------------|------------------------------|-------------------|
|Characters  |Appearance |white to yellow powder        |Visual inspection  |
|            |-----------|------------------------------|-------------------|
|            |Solubility |This product should be        |In-house method    |
|            |           |dissolved in methanol,        |                   |
|            |           |slightly soluble in ethanol,  |                   |
|            |           |acetonitrile and acetone,     |                   |
|            |           |slightly soluble in isopropyl |                   |
|            |           |alcohol, and almost insoluble |                   |
|            |           |in water                      |                   |
|------------|-----------|------------------------------|-------------------|
|Identificati|IR         |The infrared light absorption |Operating          |
|on          |           |pattern of this product should|procedures of      |
|            |           |be consistent with that of the|infrared absorption|
|            |           |control product               |spectrophotometry  |
|            |           |                              |(in-house method)  |
|            |-----------|------------------------------|-------------------|
|            |HPLC       |In the chromatogram recorded  |Operating          |
|            |           |under the enantiomer          |procedures of HPLC |
|            |           |determination item, the       |(in-house method)  |
|            |           |retention time of the main    |                   |
|            |           |peak of the test solution     |                   |
|            |           |should be consistent with the |                   |
|            |           |retention time of the main    |                   |
|            |           |peak of the system suitability|                   |
|            |           |solution                      |                   |
|------------|-----------|------------------------------|-------------------|
|Tests       |Related    |YA2304-10 NMT 0.10%; YA2304-14|Operating          |
|            |substances |NMT 0.15%; YA2304-15 NMT      |procedures of HPLC |
|            |           |0.15%; YA2304-19 NMT 0.15%;   |(in-house method)  |
|            |           |Other single impurities NMT   |                   |
|            |           |0.10%; Total impurities NMT   |                   |
|            |           |1.0%                          |                   |
|            |-----------|------------------------------|-------------------|
|            |Enantiomers|YA2304-20 NMT 0.15%           |Operating          |
|            |           |                              |procedures of HPLC |
-----------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 143 of 542 





Page 144
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 
























-----------------------------------------------------------------------
|Test Items        |Acceptance Criteria           |Method             |
|------------------|------------------------------|-------------------|
|       |          |                              |(in-house method)  |
|       |----------|------------------------------|-------------------|
|       |Genotoxic |Dimethyl sulfate NMT 75ppm;   |Operating          |
|       |impurities|Diethyl sulfate NMT 75ppm;    |procedures of GC-MS|
|       |          |Diisopropyl sulfate NMT 75ppm;|(in-house method)  |
|       |          |Disec-butyl sulfate NMT 75ppm;|                   |
|       |          |The sum of genotoxic          |                   |
|       |          |impurities NMT 250ppm         |                   |
|       |----------|------------------------------|-------------------|
|       |Residual  |Ethanol NMT 0.5 %             |Operating          |
|       |solvents  |Tetrahydrofuran NMT 0.072%    |procedures of GC   |
|       |          |Toluene NMT 0.089%            |(in-house method)  |
|       |          |N-methylpyrrolidone NMT 0.053%|                   |
|       |----------|------------------------------|-------------------|
|       |Water     |NMT 0.5%                      |Operating          |
|       |          |                              |procedures of Loss |
|       |          |                              |on drying          |
|       |          |                              |determination      |
|       |          |                              |(in-house method)  |
|       |----------|------------------------------|-------------------|
|       |Residue on|NMT 0.1%                      |Operating          |
|       |ignition  |                              |procedures of      |
|       |          |                              |residue on ignition|
|       |          |                              |determination      |
|       |          |                              |(in-house method)  |
|       |----------|------------------------------|-------------------|
|       |Heavy     |NMT 10 ppm                    |Operating          |
|       |metals    |                              |procedures of heavy|
|       |          |                              |metals             |
|       |          |                              |determination      |
|       |          |                              |(in-house method)  |
|       |----------|------------------------------|-------------------|
|       |Microbial |TAMC: NMT 103CFU/g TYMC: NMT  |Operating          |
|       |limits    |102CFU/g Absence of           |procedures of      |
|       |          |Escherichia coli (1g)         |microbial limits   |
|       |          |                              |determination      |
|       |          |                              |(in-house method)  |
|-------|          |------------------------------|-------------------|
|Assay             |98.0% to 102.0% (anhydrous    |Operating          |
|                  |substance)                    |procedures of HPLC |
|                  |                              |(in-house method)  |
-----------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 144 of 542 





Page 145
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4.2** **Analytical Procedures** 



**CHARACTERS** 



**Appearance** 



white to yellow powder by visual inspection. 



**Solubility** 



It is dissolved in methanol, slightly soluble in ethanol, acetonitrile and 



acetone, slightly soluble in isopropyl alcohol and almost insoluble in water. 



**IDENTIFICATION** 



**Infrared Absorption Spectrophotometry** 



Examine by _Operating procedures of infrared absorption spectrophotometry_ 



(in-house method) _._ 



Comparison: Finerenone reference standard. 



The IR spectra of the substance to be examined should comply with that of 



the Finerenone reference standard. 



**High Performance Liquid Chromatography** 



In the chromatogram recorded under the enantiomer determination, the 



retention time of the main peak of the test solution should be consistent with 



the retention time of the main peak of the system suitability solution. _(refers_ 



_to enantiomer)._ 



**TESTS** 



**Related Substances** 



Examine by _Operating procedures of high performance liquid chromatography_ 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 145 of 542 





Page 146
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



(in-house method) _._ 



Solvent acetonitrile-water (30:70, v/v) 



_Test solution:_ Take an appropriate amount of this product, weigh it 



accurately, dissolve it in a brown volumetric flask with a suitable amount of 



solvent and sonicate it, and dilute it quantitatively to make a solution 



containing about 0.4mg per 1ml. Shake well to obtain the solution. 



_Reference solution:_ Accurately measure an appropriate amount of the test 



sample solution, dilute it quantitatively with solvent to prepare a solution 



containing approximately 0.4 μ g per 1ml, shake well, and obtain. 



_Reference stock solution_ ① _:_ Take appropriate amounts of YA2304-10 and 



YA2304-17 reference standards, weigh them accurately, dissolve them in a 



solvent, and dilute them quantitatively to prepare a mixed solution 



containing approximately 200 μ g of YA2304-10 and YA2304-17 per 1ml. 



_Reference solution:_ Precisely measure an appropriate amount of reference 



stock solution ①, dissolve it in a solvent and dilute it quantitatively to 



prepare a mixed solution containing approximately 0.4 μ g of YA2304-10 and 



0.4 μ g of YA2304-17 per 1ml. 



_Reference stock solution_ ② _:_ Take appropriate amounts of YA2304-14, 



YA2304-15, YA2304-16, and YA2304-19 reference samples, weigh them 



accurately, dissolve and dilute them in acetonitrile to prepare a mixed 



solution containing approximately 200 μ g of YA2304-14, YA2304-15, 



YA2304-16, and YA2304-19 per 1ml. 



_System_ _suitability_ _solution:_ Accurately weigh about 10mg of YA2304 



reference substance and place it in a 25ml volumetric flask. Add an 



appropriate amount of solvent and sonicate to dissolve it. Accurately add 100 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 146 of 542 





Page 147
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



μ l each of reference stock solution ① and reference stock solution ②, dilute 



to the mark with solvent, shake well, and obtain the solution. 



_Chromatographic system_ 



_—stationary phase:_ Octadecylsilane bonded silica gel (YMC Trairt C18 ， 



4.6mm×150mm，3μm, or other similar column). 



_—temperature:_ 20℃. 



_Mobile phase:_ see the gradient table blow. 



_- mobile phase A:_ phosphoric acid solution (take 300μl phosphoric acid, add 



1000ml water, mix well); 



_- mobile phase B:_ acetonitrile; 



Time(min) Mobile phase A(%) Mobile phase B(%) 



0 85 15 


2 80 20 



5 80 20 


8 69 31 


13 55 45 



14 55 45 


18 50 50 


22 20 80 



_Flow rate:_ 1.0 mL/min. 



_Detection:_ at 251nm or 230 nm . 



_Injection volume:_ 5 μL. 



_System suitability_ : System suitability solution: 



- Reference solution (230nm): The peak order is YA2304-17, YA2304-10; 



- System suitability solution (251nm): The peak order is YA2304-14 YA2304 、 



YA2304-15、YA2304-17、YA2304-16、YA2304-10、YA2304-19; The separation 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 147 of 542 





Page 148
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



degree between YA2304, YA2304-14, and YA2304-15 NLT 1.5; The separation 



degree between YA2304-17 and YA2304-16 and adjacent peaks NLT 1.0; 



- Reference solution (251nm): The signal-to-noise ratio (S/N) of the main peak 



NLT 20. 



**Impurity Table 1** 










------------------------------------------------------
|Name                     |Correction|Acceptance     |
|                         |factor    |criteria,      |
|                         |          |NMT(%)         |
|-------------------------|----------|---------------|
|YA2304-14                |1.0       |0.10 (at 230nm)|
|-------------------------|----------|---------------|
|YA2304                   |1.0       |0.15 (at 251m) |
|-------------------------|----------|---------------|
|YA2304-15                |1.2       |0.15 (at 251m) |
|-------------------------|----------|---------------|
|YA2304-19                |0.7       |0.15 (at 251m) |
|-------------------------|----------|---------------|
|Other individual impurity|1.0       |0.10           |
|-------------------------|----------|---------------|
|Total impurities         |-         |1.0            |
------------------------------------------------------

Typical chromatogram of system suitability solution 



**Enantiomers** 



Examine by _Operating procedures of high performance liquid chromatography_ 



(in-house method) _._ 



Solvent acetonitrile-water (30:70, v/v) 



_Test solution:_ Take an appropriate amount of this product, weigh it 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 148 of 542 





Page 149
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



accurately, dissolve it in a solvent and dilute it to make a solution containing 



approximately 1mg per 1ml. 



_Reference solution:_ Take an appropriate amount of YA2304-20 reference 



substance, weigh it accurately, dissolve it in a solvent and dilute it to prepare 



a solution containing approximately 1.5 μ g per 1ml. 



_System_ _suitability_ _solution:_ Accurately weigh about 20mg of YA2304 



reference substance, place it in a 20ml volumetric flask, dissolve and dilute 



to the mark with the reference substance solution, shake well, and obtain. 



_Chromatographic system_ 



_—stationary_ _phase:_ Covalent bonding of cellulose tri - (3,5- 



dichlorophenylcarbamate) on the surface of silicone gell (Da Sai Lu 



CHIRALPAK IC, 250 × 4.6mm, 5 μ m, or other similar column). 



_—temperature:_ 40℃. 



_Mobile phase:_ see the gradient table blow. 



_-_ 
20mmol/L ammonium acetate buffer (pH adjusted to 3.1±0.05 with 



phosphoric acid) -acetonitrile (70:30, v/v); 



_Flow rate:_ 1.0 mL/min. 



_Detection:_ at 251nm. 



_Injection volume:_ 5 μL. 



_Run time:_ 40 min 



_System suitability_ : System suitability solution: 



- System suitability solution: The peak order is YA230420, YA2304; The 



separation degree between YA2304, YA2304-14 NLT 1.5; 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 149 of 542 





Page 150
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



- Reference solution : The signal-to-noise ratio (S/N) of the main peak NLT 30. 



_Limits_ (calculate by external standard method): 



– YA2304-20 NMT 0.15% 



**Residual solvents** 



**Acetonitrile , Tetrahydrofuran , and n-butanol** 



Examine by _Operating procedures of gas chromatography_ (in-house method). 



_Solvent:_ N, N-dimethylformamide (DMF) 



_Test solution:_ Take an appropriate amount of this product, weigh it 



accurately, dissolve it in a solvent and dilute it to prepare a solution 



containing approximately 50mg of non nalide per 1ml _._ 



_Reference solution:_ Take appropriate amounts of ethanol, tetrahydrofuran, 



toluene, and N-methylpyrrolidone, accurately weigh them, and dilute with 



solvent to prepare a mixed solution containing approximately 250 μ g of 



ethanol, 36 μ g of tetrahydrofuran, 44.5 μ g of toluene, and 26.5 μ g of 



N-methylpyrrolidone per 1ml. 



Operating conditions: 










----------------------------------------------------------------------------
|Column        |6% cyanopropyl phenyl-94% dimethylpolysiloxane, DB-624,    |
|              |60m×0.53mm, 3.00μm, or other column with similar         |  
|              |polarity.                                                  |
|--------------|-----------------------------------------------------------|
|Column        |Initial keep at 40 ℃for 5min, raise to 60 ℃at rate of 10 |  
|temperature   |℃/min, keep at 60 ℃for 5min. raise to 120 ℃at rate of 10|   
|              |℃/min, keep at 120 ℃for 5min. raise to 240 ℃at rate of  |   
|              |10 ℃/min, keep at 240 ℃for 5min.                         |  
|--------------|-----------------------------------------------------------|
|Injection port|240 ℃             |Split ratio        |10:1               | 
|temperature   |                   |                   |(recommended)      |
|--------------|-------------------|-------------------|-------------------|
|Detector      |FID                |Detector           |240 ℃             | 
|              |                   |temperature        |                   |
|--------------|-------------------|-------------------|-------------------|
|Carrier gas   |N2                 |Flow rate          |1.5 mL/min         |
|--------------|-------------------|-------------------|-------------------|
|Injection volume                  |1.0 uL                                 |
----------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 150 of 542 





Page 151
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



_System suitability_ : reference solution 



– elution order: ethanol, tetrahydrofuran, toluene, N-methylpyrrolidone. 



– _resolution_ : minimum 1.5 between the adjacent peaks. 



_Limits_ (calculate by external standard method): 



– ethanol NMT 0.5%; 



- tetrahydrofuran NMT 0.072%; 



- toluene NMT 0.089%; 



- N-methylpyrrolidone NMT 0.053% 



**Water** 



Examine in accordance with Standard operating procedure of Water 



determination (in-house method) 



NMT 0.5%, determined on 0.2 g. 



**Residue on ignition** 



Examine by _Operating procedures of residue on ignition determination_ 



(in-house method). 



NMT 0.1%, determined on 1.0 g. 



**Heavy metals** 



Examine by _Operating procedures of heavy metals determination_ (in-house 



method). 



NMT 10 ppm, determined on the residue obtained in the test for _Residue on_ 



_ignition_ . 



**Microbial limits** 



Examine by _Operating procedures of microbial limits determination_ (in-house 



method) 



Limits: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 151 of 542 





Page 152
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Total aerobic microbial counts (TAMC) is NMT 10 [3] CFU/g; 



mould and yeast count (TYMC) is NMT 10 [2] CFU/g; and 



_E.coli_ is absent in each 1 g of the substance to be examined. 



**Assay** 



Examine by Operating procedures of high performance liquid 



chromatography (in-house method). 



Solvent mixture: acetonitrile, water (30:70 V/V); 



Test solution: Take an appropriate amount of this product, weigh it 



accurately, dissolve it in a solvent with ultrasound, and dilute it to make a 



solution containing approximately 0.02mg per 1ml. 



Reference solution: Take an appropriate amount of non maleketone reference 



substance, accurately weigh it, dissolve it in solvent ultrasound and dilute it 



to prepare a solution containing approximately 0.02mg of non maleketone 



per 1ml. 



_Chromatographic system_ 



Except for the detection wavelength of 251nm, all others are Refer to the 



relevant material items. 



_System suitability_ 



-Reference solution: The theoretical number of trays NLT 3000 calculated 



based on the Finerenone peak, and the tailing factor NMT 1.5; 



-The reference solution should be injected 6 times, and the relative standard 



deviation of the main peak area NMT 2%. 



Calculate the percentage content of Finerenone (C21H22N4O3) by external 



standard method. 



It contains 98.0% to 102.0% of C21H22N4O3, calculated on the anhydrous 



basis. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 152 of 542 





Page 153
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4.3 Validation of Analytical Procedure** 



**3.2.S.4.3.1 Method Validation of Related Substances in Finerenone** 



**I. Analytical Procedures** 



Please refer to the analytical procedures of related substances in Finerenone 



in _section 3.2.S.4.2_ . 



**II. Validation Results and Discussion** 



**a. Selection of Detection Wavelength** 



 **Acceptance Criteria** 



The selection of the detection wavelength is carried out by measuring 



Finerenone (YA2304), YA2304-10, YA2304-12, YA2304-14, YA2304-15, 



YA2304-16, YA2304-17, YA2304-18 and YA2304-19 at 200nm ~ 400nm 



wavelengths Uv scanning, YA2304-10 and YA2304-17 should have large 



absorption at 230nm; Finerenone (YA2304), YA2304-12, YA2304-14, 



YA2304-15, YA2304-16, YA2304-18 and ya2304-19 should have greater 



absorption at 251nm. 



 **Solution Preparation** 



Blank solution: solvent. 



YA2304-12 Reference product reserve liquid: Take YA2304-12 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with solvent and dilute to scale, shake well, and then get. (About 



200μg/ml) 



YA2304-14 reference product reserve liquid: Take YA2304-14 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with acetonitrile and dilute to scale, shake well, ready. (Approx. 



200μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 153 of 542 





Page 154
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304 reference product reserve liquid: Take YA2304 reference product 



about 5mg, accurately weigh, put into 25ml measuring bottle, dissolve with 



acetonitrile and dilute to scale, shake well, ready. (Approx. 200μg/ml) 



YA2304-15 reference product reserve liquid: Take YA2304-15 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with acetonitrile and dilute to scale, shake well, ready. (Approx. 



200μg/ml) 



YA2304-16 reference product reserve liquid: Take YA2304-16 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with acetonitrile and dilute to scale, shake well, ready. (Approx. 



200μg/ml) 



YA2304-18 reference product reserve liquid: Take YA2304-18 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with acetonitrile and dilute to scale, shake well, ready. (Approx. 



200μg/ml) 



YA2304-19 reference product reserve liquid: Take YA2304-19 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with acetonitrile and dilute to scale, shake well, ready. (Approx. 



200μg/ml) 



YA2304-10 reference product reserve liquid: Take YA2304-10 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with solvent and dilute to scale, shake well, and then obtain. (About 



200μg/ml) 



YA2304-17 reference product reserve liquid: Take YA2304-17 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with solvent and dilute to scale, shake well, and then obtain. (About 



200μg/ml) 



Mixed control solution ① : Take 0.6ml of each control product reserve 



solution of YA2304-12, YA2304-14, YA2304, YA2304-15, YA2304-16, 



YA2304-18, YA2304-19, YA2304-10 and YA2304-17 and put them into a 



20ml measuring bottle. Dilute it with solvent to scale and shake well; Then 



accurately measure 1ml of the above solution, place it in a 10ml measuring 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 154 of 542 





Page 155
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



bottle, dilute it with solvent to the scale, shake well, and then get. (Both 



about 0.6μg/ml) 



 **Injection Sequence** 



After the blank solution, inject 1 needle mixed with reference solution ① and 



record the chromatogram. 



 **Results and Discussion** 



Wavelength Scanning Spectrum of Reference solution: 



Results of Detection Wavelength Selection: 













------------------------------------------------------------------------------
|Ingredient             |Retention time (min)   |Whether there is a large    |
|name                   |                       |absorption at 230nm or 251nm|
|-----------------------|-----------------------|----------------------------|
|YA2304-10              |15.278                 |Yes, at 230nm               |
|-----------------------|-----------------------|----------------------------|
|YA2304-17              |11.524                 |Yes, at 230nm               |
|-----------------------|-----------------------|----------------------------|
|YA2304-12              |3.791                  |Yes, at 251nm               |
|-----------------------|-----------------------|----------------------------|
|YA2304-14              |8.175                  |Yes, at 251nm               |
|-----------------------|-----------------------|----------------------------|
|YA2304                 |9.329                  |Yes, at 251nm               |
|-----------------------|-----------------------|----------------------------|
|YA2304-15              |10.295                 |Yes, at 251nm               |
|-----------------------|-----------------------|----------------------------|
|YA2304-16              |11.942                 |Yes, at 251nm               |
|-----------------------|-----------------------|----------------------------|
|YA2304-18              |13.183                 |Yes, at 251nm               |
|-----------------------|-----------------------|----------------------------|
|YA2304-19              |16.435                 |Yes, at 251nm               |
|-----------------------|-----------------------|----------------------------|
|Conclusion: Impurities YA2304-10 and YA2304-17 have large absorption at     |
|230nm wavelength; The principal component and impurities YA2304-12,         |
|YA2304-14, YA2304-15, YA2304-16, YA2304-18 and YA2304-19 all have large     |
|absorption at 251nm.                                                        |
------------------------------------------------------------------------------

**b. System Suitability Determination** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 155 of 542 





Page 156
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



 **Acceptance Criteria** 



The blank solution should be free of interference; Reference solution 



chromatogram (230nm), the peak order is YA2304-17, YA2304-10; In the 



chromatogram of system suitability solution (251nm), the peak order is 



YA2304-14, YA2304, YA2304-15, YA2304-17, YA2304-16, YA2304-10, 



YA2304-19. The separation degree between YA2304 and YA2304-14 and 



YA2304-15 should be NLT 1.5, and the separation degree between 



YA2304-17 and YA2304-16 and adjacent peaks should be NLT 1.0; In the 



chromatogram obtained by contrast solution (251nm) for 6 consecutive days, 



the RSD of the main peak NMT 1.0%, the RSD of the peak area NMT 5%, and 



the signal-to-noise ratio (S/N) should NLT 20. 



 **Solution preparation** 



Blank solution: solvent. 



YA2304-12 Reference storage solution: Share "YA2304-12 Reference Storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304 Reference stock: Share "YA2304 Reference Stock" under "4.1 



Wavelength Selection". (Approx. 200μg/ml) 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 156 of 542 





Page 157
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-18 Reference storage solution: Share "YA2304-18 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Test product solution: Take about 10mg of this product, weigh it accurately, 



put it in a 25ml measuring bottle, dissolve it with solvent and dilute it to the 



scale, shake well, then get. (About 0.4mg/ml) 



Control solution: accurately measure 1ml of the test product solution, place 



it in a 20ml measuring bottle, dilute it with solvent to the scale, and shake 



well; Precision measure 1ml of the above solution, place it in a 50ml 



measuring bottle, dilute it with solvent to the scale, shake well, and then get. 



(About 0.4μg/ml) 



Reference solution: accurately measure 1ml each of YA2304-10 and 



YA2304-17 reference solution, place them in a 50ml measuring bottle, dilute 



them with solvent to scale, and shake well; Accurately measure 1ml of the 



above solution, place it in a 10ml measuring bottle, dilute it with solvent to 



the scale, shake well, and then obtain. (YA2304-10 and YA2304-17 contain 



about 0.4μg/ml) 



System suitability solution: Accurately weigh YA2304 reference product 



about 10mg, place it in 25ml bottle, add appropriate amount of solvent to 



dissolve by ultrasound, then accurately add 100μl each of YA2304-14, 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 157 of 542 





Page 158
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-15, YA2304-16, YA2304-19, YA2304-10 and YA2304-17 reference 



product reserve solution. Dilute with solvent to scale, shake well, ready. 



(YA2304-14, YA2304-15, YA2304-16, YA2304-19, YA2304-10 and 



YA2304-17 all about 0.8μg/ml) 



 **Injection Sequence** 



After the blank solution, inject 1 needle of system suitability solution, 1 



needle of reference solution, 6 needles of reference solution, and record the 



chromatogram. 



 **Results and Discussion** 



Results of System Suitability: 






















































-----------------------------------------------------------------------------------
|Name of   |Substance|YA2304-1 4|YA2304   |YA2304-1 5|YA2304-1 7       |YA2304-1 6|
|spectru m |name     |          |         |          |                 |          |
|----------|---------|----------|---------|----------|-----------------|----------|
|System    |RT (min) |8.255     |9.307    |10.306    |11.563           |11.979    |
|suitabilit|         |          |         |          |                 |          |
|y solution|         |          |         |          |                 |          |
|(251nm)   |         |          |         |          |                 |          |
|          |---------|----------|---------|----------|-----------------|----------|
|          |Minimum separation  |4.9      |Minimum separation  |       |1.2       |
|          |between YA2304 and  |         |between YA2304-17   |       |          |
|          |YA2304-14 and       |         |and YA2304-16 and   |       |          |
|          |YA2304-15           |         |adjacent peaks      |       |          |
|----------|--------------------|         |--------------------|-------|          |
|Map name  |Number of|Main peak retention |Main peak area      |Principal peak    |
|          |samples  |time (min)          |                    |signal-to-noise   |
|          |injected |                    |                    |ratio (S/N)       |
|----------|---------|--------------------|--------------------|------------------|
|Control   |1        |9.378               |6845                |54.4              |
|solution  |         |                    |                    |                  |
|(251nm)   |         |                    |                    |                  |
|          |---------|--------------------|--------------------|------------------|
|          |2        |9.381               |6900                |44.5              |
|          |---------|--------------------|--------------------|------------------|
|          |3        |9.381               |6907                |71.7              |
|          |---------|--------------------|--------------------|------------------|
|          |4        |9.389               |6991                |73.6              |
|          |---------|--------------------|--------------------|------------------|
|          |5        |9.387               |6976                |97.1              |
|          |---------|--------------------|--------------------|------------------|
|          |6        |9.382               |6726                |78.4              |
-----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 158 of 542 





Page 159
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 

---------------------------------------------------------------------------------
|               |RSD(n=6)       |0.05%          |1.5%           |/              |
|---------------|---------------|---------------|---------------|---------------|
|Conclusion: There was no interference in the blank solution, the               |
|chromatogram of the control solution (230nm), the peak sequence was            |
|YA2304-17, YA2304-10; In the chromatogram of system suitable solution          |
|(251nm), the peak order was YA2304-14, YA2304, YA2304-15, YA2304-17,           |
|YA2304-16, YA2304-10, YA2304-19. The minimum separation degree between         |
|YA2304 and YA2304-14 and YA2304-15 is 4.9 (NLT 1.5), and the minimum           |
|separation degree between YA2304-17 and YA2304-16 and adjacent peaks is 1.2    |
|(NLT 1.0); In the chromatogram obtained by contrast solution (251nm) for 6     |
|consecutive days, the RSD of main peak retention time was 0.05% (not more      |
|than 1.0%), the RSD of main peak area was 1.5% (not more than 5%), and the     |
|signal-to-noise ratio (S/N) was NLT 20. All the above meet the verification    |
|requirements, indicating that the method has good applicability in system.     |
---------------------------------------------------------------------------------



**c. Specificity** 



**i. Peak Specificity** 



 **Acceptance Criteria** 



The blank solution should be free from interference; In the 



chromatogram of system suitability solution (251nm), the peak order is 



YA2304-14, YA2304, YA2304-15, YA2304-17, YA2304-16, YA2304-10, 



YA2304-19, The separation degree between YA2304 and YA2304-14 and 



YA2304-15 should be NLT 1.5, and the separation degree between 



YA2304-17 and YA2304-16 and adjacent peaks should be NLT 1.0; In the 



chromatogram of test product solution (251nm) and specific mixed solution 



(251nm), the separation degree between YA2304-17 and YA2304-16 and 



adjacent peaks should NLT 1.0, and the separation degree between other 



adjacent peaks should NLT 1.5; The retention time of each known impurity 



peak in the reference solution, system suitability solution, test product 



solution and specific mixed solution should be consistent with the 



corresponding main peak in the impurity positioning solution, and the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 159 of 542 





Page 160
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



relative retention time of each known impurity peak in the specific mixed 



solution should be basically consistent with the quality standard. 



 **Solution preparation** 



Blank solution: solvent 



YA2304-12 Reference storage solution: Share "YA2304-12 Reference Storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304 Reference stock: Share "YA2304 Reference Stock" under "4.1 



Wavelength Selection". (Approx. 200μg/ml) 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-18 Reference storage solution: Share "YA2304-18 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 160 of 542 





Page 161
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-12 Impurity location solution: accurately measure 0.6ml of 



YA2304-12 reference product reserve, place it in a 20ml measuring bottle, 



dilute it with solvent to the scale, and shake well; Then precisely measure 



1ml, place it in a 10ml measuring bottle, dilute it with solvent to the scale, 



and shake well, then it is ready. (About 0.6μg/ml) 



YA2304-14 Impurity location solution: accurately measure 0.6ml of 



YA2304-14 reference product reserve, place it in a 20ml measuring bottle, 



dilute it with solvent to the scale, and shake well; Then precisely measure 



1ml, place it in a 10ml measuring bottle, dilute it with solvent to the scale, 



and shake well, then it is ready. (About 0.6μg/ml) 



YA2304-15 Impurity location solution: accurately measure 0.6ml of 



YA2304-15 reference product reserve, place it in a 20ml measuring bottle, 



dilute it with solvent to the scale, and shake well; Then precisely measure 



1ml, place it in a 10ml measuring bottle, dilute it with solvent to the scale, 



shake well, and then obtain. (About 0.6μg/ml) 



YA2304-16 Impurity location solution: accurately measure 0.6ml of 



YA2304-16 reference product reserve, place it in a 20ml measuring bottle, 



dilute it with solvent to the scale, and shake well; Then precisely measure 



1ml, place it in a 10ml measuring bottle, dilute it with solvent to the scale, 



and shake well, then it is ready. (About 0.6μg/ml) 



YA2304-18 Impurity location solution: Accurately measure 0.6ml of 



YA2304-18 reference product reserve, place it in a 20ml measuring bottle, 



dilute it with solvent to the scale, and shake well; Then precisely measure 



1ml, place it in a 10ml measuring bottle, dilute it with solvent to the scale, 



and shake well, then it is ready. (About 0.6μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 161 of 542 





Page 162
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-19 Impurity location solution: accurately measure 0.6ml of 



YA2304-19 reference product reserve, place it in a 20ml measuring bottle, 



dilute it with solvent to the scale, and shake well; Then precisely measure 



1ml, place it in a 10ml measuring bottle, dilute it with solvent to the scale, 



and shake well, then it is ready. (About 0.6μg/ml) 



YA2304-17 Impurity location solution: accurately measure 0.6ml of 



YA2304-17 reference product reserve, place it in a 20ml measuring bottle, 



dilute it with solvent to the scale, and shake well; Then precisely measure 



1ml, place it in a 10ml measuring bottle, dilute it with solvent to the scale, 



and shake well, then it is ready. (About 0.6μg/ml) 



YA2304-10 Impurity location solution: accurately measure 0.6ml of 



YA2304-10 reference product reserve, place it in a 20ml measuring bottle, 



dilute it with solvent to the scale, and shake well; Then precisely measure 



1ml, place it in a 10ml measuring bottle, dilute it with solvent to the scale, 



and shake well, then it is ready. (About 0.6μg/ml) 



Reference solution: Share "Reference solution" under "4.2 System Suitability". 



(YA2304-10, YA2304-17 containing approximately 0.4μg/ml) 



Test solution: Share "test solution" under "4.2 System Suitability". (Approx. 



0.4mg/ml) 



Control solution: Share "Control solution" under "4.2 System Suitability". 



(Approx. 0.4μg/ml) 



System Suitability Solution: Share "System Suitability Solution" under "4.2 



System Suitability". (YA2304-14, YA2304-15, YA2304-16, YA2304-19, 



YA2304-10 and YA2304-17 all approx. 0.8μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 162 of 542 





Page 163
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Specific reserve liquid: Take 1.5ml of each control product reserve liquid of 



YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-18, YA2304-19, 



YA2304-17 and YA2304-10 respectively and place them in the same 20ml 



bottle and dilute them to the scale with solvent. Shake well, then it is ready. 



(Contains YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-18, 



YA2304-19, YA2304-17 and YA2304-10 about 15μg/ml each) 



Specific mixed solution: accurately weigh 10mg of this product, place it in a 



25ml measuring bottle, add an appropriate amount of solvent and ultrasonic 



to dissolve it, then precisely add 1.0ml of specific reserve solution, dilute it 



with solvent to the scale, shake well, and get. (Including YA2304-12, 



YA2304-14, YA2304-15, YA2304-16, YA2304-18, YA2304-19, YA2304-17 



and YA2304-10 are about 0.6μg/ml) 



 **Injection Sequence** 



After the blank solution, Sample system suitability solution, test product 



solution, reference product solution, reference solution, specific mixed 



solution, YA2304-12 impurity location solution, YA2304-14 impurity 



location solution, YA2304-15 impurity location solution, YA2304-16 



impurity location solution, YA2304-18 impurity location solution, YA230 



4-19 Impurity location solution, YA2304-10 impurity location solution and 



YA2304-17 impurity location solution were each injected, and the 



chromatogram was recorded. 



 **Results and Discussion** 



Results of Peak Specificity: 




Solution 



name 




Detection 



wavelength 




Component 



name 




Component 



concentration 



(μg/ml) 




Rt 



(min) 




RRT 




Minimum 



separation 



from 




Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 163 of 542 





Page 164
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



























--------------------------------------------------------------
|         |       |         |       |       |       |adjacent|
|         |       |         |       |       |       |peaks   |
|---------|-------|---------|-------|-------|-------|--------|
|YA2304-12|251nm  |YA2304-12|0.6005 |3.826  |/      |/       |
|Impurity |       |         |       |       |       |        |
|locating |       |         |       |       |       |        |
|solution |       |         |       |       |       |        |
|---------|-------|---------|-------|-------|-------|--------|
|YA2304-14|251nm  |YA2304-14|0.6032 |8.268  |/      |/       |
|Impurity |       |         |       |       |       |        |
|locating |       |         |       |       |       |        |
|solution |       |         |       |       |       |        |
|---------|-------|---------|-------|-------|-------|--------|
|Contrast |251nm  |YA2304   |0.4113 |9.378  |/      |/       |
|solution |       |         |       |       |       |        |
|---------|-------|---------|-------|-------|-------|--------|
|YA2304-15|251nm  |YA2304-15|0.6055 |10.314 |/      |/       |
|Impurity |       |         |       |       |       |        |
|locating |       |         |       |       |       |        |
|solution |       |         |       |       |       |        |
|---------|-------|---------|-------|-------|-------|--------|
|YA2304-17|251nm  |YA2304-17|0.6040 |11.563 |/      |/       |
|Impurity |       |         |       |       |       |        |
|locating |       |         |       |       |       |        |
|solution |       |         |       |       |       |        |
|         |-------|         |       |-------|-------|--------|
|         |230nm  |         |       |11.556 |/      |/       |
|---------|-------|---------|-------|-------|-------|--------|
|YA2304-16|251nm  |YA2304-16|0.5797 |11.976 |/      |/       |
|Impurity |       |         |       |       |       |        |
|locating |       |         |       |       |       |        |
|solution |       |         |       |       |       |        |
|---------|-------|---------|-------|-------|-------|--------|
|YA2304-18|251nm  |YA2304-18|0.6014 |13.221 |/      |/       |
|Impurity |       |         |       |       |       |        |
|locating |       |         |       |       |       |        |
|solution |       |         |       |       |       |        |
|---------|-------|---------|-------|-------|-------|--------|
|YA2304-10|251nm  |YA2304-10|0.6092 |15.316 |/      |/       |
|Impurity |       |         |       |       |       |        |
|locating |       |         |       |       |       |        |
|solution |       |         |       |       |       |        |
|         |-------|         |       |-------|-------|--------|
|         |230nm  |         |       |15.312 |/      |/       |
|---------|-------|---------|-------|-------|-------|--------|
|YA2304-19|251nm  |YA2304-19|0.6008 |16.496 |/      |/       |
|Impurity |       |         |       |       |       |        |
|locating |       |         |       |       |       |        |
--------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 164 of 542 





Page 165
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 












----------------------------------------------------------------
|solution   |       |         |        |       |       |       |
|-----------|-------|---------|--------|-------|-------|-------|
|Reference  |230nm  |YA2304-17|0.6040  |11.558 |/      |/      |
|solution   |       |         |        |       |       |       |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-10|0.6092  |15.319 |/      |/      |
|-----------|-------|---------|--------|-------|-------|-------|
|System     |251nm  |YA2304-14|0.8043  |8.255  |0.89   |4.9    |
|Suitability|       |         |        |       |       |       |
|solution   |       |         |        |       |       |       |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304   |402.4291|9.307  |1.00   |4.9    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-15|0.8073  |10.306 |1.11   |5.5    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-17|0.8054  |11.563 |1.24   |1.2    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-16|0.7730  |11.979 |1.29   |1.4    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-10|0.8122  |15.316 |1.65   |5.5    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-19|0.8011  |16.486 |1.77   |5.5    |
|-----------|-------|---------|--------|-------|-------|-------|
|Sample     |251nm  |YA2304-12|/       |3.815  |0.41   |4.5    |
|solution   |       |         |        |       |       |       |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304   |411.2800|9.292  |1.00   |6.8    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-19|/       |16.476 |1.77   |24.4   |
|           |-------|---------|--------|-------|-------|-------|
|           |230nm  |YA2304-17|/       |/      |/      |/      |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-10|/       |/      |/      |/      |
|-----------|-------|---------|--------|-------|-------|-------|
|Specific   |251nm  |YA2304-12|0.6005  |3.810  |0.41   |3.1    |
|mixed      |       |         |        |       |       |       |
|solution   |       |         |        |       |       |       |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-14|0.6032  |8.233  |0.89   |4.7    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304   |410.0400|9.289  |1.00   |5.0    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-15|0.6055  |10.295 |1.11   |5.6    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-17|0.6040  |11.549 |1.24   |1.2    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-16|0.5797  |11.972 |1.29   |1.4    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-18|0.6014  |13.207 |1.42   |7.4    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-10|0.6092  |15.305 |1.65   |5.7    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-19|0.6008  |16.474 |1.77   |5.7    |
|           |-------|---------|--------|-------|-------|-------|
|           |230nm  |YA2304-12|0.6005  |3.806  |0.41   |9.5    |
|           |       |---------|--------|-------|-------|-------|
|           |       |YA2304-14|0.6032  |8.229  |0.89   |5.0    |
----------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 165 of 542 





Page 166
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 

------------------------------------------------------------------------------
|          |          |YA2304    |410.0400  |9.285     |1.00      |5.0       |
|          |          |----------|----------|----------|----------|----------|
|          |          |YA2304-15 |0.6055    |10.291    |1.11      |5.6       |
|          |          |----------|----------|----------|----------|----------|
|          |          |YA2304-17 |0.6040    |11.547    |1.24      |1.2       |
|          |          |----------|----------|----------|----------|----------|
|          |          |YA2304-16 |0.5797    |11.967    |1.29      |1.5       |
|          |          |----------|----------|----------|----------|----------|
|          |          |YA2304-18 |0.6014    |13.203    |1.42      |7.4       |
|          |          |----------|----------|----------|----------|----------|
|          |          |YA2304-10 |0.6092    |15.304    |1.65      |5.6       |
|          |          |----------|----------|----------|----------|----------|
|          |          |YA2304-19 |0.6008    |16.470    |1.77      |5.6       |
|----------|----------|----------|----------|----------|----------|----------|
|Conclusion: Blank solution has no interference; In the chromatogram of      |
|system suitability solution (251nm), the peak order was YA2304-14, YA2304,  |
|YA2304-15, YA2304-17, YA2304-16, YA2304-10, YA2304-19. The minimum          |
|separation degree between YA2304 and YA2304-14 and YA2304-15 is required to |
|be 4.9 (NLT 1.5), and the minimum separation degree between YA2304-17 and   |
|YA2304-16 and adjacent peaks is 1.2 (NLT 1.0); In the chromatogram of test  |
|product solution (251nm) and specific mixed solution (251nm), the minimum   |
|separation degree between YA2304-17 and YA2304-16 and adjacent peaks is 1.2 |
|(NLT 1.0), and the minimum separation degree between other adjacent peaks   |
|is 3.1 (NLT 1.5). In the chromatogram of specific mixed solution (230nm),   |
|the minimum separation degree between YA2304-17 and YA2304-16 and adjacent  |
|peaks was 1.2 (NLT 1.0), and the minimum separation degree between other    |
|adjacent peaks was 5.0 (NLT 1.5). The retention time of each known impurity |
|peak in the reference solution, the system suitability solution, the test   |
|product solution and the specific mixed solution was consistent with the    |
|corresponding main peak in the impurity localization solution, and the      |
|relative retention time of each known impurity peak in the specific mixed   |
|solution was basically consistent with the quality standard; The above are  |
|in line with the verification requirements.                                 |
------------------------------------------------------------------------------



**ii. Forced Degradation Studies** 



 **Acceptance Criteria** 



The forced degradation test is to examine the stability of the sample 



under acid, alkali, oxidation, high temperature, light and other conditions. 



By examining the separation of impurities from the sample and the material 



balance rate, the feasibility of the method is verified. It is required that the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 166 of 542 





Page 167
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



degradation degree of the principal component NMT 20% under each 



destruction condition, and the separation degree between the peaks of 



impurities greater than 0.05% in the samples after degradation should NLT 



1.0, the purity Angle of the main peak should be less than the purity 



threshold, and the material balance rate should be between 90% and 110%. 



 **Solution preparation** 



Blank solution: solvent. 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference 



Storage solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304 Reference stock: Share "YA2304 Reference Stock" under "4.1 



Wavelength Selection". (Approx. 200μg/ml) 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference 



Storage Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference 



Storage Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference 



Storage Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference 



Storage Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference 



Storage Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



System suitability solution: Prepare by the same method as "System 



Suitability solution" under "4.2 System Suitability". (YA2304-14, YA2304-15, 



YA2304-16, YA2304-19, YA2304-10 and YA2304-17 are about 0.8μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 167 of 542 





Page 168
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Control product solution ① : Accurately measure 1ml of YA2304 control 



product reserve solution, place it in 20ml measuring bottle, dilute it with 



solvent to scale, and shake well; Accurately measure 1ml of the above 



solution, place it in a 25ml measuring bottle, dilute it with solvent to the 



scale, shake well, and then obtain. (About 0.4μg/ml) 



Control product solution ② : accurately measure 1ml of YA2304-10 and 



YA2304-17 control product reserve solution respectively, place them in 50ml 



measuring bottle, dilute them with solvent to scale, and shake well; 



Accurately measure 1ml of the above solution, place it in a 10ml measuring 



bottle, dilute it with solvent to the scale, shake well, and then obtain. 



(YA2304-10 and YA2304-17 contain about 0.4μg/ml) 



Undamaged test product solution: Take about 10mg of this product, 



weigh it accurately, place it in a 25ml measuring bottle, dissolve it with 



solvent and dilute it to the scale, shake well, and then get. (About 0.4mg/ml) 



High temperature destruction of test product solution: take appropriate 



amount of this product, 105℃ destruction for 5 days, precision weigh about 



10mg, put in 25ml measuring bottle, dissolve with solvent and dilute to the 



scale, shake well, then get. 



Light damage test product solution: Take appropriate amount of this 



product, light damage (25±2℃, 60±10%RH, 4500±500LUX, 90±5μWcm [2] ) 30 



days after damage, precision weigh about 10mg, put in 25ml measuring 



bottle, dissolve with solvent and dilute to the scale, shake well, filter, ready. 



The blank solution of acid and base destruction: take 2ml of 0.1mol/L 



hydrochloric acid solution, place it in 25ml bottle, add 2ml of 0.1mol/L 



sodium hydroxide solution to neutralize it, add 1ml acetonitrile, dilute it with 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 168 of 542 





Page 169
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



solvent to the scale, shake well, and get. 



Acid destruction of test product solution: Take about 10mg of this 



product, put it in 25ml bottle, add 2ml of 0.1mol/L hydrochloric acid 



solution to destroy it for 24h, add 2ml of 0.1mol/L sodium hydroxide solution 



to neutralize it, add 1ml of acetonitrile, dissolve it with solvent and dilute it to 



the scale, shake well, and obtain. 



Alkali destruction test solution: Take about 10mg of this product, place 



it in 25ml bottle, add 2ml of 0.1mol/L of sodium hydroxide solution to 



destroy it for 24h, add 2ml of 0.1mol/L of hydrochloric acid solution to 



neutralize it, add 1ml of acetonitrile, dissolve it with solvent and dilute it to 



the scale, shake well, and obtain. 



Oxidizing and destroying blank solution: take 2ml of 3% hydrogen 



peroxide solution, place it in 25ml measuring bottle, add 0.5ml acetonitrile, 



dilute it with solvent to scale, shake well, and get. 



Oxidizing destruction of test product solution: Take about 10mg of this 



product, weigh it accurately, put it in 25ml bottle, add 2ml of 3% hydrogen 



peroxide solution and destroy it at room temperature for 24h, then add 0.5ml 



of acetonitrile, dilute it with solvent to the scale, shake well, and obtain. 



Sample of light destruction solution: Take about 10mg of this product, 



accurately weigh it, put it in 25ml transparent measuring bottle, dissolve it 



with solvent and dilute it to the scale, shake well, and destroy it under 



(25±2℃, 60±10%RH, 4500±500LUX, 90±5μWcm [2] ) under light condition for 



24h, ready to obtain. 



 **Injection Sequence** 



After the blank solution, the system suitable solution was injected with 1 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 169 of 542 





Page 170
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



needle, the control solution (1) and the control solution (2) were injected with 



2 needles each. The blank solution of oxidation destruction, the blank 



solution of acid and alkali destruction, the undamaged test product solution, 



the acid destruction test product solution, the alkali destruction test product 



solution, the oxidation destruction test product solution, the high 



temperature destruction test product solution, the light destruction test 



product solution and the light destruction solution sample were each 1 



needle, and the chromatogram was recorded. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 170 of 542 





Page 171
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



 **Results and Discussion** 



Results of Forced Degradation Studies: 








































---------------------------------------------------------------------------------------------------------------------
|Name of solution  |Undamaged   |Acid destroys|Alkali       |Oxidation    |High         |Light        |Light        |
|                  |test product|test solution|destroys the |destroys the |temperature  |destroys the |destroys the |
|                  |solution    |             |test solution|test solution|destroys the |test solution|solution     |
|                  |            |             |             |             |test solution|             |sample       |
|------------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|
|Failure           |/           |0.1mol/l     |Destroy      |3% hydrogen  |Damage at    |4500±500Lux,|4500±500Lux,|  
|conditions        |            |hydrochloric |0.1mol/l     |peroxide 2mL |105℃for 5d  |90±5μWcm2  |90±5μWcm2  |     
|                  |            |acid 2mL     |sodium       |destruction  |             |destroy solid|destroy the  |
|                  |            |destruction  |hydroxide 2mL|for 24h      |             |samples for  |test solution|
|                  |            |for 24h      |for 24h      |             |             |30d          |for 24h      |
|------------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|
|Main peak purity  |0.313       |0.259        |0.276        |0.300        |0.266        |0.286        |0.261        |
|Angle             |            |             |             |             |             |             |             |
|------------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|
|Main peak purity  |1.170       |1.104        |1.207        |1.207        |1.231        |1.110        |1.167        |
|threshold         |            |             |             |             |             |             |             |
|------------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|
|Main peak purity  |99.93%      |97.87%       |99.89%       |99.32%       |99.95%       |99.41%       |99.02%       |
|(%)               |            |             |             |             |             |             |             |
|------------------|------------|-------------|-------------|-------------|-------------|-------------|-------------|
|I m     |YA2304-12|< 0.05%     |< 0.05%      |0.07%        |< 0.05%      |< 0.05%      |< 0.05%      |< 0.05%      |
|        |---------|------------|-------------|-------------|-------------|-------------|-------------|-------------|
|        |YA2304-14|Not detected|Not detected |Not detected |Not detected |Not detected |< 0.05%      |Not detected |
---------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 171 of 542 





Page 172
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 







----------------------------------------------------------------------------------------------------------------
|p u ri ty|YA2304-15|Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     |Not detected|
|c o nt e |         |            |            |            |            |            |            |            |
|nt       |         |            |            |            |            |            |            |            |
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |YA2304-16|Not detected|< 0.05%     |Not detected|Not detected|Not detected|< 0.05%     |< 0.05%     |
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |YA2304-18|Not detected|Not detected|Not detected|Not detected|Not detected|Not detected|Not detected|
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |YA2304-19|< 0.05%     |< 0.05%     |< 0.05%     |0.12%       |< 0.05%     |0.17%       |0.54%       |
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |YA2304-17|Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     |< 0.05%     |
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |YA2304-10|Not detected|Not detected|Not detected|Not detected|Not detected|Not detected|Not detected|
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |RRT≈0.49|Not detected|Not detected|Not detected|< 0.05%     |Not detected|Not detected|Not detected| 
|         |impurity |            |            |            |            |            |            |            |
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |RRT≈0.53|Not detected|Not detected|Not detected|< 0.05%     |Not detected|Not detected|Not detected| 
|         |impurity |            |            |            |            |            |            |            |
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |RRT≈0.58|Not detected|Not detected|Not detected|< 0.05%     |Not detected|Not detected|Not detected| 
|         |impurity |            |            |            |            |            |            |            |
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |RRT≈0.59|Not detected|2.02%       |Not detected|Not detected|Not detected|Not detected|< 0.05%     | 
|         |impurity |            |            |            |            |            |            |            |
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |RRT≈0.64|< 0.05%     |Not detected|Not detected|0.43%       |Not detected|< 0.05%     |0.06%       | 
|         |impurity |            |            |            |            |            |            |            |
|         |---------|------------|------------|------------|------------|------------|------------|------------|
|         |RRT≈0.67|Not detected|Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     | 
|         |impurity |            |            |            |            |            |            |            |
----------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 172 of 542 





Page 173
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

---------------------------------------------------------------------------------------------------------------
|       |RRT≈0.71 |Not detected|Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     | 
|       |impurity  |            |            |            |            |            |            |            |
|       |----------|------------|------------|------------|------------|------------|------------|------------|
|       |RRT≈0.73 |Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     |Not detected| 
|       |impurities|            |            |            |            |            |            |            |
|       |----------|------------|------------|------------|------------|------------|------------|------------|
|       |RRT≈0.79 |Not detected|Not detected|Not detected|< 0.05%     |Not detected|< 0.05%     |Not detected| 
|       |impurity  |            |            |            |            |            |            |            |
|       |----------|------------|------------|------------|------------|------------|------------|------------|
|       |RRT≈0.87 |Not detected|Not detected|Not detected|Not detected|Not detected|Not detected|0.06%       | 
|       |impurity  |            |            |            |            |            |            |            |
|       |----------|------------|------------|------------|------------|------------|------------|------------|
|       |RRT≈0.96 |Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     |0.08%       | 
|       |impurity  |            |            |            |            |            |            |            |
|       |----------|------------|------------|------------|------------|------------|------------|------------|
|       |RRT≈1.14 |Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     |Not detected| 
|       |impurities|            |            |            |            |            |            |            |
|       |----------|------------|------------|------------|------------|------------|------------|------------|
|       |RRT≈1.16 |Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     |Not detected| 
|       |impurity  |            |            |            |            |            |            |            |
|       |----------|------------|------------|------------|------------|------------|------------|------------|
|       |RRT≈1.27 |< 0.05%     |< 0.05%     |< 0.05%     |< 0.05%     |< 0.05%     |< 0.05%     |< 0.05%     | 
|       |impurity  |            |            |            |            |            |            |            |
|       |----------|------------|------------|------------|------------|------------|------------|------------|
|       |RRT≈1.33 |Not detected|Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     | 
|       |impurities|            |            |            |            |            |            |            |
|       |----------|------------|------------|------------|------------|------------|------------|------------|
|       |RRT≈1.38 |Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     |Not detected| 
---------------------------------------------------------------------------------------------------------------



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 173 of 542 





Page 174
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










-------------------------------------------------------------------------------------------------------------------------
|               |impurities  |            |            |            |            |            |            |           | 
|               |------------|------------|------------|------------|------------|------------|------------|-----------| 
|               |RRT≈1.45   |Not detected|Not detected|Not detected|< 0.05%     |Not detected|Not detected|Not        |  
|               |impurity    |            |            |            |            |            |            |detected   | 
|               |------------|------------|------------|------------|------------|------------|------------|-----------| 
|               |RRT≈1.52   |Not detected|Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%    |  
|               |impurity    |            |            |            |            |            |            |           | 
|               |------------|------------|------------|------------|------------|------------|------------|-----------| 
|               |RRT≈1.53   |Not detected|Not detected|Not detected|Not detected|Not detected|0.05%       |Not        |  
|               |impurities  |            |            |            |            |            |            |detected   | 
|               |------------|------------|------------|------------|------------|------------|------------|-----------| 
|               |RRT≈1.67   |Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     |Not        |  
|               |impurity    |            |            |            |            |            |            |detected   | 
|               |------------|------------|------------|------------|------------|------------|------------|-----------| 
|               |RRT≈1.74   |Not detected|Not detected|Not detected|Not detected|Not detected|< 0.05%     |Not        |  
|               |impurity    |            |            |            |            |            |            |detected   | 
|---------------|------------|------------|------------|------------|------------|------------|------------|-----------| 
|               |Total       |< 0.05%     |2.02%       |0.07%       |0.56%       |< 0.05%     |0.22%       |0.74%      | 
|               |Miscellaneous|            |            |            |            |            |            |           |
|---------------|------------|------------|------------|------------|------------|------------|------------|-----------| 
|Material balance            |/           |99.02%      |100.01%     |99.91%      |99.96%      |98.15%      |99.59%     | 
|ratio                       |            |            |            |            |            |            |           | 
|----------------------------|------------|------------|------------|------------|------------|------------|-----------| 
|Conclusion: In the chromatogram of system applicability solution (251nm), the minimum separation degree   |           | 
|between YA2304 and                                                                                        |           | 
|YA2304-14 and YA2304-15 is 5.8 (NLT 1.5), and the minimum separation degree between YA2304-17 and         |           | 
|YA2304-16 and adjacent peaks                                                                              |           | 
|is 1.7 (NLT 1.0). The signal-to-noise ratio (SNR) of the two luminous solutions ①were 37.3 and 40.4 (both|           |  
|greater than 20),                                                                                         |           | 
|respectively, indicating that the system applicability met the requirements. There was no significant     |           | 
|change in the impurity                                                                                    |           | 
|quality of Finerenone raw material under the condition of high temperature (105℃for 5d). Under the       |           |  
|condition of destruction by                                                                               |           | 
|weak acid (destruction by 2mL of 0.1mol/l hydrochloric acid                                               |           | 
-------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 174 of 542 





Page 175
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



for 24h), Finerenone was mainly degraded to produce known impurities YA2144-16 (content < 0.05%) and unknown impurities of RRT≈0.59 



(content 2.02%). The known impurity YA2304-12 (content 0.07%) was mainly degraded under the condition of weak base (destruction of 2mL of 



0.1mol/l sodium hydroxide for 24h). The degradation of Finerenone under oxidation destruction (2mL destruction of 3% hydrogen peroxide for 



24h) mainly produced unknown impurities YA2304-19 (content 0.12%) and RRT≈0.64 (content 0.43%). The solid samples of Finerenone were 



destroyed by light (4500±500Lux, 90±5μWcm [2] for 30d) degradation mainly produced 5 known impurities YA2304-14, YA2304-15, YA2304-16, 



YA2304-17, YA2304-19, and unknown impurities with RRT≈1.53 (content of 0.05%). The 5 known impurities produced by degradation except 



the impurity YA2304-19 content of 0.17%, the other known impurities produced by degradation content of < 0.05%; Two known impurities, 



YA2144-16 and YA2144-19, and three unknown impurities, RRT≈0.64, RRT≈0.87 and RRT≈0.96, were mainly produced by the degradation of 



fenelidone bulk drug solution by light (4500±500Lux, 90±5μWcm [2] destroying the test product solution for 24h). The contents of YA2304-16 and 



YA2304-19 produced by degradation were < 0.05% and 0.54%, and the contents of RRT≈0.64, RRT≈0.87 and RRT≈0.96 produced by degradation 



were 0.06%, 0.06% and 0.08%, respectively. Under each failure condition, the degradation degree of principal component was less than 20%, 



and the purity Angle of main peak was less than the purity threshold. The material balance rate under each destruction condition is in the range 



of 90%~110%, and the peaking separation degree of impurities greater than 0.05% in the degraded samples is NLT 1.0, which can be effectively 



separated, indicating that the method has good specificity. Meet the verification requirements. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 175 of 542 





Page 176
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**d. Limit of Detection (LOD) and Limit of Quantitation (LOQ)** 



 **Acceptance Criteria** 



The limit of quantitation (LOQ) and the limit of detection (LOD) are 



achieved by testing and diluting the signal-to-noise ratio of each impurity 



reference solution with a certain concentration. The signal-to-noise ratio of 



each impurity peak in 6 LOQ solutions is NLT 10, the RSD of each impurity 



peak retention time should NMT 2.0%, and the RSD of the peak area should 



NMT 10%. The signal-to-noise ratio of each impurity peak in 3-needle LOD 



solution is NLT 3. 



 **Solution preparation** 



Blank solution: solvent 



YA2304-12 Reference storage solution: Share "YA2304-12 Reference Storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304 Reference stock: Share "YA2304 Reference Stock" under "4.1 



Wavelength Selection". (Approx. 200μg/ml) 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 176 of 542 





Page 177
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-18 Reference storage solution: Share "YA2304-18 Reference Storage 



Solution" under "3.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Quantitative limited stock solution: Accurately measure 1ml of each 



reference liquid for YA2304-12, YA2304-14, YA2304, YA2304-15, YA2304-16, 



YA2304-18, YA2304-19, YA2304-10 and YA2304-17 and place them in the 



same 20ml bottle. Dilute to the scale with solvent, shake well, and then get. 



Limited quantitation solution: Accurately measure 0.3ml of limited 



quantitation reserve liquid, place it in a 25ml measuring bottle, dilute it with 



solvent to the scale, shake well, and get. (Parallel preparation of 6 parts) 



Detection limit solution: accurately measure the first dose limit solution 5ml, 



place it in a 10ml measuring bottle, dilute it with solvent to the scale, shake 



well, and then get. 



 **Injection Sequence** 



After the blank solution, 6 parts of the limited quantitative solution were 



injected with 1 needle each, and the detection limited solution was injected 



with 3 needles repeatedly, and the chromatogram was recorded. 



 **Results and Discussion** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 177 of 542 





Page 178
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Results of LOQ Determination: 










































------------------------------------------------------------------------------------
|Impurity  |Solution    |Concentratio|Equivalent  |Retentio n|Peak area |S/N       |
|Designatio|name        |n /(μg/ml) |to test     |time /min |          |          | 
|n         |            |            |product     |          |          |          |
|          |            |            |solution    |          |          |          |
|          |            |            |concentratio|          |          |          |
|          |            |            |n /%        |          |          |          |
|----------|------------|------------|------------|----------|----------|----------|
|YA2304-12 |Limited     |0.1201      |0.0300      |3.796     |162 9     |14. 3     |
|          |quantitative|            |            |          |          |          |
|          |solution ① |            |            |          |          |          | 
|          |------------|            |            |----------|----------|----------|
|          |Limited                  |            |3.799     |164 2     |15. 1     |
|          |quantificatio            |            |          |          |          |
|          |n solution ②            |            |          |          |          | 
|          |-------------------------|            |----------|----------|----------|
|          |Limited                  |            |3.804     |163 4     |15. 1     |
|          |quantificatio            |            |          |          |          |
|          |n solution ③            |            |          |          |          | 
|          |-------------------------|            |----------|----------|----------|
|          |Limited                  |            |3.798     |168 3     |14. 1     |
|          |quantificatio            |            |          |          |          |
|          |n solution ④            |            |          |          |          | 
|          |-------------------------|            |----------|----------|----------|
|          |Limited                  |            |3.801     |155 6     |14. 6     |
|          |quantitation             |            |          |          |          |
|          |solution ⑤              |            |          |          |          | 
|          |-------------------------|            |----------|----------|----------|
|          |Limited                  |            |3.803     |173 5     |15. 4     |
|          |quantificatio            |            |          |          |          |
|          |n solution ⑥            |            |          |          |          | 
|          |-------------------------|------------|----------|----------|----------|
|          |RSD                                   |0.09%     |4%        |/         |
|          |--------------------------------------|----------|----------|----------|
|          |Verdict: The limiting solution concentration of impurity               |
|          |YA2304-12 was 0.1201μg/ml (relative to 0.0300% of the test            | 
|          |product concentration), the RSD of the retention time of 6             |
|          |parts of the limiting solution was 0.09% (no more than 2.0%),          |
|          |the RSD of the peak area was 4% (no more than 10%), and the S/N        |
|          |ranged from 14.1 to 15.4. All of them were greater than 10.            |
|          |Meet verification requirements.                                        |
|----------|-----------------------------------------------------------------------|
|YA2304-14 |Limited     |0.1206      |0.0302      |8.167     |204 4     |11. 1     |
|          |quantitative|            |            |          |          |          |
------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 178 of 542 





Page 179
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 





































----------------------------------------------------------------------------------
|           |solution ①  |          |          |          |          |          | 
|           |-------------|          |          |----------|----------|----------|
|           |Limited                 |          |8.173     |200 4     |11. 7     |
|           |quantificatio           |          |          |          |          |
|           |n solution ②           |          |          |          |          | 
|           |------------------------|          |----------|----------|----------|
|           |Limited                 |          |8.180     |202 2     |11. 8     |
|           |quantificatio           |          |          |          |          |
|           |n solution ③           |          |          |          |          | 
|           |------------------------|          |----------|----------|----------|
|           |Limited                 |          |8.174     |187 0     |10. 4     |
|           |quantificatio           |          |          |          |          |
|           |n solution ④           |          |          |          |          | 
|           |------------------------|          |----------|----------|----------|
|           |Limited                 |          |8.178     |200 7     |11. 2     |
|           |quantificatio           |          |          |          |          |
|           |n solution ⑤           |          |          |          |          | 
|           |------------------------|----------|----------|----------|----------|
|           |Limited                 |          |8.174     |199 7     |11. 7     |
|           |quantificatio           |          |          |          |          |
|           |n solution ⑥           |          |          |          |          | 
|           |------------------------|----------|----------|----------|----------|
|           |RSD                                |0.06%     |4%        |/         |
|           |-----------------------------------|----------|----------|----------|
|           |Verdict: The limiting solution concentration of impurity            |
|           |YA2304-14 was 0.1206μg/ml (relative to 0.0302% of the test         | 
|           |product), the RSD of the retention time of 6 parts of the           |
|           |limiting solution was 0.06% (no more than 2.0%), the RSD of the     |
|           |peak area was 4% (no more than 10%), and the S/N ranged from        |
|           |10.4 to 11.8. Were all greater than 10. Meet verification           |
|           |requirements.                                                       |
|-----------|--------------------------------------------------------------------|
|YA2304 (in |Limited      |0.1229    |0.0307    |9.319     |209 5     |15. 2     |
|place of   |quantificatio|          |          |          |          |          |
|unknown    |n solution ①|          |          |          |          |          | 
|impurities)|             |          |          |          |          |          |
|           |-------------|          |          |----------|----------|----------|
|           |Limited                 |          |9.322     |199 9     |16. 1     |
|           |quantificatio           |          |          |          |          |
|           |n solution ②           |          |          |          |          | 
|           |------------------------|          |----------|----------|----------|
|           |Limited                 |          |9.329     |202 4     |16. 0     |
|           |quantitation            |          |          |          |          |
|           |solution ③             |          |          |          |          | 
|-----------|------------------------|----------|----------|----------|----------|
|           |Limited                 |          |9.324     |210       |15.       |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 179 of 542 





Page 180
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 







































--------------------------------------------------------------------------------
|         |quantificatio|          |          |          |6         |1         |
|         |n solution ④|          |          |          |          |          | 
|         |-------------|          |          |----------|----------|----------|
|         |Limited                 |          |9.328     |208 3     |16. 1     |
|         |quantificatio           |          |          |          |          |
|         |n solution ⑤           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |9.327     |209 7     |16. 8     |
|         |quantificatio           |          |          |          |          |
|         |n solution ⑥           |          |          |          |          | 
|         |------------------------|----------|----------|----------|----------|
|         |RSD                                |0.05%     |2.2 %     |/         |
|         |-----------------------------------|----------|----------|----------|
|         |Verdict: The RSD of principal component YA2304 (in place of         |
|         |unknown impurity) was 0.1229μg/ml (relative to 0.0307% of test     | 
|         |substance), the RSD of retention time and peak area of 6 parts      |
|         |of RSD were 0.05% (no more than 2.0%) and 2.2% (no more than        |
|         |10%), respectively. S/N ranged from 15.1 to 16.8, all of which      |
|         |were greater than 10. Meet the verification requirements.           |
|---------|--------------------------------------------------------------------|
|YA2304-15|Limited      |0.1211    |0.0303    |10.266    |173 7     |14. 4     |
|         |quantitation |          |          |          |          |          |
|         |solution ①  |          |          |          |          |          | 
|         |-------------|          |          |----------|----------|----------|
|         |Limited                 |          |10.269    |178 7     |15. 4     |
|         |quantificatio           |          |          |          |          |
|         |n solution ②           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |10.276    |169 5     |15. 3     |
|         |quantificatio           |          |          |          |          |
|         |n solution ③           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |10.269    |168 9     |14. 1     |
|         |quantificatio           |          |          |          |          |
|         |n solution ④           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |10.273    |182 5     |15. 3     |
|         |quantificatio           |          |          |          |          |
|         |n solution ⑤           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |10.276    |169 4     |15. 3     |
|         |quantificatio           |          |          |          |          |
|         |n solution ⑥           |          |          |          |          | 
--------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 180 of 542 





Page 181
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

























-------------------------------------------------------------------------------
|         |RSD                               |0.05%     |4%        |/         |
|         |----------------------------------|----------|----------|----------|
|         |Verdict: The limiting solution concentration of impurity           |
|         |YA2304-15 was 0.1211μg/ml (relative to 0.0303% of the test        | 
|         |product), the RSD of the retention time of 6 parts of the          |
|         |limiting solution was 0.05% (no more than 2.0%), the RSD of the    |
|         |peak area was 4% (no more than 10%), and the S/N ranged from       |
|         |14.1 to 15.4. All of them were greater than 10. Meet               |
|         |verification requirements.                                         |
|---------|-------------------------------------------------------------------|
|YA2304-17|Limited     |0.1208    |0.0302    |11.493    |314 3     |15. 4     |
|(230nm)  |quantitation|          |          |          |          |          |
|         |solution ① |          |          |          |          |          | 
|         |------------|          |          |----------|----------|----------|
|         |Limited                |          |11.496    |325 8     |16. 5     |
|         |quantificatio          |          |          |          |          |
|         |n solution ②          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |11.503    |323 3     |14. 7     |
|         |quantificatio          |          |          |          |          |
|         |n solution ③          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |11.496    |318 1     |14. 3     |
|         |quantificatio          |          |          |          |          |
|         |n solution ④          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |11.501    |317 0     |14. 1     |
|         |quantificatio          |          |          |          |          |
|         |n solution ⑤          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |11.504    |322 0     |15. 0     |
|         |quantificatio          |          |          |          |          |
|         |n solution ⑥          |          |          |          |          | 
|         |-----------------------|----------|----------|----------|----------|
|         |RSD                               |0.04%     |1.4 %     |/         |
|         |----------------------------------|----------|----------|----------|
|         |Verdict: The limited quantification solution concentration of      |
|         |impurity YA2304-17 was 0.1208μg/ml (relative to 0.0302% of the    | 
|         |test product), the RSD of the retention time of 6 parts of the     |
|         |limited quantification solution was 0.04% (no more than 2.0%),     |
|         |the RSD of the peak area was 1.4% (no more than 10%), and the      |
|         |S/N ranged from 14.1 to 16.5. Were all greater than 10. Meet       |
|         |verification requirements.                                         |
-------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 181 of 542 





Page 182
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 











































-------------------------------------------------------------------------------
|YA2304-16|Limited     |0.1159    |0.0290    |11.919    |195 3     |14. 8     |
|         |quantitative|          |          |          |          |          |
|         |solution ① |          |          |          |          |          | 
|         |------------|          |          |----------|----------|----------|
|         |Limited                |          |11.924    |190 7     |15. 6     |
|         |quantificatio          |          |          |          |          |
|         |n solution ②          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |11.931    |189 8     |15. 3     |
|         |quantificatio          |          |          |          |          |
|         |n solution ③          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |11.922    |186 2     |14. 2     |
|         |quantificatio          |          |          |          |          |
|         |n solution ④          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |11.928    |192 8     |15. 2     |
|         |quantificatio          |          |          |          |          |
|         |n solution ⑤          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |11.932    |184 8     |15. 5     |
|         |quantificatio          |          |          |          |          |
|         |n solution ⑥          |          |          |          |          | 
|         |-----------------------|----------|----------|----------|----------|
|         |RSD                               |0.05%     |2.1 %     |/         |
|         |----------------------------------|----------|----------|----------|
|         |Conclusion: The limiting solution concentration of impurity        |
|         |YA2304-16 was 0.1159μg/ml (relative to 0.0290% of the test        | 
|         |product), the RSD of the retention time of 6 parts of the          |
|         |limiting solution was 0.05% (no more than 2.0%), the RSD of the    |
|         |peak area was 2.1% (no more than 10%), and the S/N ranged from     |
|         |14.2 to 15.6. Were all greater than 10. Meet verification          |
|         |requirements.                                                      |
|---------|-------------------------------------------------------------------|
|YA2304-18|Limited     |0.1203    |0.0301    |13.167    |187 2     |13. 9     |
|         |quantitative|          |          |          |          |          |
|         |solution ① |          |          |          |          |          | 
|         |------------|          |          |----------|----------|----------|
|         |Limited                |          |13.169    |170 6     |14. 6     |
|         |quantificatio          |          |          |          |          |
|         |n solution ②          |          |          |          |          | 
|---------|-----------------------|----------|----------|----------|----------|
|         |Limited                |          |13.177    |186       |14.       |
-------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 182 of 542 





Page 183
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 







































--------------------------------------------------------------------------------
|         |quantificatio|          |          |          |7         |8         |
|         |n solution ③|          |          |          |          |          | 
|         |-------------|          |          |----------|----------|----------|
|         |Limited                 |          |13.170    |185 0     |13. 7     |
|         |quantificatio           |          |          |          |          |
|         |n solution ④           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |13.171    |188 3     |14. 6     |
|         |quantificatio           |          |          |          |          |
|         |n solution ⑤           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |13.178    |175 1     |14. 8     |
|         |quantificatio           |          |          |          |          |
|         |n solution ⑥           |          |          |          |          | 
|         |------------------------|----------|----------|----------|----------|
|         |RSD                                |0.04%     |5%        |/         |
|         |-----------------------------------|----------|----------|----------|
|         |Verdict: The limiting solution concentration of impurity            |
|         |YA2304-18 was 0.1203μg/ml (relative to 0.0301% of the test         | 
|         |product), the RSD of the retention time of 6 parts of the           |
|         |limiting solution was 0.04% (no more than 2.0%), the RSD of the     |
|         |peak area was 5% (no more than 10%), and the S/N was between        |
|         |13.7 and 14.8. Were all greater than 10. Meet verification          |
|         |requirements.                                                       |
|---------|--------------------------------------------------------------------|
|YA2304-10|Limited      |0.1218    |0.0305    |15.271    |276 2     |12. 1     |
|(230nm)  |quantificatio|          |          |          |          |          |
|         |n solution ①|          |          |          |          |          | 
|         |-------------|          |          |----------|----------|----------|
|         |Limited                 |          |15.274    |273 5     |12. 6     |
|         |quantificatio           |          |          |          |          |
|         |n solution ②           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |15.282    |259 7     |11. 1     |
|         |quantificatio           |          |          |          |          |
|         |n solution ③           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |15.275    |274 2     |11. 0     |
|         |quantificatio           |          |          |          |          |
|         |n solution ④           |          |          |          |          | 
|         |------------------------|          |----------|----------|----------|
|         |Limited                 |          |15.277    |266 0     |10. 6     |
|         |quantificatio           |          |          |          |          |
|         |n solution ⑤           |          |          |          |          | 
--------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 183 of 542 





Page 184
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 








































-------------------------------------------------------------------------------
|         |Limited     |          |          |15.281    |258 6     |11. 2     |
|         |quantitation|          |          |          |          |          |
|         |solution ⑥ |          |          |          |          |          | 
|         |------------|----------|----------|----------|----------|----------|
|         |RSD                               |0.028%    |2.9 %     |/         |
|         |----------------------------------|----------|----------|----------|
|         |Verdict: The limiting solution concentration of impurity           |
|         |YA2304-10 was 0.1218μg/ml (relative to 0.0305% of the test        | 
|         |product), the RSD of the retention time of 6 parts of the          |
|         |limiting solution was 0.028% (no more than 2.0%), the RSD of       |
|         |the peak area was 2.9% (no more than 10%), and the S/N was         |
|         |between 10.6 and 12.6. Were all greater than 10. Meet              |
|         |verification requirements.                                         |
|---------|-------------------------------------------------------------------|
|YA2304-19|Limited     |0.1202    |0.0300    |16.431    |299 4     |17. 5     |
|         |quantitative|          |          |          |          |          |
|         |solution ① |          |          |          |          |          | 
|         |------------|          |          |----------|----------|----------|
|         |Limited                |          |16.434    |318 8     |19. 1     |
|         |quantificatio          |          |          |          |          |
|         |n solution ②          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |16.442    |304 6     |19. 0     |
|         |quantificatio          |          |          |          |          |
|         |n solution ③          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |16.437    |312 2     |17. 6     |
|         |quantificatio          |          |          |          |          |
|         |n solution ④          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |16.438    |300 5     |18. 5     |
|         |quantificatio          |          |          |          |          |
|         |n solution ⑤          |          |          |          |          | 
|         |-----------------------|          |----------|----------|----------|
|         |Limited                |          |16.438    |313 9     |19. 5     |
|         |quantificatio          |          |          |          |          |
|         |n solution ⑥          |          |          |          |          | 
|         |-----------------------|----------|----------|----------|----------|
|         |RSD                               |0.023%    |2.6 %     |/         |
|---------|----------------------------------|----------|----------|----------|
|         |Verdict: The limiting solution concentration of impurity           |
|         |YA2304-19 was 0.1202μg/ml (relative to 0.0300% of the test        | 
|         |product), the RSD of the                                           |
-------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 184 of 542 





Page 185
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



retention time of 6 parts of the limiting solution was 0.023% (no more 



than 2.0%), the RSD of the peak area was 2.6% (no more than 10%), 



and the S/N was between 17.5 and 19.5. Were all greater than 10. Meet 



verification requirements. 



Results of LOD Determination: 

























































------------------------------------------------------------------------------------
|Names of  |Detection |Concentration|Equivalent   |Retention |Peak area |S/N       |
|impurities|limit     |/(μg/ml)    |to test      |time /min |          |          | 
|          |solution  |             |product      |          |          |          |
|          |Sample    |             |concentration|          |          |          |
|          |injection |             |/%           |          |          |          |
|----------|----------|-------------|-------------|----------|----------|----------|
|YA2304-12 |1         |0.0601       |0.0150       |3.799     |832       |7.3       |
|          |----------|             |             |----------|----------|----------|
|          |2                       |             |3.799     |831       |7.3       |
|          |------------------------|             |----------|----------|----------|
|          |3                       |             |3.802     |804       |6.8       |
|          |------------------------|-------------|----------|----------|----------|
|          |Conclusion: The detection limit solution concentration of              |
|          |impurity YA2304-12 is 0.0601μg/ml (relative to 0.0150% of the         | 
|          |test product concentration), and the S/N of the 3-needle               |
|          |detection limit solution is between 6.8 and 7.3, all of which          |
|          |are greater than 3. In line with the verification requirements.        |
|----------|-----------------------------------------------------------------------|
|YA2304-14 |1         |0.0603       |0.0151       |8.175     |1000      |5.8       |
|          |----------|             |             |----------|----------|----------|
|          |2                       |             |8.167     |936       |5.5       |
|          |------------------------|             |----------|----------|----------|
|          |3                       |             |8.176     |964       |5.2       |
|          |------------------------|-------------|----------|----------|----------|
|          |Conclusion: The limit solution concentration of impurity               |
|          |YA2304-14 is 0.0603μg/ml (relative to 0.0151% of the test             | 
|          |product), and the S/N of the 3-needle limit solution is between        |
|          |5.2 and 5.8, all of which are greater than 3. In line with the         |
|          |verification requirements.                                             |
|----------|-----------------------------------------------------------------------|
|YA2304    |1         |0.0615       |0.0154       |9.322     |1234      |9.3       |
|          |----------|             |             |----------|----------|----------|
|          |2                       |             |9.321     |1138      |8.9       |
|          |------------------------|             |----------|----------|----------|
|          |3                       |             |9.327     |1166      |8.5       |
|          |------------------------|-------------|----------|----------|----------|
|          |Conclusion: The limited solution concentration of principal            |
|          |component YA2304 (in place of unknown impurity) was 0.0615μg/ml       | 
|          |(relative to 0.0154% of the test substance), and the S/N of the        |
|          |3-needle limited                                                       |
------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 185 of 542 





Page 186
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




















































-----------------------------------------------------------------------------
|         |solution was between 8.5 and 9.3, all of which were greater      |
|         |than 3. It met the verification requirements.                    |
|---------|-----------------------------------------------------------------|
|YA2304-15|1         |0.0605    |0.0151    |10.270    |909       |7.7       |
|         |----------|          |          |----------|----------|----------|
|         |2                    |          |10.271    |911       |8.1       |
|         |---------------------|          |----------|----------|----------|
|         |3                    |          |10.274    |851       |6.9       |
|         |---------------------|----------|----------|----------|----------|
|         |Conclusion: The limit solution concentration of impurity         |
|         |YA2304-15 is 0.0605μg/ml (relative to 0.0151% of the test       | 
|         |product), and the S/N of the 3-needle limit solution is between  |
|         |6.9 and 8.1, all of which are greater than 3. In line with the   |
|         |verification requirements.                                       |
|---------|-----------------------------------------------------------------|
|YA2304-17|1         |0.0604    |0.0151    |11.498    |1613      |7.6       |
|(230nm)  |          |          |          |          |          |          |
|         |----------|          |          |----------|----------|----------|
|         |2                    |          |11.497    |1637      |8.0       |
|         |---------------------|          |----------|----------|----------|
|         |3                    |          |11.503    |1624      |7.8       |
|         |---------------------|----------|----------|----------|----------|
|         |Conclusion: The limit solution concentration of impurity         |
|         |YA2304-17 is 0.0604μg/ml (relative to 0.0151% of the test       | 
|         |product), and the S/N of the 3-needle limit solution ranges      |
|         |from 7.6 to 8.0, all of which are greater than 3. In line with   |
|         |the verification requirements.                                   |
|---------|-----------------------------------------------------------------|
|YA2304-16|1         |0.0580    |0.0145    |11.926    |961       |7.6       |
|         |----------|          |          |----------|----------|----------|
|         |2                    |          |11.921    |984       |7.6       |
|         |---------------------|          |----------|----------|----------|
|         |3                    |          |11.930    |1006      |7.3       |
|         |---------------------|----------|----------|----------|----------|
|         |Conclusion: The limit solution concentration of impurity         |
|         |YA2304-16 is 0.0580μg/ml (relative to 0.0145% of the test       | 
|         |product), and the S/N of the 3-needle limit solution ranges      |
|         |from 7.3 to 7.6, all of which are greater than 3. In line with   |
|         |the verification requirements.                                   |
|---------|-----------------------------------------------------------------|
|YA2304-18|1         |0.0601    |0.0150    |13.174    |976       |7.5       |
|         |----------|          |          |----------|----------|----------|
|         |2                    |          |13.171    |965       |7.3       |
|         |---------------------|          |----------|----------|----------|
|         |3                    |          |13.176    |913       |6.6       |
|         |---------------------|----------|----------|----------|----------|
|         |Conclusion: The limit solution concentration of impurity         |
|         |YA2304-18 is 0.0601μg/ml (relative to 0.0150% of the test       | 
|         |product), and the S/N of the 3-needle limit solution is between  |
|         |6.6 and 7.5, all of which are greater than 3. In line with the   |
|         |verification requirements.                                       |
-----------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 186 of 542 





Page 187
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




























-----------------------------------------------------------------------------
|YA2304-10|1         |0.0609    |0.0152    |15.274    |1373      |5.8       |
|(230nm)  |          |          |          |          |          |          |
|         |----------|          |          |----------|----------|----------|
|         |2                    |          |15.274    |1443      |5.9       |
|         |---------------------|          |----------|----------|----------|
|         |3                    |          |15.278    |1364      |5.9       |
|         |---------------------|----------|----------|----------|----------|
|         |Conclusion: The limit solution concentration of impurity         |
|         |YA2304-10 is 0.0609μg/ml (relative to 0.0152% of the test       | 
|         |product), and the S/N of the 3-needle limit solution is between  |
|         |5.8 and 5.9, all of which are greater than 3. In line with the   |
|         |verification requirements.                                       |
|---------|-----------------------------------------------------------------|
|YA2304-19|1         |0.0601    |0.0150    |16.435    |1486      |9.1       |
|         |----------|          |          |----------|----------|----------|
|         |2                    |          |16.437    |1557      |9.6       |
|         |---------------------|          |----------|----------|----------|
|         |3                    |          |16.440    |1557      |8.6       |
|         |---------------------|----------|----------|----------|----------|
|         |Conclusion: The detection limit solution concentration of        |
|         |impurity YA2304-19 is 0.0601μg/ml (relative to 0.0150% of the   | 
|         |test product), and the S/N of the 3-needle detection limit       |
|         |solution is between 8.6 and 9.6, all of which are greater than   |
|         |3. In line with the verification requirements.                   |
-----------------------------------------------------------------------------

**e. Linearity and Range** 



 **Acceptance Criteria** 



Known impurities at 251nm wavelength (YA2304-12, YA2304-14, 



YA2304-15, YA2304-16, YA2304-18 and YA2304-19) and 230nm wavelength 



(YA2304-10, YA2304-17) : Within the range of limited quantitation 



concentration ~ equivalent to 0.3% of the test product solution concentration, 



6 concentration points were selected fairly evenly, and the concentration of 



each impurity was taken as the horizontal coordinate and the peak area was 



taken as the vertical coordinate as the linear regression curve. The regression 



coefficient R of the obtained linear graph should NLT 0.990, and the RSD of 



the response factor should NMT 10%. Y-axis intercepts are within 25% of 



100% response value. 



Unknown impurities at 251nm wavelength (substituted by YA2304) : Within 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 187 of 542 





Page 188
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



the range of limited quantitation concentration ~ equivalent to 0.3% of the 



test product solution concentration, 6 concentration points were selected 



fairly uniformly, and the concentration of each impurity was taken as the 



horizontal coordinate and the peak area was taken as the vertical coordinate 



as the linear regression curve. The regression coefficient (R) of the regression 



curve was NLT 0.990, and the RSD of the response factor was not more than 



10%. Y-axis intercept accounted for 100% of the response value of the 



percentage within 25%. 



 **Solution Preparation** 



Blank solution: solvent 



YA2304-12 Reference storage solution: Share "YA2304-12 Reference Storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304 Reference stock: Share "YA2304 Reference Stock" under "4.1 



Wavelength Selection". (Approx. 200μg/ml) 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-18 Reference storage solution: Share "YA2304-18 Reference storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 188 of 542 





Page 189
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Linear reserve solution: Take 1.0ml of each control product reserve liquid of 



YA2304-12, YA2304-14, YA2304, YA2304-15, YA2304-16, YA2304-18, 



YA2304-19, YA2304-10 and YA2304-17 and place them in a 20ml measuring 



bottle. Dilute to the scale with solvent, shake well, and then get. (Both about 



10μg/ml) 



Linear solution ① (LOQ solution) : prepared by the same method as "Limit of 



quantification solution" under "Limits of quantification and Detection Limits 



4.4". 



Linear solution ② (equivalent to 0.05% of the test product solution) : 



accurately measure 0.5ml of linear reserve solution, place it in a 25ml 



measuring bottle, dilute it with solvent to the scale, shake well, and obtain. 



(About 0.2μg/ml) 



Linear solution ③ (equivalent to 0.10% of the test product solution) : 



accurately measure 1.0ml of linear reserve solution, place it in a 25ml 



measuring bottle, dilute it with solvent to the scale, shake well, and obtain. 



(About 0.4μg/ml) 



Linear solution ④ (equivalent to 0.15% of the test solution) : accurately 



measure 1.5ml of linear reserve liquid, place it in 25ml measuring bottle, 



dilute it with solvent to the scale, shake well, and get. (About 0.6μg/ml) 



Linear solution ⑤ (equivalent to 0.20% of the test product solution) : 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 189 of 542 





Page 190
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



accurately measure 2.0ml of linear reserve liquid, place it in a 25ml 



measuring bottle, dilute it with solvent to the scale, shake well, and get. 



(About 0.8μg/ml) 



Linear solution ⑥ (equivalent to 0.30% of the test product solution) : 



accurately measure 3.0ml of linear reserve liquid, place it in a 25ml 



measuring bottle, dilute it with solvent to the scale, shake well, and get. 



(About 1.2μg/ml) 



 **Injection Sequence** 



~ 
After the blank solution, the linear solution ① ⑥ was injected with 1 needle 



each from low concentration to high concentration, and the chromatogram 



was recorded. 



 **Results and Discussion** 
























-----------------------------------------------------------------------
|Names of  |Solution   |Equivalent   |Concentration|Peak area|Response|
|impuritie |name       |to test      |/(μg/ml)    |         |factor  | 
|s         |           |product      |             |         |        |
|          |           |solution     |             |         |        |
|          |           |concentration|             |         |        |
|          |           |percentage /%|             |         |        |
|----------|-----------|-------------|-------------|---------|--------|
|YA2304- 12|Linear     |0.0300       |0.1201       |1669     |13896   |
|          |solution ①|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.0500       |0.2002       |2892     |14447   |
|          |solution ②|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.1001       |0.4004       |5582     |13943   |
|          |solution ③|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.1501       |0.6005       |8337     |13883   |
|          |solution ④|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.2002       |0.8007       |11146    |13920   |
|          |solution ⑤|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.3003       |1.2011       |16748    |13944   |
|          |solution ⑥|             |             |         |        | 
-----------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 190 of 542 





Page 191
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















----------------------------------------------------------------------------------
|          |Response factor RSD/%      |1.6                                      |
|          |---------------------------|-----------------------------------------|
|          |Linear graph               |                                         |
|          |---------------------------|-----------------------------------------|
|          |Linear equations           |y = 13896x + 33.018                      |
|          |---------------------------|-----------------------------------------|
|          |Correlation coefficient R  |0.99997                                  |
|          |---------------------------|-----------------------------------------|
|          |Absolute value of Y-axis   |0.39                                     |
|          |intercept as % /% of 100%  |                                         |
|          |response value             |                                         |
|          |---------------------------|-----------------------------------------|
|          |Conclusion: At 251nm wavelength, the RSD of YA2304-12 in the         |
|          |concentration range of 0.1201μg/ml~1.2011μg/ml is 1.6%, less than  |  
|          |10%. The linear equation is y = 13896x + 33.018, and the             |
|          |correlation coefficient R is 0.99997, greater than 0.990. The        |
|          |absolute value of Y-axis intercept accounts for 0.39% of 100%        |
|          |response value, which is less than 25%; It indicates that            |
|          |impurity YA2304-12 has a good linear relationship in the             |
|          |concentration range of 0.1201μg/ml~1.2011μg/ml.                    |  
|----------|---------------------------------------------------------------------|
|YA2304- 14|Linear       |0.0302       |0.1206       |1957         |16221        |
|          |solution ①  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.0503       |0.2011       |3275         |16288        |
|          |solution ②  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1005       |0.4021       |6460         |16064        |
|          |solution ③  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1508       |0.6032       |9837         |16308        |
|          |solution ④  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.2011       |0.8043       |13285        |16518        |
|          |solution ⑤  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.3016       |1.2064       |19868        |16468        |
|          |solution ⑥  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Response factor RSD/%      |1.1                                      |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 191 of 542 





Page 192
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















----------------------------------------------------------------------------------
|          |Linear graph               |                                         |
|          |---------------------------|-----------------------------------------|
|          |Linear equations           |y = 16536x - 85.568                      |
|          |---------------------------|-----------------------------------------|
|          |Correlation coefficient R  |0.99995                                  |
|          |---------------------------|-----------------------------------------|
|          |Absolute value of Y-axis   |0.87                                     |
|          |intercept as % /% of 100%  |                                         |
|          |response value             |                                         |
|          |---------------------------|-----------------------------------------|
|          |Conclusion: At 251nm wavelength, the RSD of YA2304-14 in the         |
|          |concentration range of 0.1206μg/ml~1.2064μg/ml is 1.1%, less than  |  
|          |10%. The linear equation is y = 16536x-85.568, and the               |
|          |correlation coefficient R is 0.99995, greater than 0.990. The        |
|          |absolute value of Y-axis intercept accounts for 0.87% of 100%        |
|          |response value, which is less than 25%; It indicates that            |
|          |impurity YA2304-14 has a good linear relationship in the             |
|          |concentration range of 0.1206μg/ml~1.2064μg/ml.                    |  
|----------|---------------------------------------------------------------------|
|YA2304    |Linear       |0.0307       |0.1229       |2058         |16740        |
|(principa |solution ①  |             |             |             |             | 
|l compone |             |             |             |             |             |
|nt instead|             |             |             |             |             |
|of unknow |             |             |             |             |             |
|n         |             |             |             |             |             |
|impurity) |             |             |             |             |             |
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.0512       |0.2049       |3438         |16779        |
|          |solution ②  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1025       |0.4098       |6805         |16605        |
|          |solution ③  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1537       |0.6147       |10130        |16479        |
|          |solution ④  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.2049       |0.8196       |13463        |16426        |
|          |solution ⑤  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.3074       |1.2294       |20246        |16468        |
|          |solution ⑥  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Response factor RSD/%      |1.0                                      |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 192 of 542 





Page 193
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















----------------------------------------------------------------------------------
|          |Linear graph               |                                         |
|          |---------------------------|-----------------------------------------|
|          |Linear equations           |y = 16404x + 57.399                      |
|          |---------------------------|-----------------------------------------|
|          |Correlation coefficient R  |1.000                                    |
|          |---------------------------|-----------------------------------------|
|          |Absolute value of Y-axis   |0.87                                     |
|          |intercept as % /% of 100%  |                                         |
|          |response value             |                                         |
|          |---------------------------|-----------------------------------------|
|          |Conclusion: At 251nm wavelength, the RSD of YA2304 (principal        |
|          |component instead of unknown impurity) is 1.0%, less than 10%, in    |
|          |the concentration range of 0.1229μg/ml~1.2294μg/ml. The linear     |  
|          |equation is y = 16404x + 57.399, and the correlation coefficient     |
|          |R is 1.000, greater than 0.990. The percentage of Y-axis             |
|          |intercept in 100% response value is 0.87%, which is within 25%;      |
|          |This indicates that YA2304 (principal component instead of           |
|          |unknown impurity) has a good linear relationship in the              |
|          |concentration range of 0.1229μg/ml~1.2294μg/ml.                    |  
|----------|---------------------------------------------------------------------|
|YA2304- 15|Linear       |0.0303       |0.1211       |1801         |14873        |
|          |solution ①  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.0505       |0.2018       |2828         |14013        |
|          |solution ②  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1009       |0.4036       |5854         |14503        |
|          |solution ③  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1514       |0.6055       |8660         |14303        |
|          |solution ④  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.2018       |0.8073       |11573        |14336        |
|          |solution ⑤  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.3027       |1.2109       |17425        |14390        |
|          |solution ⑥  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Response factor RSD/%      |2.0                                      |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 193 of 542 





Page 194
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















----------------------------------------------------------------------------------
|          |Linear graph               |                                         |
|          |---------------------------|-----------------------------------------|
|          |Linear equations           |y = 14367x + 1.2724                      |
|          |---------------------------|-----------------------------------------|
|          |Correlation coefficient R  |0.99996                                  |
|          |---------------------------|-----------------------------------------|
|          |Absolute value of Y-axis   |0.015                                    |
|          |intercept as % /% of 100%  |                                         |
|          |response value             |                                         |
|          |---------------------------|-----------------------------------------|
|          |Conclusion: At 251nm wavelength, the RSD of YA2304-15 in the         |
|          |concentration range of 0.1211μg/ml~1.2109μg/ml is 2.0%, less than  |  
|          |10%. The linear equation is y = 14367x + 1.2724, and the             |
|          |correlation coefficient R is 0.99996, greater than 0.990. The        |
|          |absolute value of Y-axis intercept as a percentage of 100%           |
|          |response value is 0.015%, within 25%; It indicates that impurity     |
|          |YA2304-15 has a good linear relationship in the concentration        |
|          |range of 0.1211μg/ml~1.2109μg/ml.                                  |  
|----------|---------------------------------------------------------------------|
|YA2304- 16|Linear       |0.0290       |0.1159       |1942         |16749        |
|          |solution     |             |             |             |             |
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.0483       |0.1932       |3175         |16430        |
|          |solution ②  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.0966       |0.3865       |6371         |16484        |
|          |solution ③  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1449       |0.5797       |9607         |16571        |
|          |solution ④  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1932       |0.7730       |12706        |16438        |
|          |solution ⑤  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.2899       |1.1595       |19121        |16491        |
|          |solution ⑥  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Response factor RSD/%      |0.8                                      |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 194 of 542 





Page 195
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















----------------------------------------------------------------------------------
|          |Linear graph               |                                         |
|          |---------------------------|-----------------------------------------|
|          |Linear equations           |y = 16470x + 14.525                      |
|          |---------------------------|-----------------------------------------|
|          |Correlation coefficient R  |1.000                                    |
|          |---------------------------|-----------------------------------------|
|          |Absolute value of Y-axis   |0.15                                     |
|          |intercept as % /% of 100%  |                                         |
|          |response value             |                                         |
|          |---------------------------|-----------------------------------------|
|          |Conclusion: At 251nm wavelength, the RSD of YA2304-16 in the         |
|          |concentration range of 0.1159μg/ml~1.1595μg/ml is 0.8%, less than  |  
|          |10%. The linear equation is y = 16470x + 14.525, and the             |
|          |correlation coefficient R is 1.000, greater than 0.990. The          |
|          |absolute value of Y-axis intercept as a percentage of 100%           |
|          |response value is 0.15%, within 25%; It indicates that impurity      |
|          |YA2304-16 has a good linear relationship in the concentration        |
|          |range of 0.1159μg/ml~1.1595μg/ml.                                  |  
|----------|---------------------------------------------------------------------|
|YA2304- 18|Linear       |0.0301       |0.1203       |1751         |14559        |
|          |solution ①  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.0501       |0.2005       |2973         |14832        |
|          |solution ②  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1002       |0.4009       |6094         |15201        |
|          |solution ③  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1503       |0.6014       |9008         |14980        |
|          |solution ④  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.2005       |0.8018       |12043        |15020        |
|          |solution ⑤  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.3007       |1.2027       |17988        |14956        |
|          |solution ⑥  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Response factor RSD/%      |1.5                                      |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 195 of 542 





Page 196
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















----------------------------------------------------------------------------------
|          |Linear graph               |                                         |
|          |---------------------------|-----------------------------------------|
|          |Linear equations           |y = 14990x-3.7556                        |
|          |---------------------------|-----------------------------------------|
|          |Correlation coefficient R  |0.99996                                  |
|          |---------------------------|-----------------------------------------|
|          |Absolute value of Y-axis   |0.042                                    |
|          |intercept as % /% of 100%  |                                         |
|          |response value             |                                         |
|          |---------------------------|-----------------------------------------|
|          |Conclusion: At 251nm wavelength, the RSD of YA2304-18 in the         |
|          |concentration range of 0.1203μg/ml~1.2027μg/ml is 1.5%, less than  |  
|          |10%. The linear equation is y = 14990x-3.7556, and the               |
|          |correlation coefficient R is 0.99996, greater than 0.990. The        |
|          |absolute value of Y-axis intercept as a percentage of 100%           |
|          |response value is 0.042%, which is within 25%; It indicates that     |
|          |impurity YA2304-18 has a good linear relationship in the             |
|          |concentration range of 0.1203μg/ml~1.2027μg/ml.                    |  
|----------|---------------------------------------------------------------------|
|YA2304- 17|Linear       |0.0302       |0.1208       |3143         |26017        |
|          |solution ①  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.0503       |0.2013       |5288         |26264        |
|          |solution ②  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1007       |0.4027       |10626        |26388        |
|          |solution ③  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.1510       |0.6040       |16044        |26562        |
|          |solution ④  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.2013       |0.8054       |21376        |26542        |
|          |solution ⑤  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.3020       |1.2080       |32097        |26569        |
|          |solution ⑥  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Response factor RSD/%      |0.9                                      |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 196 of 542 





Page 197
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-----------------------------------------------------------------------------
|          |Linear graph             |                                      |
|          |-------------------------|--------------------------------------|
|          |Linear equations         |y = 26638x - 75.991                   |
|          |-------------------------|--------------------------------------|
|          |Correlation coefficient R|1.000                                 |
|          |-------------------------|--------------------------------------|
|          |Absolute value of Y-axis |0.48                                  |
|          |intercept as % /% of 100%|                                      |
|          |response value           |                                      |
|          |-------------------------|--------------------------------------|
|          |Conclusion: Under the condition of 230nm wavelength, the RSD of |
|          |YA2304-17 is 0.9%, less than 10%, in the concentration range of |
|          |0.1208μg/ml~1.2080μg/ml. The linear equation is y =           |  
|          |26638x-75.991, and the correlation coefficient R is 1.000,      |
|          |greater than 0.990. The absolute value of Y-axis intercept as a |
|          |percentage of 100% response value is 0.48%, within 25%; It      |
|          |indicates that impurity YA2304-17 has a good linear relationship|
|          |in the concentration range of 0.1208μg/ml~1.2080μg/ml.        |  
|----------|----------------------------------------------------------------|
|YA2304- 10|Linear      |0.0305      |0.1218      |2603        |21366       |
|          |solution ① |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.0508      |0.2031      |4267        |21014       |
|          |solution ② |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.1015      |0.4061      |8180        |20143       |
|          |solution ③ |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.1523      |0.6092      |12086       |19841       |
|          |solution ④ |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.2031      |0.8122      |16286       |20052       |
|          |solution ⑤ |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.3046      |1.2183      |24255       |19909       |
|          |solution ⑥ |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Response factor RSD/%    |4                                     |
-----------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 197 of 542 





Page 198
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-----------------------------------------------------------------------------
|          |Linear graph             |                                      |
|          |-------------------------|--------------------------------------|
|          |Linear equations         |y = 19735x + 192.83                   |
|          |-------------------------|--------------------------------------|
|          |Correlation coefficient R|0.99996                               |
|          |-------------------------|--------------------------------------|
|          |Absolute value of Y-axis |2.4                                   |
|          |intercept as % /% of 100%|                                      |
|          |response value           |                                      |
|          |-------------------------|--------------------------------------|
|          |Conclusion: Under the condition of 230nm wavelength, the RSD of |
|          |YA2304-10 is 4%, less than 10%, in the concentration range of   |
|          |0.1218μg/ml~1.2183μg/ml. The linear equation is y = 19735x +  |  
|          |192.83, and the correlation coefficient R is 0.99996, greater   |
|          |than 0.990. The absolute value of Y-axis intercept accounts for |
|          |2.4% of 100% response value, which is within 25%; It indicates  |
|          |that impurity YA2304-10 has a good linear relationship in the   |
|          |concentration range of 0.1218μg/ml~1.2183μg/ml.               |  
|----------|----------------------------------------------------------------|
|YA2304- 19|Linear      |0.0300      |0.1202      |3087        |25690       |
|          |solution ① |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.0501      |0.2003      |5054        |25236       |
|          |solution ② |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.1001      |0.4005      |10300       |25715       |
|          |solution ③ |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.1502      |0.6008      |15189       |25281       |
|          |solution ④ |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.2003      |0.8011      |20363       |25419       |
|          |solution ⑤ |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Linear      |0.3004      |1.2016      |30691       |25541       |
|          |solution ⑥ |            |            |            |            | 
|          |------------|------------|------------|------------|------------|
|          |Response factor RSD/%    |0.8                                   |
-----------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 198 of 542 





Page 199
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










-----------------------------------------------------------------------------
|       |Linear graph                     |                                 |
|       |---------------------------------|---------------------------------|
|       |Linear equation                  |y = 25507x - 18.855              |
|       |---------------------------------|---------------------------------|
|       |Correlation coefficient R        |0.99997                          |
|       |---------------------------------|---------------------------------|
|       |Absolute value of Y-axis         |0.12                             |
|       |intercept as % /% of 100%        |                                 |
|       |response value                   |                                 |
|       |---------------------------------|                                 |
|       |Conclusion: At 251nm wavelength, the RSD of YA2304-19 in the       |
|       |concentration range of 0.1202μg/ml~1.2016μg/ml is 0.8%, less than|  
|       |10%. The linear equation is y = 25507x-18.855, and the             |
|       |correlation coefficient R is 0.99997, greater than 0.990. The      |
|       |absolute value of Y-axis intercept as a percentage of 100%         |
|       |response value is 0.12%, within 25%; It indicates that impurity    |
|       |YA2304-19 has a good linear relationship in the concentration      |
|       |range of 0.1202μg/ml~1.2016μg/ml.                                |  
-----------------------------------------------------------------------------

Validation Results of Correction Factor (f): 
















-----------------------------------------------------------------------------
|Names of          |Linear equation   |Correction factor                    |
|impurities        |slope             |                                     |
|                  |                  |-------------------------------------|
|                  |                  |Standard          |Determination     |
|                  |                  |regulations       |results           |
|------------------|------------------|------------------|------------------|
|YA2304-12         |13896             |1.2               |1.2               |
|------------------|------------------|------------------|------------------|
|YA2304-14         |16536             |1.0               |1.0               |
|------------------|------------------|------------------|------------------|
|YA2304            |16404             |1.0               |1.0               |
|------------------|------------------|------------------|------------------|
|YA2304-15         |14367             |1.2               |1.1               |
|------------------|------------------|------------------|------------------|
|YA2304-16         |16470             |1.0               |1.0               |
|------------------|------------------|------------------|------------------|
|YA2304-18         |14990             |1.1               |1.1               |
|------------------|------------------|------------------|------------------|
|YA2304-19         |25507             |0.7               |0.6               |
|------------------|------------------|------------------|------------------|
|Verdict: The correction factors of YA2304-12, YA2304-14, YA2304-15,        |
|YA2304-16, YA2304-18, YA2304-18 and YA2304-19 relative to the principal    |
|component YA2304 are 1.18, 0.99, 1.14, 1.00 and 1.0, respectively, based on|
|the impurities and the slope of the principal component linear equation 9, |
|0.64, revised to approximately 1.2, 1.0,                                   |
-----------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 199 of 542 





Page 200
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



1.1, 1.0, 1.1, 0.6. Compared with the correction factors specified in the quality 



standard, except for impurity YA2304-15 and impurity YA2304-19, the correction 



factors are 0.1 different from the standard comparison, and the other impurities are 



consistent within the deviation range. Therefore, the correction factor in the quality 



standard is not revised. 



**f. Accuracy** 



 **Acceptance Criteria** 



The accuracy of unknown impurities is achieved by determining the recovery 



rate between the theoretical addition and the actual detected amount of 



YA2304 reference in the solvent at different concentrations (LOQ 



concentration, 100% limit concentration and 150% limit concentration). It is 



required that the recovery rate of unknown impurity LOQ concentration 



solution ~150% limit concentration solution should be 85%~110%, and the 



RSD of recovery NMT 10%. 



The recovery rate of known impurities is by adding each impurity in the test 



product solution within the range of 30% limit concentration ~ 150% limit 



concentration of each impurity reference products (note: Impurity 



YA2304-10 is added to 0.045% test product solution concentration ~ 0.225% 



test product solution concentration impurity reference), and the recovery 



rate between the theoretical added amount and the actual detected amount 



is achieved. It is required that the recovery rate of known impurity 30% limit 



concentration sampling solution ~150% limit concentration solution is 



85%~110%, and the RSD of each impurity recovery rate NMT 10%. 



 **Solution Preparation** 



**i. Identified Impurities** 



Blank solution: solvent 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 200 of 542 





Page 201
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-12 Reference storage solution: Share "YA2304-12 Reference Storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-18 Reference storage solution: Share "YA2304-18 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Test product solution: Take YA2304 sample about 10mg, weigh it accurately, 



put it in 25ml measuring bottle, dissolve it with solvent and dilute it to scale, 



shake well, and then get it. Prepare 2 parts in parallel. (About 0.4mg/ml) 



Mixed reference solution: accurately measure 1ml each of YA2304-10 



reference solution, YA2304-17 reference solution and YA2304 reference 



solution, place them in the same 20ml bottle, dilute to scale with solvent, and 



shake well; Precisely measure 1ml of the above solution, place it in a 25ml 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 201 of 542 





Page 202
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



measuring bottle, dilute it with solvent to the scale, shake well, and then 



obtain. (YA2304-10, YA2304-17 and YA2304 contain about 0.4μg/ml) 



System suitability solution: Accurately weigh YA2304 reference product 



about 10mg, place it in 25ml bottle, add appropriate amount of solvent to 



dissolve by ultrasound, then accurately add 100μl each of YA2304-14, 



YA2304-15, YA2304-16, YA2304-19, YA2304-10 and YA2304-17 reference 



product reserve solution. Dilute with solvent to scale, shake well, ready. 



(YA2304-14, YA2304-15, YA2304-16, YA2304-19, YA2304-10 and 



YA2304-17 all about 0.8μg/ml) 



Sample recovery reserve liquid: Take 1.5ml of each control product reserve 



liquid of YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-18, 



YA2304-19, YA2304-17 and YA2304-10 into the same 20ml measuring bottle 



and dilute it to the scale with solvent. Shake well, then it is ready. (About 



15μg/ml) 



30% sample recovery solution (Note: YA2304-10 is 0.045% test solution 



concentration) : Take YA2304 sample about 10mg, accurately weigh, put into 



25ml measuring bottle, add appropriate amount of solvent to dissolve by 



ultrasound, accurately add 0.3ml of sample recovery liquid, dilute with 



solvent to scale, shake well, and then obtain. Prepare 3 parts in parallel. 



100% sample recovery solution (Note: YA2304-10 is 0.15% test product 



solution concentration) : Take about 10mg of YA2304 sample, accurately 



weigh it, place it in a 25ml measuring bottle, add an appropriate amount of 



solvent to dissolve it by ultrasound, accurately add 1.0ml of the reserve liquid 



with sample recovery rate, dilute it with solvent to the scale, shake well, and 



obtain. Prepare 3 parts in parallel. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 202 of 542 





Page 203
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



150% sample recovery solution (Note: YA2304-10 is 0.225% test product 



solution concentration) : Take about 10mg of YA2304 sample, accurately 



weigh it, place it in 25ml measuring bottle, add an appropriate amount of 



solvent to dissolve by ultrasound, accurately add 1.5ml of the reserve liquid 



with sample recovery rate, dilute it with solvent to the scale, shake well, and 



obtain. Prepare 3 parts in parallel. 



**ii. Unidentified Impurities** 



Blank solution: solvent 



YA2304 Reference storage solution: Share "YA2304 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Recovery rate of reserve liquid: accurately measure YA2304 reference 



product reserve liquid 1ml, place it in 20ml measuring bottle, dilute it with 



solvent to scale, shake well, then obtain. (About 10μg/ml) 



Control product solution: accurately measure the recovery rate of 1ml of 



reserve liquid, put it in a 25ml measuring bottle, dilute it with solvent to the 



scale, shake well, and then get. (About 0.4μg/ml) 



LOQ recovery solution: accurately measure the recovery rate of 0.3ml of 



reserve liquid, put it in a 25ml measuring bottle, dilute it with solvent to the 



scale, shake well, and then get. 3 parts in parallel (about 0.12μg/ml) 



100% recovery solution: accurately measure the recovery rate of the reserve 



liquid 1.0ml, put it in a 25ml measuring bottle, dilute it with solvent to the 



scale, shake well, and then obtain. 3 parts in parallel (about 0.4μg/ml) 



150% recovery solution: accurately measure the recovery rate of 1.5ml of the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 203 of 542 





Page 204
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



reserve liquid, put it in a 25ml measuring bottle, dilute it with solvent to the 



scale, shake well, and then obtain. 3 parts in parallel (about 0.6μg/ml) 



 **Injection Sequence** 



After the blank solution, 1 needle was injected into the system suitability 



solution, 2 needles into the mixed control solution, 1 needle into each of 2 



sample solutions and 9 sample recovery solutions; 2 needles were injected 



into the control solution and 1 needle into each of the 9 recovery solutions, 



and the chromatogram was recorded. 



 **Results and Discussion** 



Results of Accuracy Study: 
























------------------------------------------------------------------------
|Impuritie |Solution name      |Quantity of|Amount  |Measured|Recover y|
|s Name    |                   |test       |added   |amount  |rate (%) |
|          |                   |product    |(μg/ml)|(μg/ml)|         |  
|          |                   |detected   |        |        |         |
|          |                   |(μg/ml)   |        |        |         | 
|----------|-------------------|-----------|--------|--------|---------|
|YA2304- 12|30% sample recovery|0.0248     |0.1802  |0.1992  |96.8     |
|          |solution ①        |           |        |        |         | 
|          |-------------------|-----------|--------|--------|---------|
|          |30% sample recovery|0.0249     |0.1802  |0.2054  |100.1    |
|          |solution ②        |           |        |        |         | 
|          |-------------------|-----------|--------|--------|---------|
|          |30% recovery       |0.0249     |0.1802  |0.2048  |99.9     |
|          |solution ③        |           |        |        |         | 
|          |-------------------|-----------|--------|--------|---------|
|          |100% recovery      |0.0251     |0.6005  |0.6142  |98.1     |
|          |solution ①        |           |        |        |         | 
|          |-------------------|-----------|--------|--------|---------|
|          |100% recovery      |0.0252     |0.6005  |0.6143  |98.1     |
|          |solution ②        |           |        |        |         | 
|          |-------------------|-----------|--------|--------|---------|
|          |100% recovery      |0.0251     |0.6005  |0.6266  |100.2    |
|          |solution ③        |           |        |        |         | 
|          |-------------------|-----------|--------|--------|---------|
|          |150% recovery      |0.0251     |0.9008  |0.9121  |98.5     |
|          |solution ①        |           |        |        |         | 
|          |-------------------|-----------|--------|--------|---------|
|          |150% recovery      |0.0251     |0.9008  |0.9046  |97.6     |
|          |solution ②        |           |        |        |         | 
|          |-------------------|-----------|--------|--------|---------|
|          |150% recovery      |0.0252     |0.9008  |0.9083  |98.0     |
|          |solution ③        |           |        |        |         | 
------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 204 of 542 





Page 205
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 







































----------------------------------------------------------------------------------
|          |Average recovery rate (%)                              |98.6         |
|          |-------------------------------------------------------|-------------|
|          |RSD (%)                                                |1.3          |
|          |-------------------------------------------------------|-------------|
|          |Verdict: The impurity YA2304-12 in the test product was 0.006%.      |
|          |The control product YA2304-12 was added to the test product in       |
|          |the limit concentration range of 30%~150% (that is,                  |
|          |0.1802μg/ml~0.9008μg/ml). The recovery rate of each concentration  |  
|          |point was 96.8%~100.2%. In the range of 85%~110%; The average        |
|          |recovery rate was 98.6%. The RSD of recovery was 1.3%, less than     |
|          |10%; Therefore, the accuracy of impurity YA2304-12 is good in the    |
|          |range of 0.1802μg/ml~0.9008μg/ml.                                  |  
|----------|---------------------------------------------------------------------|
|Impuritie |Solution name|Test         |Amount       |Measured     |Recover y    |
|s Name    |             |quantity     |added        |amount       |rate (%)     |
|          |             |(μg/ml)     |(μg/ml)     |(μg/ml)     |             |   
|----------|-------------|-------------|-------------|-------------|-------------|
|YA2304- 14|30% recovery |Not          |0.1810       |0.1830       |101.1        |
|          |solution ①  |detected     |             |             |             | 
|          |-------------|             |-------------|-------------|-------------|
|          |30% sample recovery        |0.1810       |0.1810       |100.0        |
|          |solution ②                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |30% recovery               |0.1810       |0.1849       |102.2        |
|          |solution ③                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |100% recovery              |0.6032       |0.5880       |97.5         |
|          |solution ①                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |100% recovery              |0.6032       |0.5879       |97.5         |
|          |solution ②                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |100% recovery              |0.6032       |0.5846       |96.9         |
|          |solution ③                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |150% recovery              |0.9048       |0.8827       |97.6         |
|          |solution ①                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |150% recovery              |0.9048       |0.8781       |97.0         |
|          |solution ②                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |150% recovery              |0.9048       |0.8760       |96.8         |
|          |solution ③                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |Average recovery rate (%)                              |98.5         |
|          |-------------------------------------------------------|-------------|
|          |RSD (%)                                                |2.1          |
|          |-------------------------------------------------------|-------------|
|          |Conclusions: The impurity YA2304-14 was not detected in the test     |
|          |product, and the control product YA2304-14 was added to the test     |
|          |product in the limit concentration range of 30% to 150% (that is,    |
|          |in the range of 0.1810μg/ml to 0.9048μg/ml). The recoveries of     |  
|          |each concentration point were 96.8% to 102.2%, and the recoveries    |
|          |were 85% to 110%. The average recoveries were 98.5%; The RSD of      |
|          |recovery was 2.1%, less than 10%; Therefore, the accuracy of         |
|          |impurity YA2304-14 was                                               |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 205 of 542 





Page 206
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

























































----------------------------------------------------------------------------------
|          |good in the range of 0.1810μg/ml~0.9048μg/ml.                      |  
|----------|---------------------------------------------------------------------|
|Impuritie |Solution name|Quantity of  |Amount       |Measured     |Recover y    |
|s Name    |             |test         |added        |amount       |rate (%)     |
|          |             |product      |(μg/ml)     |(μg/ml)     |             |  
|          |             |detected     |             |             |             |
|          |             |(μg/ml)     |             |             |             | 
|----------|-------------|-------------|-------------|-------------|-------------|
|YA2304- 15|30% recovery |Not          |0.1816       |0.1867       |102.8        |
|          |solution ①  |detected     |             |             |             | 
|          |-------------|             |-------------|-------------|-------------|
|          |30% sample recovery        |0.1816       |0.1858       |102.3        |
|          |solution ②                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |30% recovery               |0.1816       |0.1857       |102.2        |
|          |solution ③                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |100% recovery              |0.6055       |0.5950       |98.3         |
|          |solution ①                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |100% recovery              |0.6055       |0.6005       |99.2         |
|          |solution ②                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |100% sample                |0.6055       |0.5982       |98.8         |
|          |recovery solution ③       |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |150% recovery              |0.9082       |0.8881       |97.8         |
|          |solution ①                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |150% recovery              |0.9082       |0.8878       |97.8         |
|          |solution ②                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |150% recovery              |0.9082       |0.8951       |98.6         |
|          |solution ③                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |Average recovery rate (%)                              |99.7         |
|          |-------------------------------------------------------|-------------|
|          |RSD (%)                                                |2.1          |
|          |-------------------------------------------------------|-------------|
|          |Conclusions: The impurity YA2304-15 was not detected in the test     |
|          |product. The control product YA2304-15 was added in the limit        |
|          |concentration range of 30%~150% (0.1816μg/ml~0.9082μg/ml). The     |  
|          |recoveries of each concentration point were 97.8%~102.8%, and the    |
|          |recoveries were 85%~110%. The average recoveries were 99.7%; The     |
|          |RSD of recovery was 2.1%, less than 10%; Therefore, the accuracy     |
|          |of impurity YA2304-15 was good in the range of                       |
|          |0.1816μg/ml~0.9082μg/ml.                                           |  
|----------|---------------------------------------------------------------------|
|Impuritie |Solution name|Quantity of  |Amount       |Measured     |Recover y    |
|s Name    |             |test         |added        |amount       |rate (%)     |
|          |             |product      |(μg/ml)     |(μg/ml)     |             |  
|          |             |detected     |             |             |             |
|          |             |(μg/ml)     |             |             |             | 
|----------|-------------|-------------|-------------|-------------|-------------|
|YA2304- 16|30% recovery |Not          |0.1739       |0.1606       |92.4         |
|          |solution ①  |detected     |             |             |             | 
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 206 of 542 





Page 207
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 





































----------------------------------------------------------------------------------------
|          |30% sample recovery|             |0.1739       |0.1588       |91.3         |
|          |solution ②        |             |             |             |             | 
|          |-------------------|             |-------------|-------------|-------------|
|          |30% recovery                     |0.1739       |0.1625       |93.4         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |100% recovery                    |0.5797       |0.5519       |95.2         |
|          |solution ①                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |100% recovery                    |0.5797       |0.5515       |95.1         |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |100% recovery                    |0.5797       |0.5516       |95.1         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.8696       |0.8297       |95.4         |
|          |solution ①                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.8696       |0.8282       |95.2         |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.8696       |0.8240       |94.7         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |Average recovery rate (%)                                    |94.2         |
|          |-------------------------------------------------------------|-------------|
|          |RSD (%)                                                      |1.6          |
|          |-------------------------------------------------------------|-------------|
|          |Conclusions: The impurity YA2304-16 was not detected in the test           |
|          |product, and the control product YA2304-16 was added in the limit          |
|          |concentration range of 30%~150% (0.1739μg/ml~0.8696μg/ml). The           |  
|          |recoveries of each concentration point were 91.3%~95.4%, and the           |
|          |recoveries were 85%~110%. The average recoveries were 94.2%; The           |
|          |RSD of recovery was 1.6%, less than 10%. Therefore, the accuracy           |
|          |of impurity YA2304-16 was good in the range of                             |
|          |0.1739μg/ml~0.8696μg/ml.                                                 |  
|----------|---------------------------------------------------------------------------|
|Impuritie |Solution name      |Quantity of  |Dosage       |Measured     |Recover y    |
|s Name    |                   |test         |(μg/ml)     |amount       |rate (%)     | 
|          |                   |product      |             |(μg/ml)     |             | 
|          |                   |detected     |             |             |             |
|          |                   |(μg/ml)     |             |             |             | 
|----------|-------------------|-------------|-------------|-------------|-------------|
|YA2304- 18|30% recovery       |Not          |0.1804       |0.1762       |97.7         |
|          |solution ①        |detected     |             |             |             | 
|          |-------------------|             |-------------|-------------|-------------|
|          |30% sample recovery              |0.1804       |0.1777       |98.5         |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |30% recovery                     |0.1804       |0.1760       |97.5         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |100% recovery                    |0.6014       |0.5856       |97.4         |
|          |solution ①                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |100% recovery                    |0.6014       |0.5921       |98.5         |
|          |solution ②                      |             |             |             | 
----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 207 of 542 





Page 208
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 
























----------------------------------------------------------------------------------------
|          |100% recovery      |             |0.6014       |0.5892       |98.0         |
|          |solution ③        |             |             |             |             | 
|          |-------------------|             |-------------|-------------|-------------|
|          |150% recovery                    |0.9020       |0.8734       |96.8         |
|          |solution ①                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.9020       |0.8742       |96.9         |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.9020       |0.8775       |97.3         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |Average recovery rate (%)                                    |97.6         |
|          |-------------------------------------------------------------|-------------|
|          |RSD (%)                                                      |0.7          |
|          |-------------------------------------------------------------|-------------|
|          |Conclusions: The impurity YA2304-18 was not detected in the test           |
|          |product, and the control product YA2304-18 was added to the test           |
|          |product in the limit concentration range of 30% to 150% (that is,          |
|          |0.1804μg/ml to 0.9020μg/ml). The recoveries of each concentration        |  
|          |point were 96.8% to 98.5%, and all were 85% to 110%. The average           |
|          |recoveries were 97.6%; The RSD of recovery was 0.7%, less than             |
|          |10%; Therefore, the accuracy of impurity YA2304-18 was good in             |
|          |the range of 0.1804μg/ml~0.9020μg/ml.                                    |  
|----------|---------------------------------------------------------------------------|
|Impuritie |Solution name      |Quantity of  |Amount       |Measured     |Recover y    |
|s Name    |                   |test         |added        |amount       |rate (%)     |
|          |                   |product      |(μg/ml)     |(μg/ml)     |             |  
|          |                   |detected     |             |             |             |
|          |                   |(μg/ml)     |             |             |             | 
|----------|-------------------|-------------|-------------|-------------|-------------|
|YA2304- 19|30% recovery       |0.0359       |0.1802       |0.2094       |96.3         |
|          |solution ①        |             |             |             |             | 
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% sample recovery|0.0360       |0.1802       |0.2271       |106.0        |
|          |solution ②        |             |             |             |             | 
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% recovery       |0.0359       |0.1802       |0.2021       |92.2         |
|          |solution ③        |             |             |             |             | 
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% recovery      |0.0362       |0.6008       |0.6206       |97.3         |
|          |solution ①        |             |             |             |             | 
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% recovery      |0.0363       |0.6008       |0.6123       |95.9         |
|          |solution ②        |             |             |             |             | 
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% recovery      |0.0362       |0.6008       |0.6123       |95.9         |
|          |solution ③        |             |             |             |             | 
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% recovery      |0.0363       |0.9012       |0.9011       |96.0         |
|          |solution ①        |             |             |             |             | 
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% recovery      |0.0363       |0.9012       |0.9003       |95.9         |
|          |solution ②        |             |             |             |             | 
----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 208 of 542 





Page 209
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 







































----------------------------------------------------------------------------------------
|          |150% recovery      |0.0363       |0.9012       |0.9039       |96.3         |
|          |solution ③        |             |             |             |             | 
|          |-------------------|-------------|-------------|-------------|-------------|
|          |Average recovery rate (%)                                    |96.8         |
|          |-------------------------------------------------------------|-------------|
|          |RSD (%)                                                      |4            |
|          |-------------------------------------------------------------|-------------|
|          |Verdict: The impurity YA2304-19 in the test product was 0.009%.            |
|          |The control product YA2304-19 in the limit concentration range of          |
|          |30%~150% was added to the test product (that is,                           |
|          |0.1802μg/ml~0.9012μg/ml). The recovery rate of each concentration        |  
|          |point was 92.2%~106.0%. In the range of 85%~110%; The average              |
|          |recovery rate was 96.8%. The RSD of recovery was 4%, less than             |
|          |10%; Therefore, the accuracy of impurity YA2304-19 is good in the          |
|          |range of 0.1802μg/ml~0.9012μg/ml.                                        |  
|----------|---------------------------------------------------------------------------|
|Impuritie |Solution name      |Quantity of  |Amount       |Measured     |Recover y    |
|s Name    |                   |test         |added        |amount       |rate (%)     |
|          |                   |product      |(μg/ml)     |(μg/ml)     |             |  
|          |                   |detected     |             |             |             |
|          |                   |(μg/ml)     |             |             |             | 
|----------|-------------------|-------------|-------------|-------------|-------------|
|YA2304- 10|45% sample recovery|Not          |0.1827       |0.1848       |101.1        |
|(230nm)   |solution ①        |detected     |             |             |             | 
|          |-------------------|             |-------------|-------------|-------------|
|          |45% sample recovery              |0.1827       |0.1848       |101.1        |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |45% sample recovery              |0.1827       |0.1815       |99.3         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.6092       |0.5928       |97.3         |
|          |solution ①                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.6092       |0.5990       |98.3         |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.6092       |0.5948       |97.6         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |225% recovery                    |0.9137       |0.8880       |97.2         |
|          |solution ①                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |225% recovery                    |0.9137       |0.8936       |97.8         |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |225% recovery                    |0.9137       |0.8880       |97.2         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |Average recovery (%)                                         |98.6         |
|          |-------------------------------------------------------------|-------------|
|          |RSD (%)                                                      |1.7          |
|          |-------------------------------------------------------------|-------------|
|          |Verdict: The impurity YA2304-10 was not detected in the test               |
|          |product, and the control product YA2304-10 was added in the                |
|          |concentration range of 0.045%~0.225% of the test product (that             |
|          |is, 0.1827μg/ml~0.9137μg/ml). The recovery rate of each                  |  
|          |concentration point was 97.2%~101.1%. In the                               |
----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 209 of 542 





Page 210
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 






















































----------------------------------------------------------------------------------------
|          |range of 85%~110%; The average recovery rate was 98.6%. The RSD            |
|          |of recovery was 1.7%, less than 10%; The results indicated that            |
|          |impurity YA2304-10 was in the range of 0.1827μg/ml~0.9137μg/ml,          |  
|          |and the accuracy was good.                                                 |
|----------|---------------------------------------------------------------------------|
|Impuritie |Solution name      |Quantity of  |Amount       |Measured     |Recover y    |
|s Name    |                   |test         |added        |amount       |rate (%)     |
|          |                   |product      |(μg/ml)     |(μg/ml)     |             |  
|          |                   |detected     |             |             |             |
|          |                   |(μg/ml)     |             |             |             | 
|----------|-------------------|-------------|-------------|-------------|-------------|
|YA2304- 17|30% sample recovery|Not          |0.1812       |0.1757       |96.9         |
|(230nm)   |solution ①        |detected     |             |             |             | 
|          |-------------------|             |-------------|-------------|-------------|
|          |30% sample recovery              |0.1812       |0.1779       |98.2         |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |30% recovery                     |0.1812       |0.1779       |98.2         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |100% recovery                    |0.6040       |0.5915       |97.9         |
|          |solution ①                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |100% recovery                    |0.6040       |0.5944       |98.4         |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |100% recovery                    |0.6040       |0.5925       |98.1         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.9060       |0.8922       |98.5         |
|          |solution ①                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.9060       |0.8903       |98.3         |
|          |solution ②                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |150% recovery                    |0.9060       |0.8929       |98.5         |
|          |solution ③                      |             |             |             | 
|          |---------------------------------|-------------|-------------|-------------|
|          |Average recovery rate (%)                                    |98.1         |
|          |-------------------------------------------------------------|-------------|
|          |RSD (%)                                                      |0.5          |
|          |-------------------------------------------------------------|-------------|
|          |Conclusions: The impurity YA2304-17 was not detected in the test           |
|          |product, and the control product YA2304-17 was added to the test           |
|          |product in the limit concentration range of 30% to 150% (that is,          |
|          |0.1812μg/ml to 0.9060μg/ml). The recoveries of each concentration        |  
|          |point were 96.9% to 98.5%, and all were 85% to 110%. The average           |
|          |recoveries were 98.1%; The RSD of recovery was 0.5%, less than             |
|          |10%; Therefore, the accuracy of impurity YA2304-17 was good in             |
|          |the range of 0.1812μg/ml~0.9060μg/ml.                                    |  
|----------|---------------------------------------------------------------------------|
|Impuritie |Solution name      |Quantity of  |Amount       |Measured     |Recover y    |
|s Name    |                   |test         |added        |quantity     |rate (%)     |
|          |                   |product      |(μg/ml)     |(μg/ml)     |             |  
|          |                   |detected     |             |             |             |
----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 210 of 542 





Page 211
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



























----------------------------------------------------------------------------------
|          |             |(μg/ml)     |             |             |             | 
|----------|-------------|-------------|-------------|-------------|-------------|
|YA2304    |LOQ recovery |/            |0.1229       |0.1270       |103.3        |
|(principa |solution ①  |             |             |             |             | 
|l compone |             |             |             |             |             |
|nt instead|             |             |             |             |             |
|of unknow |             |             |             |             |             |
|n         |             |             |             |             |             |
|impurity) |             |             |             |             |             |
|          |-------------|             |-------------|-------------|-------------|
|          |LOQ recovery               |0.1229       |0.1232       |100.2        |
|          |solution ②                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |LOQ recovery               |0.1229       |0.1295       |105.3        |
|          |solution ③                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |100% recovery              |0.4098       |0.4078       |99.5         |
|          |solution ①                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |100% recovery              |0.4098       |0.4114       |100.4        |
|          |solution ②                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |100% recovery              |0.4098       |0.4139       |101.0        |
|          |solution ③                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |150% recovery              |0.6147       |0.6227       |101.3        |
|          |solution ①                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |150% recovery              |0.6147       |0.6139       |99.9         |
|          |solution ②                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |150% recovery              |0.6147       |0.6176       |100.5        |
|          |solution ③                |             |             |             | 
|          |---------------------------|-------------|-------------|-------------|
|          |Average recovery rate (%)                              |101.3        |
|          |-------------------------------------------------------|-------------|
|          |RSD (%)                                                |1.9          |
|          |-------------------------------------------------------|-------------|
|          |Conclusion: YA2304 (principal component instead of unknown           |
|          |impurity) was added to the solvent in the limit concentration        |
|          |range of LOQ~150% (that is, 0.1229μg/ml~0.6147μg/ml), and the      |  
|          |recoveries of each concentration point were 99.5%-105.3%, and all    |
|          |were between 85% and 110%. The average recovery rate was 101.3%.     |
|          |The RSD of recovery was 1.9%, less than 10%; Therefore, the          |
|          |impurity YA2304 (principal component instead of unknown impurity)    |
|          |was in the range of 0.1229μg/ml~0.6147μg/ml, and the accuracy was  |  
|          |good.                                                                |
----------------------------------------------------------------------------------

**g. Precision** 



Precision refers to the proximity between the results obtained by multiple 



sampling of the same uniform test product under specified test conditions, 



and its precision is judged by examining repeatability and intermediate 



precision. 



**i. Repeatability** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 211 of 542 





Page 212
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



 **Acceptance Criteria** 



6 repeatable sample solutions were prepared by Analyst A on date A and 



determined by instrument A. The blank solution should be free of 



interference; Reference solution chromatogram (230nm), the peak order is 



YA2304-17, YA2304-10; In the chromatogram of system suitability solution 



(251nm), the peak order is YA2304-14, YA2304, YA2304-15, YA2304-17, 



YA2304-16, YA2304-10, YA2304-19. The separation degree between YA2304 



and YA2304-14 and YA2304-15 should be NLT 1.5, and the separation 



degree between YA2304-17 and YA2304-16 and adjacent peaks should be 



NLT 1.0; In the contrast solution chromatogram (251nm), the signal-to-noise 



ratio (S/N) of the main peak should NLT 20. In 6 samples of repetitive test 



solution with limited concentration, the impurity peak less than 0.5 times of 



the main peak area of the control solution should be ignored, and the RSD of 



other impurities should NMT 5%, and the RSD of total impurity should NMT 



5%. 



 **Solution Preparation** 



Blank solution: solvent 



YA2304-12 Reference storage solution: Share "YA2304-12 Reference Storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304 Reference stock: Share "YA2304 Reference Stock" under "4.1 



Wavelength Selection". (Approx. 200μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 212 of 542 





Page 213
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-18 Reference storage solution: Share "YA2304-18 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



System suitability solution: Share "System Suitability Solution" under "4.3.2 



Forced degradation Test". 



Reference solution: share "reference solution ②" under "4.3.2 Forced 



degradation Test". (YA2304-10, YA2304-17 containing about 0.4μg/ml) 



Repeatable reference stock solution: Accurately measure 0.75ml of each of 



YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-18, YA2304-19, 



YA2304-17 and YA2304-10 of the reference product reserves, place them in a 



10ml measuring bottle, and dilute them to the scale with solvent. Shake well, 



then it is ready. 



Repeatable test product solution: accurately weigh the YA2304 sample about 



10mg, place it in 25ml measuring bottle, add an appropriate amount of 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 213 of 542 





Page 214
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



solvent to dissolve by ultrasound, accurately add 1ml repeatable reference 



product reserve solution, dilute it with solvent to scale, shake well, and 



obtain. (6 copies were prepared in parallel, named as repeatable test product 



solution ①~⑥) 



Control solution: accurately measure 1ml of the test product solution, place 



it in a 20ml measuring bottle, dilute it with solvent to the scale, and shake 



well; Precision measure 1ml of the above solution, place it in a 50ml 



measuring bottle, dilute it with solvent to the scale, shake well, and then get. 



~ 
(named as control solution ① ⑥) 



 **Injection Sequence** 



After the blank solution, 1 needle was injected into the system suitability 



solution, 2 needles into the control solution, 1 needle into each of 6 control 



solutions and 6 repetitive test solutions, and the chromatogram was 



recorded. 



 **Results and Discussion** 



Results of Repeatability Study: 





































-------------------------------------------------------------------------------------------------
|Name of solution    |Repeatab  |Repea t   |Repea t   |Repea t   |Repetiti  |Repetiti  |RS D (%)|
|                    |le test   |test produ|sampl e ③|sampl e ④|ve test   |ve test   |(n= 6)  |  
|                    |product ①|ct ②     |          |          |product ⑤|product ⑥|        |    
|--------------------|----------|----------|----------|----------|----------|----------|--------|
|Impuri ty|Impurity  |0.156     |0.154     |0.157     |0.155     |0.155     |0.156     |0.7     |
|conten t |YA2304- 12|          |          |          |          |          |          |        |
|/%       |          |          |          |          |          |          |          |        |
|         |----------|----------|----------|----------|----------|----------|----------|--------|
|         |Impurity  |0.149     |0.148     |0.148     |0.150     |0.149     |0.149     |0.5     |
|         |YA2304- 14|          |          |          |          |          |          |        |
|         |----------|----------|----------|----------|----------|----------|----------|--------|
|         |Impurity  |0.158     |0.155     |0.157     |0.156     |0.156     |0.156     |0.7     |
-------------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 214 of 542 





Page 215
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




























------------------------------------------------------------------------------------
|        |YA2304- 15|        |        |        |        |        |        |        |
|        |----------|--------|--------|--------|--------|--------|--------|--------|
|        |Impurity  |0.141   |0.138   |0.139   |0.139   |0.140   |0.139   |0.9     |
|        |YA2304- 16|        |        |        |        |        |        |        |
|        |----------|--------|--------|--------|--------|--------|--------|--------|
|        |Impurity  |0.148   |0.146   |0.148   |0.147   |0.147   |0.146   |0.5     |
|        |YA2304- 18|        |        |        |        |        |        |        |
|        |----------|--------|--------|--------|--------|--------|--------|--------|
|        |Impurity  |0.166   |0.165   |0.167   |0.172   |0.164   |0.164   |1.7     |
|        |YA2304- 19|        |        |        |        |        |        |        |
|        |----------|--------|--------|--------|--------|--------|--------|--------|
|        |Impurity  |0.147   |0.147   |0.148   |0.148   |0.148   |0.146   |0.6     |
|        |YA2304- 17|        |        |        |        |        |        |        |
|        |----------|--------|--------|--------|--------|--------|--------|--------|
|        |Impurity  |0.148   |0.147   |0.148   |0.148   |0.148   |0.147   |0.4     |
|        |YA2304- 10|        |        |        |        |        |        |        |
|        |----------|--------|--------|--------|--------|--------|--------|--------|
|        |Unknow n  |<0.05%  |<0.05 % |<0.05 % |<0.05 % |<0.05%  |<0.05%  |/       |
|        |impurity  |        |        |        |        |        |        |        |
|        |(RRT≈0.6 |        |        |        |        |        |        |        | 
|        |4)        |        |        |        |        |        |        |        |
|        |----------|--------|--------|--------|--------|--------|--------|--------|
|        |Unknow n  |<0.05%  |<0.05 % |<0.05 % |<0.05 % |<0.05%  |<0.05%  |/       |
|        |impurity  |        |        |        |        |        |        |        |
|        |(RRT≈1.2 |        |        |        |        |        |        |        | 
|        |7)        |        |        |        |        |        |        |        |
|        |----------|--------|--------|--------|--------|--------|--------|--------|
|        |Total     |1.213   |1.201   |1.212   |1.215   |1.206   |1.204   |0.5     |
|        |impurity  |        |        |        |        |        |        |        |
|--------|----------|--------|--------|--------|--------|--------|--------|--------|
|Verdict: Impurities YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-18         |
|and YA2304-19 were calculated by the principal component self-control             |
|method with correction factor under the wavelength of 251nm. Impurities           |
|YA2304-10 and YA2304-17 were calculated at 230nm wavelength by external           |
|standard method. The impurity peak less than 0.5 times of the main peak           |
|area of the control solution was ignored in the 6 samples with limited            |
|concentration repeatable test solution. The RSD of other impurities was           |
|less than 5%, and the RSD of total impurities was less than 5%, which met         |
|the requirements. The method has good repeatability.                              |
------------------------------------------------------------------------------------

**ii. Intermediate Precision** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 215 of 542 





Page 216
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



 **Acceptance Criteria** 



6 parts of intermediate precision test product solution were prepared by 



Analyst B on date B and determined by instrument B. The blank solution 



should be free of interference; Reference solution chromatogram (230nm), 



the peak order is YA2304-17, YA2304-10; In the chromatogram of system 



suitability solution (251nm), the peak order is YA2304-14, YA2304, 



YA2304-15, YA2304-17, YA2304-16, YA2304-10, YA2304-19. The 



separation degree between YA2304 and YA2304-14 and YA2304-15 should 



be NLT 1.5, and the separation degree between YA2304-17 and YA2304-16 



and adjacent peaks should be NLT 1.0; In the chromatogram obtained by 



contrast solution (251nm) for 6 consecutive days, the RSD of the main peak 



NMT 1.0%, the RSD of the peak area NMT 5%, and the signal-to-noise ratio 



(S/N) should NLT 20. In 6 intermediate precision test solutions, the impurity 



peak less than 0.5 times of the main peak area of the control solution should 



be ignored, the RSD of other impurities should NMT 5%, and the RSD of total 



impurity should NMT 5%. 



In the results of 12 tests of repeatability and intermediate precision, the RSD 



of other impurities NMT 10% and the RSD of total impurities NMT 10% if the 



impurity peak is less than 0.5 times the main peak area of the control 



solution. 



 **Solution Preparation** 



Blank solution: solvent 



YA2304-12 Reference storage solution: Share "YA2304-12 Reference Storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 216 of 542 





Page 217
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304 Reference stock: Share "YA2304 Reference Stock" under "4.1 



Wavelength Selection". (Approx. 200μg/ml) 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-18 Reference storage solution: Share "YA2304-18 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



System suitability solution: Prepare by the same method as "System 



Suitability solution" under "4.2 System Suitability". (YA2304-14, YA2304-15, 



YA2304-16, YA2304-19, YA2304-10 and YA2304-17 are about 0.8μg/ml) 



Reference solution: Prepare it by the same method as "reference solution" 



under "4.2 System Suitability". (YA2304-10 and YA2304-17 both contain 



about 0.4μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 217 of 542 





Page 218
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Intermediate precision control product reserve liquid: Take 0.75ml of each 



control product reserve liquid of YA2304-12, YA2304-14, YA2304-15, 



YA2304-16, YA2304-18, YA2304-19, YA2304-17 and YA2304-10 and place 



them in a 10ml measuring bottle and dilute them to the scale with solvent. 



Shake well, then it is ready. 



Intermediate precision test product solution: accurately weigh the YA2304 



sample about 10mg, place it in a 25ml measuring bottle, add an appropriate 



amount of solvent and ultrasonic to dissolve it, then precisely add 1ml of the 



intermediate precision control product reserve, dilute it with solvent to the 



scale, shake well, and obtain. (6 parts were prepared in parallel, named as 



~ 
intermediate precision test product solution ① ⑥) 



Control solution: accurately measure 1ml of the test product solution, place 



it in a 20ml measuring bottle, dilute it with solvent to the scale, and shake 



well; Precision measure 1ml of the above solution, place it in a 50ml 



measuring bottle, dilute it with solvent to the scale, shake well, and then get. 



~ 
(named as control solution ① ⑥) 



 **Injection Sequence** 



After the blank solution, 1 needle was injected into the system suitable 



solution, 2 needles were injected into the control solution, 6 needles were 



repeated into the control solution, 1 needle was injected into the control 



solution ②~⑥ and 1 needle was injected into the intermediate precision test 



solution ①~⑥, and the chromatogram was recorded. 



 **Results and Discussion** 



System Suitability of Intermediate Precision Study: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 218 of 542 





Page 219
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 























































-----------------------------------------------------------------------------------------
|Map Name  |Substance |YA2304-1 4|YA2304    |YA2304-1 5|YA2304-1 7           |YA2304-1 6|
|          |name      |          |          |          |                     |          |
|----------|----------|----------|----------|----------|---------------------|----------|
|System    |RT (min)  |8.335     |9.348     |10.352    |11.561               |12.027    |
|suitabilit|          |          |          |          |                     |          |
|y solution|          |          |          |          |                     |          |
|(251nm)   |          |          |          |          |                     |          |
|          |----------|----------|----------|----------|---------------------|----------|
|          |Minimum separation   |5.7       |Minimum separation   |          |1.6       |
|          |between YA2304 and   |          |between YA2304-17    |          |          |
|          |YA2304-14 and        |          |and YA2304-16 and    |          |          |
|          |YA2304-15            |          |adjacent peaks       |          |          |
|----------|---------------------|          |---------------------|----------|          |
|Map name  |Number of |Main peak retention  |Main peak area       |Principal peak       |
|          |samples   |time (min)           |                     |signal-to-noise      |
|          |injected  |                     |                     |ratio (S/N)          |
|----------|----------|---------------------|---------------------|---------------------|
|Control   |1         |9.394                |7013                 |93.2                 |
|solution  |          |                     |                     |                     |
|(251nm)   |          |                     |                     |                     |
|          |----------|---------------------|---------------------|---------------------|
|          |2         |9.380                |6926                 |99.1                 |
|          |----------|---------------------|---------------------|---------------------|
|          |3         |9.384                |6843                 |107.0                |
|          |----------|---------------------|---------------------|---------------------|
|          |4         |9.404                |6972                 |107.7                |
|          |----------|---------------------|---------------------|---------------------|
|          |5         |9.414                |7098                 |139.5                |
|          |----------|---------------------|---------------------|---------------------|
|          |6         |9.409                |7247                 |83.1                 |
|          |----------|---------------------|---------------------|---------------------|
|          |RSD(n=6)  |0.15                 |2.1                  |/                    |
|----------|----------|---------------------|---------------------|---------------------|
|Conclusion: There was no interference in the blank solution, the            |          |
|chromatogram of the control solution (230nm), the peak sequence was         |          |
|YA2304-17, YA2304-10; In the chromatogram of system suitable solution       |          |
|(251nm), the peak order was YA2304-14, YA2304, YA2304-15, YA2304-17,        |          |
|YA2304-16, YA2304-10, YA2304-19. The minimum separation degree between      |          |
|YA2304 and YA2304-14 and YA2304-15 is 5.7 (NLT 1.5), and the minimum        |          |
|separation degree between YA2304-17 and YA2304-16 and adjacent peaks is 1.6 |          |
|(NLT 1.0); In the chromatogram obtained by contrast solution (251nm) for 6  |          |
|consecutive days, the RSD of the main peak retention time was 0.15% (not    |          |
|more than 1.0%), the RSD of the main peak area was 2.1% (not more than 5%), |          |
|and the signal-to-noise ratio (S/N) was NLT 20. In accordance with the      |          |
|verification requirements.                                                  |          |
-----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 219 of 542 





Page 220
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 








































-------------------------------------------------------------------------------------------------------------
|Name of solution             |Repeatable|Repeat    |Repeat   |Repeat   |Repetitive|Repetitive|RSD (%) (n=6)|
|                             |test      |test      |sample ③|sample ④|test      |test      |             |  
|                             |product ①|product ②|         |         |product ⑤|product ⑥|             |    
|-----------------------------|----------|----------|---------|---------|----------|----------|-------------|
|I m p ur  |Impurity YA2304-12|0.156     |0.154     |0.157    |0.155    |0.155     |0.156     |0.7          |
|it y co nt|                  |          |          |         |         |          |          |             |
|e nt / %  |                  |          |          |         |         |          |          |             |
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Impurity YA2304-14|0.149     |0.148     |0.148    |0.150    |0.149     |0.149     |0.5          |
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Impurity YA2304-15|0.158     |0.155     |0.157    |0.156    |0.156     |0.156     |0.7          |
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Impurity YA2304-16|0.141     |0.138     |0.139    |0.139    |0.140     |0.139     |0.9          |
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Impurity YA2304-18|0.148     |0.146     |0.148    |0.147    |0.147     |0.146     |0.5          |
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Impurity YA2304-19|0.166     |0.165     |0.167    |0.172    |0.164     |0.164     |1.7          |
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Impurity YA2304-17|0.147     |0.147     |0.148    |0.148    |0.148     |0.146     |0.6          |
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Impurity YA2304-10|0.148     |0.147     |0.148    |0.148    |0.148     |0.147     |0.4          |
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Unknown impurity  |<0.05%    |<0.05%    |<0.05%   |<0.05%   |<0.05%    |<0.05%    |/            |
|          |(RRT≈0.64)       |          |          |         |         |          |          |             | 
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Unknown impurity  |<0.05%    |<0.05%    |<0.05%   |<0.05%   |<0.05%    |<0.05%    |/            |
|          |(RRT≈1.27)       |          |          |         |         |          |          |             | 
|          |------------------|----------|----------|---------|---------|----------|----------|-------------|
|          |Total impurity    |1.213     |1.201     |1.212    |1.215    |1.206     |1.204     |0.5          |
-------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 220 of 542 





Page 221
------------------------------------------------------------------------------------------------------------------------------
|Verdict: Impurities YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-18 and YA2304-19 were calculated by the        |      
|principal                                                                                                             |      
|component self-control method with correction factor under the wavelength of 251nm. Impurities YA2304-10 and YA2304-17|      
|were                                                                                                                  |      
|calculated at 230nm wavelength by external standard method. The impurity peak less than 0.5 times of the main peak    |      
|area of the                                                                                                           |      
|control solution was ignored in the 6 samples with limited concentration repeatable test solution. The RSD of other   |      
|impurities                                                                                                            |      
|was less than 5%, and the RSD of total impurities was less than 5%, which met the requirements. The method has good   |      
|repeatability.                                                                                                        |      
|----------------------------------------------------------------------------------------------------------------------|      
|Solution name                 |Intermediat|Intermediat|Intermediat|Intermediat|Intermediat|Intermediat|RSD (%)   |RSD (%)   |
|                              |e         |e         |e         |e         |e         |e         |(n=6)     |(n=12)    |      
|                              |precision |precision |precision |precision |precision |precision |          |          |      
|                              |test      |test      |sample ③ |test      |test      |test      |          |          |       
|                              |product ①|product ②|          |product ④|product ⑤|product ⑥|          |          |           
|------------------------------|----------|----------|----------|----------|----------|----------|----------|----------|      
|Im pur ity|Impurity YA2304-12 |0.145     |0.148     |0.150     |0.150     |0.151     |0.149     |1.5       |2.6       |      
|con ten t |                   |          |          |          |          |          |          |          |          |      
|/%        |                   |          |          |          |          |          |          |          |          |      
|          |-------------------|----------|----------|----------|----------|----------|----------|----------|----------|      
|          |Impurity YA2304-14 |0.142     |0.142     |0.147     |0.144     |0.146     |0.143     |1.4       |2.0       |      
|          |-------------------|----------|----------|----------|----------|----------|----------|----------|----------|      
|          |Impurity YA2304-15 |0.151     |0.151     |0.154     |0.153     |0.154     |0.153     |1.0       |1.5       |      
|          |-------------------|----------|----------|----------|----------|----------|----------|----------|----------|      
|          |Impurity YA2304-16 |0.131     |0.131     |0.135     |0.135     |0.135     |0.133     |1.6       |2.6       |      
|          |-------------------|----------|----------|----------|----------|----------|----------|----------|----------|      
|          |Impurity YA2304-18 |0.140     |0.140     |0.145     |0.144     |0.143     |0.141     |1.4       |2.0       |      
|          |-------------------|----------|----------|----------|----------|----------|----------|----------|----------|      
|          |Impurity YA2304-19 |0.164     |0.163     |0.171     |0.171     |0.167     |0.165     |2.1       |1.9       |      
|          |-------------------|----------|----------|----------|----------|----------|----------|----------|----------|      
|          |Impurity YA2304-17 |0.142     |0.142     |0.142     |0.142     |0.142     |0.142     |0.22      |2.1       |      
|          |-------------------|----------|----------|----------|----------|----------|----------|----------|----------|      
|          |Impurity YA2304-10 |0.148     |0.146     |0.144     |0.146     |0.146     |0.148     |1.1       |0.9       |      
|          |-------------------|----------|----------|----------|----------|----------|----------|----------|----------|      
|          |Unknown impurity   |<0.05%    |<0.05%    |<0.05%    |<0.05%    |<0.05%    |<0.05%    |/         |<0.05%    |      
|          |(RRT≈0.64)        |          |          |          |          |          |          |          |          |       
------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 221 of 542 





Page 222
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










------------------------------------------------------------------------------------------------------------------------
|          |Unknown impurity   |<0.05%    |<0.05%    |<0.05%    |<0.05%    |<0.05%    |<0.05%    |/         |<0.05%    |
|          |(RRT≈1.27)        |          |          |          |          |          |          |          |          | 
|          |-------------------|----------|----------|----------|----------|----------|----------|----------|----------|
|          |Total impurity     |1.163     |1.162     |1.188     |1.185     |1.185     |1.174     |1.0       |1.6       |
|----------|-------------------|----------|----------|----------|----------|----------|----------|----------|----------|
|Conclusion: Impurities YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-18 and YA2304-19 were calculated by the     |
|principal                                                                                                             |
|component self-control method with correction factor under the wavelength of 251nm. Impurities YA2304-10 and YA2304-17|
|were                                                                                                                  |
|calculated at 230nm wavelength by external standard method. The impurity peak less than 0.5 times of the main peak    |
|area of the                                                                                                           |
|control solution was ignored in the 6 parts of intermediate precision test solution with limit concentration. The RSD |
|of other                                                                                                              |
|impurities was less than 5%, and the RSD of total impurities was less than 5%, which met the requirements. The        |
|intermediate                                                                                                          |
|precision of this method is good. In the 12 tests of repeatability and intermediate precision, the impurity peak less |
|than 0.5                                                                                                              |
|times of the main peak area of the control solution was ignored, the RSD of other impurities was less than 10%, and   |
|the RSD of                                                                                                            |
|total impurities was less than 10%, which met the requirements.                                                       |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 222 of 542 





Page 223
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**h. Solution Stability Studies** 



 **Acceptance Criteria** 



Each solution is placed under 5℃ (refrigerated) condition, and the control 



solution, system suitability solution and test product solution are injected at 



different times. The chromatogram of system suitability solution is required 



to be (251nm). The peak order is YA2304-14, YA2304, YA2304-15, 



YA2304-16, YA2304-17, YA2304-10, YA2304-19, and the separation degree 



between YA2304 and YA2304-14 and YA2304-15 should NLT 1.5. The 



separation degree between YA2304-17 and YA2304-16 and adjacent peaks 



should NLT 1.0; In the chromatogram of the control product solution 



(230nm), the peak sequence was YA2304-17, YA2304-10; The RSD of the 



peak-peak area of each impurity in the chromatogram of the reference 



solution NMT 10%. In the chromatogram of the control solution (251nm), the 



signal-to-noise ratio (S/N) of the main peak should NLT 20, the RSD of the 



peak area NMT 10%, the impurity peak less than 0.5 times the main peak 



area of the control solution should not be ignored in the chromatogram of the 



test solution and the solution with the maximum concentration and 



miscellaneous test product, and the RSD of the peak area of other single 



impurities NMT 10%. And there should be no new impurities that interfere 



with the detection of related substances. 



 **Solution Preparation** 



Blank solution: solvent 



YA2304-12 Reference storage solution: Share "YA2304-12 Reference Storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 223 of 542 





Page 224
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-18 Reference storage solution: Share "YA2304-18 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Reference solution: Prepare it by the same method as "reference solution" 



under "4.2 System Suitability". (YA2304-10, YA2304-17 containing about 



0.4μg/ml) 



Test solution: Prepare the test solution by the same method as "test solution" 



under "4.2 System Suitability". (Approx. 0.4mg/ml) 



Reference solution: Prepare it by the same method as "reference solution" 



under "4.2 System Applicability". (Approx. 0.4μg/ml) 



System Suitability Solution: Share "System Suitability Solution" from "4.6 



Accuracy" known impurity. (YA2304-14, YA2304-15, YA2304-16, YA2304-19, 



YA2304-10 and YA2304-17 all approx. 0.8μg/ml) 



Impurity reserve liquid: Accurately measure 0.75ml of each control product 



reserve liquid of YA2304-12, YA2304-14, YA2304-15, YA2304-16, 



YA2304-18, YA2304-19, YA2304-17 and YA2304-10 into the same 10ml 



bottle and dilute it to the scale with solvent. Shake well, then it is ready. 



(Contains YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-18, 



YA2304-19, YA2304-17 and YA2304-10 about 15μg/ml each) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 224 of 542 





Page 225
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Add mixed test product solution: accurately weigh 10mg of this product, 



place it in a 25ml measuring bottle, add an appropriate amount of solvent 



and ultrasonic to dissolve it, then accurately add 1.0ml of impurity reserve 



liquid, dilute it with solvent to the scale, shake well, and get. (Including 



YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-18, YA2304-19, 



YA2304-17 and YA2304-10 are about 0.6μg/ml) 



 **Injection Sequence** 



The suitable solution of the system was placed at 5℃, 1 needle was injected 



at 0h, 8h, 19h, 26.5h, 46h, 59h and 100h respectively, and the 



chromatogram was recorded. 



The mixed test solution was placed at 5℃, and 1 needle was injected at 0h, 



8h, 19h, 25h, 46h, 59h and 100h, respectively, and the chromatogram was 



recorded. 



The test solution was placed at 5℃, and 1 needle was injected at 0h, 8h, 19h, 



38.5h, 46h, 59h and 100h, respectively, and the chromatogram was 



recorded. 



The control solution was placed at 5℃ and injected with 1 needle each at 0h, 



8h, 19h, 39h, 46h, 59h and 100h, respectively, and the chromatogram was 



recorded. 



The control solution was placed at 5℃, and 1 needle was injected at 0h, 8h, 



19h, 38h, 46h, 59h and 100h, respectively, and the chromatogram was 



recorded. 



 **Results and Discussion** 



System suitability solution stability test results: 









-----------------------------------------------------------------------------
|Investigati|Control solution                                       |RSD %  |
|on items   |                                                       |       |
|           |-------------------------------------------------------|       |
|           |0h     |8h     |19h    |38h    |46h    |59h    |100h   |       |
-----------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 225 of 542 





Page 226
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 










-------------------------------------------------------------------------------------
|Main peak  |6709    |6535    |6563    |6771    |6836    |6606    |6732    |1.7     |
|area       |        |        |        |        |        |        |        |        |
|-----------|--------|--------|--------|--------|--------|--------|--------|--------|
|Principal  |75.4    |65.3    |92.2    |89.8    |54.0    |103.0   |92.8    |/       |
|peak       |        |        |        |        |        |        |        |        |
|signal-to-n|        |        |        |        |        |        |        |        |
|oise ratio |        |        |        |        |        |        |        |        |
|-----------|        |        |        |        |        |        |        |        |
|Conclusion: When the control solution was placed at 5℃for 100h, the               | 
|chromatogram of the control solution (251nm) showed that the main peak             |
|signal-to-noise ratio (S/N) was NLT 54.0 (required to be NLT 20), and the          |
|RSD of the peak area was 1.7% (required to be no more than 10%). All of the        |
|above meet the verification requirements, indicating that the control              |
|solution is stable within 100h under 5℃.                                          | 
-------------------------------------------------------------------------------------

Stability test results of control solution: 





































----------------------------------------------------------------------------------------
|Investigati|Impurity  |Reference solution                                     |RSD %  |
|on Items   |names     |                                                       |       |
|           |          |-------------------------------------------------------|       |
|           |          |0h     |8h     |19h    |39h    |46h    |59h    |100h   |       |
|-----------|----------|-------|-------|-------|-------|-------|-------|-------|-------|
|Peak area  |YA2304- 17|1103 7 |1099 0 |1104 2 |1109 6 |1100 6 |1123 5 |1103 1 |0.8    |
|           |----------|-------|-------|-------|-------|-------|-------|-------|-------|
|           |YA2304- 10|8322   |8233   |8327   |8411   |8336   |8361   |8219   |0.9    |
|-----------|          |       |       |       |       |       |       |       |       |
|Conclusion: When the control solution was placed at 5℃for 100h, the                  | 
|chromatogram of the control solution (230nm) was followed by YA2304-17 and            |
|YA2304-10, and the RSD of the peak-peak area of each impurity in the                  |
|chromatogram was no more than 0.9% (required to be no more than 10%). The             |
|verification requirements were met, indicating that the control solution              |
|was stable within 100h under 5℃.                                                     | 
----------------------------------------------------------------------------------------

Stability test results of system suitability solution: 































------------------------------------------------------------------------------------------------------
|Investigation Items           |Time of visit                                                        |
|                              |---------------------------------------------------------------------|
|                              |0h       |8h       |19h      |26.5 h.  |46h      |59h      |100h     |
|------------------------------|---------|---------|---------|---------|---------|---------|---------|
|Degree of separation between  |5.9      |6.0      |5.9      |5.9      |5.9      |5.8      |5.8      |
|YA2304 and YA2304-14          |         |         |         |         |         |         |         |
|------------------------------|---------|---------|---------|---------|---------|---------|---------|
|Degree of separation between  |6.8      |6.9      |6.8      |6.8      |6.8      |6.8      |6.7      |
|YA2304 and YA2304-15          |         |         |         |         |         |         |         |
|------------------------------|---------|---------|---------|---------|---------|---------|---------|
|Minimum separation between    |1.6      |1.6      |1.6      |1.6      |1.6      |2.2      |2.2      |
|YA2304-17 and adjacent peaks  |         |         |         |         |         |         |         |
|------------------------------|---------|---------|---------|---------|---------|---------|---------|
|Minimum separation degree     |1.6      |1.6      |1.6      |1.6      |1.6      |1.6      |1.6      |
|between YA2304-16 and adjacent|         |         |         |         |         |         |         |
|peaks                         |         |         |         |         |         |         |         |
|------------------------------|---------|---------|---------|---------|---------|---------|---------|
|Verdict: The system suitable solution was placed at 5℃ for 100h, and the                           | 
------------------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 226 of 542 





Page 227
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



chromatogram of the system suitable solution was 251nm. The peak order was 



YA2304-14, YA2304, YA2304-15, YA2304-17, YA2304-16, YA2304-10, YA2304-19. 



The minimum separation degree between YA2304 and YA2304-14 and YA2304-15 is 



NLT 5.8 (NLT 1.5 required), and the minimum separation degree between YA2304-17 



and YA2304-16 and adjacent peaks is NLT 1.6 (NLT 1.0 required); All of the above 



meet the verification requirements, indicating that the system suitable solution is 



stable within 100h under 5℃. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 227 of 542 





Page 228
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Stability test results of test solutions： 





































































-------------------------------------------------------------------------------------------------------------------------
|Time Point           |Detection|0h       |8h       |19h      |38.5 h.  |46h      |59h      |100h     |RSD/%           | 
|                     |wavelength|         |         |         |         |         |         |         |                |
|---------------------|---------|---------|---------|---------|---------|---------|---------|---------|----------------| 
|I m p u  |Impurity   |251nm    |382      |333      |343      |386      |467      |337      |356      |Content < 0.05%,| 
|ri       |YA2304-12  |         |         |         |         |         |         |         |         |RSD             | 
|ty p e a |           |         |         |         |         |         |         |         |         |does not do     | 
|k        |           |         |         |         |         |         |         |         |         |statistics      | 
|ar e a   |           |         |         |         |         |         |         |         |         |                | 
|         |-----------|         |---------|---------|---------|---------|---------|---------|---------|----------------| 
|         |Unknown impurity     |1182     |1090     |1360     |1327     |1308     |1166     |458      |Content < 0.05%,| 
|         |(RRT≈0.64)          |         |         |         |         |         |         |         |RSD did         |  
|         |                     |         |         |         |         |         |         |         |not do          | 
|         |                     |         |         |         |         |         |         |         |statistics      | 
|         |---------------------|---------|---------|---------|---------|---------|---------|---------|----------------| 
|         |Impurity YA2304-14   |Not      |Not      |Not      |Not      |Not      |Not      |Not      |Content < 0.05%,| 
|         |                     |detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|RSD             | 
|         |                     |         |         |         |         |         |         |         |does not do     | 
|         |                     |         |         |         |         |         |         |         |statistics      | 
|         |---------------------|---------|---------|---------|---------|---------|---------|---------|----------------| 
|         |Impurity YA2304-15   |Not      |Not      |Not      |Not      |Not      |Not      |Not      |Content < 0.05%,| 
|         |                     |detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|RSD             | 
|         |                     |         |         |         |         |         |         |         |does not do     | 
|         |                     |         |         |         |         |         |         |         |statistics      | 
|         |---------------------|---------|---------|---------|---------|---------|---------|---------|----------------| 
|         |Unknown impurity     |1220     |1198     |1161     |1174     |1266     |1201     |1181     |Content < 0.05%,| 
|         |(RRT≈1.27)          |         |         |         |         |         |         |         |RSD             |  
|         |                     |         |         |         |         |         |         |         |does not do     | 
|         |                     |         |         |         |         |         |         |         |statistics      | 
|         |---------------------|---------|---------|---------|---------|---------|---------|---------|----------------| 
|         |Impurity YA2304-16   |Not      |Not      |Not      |Not      |Not      |Not      |Not      |Content < 0.05%,| 
|         |                     |detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|RSD             | 
|         |                     |         |         |         |         |         |         |         |does not do     | 
|         |                     |         |         |         |         |         |         |         |statistics      | 
|         |---------------------|---------|---------|---------|---------|---------|---------|---------|----------------| 
|         |Impurity YA2304-18   |Not      |Not      |Not      |Not      |Not      |Not      |Not      |Content < 0.05%,| 
|         |                     |detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|RSD             | 
|         |                     |         |         |         |         |         |         |         |does not do     | 
|         |                     |         |         |         |         |         |         |         |statistics      | 
|         |---------------------|---------|---------|---------|---------|---------|---------|---------|----------------| 
|         |Impurity YA2304-19   |560      |481      |575      |611      |588      |767      |409      |Content < 0.05%,| 
|         |                     |         |         |         |         |         |         |         |RSD             | 
|         |                     |         |         |         |         |         |         |         |does not do     | 
|         |                     |         |         |         |         |         |         |         |statistics      | 
-------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 228 of 542 





Page 229
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 


































------------------------------------------------------------------------------------------------------------------------
|         |Impurity        |230nm    |Not      |Not      |Not      |Not      |Not      |Not      |Not      |Content <  |
|         |YA2304-17       |         |detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|0.05%, RSD |
|         |                |         |         |         |         |         |         |         |         |does not do|
|         |                |         |         |         |         |         |         |         |         |statistics |
|         |----------------|         |---------|---------|---------|---------|---------|---------|---------|-----------|
|         |Impurity YA2304-10        |Not      |Not      |Not      |Not      |Not      |Not      |Not      |Content <  |
|         |                          |detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|detecte d|0.05%, RSD |
|         |                          |         |         |         |         |         |         |         |does not do|
|         |                          |         |         |         |         |         |         |         |statistics |
|---------|--------------------------|---------|---------|---------|---------|---------|---------|---------|-----------|
|Conclusion: When the test solution was placed at 5℃for 100h, the impurity peak smaller than 0.5 times of the main    | 
|peak area of                                                                                                          |
|the control solution was ignored in the chromatogram of the test solution. The known impurities were detected except  |
|YA2304-12                                                                                                             |
|and YA2304-19, and both were less than 0.05%, and the rest were not detected. Other single unknown impurities were all|
|less                                                                                                                  |
|than 0.05%, the RSD of each impurity peak area was not counted (not more than 10%), and no new impurities were added  |
|to                                                                                                                    |
|interfere with the detection of related substances. The above are in line with the verification requirements,         |
|indicating that                                                                                                       |
|the test solution is stable within 100h under 5℃.                                                                    | 
------------------------------------------------------------------------------------------------------------------------

Stability test results of solution with miscellaneous test products 


































--------------------------------------------------------------------------------------------------------------------------
|Time Point                   |Detection|0h     |8h     |19h    |25h    |46h    |59h    |100h   |RSD/%                   |
|                             |wavelengt|       |       |       |       |       |       |       |                        |
|                             |h        |       |       |       |       |       |       |       |                        |
|-----------------------------|---------|-------|-------|-------|-------|-------|-------|-------|------------------------|
|Im pur ity|Impurity YA2304-12|251nm    |8738   |8628   |8837   |8744   |8810   |8825   |8731   |0.9                     |
|pea k are |                  |         |       |       |       |       |       |       |       |                        |
|a         |                  |         |       |       |       |       |       |       |       |                        |
|          |------------------|         |-------|-------|-------|-------|-------|-------|-------|------------------------|
|          |Unknown impurity            |/      |945    |1233   |1061   |1491   |1223   |1666   |Content < 0.05%, RSD    |
|          |(RRT≈0.64)                 |       |       |       |       |       |       |       |does not do statistics  | 
|          |----------------------------|-------|-------|-------|-------|-------|-------|-------|------------------------|
|          |Impurity YA2304-14          |10267  |9809   |9895   |10078  |10015  |10050  |9889   |1.6                     |
|          |----------------------------|-------|-------|-------|-------|-------|-------|-------|------------------------|
|          |Impurity YA2304-15          |8793   |8747   |8744   |8807   |8888   |8899   |8669   |1.0                     |
|          |----------------------------|-------|-------|-------|-------|-------|-------|-------|------------------------|
|          |Unknown impurity            |1082   |1049   |1104   |1109   |1096   |1102   |1107   |Content < 0.05%, RSD did|
|          |(RRT≈1.27)                 |       |       |       |       |       |       |       |not do statistics       | 
|          |----------------------------|-------|-------|-------|-------|-------|-------|-------|------------------------|
|          |Impurity YA2304-16          |9394   |9292   |9227   |9074   |8798   |8843   |8449   |4                       |
--------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 229 of 542 





Page 230
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 













------------------------------------------------------------------------------------------------------------------------
|         |Impurity YA2304-18|         |9107     |9027     |8791     |8755     |8574     |8452     |8111     |4        |
|         |------------------|         |---------|---------|---------|---------|---------|---------|---------|---------|
|         |Impurity YA2304-19          |15639    |15602    |15665    |15644    |15942    |15998    |15712    |1.1      |
|         |----------------------------|---------|---------|---------|---------|---------|---------|---------|---------|
|         |Impurity YA2304-17|230nm    |16023    |15969    |15952    |15986    |16017    |16400    |16199    |1.1      |
|         |------------------|         |---------|---------|---------|---------|---------|---------|---------|---------|
|         |Impurity YA2304-10          |12233    |12086    |12173    |12076    |12218    |12178    |11975    |0.8      |
|---------|----------------------------|---------|---------|---------|---------|---------|---------|---------|---------|
|Conclusions: The impurity peak less than 0.5 times the main peak area of the control solution was ignored in the      |
|chromatogram                                                                                                          |
|of the impurity solution added at 5℃for 100h. At 230m wavelength, the RSD of the known impurity YA2304-17 and        | 
|YA2304-10 was                                                                                                         |
|not greater than 1.1% (10% is not required). At 251nm wavelength, the RSD of known impurities YA2304-12, YA2304-14,   |
|YA2304-15,                                                                                                            |
|YA2304-16, YA2304-18 and YA2304-19 are not greater than 4% (10% is not required); The RSD of other single unknown     |
|impurity is                                                                                                           |
|less than 0.05%, the RSD of the single unknown impurity is not counted (not more than 10%), and no new impurity       |
|interferes                                                                                                            |
|with the detection of related substances; The above are in line with the verification requirements, indicating that   |
|the                                                                                                                   |
|solution of added impurity is stable within 100h at 5℃.                                                              | 
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 230 of 542 





Page 231
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**i. Robustness** 



 **Acceptance Criteria** 



Durability is achieved by examining the content of various impurities in 



the test solution under normal chromatographic conditions (changing the 



column temperature, the initial proportion of mobile phase, the flow rate, the 



column lot number) and testing the limit concentration under normal 



chromatographic conditions. It is required that in the spectrum obtained by 



the system applicable solution under each condition (251nm), the peak order 



is YA2304-14, YA2304, YA2304-15, YA2304-17, YA2304-16, YA2304-10, 



YA2304-19. The separation degree between YA2304 and YA2304-14 and 



YA2304-15 should be NLT 1.5, and the separation degree between 



YA2304-17 and YA2304-16 and adjacent peaks should be NLT 1.0; In the 



chromatogram of the reference product solution (230nm), the order of the 



peaks is YA2304-17, YA2304-10; In the control solution chromatogram 



(251nm), the signal-to-noise ratio (S/N) of the main peak should NLT 20. 



Under different conditions of the same chromatographic parameters, the 



RSDS of each impurity content greater than 0.05% in the test product NMT 



10%, and the RSDS of total impurity content NMT 10%; Or the absolute 



deviation of the impurity content NMT 20% of the limit value, the absolute 



deviation of the total impurity content NMT 40% of the limit value. 



Variations of Method Parameters in Robustness Study 









------------------------------------------------
|Chromato |Standard conditions|Variable Values |
|graphic  |                   |                |
|Parameter|                   |                |
|s        |                   |                |
|---------|-------------------|----------------|
|Column   |20 ℃              |18 ° C, 22 ° C|   
|temperatu|                   |                |
------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 231 of 542 





Page 232
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 
























-------------------------------------------------------------------------
|re       |                              |                              |
|---------|------------------------------|------------------------------|
|Initial  |Mobile phase A- Mobile phase B|Mobile phase A- Mobile phase B|
|ratio of |(85:15)                       |(87:13), Mobile phase A-      |
|mobile   |                              |Mobile phase B (83:17)        |
|phase    |                              |                              |
|---------|------------------------------|------------------------------|
|Flow rate|1.0 ml/min                    |0.95ml/min, 1.05ml/min        |
|---------|------------------------------|------------------------------|
|Chromato |Column 1 (YMC Trairt C18      |Column 2 (YMC Trairt C18      |
|graphic  |4.6×150mm, 3μm, SN:         |4.6×150mm, 3μm, SN:         |    
|column   |117EB10004, Serial No. :      |129ZB00034, No. : ZJC18-35)   |
|         |CXC18-05)                     |                              |
-------------------------------------------------------------------------

 **Solution Preparation** 



Blank solution: solvent 



YA2304-12 Reference storage solution: Share "YA2304-12 Reference Storage 



solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-14 Reference storage solution: Share "YA2304-14 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304 Reference stock: Share "YA2304 Reference Stock" under "4.1 



Wavelength Selection". (Approx. 200μg/ml) 



YA2304-15 Reference storage solution: Share "YA2304-15 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-16 Reference storage solution: Share "YA2304-16 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-18 Reference storage solution: Share "YA2304-18 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-19 Reference storage solution: Share "YA2304-19 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 232 of 542 





Page 233
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-10 Reference storage Solution: Share "YA2304-10 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



YA2304-17 Reference storage solution: Share "YA2304-17 Reference Storage 



Solution" under "4.1 Wavelength Selection". (Approx. 200μg/ml) 



Reference solution: share "Reference solution ②" under "4.3.2 Forced 



degradation Test". (YA2304-10, YA2304-17 containing about 0.4μg/ml) 



System suitability solution: Share "System Suitability solution" under "4.3.2 



Forced degradation Test". 



Impurity reserve solution: Prepare by the same method as "impurity reserve 



solution" under "4.8 Solution stability". (Each about 15μg/ml) 



Add impurity test product solution: accurately weigh YA2304 sample about 



10mg, put it in 25ml measuring bottle, add appropriate amount of solvent to 



dissolve by ultrasound, accurately add 1ml of impurity reserve liquid, dilute 



it with solvent to scale, shake well, and then get. (Prepared 2 parts in parallel, 



~ 
named as adding miscellaneous test product solution ① ②) 



Control solution: accurately measure 1ml of mixed test product solution, 



place it in a 20ml measuring bottle, dilute it with solvent to the scale, and 



shake well; Precision measure 1ml of the above solution, place it in a 50ml 



measuring bottle, dilute it with solvent to the scale, shake well, and then get. 



~ 
(named as control solution ① ②) 



 **Injection Sequence** 



After the blank solution, under different durability conditions (normal 



condition, column temperature, flow rate, initial proportion of mobile phase, 



column), the system suitable solution was injected with 1 needle, the control 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 233 of 542 





Page 234
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



solution was injected with 2 needles, 2 control solution and 2 mixed test 



solution with 1 needle each, and the chromatogram was recorded. 



 **Results and Discussion** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 234 of 542 





Page 235
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.4.3.1-19 Durability test results - Test of system suitability 


































------------------------------------------------------------------------------------------------------------------------
|Chromato     |Parameter    |Separation degree  |Degree of     |Minimum      |Minimum      |Main peak                  |
|graphic      |values       |between YA2304 and |separation    |separation   |separation   |signal-to-noise            |
|Condition    |             |YA2304-14          |between       |degree       |degree       |ratio of control           |
|s            |             |                   |YA2304 and    |between      |between      |solution                   |
|             |             |                   |YA2304-15     |YA2304-17 and|YA2304-16 and|                           |
|             |             |                   |              |adjacent     |adjacent     |                           |
|             |             |                   |              |peaks        |peaks        |                           |
|             |             |                   |              |             |             |---------------------------|
|             |             |                   |              |             |             |Sample       |Sample       |
|             |             |                   |              |             |             |Injection    |Injectio n   |
|             |             |                   |              |             |             |1            |2            |
|-------------|-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|Column       |20           |5.8                |6.8           |2.2          |1.6          |99.1         |107.5        |
|temperatu    |             |                   |              |             |             |             |             |
|re (C)       |             |                   |              |             |             |             |             |
|             |-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|             |18           |5.7                |6.6           |1.2          |1.9          |104.4        |75.9         |
|             |-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|             |22           |5.8                |6.9           |3.5          |1.4          |86.0         |91.1         |
|-------------|-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|Flow rate    |1.0          |5.8                |6.8           |2.2          |1.6          |99.1         |107.5        |
|(ml/min)     |             |                   |              |             |             |             |             |
|             |-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|             |0.95         |5.7                |6.7           |1.7          |1.7          |109.8        |106.6        |
|             |-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|             |1.05         |5.9                |6.9           |2.8          |1.6          |96.8         |106.5        |
|-------------|-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|Mobile       |85:15        |5.8                |6.8           |2.2          |1.6          |99.1         |107.5        |
|phase A-     |             |                   |              |             |             |             |             |
|Mobile       |             |                   |              |             |             |             |             |
|phase B      |             |                   |              |             |             |             |             |
|             |-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|             |83:17 (ratio |6.0                |6.9           |2.5          |1.6          |78.8         |81.5         |
|             |1)           |                   |              |             |             |             |             |
|             |-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|             |87:13 (ratio |5.6                |6.7           |2.0          |1.7          |96.5         |90.9         |
|             |2)           |                   |              |             |             |             |             |
|-------------|-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|Column       |Column 1     |5.8                |6.8           |2.2          |1.6          |99.1         |107.5        |
|             |-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|             |Column 2     |5.6                |6.4           |1.7          |1.6          |72.5         |67.2         |
|-------------|-------------|-------------------|--------------|-------------|-------------|-------------|-------------|
|Conclusion: Under single factor change of column temperature, flow rate, initial ratio of fluidity, chromatographic   |
|column and                                                                                                            |
|normal chromatographic conditions, the peak order of contrast solution (230nm) is YA2304-17, YA2304-10; In the        |
|chromatogram of                                                                                                       |
|system suitability solution (251nm), the peak order was YA2304-14, YA2304, YA2304-15, YA2304-17, unknown impurities,  |
|YA2304-16, YA2304-10, YA2304-19. The minimum separation degree between YA2304 and YA2304-14 and YA2304-15 is NLT 5.6  |
|(NLT 1.5                                                                                                              |
|required), and the minimum separation degree between YA2304-17 and YA2304-16 and adjacent peaks is 1.2 (NLT 1.0       |
|required); In                                                                                                         |
|the contrast solution chromatogram (251nm), the signal-to-noise ratio of the main peak was NLT 67.2 (NLT 20), and the |
|system                                                                                                                |
|applicability met the verification requirements.                                                                      |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 235 of 542 





Page 236
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Durability test results 


































































-------------------------------------------------------------------------------------------------------------------------
|Chromato   |Paramet |Impurity content (%)                                                                             | 
|graphy     |er      |                                                                                                 | 
|Condition  |Values  |                                                                                                 | 
|s          |        |                                                                                                 | 
|           |        |-------------------------------------------------------------------------------------------------| 
|           |        |Impurity|Impurity|Impurity|Impurity|Impurity|Impurity|Impurity|Impurity|Unknow n|Unknow n|Total  | 
|           |        |YA2304- |YA2304- |YA2304- |YA2304- |YA2304- |YA2304- |YA2304- |YA2304- |impurity|impurity|impurity|
|           |        |12      |14      |15      |16      |18      |19      |17      |10      |(RRT≈0.|(RRT≈1.|       |   
|           |        |        |        |        |        |        |        |        |        |64)     |26)     |       | 
|-----------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|Column     |20      |0.152   |0.146   |0.153   |0.130   |0.137   |0.163   |0.143   |0.145   |< 0.05% |< 0.05% |1.169  | 
|temperat   |        |        |        |        |        |        |        |        |        |        |        |       | 
|ure (C)    |        |        |        |        |        |        |        |        |        |        |        |       | 
|           |        |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |        |0.152   |0.145   |0.155   |0.130   |0.137   |0.165   |0.147   |0.149   |< 0.05% |< 0.05% |1.180  | 
|           |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |18      |0.150   |0.142   |0.151   |0.128   |0.136   |0.161   |0.144   |0.144   |< 0.05% |< 0.05% |1.155  | 
|           |        |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |        |0.157   |0.150   |0.157   |0.135   |0.141   |0.169   |0.147   |0.147   |< 0.05% |< 0.05% |1.202  | 
|           |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |22      |0.149   |0.146   |0.151   |0.128   |0.134   |0.161   |0.143   |0.145   |< 0.05% |< 0.05% |1.155  | 
|           |        |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |        |0.156   |0.150   |0.159   |0.133   |0.138   |0.169   |0.146   |0.149   |< 0.05% |< 0.05% |1.200  | 
|-----------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|RSD/%               |2.2     |2.3     |2.1     |2.2     |1.7     |2.3     |1.4     |1.5     |Content |Content |1.8    | 
|                    |        |        |        |        |        |        |        |        |<       |<       |       | 
|                    |        |        |        |        |        |        |        |        |0.05%,  |0.05%,  |       | 
|                    |        |        |        |        |        |        |        |        |do      |no      |       | 
|                    |        |        |        |        |        |        |        |        |not do  |statistic|       |
|                    |        |        |        |        |        |        |        |        |statistic|s       |       |
|                    |        |        |        |        |        |        |        |        |s       |        |       | 
|--------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|Flow rate  |1.0     |0.152   |0.146   |0.153   |0.130   |0.137   |0.163   |0.143   |0.145   |< 0.05% |< 0.05% |1.169  | 
|(ml/min)   |        |        |        |        |        |        |        |        |        |        |        |       | 
|           |        |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |        |0.152   |0.145   |0.155   |0.130   |0.137   |0.165   |0.147   |0.149   |< 0.05% |< 0.05% |1.180  | 
|           |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |0.95    |0.150   |0.142   |0.150   |0.125   |0.131   |0.161   |0.142   |0.144   |< 0.05% |< 0.05% |1.145  | 
|           |        |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |        |0.156   |0.147   |0.156   |0.130   |0.136   |0.168   |0.145   |0.146   |< 0.05% |< 0.05% |1.184  | 
|           |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |1.05    |0.150   |0.147   |0.154   |0.127   |0.132   |0.163   |0.143   |0.144   |< 0.05% |< 0.05% |1.161  | 
|           |        |--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|-------| 
|           |        |0.156   |0.151   |0.158   |0.129   |0.138   |0.168   |0.148   |0.148   |< 0.05% |< 0.05% |1.196  | 
-------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 236 of 542 





Page 237
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

























































----------------------------------------------------------------------------------------------------------------
|RSD/%             |1.9    |2.1    |1.7    |1.7    |2.1    |1.7    |1.6    |1.6    |Content <|Content <|1.6    |
|                  |       |       |       |       |       |       |       |       |0.05%, do|0.05%, no|       |
|                  |       |       |       |       |       |       |       |       |not do   |statistic|       |
|                  |       |       |       |       |       |       |       |       |statistic|s        |       |
|                  |       |       |       |       |       |       |       |       |s        |         |       |
|------------------|-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|Mobile  |85:15    |0.152  |0.146  |0.153  |0.130  |0.137  |0.163  |0.143  |0.145  |< 0.05%  |< 0.05%  |1.169  |
|phase A-|         |       |       |       |       |       |       |       |       |         |         |       |
|Mobile  |         |       |       |       |       |       |       |       |       |         |         |       |
|phase B |         |       |       |       |       |       |       |       |       |         |         |       |
|        |         |-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|        |         |0.152  |0.145  |0.155  |0.130  |0.137  |0.165  |0.147  |0.149  |< 0.05%  |< 0.05%  |1.180  |
|        |---------|-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|        |83:17    |0.152  |0.149  |0.152  |0.126  |0.131  |0.163  |0.143  |0.142  |< 0.05%  |< 0.05%  |1.158  |
|        |(ratio 1)|       |       |       |       |       |       |       |       |         |         |       |
|        |         |-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|        |         |0.159  |0.150  |0.158  |0.129  |0.137  |0.170  |0.148  |0.147  |< 0.05%  |< 0.05%  |1.198  |
|        |---------|-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|        |87:13    |0.148  |0.143  |0.149  |0.123  |0.130  |0.162  |0.143  |0.142  |< 0.05%  |< 0.05%  |1.139  |
|        |(ratio 2)|       |       |       |       |       |       |       |       |         |         |       |
|        |         |-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|        |         |0.154  |0.148  |0.156  |0.126  |0.134  |0.169  |0.146  |0.147  |< 0.05%  |< 0.05%  |1.179  |
|--------|---------|-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|RSD/%             |2.4    |1.8    |2.2    |2.6    |2.6    |2.0    |1.6    |1.9    |Content <|Content <|1.8    |
|                  |       |       |       |       |       |       |       |       |0.05%, do|0.05%, no|       |
|                  |       |       |       |       |       |       |       |       |not do   |statistic|       |
|                  |       |       |       |       |       |       |       |       |statistic|s        |       |
|                  |       |       |       |       |       |       |       |       |s        |         |       |
|------------------|-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|Column  |Column 1 |0.152  |0.146  |0.153  |0.130  |0.137  |0.163  |0.143  |0.145  |< 0.05%  |< 0.05%  |1.169  |
|        |         |-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|        |         |0.152  |0.145  |0.155  |0.130  |0.137  |0.165  |0.147  |0.149  |< 0.05%  |< 0.05%  |1.180  |
|        |---------|-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|        |Column 2 |0.153  |0.144  |0.150  |0.119  |0.125  |0.162  |0.141  |0.142  |< 0.05%  |< 0.05%  |1.136  |
|        |         |-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|        |         |0.158  |0.149  |0.156  |0.120  |0.127  |0.169  |0.144  |0.145  |< 0.05%  |< 0.05%  |1.169  |
|--------|---------|-------|-------|-------|-------|-------|-------|-------|-------|---------|---------|-------|
|RSD/%             |1.8    |1.7    |1.7    |6%     |5%     |1.9    |1.9    |2.1    |Content <|Content <|1.7    |
|                  |       |       |       |       |       |       |       |       |0.05%, do|0.05%, no|       |
|                  |       |       |       |       |       |       |       |       |not do   |statistic|       |
----------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 237 of 542 





Page 238
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










-------------------------------------------------------------------------------------------------------------------------
|                   |        |        |        |        |        |        |        |        |statistic|s       |        |
|                   |        |        |        |        |        |        |        |        |s       |        |        | 
|-------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------| 
|Conclusion: RSD of impurity YA2304-12 is less than 2.4% (less than 10% is required) under column temperature, flow    | 
|rate,                                                                                                                 | 
|initial ratio of mobile phase and normal chromatography conditions. RSDS of YA2304-14 were no more than 2.3% (no more | 
|than 10%                                                                                                              | 
|required). RSD of YA2304-15 content shall NMT 2.2% (NMT 10%); RSD of YA2304-16 content shall NMT 6% (NMT 10%); RSD of | 
|YA2304-18 content shall NMT 5% (NMT 10%); RSD of YA2304-19 content shall NMT 2.3% (NMT 10%); RSD of YA2304-17 content | 
|should                                                                                                                | 
|NMT 1.9% (NMT 10%); RSD of YA2304-10 content should NMT 2.1% (NMT 10%); The contents of unknown impurity RRT≈0.64 and|  
|unknown                                                                                                               | 
|impurity RRT≈1.26 are less than 0.05, and RSD is not used for statistics. All of them met the verification           |  
|conditions.                                                                                                           | 
-------------------------------------------------------------------------------------------------------------------------

**III. Summary of Method Validation** 



Summaries of Method Validation of Related Substances in Finerenone 












------------------------------------------------------------------------------------------------------------------------
|Item          |Acceptable criteria               |Verification of results                                             |
|--------------|----------------------------------|--------------------------------------------------------------------|
|Wavele        |Impurities YA2304-10 and YA2304-17|Impurities YA2304-10 and YA2304-17 have greater absorption at 230nm |
|ngth          |have large absorption at 230nm    |wavelength;                                                         |
|selectio n    |wavelength; The principal         |The principal component and impurities YA2304-12, YA2304-14,        |
|              |component                         |YA2304-15,                                                          |
|              |and impurities YA2304-12,         |YA2304-16, YA2304-18 and YA2304-19 all have large absorption at     |
|              |YA2304-14,                        |251nm. In the                                                       |
|              |YA2304-15, YA2304-16, YA2304-18   |mixed control product solution ①, The retention times of YA2304-10,| 
|              |and                               |ya2304-17,                                                          |
|              |YA2304-19 all have large          |ya2304-12, ya2304-14, YA2304, ya2304-15, YA2304-16, ya2304-18 and   |
|              |absorption                        |ya2304-19                                                           |
|              |at 251nm wavelength.              |were 15.278min, 11.524min and 3.791m, respectively in, 8.175min,    |
|              |                                  |9.329min,                                                           |
|              |                                  |10.295min, 11.942min, 13.183min, 16.435min, mixed control solution  |
|              |                                  |①spectral                                                          | 
|              |                                  |diagram is as follows:                                              |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 238 of 542 





Page 239
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 












------------------------------------------------------------------------------------------------------------------------
|             |                                  |                                                                     |
|-------------|----------------------------------|---------------------------------------------------------------------|
|System       |The blank solution should have no |There was no interference in the blank solution, and in the          |
|suitabil     |interference, and the chromatogram|chromatogram of the                                                  |
|ity          |of the reference solution (230nm),|control solution (230nm), the peak exit sequence was YA2304-17 and   |
|             |the peak order is YA2304-17,      |YA2304-10;                                                           |
|             |YA2304-10; In the chromatogram of |In the chromatogram of system suitability solution (251nm), the peak |
|             |system suitability solution       |order is                                                             |
|             |(251nm),                          |YA2304-14, YA2304, YA2304-15, YA2304-17, YA2304-16, YA2304-10,       |
|             |the peak order is YA2304-14,      |YA2304-19. The                                                       |
|             |YA2304,                           |minimum separation degree between YA2304 and YA2304-14 and YA2304-15 |
|             |YA2304-15, YA2304-17, YA2304-16,  |is 4.9                                                               |
|             |YA2304-10, YA2304-19. The         |(NLT 1.5), and the minimum separation degree between YA2304-17 and   |
|             |separation                        |YA2304-16                                                            |
|             |degree between YA2304 and         |and adjacent peaks is 1.2 (NLT 1.0); In the chromatogram obtained by |
|             |YA2304-14                         |contrast                                                             |
|             |and YA2304-15 should be NLT 1.5,  |solution (251nm) for 6 consecutive days, the RSD of main peak        |
|             |and                               |retention time                                                       |
|             |the separation degree between     |was 0.05% (not more than 1.0%), the RSD of main peak area was 1.5%   |
|             |YA2304-17 and YA2304-16 and       |(not more                                                            |
|             |adjacent                          |than 5%), and the signal-to-noise ratio (S/N) was NLT 20. All the    |
|             |peaks should be NLT 1.0; Compared |above meet                                                           |
|             |with the chromatogram of solution |the verification requirements, indicating that the method has good   |
|             |(251nm) for 6 consecutive days,   |applicability in system.                                             |
|             |the                               |                                                                     |
|             |RSD of the main                   |                                                                     |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 239 of 542 





Page 240
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




































------------------------------------------------------------------------------------------------------------------------
|                         |peak retention time NMT 1.0%, |                                                             |
|                         |the                           |                                                             |
|                         |RSD of the peak area NMT 5%,  |                                                             |
|                         |and the                       |                                                             |
|                         |signal-to-noise ratio (S/N)   |                                                             |
|                         |should                        |                                                             |
|                         |NLT 20.                       |                                                             |
|-------------------------|------------------------------|-------------------------------------------------------------|
|Sp eci     |Pe ak id     |Blank solution should be free |The blank solution has no interference; In the chromatogram  |
|fici ty    |en tifi ca   |of                            |of system                                                    |
|           |tio n        |interference; In the          |suitability solution (251nm), the peak order is YA2304-14,   |
|           |             |chromatogram of               |YA2304, YA2304-15,                                           |
|           |             |system suitability solution   |YA2304-17, YA2304-16, YA2304-10, YA2304-19, The minimum      |
|           |             |(251nm),                      |separation degree                                            |
|           |             |the peak order is YA2304-14,  |between YA2304 and YA2304-14 and YA2304-15 is required to be |
|           |             |YA2304,                       |4.9 (NLT 1.5), and                                           |
|           |             |YA2304-15, YA2304-17,         |the minimum separation degree between YA2304-17 and YA2304-16|
|           |             |YA2304-16,                    |and adjacent                                                 |
|           |             |YA2304-10, YA2304-19, The     |peaks is 1.2 (NLT 1.0); In the chromatogram of test product  |
|           |             |separation                    |solution (251nm)                                             |
|           |             |degree between YA2304 and     |and specific mixed solution (251nm), the minimum separation  |
|           |             |YA2304-14                     |degree between                                               |
|           |             |and YA2304-15 should be NLT   |YA2304-17 and YA2304-16 and adjacent peaks is 1.2 (NLT 1.0), |
|           |             |1.5, and                      |and the minimum                                              |
|           |             |the separation degree between |separation degree between other adjacent peaks is 3.1 (NLT   |
|           |             |YA2304-17 and YA2304-16 and   |1.5). In the                                                 |
|           |             |adjacent                      |chromatogram of specific mixed solution (230nm), the minimum |
|           |             |peaks should be NLT 1.0; In   |separation degree                                            |
|           |             |the                           |between YA2304-17 and YA2304-16 and adjacent peaks was 1.2   |
|           |             |chromatogram of test product  |(NLT 1.0), and the                                           |
|           |             |solution (251nm) and specific |minimum separation degree between other adjacent peaks was   |
|           |             |mixed                         |5.0 (NLT 1.5). The                                           |
|           |             |solution (251nm), the         |retention time of each known impurity peak in the reference  |
|           |             |separation                    |solution, the                                                |
|           |             |degree between YA2304-17 and  |system suitability solution, the test product solution and   |
|           |             |YA2304-16 and adjacent peaks  |the specific mixed                                           |
|           |             |should                        |solution was consistent with the corresponding main peak in  |
|           |             |NLT 1.0, and the separation   |the impurity                                                 |
|           |             |degree                        |localization solution, and the relative retention time of    |
|           |             |between other adjacent peaks  |each known impurity                                          |
|           |             |should                        |peak in the specific mixed solution was basically consistent |
|           |             |NLT 1.5; The retention time of|with the quality                                             |
|           |             |each                          |standard. The concentration of YA2304-10, YA2304-17,         |
|           |             |known impurity peak in the    |YA2304-12, YA2304-14,                                        |
|           |             |reference                     |YA2304-15, YA2304-16, YA2304-18 and YA2304-19 in the specific|
|           |             |solution, system suitability  |mixed solution                                               |
|           |             |solution, test product        |was 0.15% of the concentration of principal components in the|
|           |             |solution and                  |test solution.                                               |
|           |             |specific mixed solution should|Nam e of the Testi ng Wavel Component name Compone nt        |
|           |             |be                            |concentr Rt (min) RRT                                        |
|           |             |                              |Minimu m separati The percentage equivalent                  |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 240 of 542 





Page 241
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 
























-------------------------------------------------------------------------------------------------------------------------------------------------
|       |       |consistent with the corresponding  |       |solut ion|ength  |         |ation   |       |       |on from  |to the      |       |
|       |       |main peak in the impurity          |       |         |       |         |(μg/ml)|       |       |adjacen t|concentratio|       | 
|       |       |positioning solution, and the      |       |         |       |         |        |       |       |peaks    |n of the    |       |
|       |       |relative retention time of each    |       |         |       |         |        |       |       |         |principal   |       |
|       |       |known impurity peak in the specific|       |         |       |         |        |       |       |         |component in|       |
|       |       |mixed solution should be basically |       |         |       |         |        |       |       |         |the test    |       |
|       |       |consistent with the quality        |       |         |       |         |        |       |       |         |solution    |       |
|       |       |standard.                          |       |         |       |         |        |       |       |         |            |       |
|       |       |                                   |       |---------|-------|---------|--------|-------|-------|---------|------------|       |
|       |       |                                   |       |Speci fic|251n m |YA2304-12|0.6005  |3.810  |0.41   |3.1      |0.15%               |
|       |       |                                   |       |mixe d   |       |         |        |       |       |         |                    |
|       |       |                                   |       |soluti on|       |         |        |       |       |         |                    |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-14|0.6032  |8.233  |0.89   |4.7      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304   |410.0400|9.289  |1.00   |5.0      |100%                |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-15|0.6055  |10.295 |1.11   |5.6      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-17|0.6040  |11.549 |1.24   |1.2      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-16|0.5797  |11.972 |1.29   |1.4      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-18|0.6014  |13.207 |1.42   |7.4      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-10|0.6092  |15.305 |1.65   |5.7      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-19|0.6008  |16.474 |1.77   |5.7      |0.15%               |
|       |       |                                   |       |         |-------|---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |230n m |YA2304-12|0.6005  |3.806  |0.41   |9.5      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-14|0.6032  |8.229  |0.89   |5.0      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304   |410.0400|9.285  |1.00   |5.0      |100%                |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-15|0.6055  |10.291 |1.11   |5.6      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-17|0.6040  |11.547 |1.24   |1.2      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-16|0.5797  |11.967 |1.29   |1.5      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-18|0.6014  |13.203 |1.42   |7.4      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-10|0.6092  |15.304 |1.65   |5.6      |0.15%               |
|       |       |                                   |       |         |       |---------|--------|-------|-------|---------|--------------------|
|       |       |                                   |       |         |       |YA2304-19|0.6008  |16.470 |1.77   |5.6      |0.15%               |
-------------------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 241 of 542 





Page 242
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The chromatogram of the specific mixed solution at 251nm is as follows: 



The chromatogram of the specific mixture at 230nm is as follows: 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 242 of 542 





Page 243
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 
























------------------------------------------------------------------------------------------------------------------------
|           |       |                        |                                                                         |
|-----------|       |------------------------|-------------------------------------------------------------------------|
|Limits of  |       |The S/N of non-nellidone|       |Impurity   |Detection limits     |Limit of        |              |
|quantifi   |       |and all                 |       |/principa  |                     |quantitation    |              |
|cation and |       |impurities in the 6 RMS |       |l compone  |                     |                |              |
|detectio n |       |should be               |       |nt         |                     |                |              |
|           |       |NLT 10, the RSD of the  |       |           |                     |                |              |
|           |       |peak                    |       |           |                     |                |              |
|           |       |retention time of each  |       |           |                     |                |              |
|           |       |component               |       |           |                     |                |              |
|           |       |should be no more than  |       |           |                     |                |              |
|           |       |2.0%, and the           |       |           |                     |                |              |
|           |       |RSD of the peak area    |       |           |                     |                |              |
|           |       |should be NLT           |       |           |                     |                |              |
|           |       |10%. The S/N of         |       |           |                     |                |              |
|           |       |fineridone and each     |       |           |                     |                |              |
|           |       |impurity in the 3-needle|       |           |                     |                |              |
|           |       |detection               |       |           |                     |                |              |
|           |       |limited solution atlas  |       |           |                     |                |              |
|           |       |was NLT 3.              |       |           |                     |                |              |
|           |       |                        |       |           |---------------------|----------------|              |
|           |       |                        |       |           |Concentration        |Concentration (equivalent to   |
|           |       |                        |       |           |(equivalent to the   |the                            |
|           |       |                        |       |           |percentage of        |test product solution          |
|           |       |                        |       |           |solution             |concentration percentage)      |
|           |       |                        |       |           |concentration of the |                               |
|           |       |                        |       |           |test                 |                               |
|           |       |                        |       |           |product)             |                               |
|           |       |                        |       |-----------|---------------------|-------------------------------|
|           |       |                        |       |YA2304-1 2 |0.0601μg/ml         |0.1201μg/ml (0.0300%)         |  
|           |       |                        |       |           |(0.0150%)            |                               |
|           |       |                        |       |-----------|---------------------|-------------------------------|
|           |       |                        |       |YA2304-1 4 |0.0603μg/ml         |0.1206μg/ml (0.0302%)         |  
|           |       |                        |       |           |(0.0151%)            |                               |
|           |       |                        |       |-----------|---------------------|-------------------------------|
|           |       |                        |       |YA2304     |0.0615μg/ml         |0.1229μg/ml (0.0307%)         |  
|           |       |                        |       |           |(0.0154%)            |                               |
|           |       |                        |       |-----------|---------------------|-------------------------------|
|           |       |                        |       |YA2304-1 5 |0.0605μg/ml         |0.1211μg/ml (0.0303%)         |  
|           |       |                        |       |           |(0.0151%)            |                               |
|           |       |                        |       |-----------|---------------------|-------------------------------|
|           |       |                        |       |YA2304-1   |0.0604μg/ml         |0.1208μg/ml (0.0302%)         |  
|           |       |                        |       |           |(0.0151%)            |                               |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 243 of 542 





Page 244
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 
















































------------------------------------------------------------------------------------------------------------------------
|          |                        |       |7         |               |                                      |        |
|          |                        |       |----------|---------------|--------------------------------------|        |
|          |                        |       |YA2304-1 6|0.0580μg/ml   |0.1159μg/ml (0.0290%)                         |  
|          |                        |       |          |(0.0145%)      |                                               |
|          |                        |       |----------|---------------|-----------------------------------------------|
|          |                        |       |YA2304-1 8|0.0601μg/ml   |0.1203μg/ml (0.0301%)                         |  
|          |                        |       |          |(0.0150%)      |                                               |
|          |                        |       |----------|---------------|-----------------------------------------------|
|          |                        |       |YA2304-1 0|0.0609μg/ml   |0.1218μg/ml (0.0305%)                         |  
|          |                        |       |          |(0.0152%)      |                                               |
|          |                        |       |----------|---------------|-----------------------------------------------|
|          |                        |       |YA2304-1 9|0.0601μg/ml   |0.1202μg/ml (0.0300%)                         |  
|          |                        |       |          |(0.0150%)      |                                               |
|----------|------------------------|-------|----------|---------------|-----------------------------------------------|
|Linearit  |Known impurities at     |       |Impuritie |Concentration (equivalent to  |Linear       |Corre    |        |
|y, range  |251nm wavelength        |       |s /       |percentage                    |equation     |ction    |        |
|and       |(YA2304-12, YA2304-14,  |       |Principal |of solution concentration of  |             |facto r  |        |
|correcti  |YA2304-15,              |       |compone nt|test                          |             |         |        |
|on factors|YA2304-16, YA2304-18 and|       |          |product)                      |             |         |        |
|          |YA2304-19)              |       |          |                              |             |         |        |
|          |and 230nm wavelength    |       |          |                              |             |         |        |
|          |(YA2304-10,             |       |          |                              |             |         |        |
|          |YA2304-17) : Within the |       |          |                              |             |         |        |
|          |range of                |       |          |                              |             |         |        |
|          |limited quantitation    |       |          |                              |             |         |        |
|          |concentration ~         |       |          |                              |             |         |        |
|          |equivalent to 0.3% of   |       |          |                              |             |         |        |
|          |the test                |       |          |                              |             |         |        |
|          |product solution        |       |          |                              |             |         |        |
|          |concentration, 6        |       |          |                              |             |         |        |
|          |concentration points    |       |          |                              |             |         |        |
|          |were selected           |       |          |                              |             |         |        |
|          |fairly evenly, and the  |       |          |                              |             |         |        |
|          |concentration           |       |          |                              |             |         |        |
|          |of each impurity was    |       |          |                              |             |         |        |
|          |taken as the            |       |          |                              |             |         |        |
|          |horizontal coordinate   |       |          |                              |             |         |        |
|          |and the peak            |       |          |                              |             |         |        |
|          |area was taken as the   |       |          |                              |             |         |        |
|          |vertical                |       |          |                              |             |         |        |
|          |coordinate as the linear|       |          |                              |             |         |        |
|          |regression              |       |          |                              |             |         |        |
|          |curve. The regression   |       |          |                              |             |         |        |
|          |coefficient R           |       |          |                              |             |         |        |
|          |of the obtained linear  |       |          |                              |             |         |        |
|          |graph should            |       |          |                              |             |         |        |
|          |NLT 0.990, and the RSD  |       |          |                              |             |         |        |
|          |of the                  |       |          |                              |             |         |        |
|          |response factor should  |       |          |                              |             |         |        |
|          |NMT 10%.                |       |          |                              |             |         |        |
|          |Y-axis                  |       |          |                              |             |         |        |
|          |                        |       |----------|------------------------------|-------------|---------|        |
|          |                        |       |YA2304-1 2|0.1201μg/ml to 1.2011μg/ml  |y = 13896x + |1.2      |        |  
|          |                        |       |          |(0.0300% to                   |33.018       |         |        |
|          |                        |       |          |0.3003%)                      |             |         |        |
|          |                        |       |----------|------------------------------|-------------|---------|        |
|          |                        |       |YA2304-1 4|0.1206μg/ml to 1.2064μg/ml  |y =          |1.0      |        |  
|          |                        |       |          |(0.0302% to                   |16536x-85.568|         |        |
|          |                        |       |          |0.3016%)                      |             |         |        |
|          |                        |       |----------|------------------------------|-------------|---------|        |
|          |                        |       |YA2304    |0.1229μg/ml to 1.2294μg/ml  |y = 16404x + |1.0      |        |  
|          |                        |       |          |(0.0307% to                   |57.399       |         |        |
|          |                        |       |          |0.3074%)                      |             |         |        |
|          |                        |       |----------|------------------------------|-------------|---------|        |
|          |                        |       |YA2304-1 5|0.1211μg/ml to 1.2109μg/ml  |y = 14367x + |1.1      |        |  
|          |                        |       |          |(0.0303% to                   |1.2724       |         |        |
|          |                        |       |          |0.3027%)                      |             |         |        |
|          |                        |       |----------|------------------------------|-------------|---------|        |
|          |                        |       |YA2304-1 6|0.1159μg/ml to 1.1595μg/ml  |y = 16470x + |1.0      |        |  
|          |                        |       |          |(0.0290% to                   |14.525       |         |        |
|          |                        |       |          |0.2899%)                      |             |         |        |
|          |                        |       |----------|------------------------------|-------------|---------|        |
|          |                        |       |YA2304-1 8|0.1203μg/ml to 1.2027μg/ml  |y =          |1.1      |        |  
|          |                        |       |          |(0.0301% to                   |14990x-3.7556|         |        |
|          |                        |       |          |0.3007%)                      |             |         |        |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 244 of 542 





Page 245
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



--------------------------------------------------------------------------
|YA2304-1 7|0.1208μg/ml to 1.2080μg/ml (0.0302% to|y = 26638x -|/      |  
|          |0.3020%)                                |75.991      |       |
|----------|----------------------------------------|------------|-------|
|YA2304-1 0|0.1218μg/ml to 1.2183μg/ml (0.0305% to|y = 19735x +|/      |  
|          |0.3046%)                                |192.83      |       |
|----------|----------------------------------------|------------|-------|
|YA2304-1 9|0.1202μg/ml~1.2016μg/ml               |y = 25507x -|0.6    |  
|          |(0.0300%~0.3004%)                       |18.855      |       |
--------------------------------------------------------------------------






























------------------------------------------------------------------------------------------------------------------------------
|          |intercepts are within 25%|YA2304-1 7 0.1208μg/ml to 1.2080μg/ml (0.0302% to 0.3020%) y = 26638x -|       |        
|          |of 100%                  |75.991                                                                   |       |      
|          |response value. Unknown  |/ YA2304-1 0 0.1218μg/ml to 1.2183μg/ml (0.0305% to 0.3046%) y = 19735x|       |        
|          |impurities               |+                                                                        |       |      
|          |at 251m wavelength       |192.83 / YA2304-1 9 0.1202μg/ml~1.2016μg/ml (0.0300%~0.3004%) y =      |       |        
|          |(substituted by          |25507x -                                                                 |       |      
|          |YA2304) : Within the     |18.855 0.6                                                               |       |      
|          |range of                 |                                                                         |       |      
|          |limited quantitation     |                                                                         |       |      
|          |concentration ~          |                                                                         |       |      
|          |equivalent to 0.3% of the|                                                                         |       |      
|          |test                     |                                                                         |       |      
|          |product solution         |                                                                         |       |      
|          |concentration, 6         |                                                                         |       |      
|          |concentration points were|                                                                         |       |      
|          |selected                 |                                                                         |       |      
|          |fairly uniformly, and the|                                                                         |       |      
|          |concentration of each    |                                                                         |       |      
|          |impurity was             |                                                                         |       |      
|          |taken as the horizontal  |                                                                         |       |      
|          |coordinate               |                                                                         |       |      
|          |and the peak area was    |                                                                         |       |      
|          |taken as the             |                                                                         |       |      
|          |vertical coordinate as   |                                                                         |       |      
|          |the linear               |                                                                         |       |      
|          |regression curve. The    |                                                                         |       |      
|          |regression               |                                                                         |       |      
|          |coefficient (R) of the   |                                                                         |       |      
|          |regression               |                                                                         |       |      
|          |curve was NLT 0.990, and |                                                                         |       |      
|          |the RSD of               |                                                                         |       |      
|          |the response factor was  |                                                                         |       |      
|          |not more                 |                                                                         |       |      
|          |than 10%. Y-axis         |                                                                         |       |      
|          |intercept accounted      |                                                                         |       |      
|          |for 100% of the response |                                                                         |       |      
|          |value of                 |                                                                         |       |      
|          |the percentage within    |                                                                         |       |      
|          |25%.                     |                                                                         |       |      
|----------|-------------------------|-------------------------------------------------------------------------|-------|      
|Accura cy |Unknown impurities: The  |             |Impurity/prin|Conditions of    |Average      |RSD          |       |      
|          |recovery                 |             |cipal        |labeling         |recovery rate|             |       |      
|          |rate of unknown impurity |             |component    |                 |             |             |       |      
|          |LOQ                      |             |             |                 |             |             |       |      
|          |concentration sampling   |             |             |                 |             |             |       |      
|          |solution                 |             |             |                 |             |             |       |      
|          |~150% limit concentration|             |             |                 |             |             |       |      
|          |solution                 |             |             |                 |             |             |       |      
|          |is 85%~110%, and the RSD |             |             |                 |             |             |       |      
|          |of recovery              |             |             |                 |             |             |       |      
|          |rate NMT 10%. Known      |             |             |                 |             |             |       |      
|          |impurities: The          |             |             |                 |             |             |       |      
|          |recovery rate            |             |             |                 |             |             |       |      
|          |                         |             |-------------|-----------------|-------------|-------------|       |      
|          |                         |             |YA2304-12    |Added            |98.6%, n=9   |1.3%, n=9    |       |      
|          |                         |             |             |0.1802μg/ml~0.9008μg/m|             |             |       | 
|          |                         |             |-------------|-----------------|-------------|-------------|       |      
|          |                         |             |YA2304-14    |Added            |98.5%, n=9   |2.1%, n=9    |       |      
|          |                         |             |             |0.1810μg/ml~0.9048μg/ml|             |             |       |
------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 245 of 542 





Page 246
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

































-------------------------------------------------------------
|Impurities|repeatability |Intermediate    |Precision       |
|          |              |precision       |                |
|----------|--------------|----------------|----------------|
|YA2304-12 |0.7%, n=6     |1.5%, n=6       |2.6%, n=12      |
|----------|--------------|----------------|----------------|
|YA2304-14 |0.5%, n=6     |1.4%, n=6       |2.0%, n=12      |
|----------|--------------|----------------|----------------|
|YA2304-15 |0.7%, n=6     |1.0%, n=6       |1.5%, n=12      |
|----------|--------------|----------------|----------------|
|YA2304-16 |0.9%, n=6     |1.6%, n=6       |2.6%, n=12      |
|----------|--------------|----------------|----------------|
|YA2304-18 |0.5%, n=6     |1.4%, n=6       |2.0%, n=12      |
|----------|--------------|----------------|----------------|
|YA2304-19 |1.7%, n=6     |2.1%, n=6       |1.9%, n=12      |
|----------|--------------|----------------|----------------|
|YA2304-10 |0.6%, n=6     |0.22%, n=6      |2.1%, n=12      |
|----------|--------------|----------------|----------------|
|YA2304-17 |0.4%, n=6     |1.1%, n=6       |0.9%, n=12      |
|----------|--------------|----------------|----------------|
|Other     |Contents all <|Content < 0.05%,|Content < 0.05%,|
|          |0.05%,        |not             |not             |
-------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------
|           |of known impurity 30%  |             |YA2304-15    |Added             |99.7%, n=9   |2.1%, n=9    |       |     
|           |limit                  |             |             |0.1816μg/ml~0.9082μg/ml|             |             |       |
|           |concentration solution |             |             |                  |             |             |       |     
|           |~150% limit            |             |             |                  |             |             |       |     
|           |concentration solution |             |             |                  |             |             |       |     
|           |is 85%~110%,           |             |             |                  |             |             |       |     
|           |and the RSD of each    |             |             |                  |             |             |       |     
|           |impurity               |             |             |                  |             |             |       |     
|           |recovery rate NMT 10%. |             |             |                  |             |             |       |     
|           |                       |             |-------------|------------------|-------------|-------------|       |     
|           |                       |             |YA2304-16    |Added             |94.2%, n=9   |1.6%, n=9    |       |     
|           |                       |             |             |0.1739μg/ml~0.8696μg/ml|             |             |       |
|           |                       |             |-------------|------------------|-------------|-------------|       |     
|           |                       |             |YA2304-18    |Added             |97.6%, n=9   |0.7%, n=9    |       |     
|           |                       |             |             |0.1804μg/ml~0.9020μg/ml|             |             |       |
|           |                       |             |-------------|------------------|-------------|-------------|       |     
|           |                       |             |YA2304-19    |Added             |96.8%, n=9   |4%. n=9      |       |     
|           |                       |             |             |0.1802μg/ml~0.9012μg/ml|             |             |       |
|           |                       |             |-------------|------------------|-------------|-------------|       |     
|           |                       |             |YA2304-10    |Added             |98.6%, n=9   |1.7%, n=9    |       |     
|           |                       |             |             |0.1827μg/ml~0.9137μg/ml|             |             |       |
|           |                       |             |-------------|------------------|-------------|-------------|       |     
|           |                       |             |YA2304-17    |Added             |98.1%, n=9   |0.5%, n=9    |       |     
|           |                       |             |             |0.1812μg/ml~0.9060μg/ml|             |             |       |
|           |                       |             |-------------|------------------|-------------|-------------|       |     
|           |                       |             |YA2304       |Add               |101.3%, n=9  |1.9%, n=9    |       |     
|           |                       |             |             |0.1229μg/ml~0.6147μg/ml|             |             |       |
|-----------|-----------------------|-------------|-------------|------------------|-------------|-------------|-------|     
|Precisio n |Repeatability and      |Impurities repeatability Intermediate precision Precision YA2304-12 0.7%, |       |     
|           |intermediate           |n=6                                                                       |       |     
|           |precision: The impurity|1.5%, n=6 2.6%, n=12 YA2304-14 0.5%, n=6 1.4%, n=6 2.0%, n=12 YA2304-15   |       |     
|           |peak less              |0.7%,                                                                     |       |     
|           |than 0.5 times the main|n=6 1.0%, n=6 1.5%, n=12 YA2304-16 0.9%, n=6 1.6%, n=6 2.6%, n=12         |       |     
|           |peak area of           |YA2304-18                                                                 |       |     
|           |the control solution   |0.5%, n=6 1.4%, n=6 2.0%, n=12 YA2304-19 1.7%, n=6 2.1%, n=6 1.9%, n=12   |       |     
|           |was ignored in         |YA2304-10 0.6%, n=6 0.22%, n=6 2.1%, n=12 YA2304-17 0.4%, n=6 1.1%, n=6   |       |     
|           |the repetitive test    |0.9%,                                                                     |       |     
|           |solution of 6          |n=12 Other Contents all < 0.05%, Content < 0.05%, not Content < 0.05%, not|       |     
|           |parts plus limit       |                                                                          |       |     
|           |concentration. The     |                                                                          |       |     
|           |RSD of other impurities|                                                                          |       |     
|           |should NMT             |                                                                          |       |     
|           |5%, and the RSD of     |                                                                          |       |     
|           |total impurity         |                                                                          |       |     
|           |should NMT 5%. In the  |                                                                          |       |     
|           |results of 12          |                                                                          |       |     
|           |tests of repeatability |                                                                          |       |     
|           |and                    |                                                                          |       |     
|           |intermediate precision,|                                                                          |       |     
|           |the RSDS of            |                                                                          |       |     
|           |other impurities that  |                                                                          |       |     
|           |are less than          |                                                                          |       |     
|           |0.5 times of the main  |                                                                          |       |     
|           |peak area              |                                                                          |       |     
-----------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 246 of 542 





Page 247
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















------------------------------------------------------------------------------------------------------------------------
|          |of the control solution     |            |individual  |not          |applicable  |applicable  |            |
|          |should not                  |            |impurities  |applicable   |            |            |            |
|          |be more than 10%, and the   |            |            |             |            |            |            |
|          |RSDS of                     |            |            |             |            |            |            |
|          |total impurities should not |            |            |             |            |            |            |
|          |be more                     |            |            |             |            |            |            |
|          |than 10%.                   |            |            |             |            |            |            |
|          |                            |            |------------|-------------|------------|------------|            |
|          |                            |            |Total       |0.5%, n=6    |1.0%, n=6   |1.6%, n=12               |
|          |                            |            |Clutter     |             |            |                         |
|----------|----------------------------|------------|------------|-------------|------------|-------------------------|
|Solutio n |Each solution was placed at |Control solution: under the condition of 5℃for 100h, the chromatogram of the | 
|stability |5℃                         |control solution (251nm), the main peak signal-to-noise ratio (S/N) is NLT    | 
|          |(refrigerated) for a period |54.0                                                                          |
|          |of time.                    |(NLT 20), and the peak area RSD is 1.7% (NMT 10%); The above are in line with |
|          |During the investigation,   |the verification requirements, indicating that the control solution is stable |
|          |the                         |within 100h under 5℃. Reference solution: placed at 5℃for 100h, the         |  
|          |signal-to-noise ratio (S/N) |chromatogram of the reference solution (230nm), the peak order is YA2304-17,  |
|          |of the                      |YA2304-10, the RSD of the peak-peak area of each impurity in the chromatogram |
|          |main peak (251nm) in the    |of the reference solution is not more than 0.9% (the requirement is not more  |
|          |chromatogram of the control |than 10%); The verification requirements were met, indicating that the control|
|          |solution                    |solution was stable within 100h under 5℃. System suitability solution: Placed| 
|          |should NLT 20, and the RSD  |at 5℃for 100h, the chromatogram of system suitability solution (251nm), the  | 
|          |of the                      |peak order is YA2304-14, YA2304, YA2304-15, YA2304-17, YA2304-16, YA2304-10,  |
|          |peak area NMT 10%; The peak |YA2304-19, The minimum separation degree between YA2304 and YA2304-14 and     |
|          |area RSD                    |YA2304-15 is NLT 5.8 (NLT 1.5 required), and the minimum separation degree    |
|          |of each impurity in the     |between YA2304-17 and YA2304-16 and adjacent peaks is NLT 1.6 (NLT 1.0        |
|          |chromatogram                |required); All of the above meet the verification requirements, indicating    |
|          |of the control solution     |that                                                                          |
|          |(230nm) NMT                 |the system suitable solution is stable within 100h under 5℃. Test solution:  | 
|          |10%; In the chromatogram of |After being placed at 5℃for 100h, impurity peaks smaller than 0.5 times the  | 
|          |system                      |main peak-peak area of control solution were ignored in the chromatogram of   |
|          |suitability solution        |test solution. Known impurities were detected except YA2304-12 and YA2304-19, |
|          |(251nm), the                |both of which were less than 0.05%, and other impurities were not detected.   |
|          |peak exit sequence is       |Other single unknown impurities were all less than 0.05%, the RSD of each     |
|          |YA2304-14,                  |impurity peak area was not counted (not more than 10%), and no new impurities |
|          |YA2304, YA2304-15,          |were added to interfere with the detection of related substances. The above   |
|          |YA2304-17,                  |are                                                                           |
|          |YA2304-16, YA2304-10,       |in line with the verification requirements,                                   |
|          |YA2304-19. The              |                                                                              |
|          |separation degree between   |                                                                              |
|          |YA2304 and                  |                                                                              |
|          |YA2304-14 and YA2304-15     |                                                                              |
|          |should be                   |                                                                              |
|          |NLT 1.5, and the separation |                                                                              |
|          |degree                      |                                                                              |
|          |between YA2304-17 and       |                                                                              |
|          |YA2304-16 and               |                                                                              |
|          |adjacent peaks should be NLT|                                                                              |
|          |1.0; If                     |                                                                              |
|          |the impurity peak less than |                                                                              |
|          |0.5                         |                                                                              |
|          |times the main peak area of |                                                                              |
|          |the                         |                                                                              |
|          |control solution is ignored |                                                                              |
|          |in the                      |                                                                              |
|          |chromatogram of the test    |                                                                              |
|          |product                     |                                                                              |
|          |solution and the limited    |                                                                              |
|          |concentration of            |                                                                              |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 247 of 542 





Page 248
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 












------------------------------------------------------------------------------------------------------------------------
|            |impurities, the RSD of the other  |indicating that the test solution is stable within 100h under 5℃. The| 
|            |impurity peak area NMT 10%, and   |sample                                                                |
|            |there shall not be any new        |solution with limited concentration of impurities: under the condition|
|            |impurities that interfere with the|of 5℃for                                                             | 
|            |detection of related substances.  |100h, the impurity peak less than 0.5 times the main peak area of the |
|            |                                  |control                                                               |
|            |                                  |solution was ignored in the chromatogram of the sample solution with  |
|            |                                  |mixed                                                                 |
|            |                                  |impurities. At 230m wavelength, the RSD of the peak area of the known |
|            |                                  |impurities YA2304-17 and YA2304-10 was not more than 1.1% (the        |
|            |                                  |requirement NMT                                                       |
|            |                                  |10%). At 251nm wavelength: the RSD of known impurities YA2304-12,     |
|            |                                  |YA2304-14,                                                            |
|            |                                  |YA2304-15, YA2304-16, YA2304-18 and YA2304-19 are not greater than 4% |
|            |                                  |(required                                                             |
|            |                                  |not to exceed 10%); The RSD of other single unknown impurity is less  |
|            |                                  |than                                                                  |
|            |                                  |0.05%, the RSD of the single unknown impurity is not counted (not more|
|            |                                  |than                                                                  |
|            |                                  |10%), and no new impurity interferes with the detection of related    |
|            |                                  |substances;                                                           |
|            |                                  |The above are in line with the verification requirements, indicating  |
|            |                                  |that the                                                              |
|            |                                  |solution of added impurity is stable within 100h at 5℃. The above    | 
|            |                                  |solutions do                                                          |
|            |                                  |not need to be used in the new preparation.                           |
|------------|----------------------------------|----------------------------------------------------------------------|
|Durabil     |Under the condition of single     |Column temperature 20℃±2℃, mobile phase ratio (85:15) ±2, flow    |    
|ity         |factor                            |rate                                                                  |
|            |change column temperature, flow   |1.0ml/min±0.05ml/min, different batches of chromatographic columns   | 
|            |rate, initial gradient of mobile  |were                                                                  |
|            |phase, column lot number and      |investigated as follows: System applicability: Reference solution     |
|            |normal                            |chromatogram                                                          |
|            |chromatographic conditions, the   |(230nm), the peak sequence was YA2304-17, YA2304-10; In the           |
|            |chromatogram obtained by system   |chromatogram of                                                       |
|            |suitability solution under each   |system suitability solution (251nm), the peak exit sequence was       |
|            |condition (251nm) is required. The|YA2304-14,                                                            |
|            |peak order is YA2304-14, YA2304,  |YA2304, YA2304-15, YA2304-17, unknown impurities, YA2304-16,          |
|            |YA2304-15, YA2304-17, YA2304-16,  |YA2304-10,                                                            |
|            |YA2304-10, YA2304-19, and the     |YA2304-19, The minimum separation degree between YA2304 and YA2304-14 |
|            |separation degree between YA2304  |and                                                                   |
|            |and                               |YA2304-15 is NLT 5.6 (NLT 1.5 required), and the minimum separation   |
|            |YA2304-14 and YA2304-15 should NLT|degree                                                                |
|            |1.5. The separation degree between|between YA2304-17 and YA2304-16 and adjacent peaks is 1.2 (NLT 1.0    |
|            |                                  |required);                                                            |
|            |                                  |In the contrast solution chromatogram (251nm), the signal-to-noise    |
|            |                                  |ratio of the                                                          |
|            |                                  |main peak was NLT 67.2 (NLT 20), and the system applicability met the |
|            |                                  |verification requirements. Sample solution: the RSD of impurity       |
|            |                                  |YA2304-12 is no                                                       |
|            |                                  |more than 2.4% (the                                                   |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 248 of 542 





Page 249
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




YA2304-17 and YA2304-16 and adjacent 



peaks should NLT 1.0; In the 



chromatogram of the control product 



solution (230nm), the peak sequence 



was YA2304-17, YA2304-10; In the 



control solution chromatogram (251nm), 



the signal-to-noise ratio (S/N) of the 



main peak should NLT 20. 



Under different conditions of the 



same chromatographic parameters, the 



RSDS of each impurity content greater 



than 0.05% in the test product NMT 



10%, and the RSDS of total impurity 



content NMT 10%; Or the absolute 



deviation of the impurity content NMT 



20% of the limit value, the absolute 



deviation of the total impurity content 



NMT 40% of the limit value. 




requirement is no more than 10%); RSD of YA2304-14 shall NMT 2.3% (NMT 10%); RSD of 



YA2304-15 content shall NMT 2.2% (NMT 10%); RSD of YA2304-16 content shall NMT 6% 



(NMT 10%); RSD of YA2304-18 content shall NMT 5% (NMT 10%); RSD of YA2304-19 



content shall NMT 2.3% (NMT 10%); RSD of YA2304-17 content should NMT 1.9% (NMT 



10%); RSD of YA2304-10 content should NMT 2.1% (NMT 10%); The contents of unknown 



impurity RRT≈0.64 and unknown impurity RRT≈1.26 are less than 0.05, and RSD is not 



used for statistics. All of them met the verification conditions. 




Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 249 of 542 





Page 250
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4.3.2 Methodological verification of relevant substances II of** 


**finished products** 



**I. Analytical Procedures** 



Please refer to the analytical procedures of related substances in Finerenone 



in _section 3.2.S.4.2_ . 



**II. Validation Results and Discussion** 



**a. Wavelength selection** 



 **Acceptance Criteria** 



The detection wavelength is selected by ultraviolet scanning of the principal 



component at 200nm ~ 400nm wavelength, requiring all impurities 



(YA2304-52, imidazole and 4-dimethylaminopyridine) to have greater 



absorption at 210nm wavelength. 



 **Solution preparation** 



Solvent: acetonitrile: water (50:50) 



Blank solution: solvent. 



YA2304-52 reference product reserve liquid (about 100μg/ml) : accurately 



weigh YA2304-52 reference product about 5mg, place it in a 50ml bottle, add 



an appropriate amount of solvent to dissolve by ultrasound, dilute it with 



solvent to the scale, shake well, and obtain. 



Imidazole reference liquid (about 100μg/ml) : accurately weigh imidazole 



reference liquid (about 5mg), place it in a 50ml measuring bottle, add 



appropriate amount of solvent and ultrasonic to dissolve it, dilute it with 



solvent to the scale, shake well, and then obtain. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 250 of 542 





Page 251
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



4-dimethylaminopyridine (DMAP) reference product reserve liquid (about 



100μg/ml) : precision weigh 4-dimethylaminopyridine reference product 



about 5mg, put in a 50ml bottle, add the appropriate amount of solvent 



ultrasonic to dissolve, dilute with solvent to the scale, shake well, ready. 



Reference product solution: precisely measure YA2304-52 reference product 



reserve liquid, imidazole reference product reserve liquid and 



4-dimethylaminopyridine reference product reserve liquid 1ml, put in the 



same 20ml bottle, dilute with solvent to the scale, shake well, ready. (About 



5μg/ml for each) 



 **Injection procedure** 



After the chromatographic system balance, take the blank solution and the 



reference solution each injection 1 needle, record the chromatogram. 



 **Measurement results** 



test results of detection wavelength selection 


















-------------------------------------------------------------------
|Name of   |Test substance|Retention time|Whether there is a large|
|solution  |              |(min)         |absorption at 210nm     |
|----------|--------------|--------------|------------------------|
|Reference |YA2304-52     |6.392         |is                      |
|solution  |              |              |                        |
|          |--------------|--------------|------------------------|
|          |Imidazole     |7.362         |is                      |
|          |--------------|--------------|------------------------|
|          |DMAP          |16.667        |is                      |
|----------|--------------|--------------|------------------------|
|Reference |                                                      |
|solution  |                                                      |
|wavelength|                                                      |
|scan      |                                                      |
-------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 251 of 542 





Page 252
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Conclusion: All impurities (YA2304-52, imidazole and 4-dimethylaminopyridine) have 



great absorption at 210nm wavelength. 



**(4.2) System applicability** 



 **Acceptance Criteria** 



The blank solution should be free of interference; The control solution should 



be injected for 6 consecutive times, and the peak order should be YA2304-52, 



imidazole and 4-dimethylaminopyridine. The separation degree between 



imidazole peak and YA2304-52 peak should be NLT 1.5, the retention time 



RSD of each impurity peak should be no more than 1.0%, and the RSD of the 



peak area of each impurity peak should be no more than 5%. 



 **Solution preparation** 



Blank solution: solvent. 



YA2304-52 Reference storage solution (approx. 100μg/ml) : Share 



YA2304-52 reference storage solution under "4.1 wavelength selection". 



Imidazole reference product reserve (approx. 100μg/ml) : Imidazole reference 



product reserve under "4.1 wavelength selection". 



4-dimethylaminopyridine (DMAP) reference storage solution (about 



100μg/ml) : 4-dimethylaminopyridine (DMAP) storage solution under "4.1 



wavelength selection". 



Reference product solution: according to "4.1 wavelength selection" under 



the reference product solution prepared by the same method. (Each about 



5μg/ml) 



 **Injection procedure** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 252 of 542 





Page 253
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



After the chromatographic system was balanced, the blank solution was 



injected with 1 needle, the control solution was injected with 6 needles again, 



and the chromatogram was recorded. 



 **Measurement results** 



Results of system suitability test 



































































-------------------------------------------------------------------------------------
|Investigation       |Control solution was injected                        |RSD     |
|parameters          |                                                     |        |
|                    |-----------------------------------------------------|        |
|          |         |1       |2       |3       |4       |5       |6       |        |
|----------|---------|--------|--------|--------|--------|--------|--------|--------|
|YA230 4-52|RT (min) |6.348   |6.354   |6.361   |6.357   |6.347   |6.347   |0.10%   |
|          |---------|--------|--------|--------|--------|--------|--------|--------|
|          |Peak area|24168   |24307   |23941   |24129   |23890   |24107   |0.7%    |
|----------|---------|--------|--------|--------|--------|--------|--------|--------|
|Imidaz ole|RT (min) |7.389   |7.388   |7.390   |7.390   |7.386   |7.384   |0.04%   |
|          |---------|--------|--------|--------|--------|--------|--------|--------|
|          |Peak area|41795 3 |41800 4 |41776 4 |41971 1 |41871 1 |41875 6 |0.18%   |
|----------|---------|--------|--------|--------|--------|--------|--------|--------|
|DMAP      |RT (min) |16.764  |16.764  |16.771  |16.774  |16.771  |16.767  |0.025 % |
|          |---------|--------|--------|--------|--------|--------|--------|--------|
|          |Peak area|45883 2 |45868 8 |45820 8 |45761 9 |46089 2 |46086 8 |0.4%    |
|----------|         |--------|--------|--------|--------|--------|--------|--------|
|Degree of           |1.9     |1.9     |1.9     |1.9     |1.9     |1.9     |/       |
|separation          |        |        |        |        |        |        |        |
|between imidazole   |        |        |        |        |        |        |        |
|peak and            |        |        |        |        |        |        |        |
|YA2304-52 peak      |        |        |        |        |        |        |        |
|--------------------|        |        |        |        |        |        |        |
|Conclusion: The blank solution has no interference; The control solution           |
|was injected for 6 consecutive times, and the peak order was YA2304-52,            |
|imidazole and 4-dimethylaminopyridine. The separation degree between               |
|imidazole peak and YA2304-52 peak was 1.9 (NLT 1.5), and the retention time        |
|RSD of each impurity peak was no more than 0.10% (NMT 1.0%). The RSD of the        |
|peak area of each impurity peak was no more than 0.7% (NMT 5%); All the            |
|above meet the verification requirements, indicating that the method has           |
|good system applicability.                                                         |
-------------------------------------------------------------------------------------

**(4.3) Specificity** 



 **Acceptance Criteria** 



The blank solution should be free of interference; In the chromatogram 



obtained from the control solution, the peak order is YA2304-52, imidazole, 



4-dimethylaminopyridine, and the separation degree between the imidazole 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 253 of 542 





Page 254
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



peak and YA2304-52 peak should NLT 1.5. The retention time of each 



impurity peak in the control solution, the test solution and the specific mixed 



solution should be consistent with the retention time of the main peak in the 



impurity localization solution. The separation degree between the imidazole 



peak and YA2304-52 peak in the specific mixed solution should be NLT 1.5. 



All impurities studied under the related substances of the finished product 



(including YA2304-10, YA2304-12, YA2304-14, YA2304-15, YA2304-16, 



YA2304-17, YA2304-18 and YA2304-19) shall not interfere with YA2304-52, 



imidazole and imidazole in the tested product 4-dimethylaminopyridine test. 



 **Solution preparation** 



Blank solution: solvent. 



YA2304-52 Reference storage solution (approx. 100μg/ml) : Share 



YA2304-52 reference storage solution under "4.1 wavelength selection". 



Imidazole reference product reserve (approx. 100μg/ml) : Imidazole reference 



product reserve under "4.1 wavelength selection". 



4-dimethylaminopyridine (DMAP) reference reserve liquid (about 100μg/ml) : 



Share 4-dimethylaminopyridine (DMAP) reserve liquid under "4.1 wavelength 



selection". 



YA2304-10 reference product reserve liquid (about 200μg/ml) : accurately 



weigh YA2304-10 reference product about 5mg, put it in 25ml measuring 



bottle, add appropriate amount of solvent to dissolve by ultrasound, dilute it 



with solvent to the scale, shake well, and then obtain. 



YA2304-12 reference product reserve (about 200μg/ml) : precision weigh 



YA2304-12 reference product about 5mg, place in 25ml measuring bottle, 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 254 of 542 





Page 255
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



add appropriate amount of solvent and ultrasonic to dissolve, dilute with 



solvent to the scale, shake well, ready. 



YA2304-14 reference product reserve liquid (about 200μg/ml) : precisely 



weigh YA2304-14 reference product about 5mg, place it in 25ml measuring 



bottle, add acetonitrile to dissolve by ultrasound, dilute it with acetonitrile to 



the scale, shake well, and then obtain. 



YA2304-15 reference product reserve liquid (about 200μg/ml) : precisely 



weigh YA2304-15 reference product about 5mg, place it in 25ml measuring 



bottle, add appropriate amount of acetonitrile to dissolve, dilute it with 



acetonitrile to the scale, shake well, and then obtain. 



YA2304-16 reference product reserve liquid (about 200μg/ml) : Accurately 



weigh about 5mg of YA2304-16 reference product, place it in a 25ml bottle, 



add acetonitrile to dissolve by ultrasound, dilute it with acetonitrile to the 



scale, shake well, and obtain. 



YA2304-17 reference product reserve liquid (about 200μg/ml) : precisely 



weigh YA2304-17 reference product about 5mg, place it in 25ml measuring 



bottle, add appropriate amount of solvent to dissolve by ultrasound, dilute it 



with solvent to the scale, shake well, and then obtain. 



YA2304-18 reference product reserve liquid (about 200μg/ml) : precisely 



weigh YA2304-18 reference product about 5mg, place it in 25ml measuring 



bottle, add acetonitrile to dissolve by ultrasound, dilute it with acetonitrile to 



the scale, shake well, and then obtain. 



YA2304-19 reference product reserve liquid (about 200μg/ml) : precisely 



weigh YA2304-19 reference product about 5mg, place it in 25ml measuring 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 255 of 542 





Page 256
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



bottle, add appropriate amount of acetonitrile to dissolve, dilute it with 



acetonitrile to the scale, shake well, and then obtain. 



Reference solution: Share the reference solution under "4.2 System 



Suitability". (Approx. 5μg/ml each) 



YA2304-52 positioning solution: Accurately measure 1ml of YA2304-52 



reference product reserve, place it in a 20ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. (About 5μg/ml) 



Imidazole positioning solution: accurately measure 1ml of imidazole 



reference product reserve liquid, place it in 20ml measuring bottle, dilute it 



with solvent to the scale, shake well, and then obtain. (About 5μg/ml) 



4-dimethylaminopyridine (DMAP) positioning solution: accurately measure 



4-dimethylaminopyridine (DMAP) reference product reserve liquid 1ml, 



placed in 20ml measuring bottle, diluted with solvent to scale, shake well, 



ready. (About 5μg/ml) 



YA2304-10 positioning solution: Accurately measure 1ml of YA2304-10 



reference product reserve, place it in a 25ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. (About 8μg/ml) 



YA2304-12 positioning solution: accurately measure 1ml of YA2304-12 



reference product reserve, place it in a 25ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. (About 8μg/ml) 



YA2304-14 positioning solution: accurately measure 1ml of YA2304-14 



reference product reserve, place it in a 25ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. (About 8μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 256 of 542 





Page 257
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-15 positioning solution: accurately measure 1ml of YA2304-15 



reference product reserve liquid, place it in a 25ml measuring bottle, dilute it 



with solvent to the scale, shake well, and then obtain. (About 8μg/ml) 



YA2304-16 positioning solution: accurately measure 1ml of YA2304-16 



reference product reserve, place it in a 25ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. (About 8μg/ml) 



YA2304-17 Positioning solution: Accurately measure 1ml of YA2304-17 



reference product reserve, place it in a 25ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. (About 8μg/ml) 



YA2304-18 positioning solution: Accurately measure 1ml of YA2304-18 



reference product reserve, place it in a 25ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. (About 8μg/ml) 



YA2304-19 positioning solution: Accurately measure 1ml of YA2304-19 



reference product reserve, place it in a 25ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. (About 8μg/ml) 



Test product solution: Take YA2304 about 100mg, accurately weigh it, place 



it in a 20ml measuring bottle, add an appropriate amount of solvent and 



ultrasonic to dissolve it, dilute it with solvent to the scale, shake well, and get 



it. (About 5mg/ml) 



Specific mixed solution: Take YA2304 test product about 100mg, weigh it 



accurately, place it in a 20ml bottle, add an appropriate amount of solvent to 



dissolve by ultrasound, then add YA2304-52 reference product reserve, 



imidazole reference product reserve and 4-dimethylaminopyridine reference 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 257 of 542 





Page 258
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



product reserve 1ml each, dilute it with solvent to the scale, shake well, and 



obtain. (Finerenone about 5mg/ml, each impurity about 5μg/ml) 



 **Injection procedure** 



After the chromatographic system balance, take blank solution, reference 



solution, test solution, specific mixed solution and each impurity location 



solution into 1 needle, record the chromatogram. (The chromatogram was 



obtained by sharing the test solution under the item "4.8 solution stability" 



for 2h; The control product solution shared the atlas obtained from the test 



product solution under "4.8 solution stability" for 16h) 



 **Measurement results** 



























-------------------------------------------------------------------
|Name of solution|Substance|Concentr|RT (min)|Interference with   |
|                |name     |ation   |        |YA2304-52, imidazole|
|                |         |(μg/ml)|        |and DMAP detection  | 
|----------------|---------|--------|--------|--------------------|
|Blank solution  |/        |/       |/       |no                  |
|----------------|---------|--------|--------|--------------------|
|YA2304-10       |YA2304-10|8.9522  |19.424  |no                  |
|Positioning     |         |        |        |                    |
|solution        |         |        |        |                    |
|----------------|---------|--------|--------|--------------------|
|YA2304-12       |YA2304-12|8.4174  |19.649  |no                  |
|Positioning     |         |        |        |                    |
|solution        |         |        |        |                    |
|----------------|---------|--------|--------|--------------------|
|YA2304-14       |YA2304-14|8.1736  |21.933  |no                  |
|Positioning     |         |        |        |                    |
|solution        |         |        |        |                    |
|----------------|---------|--------|--------|--------------------|
|YA2304-15       |YA2304-15|7.9170  |24.256  |no                  |
|Positioning     |         |        |        |                    |
|solution        |         |        |        |                    |
|----------------|---------|--------|--------|--------------------|
|YA2304-16       |YA2304-16|7.5335  |23.470  |no                  |
|Positioning     |         |        |        |                    |
|solution        |         |        |        |                    |
|----------------|---------|--------|--------|--------------------|
|YA2304-17       |YA2304-17|8.6177  |11.377  |no                  |
|Positioning     |         |        |        |                    |
|solution        |         |        |        |                    |
|----------------|---------|--------|--------|--------------------|
|YA2304-18       |YA2304-18|8.1525  |25.279  |no                  |
|Positioning     |         |        |        |                    |
|solution        |         |        |        |                    |
|----------------|---------|--------|--------|--------------------|
|YA2304-19       |YA2304-19|7.8582  |20.263  |no                  |
|Positioning     |         |        |        |                    |
|solution        |         |        |        |                    |
|----------------|---------|--------|--------|--------------------|
|YA2304-52       |YA2304-52|5.2991  |6.354   |/                   |
|Positioning     |         |        |        |                    |
|solution        |         |        |        |                    |
-------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 258 of 542 





Page 259
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




















































-----------------------------------------------------------------------------------------
|Imidazole         |Imidazole      |5.1637         |7.380          |/                   |
|positioning       |               |               |               |                    |
|solution          |               |               |               |                    |
|------------------|---------------|---------------|---------------|--------------------|
|DMAP positioning  |DMAP           |5.1695         |16.747         |/                   |
|solution          |               |               |               |                    |
|------------------|---------------|---------------|---------------|--------------------|
|Solution name     |Substance      |Concentr       |RT (min)       |Degree of separation|
|                  |name           |ation          |               |from the previous   |
|                  |               |(μg/ml)       |               |peak                | 
|------------------|---------------|---------------|---------------|--------------------|
|Reference solution|YA2304-52      |5.2991         |6.332          |/                   |
|                  |---------------|---------------|---------------|--------------------|
|                  |Imidazole      |5.1637         |7.380          |1.9                 |
|                  |---------------|---------------|---------------|--------------------|
|                  |DMAP           |5.1695         |16.750         |14.9                |
|------------------|---------------|---------------|---------------|--------------------|
|Solution for the  |YA2304-52      |/              |/              |/                   |
|test product      |               |               |               |                    |
|                  |---------------|---------------|---------------|--------------------|
|                  |Imidazole      |/              |/              |/                   |
|                  |---------------|---------------|---------------|--------------------|
|                  |DMAP           |/              |/              |/                   |
|                  |---------------|---------------|---------------|--------------------|
|                  |YA2304         |5014.600 0     |Peak           |/                   |
|                  |               |               |overload,      |                    |
|                  |               |               |uncredite      |                    |
|                  |               |               |d              |                    |
|------------------|---------------|---------------|---------------|--------------------|
|Specific mixed    |YA2304-52      |5.2991         |6.354          |/                   |
|solution          |               |               |               |                    |
|                  |---------------|---------------|---------------|--------------------|
|                  |Imidazole      |5.1637         |7.386          |1.9                 |
|                  |---------------|---------------|---------------|--------------------|
|                  |DMAP           |5.1695         |16.756         |15.0                |
|                  |---------------|---------------|---------------|--------------------|
|                  |YA2304         |5017.350 0     |Peak           |/                   |
|                  |               |               |overload,      |                    |
|                  |               |               |uncredite      |                    |
|                  |               |               |d              |                    |
|------------------|               |               |               |                    |
|Conclusion: the blank solution has no interference; In the chromatogram                |
|obtained from the control solution, the sequence of peaks was YA2304-52,               |
|imidazole, 4-dimethylaminopyridine, and the separation degree between                  |
|imidazole peaks and YA2304-52 peaks was 1.9 (required to be NLT 1.5). The              |
|retention time of each impurity peak in the control solution, the test                 |
|solution and the specific mixed solution was consistent with that of the               |
|main peak in the impurity positioning solution. The separation degree                  |
|between the imidazole peak and YA2304-52 peak in the specific mixed                    |
|solution was 1.9 (NLT 1.5); The impurities studied under the related                   |
|substances of finished products (including YA2304-10, YA2304-12, YA2304-14,            |
|YA2304-15, YA2304-16, YA2304-17, YA2304-18 and YA2304-19) did not interfere            |
|with YA2304-52, imidazole and 4- in the test product Detection of                      |
|dimethylaminopyridine.                                                                 |
-----------------------------------------------------------------------------------------

**(4.4) Limits of quantification and detection** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 259 of 542 





Page 260
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



 **Acceptance Criteria** 



The S/N of each impurity in the 6 limited quantification solution maps 



should NLT 10, the RSD of the peak retention time of each impurity should 



not be more than 2.0%, and the RSD of the peak area should not be more 



than 10%. The S/N of each impurity in the 3-needle detection limited 



solution atlas should NLT 3. 



 **Solution preparation** 



Blank solution: solvent. 



YA2304-52 Reference storage solution (approx. 100μg/ml) : Share 



YA2304-52 reference storage solution under "4.1 wavelength selection". 



Imidazole reference product reserve (approx. 100μg/ml) : Imidazole reference 



product reserve under "4.1 wavelength selection". 



4-dimethylaminopyridine (DMAP) reference reserve liquid (about 100μg/ml) : 



Share 4-dimethylaminopyridine (DMAP) reserve liquid under "4.1 wavelength 



selection". 



Quantitative limited reserve liquid: accurately measure imidazole reference 



product reserve liquid 400μl and 4-dimethylaminopyridine (DMAP) reference 



product reserve liquid 300μl, put in the same 20ml bottle, dilute with solvent 



to the scale, shake well, it is obtained. 



Limited quantitative solution: precisely measure YA2304-52 reference 



product reserve liquid 250μl and limit quantitative reserve liquid 1ml, place 



in the same 20ml measuring bottle, dilute with solvent to scale, shake well, 



ready. Prepare 6 parts in parallel. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 260 of 542 





Page 261
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Detection limit solution: accurately remove the first limit of quantification 



solution 3ml, place it in a 10ml measuring bottle, dilute it with solvent to the 



scale, shake well, and then get. 



 **Injection procedure** 



After the chromatographic system was balanced, the blank solution and the 



parallel preparation of 6 parts of the limited quantitative solution were 



injected with 1 needle each, the detection of the limited solution was repeated 



with 3 needles, and the chromatogram was recorded. 



 **Measurement results** 



Results of limit of quantitation test 






























------------------------------------------------------------------------------
|Impurit   |Solution name|Concent  |Equivalent   |Retention|Peak area|S/N    |
|ies Name  |             |ration   |to test      |time /min|         |       |
|          |             |/(μg/ml)|product      |         |         |       | 
|          |             |         |concentration|         |         |       |
|          |             |         |percentage   |         |         |       |
|----------|-------------|---------|-------------|---------|---------|-------|
|YA2304 -52|Limited      |1.3248   |0.03%        |6.337    |5472     |24.0   |
|          |quantitative |         |             |         |         |       |
|          |solution ①  |         |             |         |         |       | 
|          |-------------|         |             |---------|---------|-------|
|          |Limited                |             |6.348    |5344     |23.5   |
|          |quantification         |             |         |         |       |
|          |solution ②            |             |         |         |       | 
|          |-----------------------|             |---------|---------|-------|
|          |Limited                |             |6.352    |5352     |34.9   |
|          |quantification         |             |         |         |       |
|          |solution ③            |             |         |         |       | 
|          |-----------------------|             |---------|---------|-------|
|          |Limited                |             |6.340    |5391     |26.9   |
|          |quantification         |             |         |         |       |
|          |solution ④            |             |         |         |       | 
|          |-----------------------|             |---------|---------|-------|
|          |Limited                |             |6.355    |5307     |27.5   |
|          |quantification         |             |         |         |       |
|          |solution ⑤            |             |         |         |       | 
|          |-----------------------|             |---------|---------|-------|
|          |Limited                |             |6.337    |5087     |27.8   |
|          |quantification         |             |         |         |       |
|          |solution ⑥            |             |         |         |       | 
------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 261 of 542 





Page 262
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




























---------------------------------------------------------------------------------------
|          |RSD                                   |0.13%      |2.5%       |/          |
|          |--------------------------------------|-----------|-----------|-----------|
|          |Conclusion: The limited quantification concentration of YA2304-52         |
|          |was 1.3248μg/ml, which was equivalent to 0.03% of the solution           | 
|          |concentration of the tested product. The signal to noise ratio            |
|          |(S/N) of YA2304-52 peaks in the 6 limited quantification solutions        |
|          |were all in the range of 23.5~34.9 (the requirement should be             |
|          |greater than 10). The RSD of retention time was 0.13% (no more            |
|          |than 2.0% required), and the RSD of peak area was 2.5% (no more           |
|          |than 10% required); All of the above meet the verification                |
|          |requirements.                                                             |
|----------|--------------------------------------------------------------------------|
|Imidazo le|Limited       |0.1033     |0.002%     |7.384      |8362       |39.4       |
|          |quantitative  |           |           |           |           |           |
|          |solution ①   |           |           |           |           |           | 
|          |--------------|           |           |-----------|-----------|-----------|
|          |Limited                   |           |7.383      |8180       |39.3       |
|          |quantification            |           |           |           |           |
|          |solution ②               |           |           |           |           | 
|          |--------------------------|           |-----------|-----------|-----------|
|          |Limited                   |           |7.385      |8001       |56.5       |
|          |quantification            |           |           |           |           |
|          |solution ③               |           |           |           |           | 
|          |--------------------------|           |-----------|-----------|-----------|
|          |Limited                   |           |7.378      |8414       |46.0       |
|          |quantification            |           |           |           |           |
|          |solution ④               |           |           |           |           | 
|          |--------------------------|           |-----------|-----------|-----------|
|          |Limited                   |           |7.390      |8005       |44.2       |
|          |quantification            |           |           |           |           |
|          |solution ⑤               |           |           |           |           | 
|          |--------------------------|           |-----------|-----------|-----------|
|          |Limited                   |           |7.389      |7675       |45.4       |
|          |quantification            |           |           |           |           |
|          |solution ⑥               |           |           |           |           | 
|          |--------------------------|-----------|-----------|-----------|-----------|
|          |RSD                                   |0.06%      |4%         |/          |
|          |--------------------------------------|-----------|-----------|-----------|
|          |Verdict: The limit of quantization of imidazole was 0.1033μg/ml,         | 
|          |which was equivalent to 0.002% of the concentration of the tested         |
|          |solution. The signal to noise ratio (S/N) of the imidazole peak in        |
|          |the 6 limited quantization solutions were all in the range of             |
|          |39.3~56.5 (the requirement should be greater than 10), and the RSD        |
|          |of the retention time was 0.06% (the requirement should NMT 2.0%).        |
|          |The RSD of the peak area was 4% (NMT 10%); All of the above meet          |
|          |the verification requirements.                                            |
|----------|--------------------------------------------------------------------------|
|DMAP      |Limited       |0.0775     |0.002%     |16.749     |6368       |22.3       |
|          |quantification|           |           |           |           |           |
|          |solution ①   |           |           |           |           |           | 
|          |--------------|-----------|-----------|-----------|-----------|-----------|
|          |Limited                   |           |16.822     |7206       |22.4       |
---------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 262 of 542 





Page 263
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










------------------------------------------------------------------------------------
|       |quantification|           |           |           |           |           |
|       |solution ②   |           |           |           |           |           | 
|       |--------------|           |           |-----------|-----------|-----------|
|       |Limited                   |           |16.765     |6718       |32.8       |
|       |quantification            |           |           |           |           |
|       |solution ③               |           |           |           |           | 
|       |--------------------------|           |-----------|-----------|-----------|
|       |Limited                   |           |16.789     |7661       |27.4       |
|       |quantification            |           |           |           |           |
|       |solution ④               |           |           |           |           | 
|       |--------------------------|           |-----------|-----------|-----------|
|       |Limited                   |           |16.784     |7547       |28.0       |
|       |quantification            |           |           |           |           |
|       |solution ⑤               |           |           |           |           | 
|       |--------------------------|           |-----------|-----------|-----------|
|       |Limited                   |           |16.767     |6117       |23.6       |
|       |quantitation              |           |           |           |           |
|       |solution ⑥               |           |           |           |           | 
|       |--------------------------|           |-----------|-----------|-----------|
|       |RSD                                   |0.16%      |10%        |/          |
|       |--------------------------------------|-----------|-----------|-----------|
|       |Verdict: The limit of quantitation concentration of                       |
|       |4-dimethylaminopyridine (DMAP) was 0.0775μg/ml, which was                | 
|       |equivalent to 0.002% of the solution concentration. The signal to         |
|       |noise ratio (S/N) of DMAP peaks in 6 limited quantitation                 |
|       |solutions were all in the range of 22.3~32.8 (the requirement             |
|       |should be greater than 10). The RSD of retention time was 0.16%           |
|       |(NMT 2.0%), and the RSD of peak area was 10% (NMT 10%); All of the        |
|       |above meet the verification requirements.                                 |
------------------------------------------------------------------------------------

Test results of detection limits 


































--------------------------------------------------------------------------------------
|Impurit   |Detection  |Concent    |Equivalent   |Retention  |Peak area  |S/N        |
|ies Name  |limit      |ration     |to test      |time /min  |           |           |
|          |solution   |/(μg/ml)  |product      |           |           |           | 
|          |injection  |           |concentration|           |           |           |
|          |           |           |percentage /%|           |           |           |
|----------|-----------|-----------|-------------|-----------|-----------|-----------|
|YA2304 -52|1          |0.3974     |0.008%       |6.340      |1263       |6.5        |
|          |-----------|           |             |-----------|-----------|-----------|
|          |2                      |             |6.362      |946        |5.2        |
|          |-----------------------|             |-----------|-----------|-----------|
|          |3                      |             |6.346      |1129       |6.3        |
|          |-----------------------|-------------|-----------|-----------|-----------|
|          |Conclusion: The detection limit concentration of YA2304-52 is            |
|          |0.3974μg/ml, which is equivalent to 0.008% of the concentration of      | 
|          |the test solution. The signal-to-noise ratio (S/N) of YA2304-52          |
|          |peak after repeated injection of the detection limit solution is         |
|          |in the range of 5.2~6.5 (the requirement should be greater than          |
|          |3), which meets the verification requirements.                           |
|----------|-------------------------------------------------------------------------|
|3.        |1          |0.0310     |0.0006%      |7.396      |2597       |11.9       |
--------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 263 of 542 





Page 264
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 





















------------------------------------------------------------------------------------
|Imidazo le|2          |           |           |7.389      |2537       |11.8       |
|          |-----------|           |           |-----------|-----------|-----------|
|          |3                      |           |7.387      |2584       |13.6       |
|          |-----------------------|-----------|-----------|-----------|-----------|
|          |Conclusion: The detection limit concentration of imidazole is          |
|          |0.0310μg/ml, which is equivalent to 0.0006% of the concentration      | 
|          |of the test solution. The signal-to-noise ratio (S/N) of the           |
|          |3-needle imidazole peak after repeated injection of the detection      |
|          |limit solution is in the range of 11.8~13.6 (the requirement           |
|          |should be greater than 3), which meets the verification                |
|          |requirements.                                                          |
|----------|-----------------------------------------------------------------------|
|DMAP      |1          |0.0233     |0.0005%    |16.879     |1814       |5.0        |
|          |-----------|           |           |-----------|-----------|-----------|
|          |2                      |           |16.804     |1708       |4.6        |
|          |-----------------------|           |-----------|-----------|-----------|
|          |3                      |           |16.844     |1164       |4.7        |
|          |-----------------------|-----------|-----------|-----------|-----------|
|          |Conclusion: The detection limit concentration of                       |
|          |4-dimethylaminopyridine (DMAP) is 0.0233μg/ml, which is equivalent    | 
|          |to 0.0005% of the concentration of the test solution. The              |
|          |signal-to-noise ratio (S/N) of the DMAP peak of the detection          |
|          |limit solution is in the range of 4.6~5.0 (the requirement should      |
|          |be greater than 3), which meets the verification requirements.         |
------------------------------------------------------------------------------------

**(4.5) Linearity and range** 



 **Acceptance Criteria** 



In the range equivalent to the LOQ concentration of each impurity ~ 200% 



limit concentration, take 6 concentration points more evenly, take the 



concentration of each impurity as the horizontal coordinate, the peak area as 



the vertical coordinate as the linear regression curve, the regression 



coefficient R of the linear graph should NLT 0.990, the RSD of the response 



factor should NMT 10%. Y-axis intercepts are within 25% of 100% response 



value. 



 **Solution Preparation** 



Blank solution: solvent. 



YA2304-52 Reference storage solution (approx. 100μg/ml) : Share 



YA2304-52 reference storage solution under "4.1 wavelength selection". 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 264 of 542 





Page 265
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Imidazole reference product reserve (approx. 100μg/ml) : Imidazole reference 



product reserve under "4.1 wavelength selection". 



4-dimethylaminopyridine (DMAP) reference reserve liquid (about 100μg/ml) : 



Share 4-dimethylaminopyridine (DMAP) reserve liquid under "4.1 wavelength 



selection". 



Linear solution ① : share the 6th dose limit solution prepared in parallel 



under the item "4.4 dose limit and detection limit". 



Linear solution ② : precisely measure 0.5ml of YA2304-52 reference product 



reserve, imidazole reference product reserve and 4-dimethylaminopyridine 



reference product reserve in the same 20ml bottle, dilute to the scale with 



solvent, shake well, and obtain. (Each about 2.5μg/ml) 



Linear solution ③ : Precision measure YA2304-52 reference product reserve 



liquid, imidazole reference product reserve liquid and 



4-dimethylaminopyridine reference product reserve liquid of 0.75ml, place in 



the same 20ml bottle, dilute with solvent to scale, shake well, then obtain. 



(Each about 3.75μg/ml) 



Linear solution ④ : Accurately measure YA2304-52 reference product reserve, 



imidazole reference product reserve and 4-dimethylaminopyridine reference 



product reserve of 1ml each, place in the same 20ml bottle, dilute with 



solvent to scale, shake well, and obtain. (Each about 5μg/ml) 



Linear solution ⑤ : precisely measure YA2304-52 reference product reserve 



liquid, imidazole reference product reserve liquid and 



4-dimethylaminopyridine reference product reserve liquid of 1.5ml, place in 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 265 of 542 





Page 266
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



the same 20ml bottle, dilute to the scale with solvent, shake well, then obtain. 



(Each about 7.5μg/ml) 



Linear solution ⑥ : Accurately measure YA2304-52 reference product reserve 



liquid, imidazole reference product reserve liquid and 



4-dimethylaminopyridine reference product reserve liquid 2ml, place in the 



same 20ml bottle, dilute with solvent to scale, shake well, and obtain. (Each 



about 10μg/ml) 



 **Injection procedure** 



After the chromatographic system is balanced, take a blank solution into 1 



needle, linear solution ①~ linear solution ⑥ from low concentration to high 



concentration into 1 needle, record the chromatogram. 



 **Measurement results** 
























-----------------------------------------------------------------------
|Subst     |Solution   |Equivalent to|Concentration|Peak area|Response|
|ances Name|name       |percentage of|(μg/ml)     |         |factor  | 
|          |           |reference    |             |         |        |
|          |           |solution     |             |         |        |
|          |           |concentration|             |         |        |
|----------|-----------|-------------|-------------|---------|--------|
|YA230 4-52|Linear     |0.03%        |1.3248       |5103     |3852    |
|          |solution ①|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.05%        |2.6495       |11692    |4413    |
|          |solution ②|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.08%        |3.9743       |18083    |4550    |
|          |solution ③|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.11%        |5.2991       |24926    |4704    |
|          |solution ④|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.16%        |7.9486       |38602    |4856    |
|          |solution ⑤|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Linear     |0.21%        |10.5982      |52524    |4956    |
|          |solution ⑥|             |             |         |        | 
|          |-----------|-------------|-------------|---------|--------|
|          |Response factor RSD      |9%                              |
-----------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 266 of 542 





Page 267
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















----------------------------------------------------------------------------------
|          |Linear graph               |                                         |
|          |---------------------------|-----------------------------------------|
|          |Linear equations           |Y = 5118-1965.5 x                        |
|          |---------------------------|-----------------------------------------|
|          |Slope                      |5118                                     |
|          |---------------------------|-----------------------------------------|
|          |Correlation coefficient r  |0.9999                                   |
|          |---------------------------|-----------------------------------------|
|          |Absolute value of Y-axis   |8.32%                                    |
|          |intercept as a percentage  |                                         |
|          |of 100% response value     |                                         |
|          |---------------------------|-----------------------------------------|
|          |Conclusion: When YA2304-52 is in the concentration range of          |
|          |1.3248μg/ml~10.5982μg/ml, the linear equation is y=5118x-1965.5,   |  
|          |the correlation coefficient r is 0.9999 (NLT 0.990), and the RSD of  |
|          |the response factor is 9% (NMT 10%). The absolute value of Y-axis    |
|          |intercept as a percentage of 100% response value is 8.32% (not more  |
|          |than 25% required). All the above meet the requirements, indicating  |
|          |that under this method, when YA2304-52 is in the concentration       |
|          |range of 1.3248μg/ml~10.5982μg/ml, the linear relationship between |  
|          |peak area and concentration is good.                                 |
|----------|---------------------------------------------------------------------|
|Imidaz ole|Linear       |0.002%       |0.1033       |7966         |77135        |
|          |solution ①  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.05%        |2.5818       |207402       |80332        |
|          |solution ②  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.08%        |3.8727       |314281       |81152        |
|          |solution ③  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.10%        |5.1637       |417642       |80881        |
|          |solution ④  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.15%        |7.7455       |636837       |82220        |
|          |solution ⑤  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.21%        |10.3273      |856435       |82929        |
|          |solution ⑥  |             |             |             |             | 
|          |-------------|-------------|-------------|-------------|-------------|
|          |Response factor RSD        |2.5%                                     |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 267 of 542 





Page 268
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-------------------------------------------------------------------------------
|       |Linear graph               |                                         |
|       |---------------------------|-----------------------------------------|
|       |Linear equations           |Y = 83064-5713.7 x                       |
|       |---------------------------|-----------------------------------------|
|       |Slope                      |83064                                    |
|       |---------------------------|-----------------------------------------|
|       |Correlation coefficient r  |0.9999                                   |
|       |---------------------------|-----------------------------------------|
|       |Absolute value of Y-axis   |1.39%                                    |
|       |intercept as a percentage  |                                         |
|       |of 100% response value     |                                         |
|       |---------------------------|-----------------------------------------|
|       |Conclusion: When imidazole is in the concentration range of          |
|       |0.1033μg/ml~10.3273μg/ml, the linear equation is y=83064x-5713.7,  |  
|       |the correlation coefficient r is 0.9999 (NLT 0.990), and the RSD of  |
|       |the response factor is 2.5% (NMT 10%). The absolute value of Y-axis  |
|       |intercept as a percentage of 100% response value is 1.39% (required  |
|       |not to be greater than 25%). All the above meet the requirements,    |
|       |indicating that under this method, when imidazole is in the          |
|       |concentration range of 0.1033μg/ml~10.3273μg/ml, the linear        |  
|       |relationship between peak area and concentration is good.            |
|-------|---------------------------------------------------------------------|
|DMAP   |Linear       |0.002%       |0.0775       |6879         |88713        |
|       |solution ①  |             |             |             |             | 
|       |-------------|-------------|-------------|-------------|-------------|
|       |Linear       |0.05%        |2.5848       |230453       |89159        |
|       |solution ②  |             |             |             |             | 
|       |-------------|-------------|-------------|-------------|-------------|
|       |Linear       |0.08%        |3.8771       |346096       |89266        |
|       |solution ③  |             |             |             |             | 
|       |-------------|-------------|-------------|-------------|-------------|
|       |Linear       |0.10%        |5.1695       |465309       |90010        |
|       |solution ④  |             |             |             |             | 
|       |-------------|-------------|-------------|-------------|-------------|
|       |Linear       |0.16%        |7.7543       |710454       |91621        |
|       |solution ⑤  |             |             |             |             | 
|       |-------------|-------------|-------------|-------------|-------------|
|       |Linear       |0.21%        |10.3390      |969730       |93793        |
|       |solution ⑥  |             |             |             |             | 
|       |-------------|-------------|-------------|-------------|-------------|
|       |Response factor RSD        |2.2%                                     |
-------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 268 of 542 





Page 269
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










-----------------------------------------------------------------------------
|       |Linear graph                     |                                 |
|       |---------------------------------|---------------------------------|
|       |Linear equations                 |y=93774x-10958                   |
|       |---------------------------------|---------------------------------|
|       |Slope                            |93774                            |
|       |---------------------------------|---------------------------------|
|       |Correlation coefficient r        |0.9997                           |
|       |---------------------------------|---------------------------------|
|       |Absolute value of Y-axis         |2.39%                            |
|       |intercept as a percentage        |                                 |
|       |of 100% response value           |                                 |
|       |---------------------------------|                                 |
|       |Conclusion: When 4-dimethylaminopyridine (DMAP) was in the         |
|       |concentration range of 0.0775μg/ml~10.3390μg/ml, the linear      |  
|       |equation was y=93774x-10958, the correlation coefficient r was     |
|       |0.9997 (NLT 0.990), and the RSD of the response factor was 2.2%    |
|       |(NMT 10%). The absolute value of Y-axis intercept as a percentage  |
|       |of 100% response value is 2.39% (not more than 25% required). All  |
|       |of the above meet the requirements, indicating that under this     |
|       |method, when 4-dimethylaminopyridine (DMAP) is in the concentration|
|       |range of 0.0775μg/ml to 10.3390μg/ml, the peak area has a good   |  
|       |linear relationship with the concentration.                        |
-----------------------------------------------------------------------------

**(4.6) Accuracy** 



 **Acceptance Criteria** 



The recovery rate of known impurities is achieved by adding each impurity 



reference in the test product solution within the range of 50% concentration 



to 150% limit concentration, and testing the recovery rate between the 



theoretical addition amount and the actual detection amount. The required 



recovery rate is 80%~115%, and the RSD of the recovery rate of each 



impurity is not more than 10%. 



 **Solution preparation** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 269 of 542 





Page 270
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Blank solution: solvent. 



YA2304-52 Reference storage solution (approx. 100μg/ml) : Share 



YA2304-52 reference storage solution under "4.1 wavelength selection". 



Imidazole reference product reserve (approx. 100μg/ml) : Imidazole reference 



product reserve under "4.1 wavelength selection". 



4-dimethylaminopyridine (DMAP) reference storage solution (about 



100μg/ml) : Share 4-dimethylaminopyridine (DMAP) storage solution under 



"4.1 wavelength selection". 



Reference product solution: according to "4.1 wavelength selection" under 



the reference product solution prepared by the same method. (Each about 



5μg/ml) 



Test product solution: Prepare the test product solution under "4.3 specific 



properties" by the same method. Prepare 2 parts in parallel. 



50% recovery solution: Take YA2304 test product about 100mg, weigh it 



accurately, place it in 20ml measuring bottle, add appropriate amount of 



solvent to dissolve by ultrasound, then add YA2304-52 reference product 



reserve, imidazole reference product reserve and 4-dimethylaminopyridine 



reference product reserve 0.5ml each, dilute with solvent to scale, shake well, 



and obtain. 3 parts were prepared in parallel. (Finerenone about 5mg/ml, 



each impurity about 2.5μg/ml) 



100% recovery solution: Take YA2304 test product about 100mg, accurately 



weigh, put into 20ml bottle, add appropriate amount of solvent to dissolve by 



ultrasound, add YA2304-52 reference product reserve liquid, imidazole 



reference product reserve liquid and 4-dimethylaminopyridine reference 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 270 of 542 





Page 271
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



product reserve liquid 1.0ml each, dilute with solvent to scale, shake well, 



then obtain. 3 parts were prepared in parallel. (Finerenone about 5mg/ml, 



each impurity about 5μg/ml) 



150% recovery solution: Take YA2304 test product about 100mg, accurately 



weigh, put into 20ml bottle, add appropriate amount of solvent to dissolve by 



ultrasound, add YA2304-52 reference product reserve, imidazole reference 



product reserve and 4-dimethylaminopyridine reference product reserve 



1.5ml each, dilute with solvent to scale, shake well, then obtain. 3 parts were 



prepared in parallel. (Finerenone about 5mg/ml, each impurity about 



7.5μg/ml) 



 **Injection procedure** 



After the chromatographic system was balanced, the blank solution was 



injected with 1 needle, the control solution was injected with 2 needles 



repeatedly, 2 samples of test solution and 9 recovery solutions were injected 



with 1 needle each, and the chromatogram was recorded. 



 **Measurement results** 






























-------------------------------------------------------------------------
|Substanc e|Solution name|Amount to|Measure d|Recovery|Averag e |RSD    |
|Name      |             |add      |amount   |rate    |recover y|       |
|          |             |(μg/ml) |(μg/ml) |        |rate     |       |  
|----------|-------------|---------|---------|--------|---------|-------|
|YA2304-5 2|50% recovery |2.6495   |2.4303   |91.7%   |99.3%    |5%     |
|          |solution -1  |         |         |        |         |       |
|          |-------------|---------|---------|--------|         |       |
|          |50% recovery |2.6495   |2.5275   |95.4%   |         |       |
|          |solution -2  |         |         |        |         |       |
|          |-------------|---------|---------|--------|         |       |
|          |50% recovery |2.6495   |2.4833   |93.7%   |         |       |
|          |solution -3  |         |         |        |         |       |
|          |-------------|---------|---------|--------|         |       |
|          |100% recovery|5.2991   |5.3386   |100.7%  |         |       |
|          |solution -1  |         |         |        |         |       |
|          |-------------|---------|---------|--------|         |       |
|          |100% recovery|5.2991   |5.4065   |102.0%  |         |       |
-------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 271 of 542 





Page 272
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 













--------------------------------------------------------------------------------
|         |solution -2  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |100% recovery|5.2991    |5.4013    |101.9%    |          |          |
|         |solution -3  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |150% recovery|7.9486    |8.0957    |101.8%    |          |          |
|         |solution -1  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |150% recovery|7.9486    |8.1642    |102.7%    |          |          |
|         |solution -2  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |150% recovery|7.9486    |8.2538    |103.8%    |          |          |
|         |solution -3  |          |          |          |          |          |
|         |-------------|----------|----------|----------|----------|----------|
|         |Conclusions: YA2304-52 was added into the test samples at           |
|         |concentrations ranging from 2.6495μg/ml to 7.9486μg/ml. The       |  
|         |recoveries were all in the range of 91.7% to 103.8% (85% to         |
|         |110%), and the RSD of the recoveries was 5% (less than 10%). All    |
|         |the above met the requirements, indicating that the method had      |
|         |good accuracy in detecting YA2304-52 content.                       |
|---------|--------------------------------------------------------------------|
|Imidazole|50% recovery |2.5818    |2.5271    |97.9%     |99.5%     |1.5%      |
|         |solution -1  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |50% recovery |2.5818    |2.5098    |97.2%     |          |          |
|         |solution -2  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |50% recovery |2.5818    |2.5329    |98.1%     |          |          |
|         |solution -3  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |100% recovery|5.1637    |5.1654    |100.0%    |          |          |
|         |solution -1  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |100% recovery|5.1637    |5.2085    |100.9%    |          |          |
|         |solution -2  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |100% recovery|5.1637    |5.1694    |100.1%    |          |          |
|         |solution -3  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |150% recovery|7.7455    |7.8567    |101.4%    |          |          |
|         |solution -1  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |150% recovery|7.7455    |7.7757    |100.4%    |          |          |
|         |solution -2  |          |          |          |          |          |
|         |-------------|----------|----------|----------|          |          |
|         |150% recovery|7.7455    |7.7179    |99.6%     |          |          |
|         |solution -3  |          |          |          |          |          |
|         |-------------|----------|----------|----------|----------|----------|
|         |Conclusions: The recoveries of imidazole control products in the    |
|         |concentration range of 2.5818μg/ml to 7.7455μg/ml were in the     |  
|         |range of 97.2% to 101.4% (85% to 110%), and the RSD of recovery     |
|         |was 1.5% (no more than 10%). All of the above met the               |
|         |requirements, indicating that the method was accurate in            |
|         |detecting imidazole content.                                        |
--------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 272 of 542 





Page 273
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 
















------------------------------------------------------------------------------
|DMAP   |50% recovery |2.5848    |2.5840    |100.0%    |102.1 %   |1.8%      |
|       |solution -1  |          |          |          |          |          |
|       |-------------|----------|----------|----------|          |          |
|       |50% recovery |2.5848    |2.6040    |100.7%    |          |          |
|       |solution -2  |          |          |          |          |          |
|       |-------------|----------|----------|----------|          |          |
|       |50% recovery |2.5848    |2.6423    |102.2%    |          |          |
|       |solution -3  |          |          |          |          |          |
|       |-------------|----------|----------|----------|          |          |
|       |100% recovery|5.1695    |5.2211    |101.0%    |          |          |
|       |solution-1   |          |          |          |          |          |
|       |-------------|----------|----------|----------|          |          |
|       |100% recovery|5.1695    |5.2575    |101.7%    |          |          |
|       |solution -2  |          |          |          |          |          |
|       |-------------|----------|----------|----------|          |          |
|       |100% recovery|5.1695    |5.1986    |100.6%    |          |          |
|       |solution -3  |          |          |          |          |          |
|       |-------------|----------|----------|----------|          |          |
|       |150% recovery|7.7543    |8.0727    |104.1%    |          |          |
|       |solution -1  |          |          |          |          |          |
|       |-------------|----------|----------|----------|          |          |
|       |150% recovery|7.7543    |8.1400    |105.0%    |          |          |
|       |solution -2  |          |          |          |          |          |
|       |-------------|----------|----------|----------|          |          |
|       |150% recovery|7.7543    |8.0275    |103.5%    |          |          |
|       |solution -3  |          |          |          |          |          |
|       |-------------|----------|----------|----------|----------|----------|
|       |Conclusions: The recoveries of 4-dimethylaminopyridine (DMAP) in    |
|       |the concentration range of 2.5848μg/ml to 7.7543μg/ml were all    |  
|       |in the range of 100.0% to 105.0% (85% to 110%), and the RSD of      |
|       |recovery was 1.8% (less than 10%). All the above met the            |
|       |requirements, indicating that the method was accurate in            |
|       |detecting the content of 4-dimethylaminopyridine (DMAP).            |
------------------------------------------------------------------------------

**(4.7) Precision** 



Precision refers to the proximity between the results obtained by multiple 



sampling of the same uniform test product under specified test conditions, 



and its precision is judged by examining repeatability and intermediate 



precision. 



**(4.7.1) Repeatability** 



 **Acceptance Criteria** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 273 of 542 





Page 274
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



6 copies of repeatable sample solution were prepared by analyst A on date A 



and measured by instrument A. The blank solution was required to be free of 



interference; The separation degree between the imidazole peak and 



YA2304-52 peak in the control solution should be NLT 1.5; The RSD of all 



impurities in the solution of 6 repeatable test products NMT 10%. 



 **Solution preparation** 



Blank solution: solvent. 



YA2304-52 Reference storage solution (approx. 100μg/ml) : Share 



YA2304-52 reference storage solution under "4.1 wavelength selection". 



Imidazole reference product reserve (approx. 100μg/ml) : Imidazole reference 



product reserve under "4.1 wavelength selection". 



4-dimethylaminopyridine (DMAP) reference solution (approx. 100μg/ml) : 



Share 4-dimethylaminopyridine (DMAP) under "43.1 wavelength selection". 



Reference solution: Prepare it by the same method as the reference solution 



under "4.1 wavelength selection". (Each about 5μg/ml) 



Repetitive test product solution: Take YA2304 test product about 100mg, 



accurately weigh it, place it in a 20ml measuring bottle, add appropriate 



amount of solvent to dissolve by ultrasound, then add YA2304-52 reference 



product reserve, imidazole reference product reserve and 



4-dimethylaminopyridine reference product reserve 1.0ml each, dilute with 



solvent to scale, shake well, and obtain. 6 parts were prepared in parallel. 



(YA2304 about 5mg/ml, each impurity about 5μg/ml) 



 **Injection procedure** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 274 of 542 





Page 275
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



After the chromatographic system was balanced, 1 needle was injected into 



the blank solution, 2 needles into the control solution, 1 needle into each of 



the 6 repetitive test product solutions, and the chromatogram was recorded. 



 **Determination result** 











































--------------------------------------------------------------------------------------------
|Name of      |Inspection items            |Sample number               |         |RESU LTS|
|solution     |                            |                            |         |        |
|-------------|----------------------------|----------------------------|---------|--------|
|Reference    |Degree of separation        |1                           |         |2.0     |
|solution     |between imidazole           |                            |         |        |
|             |peaks and YA2304-52         |                            |         |        |
|             |peaks                       |                            |         |        |
|             |                            |----------------------------|---------|--------|
|             |         |         |        |2                           |         |2.0     |
|-------------|---------|---------|--------|----------------------------|---------|--------|
|Investigation|Solution name                                            |         |RSD     |
|Items        |                                                         |         |        |
|             |---------------------------------------------------------|---------|        |
|             |Repeate d|Repetiti |Repetiti         |Repetiti |Repetiti |Repetiti |        |
|             |test     |ve test  |ve test          |ve test  |ve test  |ve test  |        |
|             |product  |product  |product          |product  |product  |product  |        |
|             |solutio n|solutio n|solutio n        |solutio n|solutio n|solutio n|        |
|             |1        |2        |3                |4        |5        |6        |        |
|-------------|---------|---------|-----------------|---------|---------|---------|--------|
|YA2304-52    |0.11%    |0.10%    |0.10%            |0.10%    |0.10%    |0.11%    |1.2%    |
|content      |         |         |                 |         |         |         |        |
|-------------|---------|---------|-----------------|---------|---------|---------|--------|
|Imidazole    |0.10%    |0.10%    |0.10%            |0.10%    |0.10%    |0.10%    |0.9%    |
|content      |         |         |                 |         |         |         |        |
|-------------|---------|---------|-----------------|---------|---------|---------|--------|
|DMAP content |0.10%    |0.10%    |0.10%            |0.10%    |0.10%    |0.10%    |1.6%    |
|-------------|---------|---------|-----------------|---------|---------|---------|--------|
|Conclusion: The blank solution has no interference; The separation degree                 |
|between imidazole peaks and YA2304-52 peaks in control solution was 2.0                   |
|(NLT 1.5 required). The RSDS of all impurities in the 6 repeatable samples                |
|were no more than 1.6% (no more than 10% required); All the above met the                 |
|verification requirements, indicating that the method has good                            |
|repeatability.                                                                            |
--------------------------------------------------------------------------------------------

**(4.7.2) Intermediate precision** 



 **Brief Description** 



6 intermediate precision sample solutions were prepared by Analyst B on 



date B. It is required that the blank solution should be interference free; The 



control solution was injected for 6 consecutive times, and the peak order was 



YA2304-52, imidazole and 4-dimethylaminopyridine. The separation degree 



between imidazole peak and YA2304-52 peak should be NLT 1.5, the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 275 of 542 





Page 276
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



retention time RSD of each impurity peak should be no more than 1.0%, and 



the RSD of the peak area of each impurity peak should be no more than 5%. 



RSD of all impurities in 6 intermediate precision test solutions NMT 10%. 



The RSD of each impurity content NMT 10% for the results of 12 tests of 



repeatability and intermediate precision. 



 **Solution preparation** 



Blank solution: solvent. 



YA2304-52 Reference storage solution (about 100μg/ml) : Share YA2304-52 



reference storage solution under "4.1 Wavelength selection". 



Imidazole reference product reserve (approx. 100μg/ml) : Imidazole reference 



product reserve under "4.1 wavelength selection". 



4-dimethylaminopyridine (DMAP) reference reserve liquid (about 100μg/ml) : 



Share 4-dimethylaminopyridine (DMAP) reserve liquid under "4.1 wavelength 



selection". 



Reference product solution: according to "4.1 wavelength selection" under 



the reference product solution prepared by the same method. (Each about 



5μg/ml) 



Intermediate precision test solution: Take YA2304 test product about 100mg, 



weigh it accurately, place it in a 20ml measuring bottle, add appropriate 



amount of solvent to dissolve by ultrasound, then add YA2304-52 reference 



product reserve liquid, imidazole reference product reserve liquid and 



4-dimethylaminopyridine reference product reserve liquid 1.0ml each, dilute 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 276 of 542 





Page 277
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



it with solvent to the scale, shake well, and obtain. 6 parts were prepared in 



parallel. (YA2304 about 5mg/ml, each impurity about 5μg/ml) 



 **Injection procedure** 



Intermediate precision - System applicability: After the chromatographic 



system balance, take blank solution into 1 needle, control solution into 6 



needles, record the chromatogram. 



Intermediate precision - Sample detection: After the chromatographic system 



was balanced, 1 needle was injected into the blank solution, 2 needles were 



injected into the control solution, and 1 needle was injected into each of the 6 



intermediate precision test solutions, and the chromatogram was recorded. 



 **Determination result** 



Results of intermediate precision - system suitability test 









































































-------------------------------------------------------------------------------------
|Investigation       |Control solution was injected                        |RSD     |
|parameters          |                                                     |        |
|                    |-----------------------------------------------------|        |
|          |         |1       |2       |3       |4       |5       |6       |        |
|----------|---------|--------|--------|--------|--------|--------|--------|--------|
|YA230 4-52|RT (min) |6.348   |6.348   |6.351   |6.351   |6.354   |6.351   |0.04%   |
|          |---------|--------|--------|--------|--------|--------|--------|--------|
|          |Peak area|25275   |25258   |25184   |25462   |25289   |25551   |0.6%    |
|----------|---------|--------|--------|--------|--------|--------|--------|--------|
|imidaz ole|RT (min) |7.348   |7.348   |7.350   |7.352   |7.353   |7.352   |0.030 % |
|          |---------|--------|--------|--------|--------|--------|--------|--------|
|          |Peak area|41650 3 |41639 8 |41707 9 |41785 9 |41758 3 |41799 7 |0.17%   |
|----------|---------|--------|--------|--------|--------|--------|--------|--------|
|DMAP      |RT (min) |16.646  |16.647  |16.652  |16.657  |16.659  |16.657  |0.04%   |
|          |---------|--------|--------|--------|--------|--------|--------|--------|
|          |Peak area|47114 1 |47143 3 |47226 3 |47320 7 |46753 7 |47310 5 |0.5%    |
|----------|         |--------|--------|--------|--------|--------|--------|--------|
|Degree of           |1.9     |1.9     |1.9     |1.9     |1.9     |1.9     |/       |
|separation          |        |        |        |        |        |        |        |
|between imidazole   |        |        |        |        |        |        |        |
|peak and            |        |        |        |        |        |        |        |
|YA2304-52 peak      |        |        |        |        |        |        |        |
|--------------------|        |        |        |        |        |        |        |
|Conclusion: The blank solution has no interference; The control solution           |
|was injected for 6 consecutive times, and the peak order was YA2304-52,            |
|imidazole and 4-dimethylaminopyridine. The separation degree between               |
|imidazole peak and                                                                 |
-------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 277 of 542 





Page 278
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



YA2304-52 peak was 1.9 (NLT 1.5), and the retention time RSD of each impurity peak 



was no more than 0.04%(NMT 1.0%). The RSD of the peak area of each impurity peak 



was no more than 0.6% (NMT 5%); All the above meet the verification requirements, 



indicating that the method has good system applicability. 



Results of repeatability test 


























































---------------------------------------------------------------------------------------------------
|Investigati|Solution name                                                    |RSD (n=6)          |
|on items   |                                                                 |                   |
|           |-----------------------------------------------------------------|                   |
|           |RSD (n =  |Repetiti  |Repetiti  |Repetiti  |Repeat ed |Repetiti  |          |        |
|           |6) 1      |ve test   |ve test   |ve test   |test      |ve test   |          |        |
|           |Repeat    |produc t  |produc t  |produc t  |produc t  |produc t  |          |        |
|           |test      |solutio n |solutio n |solutio n |solutio n |solutio n |          |        |
|           |solutio n |2         |3         |4         |5         |6         |          |        |
|-----------|----------|----------|----------|----------|----------|----------|----------|--------|
|YA2304-52  |0.11%     |0.10%     |0.10%     |0.10%     |0.10%     |0.11%     |1.2%               |
|content    |          |          |          |          |          |          |                   |
|-----------|----------|----------|----------|----------|----------|----------|-------------------|
|Imidazole  |0.10%     |0.10%     |0.10%     |0.10%     |0.10%     |0.10%     |0.9%               |
|content    |          |          |          |          |          |          |                   |
|-----------|----------|----------|----------|----------|----------|----------|-------------------|
|DMAP       |0.10%     |0.10%     |0.10%     |0.10%     |0.10%     |0.10%     |1.6%               |
|content    |          |          |          |          |          |          |                   |
|-----------|----------|----------|----------|----------|----------|----------|-------------------|
|Survey     |Solution name                                                    |RSD (n=6 )|RSD (n=1|
|items      |                                                                 |          |2)      |
|           |-----------------------------------------------------------------|          |        |
|           |Interme   |Interme   |Interme   |Interme   |Interme   |Interme   |          |        |
|           |diate     |diate     |diate     |diate     |diate     |diate     |          |        |
|           |precisio n|precisio n|precisio n|precisio n|precisio n|precisio n|          |        |
|           |test      |sample    |sample    |sample    |sample    |sample    |          |        |
|           |sample    |solutio n |solutio n |solutio n |solutio n |solutio n |          |        |
|           |solutio n |2         |3         |4         |5         |6         |          |        |
|           |1         |          |          |          |          |          |          |        |
|-----------|----------|----------|----------|----------|----------|----------|----------|--------|
|YA2304-52  |0.10%     |0.11%     |0.11%     |0.11%     |0.11%     |0.10%     |1.1 %     |1.1 %   |
|content    |          |          |          |          |          |          |          |        |
|-----------|----------|----------|----------|----------|----------|----------|----------|--------|
|Imidazole  |0.10%     |0.10%     |0.10%     |0.10%     |0.10%     |0.10%     |1.1 %     |1.8 %   |
|content    |          |          |          |          |          |          |          |        |
|-----------|----------|----------|----------|----------|----------|----------|----------|--------|
|DMAP       |0.10%     |0.10%     |0.11%     |0.11%     |0.11%     |0.10%     |1.3 %     |2.2 %   |
|content    |          |          |          |          |          |          |          |        |
|-----------|----------|----------|----------|----------|----------|----------|----------|--------|
|Conclusion: RSDS of all impurities in 6 intermediate precision test                              |
|solutions are not more than 1.3% (the requirement is not more than 10%).                         |
|All the above meet the verification requirements, indicating that the                            |
|intermediate precision of the method is good; RSDS of all impurities in 12                       |
|repetitive test products and intermediate precision test products were not                       |
|more than 2.2% (the requirement was not more than 10%); The above all meet                       |
|the verification requirements, indicating that the method has good                               |
---------------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 278 of 542 





Page 279
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



precision. 



**(4.8) Solution stability** 



 **Brief Description** 



Each solution is placed in a 5℃ injector, and the control solution and test 



solution are injected at different times. The separation degree between 



imidazole peak and YA2304-52 peak in the control solution should be NLT 



1.5, and the RSD of the peak area of each impurity peak should be no more 



than 5%; The RSDS of all impurities in the test solution should NMT 10%, 



and no new impurities to be measured (YA2304-52, imidazole, 



4-dimethylaminopyridine) should be detected. 



 **Solution preparation** 



Blank solution: solvent. 



Reference solution: Share the reference solution under "4.2 System 



Suitability". (Approx. 5μg/ml) 



Test solution: Share the test solution under "4.3 specific Properties". 



 **Injection Sequence** 



After the chromatographic system was balanced, the control solution placed 



in the 5℃ injector was injected with 1 needle at 0h, 2h, 4h, 16h, 24h, 40h 



and 48h respectively, and the test solution placed in the 5℃ injector was 



injected with 1 needle at 0h, 2h, 4h, 12h, 20h, 36h and 44h respectively to 



record the chromatogram. (The chromatogram of reference solution 0h and 



2h shared the chromatogram of reference solution 1 and 4 needles of 



repeated injection of 6 needles under "4.2 system applicability", and the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 279 of 542 





Page 280
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



chromatogram of reference solution 16h shared the chromatogram of 



reference solution under "4.3 specificity"; The test product solution 2h atlas 



was shared with the test product solution under "4.3 specificity") 



 **Measurement results** 



Stability test results of reference solution 
















































--------------------------------------------------------------------------------------
|Investigation       |Reference solution                                     |RSD    |
|Items               |                                                       |       |
|                    |-------------------------------------------------------|-------|
|         |          |0h     |2h     |4h     |16h    |24h    |40h    |48h            |
|---------|----------|-------|-------|-------|-------|-------|-------|---------------|
|Peak area|YA230 4-52|24168  |24129  |23898  |24389  |24371  |24282  |24439  |0.8 %  |
|         |----------|-------|-------|-------|-------|-------|-------|-------|-------|
|         |Imida zole|41795 3|41971 1|41872 0|42153 2|42406 2|41994 6|42191 7|0.5 %  |
|         |----------|-------|-------|-------|-------|-------|-------|-------|-------|
|         |DMAP      |45883 2|45761 9|46219 1|46923 3|47399 0|47453 2|47218 2|1.6 %  |
|---------|----------|-------|-------|-------|-------|-------|-------|-------|-------|
|Degree of           |1.9    |1.9    |1.9    |1.9    |1.9    |2.0    |2.0    |/      |
|separation          |       |       |       |       |       |       |       |       |
|between             |       |       |       |       |       |       |       |       |
|imidazole           |       |       |       |       |       |       |       |       |
|peaks and           |       |       |       |       |       |       |       |       |
|YA2304-52           |       |       |       |       |       |       |       |       |
|peaks               |       |       |       |       |       |       |       |       |
|--------------------|       |       |       |       |       |       |       |       |
|Conclusion: When the control solution was placed in the 5℃injector for 48          | 
|h, the separation degree between imidazole peak and YA2304-52 peak was NLT          |
|1.9 (required to be NLT 1.5), and the RSD of the peak-peak area of each             |
|impurity was not more than 1.6% (required to be no more than 5%). All the           |
|above met the verification requirements, indicating that the control                |
|product solution was stable within 48h after being placed in the                    |
|5℃injector.                                                                        | 
--------------------------------------------------------------------------------------




































---------------------------------------------------------------------------------------------------------
|Investigation        |Test solution                                                            |RSD    |
|Items                |                                                                         |       |
|                     |-------------------------------------------------------------------------|       |
|          |          |0h        |2h        |4h        |12h       |20h      |36h      |44h      |       |
|----------|----------|----------|----------|----------|----------|---------|---------|---------|-------|
|Co nt en t|YA2304 -52|Not detect|Not detect|Not detect|Not detect|Not      |Not      |Not      |/      |
|          |          |ed        |ed        |ed        |ed        |detecte d|detecte d|detecte d|       |
|          |----------|----------|----------|----------|----------|---------|---------|---------|-------|
|          |Imidazo le|Not detect|Not detect|Not detect|Not detect|Not      |Not      |Not      |/      |
|          |          |ed        |ed        |ed        |ed        |detecte d|detecte d|detecte d|       |
---------------------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 280 of 542 





Page 281
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 































-----------------------------------------------------------------------------------------------------
|        |DMAP    |Not detect|Not detect|Not detect|Not detect|Not      |Not      |Not      |/      |
|        |        |ed        |ed        |ed        |ed        |detecte d|detecte d|detecte d|       |
|--------|--------|----------|----------|----------|----------|---------|---------|---------|-------|
|Conclusion: YA2304-52, imidazole and 4-dimethylaminopyridine (DMAP) were                   |       |
|not detected when the sample solution was placed in the sample injector at                 |       |
|5℃for 44h, and no other impurity peaks affecting the detection of the above               |       | 
|three impurities were detected. The results indicated that the tested                      |       |
|product solution was stable for 44h after being placed in the 5℃injector.                 |       | 
-----------------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 281 of 542 





Page 282
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**III. Summary of Method Validation** 



Methodological Verification Results of Finished Product Related Substances II 












------------------------------------------------------------------------------------------------------------------------
|Item          |Acceptable criteria               |Verification of results                                             |
|--------------|----------------------------------|--------------------------------------------------------------------|
|Wavele        |All impurities (YA2304-52,        |All impurities (YA2304-52, imidazole and 4-dimethylaminopyridine)   |
|ngth          |imidazole                         |have greater                                                        |
|selectio n    |and 4-dimethylaminopyridine) have |absorption at 210nm wavelength. In the control solution, the        |
|              |greater absorption at 210nm       |retention time of                                                   |
|              |wavelength                        |YA2144-52, imidazole and 4-dimethylaminopyridine was 6.392min,      |
|              |                                  |7.362min and                                                        |
|              |                                  |16.667min, respectively. The spectral diagram of the control        |
|              |                                  |solution is as                                                      |
|              |                                  |follows:                                                            |
|--------------|----------------------------------|--------------------------------------------------------------------|
|System        |The blank solution should be free |There was no interference in the blank solution; The control        |
|suitabil      |of                                |solution was                                                        |
|ity           |interference; The control solution|injected for 6 consecutive times, the peak order was YA2304-52,     |
|              |should be injected for 6          |imidazole,                                                          |
|              |consecutive                       |4-dimethylaminopyridine, the separation degree between imidazole    |
|              |times, and the peak order should  |peak and                                                            |
|              |be                                |YA2304-52 peak was 1.9 (NLT 1.5), and the retention time RSD of each|
|              |YA2304-52, imidazole and          |impurity                                                            |
|              |4-dimethylaminopyridine. The      |peak was no more than 0.10%(NMT 1.0%). The RSD of the peak area of  |
|              |separation degree between         |each                                                                |
|              |imidazole                         |impurity peak was no more than 0.7% (NMT 5%); All the above meet the|
|              |                                  |verification requirements, indicating that the method has good      |
|              |                                  |system                                                              |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 282 of 542 





Page 283
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

































------------------------------------------------------------------------------------------------------------------------
|             |peak and YA2304-52 peak should be |applicability.                                                       |
|             |NLT 1.5, the retention time RSD of|                                                                     |
|             |each impurity peak should be no   |                                                                     |
|             |more                              |                                                                     |
|             |than 1.0%, and the RSD of the peak|                                                                     |
|             |area of each impurity peak NMT 5%.|                                                                     |
|-------------|----------------------------------|---------------------------------------------------------------------|
|Specific     |The blank solution should be free |Blank solution without interference; In the chromatogram obtained    |
|ity          |of                                |from the                                                             |
|             |interference; In the chromatogram |control solution, the peak order was YA2304-52, imidazole,           |
|             |obtained from the control         |4-dimethylaminopyridine, and the separation degree between the       |
|             |solution,                         |imidazole peak                                                       |
|             |the peak order is YA2304-52,      |and YA2304-52 peak was 1.9 (required to be NLT 1.5); The retention   |
|             |imidazole,                        |time of each                                                         |
|             |4-dimethylaminopyridine,          |impurity peak in the control solution, the test solution and the     |
|             |and the separation degree between |specific mixed                                                       |
|             |the imidazole peak and YA2304-52  |solution was consistent with that of the main peak in the impurity   |
|             |peak should NLT 1.5. The retention|positioning                                                          |
|             |time of each impurity peak in the |solution. The separation degree between the imidazole peak and       |
|             |control solution, the test        |YA2304-52 peak                                                       |
|             |solution                          |in the specific mixed solution was 1.9 (NLT 1.5); The impurities     |
|             |and the specific mixed solution   |studied under                                                        |
|             |should be consistent with the     |the related substances of finished products (including YA2304-10,    |
|             |retention time of the main peak in|YA2304-12,                                                           |
|             |the impurity localization         |YA2304-14, YA2304-15, YA2304-16, YA2304-17, YA2304-18 and YA2304-19) |
|             |solution.                         |did not                                                              |
|             |The separation degree between the |interfere with YA2304-52, imidazole and 4- in the test product       |
|             |imidazole peak and YA2304-52 peak |Detection of                                                         |
|             |in                                |dimethylaminopyridine. The concentration of YA2304-52, imidazole and |
|             |the specific mixed solution should|4-dimethylaminopyridine in the specific mixed solution was 0.10% of  |
|             |be NLT 1.5. All impurities studied|the                                                                  |
|             |under the related substances of   |principal component concentration in the test solution. Name of      |
|             |the                               |soluti on                                                            |
|             |finished product (including       |Compone nt name Compone nt concentra tion (μg/ml) Rt (min) Degree of| 
|             |YA2304-10, YA2304-12,             |separation                                                           |
|             |                                  |from the previous peak The percentage equivalent to the concentration|
|             |                                  |of the                                                               |
|             |                                  |principal component in the test solution Specifi c mixed YA2304-52   |
|             |                                  |5.2991 6.354                                                         |
|             |                                  |/ 0.10% Imidazole 5.1637 7.386 1.9 0.10% DMAP 5.1695 16.756 15.0     |
|             |                                  |0.10%                                                                |
------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------
|Name of  |Compone nt|Compone nt|Rt (min)|Degree of |The percentage   |
|soluti on|name      |concentra |        |separation|equivalent to the|
|         |          |tion      |        |from the  |concentration of |
|         |          |(μg/ml)  |        |previous  |the principal    | 
|         |          |          |        |peak      |component in the |
|         |          |          |        |          |test solution    |
|---------|----------|----------|--------|----------|-----------------|
|Specifi c|YA2304-52 |5.2991    |6.354   |/         |0.10%            |
|mixed    |          |          |        |          |                 |
|         |----------|----------|--------|----------|-----------------|
|         |Imidazole |5.1637    |7.386   |1.9       |0.10%            |
|         |----------|----------|--------|----------|-----------------|
|         |DMAP      |5.1695    |16.756  |15.0      |0.10%            |
-----------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 283 of 542 





Page 284
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 













































------------------------------------------------------------------------------------------------------------------------
|           |YA2304-14, YA2304-15,      |solutio n YA2304 5017.350 0 Peak overload, uncredited / 100% The chromatogram |
|           |YA2304-16,                 |of the specific mixed solution is as follows:                                 |
|           |YA2304-17, YA2304-18 and   |                                                                              |
|           |YA2304-19)                 |                                                                              |
|           |shall not interfere with   |                                                                              |
|           |YA2304-52,                 |                                                                              |
|           |imidazole and imidazole in |                                                                              |
|           |the                        |                                                                              |
|           |tested product             |                                                                              |
|           |4-dimethylaminopyridine    |                                                                              |
|           |test.                      |                                                                              |
|-----------|---------------------------|------------------------------------------------------------------------------|
|Limits of  |The S/N of each impurity in|             |Impurities   |Detection Limits   |Limit of        |             |
|quantifi   |the 6                      |             |             |                   |quantitation    |             |
|cation and |limited quantitation       |             |             |                   |                |             |
|detectio n |solution maps              |             |             |                   |                |             |
|           |should NLT 10, the RSDS of |             |             |                   |                |             |
|           |the peak                   |             |             |                   |                |             |
|           |retention time of each     |             |             |                   |                |             |
|           |impurity                   |             |             |                   |                |             |
|           |should not be more than    |             |             |                   |                |             |
|           |2.0%, and                  |             |             |                   |                |             |
|           |the RSDS of the peak area  |             |             |                   |                |             |
|           |should not                 |             |             |                   |                |             |
|           |be more than 10%. The S/N  |             |             |                   |                |             |
|           |of each                    |             |             |                   |                |             |
|           |impurity in the 3-needle   |             |             |                   |                |             |
|           |detection                  |             |             |                   |                |             |
|           |limited solution atlas     |             |             |                   |                |             |
|           |                           |             |             |-------------------|----------------|             |
|           |                           |             |             |Concentration      |Concentration (equivalent to  |
|           |                           |             |             |(equivalent to     |the test product solution     |
|           |                           |             |             |the concentration  |concentration percentage)     |
|           |                           |             |             |percentage         |                              |
|           |                           |             |             |of the test product|                              |
|           |                           |             |             |solution)          |                              |
|           |                           |             |-------------|-------------------|------------------------------|
|           |                           |             |YA2304-52    |0.3974μg/ml       |1.3248μg/ml (0.03%)          |  
|           |                           |             |             |(0.008%)           |                              |
|           |                           |             |-------------|-------------------|------------------------------|
|           |                           |             |Imidazole    |0.0310μg/ml       |0.1033μg/ml (0.002%)         |  
|           |                           |             |             |(0.0006%)          |                              |
|           |                           |             |-------------|-------------------|------------------------------|
|           |                           |             |4-dimethylam |0.0233μg/ml       |0.0775μg/ml (0.002%)         |  
|           |                           |             |inopyridine  |(0.0005%)          |                              |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 284 of 542 





Page 285
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















---------------------------------------------------------------------------
|Impurities   |Concentration (equivalent to the         |Linear equation  |
|             |percentage of solution concentration of  |                 |
|             |the test product)                        |                 |
|-------------|-----------------------------------------|-----------------|
|YA2304-52    |1.3248μg/ml to 10.5982μg/ml (0.03% to  |Y = 5118-1965.5 x|  
|             |0.0.21%)                                 |                 |
|-------------|-----------------------------------------|-----------------|
|Imidazole    |0.1033μg/ml~10.3273μg/ml (0.002%~0.21%)|Y = 83064-5713.7 |  
|             |                                         |x                |
|-------------|-----------------------------------------|-----------------|
|4-           |0.0775μg/ml to 10.3390μg/ml (0.002% to |y=93774x-10958   |  
|dimethylamino|0.21%)                                   |                 |
|pyridine     |                                         |                 |
---------------------------------------------------------------------------



























-----------------------------------------------------------------
|Impurities   |Marking condition        |Average      |RSD      |
|             |                         |recovery rate|         |
|-------------|-------------------------|-------------|---------|
|YA2304-52    |Added 2.6495μg/ml to    |99.3%, n=9   |5%, n=9  | 
|             |7.9486μg/ml             |             |         | 
|-------------|-------------------------|-------------|---------|
|Imidazole    |Added 2.5818μg/ml to    |99.5%, n=9   |1.5%, n=9| 
|             |7.7455μg/ml             |             |         | 
|-------------|-------------------------|-------------|---------|
|4-           |Added                    |102.1%, n=9  |1.8%, n=9|
|dimethylamino|2.5848μg/ml~7.7543μg/ml|             |         |  
|pyridine     |                         |             |         |
-----------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
|              |NLT 3.                            |                                                                    |
|--------------|----------------------------------|--------------------------------------------------------------------|
|Linearit y    |In the range equivalent to the LOQ|Impurities Concentration (equivalent to the percentage of solution  |
|vs. Range     |concentration of each impurity ~  |concentration of the test product) Linear equation YA2304-52        |
|              |200% limit concentration, take 6  |1.3248μg/ml to                                                     | 
|              |concentration points more evenly, |10.5982μg/ml (0.03% to 0.0.21%) Y = 5118-1965.5 x Imidazole        | 
|              |take the concentration of each    |0.1033μg/ml~10.3273μg/ml (0.002%~0.21%) Y = 83064-5713.7 x 4-     |  
|              |impurity as the horizontal        |dimethylamino                                                       |
|              |coordinate and the peak area as   |pyridine 0.0775μg/ml to 10.3390μg/ml (0.002% to 0.21%)            |  
|              |the                               |y=93774x-10958                                                      |
|              |vertical coordinate as the linear |                                                                    |
|              |regression curve, the regression  |                                                                    |
|              |coefficient R of the linear graph |                                                                    |
|              |should NLT 0.990, and the RSD of  |                                                                    |
|              |the                               |                                                                    |
|              |response factor should not be more|                                                                    |
|              |than 10%. Y-axis intercepts are   |                                                                    |
|              |within 25% of 100% response value.|                                                                    |
|--------------|----------------------------------|--------------------------------------------------------------------|
|Accura cy     |The recovery rate of known        |Impurities Marking condition Average recovery rate RSD YA2304-52    |
|              |impurities is achieved by adding  |Added                                                               |
|              |each impurity reference in the    |2.6495μg/ml to 7.9486μg/ml 99.3%, n=9 5%, n=9 Imidazole Added     |  
|              |range                             |2.5818μg/ml to                                                     | 
|              |of 50% concentration to 150% limit|7.7455μg/ml 99.5%, n=9 1.5%, n=9 4- dimethylamino pyridine Added   | 
|              |concentration in the test product |2.5848μg/ml~7.7543μg/ml 102.1%, n=9 1.8%, n=9                     |  
|              |solution, and testing the recovery|                                                                    |
|              |rate between the theoretical      |                                                                    |
|              |addition amount and the actual    |                                                                    |
|              |detection amount. The required    |                                                                    |
|              |recovery rate is 80%~115%, and the|                                                                    |
|              |RSD of the recovery rate of each  |                                                                    |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 285 of 542 





Page 286
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 





















---------------------------------------------------------------
|Impurities             |Repeatability|Intermediate|Precision |
|                       |             |precision   |          |
|-----------------------|-------------|------------|----------|
|YA2304-52              |1.2%, n=6    |1.1%, n=6   |1.1%, n=12|
|-----------------------|-------------|------------|----------|
|Imidazole              |0.9%, n=6    |1.1%, n=6   |1.8%, n=12|
|-----------------------|-------------|------------|----------|
|4-dimethylaminopyridine|1.6%, n=6    |1.3%, n=6   |2.2%, n=12|
---------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
|              |impurity is NMT 10%.              |                                                                    |
|--------------|----------------------------------|--------------------------------------------------------------------|
|Precisio n    |Repeatability and intermediate    |Impurities Repeatability Intermediate precision Precision YA2304-52 |
|              |precision: the RSD of each        |1.2%, n=6                                                           |
|              |impurity                          |1.1%, n=6 1.1%, n=12 Imidazole 0.9%, n=6 1.1%, n=6 1.8%, n=12       |
|              |in 6 repeatability (or            |4-dimethylaminopyridine 1.6%, n=6 1.3%, n=6 2.2%, n=12              |
|              |intermediate                      |                                                                    |
|              |precision test product) solution  |                                                                    |
|              |NMT                               |                                                                    |
|              |10%. Precision: Repeatability and |                                                                    |
|              |intermediate precision 12 test    |                                                                    |
|              |results, each impurity content RSD|                                                                    |
|              |NMT 10%.                          |                                                                    |
|--------------|----------------------------------|--------------------------------------------------------------------|
|Solutio n     |Each solution was placed in a 5℃ |Control solution: Within 48 h of being placed in a 5℃injector, the |  
|stability     |injector, and the control solution|separation                                                          |
|              |and the test solution were        |degree between imidazole peak and YA2304-52 peak was NLT 1.9        |
|              |injected                          |(required to be                                                     |
|              |at different times. The separation|NLT 1.5), and the RSD of each impurity peak area was not more than  |
|              |degree between imidazole peak and |1.6%                                                                |
|              |YA2304-52 peak in the control     |(required to be no more than 5%); The above all met the verification|
|              |solution NLT 1.5, and the RSD of  |requirements, indicating that the control solution was stable within|
|              |the                               |48h after                                                           |
|              |peak area of each impurity peak   |being placed in the 5℃injector. Test product solution: YA2304-52,  | 
|              |should be no more than 5%; The    |imidazole and                                                       |
|              |RSDS                              |4-dimethylaminopyridine (DMAP) were not detected within 44h after   |
|              |of all impurities in the test     |being placed                                                        |
|              |solution NMT 10%, and no new      |in the sample injector at 5℃, and no other impurity peaks affecting| 
|              |impurities to be measured         |the                                                                 |
|              |(YA2304-52, imidazole,            |detection of the above three impurities were detected; The results  |
|              |4-dimethylaminopyridine) should be|indicated                                                           |
|              |detected.                         |that the test solution was stable within 44h after being placed in  |
|              |                                  |the 5℃                                                             | 
|              |                                  |injector. The above solutions do not need new preparation for       |
|              |                                  |temporary use.                                                      |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 286 of 542 





Page 287
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4.3.3 Methodological verification of Enantiomers of finished** 


**products** 



**I. Analytical Procedures** 



Please refer to the analytical procedures of Enantiomers in Finerenone in 



_section 3.2.S.4.2_ . 



**II. Validation Results and Discussion** 



**a. Wavelength selection** 



 **Acceptance Criteria** 



The selection of detection wavelength requires UV scanning of impurity 



YA2304-20 at 200nm ~ 400nm wavelength, impurity YA2304-20 should have 



greater absorption at 251nm. 



 **Solution preparation** 



Solvent: acetonitrile: water (30:70，v/v) 



Blank solution: solvent. 



Reserve liquid of reference product: Take YA2304-20 about 7.5mg of 



reference product, accurately weigh it, place it in a 50ml measuring bottle, 



add appropriate amount of solvent to dissolve by ultrasound, cool it, dilute it 



with solvent to scale, shake well, and then get. (Approx. 150μg/ml) 



Control product solution: accurately measure 1ml of the control product 



reserve solution, place it in a 100ml measuring bottle, dilute it with solvent to 



the scale, shake well, and get. 



 **Injection procedure** 



After the blank solution, 1 needle of the mixed control solution was injected 



and the chromatogram was recorded. 



 **Measurement results** 



Name of Test Retention time Maximum absorption wavelength (nm) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 287 of 542 





Page 288
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-----------------------------------------------------------------------------------
|solution  |substance            |(min)                |                          |
|----------|---------------------|---------------------|--------------------------|
|Reference |YA2304-2 0           |25.626               |205.9, 250.8, 292.4, 340.3|
|solution  |                     |                     |                          |
|----------|---------------------|                     |                          |
|Spectrogra|                                                                      |
|m of      |                                                                      |
|reference |                                                                      |
|solution  |                                                                      |
|----------|----------------------------------------------------------------------|
|Conclusio |Impurity YA2304-20 has a large absorption at 251nm, which meets       |
|n         |the verification requirements                                         |
-----------------------------------------------------------------------------------

**(4.2) System suitability** 



 **Acceptance Criteria** 



The blank solution should be free of interference; The separation degree 



between the main peak and YA2304-20 peak in the chromatogram of system 



suitability solution should be greater than 1.5; In the chromatogram 



obtained for 6 consecutive days, the signal-to-noise ratio (S/N) of YA2304-20 



peak should NLT 30, the RSD of the retention time NMT 1.0%, and the RSD of 



the peak area NMT 5%. 



 **Solution Preparation** 



Blank solution: solvent. 



Reference product reserve solution: Prepare the reference product reserve 



solution according to "4.1 wavelength selection" under the same method. 



Reference solution: prepared in the same way as the reference solution under 



"4.1 wavelength selection". 



System suitability solution: Take YA2304 reference product about 20mg, 



accurately weigh it, place it in a 20ml measuring bottle, dissolve it with the 



reference product solution and dilute it to the scale, shake well, and then get 



it. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 288 of 542 





Page 289
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



 **Injection procedure** 



After the instrument is balanced, 1 needle of blank solution is injected, 1 



needle of system suitability solution is injected, and 6 needles of control 



solution are injected continuously. 



 **Measurement results** 































------------------------------------------------------------------------------
|Name of solution|Sample        |Separation degree of main peak from         |
|                |number        |YA2304-20 peak                              |
|----------------|--------------|--------------------------------------------|
|System          |1             |3.0                                         |
|suitability     |              |                                            |
|solution        |              |                                            |
|----------------|--------------|--------------------------------------------|
|Reference       |Sample        |Retention time|Peak area     |Signal-to-nois|
|solution        |number        |(min)         |              |e ratio       |
|                |--------------|--------------|--------------|--------------|
|                |1             |24.926        |23887         |80.8          |
|                |--------------|--------------|--------------|--------------|
|                |2             |24.933        |23768         |72.6          |
|                |--------------|--------------|--------------|--------------|
|                |3             |24.922        |23570         |76.0          |
|                |--------------|--------------|--------------|--------------|
|                |4             |24.926        |23907         |72.3          |
|                |--------------|--------------|--------------|--------------|
|                |5             |24.882        |23670         |71.5          |
|                |--------------|--------------|--------------|--------------|
|                |6             |24.912        |23708         |83.4          |
|                |--------------|--------------|--------------|--------------|
|                |RSD%(n=6)     |0.08          |0.6           |/             |
|----------------|--------------|--------------|--------------|--------------|
|Conclusion: The blank solution has no interference; The separation degree   |
|between YA2304-20 peak and main peak in the system applicability solution   |
|is 3.0 (the requirement should NLT 1.5). In the chromatogram obtained from  |
|the control product solution, the signal-to-noise ratio of the main peak    |
|was between 71.5 and 83.4 (the requirement should be NLT 30); The RSD of    |
|peak retention time of YA2304-20 in the photoproduct solution for 6         |
|consecutive days was 0.08% (the requirement should NMT 1.0%); The RSD of    |
|peak area is 0.6% (the requirement should NMT 5%); All meet the             |
|verification requirements. It shows that this method has good system        |
|applicability.                                                              |
------------------------------------------------------------------------------

**(4.3) Specificity** 



**(4.3.1) Peak identification test** 



 **Acceptance Criteria** 



The blank solution should be free of interference; The separation degree 



between the main peak and YA2304-20 peak in the system suitability 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 289 of 542 





Page 290
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



solution should be greater than 1.5; The peak signal-to-noise ratio (S/N) of 



YA2304-20 in the chromatogram of reference solution should NLT 30; The 



separation degree between YA2304-20 peaks and adjacent peaks in the 



chromatogram of test solution and specific mixed solution should be greater 



than 1.5, and the retention time should be consistent with the peak retention 



time of YA2304-20 in the chromatogram of control solution. Other single 



impurity localization solutions do not interfere with YA2304-20 peak 



production. 



 **Solution preparation** 



Blank solution: solvent. 



Reference stock solution: Share reference stock solution under "4.2 System 



Suitability". 



Reference solution: Prepare the reference solution in the same way as the 



reference solution under "4.1 wavelength selection". 



System suitability solution: Share system suitability solution under "4.2 



System Suitability". 



YA2304 reference product reserve liquid: Take about 7.5mg of this product, 



accurately weigh it, place it in a 50ml measuring bottle, add an appropriate 



amount of solvent to dissolve with ultrasound, cool it, dilute it with solvent to 



the scale, shake well, and then get. 



YA2304 positioning solution: precisely measure 1ml of YA2304 reference 



product reserve solution, place it in 100ml measuring bottle, dilute it with 



solvent to scale, shake well, ready. 



Test product solution: Take about 20mg of this product, weigh it accurately, 



put it in a 20ml measuring bottle, dissolve it with solvent and dilute it to the 



scale, shake well, ready. 



Specific mixed solution: Take about 20mg of this product, accurately weigh it, 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 290 of 542 





Page 291
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



put it in a 20ml measuring bottle, dissolve it with the control product 



solution and dilute it to the scale, shake well, ready. 



YA2304-10 Reference product reserve liquid: Take YA2304-10 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with solvent and dilute to the scale, shake well, ready. (Approx. 



200μg/ml) 



YA2304-12 reference product reserve liquid: Take YA2304-12 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with solvent and dilute to scale, shake well, and then obtain. (Approx. 



200μg/ml) 



YA2304-14 reference product reserve liquid: Take YA2304-14 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with acetonitrile and dilute to scale, shake well, and then obtain. 



(Approx. 200μg/ml) 



YA2304-15 reference product reserve liquid: Take YA2304-15 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with acetonitrile and dilute to scale, shake well, and then obtain. 



(Approx. 200μg/ml) 



YA2304-16 reference product reserve liquid: Take YA2304-16 reference 



product about 5mg, accurately weigh, place in 25ml bottle, dissolve with 



acetonitrile and dilute to scale, shake well, ready. (Approx. 200μg/ml) 



YA2304-17 reference product reserve liquid: Take YA2304-17 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with solvent and dilute to scale, shake well, and then obtain. (Approx. 



200μg/ml) 



YA2304-18 reference product reserve liquid: Take YA2304-18 reference 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with acetonitrile and dilute to scale, shake well, and then obtain. 



(Approx. 200μg/ml) 



YA2304-19 reference product reserve liquid: Take YA2304-19 reference 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 291 of 542 





Page 292
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



product about 5mg, accurately weigh, put into 25ml measuring bottle, 



dissolve with acetonitrile and dilute to scale, shake well, then obtain. (Approx. 



200μg/ml) 



YA2304-10 positioning solution: Accurately measure 0.75ml of YA2304-10 



reference product reserve into 100ml measuring bottle, dilute with solvent to 



scale, shake well, and then obtain. 



YA2304-12 positioning solution: precisely measure 0.75ml of YA2304-12 



reference storage solution into 100ml measuring bottle, dilute it with solvent 



to scale, shake well, ready. 



YA2304-14 positioning solution: precisely measure 0.75ml of YA2304-14 



reference storage solution into 100ml measuring bottle, dilute with solvent to 



scale, shake well, ready. 



YA2304-15 positioning solution: precisely measure 0.75ml of YA2304-15 



reference product storage solution into 100ml measuring bottle, dilute with 



solvent to scale, shake well, ready. 



YA2304-16 positioning solution: precisely measure 0.75ml of YA2304-16 



reference storage solution into 100ml measuring bottle, dilute with solvent to 



scale, shake well, ready. 



YA2304-17 positioning solution: precisely measure 0.75ml of YA2304-17 



reference storage solution into 100ml measuring bottle, dilute with solvent to 



scale, shake well, ready. 



YA2304-18 positioning solution: precisely measure 0.75ml of YA2304-18 



reference storage solution into 100ml measuring bottle, dilute with solvent to 



scale, shake well, ready. 



YA2304-19 positioning solution: precisely measure 0.75ml of YA2304-19 



reference product storage solution into 100ml measuring bottle, dilute with 



solvent to scale, shake well, ready. 



 **Injection Sequence** 



After the instrument is balanced, 1 needle is injected into blank solution, 1 



needle is injected into system suitability solution, 1 needle is injected into 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 292 of 542 





Page 293
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



reference solution, 1 needle is injected into test solution, 1 needle is injected 



into specific mixed solution, and the other positioning solutions are injected 



into 1 needle respectively. 



 **Measurement results** 



































































-----------------------------------------------------------------------------------------
|Solution name        |Componen t  |Concentration|Rt (min)    |Separa      |S/N         |
|                     |name        |(μg/ml)     |            |tion        |            | 
|---------------------|------------|-------------|------------|------------|------------|
|System suitability   |YA2304      |1021.2271    |20.180      |3.0         |/           |
|solution             |            |             |            |            |            |
|                     |------------|-------------|------------|            |            |
|                     |YA2304-20   |1.4983       |24.852      |            |            |
|---------------------|------------|-------------|------------|------------|------------|
|Reference solution   |YA2304-20   |1.4983       |24.858      |/           |62.2        |
|---------------------|------------|-------------|------------|------------|------------|
|YA2304 Locate        |YA2304      |1.5559       |20.240      |/           |/           |
|solution             |            |             |            |            |            |
|---------------------|------------|-------------|------------|------------|------------|
|YA2304-10 Locates the|YA2304-10   |1.5534       |3.906       |/           |/           |
|solution             |            |             |            |            |            |
|---------------------|------------|-------------|------------|------------|------------|
|YA2304-12 Locate the |YA2304-12   |1.4942       |5.627       |/           |/           |
|solution             |            |             |            |            |            |
|                     |            |             |------------|------------|------------|
|                     |            |             |5.935       |/           |/           |
|---------------------|------------|-------------|------------|------------|------------|
|YA2304-14 Locate the |YA2304-14   |1.5137       |15.696      |/           |/           |
|solution             |            |             |            |            |            |
|                     |            |             |------------|------------|------------|
|                     |            |             |18.853      |/           |/           |
|---------------------|------------|-------------|------------|------------|------------|
|YA2304-15 Locate the |YA2304-15   |1.5366       |22.827      |/           |/           |
|solution             |            |             |            |            |            |
|                     |            |             |------------|------------|------------|
|                     |            |             |27.493      |/           |/           |
|---------------------|------------|-------------|------------|------------|------------|
|YA2304-16 Locate the |YA2304-16   |1.4226       |11.400      |/           |/           |
|solution             |            |             |            |            |            |
|                     |            |             |------------|------------|------------|
|                     |            |             |12.070      |/           |/           |
|---------------------|------------|-------------|------------|------------|------------|
|YA2304-17 Locate the |YA2304-17   |1.5798       |4.505       |/           |/           |
|solution             |            |             |            |            |            |
|---------------------|------------|-------------|------------|------------|------------|
|YA2304-18 Locate the |YA2304-18   |1.5268       |15.456      |/           |/           |
|solution             |            |             |            |            |            |
|                     |            |             |------------|------------|------------|
|                     |            |             |15.956      |/           |/           |
|---------------------|------------|-------------|------------|------------|------------|
|YA2304-19 Locate the |YA2304-19   |1.5790       |18.768      |/           |/           |
|solution             |            |             |            |            |            |
|                     |            |             |------------|------------|------------|
|                     |            |             |21.475      |/           |/           |
|---------------------|------------|-------------|------------|------------|------------|
|Sample solution      |YA2304      |1003.6000    |20.182      |3.0         |/           |
|                     |------------|-------------|------------|            |------------|
|                     |YA2304-20   |/            |24.794      |            |/           |
|---------------------|------------|-------------|------------|------------|------------|
|Specific mixed       |YA2304      |1033.1000    |20.183      |3.0         |/           |
|solution             |            |             |            |            |            |
|                     |------------|-------------|------------|            |------------|
|                     |YA2304-20   |1.4983       |24.872      |            |/           |
|---------------------|------------|-------------|------------|------------|------------|
|Conclusion: Blank solution has no interference; The separation degree                  |
|between YA2304-20 peak and main peak in the system applicability solution              |
|is 3.0 (the requirement should NLT 1.5). In the chromatogram obtained from             |
|the control solution, S/N was 62.2 (the requirement should NLT 30); The                |
|separation degree                                                                      |
-----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 293 of 542 





Page 294
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



between YA2304-20 peaks and adjacent peaks in the specific mixed solution and the 



test solution was greater than 1.5, and the retention time was consistent with that of 



YA2304-20 peaks in the chromatogram of the control solution. Impurities YA2304-12, 



YA2304-14, YA2304-15, YA2304-16, YA2304-18 and YA2304-19 all have a chiral 



center, so the above impurities all have two peaks under the current chromatographic 



conditions. Other single impurities (YA2304-10, YA2304-12, YA2304-14, YA2304-15, 



YA2304-16, YA2304-17, YA2304-18 and YA2304-19) do not interfere with the peak of 



YA2304-20; Meet the requirements of verification. 



**(4.3.2) Forced degradation test** 



 **Acceptance Criteria** 



The blank solution should be free of interference; The separation degree 



between the main peak and YA2304-20 peak in the system suitability 



solution should be greater than 1.5; The peak signal-to-noise ratio (S/N) of 



YA2304-20 in the chromatogram of reference solution should NLT 30; The 



degradation degree of principal component NMT 20% under each failure 



condition; After degradation, the separation degree of all impurities in the 



sample and YA2304-20 should NLT 1.0. 



 **Solution preparation** 



Blank solution: solvent. 



Reference product reserve solution: Prepare the reference product reserve 



solution according to "4.1 wavelength selection" under the same method. 



Reference solution: prepared in the same way as the reference solution under 



"4.1 wavelength selection". 



System suitability solution: prepared in the same way as system suitability 



solution under "4.1 wavelength selection". 



Undamaged test product solution: take about 20mg of this product, 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 294 of 542 





Page 295
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



accurately weigh it, place it in a 20ml measuring bottle, add an appropriate 



amount of solvent to dissolve by ultrasound, cool it, dilute it with solvent to 



the scale, shake well, and get. 



Acid destruction blank solution: take 2ml of 0.1mol/L hydrochloric acid 



solution, place it in 20ml measuring bottle, add 2ml of 0.1mol/L sodium 



hydroxide solution to neutralize it, dilute it with solvent to the scale, shake 



well, and get it. 



Acid destruction of test product solution: take about 20mg of this product, 



accurately weigh it, place it in 20ml bottle, add 2ml of 0.1mol/L hydrochloric 



acid solution at room temperature for destruction for 24h, add 2ml of 



0.1mol/L sodium hydroxide solution for neutralization, add an appropriate 



amount of solvent to dissolve by ultrasound, dilute it with solvent to the scale, 



shake well, and obtain. 



Alkali destruction blank solution: take 2ml of 0.1mol/L sodium hydroxide 



solution, place it in 20ml measuring bottle, add 2ml of 0.1mol/L hydrochloric 



acid solution to neutralize it, dilute it with solvent to the scale, shake well, 



and obtain. 



Alkali destruction test product solution: take about 20mg of this product, 



weigh it accurately, put it in 20ml measuring bottle, add 2ml of 0.1mol/L 



sodium hydroxide solution at room temperature for destruction for 24h, add 



2ml of 0.1mol/L hydrochloric acid solution for neutralization, add an 



appropriate amount of solvent to dissolve by ultrasound, dilute it with 



solvent to the scale, shake well, and obtain. 



Oxidizing destruction of blank solution: take 2ml of 3% hydrogen peroxide 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 295 of 542 





Page 296
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



solution, place it in 20ml measuring bottle, dilute it with solvent to the scale, 



shake well, and obtain. 



Oxidizing destruction of test product solution: Take about 20mg of this 



product, weigh it accurately, put it in 20ml bottle, add 2ml of 3% hydrogen 



peroxide solution and destroy it at room temperature for 24h, add an 



appropriate amount of solvent and ultrasonic to dissolve it, dilute it with 



solvent to the scale, shake well, and obtain. 



High temperature destruction of the test product solution: accurately weigh 



about 20mg of this product damaged for 5 days at 105℃, place it in a 20ml 



measuring bottle, add an appropriate amount of solvent and ultrasonic to 



dissolve it, dilute it with solvent to the scale, shake well, and obtain. 



Light damage test product solution: accurately weigh about 20mg of this 



product after 20 days of damage under light (25±2℃, 4500±500Lux, 



90±5μWcm [2] ), place it in a 20ml bottle, add an appropriate amount of solvent 



to dissolve by ultrasound, dilute it with solvent to the scale, shake well, and 



obtain. 



 **Injection Sequence** 



After the instrument balance, blank solution, system suitability solution, 



reference solution, undamaged test product solution, acid damage blank 



solution, alkali damage blank solution, oxidation damage blank solution, 



acid damage test product solution, alkali damage test product solution, 



oxidation damage test product solution, high temperature damage test 



product solution, light damage test product solution into 1 needle each. 



 **Test result** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 296 of 542 





Page 297
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 





































--------------------------------------------------------------------------------------------
|Name of solution   |Damage conditions     |YA2304-20      |Degree of      |S/N            |
|                   |                      |degree of      |degradati      |               |
|                   |                      |peak           |on of          |               |
|                   |                      |separation     |principal      |               |
|                   |                      |from           |compone nt     |               |
|                   |                      |adjacent       |               |               |
|-------------------|----------------------|---------------|---------------|---------------|
|System suitability |/                     |2.6            |/              |/              |
|solution           |                      |               |               |               |
|-------------------|----------------------|---------------|---------------|---------------|
|Reference solution |/                     |/              |/              |33.7           |
|-------------------|----------------------|---------------|---------------|---------------|
|Undamaged test     |/                     |/              |/              |/              |
|product solution   |                      |               |               |               |
|-------------------|----------------------|---------------|---------------|---------------|
|Acid destroys test |Destroy 2ml of        |/              |1.25           |/              |
|solution           |0.1mol/L              |               |               |               |
|                   |hydrochloric acid     |               |               |               |
|                   |solution for 24h      |               |               |               |
|-------------------|----------------------|---------------|---------------|---------------|
|Alkali destroys the|Destroy 2ml of        |/              |/              |/              |
|test solution      |0.1mol/L sodium       |               |               |               |
|                   |hydroxide solution    |               |               |               |
|                   |for 24h               |               |               |               |
|-------------------|----------------------|---------------|---------------|---------------|
|Destroy the test   |2ml 3% hydrogen       |/              |5.18           |/              |
|product solution by|peroxide solution     |               |               |               |
|oxidation          |was destroyed at      |               |               |               |
|                   |room temperature for  |               |               |               |
|                   |24h                   |               |               |               |
|-------------------|----------------------|---------------|---------------|---------------|
|The test product   |105℃damage for 5     |/              |/              |/              | 
|solution was       |days                  |               |               |               |
|destroyed at high  |                      |               |               |               |
|temperature        |                      |               |               |               |
|-------------------|----------------------|---------------|---------------|---------------|
|Light destroyed the|Light damage (25±2 °|/              |0.18           |/              |  
|test solution      |C, 4500±500Lux,      |               |               |               | 
|                   |90±5μWcm2) for 20   |               |               |               |  
|                   |days                  |               |               |               |
|-------------------|                      |               |               |               |
|Conclusion: The blank solution has no interference; The system                            |
|applicability meets the requirements; The degradation degree of principal                 |
|components was 1.25% under acid damage, 5.18% under oxidation damage, 0.18%               |
|under light damage, and alkali damage and high temperature damage did not                 |
|degrade principal components. Impurity YA2304-20 was not degraded under the               |
|conditions of acid, alkali, oxidation, high temperature and light.                        |
--------------------------------------------------------------------------------------------

**(4.4) Limits of quantification and detection** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 297 of 542 





Page 298
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



 **Acceptance Criteria** 



The signal to noise ratio (S/N) of each impurity peak in 6 LOQ solutions 



should NLT 10, the RSD of retention time should not be more than 2.0%, and 



the RSD of peak area should not be more than 10%. 



The SNR (S/N) of each impurity peak in the 3-pin detection limit (LOD) 



solution should NLT 3. 



 **Solution preparation** 



Blank solution: solvent. 



Reference stock solution: Share reference stock solution under "4.2 System 



Suitability". 



Reference stock solution YA2304: Share reference stock solution YA2304 



under "4.3.1 Peak Identification Test". 



LOQ solution: Accurately measure 1ml of YA2304 reference product reserve 



solution and 1ml of reference product reserve solution, place in the same 



100ml bottle, dilute to scale with solvent, and shake well; Accurately 



measure 5ml of the solution into 25ml measuring bottle, dilute it with solvent 



to the scale, shake well, and then get. (Dispense 6 parts in parallel) 



LOD solution: Accurately measure the first part of limited quantification 



solution 3ml, place it in a 10ml measuring bottle, dilute it with solvent to the 



scale, shake well, and then get. 



 **Injection Sequence** 



After the balance of the instrument, 1 needle was injected into the blank 



solution, 1 needle was injected into the 6 parts of limited quantitation 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 298 of 542 





Page 299
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



solution, and 3 needles were injected into the detection limited solution 



continuously. 



 **Measurement results** 



Results of limit of quantitation test 










































---------------------------------------------------------------------------------------
|Impurit   |Solution   |Concentr   |Equivalent to |Retentio n |Peak area  |S/N        |
|ies Name  |name       |ation      |the percentage|time /min  |           |           |
|          |           |/(μg/ml)  |/% of the     |           |           |           | 
|          |           |           |concentration |           |           |           |
|          |           |           |of the test   |           |           |           |
|          |           |           |product       |           |           |           |
|          |           |           |solution      |           |           |           |
|----------|-----------|-----------|--------------|-----------|-----------|-----------|
|YA230 4   |LOQ        |0.3112     |0.03          |20.404     |4914       |18.6       |
|          |solution 1 |           |              |           |           |           |
|          |-----------|           |              |-----------|-----------|-----------|
|          |LOQ                    |              |20.366     |4939       |18.9       |
|          |Solution 2             |              |           |           |           |
|          |-----------------------|              |-----------|-----------|-----------|
|          |LOQ                    |              |20.410     |5091       |19.9       |
|          |solution 3             |              |           |           |           |
|          |-----------------------|              |-----------|-----------|-----------|
|          |LOQ                    |              |20.408     |5200       |17.6       |
|          |Solution 4             |              |           |           |           |
|          |-----------------------|              |-----------|-----------|-----------|
|          |LOQ                    |              |20.355     |4823       |19.1       |
|          |Solution 5             |              |           |           |           |
|          |-----------------------|              |-----------|-----------|-----------|
|          |LOQ                    |              |20.424     |4925       |15.8       |
|          |solution 6             |              |           |           |           |
|          |-----------------------|--------------|-----------|-----------|-----------|
|          |RSD%                                  |0.14       |2.8        |/          |
|          |--------------------------------------|-----------|-----------|-----------|
|          |Conclusion: The concentration of YA2304 in LOQ solution is 0.3112         |
|          |μg/ml, which is equivalent to 0.03% of the concentration of test         | 
|          |product. The S/N of YA2304 peak in 6 LOQ solution spectra ranges          |
|          |from 15.8 to 19.9 (the requirement should be NLT 10), and the RSD         |
|          |of retention time is 0.14% (the requirement should be no more than        |
|          |2.0%). The RSD of the peak area was 2.8% (the requirement should          |
|          |NMT 10%), which met the verification requirements.                        |
|----------|--------------------------------------------------------------------------|
|YA230 4-20|LOQ        |0.2997     |0.03          |25.100     |4859       |14.2       |
|          |Solution 1 |           |              |           |           |           |
|          |-----------|           |              |-----------|-----------|-----------|
|          |LOQ                    |              |25.149     |4747       |14.1       |
|          |Solution 2             |              |           |           |           |
|          |-----------------------|              |-----------|-----------|-----------|
|          |LOQ                    |              |25.151     |4791       |15.1       |
|          |Solution 3             |              |           |           |           |
|          |-----------------------|              |-----------|-----------|-----------|
|          |LOQ                    |              |25.076     |4581       |12.8       |
|          |Solution 4             |              |           |           |           |
|          |-----------------------|              |-----------|-----------|-----------|
|          |LOQ                    |              |25.078     |4797       |14.5       |
|          |Solution 5             |              |           |           |           |
|          |-----------------------|              |-----------|-----------|-----------|
|          |LOQ                    |              |25.020     |4727       |12.2       |
|          |solution 6             |              |           |           |           |
|          |-----------------------|--------------|-----------|-----------|-----------|
|          |RSD%                                  |0.20       |2.0        |/          |
|          |--------------------------------------|-----------|-----------|-----------|
|          |Verdict: The concentration of YA2304-20 in LOQ solution was 0.2997        |
|          |μg/ml, equivalent to 0.03% of the concentration of test product.         | 
|          |The S/N of YA2304-20 peaks in 6 LOQ solution spectra ranged from          |
|          |12.2 to 15.1 (the requirement should be NLT 10), and the RSD of           |
|          |retention time was 0.20% (the requirement should be no more than          |
|          |2.0%). The RSD of the peak area was 2.0% (the requirement should          |
|          |NMT 10%), which met the verification requirements.                        |
---------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 299 of 542 





Page 300
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Detection limit test results 













































----------------------------------------------------------------------------------------
|Impurit   |LOD        |Concentr   |Equivalent to a|Retentio n |Peak area  |S/N        |
|ies Name  |solution   |ation      |percentage /%  |time /min  |           |           |
|          |injection  |/(μg/ml)  |of the         |           |           |           | 
|          |           |           |concentration  |           |           |           |
|          |           |           |of the test    |           |           |           |
|          |           |           |product        |           |           |           |
|----------|-----------|-----------|---------------|-----------|-----------|-----------|
|YA230 4   |1          |0.0934     |0.01           |20.443     |1503       |6.3        |
|          |-----------|           |               |-----------|-----------|-----------|
|          |2                      |               |20.379     |1874       |7.5        |
|          |-----------------------|               |-----------|-----------|-----------|
|          |3                      |               |20.469     |1643       |6.9        |
|          |-----------------------|---------------|-----------|-----------|-----------|
|          |Conclusion: The concentration of YA2304 in LOD solution is 0.0934          |
|          |μg/ml, which is equivalent to 0.01% of the concentration of the           | 
|          |test product. The S/N of YA2304 peak in the 3-needle map is                |
|          |between 6.3 and 7.5 (the requirement should be NLT 3), which meets         |
|          |the verification requirements.                                             |
|----------|---------------------------------------------------------------------------|
|YA230 4-20|1          |0.0899     |0.01           |25.037     |1564       |5.2        |
|          |-----------|           |               |-----------|-----------|-----------|
|          |2                      |               |25.075     |1529       |5.4        |
|          |-----------------------|               |-----------|-----------|-----------|
|          |3                      |               |25.262     |1335       |4.7        |
|          |-----------------------|---------------|-----------|-----------|-----------|
|          |Conclusion: The concentration of YA2304-20 in LOD solution is              |
|          |0.0899 μg/ml, which is equivalent to 0.01% of the concentration of        | 
|          |the test product. The S/N of YA2304-20 peak in the 3-needle atlas          |
|          |is between 4.7 and 5.4 (the requirement should be NLT 3), which            |
|          |meets the verification requirements.                                       |
----------------------------------------------------------------------------------------

**(4.5) Linearity and range** 



 **Acceptance Criteria** 



Within the limit concentration range of YA2304-20 LOQ concentration ~ 



200%, 6 concentration points were selected as linear regression curves with 



the concentration as the horizontal coordinate and YA2304-20 peak area as 



the vertical coordinate. The regression coefficient (R) of the regression curve 



was NLT 0.990, and the RSD of the response factor NMT 10%. Y-axis 



intercept accounts for less than 25% of 100% response value. 



 **Solution preparation** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 300 of 542 





Page 301
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Blank solution: solvent. 



Reference stock solution: Share reference stock solution under "4.2 System 



Suitability". 



Reference stock solution YA2304: Share reference stock solution YA2304 



under "4.3.1 Peak Identification Test". 



Linear reserve liquid: precisely measure 1.0ml of the reference reserve liquid 



and 1.0ml of the YA2304 reference reserve liquid, place them in the same 



10ml measuring bottle, dilute them with solvent to the scale, and shake well 



to obtain. 



Linear solution 1 (LOQ solution) : prepared in the same way as the 



quantitative limit solution under "4.4 quantitative limit and detection limit". 



Linear solution 2 (40% limit solution) : accurately measure 0.4ml linear 



reserve solution, place it in 10ml measuring bottle, dilute it with solvent to 



the scale, shake well, and then obtain. 



Linear solution 3 (80% limit solution) : Accurately measure 0.8ml linear 



reserve solution, place it in 10ml measuring bottle, dilute it with solvent to 



the scale, shake well, and obtain. 



Linear solution 4 (100% limit solution) : precisely measure 1.0ml linear 



reserve solution, place it in 10ml measuring bottle, dilute it with solvent to 



the scale, shake well, and get. 



Linear solution 5 (150% limit solution) : precisely measure 1.5ml linear 



reserve solution, place it in 10ml measuring bottle, dilute it with solvent to 



the scale, shake well, and get. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 301 of 542 





Page 302
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Linear solution 6 (200% limit solution) : accurately measure 2ml linear 



reserve solution, place it in 10ml measuring bottle, dilute it with solvent to 



the scale, shake well, and get. 



 **Injection Sequence** 



After instrument balance, blank solution 1 needle, each linear solution from 



low concentration to high concentration 1 needle injection. 



 **Measurement results** 



Results of linear and range tests 
























--------------------------------------------------------------------
|Impuri   |Solution  |Equivalent to|Concentrati |Peak area|Response|
|ties Name|name      |test product |on /(μg/ml)|         |factor  | 
|         |          |solution     |            |         |        |
|         |          |concentration|            |         |        |
|         |          |percentage /%|            |         |        |
|---------|----------|-------------|------------|---------|--------|
|YA230 4  |Linear    |0.03         |0.3112      |5080     |16324.77|
|         |Solution 1|             |            |         |        |
|         |----------|-------------|------------|---------|--------|
|         |Linear    |0.06         |0.6224      |9791     |15731.87|
|         |solution 2|             |            |         |        |
|         |----------|-------------|------------|---------|--------|
|         |Linear    |0.12         |1.2447      |19328    |15527.81|
|         |Solution 3|             |            |         |        |
|         |----------|-------------|------------|---------|--------|
|         |Linear    |0.16         |1.5559      |24393    |15677.56|
|         |solution 4|             |            |         |        |
|         |----------|-------------|------------|---------|--------|
|         |Linear    |0.23         |2.3339      |36500    |15639.21|
|         |Solution 5|             |            |         |        |
|         |----------|-------------|------------|---------|--------|
|         |Linear    |0.31         |3.1118      |49358    |15861.37|
|         |solution 6|             |            |         |        |
|         |----------|-------------|------------|---------|--------|
|         |Response factor RSD/%   |1.8                            |
|         |------------------------|-------------------------------|
|         |Linear graph            |                               |
--------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 302 of 542 





Page 303
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 






















----------------------------------------------------------------------------------
|          |Linear equations           |Y = 15788-79.892 x                       |
|          |---------------------------|-----------------------------------------|
|          |Correlation coefficient R  |0.9999                                   |
|          |---------------------------|-----------------------------------------|
|          |Absolute Y-axis intercept  |0.34                                     |
|          |percentage /% of 100%      |                                         |
|          |response value             |                                         |
|          |---------------------------|-----------------------------------------|
|          |Conclusion: YA2304 is in the range of 0.3112~3.1118 μg/ml, the      | 
|          |linear equation is y=15788x-79.892, R=0.9999 (should NLT 0.990),     |
|          |the response factor RSD is 1.8% (should not be more than 10%). The   |
|          |absolute value of Y-axis intercept accounts for 0.34% of 100%        |
|          |response value (NMT 25%), indicating that YA2304 detected by this    |
|          |method has a good linear relationship in the range of 0.3112~3.1118  |
|          |μg/ml.                                                              | 
|----------|---------------------------------------------------------------------|
|YA230 4-20|Linear       |0.03         |0.2997       |4602         |15357.23     |
|          |Solution 1   |             |             |             |             |
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.06         |0.5993       |9081         |15152.00     |
|          |Solution 2   |             |             |             |             |
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.12         |1.1987       |18112        |15110.29     |
|          |Solution 3   |             |             |             |             |
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.15         |1.4983       |22706        |15154.34     |
|          |solution 4   |             |             |             |             |
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.22         |2.2475       |33698        |14993.71     |
|          |Solution 5   |             |             |             |             |
|          |-------------|-------------|-------------|-------------|-------------|
|          |Linear       |0.30         |2.9966       |45656        |15235.76     |
|          |solution 6   |             |             |             |             |
|          |-------------|-------------|-------------|-------------|-------------|
|          |Response factor RSD/%      |0.9                                      |
|          |---------------------------|-----------------------------------------|
|          |Linear graph               |                                         |
|          |---------------------------|-----------------------------------------|
|          |Linear equations           |Y = 15161-28.894 x                       |
|          |---------------------------|-----------------------------------------|
|          |Correlation coefficient R  |0.9999                                   |
|          |---------------------------|-----------------------------------------|
|          |Absolute Y-axis intercept  |0.13                                     |
|          |percentage /% of 100%      |                                         |
|          |response value             |                                         |
|          |---------------------------|-----------------------------------------|
|          |Conclusion: YA2304-20 in the range of 0.2997~2.9966 μg/ml, the      | 
|          |linear equation is y=15161x-28.894, R=0.9999 (should NLT 0.990),     |
|          |the response factor RSD is 0.9% (should not be more than 10%). The   |
|          |absolute value of                                                    |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 303 of 542 





Page 304
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Y-axis intercept accounts for 0.13% of 100% response value (NMT 25%), 



indicating that YA2304-20 detected by this method has a good linear 



relationship in the range of 0.2997~2.9966 μg/ml. 



**(4.6) Accuracy** 



 **Brief Description** 



Accuracy is achieved by determining the ratio (recovery rate) between the 



actual detected amount and the theoretical amount of YA2304-20 reference 



product added to the test product at different concentrations (30% to 150% 



limit concentration). It is required that the signal to noise ratio (S/N) of 



YA2304-20 peak in the chromatogram of the reference product should NLT 



30; The 30% limit concentration recovery rate should be between 85% and 



110%, the 100% to 150% limit concentration recovery rate should be 



between 90% and 108%, and the RSD of the recovery rate of 9 recovery 



samples NMT 10%. 



 **Solution preparation** 



Blank solution: solvent. 



Test product solution: Take about 20mg of this product, weigh it accurately, 



place it in a 20ml measuring bottle, add an appropriate amount of solvent to 



dissolve by ultrasound, cool it, dilute it with solvent to the scale, shake well, 



and then get. (Parallel preparation of 2 parts) 



Reference product reserve liquid: The reference product reserve liquid 



under "4.1 wavelength selection" is prepared in the same way. 



Reference solution: prepared in the same way as the reference solution 



under "4.1 wavelength selection". 



System suitability solution: Share system suitability solution under "4.2 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 304 of 542 





Page 305
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



System Suitability". 



Reserve solution with sample recovery rate: accurately measure 2.5ml of 



the control product reserve solution, place it in a 25ml measuring bottle, 



dilute it with solvent to the scale, shake well, and then obtain. 



30% sample recovery solution: take about 20mg of this product, 



accurately weigh it, put it in a 20ml bottle, add an appropriate amount of 



solvent to dissolve by ultrasound, cool it, accurately add 0.6ml of sample 



recovery liquid, dilute it with solvent to the scale, shake well, and get. 



(Dispense 3 parts in parallel) 



100% sample recovery solution: Take about 20mg of this product, weigh 



it accurately, place it in a 20ml measuring bottle, add an appropriate amount 



of solvent to dissolve by ultrasound, cool it, accurately add the reserve liquid 



with sample recovery rate of 2.0ml, dilute it with solvent to the scale, shake 



well, and get. (Dispense 3 parts in parallel) 



150% sample recovery solution: Take about 20mg of this product, weigh 



it accurately, place it in a 20ml measuring bottle, add an appropriate amount 



of solvent to dissolve by ultrasound, cool it, accurately add the reserve liquid 



with sample recovery rate of 3.0ml, dilute it with solvent to the scale, shake 



well, and get. (Dispense 3 parts in parallel) 



 **Injection procedure** 



After the balance of the instrument, 1 needle was injected into the blank 



solution, 1 needle was injected into the system suitability solution, 2 needles 



were injected into the control solution, 1 needle was injected into the test 



solution, and 1 needle was injected into the solution with each recovery rate. 



 **Measurement results** 
























------------------------------------------------------------------------
|Names of  |Solution name      |Quantity of|Amount  |Measured|Recover y|
|impuritie |                   |test       |added   |amount  |rate (%) |
|s         |                   |product    |(μg/ml)|(μg/ml)|         |  
|          |                   |detected   |        |        |         |
|          |                   |(μg/ml)   |        |        |         | 
|----------|-------------------|-----------|--------|--------|---------|
|YA2304-2 0|30% sample recovery|0.1465     |0.4587  |0.5893  |96.5     |
|          |solution 1         |           |        |        |         |
------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 305 of 542 





Page 306
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

---------------------------------------------------------------------------------
|       |30% addition       |0.1515      |0.4587      |0.5901      |95.6        |
|       |recovery solution 2|            |            |            |            |
|       |-------------------|------------|------------|------------|------------|
|       |30% addition       |0.1478      |0.4587      |0.5810      |94.5        |
|       |recovery solution 3|            |            |            |            |
|       |-------------------|------------|------------|------------|------------|
|       |100% sample        |0.1452      |1.5289      |1.6581      |99.0        |
|       |recovery solution 1|            |            |            |            |
|       |-------------------|------------|------------|------------|------------|
|       |100% addition      |0.1499      |1.5289      |1.6870      |100.5       |
|       |recovery solution 2|            |            |            |            |
|       |-------------------|------------|------------|------------|------------|
|       |100% addition      |0.1493      |1.5289      |1.6798      |100.1       |
|       |recovery solution 3|            |            |            |            |
|       |-------------------|------------|------------|------------|------------|
|       |150% addition      |0.1545      |2.2933      |2.4359      |99.5        |
|       |recovery solution 1|            |            |            |            |
|       |-------------------|------------|------------|------------|------------|
|       |150% addition      |0.1474      |2.2933      |2.4672      |101.2       |
|       |recovery solution 2|            |            |            |            |
|       |-------------------|------------|------------|------------|------------|
|       |150% addition      |0.1498      |2.2933      |2.4294      |99.4        |
|       |recovery solution 3|            |            |            |            |
|       |-------------------|------------|------------|------------|------------|
|       |Average recovery rate (%)                                 |98.5        |
|       |----------------------------------------------------------|------------|
|       |RSD (%)                                                   |2.4         |
|       |----------------------------------------------------------|------------|
|       |Verdict: YA2304-20 was added into the sample in the range of           |
|       |0.4587~2.2933 ug/ml. The recovery rate of the sample was               |
|       |94.5%~96.5% (the requirement was 85%~110%). 100%~150% recovery         |
|       |The sample recovery rate was 99.0%~101.2% (the requirement was         |
|       |90%~108%), the average recovery rate of 9 recovery samples was         |
|       |98.5%, and the recovery RSD was 2.4% (the requirement was not          |
|       |more than 10%), which met the verification requirements,               |
|       |indicating that the method was accurate.                               |
---------------------------------------------------------------------------------



**(4.7) Precision** 



Precision refers to the proximity between the results obtained by multiple 



sampling of the same uniform test product under specified test conditions, 



and its precision is judged by examining repeatability and reproducibility. 



**(4.7.1) Repeatability** 



 **Acceptance Criteria** 



6 repeatable sample solutions were prepared by Analyst A on date A and 



determined by instrument A. It is required that the separation degree 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 306 of 542 





Page 307
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



between the main peak and YA2304-20 in the chromatogram of system 



suitability solution should be greater than 1.5; The signal to noise ratio (S/N) 



of YA2304-20 peak in the chromatogram of reference solution should NLT 30; 



The RSD of YA2304-20 in 6 repetitive test solutions should NMT 10%. 



 **Solution Preparation** 



Blank solution: solvent. 



Reference stock solution: Share reference stock solution under "4.6 



Accuracy". 



Reference product solution: prepared in the same way as the reference 



product solution under "4.1 wavelength selection". 



System suitability solution: Share system suitability solution under "4.2 



System Suitability". 



Repeatable reserve solution: accurately measure 2.5ml of the control product 



reserve solution, place it in a 25ml measuring bottle, dilute it with solvent to 



the scale, shake well, and then obtain. 



Repeatable test solution: take about 20mg of this product, accurately weigh 



it, place it in 20ml measuring bottle, add an appropriate amount of solvent to 



dissolve by ultrasound, cool it, add 2.0ml repeatable reserve liquid precisely, 



dilute it with solvent to the scale, shake well, ready. (Parallel preparation of 6 



parts) 



 **Injection procedure** 



After the instrument is balanced, 1 needle is injected into blank solution, 1 



needle is injected into system suitability solution, 1 needle is injected into 



control solution, and 1 needle is injected into repeated test solution. 



 **Measurement results** 













------------------------------------------------------------
|Name of solution  |Number of |Degree of separation between|
|                  |injections|main peak and YA2304-20 peak|
|------------------|----------|----------------------------|
|System suitability|1         |3.0                         |
|solution          |          |                            |
------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 307 of 542 





Page 308
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 
















-----------------------------------------------------------------------------------
|Solution name        |Number of          |Signal-to-noise ratio                  |
|                     |injections         |                                       |
|---------------------|-------------------|---------------------------------------|
|Reference solution   |1                  |91.4                                   |
|                     |-------------------|---------------------------------------|
|           |         |2                  |68.2                                   |
|-----------|---------|-------------------|---------------------------------------|
|Repeat test|1        |2        |3        |4        |5        |6        |RSD/%    |
|product    |         |         |         |         |         |         |         |
|-----------|---------|---------|---------|---------|---------|---------|---------|
|YA2304-20  |0.17     |0.17     |0.17     |0.17     |0.17     |0.18     |2.5      |
|content /% |         |         |         |         |         |         |         |
|-----------|---------|---------|---------|---------|---------|---------|---------|
|Conclusion: The system applicability meets the requirements; The RSD of          |
|YA2304-20 in 6 repetitive test products was 2.5% (the requirement NMT 10%).      |
|It met the verification requirements, indicating that the method had good        |
|repeatability.                                                                   |
-----------------------------------------------------------------------------------

**(4.7.2) Reproducibility** 



 **Brief Description** 



6 reproducible sample solutions were prepared by QC personnel B on date B 



and determined by instrument B. It is required that the separation degree 



between the main peak and YA2304-20 peak in the chromatogram of system 



suitability solution should be greater than 1.5; The signal-to-noise ratio (S/N) 



of peak YA2304-20 in the chromatogram obtained for 6 consecutive days 



should NLT 30, the RSD of the retention time NMT 1.0%, and the RSD of the 



peak area NMT 5%. In 6 reproducible sample solutions, the RSD of 



YA2304-20 NMT 10%. 



For the results of 12 repeatability and reproducibility tests, the RSD of 



YA2304-20 NMT 10%. 



 **Solution preparation** 



Blank solution: solvent 



Reference stock solution: Share the reference stock solution under "4.6 



Accuracy". 



Reference product solution: prepared in the same way as the reference 



product solution under "4.1 wavelength selection". 



System suitability solution: the system suitability solution under "4.2 



System suitability" is prepared in the same way. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 308 of 542 





Page 309
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Reproducible reserve solution: accurately measure 2.5ml of the control 



product reserve solution, place it in a 25ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain 



Reproducible test solution: Take about 20mg of this product, accurately 



weigh it, place it in a 20ml measuring bottle, add an appropriate amount of 



solvent to dissolve by ultrasound, cool it, add 2.0ml of reproducible reserve 



liquid precisely, dilute it with solvent to the scale, shake well, and obtain. 



(Parallel preparation of 6 parts) 



 **Injection procedure** 



After the balance of the instrument, 1 needle was injected into the blank 



solution, 1 needle was injected into the system suitability solution, 6 needles 



were injected into the control solution continuously, and 1 needle was 



injected into each of the reproducible test solution. 



 **Measurement results** 



Reproducibility - system suitability test results 






























------------------------------------------------------------------------------
|Name of solution|Sample        |Separation degree of main peak from         |
|                |number        |YA2304-20 peak                              |
|----------------|--------------|--------------------------------------------|
|System          |1             |2.6                                         |
|suitability     |              |                                            |
|solution        |              |                                            |
|----------------|--------------|--------------------------------------------|
|Reference       |Sample        |Retention time|Peak area     |Signal-to-nois|
|solution        |number        |(min)         |              |e ratio       |
|                |--------------|--------------|--------------|--------------|
|                |1             |21.708        |26122         |49.3          |
|                |--------------|--------------|--------------|--------------|
|                |2             |21.699        |27518         |45.7          |
|                |--------------|--------------|--------------|--------------|
|                |3             |21.657        |26997         |41.9          |
|                |--------------|--------------|--------------|--------------|
|                |4             |21.674        |27146         |43.6          |
|                |--------------|--------------|--------------|--------------|
|                |5             |21.634        |27328         |41.4          |
|                |--------------|--------------|--------------|--------------|
|                |6             |21.659        |27296         |43.5          |
|                |--------------|--------------|--------------|--------------|
|                |RSD%(n=6)     |0.13          |1.9           |/             |
|----------------|--------------|--------------|--------------|--------------|
|Conclusion: The blank solution has no interference; The separation degree   |
|between YA2304-20 peak and the main peak in the system applicability        |
|solution is 2.6 (the requirement should NLT 1.5). In the chromatogram       |
|obtained from the control product solution, the signal-to-noise ratio of    |
|the main peak was between 41.4 and 49.3 (the requirement should NLT 30);    |
|The RSD of peak retention time of YA2304-20 for 6 consecutive days was      |
|0.13% (the requirement should be no more than 1.0%); The RSD% of peak area  |
|is 1.9% (the requirement should NMT 5%); All meet the verification          |
|requirements. It shows that this method has good system applicability.      |
------------------------------------------------------------------------------

Precision test results 



Results of repeatability test Reproducibility test results 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 309 of 542 





Page 310
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 






















-----------------------------------------------------------------------------
|Solution name     |YA2304-20         |Solution name     |YA2304-20         |
|                  |content /%        |                  |content /%        |
|------------------|------------------|------------------|------------------|
|Repeatable test   |0.17              |Reproducible test |0.17              |
|product solution  |                  |product solution 1|                  |
|1                 |                  |                  |                  |
|------------------|------------------|------------------|------------------|
|Reproducible      |0.17              |Reproducible test |0.16              |
|sample solution 2 |                  |product solution 2|                  |
|------------------|------------------|------------------|------------------|
|Repeatable sample |0.17              |Reproducible test |0.16              |
|solution 3        |                  |solution 3        |                  |
|------------------|------------------|------------------|------------------|
|Reproducible      |0.17              |Reproducible test |0.18              |
|sample solution 4 |                  |product solution 4|                  |
|------------------|------------------|------------------|------------------|
|Reproducible      |0.17              |Reproducible test |0.17              |
|sample solution 5 |                  |product solution 5|                  |
|------------------|------------------|------------------|------------------|
|Repeatable sample |0.18              |Reproducible test |0.18              |
|solution 6        |                  |product solution 6|                  |
|------------------|------------------|------------------|------------------|
|RSD/% (n=6)       |2.5               |RSD/% (n=6)       |5                 |
|------------------|------------------|------------------|------------------|
|Precision RSD/% (n=12)               |4                                    |
|-------------------------------------|-------------------------------------|
|Conclusion: The RSD of YA2304-20 in 6 reproducible samples was 5% (the     |
|requirement NMT 10%). The method met the requirements of verification,     |
|indicating good reproducibility of the method. The RSD of YA2304-20        |
|measured for 12 times of repeatability and reproducibility was 4% (the     |
|requirement NMT 10%), which met the verification requirements, indicating  |
|that the method had good precision.                                        |
-----------------------------------------------------------------------------

**(4.8) Solution stability** 



 **Brief Description** 



The system suitability solution, the control solution and the test product 



solution were placed at room temperature for a period of time, and the 



samples were injected at different time points. The separation degree 



between YA2304-20 peak and the main peak in the chromatogram of the 



system suitability solution should NLT 1.5; The peak signal-to-noise ratio 



(S/N) of YA2304-20 in the chromatogram of reference solution should NLT 30, 



and the RSD of peak area should not be more than 5%; In the chromatogram 



obtained by the test product solution, the RSD of YA2304-20 NMT 10% 



according to the peak area calculation by external standard method, and 



there shall be no new peak generation that interferes with the detection of 



YA2304-20. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 310 of 542 





Page 311
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



 **Solution preparation** 



Reference solution: Share the reference solution under "4.2 System 



Suitability". 



System Suitability solution: Share system suitability solution under "4.2 



System Suitability". 



Test product solution: Share test product solution under "4.3 Specificity 



- Peak identification". 



 **Injection Sequence** 



The system suitable solution was injected at 0h, 6h, 14.5h, 22h, 29h, 



49h, 3d, 4d and 5d respectively. (System suitability solution 0h is system 



suitability solution under "System suitability", system suitability solution 6h 



is system suitability solution under "particularity-peak identification", 



system suitability solution 3d is system suitability solution under the second 



"accuracy", system suitability solution 4d is system suitability solution 



under the third "accuracy". System suitability solution 5d is system 



suitability solution under "repeatability",) 



The control solution was injected at 0h, 6h, 14.5h, 22h, 29h and 49h, 



respectively. (Reference solution 0h was the reference solution under "system 



suitability", and reference solution 6h was the reference solution under 



"particularity-peak identification") 



Sample solution was injected at 0h, 8.5h, 16h and 23h, respectively. 



 **Measurement resultss** 



Stability test results of solution 






















---------------------------------------------------------------------------
|System suitability   |Reference solution          |Test product solution |
|solution             |                            |                      |
|---------------------|----------------------------|----------------------|
|Time point|Degree of |Point in|Peak area|Signal-  |Point in  |YA2304-20  |
|          |Separation|Time    |         |to-nois e|time      |content (%)|
|          |          |        |         |ratio    |          |           |
|----------|----------|--------|---------|---------|----------|-----------|
|0h        |3.0       |0h      |23887    |80.8     |0h        |0.0111     |
|----------|----------|--------|---------|---------|----------|-----------|
|6h        |3.0       |6h      |23747    |62.2     |8.5 h.    |0.0101     |
|----------|----------|--------|---------|---------|----------|-----------|
|14.5 h.   |3.0       |14.5 h. |23929    |77.2     |16h       |0.0112     |
|----------|----------|--------|---------|---------|----------|-----------|
|22h       |3.1       |22h     |23487    |80.3     |23h       |0.0091     |
|----------|----------|--------|---------|---------|----------|-----------|
|29h       |3.1       |29h     |23527    |62.7     |/         |/          |
|----------|----------|--------|---------|---------|----------|-----------|
|49h       |3.1       |49h     |23260    |74.6     |/         |/          |
---------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 311 of 542 





Page 312
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

------------------------------------------------------------------------------
|3d        |3.1       |/         |/         |/         |/         |/         |
|----------|----------|----------|----------|----------|----------|----------|
|4d        |3.0       |/         |/         |/         |/         |/         |
|----------|----------|----------|----------|----------|----------|----------|
|5d        |3.0       |/         |/         |/         |/         |/         |
|----------|----------|----------|----------|----------|----------|----------|
|RSD/%     |/         |/         |1.1       |/         |/         |10        |
|----------|----------|----------|----------|----------|----------|----------|
|Conclusion: Within 5 days at room temperature, the separation degree        |
|between YA2304-20 peaks and main peaks in the system suitability solution   |
|is greater than 1.5 (the requirement should be NLT 1.5), which meets the    |
|verification requirements, indicating that the system suitability solution  |
|is stable within 5 days at room temperature. Within 49h at room             |
|temperature, the RSD of YA2304-20 peaks in the control solution was 1.1%    |
|(not more than 10%). The peak-to-noise ratio of YA2304-20 was between 62.2  |
|and 80.3 (the requirement should NLT 30), which met the verification        |
|requirements, indicating that the control solution was stable within 49h at |
|room temperature. Within 23h at room temperature, the RSD of YA2304-20 in   |
|the test solution is 10% (the requirement NMT 10%), which meets the         |
|verification requirements, indicating that the test solution is stable      |
|within 23h at room temperature.                                             |
------------------------------------------------------------------------------



**(4.9) Durability** 



 **Acceptance Criteria** 



The separation degree between YA2304-20 peak and main peak should NLT 



1.5 when column temperature, wavelength, flow rate, initial ratio of mobile 



phase and normal chromatographic conditions are changed by single factor. 



The peak signal-to-noise ratio of YA2304-20 in the chromatogram of 



reference solution should NLT 30; RSD of YA2304-20 in test product solution 



shall NMT 10%. 



 **Solution Preparation** 



Blank solution: solvent. 



Reference stock solution: Share reference stock solution under "4.6 



Accuracy". 



Reference product solution: prepared in the same way as the reference 



product solution under "4.1 wavelength selection". 



System suitability solution: The system suitability solution under "4.2 



System Suitability" is prepared in the same way. 



Durable reserve solution: accurately measure 2.5ml of the reference product 



reserve solution, place it in a 25ml measuring bottle, dilute it with solvent to 



the scale, shake well, and then obtain. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 312 of 542 





Page 313
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Durability test solution: Take about 20mg of this product, accurately weigh it, 



put it in 20ml measuring bottle, add appropriate amount of solvent and 



ultrasonic to dissolve it, cool it, accurately measure 2.0ml of durable storage 



liquid, put it in the same 20ml measuring bottle, dilute it with solvent to the 



scale, shake well, and get it. (Parallel preparation of 2 parts) 



The variation of the condition parameters is as follows: 
















----------------------------------------------------------------------
|Chromatograph|Standard conditions   |Variable Values                |
|ic parameters|                      |                               |
|-------------|----------------------|-------------------------------|
|Column       |40 ℃                 |38℃, 42℃                     |   
|temperature  |                      |                               |
|-------------|----------------------|-------------------------------|
|Initial ratio|Mobile phase A- Mobile|Mobile phase A- Mobile phase B |
|of mobile    |phase B (70:30)       |(72:28), Mobile phase A- Mobile|
|phase        |                      |phase B (68:32)                |
|-------------|----------------------|-------------------------------|
|Flow rate    |1.0 ml/min            |0.95ml/min, 1.05ml/min         |
|-------------|----------------------|-------------------------------|
|Wavelength   |251nm                 |249nm, 253nm                   |
----------------------------------------------------------------------

 **Injection procedure** 



Under different chromatographic conditions, 1 needle of blank solution, 1 



needle of system suitability solution, 2 needles of reference solution and 1 



needle of durability test product solution were injected respectively. 



 **Measurement results** 



Results of durability - system suitability test 





















-------------------------------------------------------------------------
|Chromatographic      |Degree of separation     |The principal          |
|Conditions           |between the main peak and|peak-to-noise ratio of |
|                     |YA2304-20 peaks in system|the reference solution |
|                     |suitability solution     |                       |
|                     |                         |-----------------------|
|                     |                         |1          |2          |
|---------------------|-------------------------|-----------|-----------|
|Normal conditions    |2.5                      |66.5       |64.4       |
|---------------------|-------------------------|-----------|-----------|
|Column temperature 38|2.5                      |60.0       |65.4       |
|° C                 |                         |           |           | 
|---------------------|-------------------------|-----------|-----------|
|Column temperature   |2.5                      |70.4       |77.1       |
|42℃                 |                         |           |           | 
|---------------------|-------------------------|-----------|-----------|
|The flow rate was    |2.5                      |63.0       |62.4       |
|0.95ml/min           |                         |           |           |
-------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 313 of 542 





Page 314
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










-----------------------------------------------------------------------------
|The flow rate is  |2.4               |64.4              |68.7              |
|1.05ml/min        |                  |                  |                  |
|------------------|------------------|------------------|------------------|
|Mobile phase ratio|1.9               |46.2              |48.9              |
|(72:28)           |                  |                  |                  |
|------------------|------------------|------------------|------------------|
|Mobile phase ratio|1.8               |64.3              |59.3              |
|(68:32)           |                  |                  |                  |
|------------------|------------------|------------------|------------------|
|Wavelength 249nm  |1.9               |31.4              |35.3              |
|------------------|------------------|------------------|------------------|
|Wavelength 253nm  |1.9               |34.7              |35.4              |
|------------------|------------------|------------------|------------------|
|Conclusion: Under different chromatographic conditions, the separation     |
|degree between YA2304-20 peak and main peak in the system suitability      |
|solution is between 1.9 and 2.5 (the requirement should be NLT 1.5), which |
|meets the verification requirements. The main peak signal-to-noise ratio   |
|(SNR) in the chromatogram of the control solution was between 31.4 and 77.1|
|(the requirement should be NLT 30), which met the verification             |
|requirements.                                                              |
-----------------------------------------------------------------------------

Durability test results 


















---------------------------------------------------------------
|Chromatographic|Parameter|Solution name   |YA2304-20 |RSD/%  |
|Conditions     |values   |                |content /%|       |
|---------------|---------|----------------|----------|-------|
|Column         |38       |Durability test |0.17      |2.6    |
|temperature (°|         |product solution|          |       | 
|C)             |         |1               |          |       |
|               |         |----------------|----------|       |
|               |         |Durability test |0.16              |
|               |         |sample solution |                  |
|               |         |2               |                  |
|               |---------|----------------|------------------|
|               |40       |Durability test |0.17              |
|               |         |sample solution |                  |
|               |         |1               |                  |
|               |         |----------------|------------------|
|               |         |Durability test |0.17              |
|               |         |sample solution |                  |
|               |         |2               |                  |
|               |---------|----------------|------------------|
|               |42       |Durability test |0.17              |
|               |         |product solution|                  |
|               |         |1               |                  |
|               |         |----------------|------------------|
|               |         |Durability test |0.16              |
|               |         |sample solution |                  |
|               |         |2               |                  |
|---------------|---------|----------------|------------------|
|Flow rate      |0.95     |Durability test |0.17      |2.4    |
|(ml/min)       |         |solution 1      |          |       |
|               |         |----------------|----------|       |
|               |         |Durability test |0.16              |
|               |         |sample solution |                  |
|               |         |2               |                  |
|               |---------|----------------|------------------|
|               |1.00     |Durability test |0.17              |
|               |         |sample solution |                  |
|               |         |1               |                  |
|               |         |----------------|------------------|
|               |         |Durability test |0.17              |
|               |         |sample solution |                  |
|               |         |2               |                  |
---------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 314 of 542 





Page 315
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



















-------------------------------------------------------------------------------------
|                  |1.05              |Durability test   |0.17              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |1                 |                  |       |
|                  |                  |------------------|------------------|       |
|                  |                  |Durability test   |0.16              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |2                 |                  |       |
|------------------|------------------|------------------|------------------|-------|
|Wavelength (nm)   |249               |Durability test   |0.17              |2.3    |
|                  |                  |solution 1        |                  |       |
|                  |                  |------------------|------------------|       |
|                  |                  |Durability test   |0.16              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |2                 |                  |       |
|                  |------------------|------------------|------------------|       |
|                  |251               |Durability test   |0.17              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |1                 |                  |       |
|                  |                  |------------------|------------------|       |
|                  |                  |Durability test   |0.17              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |2                 |                  |       |
|                  |------------------|------------------|------------------|       |
|                  |253               |Durability test   |0.17              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |1                 |                  |       |
|                  |                  |------------------|------------------|       |
|                  |                  |Durability test   |0.16              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |2                 |                  |       |
|------------------|------------------|------------------|------------------|-------|
|Mobile phase      |72:28             |Durability test   |0.16              |2.4    |
|ratio             |                  |product solution  |                  |       |
|                  |                  |1                 |                  |       |
|                  |                  |------------------|------------------|       |
|                  |                  |Durability test   |0.16              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |2                 |                  |       |
|                  |------------------|------------------|------------------|       |
|                  |70:30             |Durability test   |0.17              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |1                 |                  |       |
|                  |                  |------------------|------------------|       |
|                  |                  |Durability test   |0.17              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |2                 |                  |       |
|                  |------------------|------------------|------------------|       |
|                  |68:32             |Durability test   |0.17              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |1                 |                  |       |
|                  |                  |------------------|------------------|       |
|                  |                  |Durability test   |0.16              |       |
|                  |                  |sample solution   |                  |       |
|                  |                  |2                 |                  |       |
|------------------|------------------|------------------|------------------|-------|
|Conclusion: RSD of YA2304-20 was 2.6% (should NMT 10%) under different     |       |
|column temperature conditions, which met the verification requirements; At |       |
|different flow rates, the RSD of YA2304-20 in test samples was 2.4% (should|       |
|NMT 10%), which met the verification requirements; Under different         |       |
|wavelength conditions, the RSD of YA2304-20 in the test product was 2.3%   |       |
|(should NMT 10%), which met the verification requirements; Under different |       |
|mobile phase ratios, the RSD of YA2304-20 in the test product was 2.4%     |       |
|(should NMT 10%), which met the verification requirements, indicating that |       |
|the durability of the method was good.                                     |       |
-------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 315 of 542 





Page 316
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**III. Summary of Method Validation** 



Methodological Verification Results of Finished Product Enantiomer 


















------------------------------------------------------------------------------------------------------------------------
|Project                 |Acceptable criteria            |Verification of results                                      |
|------------------------|-------------------------------|-------------------------------------------------------------|
|Wavele                  |YA2304-20 should have a large  |Impurity YA2304-20 has greater absorption at 251nm. In the   |
|ngth                    |absorption at 251nm.           |control solution,                                            |
|selectio n              |                               |the retention time of YA2304-20 is 25.626min. The spectrogram|
|                        |                               |of the control                                               |
|                        |                               |solution is as follows:                                      |
|------------------------|-------------------------------|-------------------------------------------------------------|
|System                  |The blank solution should be   |The blank solution has no interference; The separation degree|
|applica                 |free of                        |between the main                                             |
|bility                  |interference; The separation   |peak and YA2304-20 peak in the system suitability solution is|
|                        |degree                         |3.0 (the                                                     |
|                        |between the main peak and      |requirement should NLT 1.5); In the chromatogram obtained    |
|                        |YA2304-20                      |from the control                                             |
|                        |peak in the chromatogram of    |product solution, the signal-to-noise ratio of the main peak |
|                        |system                         |was between 71.5                                             |
|                        |suitability solution should be |and 83.4 (the requirement should be NLT 30); The RSD of peak |
|                        |greater than 1.5; In the       |retention time of                                            |
|                        |chromatogram obtained for 6    |YA2304-20 in the photoproduct solution for 6 consecutive days|
|                        |consecutive days, the          |was 0.08% (the                                               |
|                        |signal-to-noise ratio (S/N) of |requirement should NMT 1.0%); The RSD of peak area is 0.6%   |
|                        |YA2304-20 peak should NLT 30,  |(the requirement                                             |
|                        |the                            |should NMT 5%); All meet the verification requirements. It   |
|                        |RSD of the retention time NMT  |shows that this                                              |
|                        |1.0%,                          |method has good system applicability.                        |
|                        |and the RSD of the peak area   |                                                             |
|                        |NMT 5%.                        |                                                             |
|------------------------|-------------------------------|-------------------------------------------------------------|
|S p e     |Pea k ide    |Blank solution should be free  |The blank solution has no interference; The separation degree|
|          |             |of                             |between the main                                             |
|          |             |interference; The separation   |peak and YA2304-20 peak in the system suitability solution is|
|          |             |degree                         |3.0 (the                                                     |
|          |             |between the main peak and      |requirement should NLT 1.5); In the chromatogram obtained    |
|          |             |YA2304-20                      |from the control                                             |
|          |             |                               |solution, S/N was 62.2 (the                                  |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 316 of 542 





Page 317
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




peak in the system suitability solution 
should be greater than 1.5; The peak 
signal-to-noise ratio (S/N) of YA2304-20 
in the chromatogram of reference 
solution should NLT 30; The separation 
degree between YA2304-20 peaks and 
adjacent peaks in the chromatogram of 
test solution and specific mixed solution 
should be greater than 1.5, and the 
retention time should be consistent with 
the peak retention time of YA2304-20 in 
the chromatogram of control solution. 
Other single impurity localization 
solutions do not interfere with 
YA2304-20 peak production. 




requirement should NLT 30); The separation degree between YA2304-20 peaks and 
adjacent peaks in the specific mixed solution and the test solution was greater than 1.5, 
and the retention time was consistent with that of YA2304-20 peaks in the chromatogram 
of the control solution. Impurities YA2304-12, YA2304-14, YA2304-15, YA2304-16, 
YA2304-18 and YA2304-19 all have a chiral center, so the above impurities all have two 
peaks under the current chromatographic conditions. Other single impurities (YA2304-10, 
YA2304-12, YA2304-14, YA2304-15, YA2304-16, YA2304-17, YA2304-18 and YA2304-19) 
do not interfere with the peak of YA2304-20; Meet the requirements of verification. The 
concentration of YA2304-20 in the specific mixed solution is equal to 0.15% of the 
principal component concentration in the test solution. 




ci 



fi 


ci 



t 


y 




ntifi 



cati 



on 


test 




































-----------------------------------------------------------------------
|Name of |Component|Componen t|Rt (min)|Separatio|The percentage      |
|solution|name     |concentrat|        |n        |equivalent to the   |
|        |         |ion       |        |         |concentration of the|
|        |         |(μg/ml)  |        |         |principal component | 
|        |         |          |        |         |in the test product |
|        |         |          |        |         |solution            |
|--------|---------|----------|--------|---------|--------------------|
|Specific|YA2304   |1033.1000 |20.183  |3.0      |100%                |
|mixed   |         |          |        |         |                    |
|solution|         |          |        |         |                    |
|        |---------|----------|--------|         |--------------------|
|        |YA2304-20|1.4983    |24.872  |         |0.15%               |
-----------------------------------------------------------------------

The chromatogram of the specific mixed solution is as follows: 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 317 of 542 





Page 318
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















------------------------------------------------------------------------------
|Impurity/ |Detection limits                |Limit of quantitation           |
|principal |                                |                                |
|compone nt|                                |                                |
|          |--------------------------------|--------------------------------|
|          |Concentration (equivalent to the|Concentration (equivalent to the|
|          |concentration percentage of the |test product solution           |
|          |test product solution)          |concentration percentage)       |
|----------|--------------------------------|--------------------------------|
|YA2304-2 0|0.0899μg/ml (0.01%)            |0.3112μg/ml (0.03%)            |  
|----------|--------------------------------|--------------------------------|
|YA2304    |0.0934μg/ml (0.01%)            |0.2997μg/ml (0.03%)            |  
------------------------------------------------------------------------------
























-----------------------------------------------------------------------
|Impuritie |Concentration (equivalent to percentage|Linear equation   |
|s /       |of solution concentration of test      |                  |
|Principal |product)                               |                  |
|compone nt|                                       |                  |
|----------|---------------------------------------|------------------|
|YA2304-2 0|0.2997μg/ml to 2.9966μg/ml (0.03% to |Y = 15161-28.894 x|  
|          |0.30%)                                 |                  |
|----------|---------------------------------------|------------------|
|YA2304    |0.3112μg/ml~3.1118μg/ml (0.03%~0.31%)|Y = 15788-79.892 x|  
-----------------------------------------------------------------------

------------------------------------------------------------------------------------------------------------------------
|          |       |                         |                                                                         |
|----------|       |-------------------------|-------------------------------------------------------------------------|
|Limits of |       |The average              |Impurity/ principal compone nt Detection limits Limit of quantitation    |
|quantifi  |       |signal-to-noise ratio    |Concentration (equivalent to the concentration percentage of the test    |
|cation and|       |(S/N) of each impurity   |product                                                                  |
|detectio n|       |peak in 6 LOQ            |solution) Concentration (equivalent to the test product solution         |
|          |       |solutions should NLT 10, |concentration                                                            |
|          |       |the RSD of               |percentage) YA2304-2 0 0.0899μg/ml (0.01%) 0.3112μg/ml (0.03%) YA2304  |  
|          |       |retention time should NMT|0.0934μg/ml (0.01%) 0.2997μg/ml (0.03%)                                |  
|          |       |2.0%, and                |                                                                         |
|          |       |the RSD of peak area     |                                                                         |
|          |       |should NMT 10%.          |                                                                         |
|          |       |The SNR (S/N) of each    |                                                                         |
|          |       |impurity peak            |                                                                         |
|          |       |in the 3-pin detection   |                                                                         |
|          |       |limit (LOD)              |                                                                         |
|          |       |solution should NLT 3.   |                                                                         |
|----------|       |-------------------------|-------------------------------------------------------------------------|
|Linearit y|       |With the concentration as|Impuritie s / Principal compone nt Concentration (equivalent to          |
|vs. range |       |the                      |percentage of                                                            |
|          |       |horizontal coordinate and|solution concentration of test product) Linear equation YA2304-2 0       |
|          |       |the peak                 |0.2997μg/ml                                                             | 
|          |       |area as the vertical     |to 2.9966μg/ml (0.03% to 0.30%) Y = 15161-28.894 x YA2304               | 
|          |       |coordinate as            |0.3112μg/ml~3.1118μg/ml (0.03%~0.31%) Y = 15788-79.892 x               |  
|          |       |the linear regression    |                                                                         |
|          |       |curve, the               |                                                                         |
|          |       |regression coefficient   |                                                                         |
|          |       |(R) of the               |                                                                         |
|          |       |regression curve is      |                                                                         |
|          |       |required to be           |                                                                         |
|          |       |NLT 0.990, the RSD of the|                                                                         |
|          |       |response                 |                                                                         |
|          |       |factor NMT 10%, and the  |                                                                         |
|          |       |Y-axis                   |                                                                         |
|          |       |intercept is less than   |                                                                         |
|          |       |25% of the               |                                                                         |
|          |       |percentage of 100%       |                                                                         |
|          |       |response value.          |                                                                         |
|----------|       |-------------------------|-------------------------------------------------------------------------|
|Accura    |       |The required 30% limit   |           |Impurities |Marking      |Average    |RSD        |           |
|          |       |                         |           |           |condition    |           |           |           |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 318 of 542 





Page 319
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 









------------------------------------------------------------
|         |                        |recovery rate|         |
|---------|------------------------|-------------|---------|
|YA2304-20|Added                   |98.5%, n=9   |2.4%, n=9|
|         |0.4587μg/ml~2.2933μg/m|             |         |  
------------------------------------------------------------






----------------------------------------------------
|Impurities|repeatability|Reproducibility|Precision|
|----------|-------------|---------------|---------|
|YA2304-20 |2.5%, n=6    |5%, n=6        |4%, n=12 |
----------------------------------------------------
------------------------------------------------------------------------------------------------------------------------
|cy            |concentration recovery rate      |recovery rate YA2304-20 Added 0.4587μg/ml~2.2933μg/m 98.5%, n=9    |  
|              |should                           |2.4%, n=9                                                            |
|              |be 85%~110%, the required        |                                                                     |
|              |100%~150%                        |                                                                     |
|              |limit concentration recovery rate|                                                                     |
|              |should be 90%~108%, and the RSD  |                                                                     |
|              |of                               |                                                                     |
|              |the recovery rate NMT 10%.       |                                                                     |
|--------------|---------------------------------|---------------------------------------------------------------------|
|Precisio n    |Repeatability and                |Impurities repeatability Reproducibility Precision YA2304-20 2.5%,   |
|              |reproducibility:                 |n=6 5%, n=6                                                          |
|              |RSD of YA2304-20 in 6            |4%, n=12                                                             |
|              |repeatability                    |                                                                     |
|              |(or reproducibility) test        |                                                                     |
|              |solution                         |                                                                     |
|              |shall NMT 10%. For the results of|                                                                     |
|              |12                               |                                                                     |
|              |repeatability and reproducibility|                                                                     |
|              |tests, the RSD of YA2304-20      |                                                                     |
|              |should                           |                                                                     |
|              |NMT 10%.                         |                                                                     |
|--------------|---------------------------------|---------------------------------------------------------------------|
|Solutio n     |The system suitability solution, |System suitability solution: within 5 days at room temperature, the  |
|stability     |the                              |separation                                                           |
|              |control solution and the test    |degree between the main peak and YA2304-20 peak was greater than 1.5 |
|              |product solution were placed at  |(the                                                                 |
|              |room                             |requirement should be NLT 1.5), which met the verification           |
|              |temperature for a period of time,|requirements,                                                        |
|              |and the samples were injected at |indicating that the system suitability solution was stable within 5  |
|              |different time points. The       |days at                                                              |
|              |separation degree between        |room temperature. Reference solution: within 49h at room temperature,|
|              |YA2304-20                        |the RSD                                                              |
|              |peak and the main peak in the    |of YA2304-20 was 1.1% (not more than 10% required); The peak-to-noise|
|              |chromatogram of the system       |ratio of                                                             |
|              |suitability solution should NLT  |YA2304-20 was between 62.2 and 80.3 (the requirement should NLT 30), |
|              |1.5;                             |which met                                                            |
|              |The peak signal-to-noise ratio   |the verification requirements, indicating that the control solution  |
|              |(S/N)                            |was stable                                                           |
|              |of YA2304-20 in the chromatogram |within 49h at room temperature. Test product solution: within 23h at |
|              |of                               |room                                                                 |
|              |reference solution should NLT 30,|temperature, the RSD of YA2304-20 in the test product solution is 10%|
|              |and the RSD of peak area should  |(the                                                                 |
|              |not                              |requirement NMT 10%), which meets the verification requirements,     |
|              |be more than 5%; In the          |indicating                                                           |
|              |chromatogram                     |that the test product solution is stable within 23h at room          |
|              |obtained by the test product     |temperature. The                                                     |
|              |solution, the RSD of YA2304-20   |above solutions do not need new preparation for temporary use.       |
|              |NMT                              |                                                                     |
|              |10% according to the peak area   |                                                                     |
|              |calculation by external standard |                                                                     |
|              |method, and there shall be no new|                                                                     |
|              |peak generation that interferes  |                                                                     |
|              |with                             |                                                                     |
|              |the detection of YA2304-20.      |                                                                     |
|--------------|---------------------------------|---------------------------------------------------------------------|
|Durabil       |The separation degree between    |The column temperature was 40℃±2℃, the mobile phase ratio was     |   
|ity           |YA2304-20 peak and main peak     |(70:30) ±2, the                                                     | 
|              |should                           |flow rate was 1.0ml/min±0.05ml/min, and the wavelength was          | 
|              |NLT 1.5 when column temperature, |251nm±2nm. The                                                      | 
|              |                                 |measurements were as follows:                                        |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 319 of 542 





Page 320
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




wavelength, flow rate, mobile phase 
initiation ratio and normal 
chromatographic conditions are changed 
by single factor; The peak signal-to-noise 
ratio of YA2304-20 in the chromatogram 
of reference solution should NLT 30; 
RSD of YA2304-20 in test product 
solution shall NMT 10%. 




System suitability: Under different chromatographic conditions, the separation degree 
between the main peak and YA2304-20 peak in the system suitability solution is between 
1.9 and 2.5 (the requirement should be NLT 1.5), which meets the verification 
requirements. The main peak signal-to-noise ratio in the chromatogram of the reference 
product solution was between 31.4 and 77.1 (the requirement should be NLT 30), which 
met the verification requirements. 

Test product solution: under different chromatographic conditions, the RSD of 
YA2304-20 in the test product was no more than 10%, which met the verification 
requirements. 




Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 320 of 542 





Page 321
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4.3.4 Method Validation of Residual Solvents in Finerenone** 



**I. Analytical Procedures** 



Please refer to the analytical procedures of residual solvents in Finerenone in 



_section 3.2.S.4.2_ . 



**II. Validation Results and Discussion** 



**a. System Suitability Determination** 



 **Acceptance Criteria** 



The blank solution should be free of interference; In the chromatogram 



obtained for 6 consecutive days, ethanol, isopropyl alcohol, ethyl acetate, 



secondary butanol, tetrahydrofuran, toluene, n-methylpyrrolidone peaks in 



turn, and the separation degree between each adjacent peak should be 



greater than 1.5. The RSD of the peak retention time of each solvent peak 



should NMT 1.0%, and the RSD of the peak area should NMT 10%. 



 **Solution Preparation** 



Solvent: N, n-dimethylformamide (DMF). 



Ethanol reference product reserve liquid: precision weigh ethanol about 



1000mg, put in 20ml bottle, dissolve with solvent and dilute to the scale, 



shake well, ready. (About 50000μg/ml) 



Isopropyl alcohol control product reserve liquid: precision weigh isopropyl 



alcohol about 1000mg, put in 20ml measuring bottle, dissolve with solvent 



and dilute to the scale, shake well, ready. (About 50000μg/ml) 



Ethyl acetate reference product reserve liquid: precision weigh about 1000mg 



of ethyl acetate, place in 20ml measuring bottle, dissolve and dilute with 



solvent to scale, shake well, ready. (Approx. 50000μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 321 of 542 





Page 322
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Secondary butanol reference product reserve liquid: precision weigh 



secondary butanol about 1000mg, place in 20ml bottle, dissolve and dilute 



with solvent to scale, shake well, then get. (About 50000μg/ml) 



Tetrahydrofuran reference product reserve liquid: accurately weigh 



tetrahydrofuran about 144mg, put it in 20ml bottle, dissolve it with solvent 



and dilute it to the scale, shake well, and then get. (About 7200μg/ml) 



Toluene control product reserve liquid: precision weigh toluene about 178mg, 



place in 20ml bottle, dissolve and dilute with solvent to scale, shake well, 



ready. (About 8900μg/ml) 



N-methylpyrrolidone reference product reserve liquid: accurately weigh 



N-methylpyrrolidone about 106mg, place in 20ml bottle, dissolve with 



solvent and dilute to the scale, shake well, ready. (About 5300μg/ml) 



Mixed reference product reserve liquid: precision measure ethanol reference 



product reserve liquid, isopropyl alcohol reference product reserve liquid, 



ethyl acetate reference product reserve liquid, secondary butanol reference 



product reserve liquid, tetrahydrofuran reference product reserve liquid, 



toluene reference product reserve liquid, N-methylpyrrolidone reference 



product reserve liquid 1.0ml each, put in 20ml bottle, dilute with solvent to 



the scale, shake well, ready. (Ethanol about 2500μg/ml, isopropyl alcohol 



about 2500μg/ml, ethyl acetate about 2500μg/ml, secondary butanol about 



2500μg/ml, tetrahydrofuran about 360μg/ml, toluene about 445μg/ml, 



N-methylpyrrolidone about 265μg/ml) 



Reference product solution: accurately measure 1.0ml of the mixed reference 



product reserve solution, place it in a 10ml bottle, dilute it with solvent to the 



scale, shake well, and obtain. (Ethanol about 250μg/ml, isopropyl alcohol 



about 250μg/ml, ethyl acetate about 250μg/ml, secondary butanol about 



250μg/ml, tetrahydrofuran about 36μg/ml, toluene about 44.5μg/ml, 



N-methylpyrrolidone about 26.5μg/ml) 



 **Injection Sequence** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 322 of 542 





Page 323
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



After the blank solution, the chromatogram was recorded by continuously 



feeding 6 samples of the sample solution. 



 **Measurement results** 



Results of system suitability test 





































































































































































































































-------------------------------------------------------------------------------------------
|Nam e of  |Paramet er|Reference solution injection                               |RS D/ %|
|solv ent  |values    |                                                           |       |
|          |          |-----------------------------------------------------------|       |
|          |          |1        |2        |3        |4        |5        |6        |       |
|----------|----------|---------|---------|---------|---------|---------|---------|-------|
|Eth anol  |RT (min)  |8.229    |8.233    |8.225    |8.222    |8.244    |8.246    |0.1 3  |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Peak area |213.384 7|212.027 1|212.046 9|214.143 1|214.544 0|210.275 3|0.8    |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Separati  |/        |/        |/        |/        |/        |/        |/      |
|          |on        |         |         |         |         |         |         |       |
|----------|----------|---------|---------|---------|---------|---------|---------|-------|
|Isop ropy |RT (min)  |9.598    |9.602    |9.592    |9.588    |9.615    |9.615    |0.1 2  |
|l alc ohol|          |         |         |         |         |         |         |       |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Peak area |234.440 3|232.133 5|233.380 2|235.553 1|235.459 3|230.100 3|1.0    |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Separati  |7.7      |7.7      |7.5      |7.7      |7.6      |7.7      |/      |
|          |on        |         |         |         |         |         |         |       |
|----------|----------|---------|---------|---------|---------|---------|---------|-------|
|Eth yl a  |RT (min)  |14.220   |14.226   |14.216   |14.212   |14.237   |14.238   |0.0 8  |
|ceta te   |          |         |         |         |         |         |         |       |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Peak area |182.367 6|180.927 4|182.574 7|183.074 1|182.910 2|178.844 8|0.9    |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Separati  |27.0     |27.1     |26.8     |27.1     |26.9     |27.2     |/      |
|          |on        |         |         |         |         |         |         |       |
|----------|----------|---------|---------|---------|---------|---------|---------|-------|
|Seco nda  |RT (min)  |14.509   |14.513   |14.506   |14.500   |14.525   |14.526   |0.0 8  |
|ry b uta  |          |         |         |         |         |         |         |       |
|nol       |          |         |         |         |         |         |         |       |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Peak area |278.148 3|273.979 9|275.482 0|280.511 2|278.060 0|276.126 7|0.9    |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Separati  |1.8      |1.8      |1.8      |1.8      |1.8      |1.8      |/      |
|          |on        |         |         |         |         |         |         |       |
|----------|----------|---------|---------|---------|---------|---------|---------|-------|
|tetr ahy  |RT (min)  |14.807   |14.809   |14.801   |14.798   |14.823   |14.822   |0.0 8  |
|drof ura n|          |         |         |         |         |         |         |       |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Peak area |36.6421  |36.1685  |36.3647  |36.9569  |36.3910  |36.6089  |0.8    |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Separati  |1.9      |1.9      |1.8      |1.9      |1.9      |1.9      |/      |
|          |on        |         |         |         |         |         |         |       |
|----------|----------|---------|---------|---------|---------|---------|---------|-------|
|Tolu ene  |RT (min)  |20.138   |20.136   |20.128   |20.129   |20.149   |20.149   |0.0 5  |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Peak area |96.0328  |94.9365  |96.0452  |96.5924  |96.2772  |94.3475  |1.0    |
|          |----------|---------|---------|---------|---------|---------|---------|-------|
|          |Separati  |37.8     |37.8     |37.7     |37.6     |37.7     |37.7     |/      |
|          |on        |         |         |         |         |         |         |       |
|----------|----------|---------|---------|---------|---------|---------|---------|-------|
|N-m       |RT (min)  |31.455   |31.450   |31.447   |31.453   |31.460   |31.454   |0.0    |
-------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 323 of 542 





Page 324
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 













-----------------------------------------------------------------------------------------
|ethy lpyr|         |         |         |         |         |         |         |15     |
|rolid one|         |         |         |         |         |         |         |       |
|         |---------|---------|---------|---------|---------|---------|---------|-------|
|         |Peak area|25.8942  |25.3002  |24.9786  |25.4332  |24.8897  |23.9517  |2.7    |
|         |---------|---------|---------|---------|---------|---------|---------|-------|
|         |Separati |94.9     |94.5     |94.5     |94.1     |94.4     |94.4     |/      |
|         |on       |         |         |         |         |         |         |       |
|---------|         |         |         |         |         |         |         |       |
|Conclusion: There was no interference in the blank solution. In the            |       |
|chromatogram obtained for 6 consecutive days, peaks of ethanol, isopropyl      |       |
|alcohol, ethyl acetate, secondary butanol, tetrahydrofuran, toluene and        |       |
|n-methylpyrrolidone appeared successively, and the separation degree           |       |
|between each adjacent solvent peak was greater than 1.5 (the requirement       |       |
|was greater than 1.5). The RSD of ethanol peak retention time was 0.13%        |       |
|(required less than 1.0%), and the RSD of peak area was 0.8% (required less    |       |
|than 10%). The RSD of isopropyl alcohol peak retention time was 0.12% (NMT     |       |
|1.0%), and the RSD of peak area was 1.0% (NMT 10%); The RSD of the ethyl       |       |
|acetate peak was 0.08% (NMT 1.0%), and the RSD of the peak area was 0.9%       |       |
|(NMT 10%); The RSD of secondary butanol was 0.08% (NMT 1.0%), and the RSD      |       |
|of peak area was 0.9% (NMT 10%); The RSD of the peak retention time of         |       |
|tetrahydrofuran was 0.08% (NMT 1.0%), and the RSD of the peak area was 0.8%    |       |
|(NMT 10%); The RSD of toluene peak was 0.05% (NMT 1.0%), and the RSD of        |       |
|peak area was 1.0% (NMT 10%); The RSD of the N-methylpyrrolidone peak was      |       |
|0.015% (NMT 1.0%), and the RSD of the peak area was 2.7% (NMT 10%); All the    |       |
|above meet the verification requirements, indicating that the method has       |       |
|good applicability in system.                                                  |       |
-----------------------------------------------------------------------------------------

**b. Specificity** 



 **Acceptance Criteria** 



There is no interference in the blank solution. In the control solution, the 



peaks of ethanol, isopropyl alcohol, ethyl acetate, secondary butanol, 



tetrahydrofuran, toluene and n-methylpyrrolidone come out successively, 



and the separation degree between the adjacent peaks should be greater 



than 1.5; The separation degree of each solvent peak and adjacent peaks in 



the specific mixed solution and the test product solution is NLT 1.5, the 



retention time of each known solvent peak in the specific mixed solution and 



the test product solution should be consistent with the retention time of each 



solvent positioning solution, and other solvent positioning solutions (benzene, 



piperidine) have no interference with the target solvent peak. 



 **Solution preparation** 



Blank solution: solvent (N, n-dimethylformamide). 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 324 of 542 





Page 325
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Ethanol reference stock: Share ethanol reference stock under "4.1 System 



Suitability". (Approx. 50,000 μg/ml) 



Isopropyl alcohol reference reserve: Share isopropyl alcohol reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Ethyl acetate reference reserve: Share the ethyl acetate reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Secondary butanol reference product reserve: Share secondary butanol 



versus reference product reserve solution under "4.1 System Suitability". 



(Approx. 50,000 μg/ml) 



Tetrahydrofuran reference storage solution: Share tetrahydrofuran reference 



storage solution under "4.1 System Suitability". (Approx. 7200μg/ml) 



Toluene reference reserve: Share toluene reference reserve under "4.1 System 



Suitability". (Approx. 8900μg/ml) 



N-methylpyrrolidone reference stock: Share the N-methylpyrrolidone 



reference stock under "4.1 System Suitability". (Approx. 5300μg/ml) 



Piperidine control product reserve liquid: precision weigh piperidine about 



1000mg, place in 20ml bottle, dissolve with solvent and dilute to scale, shake 



well, ready. (Approx. 50000μg/ml) 



Benzene reference product reserve liquid: precision weigh about 40mg 



benzene, put it in 200ml bottle, dissolve it with solvent and dilute it to the 



scale, shake well; Then accurately measure 1ml, put it in 10ml measuring 



bottle, dissolve it with solvent and dilute it to the scale, shake well, and then 



get. Get it now. (About 20μg/ml) 



Reference product reserve liquid: precision measure ethanol reference 



product reserve liquid, isopropyl alcohol reference product reserve liquid, 



ethyl acetate reference product reserve liquid, secondary butanol reference 



product reserve liquid, tetrahydrofuran reference product reserve liquid, 



toluene reference product reserve liquid, N-methylpyrrolidone reference 



product reserve liquid 1.0ml each, put in 20ml bottle, dilute with solvent to 



scale, shake well, ready. (Ethanol about 2500μg/ml, isopropyl alcohol about 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 325 of 542 





Page 326
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



2500μg/ml, ethyl acetate about 2500μg/ml, secondary butanol about 



2500μg/ml, tetrahydrofuran about 360μg/ml, toluene about 445μg/ml, 



N-methylpyrrolidone about 265μg/ml) 



Control product solution: accurately measure 1.0ml of control product 



reserve solution, place it in 10ml bottle, dilute it with solvent to scale, shake 



well, and obtain. (Ethanol about 250μg/ml, isopropyl alcohol about 



250μg/ml, ethyl acetate about 250μg/ml, secondary butanol about 



250μg/ml, tetrahydrofuran about 36μg/ml, toluene about 44.5μg/ml, 



N-methylpyrrolidone about 26.5μg/ml) 



Mixed control product reserve liquid: Take a precise measure of 1.0ml each of 



ethanol reference liquid, isopropyl alcohol reference liquid, ethyl acetate 



reference liquid, secondary butanol reference liquid, tetrahydrofuran 



reference liquid, toluene reference liquid, N-methylpyrrolidone reference 



liquid, piperidine reference liquid and benzene reference liquid, put them in a 



20ml bottle and dilute them to the scale with solvent. Shake well, then get. 



(Ethanol about 2500μg/ml, isopropyl alcohol about 2500μg/ml, ethyl 



acetate about 2500μg/ml, secondary butanol about 2500μg/ml, 



tetrahydrofuran about 360μg/ml, toluene about 445μg/ml, 



N-methylpyrrolidone about 265μg/ml, piperidine about 2500μg/ml, benzene 



about 1μg /ml) 



Ethanol positioning solution: accurately measure 0.1ml of ethanol reference 



product reserve liquid, place it in 20ml measuring bottle, dilute it with 



solvent to scale, shake well, and get. (About 250μg/ml) 



Isopropyl alcohol positioning solution: accurately measure 0.1ml of isopropyl 



alcohol reference product reserve solution, place it in 20ml measuring bottle, 



dilute it with solvent to the scale, shake well, and obtain. (About 250μg/ml) 



Ethyl acetate positioning solution: accurately measure 0.1ml of ethyl acetate 



reference product reserve solution, place it in a 20ml measuring bottle, dilute 



it with solvent to the scale, shake well, and obtain. (About 250μg/ml) 



Secondary butanol positioning solution: accurately measure secondary 



butanol reference product reserve liquid 0.1ml, place it in 20ml measuring 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 326 of 542 





Page 327
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



bottle, dilute it with solvent to the scale, shake well, and then obtain. (About 



250μg/ml) 



Tetrahydrofuran positioning solution: precisely measure tetrahydrofuran 



reference product reserve liquid 0.1ml, place in 20ml measuring bottle, dilute 



with solvent to scale, shake well, ready. (about 36μg/ml) 



Toluene positioning solution: accurately measure toluene reference product 



reserve liquid 0.1ml, place in 20ml measuring bottle, dilute with solvent to 



scale, shake well, ready. (About 44.5μg/ml) 



N-methylpyrrolidone positioning solution: accurately measure 0.1ml of 



N-methylpyrrolidone reference product reserve solution, place it in 20ml 



measuring bottle, dilute it with solvent to the scale, shake well, and obtain. 



(About 26.5μg/ml) 



Piperidine positioning solution: precisely measure 0.1ml of piperidine control 



product reserve, place it in a 20ml measuring bottle, dilute it with solvent to 



the scale, shake well, and obtain. (About 250μg/ml) 



Benzene positioning solution: Accurately measure 0.1ml of benzene 



reference product reserve liquid, place it in a 20ml measuring bottle, dilute it 



with solvent to the scale, shake well, and obtain. (About 0.1μg/ml) 



Test product solution: Accurately weigh about 0.5g of this product, place it in 



10ml measuring bottle, dissolve it with solvent and dilute it to the scale, 



shake well, and then get. (About 50mg/ml) 



Specific mixed solution: Accurately weigh about 0.5g of this product, place it 



in 10ml measuring bottle, add 1.0ml of mixed control product reserve 



solution, dissolve it with solvent and dilute it to the scale, shake well, and 



then get. 



 **Injection Sequence** 



After the blank solution, the positioning solution, the reference solution, the 



test product solution and the specific mixed solution were injected 



respectively, and the chromatogram was recorded. 



 **Measurement resultss** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 327 of 542 





Page 328
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 































































-----------------------------------------------------------------------
|Name of solution                       |Concentratio|RT (min)|Separat|
|                                       |n (μg/ml)  |        |ion    | 
|---------------------------------------|            |        |       |
|Solution name       |Component name                 |        |       |
|--------------------|-------------------------------|--------|-------|
|Ethanol locating    |Ethanol           |250.278     |8.167   |/      |
|solution            |                  |            |        |       |
|--------------------|------------------|------------|--------|-------|
|Isopropyl alcohol   |Isopropyl alcohol |250.410     |9.516   |/      |
|positioning solution|                  |            |        |       |
|--------------------|------------------|------------|--------|-------|
|Ethyl acetate       |Ethyl acetate     |248.695     |14.149  |/      |
|positioning solution|                  |            |        |       |
|--------------------|------------------|------------|--------|-------|
|Secondary butanol   |Sec-butanol       |250.585     |14.429  |/      |
|positioning solution|                  |            |        |       |
|--------------------|------------------|------------|--------|-------|
|Tetrahydrofuran     |tetrahydrofuran   |36.588      |14.731  |/      |
|locator solution    |                  |            |        |       |
|--------------------|------------------|------------|--------|-------|
|Toluene locator     |Toluene           |50.025      |20.058  |/      |
|solution            |                  |            |        |       |
|--------------------|------------------|------------|--------|-------|
|N-methylpyrrolidone |N-methylpyrrolidon|27.6875     |31.386  |/      |
|positioning solution|e                 |            |        |       |
|--------------------|------------------|------------|--------|-------|
|Piperidine          |Piperidine        |0.1033      |/       |/      |
|positioning solution|                  |            |        |       |
|--------------------|------------------|------------|--------|-------|
|Benzene locator     |benzene           |251.4725    |/       |/      |
|solution            |                  |            |        |       |
|--------------------|------------------|------------|--------|-------|
|Reference solution  |Ethyl alcohol     |250.278     |8.151   |/      |
|                    |------------------|------------|--------|-------|
|                    |Isopropyl alcohol |250.410     |9.503   |8.2    |
|                    |------------------|------------|--------|-------|
|                    |Ethyl acetate     |248.695     |14.143  |28.3   |
|                    |------------------|------------|--------|-------|
|                    |sec-butanol       |250.585     |14.429  |1.8    |
|                    |------------------|------------|--------|-------|
|                    |tetrahydrofuran   |36.588      |14.729  |1.9    |
|                    |------------------|------------|--------|-------|
|                    |Toluene           |50.025      |20.061  |37.7   |
|                    |------------------|------------|--------|-------|
|                    |N-methylpyrrolidon|27.6875     |31.388  |95.5   |
|                    |e                 |            |        |       |
|--------------------|------------------|------------|--------|-------|
|Sample solution     |Ethanol           |/           |8.166   |/      |
|                    |------------------|------------|--------|-------|
|                    |Isopropyl alcohol |/           |/       |/      |
|                    |------------------|------------|--------|-------|
|                    |Ethyl acetate     |/           |/       |/      |
|                    |------------------|------------|--------|-------|
|                    |sec-butanol       |/           |/       |/      |
|                    |------------------|------------|--------|-------|
|                    |tetrahydrofuran   |/           |/       |/      |
|                    |------------------|------------|--------|-------|
|                    |Toluene           |/           |/       |/      |
|                    |------------------|------------|--------|-------|
|                    |N-methylpyrrolidon|/           |/       |/      |
|                    |e                 |            |        |       |
|                    |------------------|------------|--------|-------|
|                    |Piperidine        |/           |/       |/      |
|                    |------------------|------------|--------|-------|
|                    |benzene           |/           |/       |/      |
|--------------------|------------------|------------|--------|-------|
|Specific mixed      |Ethanol           |250.278     |8.149   |/      |
|solution            |                  |            |        |       |
|                    |------------------|------------|--------|-------|
|                    |Isopropyl alcohol |250.410     |9.504   |8.2    |
-----------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 328 of 542 





Page 329
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










------------------------------------------------------------------------------------
|               |Ethyl acetate     |248.695        |14.145         |28.2           |
|               |------------------|---------------|---------------|---------------|
|               |sec-butanol       |250.585        |14.429         |1.8            |
|               |------------------|---------------|---------------|---------------|
|               |tetrahydrofuran   |36.588         |14.728         |1.9            |
|               |------------------|---------------|---------------|---------------|
|               |Toluene           |50.025         |20.061         |37.5           |
|               |------------------|---------------|---------------|---------------|
|               |N-methylpyrrolidon|27.6875        |31.390         |94.3           |
|               |e                 |               |               |               |
|---------------|                  |               |               |               |
|Conclusion: There was no interference in the blank solution. In the control       |
|solution, the peaks of ethanol, isopropyl alcohol, ethyl acetate, secondary       |
|butanol, tetrahydrofuran, toluene and n-methylpyrrolidone appeared                |
|successively, and the separation degree between each adjacent solvent peak        |
|was greater than 1.5 (the requirement was greater than 1.5). The separation       |
|degree between individual solvent peaks and adjacent peaks in the specific        |
|mixed solution and the test solution is NLT 1.5, the retention time of each       |
|known solvent peak in the specific mixed solution and the test solution is        |
|consistent with the retention time of each solvent-locating solution, and         |
|other solvent-locating solutions (benzene, piperidine) have no interference       |
|with the target solvent peak. All of the above meet the verification              |
|requirements, indicating that the method has good specificity.                    |
------------------------------------------------------------------------------------

**(4.3) Limits of quantification and detection** 



 **Acceptance Criteria** 



The S/N of each solvent peak in 6 LOQ solution maps should be NLT 10, the 



RSD of retention time should be no more than 2.0%, and the RSD of peak 



area should be no more than 10%. The S/N of each solvent peak in the 



3-needle Limit of detection (LOD) solution atlas should be NLT 3. 



 **Solution Preparation** 



Blank solution: solvent (N, n-dimethylformamide). 



Ethanol reference stock: Share ethanol reference stock under "4.1 System 



Suitability". (Approx. 50,000 μg/ml) 



Isopropyl alcohol reference stock: Share isopropyl alcohol reference stock 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Ethyl acetate reference reserve: Share the ethyl acetate reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 329 of 542 





Page 330
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Secondary butanol reference product reserve: Share secondary butanol 



versus reference product reserve solution under "4.1 System Suitability". 



(Approx. 50,000 μg/ml) 



Tetrahydrofuran reference storage solution: Share tetrahydrofuran reference 



storage solution under "4.1 System Suitability". (Approx. 7200μg/ml) 



Toluene reference reserve: Share toluene reference reserve under "4.1 System 



Suitability". (Approx. 8900μg/ml) 



N-methylpyrrolidone reference stock: Share the N-methylpyrrolidone 



reference stock under "4.1 System Suitability". (Approx. 5300μg/ml) 



Quantitative limited stock solution: Precise measurement of ethanol 



reference liquid 0.2ml, isopropyl alcohol reference liquid 0.2ml, ethyl acetate 



reference liquid 0.2ml, secondary butanol reference liquid 0.15ml, 



tetrahydrofuran reference liquid 1ml, toluene reference liquid 0.4ml, 



N-methylpyrrolidone reference liquid 1ml, Place in the same 10ml measuring 



bottle, dilute with solvent and set the volume to the scale, shake well, then 



measure 1ml precisely, place in 20ml measuring bottle, dilute with solvent 



and set the volume to the scale, shake well, then obtain. 



Limit of quantitation (LOQ) solution: accurately measure 1ml of limited 



quantitation reserve liquid, place it in 10ml measuring bottle, dilute it with 



solvent and set the volume to the scale, shake well, and then get. (Dispense 6 



parts in parallel) 



Limit of detection (LOD) solution: Accurately measure the first part of the 



limit of quantification solution 3ml, place it in a 10ml measuring bottle, 



dilute it with solvent to the scale, shake well, and get. 



 **Injection Sequence** 



After the blank solution, 6 parts of limited quantitation solution and 3 



needles of limited detection solution were injected respectively, and the 



chromatogram was recorded. 



 **Measurement resultss** 



Results of limit of quantitation test 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 330 of 542 





Page 331
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










































------------------------------------------------------------------------------------------
|Subst     |Solution    |Concent    |Equivalent to   |RT (min)   |Peak area  |S/N        |
|ances Name|name        |ration     |the percentage  |           |           |           |
|          |            |/(μg/ml)  |/% of the       |           |           |           | 
|          |            |           |concentration of|           |           |           |
|          |            |           |the test product|           |           |           |
|          |            |           |solution        |           |           |           |
|----------|------------|-----------|----------------|-----------|-----------|-----------|
|Ethan ol  |Limited     |5.006      |0.01            |8.261      |4.7576     |12.2       |
|          |quantitative|           |                |           |           |           |
|          |Solution 1  |           |                |           |           |           |
|          |------------|           |                |-----------|-----------|-----------|
|          |Limited                 |                |8.263      |5.0132     |15.7       |
|          |quantitative            |                |           |           |           |
|          |Solution 2              |                |           |           |           |
|          |------------------------|                |-----------|-----------|-----------|
|          |Limited                 |                |8.254      |4.8740     |14.7       |
|          |quantitative            |                |           |           |           |
|          |Solution 3              |                |           |           |           |
|          |------------------------|                |-----------|-----------|-----------|
|          |Limited                 |                |8.256      |4.7694     |13.7       |
|          |quantitative            |                |           |           |           |
|          |Solution 4              |                |           |           |           |
|          |------------------------|                |-----------|-----------|-----------|
|          |Limited                 |                |8.255      |5.0251     |15.6       |
|          |quantitative            |                |           |           |           |
|          |Solution 5              |                |           |           |           |
|          |------------------------|                |-----------|-----------|-----------|
|          |Limited                 |                |8.260      |4.9149     |14.3       |
|          |quantitative            |                |           |           |           |
|          |solution 6              |                |           |           |           |
|          |------------------------|----------------|-----------|-----------|-----------|
|          |RSD (%)                                  |0.05       |2.4        |/          |
|          |-----------------------------------------|-----------|-----------|-----------|
|          |Verdict: The S/N of ethanol in 6 limited quantification solution             |
|          |chromatograms was between 12.2-15.7 (NLT 10 required), the RSD of            |
|          |retention time was 0.05% (no more than 2.0% required), the RSD of            |
|          |peak area was 2.4% (no more than 10% required), and the limited              |
|          |quantification concentration of ethanol was 5.006μg/ml. Equivalent          | 
|          |to 0.01% of the concentration of the test product; The above are in          |
|          |line with the verification requirements.                                     |
|----------|-----------------------------------------------------------------------------|
|Isopro pyl|Limited     |5.008      |0.01            |9.613      |5.3135     |11.9       |
|alcoho l  |quantitative|           |                |           |           |           |
|          |Solution 1  |           |                |           |           |           |
|          |------------|           |                |-----------|-----------|-----------|
|          |Limited                 |                |9.617      |5.1179     |15.2       |
|          |quantificatio           |                |           |           |           |
|          |n solution 2            |                |           |           |           |
|          |------------------------|                |-----------|-----------|-----------|
|          |Limited                 |                |9.613      |4.8142     |14.2       |
|          |quantificatio           |                |           |           |           |
------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 331 of 542 





Page 332
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

























-------------------------------------------------------------------------------------
|        |n solution 3  |           |           |           |           |           |
|        |--------------|           |           |-----------|-----------|-----------|
|        |Limited                   |           |9.613      |4.7635     |13.2       |
|        |quantitative              |           |           |           |           |
|        |Solution 4                |           |           |           |           |
|        |--------------------------|           |-----------|-----------|-----------|
|        |Limited                   |           |9.611      |5.1899     |14.8       |
|        |quantitative              |           |           |           |           |
|        |Solution 5                |           |           |           |           |
|        |--------------------------|-----------|-----------|-----------|-----------|
|        |Limited                   |           |9.614      |4.7570     |13.8       |
|        |quantitative              |           |           |           |           |
|        |solution 6                |           |           |           |           |
|        |--------------------------|-----------|-----------|-----------|-----------|
|        |RSD (%)                               |0.021      |5          |/          |
|        |--------------------------------------|-----------|-----------|-----------|
|        |Verdict: The S/N of isopropyl alcohol in 6 limited quantification         |
|        |solution chromatograms ranged from 11.9 to 15.2 (NLT 10 required),        |
|        |the RSD of retention time was 0.021% (no more than 2.0% required),        |
|        |the RSD of peak area was 5% (no more than 10% required), and the          |
|        |limited quantification concentration of isopropyl alcohol was             |
|        |5.008μg/ml. Equivalent to 0.01% of the concentration of the test         | 
|        |product; The above are in line with the verification requirements.        |
|--------|--------------------------------------------------------------------------|
|Ethyl   |Limit of      |4.974      |0.01       |14.230     |3.7080     |11.2       |
|acetat e|quantification|           |           |           |           |           |
|        |Solution 1    |           |           |           |           |           |
|        |--------------|           |           |-----------|-----------|-----------|
|        |Limited                   |           |14.222     |3.6889     |14.2       |
|        |quantitative              |           |           |           |           |
|        |Solution 2                |           |           |           |           |
|        |--------------------------|           |-----------|-----------|-----------|
|        |Limited                   |           |14.227     |3.7113     |13.4       |
|        |quantitative              |           |           |           |           |
|        |Solution 3                |           |           |           |           |
|        |--------------------------|           |-----------|-----------|-----------|
|        |Limited                   |           |14.222     |3.6914     |12.4       |
|        |quantitative              |           |           |           |           |
|        |Solution 4                |           |           |           |           |
|        |--------------------------|           |-----------|-----------|-----------|
|        |Limited                   |           |14.229     |3.7151     |13.8       |
|        |quantitative              |           |           |           |           |
|        |Solution 5                |           |           |           |           |
|        |--------------------------|           |-----------|-----------|-----------|
|        |Limited                   |           |14.219     |3.6656     |12.9       |
|        |quantitative              |           |           |           |           |
|        |solution 6                |           |           |           |           |
|        |--------------------------|-----------|-----------|-----------|-----------|
|        |RSD (%)                               |0.04       |0.6        |/          |
|        |--------------------------------------|-----------|-----------|-----------|
|        |Verdict: The S/N of ethyl acetate in 6 limited quantification             |
|        |solution chromatograms was between 11.2-14.2 (NLT 10 required), the       |
|        |RSD of                                                                    |
-------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 332 of 542 





Page 333
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



























---------------------------------------------------------------------------------------
|          |retention time was 0.04% (no more than 2.0% required), the RSD of         |
|          |peak area was 0.6% (no more than 10% required), and the limited           |
|          |quantification concentration of ethyl acetate was 4.974μg/ml.            | 
|          |Equivalent to 0.01% of the concentration of the test product; The         |
|          |above are in line with the verification requirements.                     |
|----------|--------------------------------------------------------------------------|
|SEC-b     |Limited       |3.759      |0.008      |14.518     |4.1822     |10.6       |
|utanol    |quantification|           |           |           |           |           |
|          |solution 1    |           |           |           |           |           |
|          |--------------|           |           |-----------|-----------|-----------|
|          |Limited                   |           |14.519     |4.1487     |13.8       |
|          |quantitative              |           |           |           |           |
|          |Solution 2                |           |           |           |           |
|          |--------------------------|           |-----------|-----------|-----------|
|          |Limited                   |           |14.524     |4.1204     |12.8       |
|          |quantitative              |           |           |           |           |
|          |Solution 3                |           |           |           |           |
|          |--------------------------|           |-----------|-----------|-----------|
|          |Limited                   |           |14.517     |4.1730     |12.2       |
|          |quantitative              |           |           |           |           |
|          |Solution 4                |           |           |           |           |
|          |--------------------------|           |-----------|-----------|-----------|
|          |Limited                   |           |14.517     |4.0965     |13.1       |
|          |quantitative              |           |           |           |           |
|          |Solution 5                |           |           |           |           |
|          |--------------------------|           |-----------|-----------|-----------|
|          |Limited                   |           |14.514     |4.0401     |12.3       |
|          |quantitative              |           |           |           |           |
|          |solution 6                |           |           |           |           |
|          |--------------------------|-----------|-----------|-----------|-----------|
|          |RSD (%)                               |0.023      |1.3        |/          |
|          |--------------------------------------|-----------|-----------|-----------|
|          |Verdict: The S/N of secondary butanol in 6 limited quantitation           |
|          |solution chromatograms ranged from 10.6 to 13.8 (NLT 10 required),        |
|          |the RSD of retention time was 0.023% (no more than 2.0% required),        |
|          |the RSD of peak area was 1.3% (no more than 10% required), and the        |
|          |limited quantitation concentration of secondary butanol was               |
|          |3.759μg/ml. Equivalent to the concentration of the test product          | 
|          |0.008%; The above are in line with the verification requirements.         |
|----------|--------------------------------------------------------------------------|
|Tetrah    |Limited       |3.659      |0.007      |14.810     |4.2917     |13.4       |
|ydrofu ran|quantitative  |           |           |           |           |           |
|          |Solution 1    |           |           |           |           |           |
|          |--------------|           |           |-----------|-----------|-----------|
|          |Limited                   |           |14.813     |4.1655     |16.8       |
|          |quantitative              |           |           |           |           |
|          |Solution 2                |           |           |           |           |
|          |--------------------------|           |-----------|-----------|-----------|
|          |Limited                   |           |14.814     |4.1972     |15.7       |
|          |quantitative              |           |           |           |           |
---------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 333 of 542 





Page 334
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

























-----------------------------------------------------------------------------------
|        |Solution 3  |           |           |           |           |           |
|        |------------|           |           |-----------|-----------|-----------|
|        |Limited                 |           |14.813     |4.1060     |14.8       |
|        |quantitative            |           |           |           |           |
|        |Solution 4              |           |           |           |           |
|        |------------------------|           |-----------|-----------|-----------|
|        |Limited                 |           |14.810     |4.1467     |16.2       |
|        |quantitative            |           |           |           |           |
|        |Solution 5              |           |           |           |           |
|        |------------------------|-----------|-----------|-----------|-----------|
|        |Limited                 |           |14.811     |4.2390     |15.4       |
|        |quantitative            |           |           |           |           |
|        |solution 6              |           |           |           |           |
|        |------------------------|-----------|-----------|-----------|-----------|
|        |RSD (%)                             |0.012      |1.6        |/          |
|        |------------------------------------|-----------|-----------|-----------|
|        |Conclusion: The S/N of tetrahydrofuran in 6 limited quantification      |
|        |solution chromatograms was between 13.4-16.8 (NLT 10), the RSD of       |
|        |retention time was 0.012% (no more than 2.0%), the RSD of peak area     |
|        |was 1.6% (no more than 10%), and the limiting concentration of          |
|        |tetrahydrofuran was 3.659μg/ml. Equivalent to the concentration of     | 
|        |the test product 0.007%; The above are in line with the                 |
|        |verification requirements.                                              |
|--------|------------------------------------------------------------------------|
|Tolue ne|Limited     |2.001      |0.004      |20.134     |4.0267     |13.7       |
|        |quantitative|           |           |           |           |           |
|        |Solution 1  |           |           |           |           |           |
|        |------------|           |           |-----------|-----------|-----------|
|        |Limited                 |           |20.134     |4.0244     |17.5       |
|        |quantitative            |           |           |           |           |
|        |Solution 2              |           |           |           |           |
|        |------------------------|           |-----------|-----------|-----------|
|        |Limited                 |           |20.135     |4.0668     |16.5       |
|        |quantitative            |           |           |           |           |
|        |Solution 3              |           |           |           |           |
|        |------------------------|           |-----------|-----------|-----------|
|        |Limited                 |           |20.134     |3.9945     |15.5       |
|        |quantitative            |           |           |           |           |
|        |Solution 4              |           |           |           |           |
|        |------------------------|           |-----------|-----------|-----------|
|        |Limited                 |           |20.134     |4.0965     |17.1       |
|        |quantitative            |           |           |           |           |
|        |Solution 5              |           |           |           |           |
|        |------------------------|           |-----------|-----------|-----------|
|        |Limited                 |           |20.133     |4.1527     |16.2       |
|        |quantitative            |           |           |           |           |
|        |solution 6              |           |           |           |           |
|        |------------------------|-----------|-----------|-----------|-----------|
|        |RSD (%)                             |0.004      |1.5        |/          |
|        |------------------------------------|-----------|-----------|-----------|
|        |Verdict: The S/N of toluene in 6 limited quantification solution        |
|        |chromatograms was between 13.7-17.5 (NLT 10), the RSD of retention      |
|        |time was 0.004% (no more than 2.0%), the RSD of peak area was 1.5%      |
|        |(no more                                                                |
-----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 334 of 542 





Page 335
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 
















------------------------------------------------------------------------------------
|         |than 10%), and the limited quantification concentration of toluene      |
|         |was 2.001μg/ml. Equivalent to 0.004% of the concentration of the       | 
|         |test product; All the above meet the verification requirements.         |
|---------|------------------------------------------------------------------------|
|N-met    |Limited     |2.769      |0.006      |31.457     |3.2895     |10.3       |
|hylpyr   |quantitative|           |           |           |           |           |
|rolido ne|Solution 1  |           |           |           |           |           |
|         |------------|           |           |-----------|-----------|-----------|
|         |Limited                 |           |31.460     |3.4857     |14.6       |
|         |quantitative            |           |           |           |           |
|         |Solution 2              |           |           |           |           |
|         |------------------------|           |-----------|-----------|-----------|
|         |Limited                 |           |31.463     |3.5691     |13.9       |
|         |quantitative            |           |           |           |           |
|         |Solution 3              |           |           |           |           |
|         |------------------------|           |-----------|-----------|-----------|
|         |Limited                 |           |31.463     |3.3893     |12.8       |
|         |quantitative            |           |           |           |           |
|         |Solution 4              |           |           |           |           |
|         |------------------------|           |-----------|-----------|-----------|
|         |Limited                 |           |31.459     |3.5359     |14.3       |
|         |quantitative            |           |           |           |           |
|         |Solution 5              |           |           |           |           |
|         |------------------------|           |-----------|-----------|-----------|
|         |Limited                 |           |31.459     |3.3758     |13.2       |
|         |quantification          |           |           |           |           |
|         |solution 6              |           |           |           |           |
|         |------------------------|-----------|-----------|-----------|-----------|
|         |RSD (%)                             |0.008      |4          |/          |
|         |------------------------------------|-----------|-----------|-----------|
|         |Verdict: The S/N of N-methylpyrrolidone in 6 limited quantification     |
|         |solution chromatograms ranged from 10.3-14.6 (NLT 10 required), the     |
|         |RSD of retention time was 0.008% (no more than 2.0% required), the      |
|         |RSD of peak area was 4% (no more than 10% required), and the            |
|         |limited quantification concentration of N-methylpyrrolidone was         |
|         |2.769μg/ml. Equivalent to the concentration of the test product        | 
|         |0.006%; The above are in line with the verification requirements.       |
------------------------------------------------------------------------------------

Test results of detection limits 
























----------------------------------------------------------------------------------
|Substances|Solution name    |Concentrati |Equivalent |RT (min)|Peak area|S/ N   |
|Name      |                 |on /(μg/ml)|to the     |        |         |       | 
|          |                 |            |percentage |        |         |       |
|          |                 |            |/% of the  |        |         |       |
|          |                 |            |concentrati|        |         |       |
|          |                 |            |on of the  |        |         |       |
|          |                 |            |test       |        |         |       |
|          |                 |            |product    |        |         |       |
|          |                 |            |solution   |        |         |       |
|----------|-----------------|------------|-----------|--------|---------|-------|
|Ethanol   |Detection|1      |1.502       |0.003      |8.290   |1.966 4  |3.7    |
|          |limit    |       |            |           |        |         |       |
|          |solution |       |            |           |        |         |       |
|          |         |-------|            |           |--------|---------|-------|
|          |         |2      |            |           |8.277   |1.953    |3.5    |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 335 of 542 





Page 336
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 





















































































































------------------------------------------------------------------------------
|            |         |        |        |        |        |5       |        |
|            |         |--------|        |        |--------|--------|--------|
|            |         |3       |        |        |8.263   |1.932 4 |3.2     |
|            |---------|--------|--------|--------|--------|--------|--------|
|            |Conclusion: The S/N of ethanol in the 3-needle detection       |
|            |limit solution chromatogram was between 3.2-3.7 (the           |
|            |requirement was NLT 3), and the detection limit concentration  |
|            |of ethanol was 1.502μg/ml, which was equivalent to the        | 
|            |concentration of test product 0.003%. All the above are in     |
|            |line with the verification requirements.                       |
|------------|---------------------------------------------------------------|
|Isopropyl   |Detection|1       |1.502   |0.003   |9.655   |2.680 9 |4.7     |
|alcohol     |limit    |        |        |        |        |        |        |
|            |solution |        |        |        |        |        |        |
|            |         |--------|        |        |--------|--------|--------|
|            |         |2       |        |        |9.633   |2.605 1 |4.0     |
|            |         |--------|        |        |--------|--------|--------|
|            |         |3       |        |        |9.614   |2.612 5 |4.0     |
|            |---------|--------|--------|--------|--------|--------|--------|
|            |Conclusion: The S/N of isopropyl alcohol in the 3-needle       |
|            |detection limit solution chromatogram was between 4.0-4.7      |
|            |(the requirement was NLT 3), and the detection limit           |
|            |concentration of isopropyl alcohol was 1.502μg/ml, which was  | 
|            |equivalent to the concentration of test product 0.003%. All    |
|            |the above were in line with the verification requirements.     |
|------------|---------------------------------------------------------------|
|Ethyl       |Detection|1       |1.492   |0.003   |14.26 3 |2.238 2 |4.7     |
|acetate     |limit    |        |        |        |        |        |        |
|            |solution |        |        |        |        |        |        |
|            |         |--------|        |        |--------|--------|--------|
|            |         |2       |        |        |14.24 3 |2.208 0 |3.9     |
|            |         |--------|        |        |--------|--------|--------|
|            |         |3       |        |        |14.23 4 |2.056 4 |3.8     |
|            |---------|--------|--------|--------|--------|--------|--------|
|            |Conclusion: The S/N of ethyl acetate in the 3-needle           |
|            |detection limit solution chromatogram was between 3.8-4.7      |
|            |(required to be NLT 3), and the detection limit concentration  |
|            |of ethyl acetate was 1.492μg/ml, which was equivalent to the  | 
|            |concentration of test product 0.003%. All the above were in    |
|            |line with the verification requirements.                       |
|------------|---------------------------------------------------------------|
|SEC-butanol |Detection|1       |1.128   |0.002   |14.55 3 |2.370 6 |4.2     |
|            |limit    |        |        |        |        |        |        |
|            |solution |        |        |        |        |        |        |
|            |         |--------|        |        |--------|--------|--------|
|            |         |2       |        |        |14.53 0 |2.270 6 |3.7     |
|            |         |--------|        |        |--------|--------|--------|
|            |         |3       |        |        |14.51 4 |2.285 8 |3.6     |
|            |---------|--------|--------|--------|--------|--------|--------|
|            |Conclusion: The S/N of secondary butanol in the 3-needle       |
|            |detection limited solution chromatogram was between 3.6-4.2    |
|            |(the requirement was NLT 3), and the detection limited         |
|            |concentration of secondary butanol was 1.128μg/ml, which was  | 
|            |equivalent to the concentration of test product 0.002%. All    |
|            |of the above are in line with the verification requirements.   |
|------------|---------------------------------------------------------------|
|Tetrahydrofu|Detection|1       |1.098   |0.002   |14.84 1 |2.205 5 |5.0     |
|ran         |limit    |        |        |        |        |        |        |
|            |solution |        |        |        |        |        |        |
|            |         |--------|        |        |--------|--------|--------|
|            |         |2       |        |        |14.83 7 |1.921 5 |4.2     |
|            |         |--------|        |        |--------|--------|--------|
|            |         |3       |        |        |14.81 2 |2.128 6 |4.3     |
|            |---------|--------|--------|--------|--------|--------|--------|
|            |Conclusion: The S/N of tetrahydrofuran in the 3-needle         |
|            |detection limit solution chromatogram was between 4.2-5.0      |
|            |(the requirement was NLT 3), and the detection limit           |
|            |concentration of tetrahydrofuran was 1.098μg/ml, which was    | 
|            |equivalent to the concentration of test product 0.002%. All    |
|            |the above are in line with the verification                    |
------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 336 of 542 





Page 337
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 








































































-----------------------------------------------------------------------------
|           |requirements.                                                  |
|-----------|---------------------------------------------------------------|
|Toluene    |Detection|1       |0.600   |0.001   |20.15 7 |2.264 3 |5.3     |
|           |limit    |        |        |        |        |        |        |
|           |solution |        |        |        |        |        |        |
|           |         |--------|        |        |--------|--------|--------|
|           |         |2       |        |        |20.14 6 |2.171 2 |4.7     |
|           |         |--------|        |        |--------|--------|--------|
|           |         |3       |        |        |20.13 5 |2.140 3 |4.4     |
|           |---------|--------|--------|--------|--------|--------|--------|
|           |Conclusion: The S/N of toluene in the 3-needle detection       |
|           |limit solution chromatogram was between 4.4-5.3 (NLT 3), and   |
|           |the detection limit concentration of toluene was 0.600μg/ml,  | 
|           |which was equivalent to the concentration of test product      |
|           |0.001%. All the above are in line with the verification        |
|           |requirements.                                                  |
|-----------|---------------------------------------------------------------|
|N-methylpyr|Detection|1       |0.831   |0.002   |31.48 2 |2.320 9 |4.8     |
|rolidone   |limit    |        |        |        |        |        |        |
|           |solution |        |        |        |        |        |        |
|           |         |--------|        |        |--------|--------|--------|
|           |         |2       |        |        |31.47 4 |1.785 2 |3.5     |
|           |         |--------|        |        |--------|--------|--------|
|           |         |3       |        |        |31.46 1 |2.560 3 |4.4     |
|           |---------|--------|--------|--------|--------|--------|--------|
|           |Conclusion: The S/N of N-methylpyrrolidone in 3-needle         |
|           |limited solution chromatogram ranges from 3.5-4.8 (NLT 3 is    |
|           |required), and the detection limited concentration of          |
|           |N-methylpyrrolidone is 0.831μg/ml, which is equivalent to the | 
|           |concentration of test product 0.002%. All the above were in    |
|           |line with the verification requirements.                       |
-----------------------------------------------------------------------------

**(4.4) Linearity and range** 



 **Acceptance Criteria** 



In equivalent to the LOQ concentration of each solvent ~200% limit 



concentration range, relatively uniform take 6 concentration points, the 



impurity concentration as the horizontal coordinate, the peak area as the 



vertical coordinate, the regression coefficient R of the linear graph should 



NLT 0.990, the RSD of the response factor should not be more than 10%, 



Y-axis intercept absolute value accounted for 100% of the response value of 



the percentage should be less than 25%. 



 **Solution Preparation** 



Blank solution: solvent (N, n-dimethylformamide). 



Ethanol reference stock: Share ethanol reference stock under "4.1 



System Suitability". (Approx. 50,000 μg/ml) 



Isopropyl alcohol reference reserve: Share isopropyl alcohol reference 



reserve under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 337 of 542 





Page 338
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Ethyl acetate reference reserve: Share the ethyl acetate reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Secondary butanol reference product reserve: Share secondary butanol 



versus reference product reserve solution under "4.1 System Suitability". 



(Approx. 50,000 μg/ml) 



Tetrahydrofuran reference storage solution: Share tetrahydrofuran 



reference storage solution under "4.1 System Suitability". (Approx. 



7200μg/ml) 



Toluene reference reserve: Share toluene reference reserve under "4.1 



System Suitability". (Approx. 8900μg/ml) 



N-methylpyrrolidone reference stock: Share the N-methylpyrrolidone 



reference stock under "4.1 System Suitability". (Approx. 5300μg/ml) 



Linear reserve liquid: precision measure ethanol reference product 



reserve liquid, isopropyl alcohol reference product reserve liquid, ethyl 



acetate reference product reserve liquid, secondary butanol reference 



product reserve liquid, tetrahydrofuran reference product reserve liquid, 



toluene reference product reserve liquid, N-methylpyrrolidone reference 



product reserve liquid 1.0ml each, placed in a 20ml bottle, diluted with 



solvent to the scale, shake well, ready. (Ethanol about 2500μg/ml, isopropyl 



alcohol about 2500μg/ml, ethyl acetate about 2500μg/ml, secondary 



butanol about 2500μg/ml, tetrahydrofuran about 360μg/ml, toluene about 



445μg/ml, N-methylpyrrolidone about 265μg/ml) 



Linear solution 1 (LOQ solution) : Share the first limit of quantification 



solution under "4.3 limits of quantification and detection limits" 



Linear solution 2 (30% limit concentration) : Accurately measure 0.3ml 



of linear reserve solution, place it in 10ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. 



Linear solution 3 (80% limit concentration) : Accurately measure 0.8ml 



linear reserve solution, place it in a 10ml measuring bottle, dilute it with 



solvent to the scale, shake well, and obtain. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 338 of 542 





Page 339
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Linear solution 4 (100% limit concentration) : precisely measure 1.0ml of 



linear reserve liquid, place it in a 10ml measuring bottle, dilute it with solvent 



to the scale, shake well, and get. 



Linear solution 5 (150% limit concentration) : precision measure 1.5ml 



linear reserve solution, place it in 10ml measuring bottle, dilute it with 



solvent to the scale, shake well, ready. 



Linear solution 6 (200% limit concentration) : precision measure 2.0ml 



linear reserve solution, place it in 10ml measuring bottle, dilute it with 



solvent to the scale, shake well, ready. 



 **Injection Sequence** 



After the blank solution, the linear solution of each concentration was 



injected respectively, and the chromatogram was recorded. 



 **Measurement resultss** 



Results of linear and range tests 

























---------------------------------------------------------------------------
|Sub stan |Solution      |The percentage |Concentration|Peak area|Response|
|ces Nam e|name          |/% equivalent  |/(μg/ml)    |         |factor  | 
|         |              |to the         |             |         |        |
|         |              |concentration  |             |         |        |
|         |              |of the solution|             |         |        |
|         |              |of the test    |             |         |        |
|         |              |product        |             |         |        |
|---------|--------------|---------------|-------------|---------|--------|
|Eth anol |Linear        |0.0100         |5.006        |4.1186   |0.8228  |
|         |solution 1    |               |             |         |        |
|         |--------------|---------------|-------------|---------|--------|
|         |Linear        |0.1502         |75.083       |73.1266  |0.9739  |
|         |Solution 2    |               |             |         |        |
|         |--------------|---------------|-------------|---------|--------|
|         |Linear        |0.4004         |200.222      |187.5907 |0.9369  |
|         |Solution 3    |               |             |         |        |
|         |--------------|---------------|-------------|---------|--------|
|         |Linear        |0.5006         |250.278      |233.5749 |0.9333  |
|         |solution 4    |               |             |         |        |
|         |--------------|---------------|-------------|---------|--------|
|         |Linear        |0.7508         |375.416      |333.7332 |0.8890  |
|         |Solution 5    |               |             |         |        |
|         |--------------|---------------|-------------|---------|--------|
|         |Linear        |1.0011         |500.555      |470.8123 |0.9406  |
|         |solution 6    |               |             |         |        |
|         |--------------|---------------|-------------|---------|--------|
|         |RSD/% of the response factor  |6                               |
---------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 339 of 542 





Page 340
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















---------------------------------------------------------------------------------------
|          |Linear graph                 |                                            |
|          |-----------------------------|--------------------------------------------|
|          |Linear equations             |Y = 0.923 + 0.7951 x                        |
|          |-----------------------------|--------------------------------------------|
|          |Correlation coefficient R    |0.999                                       |
|          |-----------------------------|--------------------------------------------|
|          |Absolute value of Y-axis     |0.34                                        |
|          |intercept as a percentage /% |                                            |
|          |of 100% response value       |                                            |
|          |-----------------------------|--------------------------------------------|
|          |The verdict: In the concentration range of 5.006μg/ml ~ 500.555μg/ml,   |  
|          |with the concentration as the horizontal coordinate and the peak area     |
|          |as the vertical coordinate as the standard curve, the obtained linear     |
|          |equation is y=0.923x+0.7951, and the correlation coefficient is 0.999     |
|          |(the requirement is NLT 0.990). The RSD of the response factor is 6%      |
|          |(NMT 10%), and the absolute value of the Y-axis intercept accounts        |
|          |for 0.34% of the 100% response value (required within 25%); All the       |
|          |above meet the verification requirements, indicating that the             |
|          |analytical method has a good linear relationship in the concentration     |
|          |range of 5.006μg/ml ~ 500.555μg/ml for ethanol detection.               |  
|----------|--------------------------------------------------------------------------|
|Isop ropy |Linear        |0.0100        |5.008         |4.8550        |0.9694        |
|l Alco hol|Solution 1    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |0.1502        |75.123        |72.2137       |0.9613        |
|          |Solution 2    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |0.4007        |200.328       |196.5378      |0.9811        |
|          |solution 3    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |0.5008        |250.410       |240.5275      |0.9605        |
|          |solution 4    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |0.7512        |375.615       |355.4473      |0.9463        |
|          |Solution 5    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |1.0016        |500.820       |504.4516      |1.0073        |
|          |solution 6    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |RSD/% of the response factor |2.2                                         |
---------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 340 of 542 





Page 341
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-------------------------------------------------------------------------------------
|        |Linear graph                 |                                            |
|        |-----------------------------|--------------------------------------------|
|        |Linear equations             |Y = 0.9917-3.6091 x                         |
|        |-----------------------------|--------------------------------------------|
|        |Correlation coefficient R    |0.999                                       |
|        |-----------------------------|--------------------------------------------|
|        |Absolute value of Y-axis     |1.5                                         |
|        |intercept as a percentage /% |                                            |
|        |of 100% response value       |                                            |
|        |-----------------------------|--------------------------------------------|
|        |Conclusion: Isopropyl alcohol in the concentration range of               |
|        |5.008μg/ml ~ 500.820μg/ml, with the concentration as the horizontal     |  
|        |coordinate and the peak area as the vertical coordinate as the            |
|        |standard curve, the obtained linear equation is y=0.9917x-3.6091, and     |
|        |the correlation coefficient is 0.999 (the requirement is NLT 0.990).      |
|        |RSD of the response factor was 2.2% (NMT 10%), and the absolute value     |
|        |of the Y-axis intercept accounted for 1.5% of the 100% response value     |
|        |(required within 25%); All of the above meet the verification             |
|        |requirements, indicating that the analytical method has a good linear     |
|        |relationship in the concentration range of 5.008μg/ml ~ 500.820μg/ml.   |  
|--------|--------------------------------------------------------------------------|
|Ethy l  |Linear        |0.0099        |4.974         |3.8354        |0.7711        |
|acet ate|solution 1    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.1492        |74.609        |56.1242       |0.7522        |
|        |Solution 2    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.3979        |198.956       |152.6369      |0.7672        |
|        |Solution 3    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.4974        |248.695       |185.6191      |0.7464        |
|        |solution 4    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.7461        |373.043       |274.8493      |0.7368        |
|        |Solution 5    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.9948        |497.390       |388.8026      |0.7817        |
|        |solution 6    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |RSD/% of the response factor |2.3                                         |
-------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 341 of 542 





Page 342
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















--------------------------------------------------------------------------------------
|         |Linear graph                 |                                            |
|         |-----------------------------|--------------------------------------------|
|         |Linear equations             |Y = 0.7696-2.3 x                            |
|         |-----------------------------|--------------------------------------------|
|         |Correlation coefficient R    |0.999                                       |
|         |-----------------------------|--------------------------------------------|
|         |Absolute value of Y-axis     |1.2                                         |
|         |intercept as a percentage /% |                                            |
|         |of 100% response value       |                                            |
|         |-----------------------------|--------------------------------------------|
|         |The verdict: Ethyl acetate in the concentration range of 4.974μg/ml ~    | 
|         |497.390μg/ml, with the concentration as the horizontal coordinate and    | 
|         |the peak area as the vertical coordinate as the standard curve, the       |
|         |obtained linear equation is y=0.7696x-2.3, the correlation                |
|         |coefficient is 0.999 (the requirement is NLT 0.990). The RSD of the       |
|         |response factor was 2.3% (NMT 10%), and the absolute value of the         |
|         |Y-axis intercept accounted for 1.2% of the 100% response value            |
|         |(required within 25%); All of the above meet the verification             |
|         |requirements, indicating that the analytical method has a good linear     |
|         |relationship in the concentration range of 4.974μg/ml ~ 497.390μg/ml.   |  
|---------|--------------------------------------------------------------------------|
|Sec- buta|Linear        |0.0075        |3.759         |4.2595        |1.1332        |
|nol      |solution 1    |              |              |              |              |
|         |--------------|--------------|--------------|--------------|--------------|
|         |Linear        |0.1504        |75.176        |87.9476       |1.1699        |
|         |Solution 2    |              |              |              |              |
|         |--------------|--------------|--------------|--------------|--------------|
|         |Linear        |0.4009        |200.468       |240.1952      |1.1982        |
|         |Solution 3    |              |              |              |              |
|         |--------------|--------------|--------------|--------------|--------------|
|         |Linear        |0.5012        |250.585       |291.3112      |1.1625        |
|         |solution 4    |              |              |              |              |
|         |--------------|--------------|--------------|--------------|--------------|
|         |Linear        |0.7518        |375.878       |435.1142      |1.1576        |
|         |Solution 5    |              |              |              |              |
|         |--------------|--------------|--------------|--------------|--------------|
|         |Linear        |1.0023        |501.170       |615.3318      |1.2278        |
|         |solution 6    |              |              |              |              |
|         |--------------|--------------|--------------|--------------|--------------|
|         |RSD/% of the response factor |2.9                                         |
--------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 342 of 542 





Page 343
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















---------------------------------------------------------------------------------------
|          |Linear graph                 |                                            |
|          |-----------------------------|--------------------------------------------|
|          |Linear equations             |Y = 1.2102-4.7656 x                         |
|          |-----------------------------|--------------------------------------------|
|          |Correlation coefficient R    |0.999                                       |
|          |-----------------------------|--------------------------------------------|
|          |Absolute value of Y-axis     |1.6                                         |
|          |intercept as a percentage /% |                                            |
|          |of 100% response value       |                                            |
|          |-----------------------------|--------------------------------------------|
|          |The verdict: In the concentration range of 3.759μg/ml ~ 501.170μg/ml,   |  
|          |with the concentration as the horizontal coordinate and the peak area     |
|          |as the vertical coordinate as the standard curve, the obtained linear     |
|          |equation is y=1.2102x-4.7656, and the correlation coefficient is          |
|          |0.999 (the requirement is NLT 0.990). The RSD of the response factor      |
|          |was 2.9% (NMT 10%), the absolute value of the Y-axis intercept            |
|          |accounted for 1.6% of the 100% response value (required within 25%);      |
|          |All of the above meet the verification requirements, indicating that      |
|          |the analytical method has a good linear relationship in the               |
|          |concentration range of 5.045μg/ml ~ 504.54μg/ml.                        |  
|----------|--------------------------------------------------------------------------|
|Tetr ahy  |Linear        |0.0073        |3.659         |4.3828        |1.1979        |
|drof ura n|Solution 1    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |0.0220        |10.976        |11.9074       |1.0848        |
|          |Solution 2    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |0.0585        |29.270        |32.1304       |1.0977        |
|          |solution 3    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |0.0732        |36.588        |38.7867       |1.0601        |
|          |solution 4    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |0.1098        |54.881        |57.9125       |1.0552        |
|          |Solution 5    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |Linear        |0.1464        |73.175        |80.0393       |1.0938        |
|          |solution 6    |              |              |              |              |
|          |--------------|--------------|--------------|--------------|--------------|
|          |RSD/% of the response factor |5                                           |
---------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 343 of 542 





Page 344
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-------------------------------------------------------------------------------------
|        |Linear graph                 |                                            |
|        |-----------------------------|--------------------------------------------|
|        |Linear equations             |Y = 1.0779 + 0.0623 x                       |
|        |-----------------------------|--------------------------------------------|
|        |Correlation coefficient R    |0.9995                                      |
|        |-----------------------------|--------------------------------------------|
|        |Absolute value of Y-axis     |0.16                                        |
|        |intercept as a percentage /% |                                            |
|        |of 100% response value       |                                            |
|        |-----------------------------|--------------------------------------------|
|        |The verdict: In the concentration range of 3.659μg/ml ~ 73.175μg/ml,    |  
|        |with the concentration as the horizontal coordinate and the peak area     |
|        |as the vertical coordinate as the standard curve, the obtained linear     |
|        |equation is y=1.0779x+0.0623, and the correlation coefficient is          |
|        |0.9995 (the requirement is NLT 0.990). The RSD of the response factor     |
|        |is 5% (NMT 10%), and the absolute value of the Y-axis intercept           |
|        |accounts for 0.16% of the 100% response value (required within 25%);      |
|        |All the above met the verification requirements, indicating that the      |
|        |analytical method for the detection of tetrahydrofuran has a good         |
|        |linear relationship in the concentration range of 3.659μg/ml ~           | 
|        |73.175μg/ml.                                                             | 
|--------|--------------------------------------------------------------------------|
|Tolu ene|Linear        |0.0040        |2.001         |4.2723        |2.1351        |
|        |solution 1    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.0300        |15.008        |29.9444       |1.9953        |
|        |Solution 2    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.0800        |40.020        |79.6923       |1.9913        |
|        |Solution 3    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.1001        |50.025        |97.5511       |1.9500        |
|        |solution 4    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.1501        |75.038        |144.6969      |1.9283        |
|        |solution 5    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |Linear        |0.2001        |100.050       |204.0250      |2.0392        |
|        |solution 6    |              |              |              |              |
|        |--------------|--------------|--------------|--------------|--------------|
|        |RSD/% of the response factor |4                                           |
-------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 344 of 542 





Page 345
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















------------------------------------------------------------------------------------
|          |Linear graph                 |                                         |
|          |-----------------------------|-----------------------------------------|
|          |Linear equations             |Y = 2.0063-0.9813 x                      |
|          |-----------------------------|-----------------------------------------|
|          |Correlation coefficient R    |0.999                                    |
|          |-----------------------------|-----------------------------------------|
|          |Absolute value of Y-axis     |1.1                                      |
|          |intercept as a percentage /% |                                         |
|          |of 100% response value       |                                         |
|          |-----------------------------|-----------------------------------------|
|          |The verdict: The concentration of toluene in the range of 2.001μg/ml  | 
|          |~ 100.050μg/ml, with the concentration as the horizontal coordinate   | 
|          |and the peak area as the vertical coordinate as the standard curve,    |
|          |the obtained linear equation is y=2.0063x-0.9813, the correlation      |
|          |coefficient is 0.999 (the requirement is NLT 0.990). RSD of response   |
|          |factor is 4% (NMT 10%), the absolute value of Y-axis intercept         |
|          |accounts for 1.1% of 100% response value (required within 25%); All    |
|          |the above meet the verification requirements, indicating that the      |
|          |analytical method has a good linear relationship in the concentration  |
|          |range of 2.001μg/ml ~ 100.050μg/ml.                                  |  
|----------|-----------------------------------------------------------------------|
|N-m ethy  |Linear        |0.0055        |2.769        |2.9231       |1.0557       |
|lpyr rolid|Solution 1    |              |             |             |             |
|one       |              |              |             |             |             |
|          |--------------|--------------|-------------|-------------|-------------|
|          |Linear        |0.0166        |8.306        |8.4062       |1.0120       |
|          |Solution 2    |              |             |             |             |
|          |--------------|--------------|-------------|-------------|-------------|
|          |Linear        |0.0443        |22.150       |20.3112      |0.9170       |
|          |Solution 3    |              |             |             |             |
|          |--------------|--------------|-------------|-------------|-------------|
|          |Linear        |0.0554        |27.688       |25.2571      |0.9122       |
|          |solution 4    |              |             |             |             |
|          |--------------|--------------|-------------|-------------|-------------|
|          |Linear        |0.0831        |41.531       |37.7702      |0.9094       |
|          |Solution 5    |              |             |             |             |
|          |--------------|--------------|-------------|-------------|-------------|
|          |Linear        |0.1108        |55.375       |57.1453      |1.0320       |
|          |solution 6    |              |             |             |             |
|          |--------------|--------------|-------------|-------------|-------------|
|          |RSD/% of the response factor |7                                        |
------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 345 of 542 





Page 346
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










---------------------------------------------------------------------------------
|       |Linear graph                       |                                   |
|       |-----------------------------------|-----------------------------------|
|       |Linear equations                   |Y = 0.9965-0.9081 x                |
|       |-----------------------------------|-----------------------------------|
|       |Correlation coefficient R          |0.995                              |
|       |-----------------------------------|-----------------------------------|
|       |Absolute value of Y-axis           |3.6                                |
|       |intercept as a percentage /%       |                                   |
|       |of 100% response value             |                                   |
|       |-----------------------------------|                                   |
|       |The verdict: N-methylpyrrolidone was obtained in the concentration     |
|       |range of 2.769μg/ml ~ 55.375μg/ml, with the concentration as the     |  
|       |horizontal coordinate and the peak area as the vertical coordinate as  |
|       |the standard curve. The obtained linear equation was                   |
|       |y=0.9965x-0.9081, and the correlation coefficient was 0.995 (the       |
|       |requirement was NLT 0.990). RSD of response factor was 7% (NMT 10%),   |
|       |the absolute value of Y-axis intercept accounted for 3.6% of 100%      |
|       |response value (required within 25%); All the above met the            |
|       |verification requirements, indicating that the analytical method has   |
|       |a good linear relationship in the concentration range of 2.769μg/ml ~ | 
|       |55.375μg/ml for the detection of N-methylpyrrolidone.                 | 
---------------------------------------------------------------------------------

**(4.5) Accuracy** 



 **Brief Description** 



Add each solvent reference in the limit concentration range of 30%~150% to 



the test product, the recovery rate of each solvent is required to be between 



85% ~ 115%, and the recovery RSD NMT 10%. 



 **Solution preparation** 



Blank solution: solvent (N, n-dimethylformamide). 



Ethanol reference stock: Share ethanol reference stock under "4.1 System 



Suitability". (Approx. 50,000 μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 346 of 542 





Page 347
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Isopropyl alcohol reference reserve: Share isopropyl alcohol reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Ethyl acetate reference reserve: Share the ethyl acetate reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Secondary butanol reference product reserve: Share secondary butanol 



versus reference product reserve solution under "4.1 System Suitability". 



(Approx. 50,000 μg/ml) 



Tetrahydrofuran reference storage solution: Share tetrahydrofuran reference 



storage solution under "4.1 System Suitability". (Approx. 7200μg/ml) 



Toluene reference reserve: Share toluene reference reserve under "4.1 System 



Suitability". (Approx. 8900μg/ml) 



N-methylpyrrolidone reference stock: Share the N-methylpyrrolidone 



reference stock under "4.1 System Suitability". (Approx. 5300μg/ml) 



Recovery reserve: Share linear reserve under "4.4 linear and range" 



Control product solution: accurately measure the recovery rate of the reserve 



liquid 1.0ml, put it in a 10ml measuring bottle, and then dilute it with solvent 



to the scale, shake well, and then obtain. 



Test product solution: Accurately weigh about 0.5g of this product, place it in 



10ml measuring bottle, dissolve it with solvent and dilute it to the scale, 



shake well, ready. (Parallel preparation of 2 servings) 



30% sample recovery solution: precision weigh about 0.5g of this product, 



precision weigh, put in 10ml measuring bottle, then precision measure the 



recovery of 0.3ml of reserve liquid placed in the same measuring bottle, 



dissolve with solvent and dilute to the scale, shake well, and then get. 



(Parallel preparation of 3 parts) 



100% sample recovery solution: precision weigh about 0.5g of this product, 



precision weigh, put in 10ml measuring bottle, then precision measure the 



recovery of reserve liquid 1.0ml put in the same measuring bottle, dissolve 



with solvent and dilute to the scale, shake well, and then get. (Parallel 



preparation of 3 parts) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 347 of 542 





Page 348
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



150% sample recovery solution: precision weigh about 0.5g of this product, 



precision weigh, put in 10ml measuring bottle, then precision measure the 



recovery reserve liquid 1.5ml put in the same measuring bottle, dissolve with 



solvent and dilute to the scale, shake well, and then get. (Parallel preparation 



of 3 parts) 



 **Injection procedure** 



After the blank solution, the control product solution, the test product 



solution and the recovery solution of each concentration were injected 



respectively, and the chromatogram was recorded. 



 **Measurement resultss** 



Accuracy test results 



















































----------------------------------------------------------------------------------------
|Subst ance|Solution name      |Original     |Amount       |Measured     |Recove ry    |
|Name      |                   |quantity in  |added        |amount       |rate /%      |
|          |                   |test product |(μg/ml)     |(μg/ml)     |             |  
|          |                   |(μg/ml)     |             |             |             | 
|----------|-------------------|-------------|-------------|-------------|-------------|
|Etha nol  |30% sample recovery|51.2415      |75.0833      |122.8447     |95.4         |
|          |solution 1         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% addition       |51.3641      |75.0833      |124.7496     |97.7         |
|          |recovery solution 2|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% addition       |51.2293      |75.0833      |123.6445     |96.4         |
|          |recovery solution 3|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |51.1619      |250.2775     |303.9775     |101.0        |
|          |recovery solution 1|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% addition      |51.1169      |250.2775     |304.6158     |101.3        |
|          |recovery solution 2|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% addition      |51.3560      |250.2775     |305.8432     |101.7        |
|          |recovery solution 3|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% addition      |51.4449      |375.4163     |466.2005     |110.5        |
|          |recovery solution 1|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% addition      |51.2569      |375.4163     |438.8007     |103.2        |
|          |recovery solution 2|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% addition      |51.1138      |375.4163     |440.8515     |103.8        |
|          |recovery solution 3|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |Average recovery /%                                          |101.2        |
|          |-------------------------------------------------------------|-------------|
|          |Recovery rate RSD/%                                          |5            |
|          |-------------------------------------------------------------|-------------|
|          |Conclusion: Ethanol was detected in the samples, and                       |
|          |75.0833μg/ml-375.4163μg/ml ethanol control was added into the            |  
|          |samples. The recoveries of 9 samples were all in the range of              |
|          |95.4%-110.5% (the requirement was 85%-115%), and the average               |
|          |recovery was 101.2%. The recovery RSD was 5% (the requirement was          |
|          |not more than 10%); All the above met the verification requirements,       |
|          |indicating that the method was accurate in detecting solvent ethanol       |
|          |in YA2304.                                                                 |
|----------|---------------------------------------------------------------------------|
|Subst     |Solution name      |Original     |Amount       |Measured     |Recove ry    |
|ances Name|                   |amount in    |added        |amount       |rate /%      |
|          |                   |test product |(μg/ml)     |(μg/ml)     |             |  
----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 348 of 542 





Page 349
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




























--------------------------------------------------------------------------------------------
|          |                   |(μg/ml)      |              |              |              | 
|----------|-------------------|--------------|--------------|--------------|--------------|
|Isopr opyl|30% sample recovery|Not detected  |75.1230       |74.0095       |98.5          |
|alcoh ol  |solution 1         |              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |30% sample recovery|Not detected  |75.1230       |74.8906       |99.7          |
|          |solution 2         |              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |30% sample recovery|Not detected  |75.1230       |74.0543       |98.6          |
|          |solution 3         |              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |100% sample        |Not detected  |250.4100      |252.7144      |100.9         |
|          |recovery solution 1|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |100% sample        |Not detected  |250.4100      |253.0627      |101.1         |
|          |recovery solution 2|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |100% sample        |Not detected  |250.4100      |253.9289      |101.4         |
|          |recovery solution 3|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |150% sample        |Not detected  |375.6150      |409.5334      |109.0         |
|          |recovery solution 1|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |150% sample        |Not detected  |375.6150      |387.2121      |103.1         |
|          |recovery solution 2|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |150% sample        |Not detected  |375.6150      |387.0754      |103.1         |
|          |recovery solution 3|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |Average recovery rate /%                                        |101.7         |
|          |----------------------------------------------------------------|--------------|
|          |Recovery rate RSD/%                                             |4             |
|          |----------------------------------------------------------------|--------------|
|          |Conclusions: Isopropyl alcohol was not detected in the samples, and            |
|          |75.1230μg/ml-375.6150μg/ml isopropyl alcohol was added into the              |  
|          |samples. The recoveries of 9 samples were all in the range of                  |
|          |98.5%-109.0% (the requirements were in the range of 85%-115%), and             |
|          |the average recovery was 101.7%. The recovery RSD was 4% (the                  |
|          |requirement was not more than 10%); All the above met the                      |
|          |verification requirements, indicating that the method was accurate             |
|          |in detecting isopropyl alcohol in YA2304.                                      |
|----------|-------------------------------------------------------------------------------|
|Subst     |Solution name      |Original      |Amount        |Measured      |Recove ry     |
|ances Name|                   |amount in     |added         |amount        |rate /%       |
|          |                   |test product  |(μg/ml)      |(μg/ml)      |              |  
|          |                   |(μg/ml)      |              |              |              | 
|----------|-------------------|--------------|--------------|--------------|--------------|
|Ethyl     |30% sample recovery|Not detected  |74.6085       |73.3037       |98.3          |
|acetat e  |solution 1         |              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |30% sample recovery|Not detected  |74.6085       |74.2183       |99.5          |
|          |solution 2         |              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |30% sample recovery|Not detected  |74.6085       |73.1270       |98.0          |
|          |solution 3         |              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |100% sample        |Not detected  |248.6950      |250.6196      |100.8         |
|          |recovery solution 1|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |100% recovery      |Not detected  |248.6950      |251.0619      |101.0         |
|          |solution 2         |              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |100% sample        |Not detected  |248.6950      |252.0282      |101.3         |
|          |recovery solution 3|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |150% sample        |Not detected  |373.0425      |402.2260      |107.8         |
|          |recovery solution 1|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |150% sample        |Not detected  |373.0425      |383.3969      |102.8         |
|          |recovery solution 2|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |150% sample        |Not detected  |373.0425      |384.7227      |103.1         |
|          |recovery solution 3|              |              |              |              |
|          |-------------------|--------------|--------------|--------------|--------------|
|          |Average recovery rate /%                                        |101.4         |
|          |----------------------------------------------------------------|--------------|
|          |Recovery rate RSD/%                                             |3.0           |
|----------|----------------------------------------------------------------|--------------|
|          |Conclusions: No ethyl acetate was detected in the samples.                     |
|          |74.6085μg/ml-373.0425μg/ml ethyl acetate was added into the samples.         |  
--------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 349 of 542 





Page 350
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 











































----------------------------------------------------------------------------------------
|          |The recoveries of 9 samples were all in the range of 98.0%-107.8%          |
|          |(the requirement was 85%-115%), and the average recoveries were            |
|          |101.4%. The recovery RSD was 3.0% (no more than 10% required); All         |
|          |the above met the verification requirements, indicating that the           |
|          |method was accurate in detecting ethyl acetate in YA2304.                  |
|----------|---------------------------------------------------------------------------|
|Subst     |Solution name      |Original     |Amount       |Measured     |Recove ry    |
|ances Name|                   |quantity in  |added        |amount       |rate /%      |
|          |                   |test product |(μg/ml)     |(μg/ml)     |             |  
|          |                   |(μg/ml)     |             |             |             | 
|----------|-------------------|-------------|-------------|-------------|-------------|
|sec-b     |30% sample recovery|Not detected |75.1755      |74.5260      |99.1         |
|utano l   |solution 1         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% sample recovery|Not detected |75.1755      |75.1045      |99.9         |
|          |solution 2         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% sample recovery|Not detected |75.1755      |74.1757      |98.7         |
|          |solution 3         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |Not detected |250.5850     |254.1755     |101.4        |
|          |recovery solution 1|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |Not detected |250.5850     |254.9211     |101.7        |
|          |recovery solution 2|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |Not detected |250.5850     |255.8160     |102.1        |
|          |recovery solution 3|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% sample        |Not detected |375.8775     |412.4938     |109.7        |
|          |recovery solution 1|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% sample        |Not detected |375.8775     |389.1479     |103.5        |
|          |recovery solution 2|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% sample        |Not detected |375.8775     |390.5969     |103.9        |
|          |recovery solution 3|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |Average recovery rate /%                                     |102.2        |
|          |-------------------------------------------------------------|-------------|
|          |Recovery rate RSD/%                                          |4            |
|          |-------------------------------------------------------------|-------------|
|          |Conclusions: No secondary butanol was detected in the samples.             |
|          |75.1755μg/ml-375.8775μg/ml of secondary butanol was added into the       |  
|          |samples. The recoveries of 9 samples were all in the range of              |
|          |98.7%-109.7% (the requirement was 85%-115%), and the average               |
|          |recoveries were 102.2%. The RSD of recovery was 4% (NMT 10%); All          |
|          |the above met the verification requirements, indicating that the           |
|          |method was accurate in detecting secondary butanol in YA2304.              |
|----------|---------------------------------------------------------------------------|
|Subst     |Solution name      |Original     |Amount       |Measured     |Recove ry    |
|ances Name|                   |amount in    |added        |amount       |rate /%      |
|          |                   |test product |(μg/ml)     |(μg/ml)     |             |  
|          |                   |(μg/ml)     |             |             |             | 
|----------|-------------------|-------------|-------------|-------------|-------------|
|tetrah    |30% sample recovery|Not detected |10.9763      |10.8178      |98.6         |
|ydrof uran|solution 1         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% sample recovery|Not detected |10.9763      |10.9247      |99.5         |
|          |solution 2         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% sample recovery|Not detected |10.9763      |10.7783      |98.2         |
|          |solution 3         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |Not detected |36.5875      |36.8776      |100.8        |
|          |recovery solution 1|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |Not detected |36.5875      |37.0832      |101.4        |
|          |recovery solution 2|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |Not detected |36.5875      |36.9783      |101.1        |
|          |recovery solution 3|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% sample        |Not detected |54.8813      |58.3538      |106.3        |
|          |recovery solution 1|             |             |             |             |
----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 350 of 542 





Page 351
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










































----------------------------------------------------------------------------------------
|          |150% recovery      |Not detected |54.8813      |56.3252      |102.6        |
|          |solution 2         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% sample        |Not detected |54.8813      |56.8066      |103.5        |
|          |recovery solution 3|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |Average recovery rate /%                                     |101.3        |
|          |-------------------------------------------------------------|-------------|
|          |Recovery rate RSD/%                                          |2.6          |
|          |-------------------------------------------------------------|-------------|
|          |Conclusions: Tetrahydrofuran was not detected in the test products,        |
|          |and 10.9763μg/ml-54.8813μg/ml of tetrahydrofuran was added into the      |  
|          |test products. The recovery rates of 9 samples were all in the range       |
|          |of 98.2%-106.3% (the requirement was 85%-115%), and the average            |
|          |recovery rate was 101.3%. The recovery RSD was 2.6% (the requirement       |
|          |was not more than 10%); All the above met the verification                 |
|          |requirements, indicating that the method was accurate in detecting         |
|          |tetrahydrofuran in YA2304.                                                 |
|----------|---------------------------------------------------------------------------|
|Subst     |Solution name      |Original     |Amount       |Measured     |Recove ry    |
|ances Name|                   |amount in    |added        |amount       |rate /%      |
|          |                   |test product |(μg/ml)     |(μg/ml)     |             |  
|          |                   |(μg/ml)     |             |             |             | 
|----------|-------------------|-------------|-------------|-------------|-------------|
|Tolue ne  |30% sample recovery|Not detected |15.0075      |14.9077      |99.3         |
|          |solution 1         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% sample recovery|Not detected |15.0075      |15.0652      |100.4        |
|          |solution 2         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% sample recovery|Not detected |15.0075      |14.8431      |98.9         |
|          |solution 3         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |Not detected |50.0250      |50.4010      |100.8        |
|          |recovery solution 1|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |Not detected |50.0250      |50.3329      |100.6        |
|          |recovery solution 2|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |100% sample        |Not detected |50.0250      |50.7148      |101.4        |
|          |recovery solution 3|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% sample        |Not detected |75.0375      |80.9908      |107.9        |
|          |recovery solution 1|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% sample        |Not detected |75.0375      |76.8254      |102.4        |
|          |recovery solution 2|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |150% sample        |Not detected |75.0375      |77.1206      |102.8        |
|          |recovery solution 3|             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |Average recovery rate /%                                     |101.6        |
|          |-------------------------------------------------------------|-------------|
|          |Recovery rate RSD/%                                          |2.7          |
|          |-------------------------------------------------------------|-------------|
|          |Conclusions: Toluene was not detected in the test products, and            |
|          |toluene control products of 15.0075μg/ml-75.0375μg/ml were added         |  
|          |into the test products. The recoveries of 9 samples were all in the        |
|          |range of 98.9%-107.9% (the requirements were in the range of               |
|          |85%-115%), and the average recoveries were 101.6%. The recovery RSD        |
|          |was 2.7% (no more than 10% required); All the above met the                |
|          |verification requirements, indicating that the method was accurate         |
|          |in detecting toluene in YA2304.                                            |
|----------|---------------------------------------------------------------------------|
|Subst     |Solution name      |Original     |Amount       |Measured     |Recove ry    |
|ances Name|                   |amount in    |added        |amount       |rate /%      |
|          |                   |test product |(μg/ml)     |(μg/ml)     |             |  
|          |                   |(μg/ml)     |             |             |             | 
|----------|-------------------|-------------|-------------|-------------|-------------|
|N-met     |30% sample recovery|Not detected |8.3063       |7.5231       |90.6         |
|hylpy     |solution 1         |             |             |             |             |
|rrolid one|                   |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% sample recovery|Not detected |8.3063       |7.7719       |93.6         |
|          |solution 2         |             |             |             |             |
|          |-------------------|-------------|-------------|-------------|-------------|
|          |30% sample recovery|Not detected |8.3063       |8.1034       |97.6         |
|          |solution 3         |             |             |             |             |
----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 351 of 542 





Page 352
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

-------------------------------------------------------------------------------------
|       |100% sample        |Not detected |27.6875      |26.8509      |97.0         |
|       |recovery solution 1|             |             |             |             |
|       |-------------------|-------------|-------------|-------------|-------------|
|       |100% sample        |Not detected |27.6875      |27.1560      |98.1         |
|       |recovery solution 2|             |             |             |             |
|       |-------------------|-------------|-------------|-------------|-------------|
|       |100% sample        |Not detected |27.6875      |26.9525      |97.3         |
|       |recovery solution 3|             |             |             |             |
|       |-------------------|-------------|-------------|-------------|-------------|
|       |150% sample        |Not detected |41.5313      |46.2093      |111.3        |
|       |recovery solution 1|             |             |             |             |
|       |-------------------|-------------|-------------|-------------|-------------|
|       |150% sample        |Not detected |41.5313      |42.9870      |103.5        |
|       |recovery solution 2|             |             |             |             |
|       |-------------------|-------------|-------------|-------------|-------------|
|       |150% sample        |Not detected |41.5313      |39.6163      |95.4         |
|       |recovery solution 3|             |             |             |             |
|       |-------------------|-------------|-------------|-------------|-------------|
|       |Average recovery rate /%                                     |98.3         |
|       |-------------------------------------------------------------|-------------|
|       |Recovery rate RSD/%                                          |7            |
|       |-------------------------------------------------------------|-------------|
|       |Conclusion: N-methylpyrrolidone was not detected in the samples, and       |
|       |8.3063μg/ml-41.5313μg/ml of N-methylpyrrolidone was added into the       |  
|       |samples. The recoveries of 9 samples were all in the range of              |
|       |90.6%-111.3% (the requirement was 85%-115%), and the average               |
|       |recoveries were 98.3%. The recovery RSD was 7% (no more than 10%           |
|       |required); All the above met the verification requirements,                |
|       |indicating that the method was accurate in detecting                       |
|       |N-methylpyrrolidone in YA2304.                                             |
-------------------------------------------------------------------------------------



**(4.6) Precision** 



Precision refers to the proximity between the results obtained by multiple 



sampling of the same uniform test product under specified test conditions, 



and its precision is judged by examining repeatability and reproducibility. 



**(4.6.1) Repeatability** 



 **Acceptance Criteria** 



6 repeatable sample solutions were prepared by analyst A on date A and 



measured by instrument A; The blank solution should be free from 



interference; In the chromatogram obtained from the control product 



solution, ethanol, isopropyl alcohol, ethyl acetate, secondary butanol, 



tetrahydrofuran, toluene, n-methylpyrrolidone peaks in turn, and the 



separation degree between each adjacent peak should be greater than 1.5. 



The RSD of each solvent in the 6 repeatable test product solutions NMT 10%. 



 **Solution preparation** 



Blank solution: solvent (N, n-dimethylformamide). 



Ethanol reference stock: Share ethanol reference stock under "4.1 System 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 352 of 542 





Page 353
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Suitability". (Approx. 50,000 μg/ml) 



Isopropyl alcohol reference reserve: Share isopropyl alcohol reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Ethyl acetate reference reserve: Share the ethyl acetate reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Secondary butanol reference product reserve: Share secondary butanol 



versus reference product reserve solution under "4.1 System Suitability". 



(Approx. 50,000 μg/ml) 



Tetrahydrofuran reference storage solution: Share tetrahydrofuran reference 



storage solution under "4.1 System Suitability". (Approx. 7200μg/ml) 



Toluene reference reserve: Share toluene reference reserve under "4.1 System 



Suitability". (Approx. 8900μg/ml) 



N-methylpyrrolidone reference stock: Share the N-methylpyrrolidone 



reference stock under "4.1 System Suitability". (Approx. 5300μg/ml) 



Repeatable reference product reserve liquid: precision measure ethanol 



reference product reserve liquid, isopropyl alcohol reference product reserve 



liquid, ethyl acetate reference product reserve liquid, secondary butanol 



reference product reserve liquid, tetrahydrofuran reference product reserve 



liquid, toluene reference product reserve liquid, N-methylpyrrolidone 



reference product reserve liquid 1.0ml each, put in 20ml bottle, dilute with 



solvent to scale, shake well, and obtain. (Ethanol about 2500μg/ml, 



isopropyl alcohol about 2500μg/ml, ethyl acetate about 2500μg/ml, 



secondary butanol about 2500μg/ml, tetrahydrofuran about 370μg/ml, 



toluene about 445μg/ml, N-methylpyrrolidone about 265μg/ml) 



Reference product solution: Accurately measure 1.0ml of the duplicate 



reference product reserve solution, place it in a 10ml bottle, dilute it with 



solvent to the scale, and shake well. (Ethanol about 250μg/ml, isopropyl 



alcohol about 250μg/ml, ethyl acetate about 250μg/ml, secondary butanol 



about 250μg/ml, tetrahydrofuran about 37μg/ml, toluene about 44.5μg/ml, 



N-methylpyrrolidone about 26.5μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 353 of 542 





Page 354
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Repeatable test product solution: accurately weigh about 0.5g of this product, 



accurately weigh it, put it in 10ml measuring bottle, then accurately measure 



1.0ml of repeatable control product reserve liquid, put it in the same 



measuring bottle, dissolve it with solvent and dilute it to the scale, shake well, 



and obtain. (Parallel preparation of 6 parts) 



 **Injection procedure** 



After the blank solution, the control solution and 6 repetitive test product 



solutions were injected respectively, and the chromatogram was recorded. 



 **Measurement resultss** 



Results of repeatability - system suitability test 

----------------------------------------------------------------------------
|Name of solvent         |Degree of separation                             |
|                        |-------------------------------------------------|
|                        |Reference solution -1   |Control solution -2     |
|------------------------|------------------------|------------------------|
|Ethanol                 |/                       |/                       |
|------------------------|------------------------|------------------------|
|Isopropyl alcohol       |8.5                     |8.5                     |
|------------------------|------------------------|------------------------|
|Ethyl acetate           |28.6                    |28.6                    |
|------------------------|------------------------|------------------------|
|sec-butanol             |1.8                     |1.8                     |
|------------------------|------------------------|------------------------|
|tetrahydrofuran         |1.9                     |1.9                     |
|------------------------|------------------------|------------------------|
|Toluene                 |37.8                    |37.6                    |
|------------------------|------------------------|------------------------|
|N-methylpyrrolidone     |93.7                    |93.9                    |
|------------------------|------------------------|------------------------|
|Conclusion: The blank solution has no interference; Ethanol, isopropyl    |
|alcohol, ethyl acetate, secondary butanol, tetrahydrofuran, toluene and   |
|n-methylpyrrolidone peaked in sequence in the chromatogram obtained from  |
|the control solution, and the separation degree between each adjacent     |
|solvent peak was greater than 1.5 (the requirement was greater than 1.5). |
|The suitability of the system meets the requirements.                     |
----------------------------------------------------------------------------



Repeatability test results 




























-----------------------------------------------------------------------------------
|Name of      |Residual solvent content /%                                        |
|solvent      |                                                                   |
|Solution name|                                                                   |
|             |-------------------------------------------------------------------|
|             |Repetiti |Repetiti |Repetiti |Repetiti |Repetiti |Repetiti |RSD/ % |
|             |ve test  |ve test  |ve test  |ve test  |ve test  |ve test  |(n=6)  |
|             |produc t |produc t |produc t |produc t |produc t |produc t |       |
|             |solutio n|solutio n|solutio n|solutio n|solutio n|solutio n|       |
|             |1        |2        |3        |4        |5        |6        |       |
|-------------|---------|---------|---------|---------|---------|---------|-------|
|Ethanol      |0.5754   |0.5806   |0.5779   |0.5758   |0.5773   |0.5687   |0.7    |
|-------------|---------|---------|---------|---------|---------|---------|-------|
|Isopropyl    |0.4952   |0.4992   |0.4955   |0.4953   |0.4918   |0.4882   |0.8    |
-----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 354 of 542 





Page 355
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



















--------------------------------------------------------------------------------------
|alcohol       |         |         |         |         |         |         |         |
|--------------|---------|---------|---------|---------|---------|---------|---------|
|Ethyl acetate |0.5128   |0.5167   |0.5124   |0.5123   |0.5097   |0.5048   |0.8      |
|--------------|---------|---------|---------|---------|---------|---------|---------|
|Sec-butyl     |0.4972   |0.4949   |0.4925   |0.4977   |0.4880   |0.4893   |0.9      |
|alcohol       |         |         |         |         |         |         |         |
|--------------|---------|---------|---------|---------|---------|---------|---------|
|tetrahydrofura|0.0756   |0.0750   |0.0748   |0.0753   |0.0740   |0.0738   |1.0      |
|n             |         |         |         |         |         |         |         |
|--------------|---------|---------|---------|---------|---------|---------|---------|
|Toluene       |0.1033   |0.1043   |0.1031   |0.1034   |0.1027   |0.1013   |1.0      |
|--------------|---------|---------|---------|---------|---------|---------|---------|
|N-methylpyrrol|0.0592   |0.0584   |0.0583   |0.0579   |0.0574   |0.0559   |2.0      |
|idone         |         |         |         |         |         |         |         |
|--------------|         |         |         |         |         |         |         |
|Verdict: The RSD of ethanol content was 0.7% (required less than 10%), the          |
|RSD of isopropyl alcohol content was 0.8% (required less than 10%), the RSD         |
|of ethyl acetate content was 0.8% (required less than 10%), and the RSD of          |
|secondary butanol content was 0.9% (required less than 10%). RSD of                 |
|tetrahydrofuran was 1.0% (NMT 10%), RSD of toluene was 1.0% (NMT 10%), and          |
|RSD of N-methylpyrrolidone was 2.0% (NMT 10%); All the above met the                |
|verification requirements, indicating that the method had good                      |
|repeatability.                                                                      |
--------------------------------------------------------------------------------------

**(4.6.2) Reproducibility** 



 **Acceptance Criteria** 



6 reproducible sample solutions were prepared by Analyst B on date B and 



determined using analytical laboratory instruments. The blank solution 



should be free of interference; In the chromatogram obtained for 6 



consecutive days, ethanol, isopropyl alcohol, ethyl acetate, secondary 



butanol, tetrahydrofuran, toluene, n-methylpyrrolidone peaks in turn, and 



the separation degree between each adjacent peak should be greater than 1.5. 



The RSD of the peak retention time of each solvent peak should NMT 1.0%, 



and the RSD of the peak area should NMT 10%. The RSD of each solvent in 6 



reproducible sample solutions NMT 10%; 



In the results of 12 repeatability and reproducibility tests, the RSD of each 



solvent content NMT 10%. 



 **Solution preparation** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 355 of 542 





Page 356
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Blank solution: solvent (N, n-dimethylformamide). 



Ethanol reference product reserve liquid: precision weigh ethanol about 



1000mg, put in 20ml bottle, dissolve with solvent and dilute to the scale, 



shake well, ready. (About 50000μg/ml) 



Isopropyl alcohol reference product reserve liquid: precision weigh isopropyl 



alcohol about 1000mg, place in 20ml bottle, dissolve with solvent and dilute 



to the scale, shake well, ready. (About 50000μg/ml) 



Ethyl acetate reference product reserve liquid: precision weigh about 1000mg 



of ethyl acetate, place in 20ml measuring bottle, dissolve and dilute with 



solvent to scale, shake well, ready. (Approx. 50000μg/ml) 



Secondary butanol reference product reserve liquid: precision weigh 



secondary butanol about 1000mg, place in 20ml bottle, dissolve and dilute 



with solvent to scale, shake well, then get. (About 50000μg/ml) 



Tetrahydrofuran reference product reserve liquid: accurately weigh 



tetrahydrofuran about 144mg, put it in 20ml bottle, dissolve it with solvent 



and dilute it to the scale, shake well, and then get. (About 7200μg/ml) 



Toluene control product reserve liquid: precision weigh toluene about 178mg, 



place in 20ml bottle, dissolve and dilute with solvent to scale, shake well, 



ready. (About 8900μg/ml) 



N-methylpyrrolidone reference product reserve liquid: accurately weigh 



N-methylpyrrolidone about 106mg, place in 20ml measuring bottle, dissolve 



and dilute with solvent to scale, shake well, then obtain. (About 5300μg/ml) 



Repeatable reference product reserve liquid: precision measure ethanol 



reference product reserve liquid, isopropyl alcohol reference product reserve 



liquid, ethyl acetate reference product reserve liquid, secondary butanol 



reference product reserve liquid, tetrahydrofuran reference product reserve 



liquid, toluene reference product reserve liquid, N-methylpyrrolidone 



reference product reserve liquid 1.0ml each, put in a 20ml bottle, dilute with 



solvent to the scale, shake well, and obtain. (Ethanol about 2500μg/ml, 



isopropyl alcohol about 2500μg/ml, ethyl acetate about 2500μg/ml, 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 356 of 542 





Page 357
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



secondary butanol about 2500μg/ml, tetrahydrofuran about 360μg/ml, 



toluene about 445μg/ml, N-methylpyrrolidone about 265μg/ml) 



Reference solution: Accurately measure 1.0ml of the reproducible reference 



reserve solution, place it in a 10ml measuring bottle, dilute it with solvent to 



the scale, shake well, and obtain. (Ethanol about 250μg/ml, isopropyl 



alcohol about 250μg/ml, ethyl acetate about 250μg/ml, secondary butanol 



about 250μg/ml, tetrahydrofuran about 36μg/ml, toluene about 44.5μg/ml, 



N-methylpyrrolidone about 26.5μg/ml) 



Reproducible test product solution: accurately weigh about 0.5g of this 



product, accurately weigh it, place it in 10ml measuring bottle, then 



accurately measure 1.0ml of reproducible control product reserve liquid, 



place it in the same measuring bottle, dissolve it with solvent and dilute it to 



the scale, shake well, and obtain. (Parallel preparation of 6 servings) 



 **Injection procedure** 



Reproducibility - System suitability: After the blank solution, continuous 



injection 6 for the sample solution, record the chromatogram. 



Reproducibility - Sample testing: After the blank solution, continuously 



inject 2 samples for the image solution and 6 reproducible test solution, and 



record the chromatogram. 



 **Measurement results** 



Reproducibility - system suitability test results 































































------------------------------------------------------------------------------------------
|Nam e of  |Parameter|Reference solution was injected                            |RSD /% |
|solv ent  |values   |                                                           |       |
|          |         |-----------------------------------------------------------|       |
|          |         |1        |2        |3        |4        |5        |6        |       |
|----------|---------|---------|---------|---------|---------|---------|---------|-------|
|Etha nol  |RT (min) |8.529    |8.529    |8.529    |8.525    |8.527    |8.529    |0.02 0 |
|          |---------|---------|---------|---------|---------|---------|---------|-------|
|          |Peak area|222.63 71|225.75 16|225.22 03|224.29 74|223.14 25|221.57 64|0.8    |
|          |---------|---------|---------|---------|---------|---------|---------|-------|
|          |Separatio|/        |/        |/        |/        |/        |/        |/      |
|          |n        |         |         |         |         |         |         |       |
|----------|---------|---------|---------|---------|---------|---------|---------|-------|
|Isop ropy |RT (min) |9.933    |9.932    |9.932    |9.928    |9.930    |9.932    |0.01 9 |
|l alc ohol|         |         |         |         |         |         |         |       |
|          |---------|---------|---------|---------|---------|---------|---------|-------|
|          |Peak area|221.84 10|224.06 69|225.77 57|223.69 06|221.82 37|221.34 30|0.8    |
------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 357 of 542 





Page 358
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



































































































































































-------------------------------------------------------------------------------------------
|          |Separatio|8.8      |8.7      |8.7      |8.7      |8.8      |8.9      |/       |
|          |n        |         |         |         |         |         |         |        |
|----------|---------|---------|---------|---------|---------|---------|---------|--------|
|Ethy l ac |RT (min) |14.546   |14.545   |14.546   |14.543   |14.546   |14.547   |0.01 0  |
|etat e    |         |         |         |         |         |         |         |        |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Peak area|184.41 56|187.26 00|187.34 29|185.48 64|185.10 12|183.09 72|0.9     |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Separatio|29.0     |28.9     |28.8     |28.9     |29.0     |29.1     |/       |
|          |n        |         |         |         |         |         |         |        |
|----------|---------|---------|---------|---------|---------|---------|---------|--------|
|Seco ndar |RT (min) |14.815   |14.815   |14.816   |14.813   |14.816   |14.817   |0.01 0  |
|y bu tano |         |         |         |         |         |         |         |        |
|l         |         |         |         |         |         |         |         |        |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Peak area|291.66 44|297.07 76|297.74 93|295.10 50|294.48 60|290.67 89|1.0     |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Separatio|1.7      |1.7      |1.7      |1.7      |1.7      |1.7      |/       |
|          |n        |         |         |         |         |         |         |        |
|----------|---------|---------|---------|---------|---------|---------|---------|--------|
|tetra hydr|RT (min) |15.125   |15.123   |15.124   |15.122   |15.123   |15.126   |0.01 0  |
|ofur an   |         |         |         |         |         |         |         |        |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Peak area|39.618 2 |41.084 2 |40.338 7 |40.160 9 |41.254 7 |39.426 3 |1.9     |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Separatio|2.0      |2.0      |2.0      |2.0      |2.0      |2.0      |/       |
|          |n        |         |         |         |         |         |         |        |
|----------|---------|---------|---------|---------|---------|---------|---------|--------|
|Tolu ene  |RT (min) |20.400   |20.398   |20.398   |20.398   |20.401   |20.401   |0.00 8  |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Peak area|94.967 9 |96.218 0 |96.464 1 |95.508 1 |95.164 9 |94.401 7 |0.9     |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Separatio|37.4     |37.2     |37.4     |37.3     |37.2     |37.4     |/       |
|          |n        |         |         |         |         |         |         |        |
|----------|---------|---------|---------|---------|---------|---------|---------|--------|
|N-m ethy  |RT (min) |31.551   |31.549   |31.549   |31.549   |31.551   |31.552   |0.00 5  |
|lpyrr     |         |         |         |         |         |         |         |        |
|olido ne  |         |         |         |         |         |         |         |        |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Peak area|32.709 8 |32.704 6 |32.738 0 |31.226 5 |33.035 4 |32.010 2 |3.1     |
|          |---------|---------|---------|---------|---------|---------|---------|--------|
|          |Separatio|92.4     |92.6     |92.5     |92.8     |92.7     |92.6     |/       |
|          |n        |         |         |         |         |         |         |        |
|----------|---------|---------|---------|---------|---------|---------|---------|--------|
|Conclusion: There was no interference in the blank solution. In the                      |
|chromatogram obtained for 6 consecutive days, peaks of ethanol, isopropyl                |
|alcohol, ethyl acetate, secondary butanol, tetrahydrofuran, toluene and                  |
|n-methylpyrrolidone appeared successively, and the separation degree                     |
|between each adjacent solvent peak was greater than 1.5 (the requirement                 |
|was greater than 1.5). The RSD of ethanol peak retention time was 0.020%                 |
|(required less than 1.0%), and the RSD of peak area was                                  |
-------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 358 of 542 





Page 359
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



0.8% (required less than 10%). The RSD of isopropyl alcohol peak retention time was 



0.019% (NMT 1.0%), and the RSD of peak area was 0.8% (NMT 10%); The RSD of the 



ethyl acetate peak was 0.010% (NMT 1.0%), and the RSD of the peak area was 0.9% 



(NMT 10%); The RSD of secondary butanol was 0.010% (NMT 1.0%), and the RSD of 



peak area was 1.0% (NMT 10%); The RSD of the peak retention time of 



tetrahydrofuran was 0.010% (NMT 1.0%), and the RSD of the peak area was 1.9% 



(NMT 10%); The RSD of toluene peak was 0.008% (NMT 1.0%), and the RSD of peak 



area was 0.9% (NMT 10%); The RSD of the N-methylpyrrolidone peak was 0.005% 



(NMT 1.0%), and the RSD of the peak area was 2.1% (NMT 10%); The suitability of the 



system met the verification requirements. 



Precision (repeatability and reproducibility) test results 
























































































--------------------------------------------------------------------------------------
|Solvent name              |Residual solvent content /%                              |
|Solution name             |                                                         |
|                          |---------------------------------------------------------|
|          |               |Repeatability                                            |
|          |               |---------------------------------------------------------|
|          |               |1      |2      |3      |4      |5      |6      |RSD (n=6)|
|----------|---------------|-------|-------|-------|-------|-------|-------|---------|
|R e p e at|Ethanol        |0.5754 |0.5806 |0.5779 |0.5758 |0.5773 |0.5687 |0.7%     |
|a bi lit y|               |       |       |       |       |       |       |         |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |Isopropyl      |0.4952 |0.4992 |0.4955 |0.4953 |0.4918 |0.4882 |0.8%     |
|          |alcohol        |       |       |       |       |       |       |         |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |Ethyl acetate  |0.5128 |0.5167 |0.5124 |0.5123 |0.5097 |0.5048 |0.8%     |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |sec-butanol    |0.4972 |0.4949 |0.4925 |0.4977 |0.4880 |0.4893 |0.9%     |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |tetrahydrofura |0.0756 |0.0750 |0.0748 |0.0753 |0.0740 |0.0738 |1.0%     |
|          |n              |       |       |       |       |       |       |         |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |Toluene        |0.1033 |0.1043 |0.1031 |0.1034 |0.1027 |0.1013 |1.0%     |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |N-methylpyrroli|0.0592 |0.0584 |0.0583 |0.0579 |0.0574 |0.0559 |2.0%     |
|          |done           |       |       |       |       |       |       |         |
|----------|---------------|-------|-------|-------|-------|-------|-------|---------|
|R e p r o |Ethanol        |0.5943 |0.6102 |0.6295 |0.5872 |0.5492 |0.5650 |5%       |
|d u ci bi |               |       |       |       |       |       |       |         |
|lit y     |               |       |       |       |       |       |       |         |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |Isopropyl      |0.4836 |0.4946 |0.5138 |0.4762 |0.4493 |0.4600 |5%       |
|          |alcohol        |       |       |       |       |       |       |         |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |Ethyl acetate  |0.5049 |0.5139 |0.5255 |0.4973 |0.4681 |0.4797 |5%       |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |sec-butanol    |0.4795 |0.4912 |0.5135 |0.4720 |0.4461 |0.4571 |6%       |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |tetrahydrofura |0.0775 |0.0804 |0.0815 |0.0782 |0.0723 |0.0731 |5%       |
|          |n              |       |       |       |       |       |       |         |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |Toluene        |0.0996 |0.1014 |0.1042 |0.0982 |0.0926 |0.0947 |5%       |
|          |---------------|-------|-------|-------|-------|-------|-------|---------|
|          |N-methylpyrroli|0.0502 |0.0505 |0.0541 |0.0490 |0.0475 |0.0492 |5%       |
|          |done           |       |       |       |       |       |       |         |
|----------|               |-------|-------|-------|-------|-------|-------|---------|
|Precision RSD             |4%     |4%     |4%     |4%     |4%     |9%     |/        |
--------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 359 of 542 





Page 360
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

---------------------------------------------------------------------------------
|(n=12)   |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|
|Verdict: The RSD of ethanol content in 6 reproducible samples was 0.7%         |
|(required less than 10%), the RSD of isopropyl alcohol content was 0.8%        |
|(required less than 10%), the RSD of ethyl acetate content was 0.8%            |
|(required less than 10%) and the RSD of secondary butanol content was 0.9%     |
|(required less than 10%). RSD of tetrahydrofuran was 1.0% (NMT 10%), RSD of    |
|toluene was 1.0% (NMT 10%), and RSD of N-methylpyrrolidone was 2.0% (NMT       |
|10%); All the above met the verification requirements, indicating that the     |
|method has good reproducibility. The reproducibility and intermediate          |
|precision 12 results showed that RSD of ethanol content was 4% (NMT 10%),      |
|RSD of isopropyl alcohol content was 4% (NMT 10%), RSD of ethyl acetate        |
|content was 4% (NMT 10%), and RSD of secondary butanol content was 4% (NMT     |
|10%). RSD of tetrahydrofuran was 4% (NMT 10%), RSD of toluene was 4% (NMT      |
|10%), and RSD of N-methylpyrrolidone was 9% (NMT 10%); All the above meet      |
|the verification requirements, indicating that the method is of good           |
|precision.                                                                     |
---------------------------------------------------------------------------------



**(4.7) Durability** 



 **Brief Description** 



By changing the chromatographic conditions (changing the initial 



temperature, flow rate, column) and normal chromatographic conditions to 



test the solvent content of each test product solution to achieve, the 



chromatographic diagram obtained by the control product solution, methyl 



ethanol, isopropyl alcohol, ethyl acetate, secondary butanol, tetrahydrofuran, 



toluene, n-methylpyrrolidone peaks in turn, the separation degree between 



the adjacent peaks should be greater than 1.5. Under different conditions of 



the same chromatographic parameters, the RSD of each solvent content to be 



measured in the test product solution should not be 10%. 



Changes in chromatographic conditions for durability test 

----------------------------------------------------------
|Chromatographic|Standard conditions|Variable Values     |
|Parameters     |                   |                    |
|---------------|-------------------|--------------------|
|Flow rate      |3.5 ml/min         |3.4ml/min, 3.6ml/min|
|---------------|-------------------|--------------------|
|Initial column |40 ℃              |35℃, 45℃          |   
|temperature    |                   |                    |
|---------------|-------------------|--------------------|
|Column         |Column 1           |Column 2            |
----------------------------------------------------------



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 360 of 542 





Page 361
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




(DB-624, 60m*0.53mm, 
3.0μm, SN: US1501943H, 

Serial number: CXGC-1) 



 **Solution preparation** 



Blank solution: solvent (N, n-dimethylformamide). 




(DB-624, 60m*0.53mm, 
3.0μm, SN: US1111842H, 

Serial number: YLGC-2) 




Ethanol reference stock: Share ethanol reference stock under "4.1 System 



Suitability". (Approx. 50,000 μg/ml) 



Isopropyl alcohol reference reserve: Share isopropyl alcohol reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Ethyl acetate reference reserve: Share the ethyl acetate reference reserve 



under "4.1 System Suitability". (Approx. 50,000 μg/ml) 



Secondary butanol reference product reserve: Share secondary butanol 



versus reference product reserve solution under "4.1 System Suitability". 



(Approx. 50,000 μg/ml) 



Tetrahydrofuran reference storage solution: Share tetrahydrofuran reference 



storage solution under "4.1 System Suitability". (Approx. 7200μg/ml) 



Toluene reference reserve: Share toluene reference reserve under "4.1 System 



Suitability". (Approx. 8900μg/ml) 



N-methylpyrrolidone reference stock: Share the N-methylpyrrolidone 



reference stock under "4.1 System Suitability". (Approx. 5300μg/ml) 



Durable reference product reserve liquid: precision measure ethanol 



reference product reserve liquid, isopropyl alcohol reference product reserve 



liquid, ethyl acetate reference product reserve liquid, secondary butanol 



reference product reserve liquid, tetrahydrofuran reference product reserve 



liquid, toluene reference product reserve liquid, N-methylpyrrolidone 



reference product reserve liquid 1.0ml each, put in 20ml bottle, dilute with 



solvent to the scale, shake well, ready. (Ethanol about 2500μg/ml, isopropyl 



alcohol about 2500μg/ml, ethyl acetate about 2500μg/ml, secondary 



butanol about 2500μg/ml, tetrahydrofuran about 360μg/ml, toluene about 



445μg/ml, N-methylpyrrolidone about 265μg/ml) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 361 of 542 





Page 362
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Durability reference product solution: accurately measure 1.0ml of the 



durability reference product reserve solution, place it in a 10ml measuring 



bottle, dilute it with solvent to the scale, shake well, and obtain. (Ethanol 



about 250μg/ml, isopropyl alcohol about 250μg/ml, ethyl acetate about 



250μg/ml, secondary butanol about 250μg/ml, tetrahydrofuran about 



36μg/ml, toluene about 44.5μg/ml, N-methylpyrrolidone about 26.5μg/ml) 



Durability test product solution: precision weigh about 0.5g of this product, 



precision weigh, put in 10ml measuring bottle, then precision measure the 



durability control product reserve liquid 1.0ml put in the same measuring 



bottle, dissolve with solvent and dilute to the scale, shake well, and then get. 



(Parallel preparation of 2 servings) 



 **Injection procedure** 



Under each chromatographic condition, after the blank solution, the control 



product solution and the test product solution were injected respectively, 



and the chromatogram was recorded. 



 **Measurement resultss** 



Results of durability - system suitability test 




































------------------------------------------------------------------------------------------
|Name of    |Sampl e   |Degree of separation                                             |
|solvent    |injecti on|                                                                 |
|           |Numb er of|                                                                 |
|           |times     |                                                                 |
|           |          |-----------------------------------------------------------------|
|           |          |Ethan ol|Isopro pyl|Ethyl  |sec-b  |tetrah    |Tolue ne|N-methy  |
|           |          |        |alcoh ol  |acetate|utano l|ydrof uran|        |lpyrrolid|
|           |          |        |          |       |       |          |        |one      |
|-----------|----------|--------|----------|-------|-------|----------|--------|---------|
|Normal     |1         |/       |8.8       |28.9   |1.8    |1.9       |37.9    |94.7     |
|conditions |          |        |          |       |       |          |        |         |
|           |----------|--------|----------|-------|-------|----------|--------|---------|
|           |2         |/       |8.7       |29.0   |1.8    |1.9       |37.9    |95.0     |
|-----------|----------|--------|----------|-------|-------|----------|--------|---------|
|Flow rate  |1         |/       |8.9       |29.3   |1.8    |2.0       |38.1    |93.6     |
|(3.4ml/min)|          |        |          |       |       |          |        |         |
|           |----------|--------|----------|-------|-------|----------|--------|---------|
|           |2         |/       |8.8       |29.0   |1.8    |2.0       |38.2    |94.0     |
|-----------|----------|--------|----------|-------|-------|----------|--------|---------|
|Flow rate  |1         |/       |8.7       |28.9   |1.8    |1.9       |37.9    |96.0     |
|(3.6ml/min)|          |        |          |       |       |          |        |         |
|           |----------|--------|----------|-------|-------|----------|--------|---------|
|           |2         |/       |8.5       |28.6   |1.8    |1.8       |37.8    |95.7     |
|-----------|----------|--------|----------|-------|-------|----------|--------|---------|
|Initial    |1         |/       |9.2       |29.6   |1.9    |1.8       |38.4    |94.7     |
|column     |          |        |          |       |       |          |        |         |
|temperature|          |        |          |       |       |          |        |         |
|(35 ° C)  |          |        |          |       |       |          |        |         | 
|           |----------|--------|----------|-------|-------|----------|--------|---------|
|           |2         |/       |9.3       |29.8   |1.9    |1.8       |38.4    |94.7     |
------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 362 of 542 





Page 363
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 









-----------------------------------------------------------------------------
|Initial    |1      |/      |8.2    |28.3   |1.7    |2.0    |37.5   |94.4   |
|column     |       |       |       |       |       |       |       |       |
|temperature|       |       |       |       |       |       |       |       |
|(45 ° C)  |       |       |       |       |       |       |       |       | 
|           |-------|-------|-------|-------|-------|-------|-------|-------|
|           |2      |/      |8.3    |28.3   |1.7    |2.1    |37.4   |94.7   |
|-----------|-------|-------|-------|-------|-------|-------|-------|-------|
|Column 2   |1      |/      |8.8    |29.2   |1.8    |1.9    |38.0   |93.6   |
|           |-------|-------|-------|-------|-------|-------|-------|-------|
|           |2      |/      |8.9    |29.3   |1.8    |1.9    |37.8   |94.0   |
-----------------------------------------------------------------------------

Durability test results 





































-------------------------------------------------------------------------------------------------
|Changing           |Num ber of|Residual solvent content /%                                     |
|condition          |injec     |                                                                |
|s                  |tions     |                                                                |
|                   |          |----------------------------------------------------------------|
|          |        |          |Ethano l|Isopro pyl|Ethyl  |sec-bu |tetrahy  |Tolue ne|N-methy  |
|          |        |          |        |alcohol   |acetate|tanol  |drofur an|        |lpyrrolid|
|          |        |          |        |          |       |       |         |        |one      |
|----------|--------|----------|--------|----------|-------|-------|---------|--------|---------|
|V el o ci |3.4 ml/m|1         |0.5963  |0.5123    |0.5227 |0.5077 |0.0764   |0.105 3 |0.0556   |
|ty of fl o|in      |          |        |          |       |       |         |        |         |
|w         |        |          |        |          |       |       |         |        |         |
|          |        |----------|--------|----------|-------|-------|---------|--------|---------|
|          |        |2         |0.5942  |0.5115    |0.5232 |0.5096 |0.0768   |0.105 2 |0.0554   |
|          |--------|----------|--------|----------|-------|-------|---------|--------|---------|
|          |3.5 ml/m|1         |0.5810  |0.4949    |0.5091 |0.4944 |0.0745   |0.102 5 |0.0576   |
|          |in      |          |        |          |       |       |         |        |         |
|          |        |----------|--------|----------|-------|-------|---------|--------|---------|
|          |        |2         |0.5730  |0.4880    |0.5019 |0.4884 |0.0733   |0.100 9 |0.0609   |
|          |--------|----------|--------|----------|-------|-------|---------|--------|---------|
|          |3.6 ml/m|1         |0.5735  |0.4939    |0.5041 |0.4911 |0.0735   |0.102 1 |0.0556   |
|          |in      |          |        |          |       |       |         |        |         |
|          |        |----------|--------|----------|-------|-------|---------|--------|---------|
|          |        |2         |0.5790  |0.4967    |0.5095 |0.4972 |0.0743   |0.102 5 |0.0589   |
|          |--------|----------|--------|----------|-------|-------|---------|--------|---------|
|          |RSD/% (n=6)        |1.8     |2.1       |1.8    |1.8    |2.0      |1.8     |4        |
|----------|-------------------|--------|----------|-------|-------|---------|--------|---------|
|In iti al |35 ℃   |1         |0.5791  |0.4968    |0.5101 |0.4956 |0.0743   |0.103 3 |0.0605   | 
|c ol u m n|        |          |        |          |       |       |         |        |         |
|te m p er |        |          |        |          |       |       |         |        |         |
|at        |        |          |        |          |       |       |         |        |         |
|          |        |----------|--------|----------|-------|-------|---------|--------|---------|
|          |        |2         |0.5811  |0.4963    |0.5098 |0.5016 |0.0735   |0.102 9 |0.0618   |
|          |--------|----------|--------|----------|-------|-------|---------|--------|---------|
|          |40 ℃   |1         |0.5810  |0.4949    |0.5091 |0.4944 |0.0745   |0.102 5 |0.0576   | 
|          |        |----------|--------|----------|-------|-------|---------|--------|---------|
|          |        |2         |0.5730  |0.4880    |0.5019 |0.4884 |0.0733   |0.100 9 |0.0609   |
|          |--------|----------|--------|----------|-------|-------|---------|--------|---------|
|          |45 ℃   |1         |0.5829  |0.4985    |0.5117 |0.5002 |0.0738   |0.103 9 |0.0613   | 
|          |        |----------|--------|----------|-------|-------|---------|--------|---------|
|          |        |2         |0.5793  |0.4966    |0.5114 |0.4977 |0.0738   |0.103 2 |0.0591   |
|          |--------|----------|--------|----------|-------|-------|---------|--------|---------|
|          |RSD/% (n=6)        |0.6     |0.8       |0.8    |1.0    |0.7      |1.0     |2.6      |
-------------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 363 of 542 


























Page 364
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



















--------------------------------------------------------------------------------------
|u re      |                 |       |       |       |       |       |       |       |
|----------|-----------------|-------|-------|-------|-------|-------|-------|-------|
|C ol u m n|Colu mn 1|1      |0.5963 |0.5123 |0.5227 |0.5077 |0.0764 |0.105 3|0.0556 |
|          |         |-------|-------|-------|-------|-------|-------|-------|-------|
|          |         |2      |0.5942 |0.5115 |0.5232 |0.5096 |0.0768 |0.105 2|0.0554 |
|          |---------|-------|-------|-------|-------|-------|-------|-------|-------|
|          |Colu mn 2|1      |0.5669 |0.4898 |0.5009 |0.4891 |0.0723 |0.102 0|0.0576 |
|          |         |-------|-------|-------|-------|-------|-------|-------|-------|
|          |         |2      |0.5752 |0.4921 |0.5071 |0.4964 |0.0750 |0.102 4|0.0559 |
|          |---------|-------|-------|-------|-------|-------|-------|-------|-------|
|          |RSD/% (n=4)      |2.5    |2.5    |2.2    |2.0    |2.8    |1.8    |1.8    |
|----------|-----------------|-------|-------|-------|-------|-------|-------|-------|
|Conclusion: The blank solution has no interference; Ethanol, isopropyl              |
|alcohol, ethyl acetate, secondary butanol, tetrahydrofuran, toluene and             |
|n-methylpyrrolidone peaks in the chromatogram obtained from the control             |
|solution with the same chromatographic parameters under different                   |
|conditions, and the separation degree between each adjacent solvent peak is         |
|greater than 1.5 (the requirement is greater than 1.5). RSDS of each                |
|solvent content in the test product solution under different conditions of          |
|the same chromatographic parameters were all less than 10% (the requirement         |
|is not greater than 10%); All the above meet the requirements, indicating           |
|that the method has good durability.                                                |
--------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 364 of 542 





Page 365
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**III. Summary of Method Validation** 



Summaries of Method Validation of Residual Solvents in Finerenone 












------------------------------------------------------------------------------------------------------------------------
|Project      |Acceptable criteria               |Verification of results                                              |
|-------------|----------------------------------|---------------------------------------------------------------------|
|System       |The blank solution should be free |There was no interference in the blank solution. In the chromatogram |
|suitabil     |of                                |obtained                                                             |
|ity          |interference; In the chromatogram |from the irradiation solution for 6 consecutive years, the peaks of  |
|             |obtained for 6 consecutive days,  |ethanol,                                                             |
|             |ethanol, isopropyl alcohol, ethyl |isopropyl alcohol, ethyl acetate, secondary butanol, tetrahydrofuran,|
|             |acetate, secondary butanol,       |toluene                                                              |
|             |tetrahydrofuran, toluene,         |and n-methylpyrrolidone appeared successively, and the separation    |
|             |n-methylpyrrolidone peaks in turn,|degree                                                               |
|             |and the separation degree between |between each adjacent solvent peak was greater than 1.5 (the         |
|             |each adjacent peak should be      |requirement was                                                      |
|             |greater                           |greater than 1.5). The RSD of ethanol peak retention time was 0.13%  |
|             |than 1.5. The RSD of the peak     |(NMT 1.0%),                                                          |
|             |retention time of each solvent    |and the RSD of peak area was 0.8% (NMT 10%). The RSD of isopropyl    |
|             |peak                              |alcohol peak                                                         |
|             |should NMT 1.0%, and the RSD of   |retention time was 0.12% (NMT 1.0%), and the RSD of peak area was    |
|             |the                               |1.0% (NMT                                                            |
|             |peak area should NMT 10%.         |10%); The RSD of the ethyl acetate peak was 0.08% (NMT 1.0%), and the|
|             |                                  |RSD of                                                               |
|             |                                  |the peak area was 0.9% (NMT 10%); The RSD of secondary butanol was   |
|             |                                  |0.08% (NMT                                                           |
|             |                                  |1.0%), and the RSD of peak area was 0.9% (NMT 10%); The RSD of the   |
|             |                                  |peak                                                                 |
|             |                                  |retention time of tetrahydrofuran was 0.08% (NMT 1.0%), and the RSD  |
|             |                                  |of the peak                                                          |
|             |                                  |area was 0.8% (NMT 10%); The RSD of toluene peak was 0.05% (NMT      |
|             |                                  |1.0%), and the                                                       |
|             |                                  |RSD of peak area was 1.0% (NMT 10%); The RSD of the                  |
|             |                                  |N-methylpyrrolidone peak                                             |
|             |                                  |was 0.015% (NMT 1.0%), and the RSD of the peak area was 2.7% (NMT    |
|             |                                  |10%); All the                                                        |
|             |                                  |above meet the verification requirements, indicating that the method |
|             |                                  |has good                                                             |
|             |                                  |applicability in system.                                             |
|-------------|----------------------------------|---------------------------------------------------------------------|
|Specific     |There was no interference in the  |There was no interference in the blank solution. In the control      |
|ity          |blank solution. In the control    |solution, the                                                        |
|             |solution, the peaks of ethanol,   |peaks of ethanol, isopropyl alcohol, ethyl acetate, secondary        |
|             |isopropyl alcohol, ethyl acetate, |butanol,                                                             |
|             |secondary butanol,                |tetrahydrofuran, toluene and n-methylpyrrolidone appeared            |
|             |tetrahydrofuran,                  |successively, and the                                                |
|             |toluene and n-methylpyrrolidone   |separation degree between the peaks of each adjacent solvent was     |
|             |appeared                          |greater than                                                         |
|             |                                  |1.5 (the requirement was greater than 1.5). The separation degree    |
|             |                                  |between                                                              |
|             |                                  |individual solvent peaks and adjacent peaks in the specific mixed    |
|             |                                  |solution and                                                         |
|             |                                  |the test solution is NLT 1.5, the retention time of each known       |
|             |                                  |solvent                                                              |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 365 of 542 





Page 366
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 













































-------------------------------------------------------------------------------------------------------------------------
|        |successively, and  |peak in the specific mixed solution and the test solution is consistent with    |        | 
|        |the separation     |the retention time of each solvent positioning solution, and other solvent      |        | 
|        |degree between the |positioning solutions (benzene, piperidine) have no interference with the       |        | 
|        |adjacent peaks     |target solvent peak. Soluti on Name Component name Compone nt concentr ation    |        | 
|        |should be greater  |(μg/ml) Rt (min) Degree of separatio n from the previous peak The percentage   |        |  
|        |than 1.5; The      |equivalent to the concentration of the principal component in the test solution |        | 
|        |separation degree  |Specifi c mixed solutio n Ethanol 250.278 8.149 / 0.5% Isopropyl alcohol        |        | 
|        |of each solvent    |250.410 9.504 8.2 0.5% Ethyl acetate 248.695 14.145 28.2 0.5% sec-butanol       |        | 
|        |peak and adjacent  |250.585 14.429 1.8 0.5% tetrahydrofuran 36.588 14.728 1.9 0.072% Toluene 50.025 |        | 
|        |peaks in the       |20.061 37.5 0.089% N-methylpyrroli done 27.6875 31.390 94.3 0.053%              |        | 
|        |specific mixed     |                                                                                |        | 
|        |solution and the   |                                                                                |        | 
|        |test               |                                                                                |        | 
|        |product solution is|                                                                                |        | 
|        |NLT 1.5, the       |                                                                                |        | 
|        |retention time of  |                                                                                |        | 
|        |each known solvent |                                                                                |        | 
|        |peak in the        |                                                                                |        | 
|        |specific mixed     |                                                                                |        | 
|        |solution           |                                                                                |        | 
|        |and the test       |                                                                                |        | 
|        |product solution   |                                                                                |        | 
|        |should             |                                                                                |        | 
|        |be consistent with |                                                                                |        | 
|        |the retention      |                                                                                |        | 
|        |time of each       |                                                                                |        | 
|        |solvent positioning|                                                                                |        | 
|        |solution, and the  |                                                                                |        | 
|        |positioning        |                                                                                |        | 
|        |solution of other  |                                                                                |        | 
|        |solvents           |                                                                                |        | 
|        |(piperidine,       |                                                                                |        | 
|        |benzene) has no    |                                                                                |        | 
|        |interference with  |                                                                                |        | 
|        |the target solvent |                                                                                |        | 
|        |peak.              |                                                                                |        | 
|        |                   |                                                                                |--------| 
|        |                   |        |Soluti  |Component name   |Compone |Rt (min)|        |Degree  |The percentage   | 
|        |                   |        |on      |                 |nt      |        |        |of      |equivalent to the| 
|        |                   |        |Name    |                 |concentr|        |        |separatio|concentration of |
|        |                   |        |        |                 |ation   |        |        |n from  |the principal    | 
|        |                   |        |        |                 |(μg/ml)|        |        |the     |component in the |  
|        |                   |        |        |                 |        |        |        |previous|test solution    | 
|        |                   |        |        |                 |        |        |        |peak    |                 | 
|        |                   |        |--------|-----------------|--------|--------|        |--------|-----------------| 
|        |                   |        |Specifi |Ethanol          |250.278 |8.149   |        |/       |0.5%             | 
|        |                   |        |c       |                 |        |        |        |        |                 | 
|        |                   |        |mixed   |                 |        |        |        |        |                 | 
|        |                   |        |solutio |                 |        |        |        |        |                 | 
|        |                   |        |n       |                 |        |        |        |        |                 | 
|        |                   |        |        |-----------------|--------|--------|        |--------|-----------------| 
|        |                   |        |        |Isopropyl        |250.410 |9.504   |        |8.2     |0.5%             | 
|        |                   |        |        |alcohol          |        |        |        |        |                 | 
|        |                   |        |        |-----------------|--------|--------|        |--------|-----------------| 
|        |                   |        |        |Ethyl acetate    |248.695 |14.145  |        |28.2    |0.5%             | 
|        |                   |        |        |-----------------|--------|--------|        |--------|-----------------| 
|        |                   |        |        |sec-butanol      |250.585 |14.429  |        |1.8     |0.5%             | 
|        |                   |        |        |-----------------|--------|--------|        |--------|-----------------| 
|        |                   |        |        |tetrahydrofuran  |36.588  |14.728  |        |1.9     |0.072%           | 
|        |                   |        |        |-----------------|--------|--------|        |--------|-----------------| 
|        |                   |        |        |Toluene          |50.025  |20.061  |        |37.5    |0.089%           | 
|        |                   |        |        |-----------------|--------|--------|        |--------|-----------------| 
|        |                   |        |        |N-methylpyrroli  |27.6875 |31.390  |        |94.3    |0.053%           | 
|        |                   |        |        |done             |        |        |        |        |                 | 
|--------|-------------------|--------|--------|                 |        |        |--------|        |                 | 
|Limits  |The S/N of each    |        |Compone |        |Detection Limits          |Limit of quantitation     |        | 
|of      |solvent peak in the|        |nt      |        |                          |                          |        | 
|quantifi|6 LOQ solution maps|        |Name    |        |                          |                          |        | 
|cation, |should be NLT      |        |        |        |                          |                          |        | 
|detectio|10, the RSD of     |        |        |        |                          |                          |        | 
|n       |retention time     |        |        |        |                          |                          |        | 
|        |should             |        |        |        |                          |                          |        | 
|        |be no more than    |        |        |        |                          |                          |        | 
|        |2.0%, and the RSD  |        |        |        |                          |                          |        | 
|        |of                 |        |        |        |                          |                          |        | 
|        |peak area should be|        |        |        |                          |                          |        | 
|        |no more than       |        |        |        |                          |                          |        | 
|        |10%. The S/N of    |        |        |        |                          |                          |        | 
|        |each solvent peak  |        |        |        |                          |                          |        | 
|        |in                 |        |        |        |                          |                          |        | 
|        |the 3-needle Limit |        |        |        |                          |                          |        | 
|        |of detection       |        |        |        |                          |                          |        | 
|        |(LOD) solution     |        |        |        |                          |                          |        | 
|        |atlas should be NLT|        |        |        |                          |                          |        | 
|        |3.                 |        |        |        |                          |                          |        | 
|        |                   |        |        |--------|--------------------------|--------------------------|        | 
|        |                   |        |        |        |Concentration (equivalent |Concentration (equivalent to the   | 
|        |                   |        |        |        |to the                    |test product solution              | 
|        |                   |        |        |        |percentage of solution    |concentration percentage)          | 
|        |                   |        |        |        |concentration of the test |                                   | 
|        |                   |        |        |        |product)                  |                                   | 
|        |                   |        |--------|--------|--------------------------|-----------------------------------| 
|        |                   |        |Ethyl            |1.502μg/ml (0.003%)      |5.006μg/ml (0.01%)                |   
|        |                   |        |alcohol          |                          |                                   | 
|        |                   |        |-----------------|--------------------------|-----------------------------------| 
|        |                   |        |Isopropyl        |1.502μg/ml (0.003%)      |5.008μg/ml (0.01%)                |   
|        |                   |        |alcohol          |                          |                                   | 
|        |                   |        |-----------------|--------------------------|-----------------------------------| 
|        |                   |        |Ethyl            |1.492μg/ml (0.003%)      |4.974μg/ml (0.01%)                |   
-------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 366 of 542 





Page 367
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



















































------------------------------------------------------------------------------------------------------------------------
|          |                         |       |acetate   |                         |                            |       |
|          |                         |       |----------|-------------------------|----------------------------|       |
|          |                         |       |sec-butan |1.128μg/ml (0.002%)     |3.759μg/ml (0.008%)        |       |  
|          |                         |       |ol        |                         |                            |       |
|          |                         |       |----------|-------------------------|----------------------------|       |
|          |                         |       |tetrahydro|1.098μg/ml (0.002%)     |3.659μg/ml (0.007%)        |       |  
|          |                         |       |furan     |                         |                            |       |
|          |                         |       |----------|-------------------------|----------------------------|       |
|          |                         |       |Toluene   |0.600μg/ml (0.001%)     |2.001μg/ml (0.004%)        |       |  
|----------|-------------------------|-------|----------|-------------------------|----------------------------|-------|
|          |                         |       |N-methylp |0.831μg/ml (0.002%)     |2.769μg/ml (0.006%)        |       |  
|          |                         |       |yrrolidone|                         |                            |       |
|----------|-------------------------|-------|----------|-------------------------|----------------------------|-------|
|Linearit y|Within the limit         |       |Component            |Concentration (equivalent to |Linear       |       |
|and range |concentration range      |       |Names                |the                          |equation     |       |
|          |of LOQ concentration     |       |                     |concentration percentage of  |             |       |
|          |~200% of each            |       |                     |the test                     |             |       |
|          |solvent, 6 concentration |       |                     |product solution)            |             |       |
|          |points were              |       |                     |                             |             |       |
|          |selected fairly          |       |                     |                             |             |       |
|          |uniformly, with the      |       |                     |                             |             |       |
|          |concentration of each    |       |                     |                             |             |       |
|          |solvent as the           |       |                     |                             |             |       |
|          |horizontal coordinate and|       |                     |                             |             |       |
|          |the peak                 |       |                     |                             |             |       |
|          |area as the vertical     |       |                     |                             |             |       |
|          |coordinate. The          |       |                     |                             |             |       |
|          |regression coefficient R |       |                     |                             |             |       |
|          |of the                   |       |                     |                             |             |       |
|          |obtained linear graph    |       |                     |                             |             |       |
|          |should NLT               |       |                     |                             |             |       |
|          |0.990, and the RSD of the|       |                     |                             |             |       |
|          |response                 |       |                     |                             |             |       |
|          |factor should not be more|       |                     |                             |             |       |
|          |than 10%.                |       |                     |                             |             |       |
|          |The absolute Y-axis      |       |                     |                             |             |       |
|          |intercept                |       |                     |                             |             |       |
|          |accounted for 100% of the|       |                     |                             |             |       |
|          |response                 |       |                     |                             |             |       |
|          |value of the percentage  |       |                     |                             |             |       |
|          |should be                |       |                     |                             |             |       |
|          |less than 25%.           |       |                     |                             |             |       |
|          |                         |       |---------------------|-----------------------------|-------------|       |
|          |                         |       |Ethanol              |5.006μg/ml to 500.555μg/ml |Y = 0.923 +  |       |  
|          |                         |       |                     |(0.0100% to                  |0.7951 x     |       |
|          |                         |       |                     |1.0011%)                     |             |       |
|          |                         |       |---------------------|-----------------------------|-------------|       |
|          |                         |       |Isopropyl            |5.008μg/ml to 500.820μg/ml |Y =          |       |  
|          |                         |       |alcohol              |(0.0100% to                  |0.9917-3.6091|       |
|          |                         |       |                     |1.0016%)                     |x            |       |
|          |                         |       |---------------------|-----------------------------|-------------|       |
|          |                         |       |Ethyl acetate        |4.974μg/ml~497.390μg/ml    |Y =          |       |  
|          |                         |       |                     |(0.0099%~0.9948%)            |0.7696-2.3 x |       |
|          |                         |       |---------------------|-----------------------------|-------------|       |
|          |                         |       |sec-butanol          |3.759μg/ml~501.170μg/ml    |Y =          |       |  
|          |                         |       |                     |(0.0075%~1.0023%)            |1.2102-4.7656|       |
|          |                         |       |                     |                             |x            |       |
|          |                         |       |---------------------|-----------------------------|-------------|       |
|          |                         |       |tetrahydrofura       |3.659μg/ml to 73.175μg/ml  |Y = 1.0779 + |       |  
|          |                         |       |n                    |(0.0073% to                  |0.0623 x     |       |
|          |                         |       |                     |0.1464%)                     |             |       |
|          |                         |       |---------------------|-----------------------------|-------------|       |
|          |                         |       |Toluene              |2.001μg/ml~100.050μg/ml    |Y =          |       |  
|          |                         |       |                     |(0.0040%~0.2001%)            |2.0063-0.9813|       |
|          |                         |       |                     |                             |x            |       |
|          |                         |       |---------------------|-----------------------------|-------------|       |
|          |                         |       |N-                   |2.769μg/ml to 55.375μg/ml  |Y =          |       |  
|          |                         |       |methylpyrrolido      |(0.0055% to                  |0.9965-0.9081|       |
|          |                         |       |ne                   |0.1108%)                     |x            |       |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 367 of 542 





Page 368
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



















































---------------------------------------------------------------------------------------------------------------------------
|Accura cy |Each solvent with a     |       |Component  |Labeling condition     |Average            |RSD       |       |   
|          |limit                   |       |name       |                       |recovery rate      |          |       |   
|          |concentration range of  |       |           |                       |                   |          |       |   
|          |30% to 150%             |       |           |                       |                   |          |       |   
|          |was added to the test   |       |           |                       |                   |          |       |   
|          |product, and            |       |           |                       |                   |          |       |   
|          |the recovery rate of    |       |           |                       |                   |          |       |   
|          |each solvent            |       |           |                       |                   |          |       |   
|          |was required to be      |       |           |                       |                   |          |       |   
|          |between 85% and         |       |           |                       |                   |          |       |   
|          |115%, and the recovery  |       |           |                       |                   |          |       |   
|          |RSD NMT 10%.            |       |           |                       |                   |          |       |   
|          |                        |       |-----------|-----------------------|-------------------|----------|       |   
|          |                        |       |Ethanol    |Plus                   |101.2%, n=9        |5%, n=9   |       |   
|          |                        |       |           |75.0833μg/ml-375.4163μg/ml|                   |          |       |
|          |                        |       |-----------|-----------------------|-------------------|----------|       |   
|          |                        |       |Isopropyl  |Added                  |101.7%, n=9        |4%, n=9   |       |   
|          |                        |       |alcohol    |75.1230μg/ml-375.6150μg/ml|                   |          |       |
|          |                        |       |-----------|-----------------------|-------------------|----------|       |   
|          |                        |       |Ethyl      |Marked                 |101.4%, n=9        |3.0%, n=9 |       |   
|          |                        |       |acetate    |74.6085μg/ml-373.0425μg/ml|                   |          |       |
|          |                        |       |-----------|-----------------------|-------------------|----------|       |   
|          |                        |       |sec-butanol|Added                  |102.2%, n=9        |4%, n=9   |       |   
|          |                        |       |           |75.1755μg/ml-375.8775μg/ml|                   |          |       |
|          |                        |       |-----------|-----------------------|-------------------|----------|       |   
|          |                        |       |tetrahydrofura|Added                  |101.3%, n=9        |2.6%, n=9 |       |
|          |                        |       |n          |10.9763μg/ml-54.8813μg/ml|                   |          |       | 
|          |                        |       |-----------|-----------------------|-------------------|----------|       |   
|          |                        |       |Toluene    |Marked                 |101.6%, n=9        |2.7%, n=9 |       |   
|          |                        |       |           |15.0075μg/ml-75.0375μg/ml|                   |          |       | 
|          |                        |       |-----------|-----------------------|-------------------|----------|       |   
|          |                        |       |N-methylpyrrol|Added                  |%, n=9             |7%. n=9   |       |
|          |                        |       |idone      |8.3063μg/ml-41.5313μg/ml|                   |          |       |  
|----------|------------------------|-------|-----------|-----------------------|-------------------|----------|-------|   
|Precisio n|Repeatability and       |       |Component  |Repeatability|Reproducibility      |Precision           |       | 
|          |reproducibility:        |       |name       |           |                     |                    |       |   
|          |RSD of each solvent in 6|       |           |           |                     |                    |       |   
|          |repeatability (or       |       |           |           |                     |                    |       |   
|          |reproducibility)        |       |           |           |                     |                    |       |   
|          |test solution NMT 10%.  |       |           |           |                     |                    |       |   
|          |Precision: In           |       |           |           |                     |                    |       |   
|          |the results of 12       |       |           |           |                     |                    |       |   
|          |repeatability and       |       |           |           |                     |                    |       |   
|          |intermediate precision  |       |           |           |                     |                    |       |   
|          |tests, the              |       |           |           |                     |                    |       |   
|          |RSDS of each solvent    |       |           |           |                     |                    |       |   
|          |content NMT             |       |           |           |                     |                    |       |   
|          |10%.                    |       |           |           |                     |                    |       |   
|          |                        |       |-----------|-----------|---------------------|--------------------|       |   
|          |                        |       |Ethanol    |0.7%, n=6  |5%, n=6              |4%, n=12            |       |   
|          |                        |       |-----------|-----------|---------------------|--------------------|       |   
|          |                        |       |Isopropyl  |0.8%, n=6  |5%, n=6              |4%, n=12            |       |   
|          |                        |       |alcohol    |           |                     |                    |       |   
|          |                        |       |-----------|-----------|---------------------|--------------------|       |   
|          |                        |       |Ethyl      |0.8%, n=6  |5%, n=6              |4%, n=12            |       |   
|          |                        |       |acetate    |           |                     |                    |       |   
|          |                        |       |-----------|-----------|---------------------|--------------------|       |   
|          |                        |       |sec-butanol|0.9%, n=6  |6%, n=6              |4%, n=12            |       |   
|----------|------------------------|-------|-----------|-----------|---------------------|--------------------|-------|   
|          |                        |       |tetrahydrofura|1.0%, n=6  |5%, n=6              |4%, n=12            |       |
|          |                        |       |n          |           |                     |                    |       |   
---------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 368 of 542 





Page 369
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 












-------------------------------------------------------------------------------------------------------------------------
|          |                            |            |Toluene      |1.0%, n=6   |5%, n=6     |4%, n=12    |            | 
|          |                            |            |-------------|------------|------------|------------|            | 
|          |                            |            |N-methylpyrrol|2.0%, n=6   |5%, n=6     |9%, n=12                 |
|          |                            |            |idone        |            |            |                         | 
|----------|----------------------------|------------|             |            |            |                         | 
|Durabil   |By changing the             |The initial flow rate was 3.5ml/min±0.1ml/min, the initial column temperature|  
|ity       |chromatographic             |was 40℃±5℃, and the chromatographic columns with different batches were    |    
|          |conditions (changing the    |investigated as follows: System applicability: no interference from blank     | 
|          |initial                     |solution; Ethanol, isopropyl alcohol, ethyl acetate, secondary butanol,       | 
|          |temperature, flow rate,     |tetrahydrofuran, toluene and n-methylpyrrolidone peaked in sequence in the    | 
|          |column) and                 |chromatogram obtained from the control solution under different conditions of | 
|          |normal chromatographic      |the same chromatographic parameters, and the separation degree between each   | 
|          |conditions to               |adjacent solvent peak was greater than 1.5. Test product solution: RSDS of    | 
|          |test the solvent content of |each                                                                          | 
|          |each                        |solvent content in test product solution under the same chromatographic       | 
|          |test product solution to    |parameters and different conditions were all less than 10%.                   | 
|          |achieve,                    |                                                                              | 
|          |the chromatographic diagram |                                                                              | 
|          |obtained                    |                                                                              | 
|          |by the control product      |                                                                              | 
|          |solution,                   |                                                                              | 
|          |ethanol, isopropyl alcohol, |                                                                              | 
|          |ethyl                       |                                                                              | 
|          |acetate, secondary butanol, |                                                                              | 
|          |tetrahydrofuran, toluene,   |                                                                              | 
|          |n-methylpyrrolidone peaks in|                                                                              | 
|          |turn,                       |                                                                              | 
|          |the separation degree       |                                                                              | 
|          |between the                 |                                                                              | 
|          |adjacent peaks should be    |                                                                              | 
|          |greater                     |                                                                              | 
|          |than 1.5. Under different   |                                                                              | 
|          |conditions                  |                                                                              | 
|          |of the same chromatographic |                                                                              | 
|          |parameters, the RSD of the  |                                                                              | 
|          |content                     |                                                                              | 
|          |of each solvent to be       |                                                                              | 
|          |measured in                 |                                                                              | 
|          |the test product solution   |                                                                              | 
|          |NMT 10%.                    |                                                                              | 
-------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 369 of 542 





Page 370
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4.3.4 Methodological validation of genotoxic impurities in finished** 


**products** 



**I. Analytical Procedures** 



Chromatographic conditions The capillary column with (50%-phenyl) 



-methylpolysiloxane (Agilent DB-17 MS, 30m*0.25mm, 0.25μm or similar 



polarity) as the fixed liquid was used as the chromatographic column. The 



initial temperature was 50℃, maintained for 3min, and the temperature was 



heated to 230℃ at the rate of 20℃ per minute. Maintenance for 5 minutes; 



Inlet temperature 250℃; The injection volume is 1μl. (Recommended carrier 



gas is helium, carrier gas flow rate is 1.50ml per minute, no shunt injection, 



transmission line temperature 250℃) 



Mass spectrum conditions A triple quadrupole tandem mass spectrometry 



was used as the detector, an electron bombardment source (EI) was used, the 



ion source temperature was 230℃, and the collision gas was nitrogen. It is 



recommended to set scanning parameters according to the following table: 
























--------------------------------------------------------------------------
|Component   |Time to |Collection|Dwell time|Channel 1     |Channel 2    |
|name        |start   |method    |(ms)      |Detect ion    |Detect ion   |
|            |scanning|          |          |pairs (m/z)   |pairs (m/z)  |
|            |(min)   |          |          |and CE        |and CE       |
|------------|--------|----------|----------|--------------|-------------|
|Dimethyl    |5.00    |MRM       |40        |66.00 > 48.00*|95.00 > 43.00|
|sulfate     |        |          |          |15.00 V       |0.00 V       |
|------------|        |----------|----------|--------------|-------------|
|Diethyl     |        |MRM       |40        |124.90 >      |45.10 > 43.10|
|sulfate     |        |          |          |45.10* 12.00 V|18.00 V      |
|------------|        |----------|----------|--------------|-------------|
|Diisopropyl |        |MRM       |40        |87.00 > 45.10*|69.00 > 41.10|
|sulfate     |        |          |          |6.00 V        |12.00 V      |
|------------|        |----------|----------|--------------|-------------|
|Di-sec-butyl|        |MRM       |40        |101.00 >      |59.00 > 43.00|
|sulfate     |        |          |          |45.10* 6.00 V |30.00 V      |
--------------------------------------------------------------------------

Note: Bands * are quantitative ion pairs. 



The suitability of the system requires that in the chromatogram of the 



reference product solution, dimethyl sulfate, diethyl sulfate, diisopropyl 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 370 of 542 





Page 371
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



sulfate and di-sec-butyl sulfate peak in turn. The signal-to-noise ratio of 



dimethyl sulfate, diethyl sulfate, diisopropyl sulfate and di-sec-butylsulfate 



should NLT 10 in the chromatogram under quantitative ion of the sensitive 



solution. 



**Assay** 



The solvent, the sensitivity solution, the reference solution and the test 



product solution were each 1μl, and the samples were injected respectively, 



and the chromatogram was recorded. If there are peaks of dimethyl sulfate, 



diethyl sulfate, diisopropyl sulfate and disec-butyl sulfate in the 



chromatogram of the test product solution, the content of each sulfate 



impurity is calculated according to the external standard method and the 



peak area. 



The calculation formula is: 




Assay（ppm） CReference  A test  V 

W  A 




  
（ ） Reference test 




Reference test 




W  A 




Reference 




Creference is the concentration of the reference solution (ng/ml); 



V is the dilution volume (ml) of the test product solution; 



Atest is the peak area of each sulfate impurity in the test product solution; 



Areference is the peak area of each sulfate impurity in the control product solution; 



W is the weight of the test product (mg). 



Limit test product solution chromatogram, if there are dimethyl sulfate, 



diethyl sulfate, diisopropyl sulfate, dibutyl sulfate peak, according to the 



external standard method to calculate the peak area, containing dimethyl 



sulfate, diethyl sulfate, diisopropyl sulfate, dibutyl sulfate NMT 75ppm, the 



sum of genotoxic impurities NMT 250ppm. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 371 of 542 





Page 372
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**II. Validation Results and Discussion** 



**a. System applicability** 



 **Acceptance Criteria** 



The applicability of the system is achieved by examining the sensitivity 



solution and the reference solution. Take the sensitivity solution to inject 1 



needle and the reference solution to inject 6 needles continuously. The 



signal-to-noise ratio of each impurity peak in the sensitivity solution should 



NLT 10; The RSD for the retention time of each impurity in the luminous 



solution NMT 1%, and the RSD for the peak area NMT 10%. 



 **Solution preparation** 



Solvent: acetonitrile 



Dimethyl sulfate reserve liquid: Take about 15mg of dimethyl sulfate 



reference product, accurately weigh it, place it in a 100ml bottle, dissolve it 



with acetonitrile and dilute it to the scale, shake well, and obtain. 



Diethyl sulfate reserve liquid: Take about 15mg of diethyl sulfate reference 



product, accurately weigh, place in 100ml measuring bottle, dissolve with 



acetonitrile and dilute to the scale, shake well, ready. 



Diisopropyl sulfate reserve liquid: Take about 15mg of diisopropyl sulfate 



control product, accurately weigh, place in 100ml measuring bottle, dissolve 



with acetonitrile and dilute to the scale, shake well, ready. 



Diisopropyl sulfate reserve liquid: Take diisopropyl sulfate reference product 



about 15mg, precision weigh, put in 100ml bottle, dissolve with acetonitrile 



and dilute to the scale, shake well, ready. 



Control product reserve liquid: precisely measure dimethyl sulfate reserve 



liquid, diethyl sulfate reserve liquid, diisopropyl sulfate reserve liquid and 



disec-butyl sulfate reserve liquid 1ml each, in the same 20ml measuring 



bottle, dilute with acetonitrile to the scale, shake well, ready. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 372 of 542 





Page 373
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Blank solution: solvent (acetonitrile). 



Sensitivity solution: Accurately measure the control product reserve liquid 



10μl into 5ml measuring bottle, dilute with acetonitrile to the scale, shake 



well, ready. 



Control product solution: precisely measure the control product storage 



solution 100μl into 5ml measuring bottle, dilute it with acetonitrile to the 



scale, shake well, ready. 



 **Injection Sequence** 



After the blank solution, the sensitivity solution was injected with 1 



needle, the control solution was injected with 6 needles continuously, and 



the chromatogram was recorded. 



 **Measurement results** 






















































































































































































































-----------------------------------------------------------------------------------------------
|Names of             |Reference solution                                   |RS D/ %|Sensiti  |
|Components           |                                                     |       |vity     |
|                     |                                                     |       |solutio n|
|                     |                                                     |       |signal-  |
|                     |                                                     |       |to-noi se|
|                     |                                                     |       |ratio    |
|                     |-----------------------------------------------------|       |         |
|          |          |1       |2       |3       |4       |5       |6       |       |         |
|----------|----------|--------|--------|--------|--------|--------|--------|-------|---------|
|Dime thyl |Retent ion|6.468   |6.467   |6.468   |6.462   |6.462   |6.462   |0.0 5  |110.8 7  |
|sulfa te  |time      |        |        |        |        |        |        |       |         |
|          |----------|--------|--------|--------|--------|--------|--------|-------|         |
|          |Peak area |18629 00|19154 89|18883 46|18806 40|18711 34|17566 25|2.9    |         |
|----------|----------|--------|--------|--------|--------|--------|--------|-------|---------|
|Diet hyl  |Retent ion|7.769   |7.769   |7.769   |7.769   |7.769   |7.769   |0      |179.5 8  |
|sulfa te  |time      |        |        |        |        |        |        |       |         |
|          |----------|--------|--------|--------|--------|--------|--------|-------|         |
|          |Peak area |20720 58|21082 23|21371 47|20966 55|21114 52|19886 83|2.5    |         |
|----------|----------|--------|--------|--------|--------|--------|--------|-------|---------|
|Diiso prop|Retent ion|8.204   |8.204   |8.204   |8.204   |8.204   |8.204   |0      |54.31    |
|yl sulfa  |time      |        |        |        |        |        |        |       |         |
|te        |          |        |        |        |        |        |        |       |         |
|          |----------|--------|--------|--------|--------|--------|--------|-------|         |
|          |Peak area |14161 25|14500 26|14822 25|14681 36|14552 42|13626 52|3.0    |         |
|----------|----------|--------|--------|--------|--------|--------|--------|-------|---------|
|Di-se c-bu|Retent ion|9.507   |9.507   |9.512   |9.507   |9.507   |9.507   |0.0 21 |43.75    |
|tyl sulfa |time      |        |        |        |        |        |        |       |         |
|te        |          |        |        |        |        |        |        |       |         |
|          |----------|--------|--------|--------|--------|--------|--------|-------|         |
|          |Peak area |66227 6 |66990 3 |66854 4 |66579 3 |63542 8 |57546 3 |6      |         |
|----------|----------|--------|--------|--------|--------|--------|--------|-------|---------|
|Conclusion: The SNR of dimethyl sulfate, diethyl sulfate, diisopropyl sulfate                |
|and disec-butyl sulfate in the sensitivity solution were 110.87, 179.58, 54.31               |
|and 43.75, respectively, all of which were NLT 10. 6 The RSD of the retention                |
|time of dimethyl sulfate, diethyl sulfate, diisopropyl sulfate and                           |
|di-sec-butylsulfate in the irradiation solution were                                         |
-----------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 373 of 542 





Page 374
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



0.05%, 0%, 0% and 0.021%, respectively, and were all less than 1%. The RSD of the peak 
area of dimethyl sulfate, diethyl sulfate, diisopropyl sulfate and di-sec-butylsulfate in the 
irradiation solution were 2.9%, 2.5%, 3.0% and 6%, respectively, all of which were less 
than 10%, indicating that the system applicability of the method for the detection of 
dimethyl sulfate, diethyl sulfate, diisopropyl sulfate and di-sec-butylsulfate met the 
requirements. 



**(4.2) Specificity** 



 **Acceptance Criteria** 



The retention time of the impurities in the specific mixed solution and the 



reference solution should be consistent with the retention time in the 



impurity localization solution. The peak area of dimethyl sulfate, diethyl 



sulfate, diisopropyl sulfate and dibutyl sulfate in the blank solution NMT 



20% of the average value of the impurity peak area in the mass spectrum of 



the 6 limited quantification solutions. 



 **Solution preparation** 



Blank solution: Blank solution as prepared under 4.1. 



Dimethyl sulfate reserve solution: dimethyl sulfate reserve solution prepared 



under item 4.1. 



Diethyl sulfate storage solution: diethyl sulfate storage solution prepared 



under item 4.1. 



Diisopropyl sulfate reserve solution: diisopropyl sulfate reserve solution 



prepared under item 4.1. 



Disec-butyl sulfate storage solution: disec-butyl sulfate storage solution 



prepared under item 4.1. 



Reference product reserve solution: the reference product reserve solution 



prepared under item 4.1. 



Reference solution: the same reference solution prepared under item 4.1. 



Dimethyl sulfate positioning solution: accurately measure 1ml of dimethyl 



sulfate reserve solution, place it in a 20ml measuring bottle, dilute it with 



acetonitrile to the scale, and shake well; Precision measure 100μl of the 



above solution, place it in a 5ml measuring bottle, dilute it with acetonitrile to 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 374 of 542 





Page 375
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



the scale, shake well, and get. 



Diethyl sulfate positioning solution: accurately measure 1ml of diethyl 



sulfate reserve solution, place it in 20ml measuring bottle, dilute it with 



acetonitrile to the scale, and shake well; Precision measure 100μl of the 



above solution, place it in a 5ml measuring bottle, dilute it with acetonitrile to 



the scale, shake well, and get. 



Diisopropyl sulfate positioning solution: accurately measure 1ml of 



diisopropyl sulfate reserve solution, place it in a 20ml measuring bottle, 



dilute it with acetonitrile to the scale, and shake well; Precision measure 



100μl of the above solution, place it in 5ml measuring bottle, dilute it with 



acetonitrile to the scale, shake well, and get. 



Disec-butyl sulfate positioning solution: accurately measure 1ml of 



disec-butyl sulfate reserve solution, place it in a 20ml measuring bottle, 



dilute it with acetonitrile to the scale, and shake well; Precisely measure the 



above solution 100μl, place it in a 5ml measuring bottle, dilute it with 



acetonitrile to the scale, shake well, and get. 



Test product solution: Take about 10mg of this product, weigh it accurately, 



put it in 5ml measuring bottle, add acetonitrile to appropriate amount, swirl 



to dissolve, then dilute it with acetonitrile to scale, shake well, ready. 



Specific mixed solution: Take about 10mg of this product, accurately weigh it, 



place it in 5ml bottle, add an appropriate amount of acetonitrile to dissolve, 



then precisely add 100μl of control product reserve, dilute it with acetonitrile 



to the scale, shake well, ready. 



 **Injection Sequence** 



Blank solution, reference solution, dimethyl sulfate localization solution, 



diethyl sulfate localization solution, diisopropyl sulfate localization solution, 



di-sec-butyl sulfate localization solution, test product solution and specific 



mixed solution were injected into 1 needle successively, and the 



chromatogram was recorded. 



 **Measurement result** 



Name of solution Component Rt (min) MRM quantifies 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 375 of 542 





Page 376
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-------------------------------------------------------------------------
|                   |name           |                 |ions Counter     |
|                   |               |                 |peak area        |
|-------------------|---------------|-----------------|-----------------|
|Reference solution |Dimethyl       |6.462            |1604486          |
|                   |sulfate        |                 |                 |
|                   |---------------|-----------------|-----------------|
|                   |Diethyl sulfate|7.769            |2271452          |
|                   |---------------|-----------------|-----------------|
|                   |Diisopropyl    |8.204            |1468496          |
|                   |sulfate        |                 |                 |
|                   |---------------|-----------------|-----------------|
|                   |Di-sec-butyl   |9.507            |594890           |
|                   |sulfate        |                 |                 |
|-------------------|---------------|-----------------|-----------------|
|Solution for the   |Dimethyl       |Not detected     |Not detected     |
|test product       |sulfate        |                 |                 |
|                   |---------------|-----------------|-----------------|
|                   |Diethyl sulfate|Not detected     |Not detected     |
|                   |---------------|-----------------|-----------------|
|                   |Diisopropyl    |Not detected     |Not detected     |
|                   |sulfate        |                 |                 |
|                   |---------------|-----------------|-----------------|
|                   |Di-sec-butyl   |Not detected     |Not detected     |
|                   |sulfate        |                 |                 |
|-------------------|---------------|-----------------|-----------------|
|Specific mixed     |Dimethyl       |6.468            |1905636          |
|solution           |sulfate        |                 |                 |
|                   |---------------|-----------------|-----------------|
|                   |Diethyl sulfate|7.769            |2396344          |
|                   |---------------|-----------------|-----------------|
|                   |Diisopropyl    |8.204            |1722683          |
|                   |sulfate        |                 |                 |
|                   |---------------|-----------------|-----------------|
|                   |Di-sec-butyl   |9.507            |803619           |
|                   |sulfate        |                 |                 |
|-------------------|---------------|-----------------|-----------------|
|Dimethyl sulfate   |Dimethyl       |6.462            |1917908          |
|locator solution   |sulfate        |                 |                 |
|-------------------|---------------|-----------------|-----------------|
|Diethyl sulfate    |Diethyl sulfate|7.769            |2286745          |
|locating solution  |               |                 |                 |
|-------------------|---------------|-----------------|-----------------|
|Diisopropyl sulfate|Diisopropyl    |8.204            |1438239          |
|positioning        |sulfate        |                 |                 |
|solution           |               |                 |                 |
|-------------------|---------------|-----------------|-----------------|
|Disec-butyl sulfate|Di-sec-butyl   |9.507            |622794           |
|positioning        |sulfate        |                 |                 |
|solution           |               |                 |                 |
|-------------------|---------------|-----------------|-----------------|
|Blank solution     |Dimethyl       |Not detected     |Not detected     |
|                   |sulfate        |                 |                 |
|                   |---------------|-----------------|-----------------|
|                   |Diethyl sulfate|Not detected     |Not detected     |
|                   |---------------|-----------------|-----------------|
|                   |Diisopropyl    |Not detected     |Not detected     |
|                   |sulfate        |                 |                 |
|                   |---------------|-----------------|-----------------|
|                   |Di-sec-butyl   |Not detected     |Not detected     |
|                   |sulfate        |                 |                 |
|-------------------|---------------|-----------------|                 |
|Items              |Average of the |Ratio of the response value of the |
|                   |peak area of   |peak area of each component of the |
|                   |the 6 parts    |blank solution to the peak area of |
|                   |limited        |each                               |
-------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 376 of 542 





Page 377
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










-----------------------------------------------------------------------------------
|                        |quantification          |component of the 6-part limited|
|                        |solution                |quantification solution /%     |
|------------------------|------------------------|-------------------------------|
|Dimethyl sulfate        |188679                  |Not detected                   |
|------------------------|------------------------|-------------------------------|
|Diethyl sulfate         |216723                  |Not detected                   |
|------------------------|------------------------|-------------------------------|
|Diisopropyl sulfate     |139179                  |Not detected                   |
|------------------------|------------------------|-------------------------------|
|Di-sec-butyl            |56839                   |Not detected                   |
|sulfate                 |                        |                               |
|------------------------|------------------------|-------------------------------|
|Conclusion: The retention time of the impurities in the specific mixed           |
|solution and the reference solution is consistent with the retention time        |
|of the impurities in the localization solution. No dimethyl sulfate,             |
|diethyl sulfate, diisopropyl sulfate and disec-butyl sulfate were                |
|detected in the blank solution, indicating that the specificity of the           |
|method met the requirements.                                                     |
-----------------------------------------------------------------------------------

**(4.3) Limits of quantification and detection** 



 **sketch** 



Limits of quantification and detection are achieved by testing the 



signal-to-noise ratio of a reference solution diluted with a certain 



concentration. It is required that the SNR of all impurities in the 6 limited 



quantitation solutions should NLT 10, the RSD of the retention time of each 



impurity should not be more than 1.0%, and the RSD of the peak area of each 



impurity should not be more than 10%. The signal-to-noise ratio of every 



impurity in the mass spectrogram of the detection limited solution should 



NLT 3. 



 **Solution preparation** 



Blank solution: Blank solution as prepared under 4.1. 



Reference stock solution: the same as the reference stock solution prepared 



under item 4.1. 



Limited quantitation solution: Accurately measure the control product 



reserve solution 10μl into 5ml measuring bottle, dilute it with acetonitrile to 



the scale, shake well, and then obtain. Prepare 6 parts in parallel. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 377 of 542 





Page 378
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Detection limit solution: Accurately measure the first limit of quantification 



solution 1.5ml into 5ml measuring bottle, dilute with acetonitrile to the scale, 



shake well, and then get. 



 **Injection procedure** 



Take the blank solution and inject 1 needle, the detection limited solution 



and inject 3 needles continuously, 6 parts of the limited quantitative solution 



and inject 1 needle respectively, and record the chromatogram. 



 **Measurement results** 



Results of limit of quantitation test 































--------------------------------------------------------------------------------------
|To be    |Solution      |Concent   |Equivalent to  |Retentio n|Peak area |S/N       |
|measur ed|name          |ration    |test product   |time /min |          |          |
|Ingredi  |              |/(ng/ml)  |solution       |          |          |          |
|ents     |              |          |concentration  |          |          |          |
|         |              |          |percentage /ppm|          |          |          |
|---------|--------------|----------|---------------|----------|----------|----------|
|Dimeth yl|Limited       |14.9352   |7.5            |6.468     |193946    |149.9 4   |
|sulfate  |quantitative  |          |               |          |          |          |
|         |Solution 1    |          |               |          |          |          |
|         |--------------|----------|               |----------|----------|----------|
|         |Limited       |14.9352   |               |6.462     |191459    |150.6 4   |
|         |quantification|          |               |          |          |          |
|         |solution 2    |          |               |          |          |          |
|         |--------------|----------|               |----------|----------|----------|
|         |Limited       |14.9352   |               |6.462     |184126    |150.5 5   |
|         |quantitative  |          |               |          |          |          |
|         |Solution 3    |          |               |          |          |          |
|         |--------------|----------|               |----------|----------|----------|
|         |Limited       |14.9352   |               |6.462     |187606    |158.4 5   |
|         |quantitative  |          |               |          |          |          |
|         |Solution 4    |          |               |          |          |          |
|         |--------------|----------|               |----------|----------|----------|
|         |Limited       |14.9352   |               |6.462     |181354    |154.7 5   |
|         |quantitative  |          |               |          |          |          |
|         |Solution 5    |          |               |          |          |          |
|         |--------------|----------|               |----------|----------|----------|
|         |Limited       |14.9352   |               |6.468     |193581    |143.0 7   |
|         |quantitative  |          |               |          |          |          |
|         |solution 6    |          |               |          |          |          |
|         |--------------|----------|---------------|----------|----------|----------|
|         |RSD%                                     |0.05      |2.8       |/         |
|         |-----------------------------------------|----------|----------|----------|
|         |Verdict: The limited quantification concentration of dimethyl             |
|         |sulfate was 14.9352ng/ml, which was equivalent to 7.5ppm of the           |
|         |solution concentration. The RSD of the retention time in 6 parts          |
|         |of the solution was                                                       |
--------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 378 of 542 





Page 379
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 





































----------------------------------------------------------------------------------
|       |0.05%, less than 1.0%, the RSD of the peak area was 2.8%, less          |
|       |than 10%, and the S/N ranged from 143.07 to 158.45, all of which        |
|       |were greater than 10. It shows that this method has a good              |
|       |response to the detection of dimethyl sulfate.                          |
|-------|------------------------------------------------------------------------|
|Diethyl|Limited     |15.3648    |7.7        |7.769      |222581     |207.1 3    |
|sulfate|quantitative|           |           |           |           |           |
|       |solution 1  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3648    |           |7.769      |213753     |167.3 3    |
|       |quantitative|           |           |           |           |           |
|       |Solution 2  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3648    |           |7.769      |217018     |179.4 8    |
|       |quantitative|           |           |           |           |           |
|       |Solution 3  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3648    |           |7.769      |211589     |180.5 1    |
|       |quantitative|           |           |           |           |           |
|       |Solution 4  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3648    |           |7.769      |213217     |152.9 4    |
|       |quantitative|           |           |           |           |           |
|       |Solution 5  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3648    |           |7.769      |222181     |191.6 7    |
|       |quantitative|           |           |           |           |           |
|       |solution 6  |           |           |           |           |           |
|       |------------|-----------|-----------|-----------|-----------|-----------|
|       |RSD%                                |0          |2.2        |/          |
|       |------------------------------------|-----------|-----------|-----------|
|       |Conclusion: The limit of quantitation concentration of diethyl          |
|       |sulfate was 15.3648ng/ml, which was equivalent to 7.7ppm of the         |
|       |solution, the RSD of retention time in 6 parts of the solution was      |
|       |0% (less than 1.0%), the RSD of peak area was 2.2% (less than           |
|       |10%), and the S/N ranged from 152.94 to 207.13, all of which were       |
|       |greater than 10. The results indicated that the method had a good       |
|       |response for the detection of diethyl sulfate.                          |
|-------|------------------------------------------------------------------------|
|Diisopr|Limited     |15.1417    |7.6        |8.204      |139949     |71.56      |
|opyl   |quantitative|           |           |           |           |           |
|sulfate|solution 1  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.1417    |           |8.204      |139261     |60.74      |
|       |quantitative|           |           |           |           |           |
|       |Solution 2  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.1417    |           |8.204      |140461     |64.91      |
|       |quantitative|           |           |           |           |           |
|       |Solution 3  |           |           |           |           |           |
|       |------------|-----------|-----------|-----------|-----------|-----------|
|       |Limited     |15.1417                |8.204      |139189     |64.38      |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 379 of 542 





Page 380
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




























----------------------------------------------------------------------------------
|       |quantitative|           |           |           |           |           |
|       |Solution 4  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.1417    |           |8.204      |136057     |52.55      |
|       |quantitative|           |           |           |           |           |
|       |Solution 5  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.1417    |           |8.204      |140157     |67.31      |
|       |quantitative|           |           |           |           |           |
|       |solution 6  |           |           |           |           |           |
|       |------------|-----------|-----------|-----------|-----------|-----------|
|       |RSD%                                |0          |1.2        |/          |
|       |------------------------------------|-----------|-----------|-----------|
|       |Conclusion: The limited quantification concentration of                 |
|       |diisopropyl sulfate was 15.1417ng/ml, which was equivalent to           |
|       |7.6ppm of the test solution. The RSD of the retention time in 6         |
|       |parts of the limited quantification solution was 0%, less than          |
|       |1.0%, the RSD of the peak area was 1.2%, less than 10%, and the         |
|       |S/N ranged from 52.55 to 71.56, all of which were greater than 10.      |
|       |The results indicated that the response of this method was good         |
|       |for the detection of diisopropyl sulfate.                               |
|-------|------------------------------------------------------------------------|
|Di-sec-|Limited     |15.3638    |7.7        |9.507      |57846      |76.76      |
|butyl  |quantitative|           |           |           |           |           |
|sulfate|Solution 1  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3638    |           |9.507      |58220      |59.11      |
|       |quantitative|           |           |           |           |           |
|       |Solution 2  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3638    |           |9.507      |56479      |61.59      |
|       |quantitative|           |           |           |           |           |
|       |Solution 3  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3638    |           |9.507      |57117      |58.01      |
|       |quantitative|           |           |           |           |           |
|       |Solution 4  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3638    |           |9.507      |55235      |56.30      |
|       |quantitative|           |           |           |           |           |
|       |Solution 5  |           |           |           |           |           |
|       |------------|-----------|           |-----------|-----------|-----------|
|       |Limited     |15.3638    |           |9.507      |56138      |60.63      |
|       |quantitative|           |           |           |           |           |
|       |solution 6  |           |           |           |           |           |
|       |------------|-----------|-----------|-----------|-----------|-----------|
|       |RSD%                                |0          |2.0        |/          |
|       |------------------------------------|-----------|-----------|-----------|
|       |Conclusion: The limited quantitation concentration of                   |
|       |disec-butylsulfate was 15.3638ng/ml, which was equivalent to            |
|       |7.7ppm of the solution, the RSD of the retention time in 6 parts        |
|       |of the limited quantitation solution was 0%, less than 1.0%, the        |
|       |RSD of the peak area was 2.0%, less than 10%, and                       |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 380 of 542 





Page 381
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



the S/N ranged from 56.30 to 76.76, all of which were greater than 10. The 



results indicated that the method had a good response to the detection of 



di-sec-butylsulfate. 



Detection limit test results 






















































---------------------------------------------------------------------------------
|Impurit  |Detection       |Concentr        |Equivalent to test|S/N             |
|ies Name |limit           |ation           |product solution  |                |
|         |solution        |/(ng/ml)        |concentration     |                |
|         |injection       |                |percentage /ppm   |                |
|         |times           |                |                  |                |
|---------|----------------|----------------|------------------|----------------|
|Dimeth yl|1               |4.4806          |2.2               |46.09           |
|sulfate  |                |                |                  |                |
|         |----------------|                |                  |----------------|
|         |2               |                |                  |40.09           |
|         |----------------|                |                  |----------------|
|         |3               |                |                  |47.76           |
|         |----------------|----------------|------------------|----------------|
|         |Conclusion: The detection limit concentration of dimethyl sulfate    |
|         |is 4.4806ng/ml, which is equivalent to 2.2ppm of the test            |
|         |solution, and the S/N in the detection limit solution for 3          |
|         |consecutive stitches ranges from 40.09 to 47.76, all of which are    |
|         |greater than 3. It shows that this method has a good response to     |
|         |the detection of dimethyl sulfate.                                   |
|---------|---------------------------------------------------------------------|
|Diethyl  |1               |4.6094          |2.3               |53.85           |
|sulfate  |                |                |                  |                |
|         |----------------|                |                  |----------------|
|         |2               |                |                  |55.62           |
|         |----------------|                |                  |----------------|
|         |3               |                |                  |57.13           |
|         |----------------|----------------|------------------|----------------|
|         |Conclusion: The detection limit concentration of diethyl sulfate     |
|         |was 4.6094ng/ml, which was equivalent to 2.3ppm of the test          |
|         |solution. S/N in the detection limit solution for 3 consecutive      |
|         |needles ranged from 53.85 to 57.13, all of which were greater than   |
|         |3. It indicates that this method has a good response to the          |
|         |detection of diethyl sulfate.                                        |
|---------|---------------------------------------------------------------------|
|Diisopr  |1               |4.5425          |2.3               |18.46           |
|opyl     |                |                |                  |                |
|sulfate  |                |                |                  |                |
|         |----------------|                |                  |----------------|
|         |2               |                |                  |20.78           |
|         |----------------|                |                  |----------------|
|         |3               |                |                  |18.67           |
|         |----------------|----------------|------------------|----------------|
|         |Conclusion: The detection limit concentration of diisopropyl         |
|         |sulfate was 4.5425ng/ml, which was equivalent to 2.3ppm of the       |
|         |test solution, and the S/N in the detection limit solution for 3     |
|         |consecutive stitches ranged from 18.46 to 20.78, all of which were   |
|         |greater than 3. It indicates that this method has a good response    |
|         |to the detection of diisopropyl sulfate.                             |
|---------|---------------------------------------------------------------------|
|Di-sec-  |1               |4.6091          |2.3               |16.69           |
|butyl    |                |                |                  |                |
|sulfate  |                |                |                  |                |
|         |----------------|                |                  |----------------|
|         |2               |                |                  |26.77           |
|         |----------------|                |                  |----------------|
|         |3               |                |                  |19.04           |
---------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 381 of 542 





Page 382
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Conclusion: The detection limit concentration of disec-butyl sulfate is 



4.6091ng/ml, which is equivalent to 2.3ppm of the test solution, and the 



S/N in the detection limit solution for 3 consecutive stitches is between 



16.69 and 26.77, all of which are greater than 3. It indicates that this 



method has a good response to the detection of di-sec-butyl sulfate. 



**(4.4) Linearity and range** 



 **Acceptance Criteria** 



In the equivalent of the impurities LOQ~200% limit concentration range, 



more uniform take 6 concentration points, the impurity concentration as the 



horizontal coordinate, the impurity peak area response value as the ordinate, 



as a linear regression curve, the regression coefficient R of the linear graph 



should be NLT 0.990, the Y-axis intercept is within 25% of the 100% 



response value. 



 **Solution preparation** 



Blank solution: Blank solution as prepared under 4.1. 



Linear Solution 1 (LOQ) : Accurately measure the control product reserve 



solution 10μl into 5ml measuring bottle, dilute it with acetonitrile to the scale, 



shake well, and obtain. 



Linear solution 2: Accurately measure the control product reserve 



solution 50μl into a 5ml measuring bottle, dilute it with acetonitrile to the 



scale, shake well, ready. 



Linear solution 3: Accurately measure the control product reserve liquid 



80μl into 5ml measuring bottle, dilute it with acetonitrile to the scale, shake 



well, ready. 



Linear solution 4: Precisely measure the control product reserve liquid 



100μl into 5ml measuring bottle, dilute it with acetonitrile to the scale, shake 



well, ready. 



Linear solution 5: Precisely measure the control product reserve liquid 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 382 of 542 





Page 383
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



150μl into 5ml measuring bottle, dilute it with acetonitrile to the scale, shake 



well, ready. 



Linear solution 6: Accurately measure the control product reserve liquid 



200μl into 5ml measuring bottle, dilute it with acetonitrile to the scale, shake 



well, ready. 



 **Injection Sequence** 



Take a blank solution and inject 1 needle, each linear solution from low 



concentration to high concentration of 1 needle, record the chromatogram. 



 **Measurement results** 



Results of linear and range tests 



























--------------------------------------------------------------------
|impurity|Solution name    |Equivalent to  |Concentration|Peak area|
|Name    |                 |test product   |of test      |         |
|        |                 |solution       |substance    |         |
|        |                 |concentration  |(ng/ml)      |         |
|        |                 |percentage /ppm|             |         |
|--------|-----------------|---------------|-------------|---------|
|Dimethyl|Linear solution 1|7.5            |14.9352      |189843   |
|sulfate |                 |               |             |         |
|        |-----------------|---------------|-------------|---------|
|        |Linear Solution 2|37.3           |74.6760      |955650   |
|        |-----------------|---------------|-------------|---------|
|        |Linear Solution 3|59.7           |119.4816     |1503384  |
|        |-----------------|---------------|-------------|---------|
|        |Linear solution 4|74.7           |149.3520     |1990355  |
|        |-----------------|---------------|-------------|---------|
|        |Linear Solution 5|112.0          |224.0280     |2901824  |
|        |-----------------|---------------|-------------|---------|
|        |Linear solution 6|149.4          |298.7040     |3941888  |
|        |-----------------|---------------|-------------|---------|
|        |Linear Chart     |                                       |
|        |-----------------|---------------------------------------|
|        |Linear equations |y=13215x-26946                         |
|        |-----------------|---------------------------------------|
|        |Correlation      |0.9997                                 |
|        |coefficient R    |                                       |
|        |-----------------|---------------------------------------|
|        |Absolute value of|1.4                                    |
|        |Y-axis intercept |                                       |
|        |as a percentage  |                                       |
|        |of               |                                       |
--------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 383 of 542 





Page 384
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-------------------------------------------------------------------------------
|           |100% response (%)|                                               |
|           |-----------------|-----------------------------------------------|
|           |The verdict: In the concentration range of                       |
|           |14.9352~298.7040ng/ml, the linear equation is y=13215x-26946,    |
|           |the correlation coefficient is 0.9997, greater than 0.990, and   |
|           |the absolute value of y-intercept accounts for 1.4% of 100%      |
|           |response value, less than 25%. It indicates that dimethyl        |
|           |sulfate meets the requirements linearly in the concentration     |
|           |range of 14.9352-298.7040 ng/ml.                                 |
|-----------|-----------------------------------------------------------------|
|Diethyl    |Linear Solution 1|7.7            |15.3648        |225866         |
|sulfate    |                 |               |               |               |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Solution 2|38.4           |76.8240        |1184267        |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Solution 3|61.5           |122.9184       |1937152        |
|           |-----------------|---------------|---------------|---------------|
|           |Linear solution 4|76.8           |153.6480       |2377909        |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Solution 5|115.2          |230.4720       |3628004        |
|           |-----------------|---------------|---------------|---------------|
|           |Linear solution 6|153.6          |307.2960       |5096780        |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Chart     |                                               |
|           |-----------------|-----------------------------------------------|
|           |Linear equations |y=16542x-91014                                 |
|           |-----------------|-----------------------------------------------|
|           |Correlation      |0.9990                                         |
|           |coefficient R    |                                               |
|           |-----------------|-----------------------------------------------|
|           |Absolute value of|3.7                                            |
|           |Y-axis intercept |                                               |
|           |as a percentage  |                                               |
|           |of 100% response |                                               |
|           |(%)              |                                               |
|           |-----------------|                                               |
|           |The verdict: In the concentration range of                       |
|           |15.3648~307.2960ng/ml, the linear equation of diethyl sulfate    |
|           |is y=16542x ~ 91014, the correlation coefficient is 0.9990,      |
|           |greater than 0.990, and the absolute value of y-intercept        |
|           |accounts for 3.7% of 100% response value, less than 25%. It      |
|           |indicates that diethyl sulfate meets the requirements linearly   |
|           |in the concentration range of 15.3648~307.2960ng/ml.             |
|-----------|-----------------------------------------------------------------|
|Diisopropyl|Linear Solution 1|7.6            |15.1417        |137940         |
|sulfate    |                 |               |               |               |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Solution 2|37.9           |75.7085        |759103         |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Solution 3|60.6           |121.1336       |1259134        |
|           |-----------------|---------------|---------------|---------------|
|           |Linear solution 4|75.7           |151.4170       |1534192        |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Solution 5|113.6          |227.1255       |2376454        |
-------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 384 of 542 





Page 385
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-------------------------------------------------------------------------------
|           |Linear solution 6|151.4          |302.8340       |3366201        |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Chart     |                                               |
|           |-----------------|-----------------------------------------------|
|           |Linear equations |y=11126x-84402                                 |
|           |-----------------|-----------------------------------------------|
|           |Correlation      |0.9986                                         |
|           |coefficient R    |                                               |
|           |-----------------|-----------------------------------------------|
|           |Absolute value of|5.3                                            |
|           |Y-axis intercept |                                               |
|           |as a percentage  |                                               |
|           |of 100% response |                                               |
|           |(%)              |                                               |
|           |-----------------|                                               |
|           |The verdict: In the concentration range of                       |
|           |15.1417~302.8340ng/ml, the linear equation of diisopropyl        |
|           |sulfate is y=11126x-84402, the correlation coefficient is        |
|           |0.9986, greater than 0.990, and the absolute value of            |
|           |y-intercept is 5.3% of 100% response value, less than 25%. It    |
|           |indicates that diisopropyl sulfate meets the requirements        |
|           |linearly in the concentration range of 15.1417~302.8340ng/ml.    |
|-----------|-----------------------------------------------------------------|
|Disec-butyl|Linear Solution 1|7.7            |15.3638        |54810          |
|sulfate    |                 |               |               |               |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Solution 2|38.4           |76.8189        |311128         |
|           |-----------------|---------------|---------------|---------------|
|           |Linear solution 3|61.5           |122.9102       |528954         |
|           |-----------------|---------------|---------------|---------------|
|           |Linear solution 4|76.8           |153.6377       |638145         |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Solution 5|115.2          |230.4566       |988606         |
|           |-----------------|---------------|---------------|---------------|
|           |Linear solution 6|153.6          |307.2754       |1416224        |
|           |-----------------|---------------|---------------|---------------|
|           |Linear Chart     |                                               |
-------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 385 of 542 





Page 386
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










---------------------------------------------------------------------
|       |Linear equations             |Y = 4616.2 x - 41084         |
|       |-----------------------------|-----------------------------|
|       |Correlation                  |0.9982                       |
|       |coefficient R                |                             |
|       |-----------------------------|-----------------------------|
|       |Absolute value of            |6.1                          |
|       |Y-axis intercept             |                             |
|       |as a percentage              |                             |
|       |of 100% response             |                             |
|       |(%)                          |                             |
|       |-----------------------------|                             |
|       |The verdict: In the concentration range of                 |
|       |15.3638~307.2754ng/ml, the linear equation of disec-butyl  |
|       |sulfate is y=4616.2x-41084, the correlation coefficient is |
|       |0.9982, greater than 0.990, and the absolute value of      |
|       |y-intercept accounts for 6.1% of 100% response value, less |
|       |than 25%. It indicates that di-sec-butylsulfate meets the  |
|       |requirements linearly in the concentration range of        |
|       |15.3638~307.2754ng/ml.                                     |
---------------------------------------------------------------------

**(4.5) Repeatability** 



 **Acceptance Criteria** 



Repeatability is achieved by examining the repeatability of the results of 



each component to be tested in the repeatable test product solution. Prepare 



6 parts of repeatable test product solution with 100% limit of the components 



to be tested. The RSD of the content of dimethyl sulfate, diethyl sulfate, 



diisopropyl sulfate and disec-butyl sulfate in the 6 parts of repeatable test 



product solution shall NMT 20%. 



 **Preparation of solution** 



Blank solution: Blank solution as prepared under 4.1. 



Reference stock solution: the same as the reference stock solution 



prepared under item 4.1. 



Reference solution: the same as the reference solution prepared under 



4.1. 



Repeated test product solution: take about 10mg of this product, 



accurately weigh it, place it in a 5ml measuring bottle, add acetonitrile to 



dissolve, then add the control product reserve solution of 100μl, dilute with 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 386 of 542 





Page 387
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



acetonitrile to the scale, shake well, and get. 6 parts were prepared in 



parallel. 



 **Injection procedure** 



1 needle was injected into blank solution, 2 needles were injected into 



control solution continuously, and 1 needle was injected into 6 repetitive test 



product solutions respectively, and the chromatogram was recorded. 



 **Measurement results** 



















------------------------------------------------------------------------------------
|Name of solution  |Content (ppm)                                                  |
|                  |---------------------------------------------------------------|
|                  |Dimethyl       |Diethyl        |Diisopropyl    |Di-sec-butyl   |
|                  |sulfate        |sulfate        |sulfate        |sulfate        |
|------------------|---------------|---------------|---------------|---------------|
|Repetitive test   |64.4           |72.2           |67.4           |67.9           |
|product solution 1|               |               |               |               |
|------------------|---------------|---------------|---------------|---------------|
|Repetitive test   |68.5           |74.3           |69.9           |71.2           |
|product solution 2|               |               |               |               |
|------------------|---------------|---------------|---------------|---------------|
|Repetitive test   |63.1           |72.4           |67.6           |67.8           |
|product solution 3|               |               |               |               |
|------------------|---------------|---------------|---------------|---------------|
|Repetitive test   |59.3           |69.5           |64.7           |64.7           |
|product solution 4|               |               |               |               |
|------------------|---------------|---------------|---------------|---------------|
|Repeated test     |55.5           |74.6           |68.6           |70.2           |
|product solution 5|               |               |               |               |
|------------------|---------------|---------------|---------------|---------------|
|Repetitive test   |72.3           |75.7           |73.0           |76.8           |
|product solution 6|               |               |               |               |
|------------------|---------------|---------------|---------------|---------------|
|Average           |63.9           |73.1           |68.5           |69.8           |
|------------------|---------------|---------------|---------------|---------------|
|RSD/%             |10             |4              |5              |6              |
|------------------|---------------|---------------|---------------|---------------|
|Verdict: The RSD of the content of dimethyl sulfate was 10%, less than 20%,       |
|the RSD of the content of diethyl sulfate was 4%, less than 20%, the RSD of       |
|the content of diisopropyl sulfate was 5%, less than 20%, and the RSD of          |
|the content of disec-butyl sulfate was 6%, less than 20%. The results             |
|indicated that the reproducibility of dimethyl sulfate, diethyl sulfate,          |
|diisopropyl sulfate and disec-butylsulfate met the requirements.                  |
------------------------------------------------------------------------------------

**(4.6) Accuracy** 



 **Brief Description** 



Accuracy is achieved by adding each impurity reference in the range of 



30% limit concentration to 150% limit concentration of each impurity in the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 387 of 542 





Page 388
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



test product solution, and determining the recovery rate between the 



theoretical addition amount and the actual detection amount. The recovery 



rate of each impurity in the test solution should be between 80.0% and 



120.0%, and the RSD of the recovery rate of each impurity NMT 15%. 



 **Solution preparation** 



Blank solution: Blank solution as prepared under 4.1. 



Reference stock solution: the same as the reference stock solution 



prepared under item 4.1. 



Reference solution: the same reference solution prepared under item 4.1. 



Test product solution: Take about 10mg of this product, weigh it 



accurately, place it in a 5ml measuring bottle, add an appropriate amount of 



acetonitrile to dissolve, dilute it with acetonitrile to the scale, shake well, and 



get. Prepare 2 parts in parallel. 



30% standard test product solution: Take about 10mg of this product, 



accurately weigh it, place it in a 5ml measuring bottle, add an appropriate 



amount of acetonitrile to dissolve, accurately add the control product reserve 



liquid 30μl, dilute it with acetonitrile to the scale, shake well, and get. 



Dispense 3 parts in parallel. 



100% standard test product solution: take about 10mg of this product, 



weigh it accurately, place it in a 5ml measuring bottle, add acetonitrile and 



swirl to dissolve, add 100μl of control product reserve liquid precisely, dilute 



it with acetonitrile to the scale, shake well, and get. Dispense 3 parts in 



parallel 



150% standard test product solution: Take about 10mg of this product, 



accurately weigh it, place it in a 5ml measuring bottle, add acetonitrile and 



scroll to dissolve, accurately add the control product reserve liquid 150μl, 



dilute it with acetonitrile to the scale, shake well, and get. Dispense 3 parts in 



parallel. 



 **Injection procedure** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 388 of 542 





Page 389
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



After the blank solution, 2 needles were injected into the control solution 



continuously, 2 samples of test product solution and 9 samples of each 



concentration added standard test product solution were injected into 1 



needle successively, and the chromatogram was recorded. 



 **Results of determination** 






























----------------------------------------------------------------------------------
|Imp uriti|Solution name     |Peak area|Content              |Average content    |
|es Nam e |                  |         |                     |                   |
|---------|------------------|---------|---------------------|-------------------|
|Dim ethyl|Sample solution 1 |Not      |Not detected         |Not detected       |
|sulfa te |                  |detecte d|                     |                   |
|         |------------------|---------|---------------------|                   |
|         |Test product      |Not      |Not detected         |         |         |
|         |solution 2        |detecte d|                     |         |         |
|         |------------------|---------|---------------------|---------|---------|
|         |Solution name     |Peak area|Amount    |Amount    |Measure d|Recover y|
|         |                  |         |availabl e|added (ng)|amount   |rate (%) |
|         |                  |         |(ng)      |          |(ng)     |         |
|         |------------------|---------|----------|----------|---------|---------|
|         |30% standard test |562037   |Not       |0.2317    |0.2176   |93.94    |
|         |solution 1        |         |detecte d |          |         |         |
|         |------------------|---------|----------|----------|---------|---------|
|         |30% labeled test  |566838   |Not       |0.2317    |0.2195   |94.74    |
|         |product solution 2|         |detecte d |          |         |         |
|         |------------------|---------|----------|----------|---------|---------|
|         |30% labeled test  |550588   |Not       |0.2317    |0.2132   |92.02    |
|         |product solution 3|         |detecte d |          |         |         |
|         |------------------|---------|----------|----------|---------|---------|
|         |100% labeled test |195835 6 |Not       |0.7722    |0.7583   |98.19    |
|         |product solution 1|         |detecte d |          |         |         |
|         |------------------|---------|----------|----------|---------|---------|
|         |100% labeled test |195758 6 |Not       |0.7722    |0.7580   |98.15    |
|         |product solution 2|         |detecte d |          |         |         |
|         |------------------|---------|----------|----------|---------|---------|
|         |100% labeled test |192201 1 |Not       |0.7722    |0.7442   |96.37    |
|         |product solution 3|         |detecte d |          |         |         |
----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 389 of 542 





Page 390
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

















































------------------------------------------------------------------------------------------
|         |150% labeled test |291749 2   |Not        |1.1584     |1.1297     |97.52      |
|         |product solution 1|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |150% labeled test |293070 1   |Not        |1.1584     |1.1348     |97.96      |
|         |product solution 2|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |150% labeled test |293539 5   |Not        |1.1584     |1.1366     |98.12      |
|         |product solution 3|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |Average recovery  |96.33                                                      |
|         |rate (%)          |                                                           |
|         |------------------|-----------------------------------------------------------|
|         |RSD(%)            |2.4                                                        |
|         |------------------|-----------------------------------------------------------|
|         |Verdict: No dimethyl sulfate was detected in the test products. The           |
|         |average recovery rate was 96.33% when 30% limit concentration ~150%           |
|         |limit concentration of dimethyl sulfate was added to the test                 |
|         |products, the recovery rate was 92.02%~98.19%, 80%~120%, and the RSD          |
|         |of recovery was 2.4%. Less than 15%, indicating that the accuracy of          |
|         |this method in detecting dimethyl sulfate in YA2304 meets the                 |
|         |requirements.                                                                 |
|---------|------------------------------------------------------------------------------|
|impu rity|Solution name     |Peak area  |Content                |Average content        |
|Nam e    |                  |           |                       |                       |
|---------|------------------|-----------|-----------------------|-----------------------|
|Diet hyl |Sample solution 1 |Not        |Not detected           |Not detected           |
|sulfa te |                  |detecte d  |                       |                       |
|         |------------------|-----------|-----------------------|                       |
|         |Test product      |Not        |Not detected           |           |           |
|         |solution 2        |detecte d  |                       |           |           |
|         |------------------|-----------|-----------------------|-----------|-----------|
|         |Solution name     |Peak area  |Availabl e |Amount     |Measure d  |Recover y  |
|         |                  |           |amount     |added (ng) |amount     |rate (%)   |
|         |                  |           |(ng)       |           |(ng)       |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |30% standard test |642815     |Not        |0.2333     |0.2185     |93.66      |
|         |solution 1        |           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |30% labeled test  |655611     |Not        |0.2333     |0.2229     |95.53      |
|         |product solution 2|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |30% labeled test  |622481     |Not        |0.2333     |0.2116     |90.70      |
------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 390 of 542 





Page 391
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

































------------------------------------------------------------------------------------------
|         |product solution 3|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |100% labeled test |231073 2   |Not        |0.7776     |0.7855     |101.01     |
|         |product solution 1|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |100% labeled test |234822 4   |Not        |0.7776     |0.7982     |102.65     |
|         |product solution 2|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |100% labeled test |238347 4   |Not        |0.7776     |0.8102     |104.19     |
|         |product solution 3|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |150% labeled test |368677 8   |Not        |1.1665     |1.2532     |107.44     |
|         |solution 1        |           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |150% labeled test |366895 9   |Not        |1.1665     |1.2472     |106.92     |
|         |product solution 2|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |150% labeled test |365707 7   |Not        |1.1665     |1.2432     |106.57     |
|         |product solution 3|           |detecte d  |           |           |           |
|         |------------------|-----------|-----------|-----------|-----------|-----------|
|         |Average recovery  |100.96                                                     |
|         |rate (%)          |                                                           |
|         |------------------|-----------------------------------------------------------|
|         |RSD(%)            |7                                                          |
|         |------------------|-----------------------------------------------------------|
|         |Verdict: Diethyl sulfate was not detected in the test products, and           |
|         |the average recovery rate was 100.96% when 30% limit concentration            |
|         |~150% limit concentration of diethyl sulfate was added to the test            |
|         |products, the recovery rate was 90.70%~107.44%, 80%~120%, and the             |
|         |RSD of recovery was 7%. Less than 15%, indicating that the accuracy           |
|         |of this method in detecting diethyl sulfate in YA2304 meets the               |
|         |requirements.                                                                 |
|---------|------------------------------------------------------------------------------|
|Imp uriti|Solution name     |Peak area  |Content                |Average content        |
|es Nam e |                  |           |                       |                       |
|---------|------------------|-----------|-----------------------|-----------------------|
|Diis opro|Test product      |Not        |Not detected           |Not detected           |
|pyl sulfa|solution 1        |detecte d  |                       |                       |
|te       |                  |           |                       |                       |
|         |------------------|-----------|-----------------------|                       |
|         |Test product      |Not        |Not detected           |           |           |
|         |solution 2        |detecte    |                       |           |           |
------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 391 of 542 





Page 392
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 


































----------------------------------------------------------------------------------------
|       |                  |d          |                       |                       |
|       |------------------|-----------|-----------------------|-----------------------|
|       |Solution name     |Peak area  |Amount     |Amount     |Measure d  |Recover y  |
|       |                  |           |availabl e |added (ng) |amount     |rate (%)   |
|       |                  |           |(ng)       |           |(ng)       |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |30% standard test |438674     |Not        |0.2210     |0.2129     |96.31      |
|       |solution 1        |           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |30% labeled test  |442129     |Not        |0.2210     |0.2145     |97.07      |
|       |product solution 2|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |30% labeled test  |432713     |Not        |0.2210     |0.2100     |95.00      |
|       |product solution 3|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |100% labeled test |156759 1   |Not        |0.7367     |0.7607     |103.25     |
|       |product solution 1|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |100% labeled test |157909 9   |Not        |0.7367     |0.7662     |104.01     |
|       |product solution 2|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |100% labeled test |160329 9   |Not        |0.7367     |0.7780     |105.60     |
|       |product solution 3|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |150% labeled test |249530 6   |Not        |1.1051     |1.2108     |109.57     |
|       |product solution 1|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |150% labeled test |244758 0   |Not        |1.1051     |1.1877     |107.47     |
|       |product solution 2|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |150% labeled test |247512 3   |Not        |1.1051     |1.2010     |108.68     |
|       |product solution 3|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |Average recovery  |103.00                                                     |
|       |rate (%)          |                                                           |
|       |------------------|-----------------------------------------------------------|
|       |RSD(%)            |6                                                          |
|-------|------------------|-----------------------------------------------------------|
|       |Verdict: Diisopropyl sulfate was not detected in the test product.            |
|       |The average recovery of diisopropyl sulfate was 103.00% when the              |
|       |limit concentration of 30% ~150% was added to the test product. The           |
|       |recovery of each solution with added standard was 95.00%~109.57%,             |
|       |80%~120%,                                                                     |
----------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 392 of 542 





Page 393
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

































--------------------------------------------------------------------------------------
|          |and the RSD of recovery was 6%. Is less than 15%, indicating that        |
|          |the accuracy of this method in detecting diisopropyl sulfate in          |
|          |YA2304 meets the requirements.                                           |
|----------|-------------------------------------------------------------------------|
|Imp uriti |Solution name     |Peak area |Content              |Average content      |
|es Nam e  |                  |          |                     |                     |
|----------|------------------|----------|---------------------|---------------------|
|Di-s ec-b |Sample solution 1 |Not       |Not detected         |Not detected         |
|utyl sulfa|                  |detecte d |                     |                     |
|te        |                  |          |                     |                     |
|          |------------------|----------|---------------------|                     |
|          |Test product      |Not       |Not detected         |          |          |
|          |solution 2        |detecte d |                     |          |          |
|          |------------------|----------|---------------------|----------|----------|
|          |Solution name     |Peak area |Amount    |Amount    |Measure d |Recover y |
|          |                  |          |availabl e|added (ng)|amount    |rate (%)  |
|          |                  |          |(ng)      |          |(ng)      |          |
|          |------------------|----------|----------|----------|----------|----------|
|          |30% standard test |159119    |Not       |0.2306    |0.2053    |89.03     |
|          |solution 1        |          |detecte d |          |          |          |
|          |------------------|----------|----------|----------|----------|----------|
|          |30% labeled test  |160074    |Not       |0.2306    |0.2065    |89.57     |
|          |product solution 2|          |detecte d |          |          |          |
|          |------------------|----------|----------|----------|----------|----------|
|          |30% labeled test  |164782    |Not       |0.2306    |0.2126    |92.20     |
|          |product solution 3|          |detecte d |          |          |          |
|          |------------------|----------|----------|----------|----------|----------|
|          |100% labeled test |583727    |Not       |0.7687    |0.7532    |97.98     |
|          |product solution 1|          |detecte d |          |          |          |
|          |------------------|----------|----------|----------|----------|----------|
|          |100% labeled test |602244    |Not       |0.7687    |0.7771    |101.09    |
|          |product solution 2|          |detecte d |          |          |          |
|          |------------------|----------|----------|----------|----------|----------|
|          |100% labeled test |603209    |Not       |0.7687    |0.7783    |101.25    |
|          |product solution 3|          |detecte d |          |          |          |
|          |------------------|----------|----------|----------|----------|----------|
|          |150% labeled test |947602    |Not       |1.1530    |1.2227    |106.04    |
|          |product solution 1|          |detecte d |          |          |          |
--------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 393 of 542 





Page 394
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 













----------------------------------------------------------------------------------------
|       |150% labeled test |934005     |Not        |1.1530     |1.2052     |104.52     |
|       |product solution 2|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |150% labeled test |942394     |Not        |1.1530     |1.2160     |105.46     |
|       |product solution 3|           |detecte d  |           |           |           |
|       |------------------|-----------|-----------|-----------|-----------|-----------|
|       |Average recovery  |98.57                                                      |
|       |rate (%)          |                                                           |
|       |------------------|-----------------------------------------------------------|
|       |RSD(%)            |7                                                          |
|       |------------------|-----------------------------------------------------------|
|       |Verdict: Di-sec-butylsulfate was not detected in the test product.            |
|       |The average recovery was 98.57% when 30% ~150% limit concentration            |
|       |of di-sec-butylsulfate was added to the test product. The recovery            |
|       |was 89.03%~106.04%, 80%~120%, and the RSD of recovery was 7%. Less            |
|       |than 15%, indicating that the accuracy of this method in detecting            |
|       |di-sec-butylsulfate in YA2304 meets the requirements.                         |
----------------------------------------------------------------------------------------

**(4.7) Durability** 



 **Brief Description** 



Durability is achieved by changing the chromatographic conditions (starting 



temperature, inlet temperature, carrier gas flow rate) and testing the content 



of various impurities in the test solution with 100% limit concentration of 



impurities under normal chromatographic conditions. Under different 



conditions with the same chromatographic parameters, the signal-to-noise 



ratio of each impurity peak in the sensitivity solution should NLT 10, and the 



RSD of each impurity content in the durability test product NMT 20%. 



Changes in chromatographic conditions of durability test 










---------------------------------------------------------------
|Chromatographic      |Standard condition|Variable Values     |
|Parameters           |                  |                    |
|---------------------|------------------|--------------------|
|Starting temperature |50 ℃             |45 ° C, 55 ° C    |   
|---------------------|------------------|--------------------|
|Carrier gas flow rate|1.5 ml/min        |1.4ml/min, 1.6ml/min|
|---------------------|------------------|--------------------|
|Inlet temperature    |250 ℃            |245 ° C, 255 ° C  |   
---------------------------------------------------------------

 **Solution preparation** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 394 of 542 





Page 395
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Blank solution: Blank solution as prepared under 4.1. 



Sensitivity solution: Sensitivity solution prepared under item 4.1. 



Reference stock solution: the same as the reference stock solution prepared 



under item 4.1. 



Reference solution: the same reference solution prepared under item 4.1. 



Durability test product solution: Take about 10mg of this product, accurately 



weigh it, place it in a 5ml measuring bottle, add an appropriate amount of 



acetonitrile, swirl to dissolve, then add 100μl of control product reserve 



solution, dilute with acetonitrile to the scale, shake well, and get. Parallel 



preparation of 2 parts. 



 **Injection procedure** 



Under each durability chromatographic condition, after the blank solution, 



the sensitivity solution was injected with 1 needle, the control solution was 



injected with 2 needles continuously, and the 2 durability test solution was 



injected with 1 needle each, and the chromatographic diagram was recorded. 



 **Measurement resultss** 



























----------------------------------------------------------------------
|Chromat   |Paramete r|Sensitivity solution signal-to-noise ratio    |
|ographic  |values    |                                              |
|Condition |          |                                              |
|s         |          |                                              |
|          |          |----------------------------------------------|
|          |          |Dimethyl  |Diethyl   |Diisopropyl|Di-sec-butyl|
|          |          |sulfate   |sulfate   |sulfate    |sulfate     |
|----------|----------|----------|----------|-----------|------------|
|Initial   |45        |114.84    |95.45     |73.79      |88.31       |
|temperat  |          |          |          |           |            |
|ure (° C)|          |          |          |           |            | 
|          |----------|----------|----------|-----------|------------|
|          |50        |122.23    |111.70    |74.11      |79.46       |
|          |----------|----------|----------|-----------|------------|
|          |55        |81.76     |115.68    |77.89      |79.38       |
|----------|----------|----------|----------|-----------|------------|
|Inlet     |245       |93.93     |112.23    |80.10      |93.18       |
|temperat  |          |          |          |           |            |
|          |----------|----------|----------|-----------|------------|
|          |250       |122.23    |111.70    |74.11      |79.46       |
----------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 395 of 542 





Page 396
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










-------------------------------------------------------------------------------
|ure (° C)  |255         |79.80       |89.71       |70.61       |63.19       | 
|------------|------------|------------|------------|------------|------------|
|Flow rate   |1.4         |70.22       |125.68      |70.44       |69.16       |
|(ml/min)    |            |            |            |            |            |
|            |------------|------------|------------|------------|------------|
|            |1.5         |122.23      |111.70      |74.11       |79.46       |
|            |------------|------------|------------|------------|------------|
|            |1.6         |53.48       |92.02       |69.59       |67.67       |
|------------|------------|------------|------------|------------|------------|
|Conclusion: The SNR of dimethyl sulfate, diethyl sulfate, diisopropyl        |
|sulfate and disec-butyl sulfate in the sensitivity solution were all         |
|greater than 10 under the conditions of normal chromatographic parameters,   |
|changing the initial temperature, carrier gas flow rate, inlet temperature   |
|and column. The suitability of the system met the requirements.              |
-------------------------------------------------------------------------------

Durability - Sample test results 

































-------------------------------------------------------------------------
|Chromat   |Para met  |Sam ple|Content (ppm)                            |
|ographic  |er valu es|num ber|                                         |
|Conditio  |          |       |                                         |
|ns        |          |       |                                         |
|          |          |       |-----------------------------------------|
|          |          |       |Dimethyl|Diethyl|Diisopropyl|Di-sec-butyl|
|          |          |       |sulfate |sulfate|sulfate    |sulfate     |
|----------|----------|-------|--------|-------|-----------|------------|
|Initial   |45        |1      |65.1    |65.7   |63.8       |65.3        |
|temperat  |          |       |        |       |           |            |
|ure (° C)|          |       |        |       |           |            | 
|          |          |-------|--------|-------|-----------|------------|
|          |          |2      |70.9    |68.8   |64.5       |66.0        |
|          |----------|-------|--------|-------|-----------|------------|
|          |50        |1      |63.6    |70.3   |65.2       |66.9        |
|          |          |-------|--------|-------|-----------|------------|
|          |          |2      |68.1    |71.9   |66.6       |67.1        |
|          |----------|-------|--------|-------|-----------|------------|
|          |55        |1      |65.5    |69.6   |64.5       |64.3        |
|          |          |-------|--------|-------|-----------|------------|
|          |          |2      |69.3    |69.7   |63.9       |62.8        |
|          |----------|-------|--------|-------|-----------|------------|
|          |RSD/%             |5       |3.0    |1.7        |2.6         |
|----------|------------------|--------|-------|-----------|------------|
|Inlet     |245       |1      |66.6    |70.6   |66.5       |67.9        |
|temperat  |          |       |        |       |           |            |
|ure (° C)|          |       |        |       |           |            | 
|          |          |-------|--------|-------|-----------|------------|
|          |          |2      |72.0    |71.7   |66.8       |67.6        |
|          |----------|-------|--------|-------|-----------|------------|
|          |250       |1      |63.6    |70.3   |65.2       |66.9        |
|          |          |-------|--------|-------|-----------|------------|
|          |          |2      |68.1    |71.9   |66.6       |67.1        |
|          |----------|-------|--------|-------|-----------|------------|
|          |255       |1      |66.7    |68.9   |63.6       |64.0        |
|          |          |-------|--------|-------|-----------|------------|
|          |          |2      |73.1    |70.3   |64.6       |64.3        |
|          |----------|-------|--------|-------|-----------|------------|
|          |RSD/%             |6       |1.6    |2.0        |2.6         |
|----------|------------------|--------|-------|-----------|------------|
|Flow rate |1.4       |1      |67.5    |68.7   |63.2       |64.3        |
|(ml/min)  |          |       |        |       |           |            |
|          |          |-------|--------|-------|-----------|------------|
|          |          |2      |73.8    |70.0   |64.2       |64.5        |
|          |----------|-------|--------|-------|-----------|------------|
|          |1.5       |1      |63.6    |70.3   |65.2       |66.9        |
|          |          |-------|--------|-------|-----------|------------|
|          |          |2      |68.1    |71.9   |66.6       |67.1        |
|          |----------|-------|--------|-------|-----------|------------|
|          |1.6       |1      |67.9    |67.9   |63.9       |64.4        |
-------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 396 of 542 





Page 397
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

---------------------------------------------------------------------------------------
|            |            |2           |74.2        |69.6        |64.5        |64.0   |
|            |------------|------------|------------|------------|------------|-------|
|            |RSD/%                    |6           |2.0         |1.9         |2.2    |
|------------|-------------------------|------------|------------|------------|-------|
|Conclusion: The RSDS of dimethyl sulfate, diethyl sulfate, diisopropyl       |       |
|sulfate and disec-butyl sulfate were 5%, 3.0%, 1.7% and 2.6%, respectively,  |       |
|when the initial column temperature of the two durability test solutions     |       |
|was 45℃, 50℃and 55℃, all of which were less than 20%. RSDS of dimethyl    |       |   
|sulfate, diethyl sulfate, diisopropyl sulfate and di-sec-butylsulfate were   |       |
|6%, 2.0%, 1.9% and 2.2%, respectively, at the flow rates of 1.4ml/min,       |       |
|1.5ml/min and 1.6ml/min for durability test solutions, all of which were     |       |
|less than 20%. The RSDS of dimethyl sulfate, diethyl sulfate, diisopropyl    |       |
|sulfate and di-sec-butylsulfate were 6%, 1.6%, 2.0% and 2.6%, respectively,  |       |
|when the temperature of the 2 durability test solutions was 245℃, 250℃and  |       |  
|255℃, respectively, and were all less than 20%. The durability of the       |       | 
|method met the requirements.                                                 |       |
---------------------------------------------------------------------------------------



**(4.8) Solution stability** 



 **Brief Description** 



Each solution is placed at room temperature, and the sensitivity solution, the 



reference solution and the 100% labeled test product solution are injected at 



different times. The RSD of the peak area response value of each impurity in 



the sensitivity solution, the reference solution and the 100% labeled test 



product solution NMT 10%. 



 **Solution preparation** 



Blank solution: Blank solution as prepared under 4.1. 



Reference stock solution: the same as the reference stock solution prepared 



under item 4.1. 



Sensitivity solution: Sensitivity solution as prepared under item 4.1. 



Reference solution: the same as the reference solution prepared under item 



4.1. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 397 of 542 





Page 398
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



100% standard test product solution: take about 10mg of this product, 



accurately weigh it, place it in a 5ml measuring bottle, add acetonitrile 



appropriate amount 4 vortex to dissolve, accurately add the reference 



product reserve solution 100μl, dilute it with acetonitrile to the scale, shake 



well, and get. 



 **Injection Sequence** 



Each solution was placed at room temperature, the sensitivity solution, the 



control solution and the 100% standard test solution were injected with 1 



needle at 0h, 1.5h, 3.0h, 4.6h, 6.1h, 7.7h, 9.2h, 10.7h, 12.3h, 13.8h and 



15.3h respectively, and the chromatogram was recorded. 



 **Measurement result** 



Stability test results of sensitivity solution 



















---------------------------------------------------------------------------------
|Time point     |Impurity peak area response value                              |
|(h)            |                                                               |
|               |---------------------------------------------------------------|
|               |Dimethyl       |Diethyl        |Diisopropyl    |Di-sec-butyl   |
|               |sulfate        |sulfate        |sulfate        |sulfate        |
|---------------|---------------|---------------|---------------|---------------|
|0              |190403         |188948         |119008         |44718          |
|---------------|---------------|---------------|---------------|---------------|
|1.5            |188412         |187452         |120001         |45940          |
|---------------|---------------|---------------|---------------|---------------|
|3.0            |184496         |189022         |119921         |46351          |
|---------------|---------------|---------------|---------------|---------------|
|4.6            |176755         |186169         |117991         |45666          |
|---------------|---------------|---------------|---------------|---------------|
|6.1            |171826         |183690         |117573         |44664          |
|---------------|---------------|---------------|---------------|---------------|
|7.7            |168783         |186301         |117518         |44549          |
|---------------|---------------|---------------|---------------|---------------|
|9.2            |162656         |180525         |112729         |43637          |
|---------------|---------------|---------------|---------------|---------------|
|10.7           |159591         |175216         |111716         |43572          |
|---------------|---------------|---------------|---------------|---------------|
|12.3           |155049         |171937         |107037         |42250          |
|---------------|---------------|---------------|---------------|---------------|
|13.8           |151390         |169294         |105405         |40626          |
|---------------|---------------|---------------|---------------|---------------|
|15.3           |148599         |166753         |101765         |39844          |
|---------------|---------------|---------------|---------------|---------------|
|RSD/%          |9              |5              |6              |5              |
|---------------|---------------|---------------|---------------|---------------|
|Conclusion: The RSD of the peak area response of dimethyl sulfate in the       |
|sensitive solution is 9%, not more than 10%; The RSD of the peak area          |
|response of diethyl sulfate was 5%, less than 10%; The RSD of the peak area    |
|response of diisopropyl sulfate was 6%, less than 10%; The RSD of the peak     |
|area response of disec-butyl                                                   |
---------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 398 of 542 





Page 399
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



sulfate is 5%, not more than 10%, indicating that the stability of the impurities in the 



sensitive solution meets the requirements, that is, stable within 15.3 h. 



Stability test results of reference solution 



















---------------------------------------------------------------------------------
|Time point     |Impurity peak area response value                              |
|(h)            |                                                               |
|               |---------------------------------------------------------------|
|               |Dimethyl       |Diethyl        |Diisopropyl    |Di-sec-butyl   |
|               |sulfate        |sulfate        |sulfate        |sulfate        |
|---------------|---------------|---------------|---------------|---------------|
|0              |2072209        |2282778        |1414237        |546582         |
|---------------|---------------|---------------|---------------|---------------|
|1.5            |2010329        |2212930        |1351951        |514373         |
|---------------|---------------|---------------|---------------|---------------|
|3.0            |1952305        |2180200        |1337131        |514936         |
|---------------|---------------|---------------|---------------|---------------|
|4.6            |1859120        |2130727        |1304841        |498932         |
|---------------|---------------|---------------|---------------|---------------|
|6.1            |1817613        |2118867        |1290160        |497691         |
|---------------|---------------|---------------|---------------|---------------|
|7.7            |1746971        |2088184        |1262308        |481474         |
|---------------|---------------|---------------|---------------|---------------|
|9.2            |1746533        |2027443        |1225627        |471398         |
|---------------|---------------|---------------|---------------|---------------|
|10.7           |1698288        |1992264        |1199260        |456705         |
|---------------|---------------|---------------|---------------|---------------|
|12.3           |1628748        |1944962        |1172415        |454139         |
|---------------|---------------|---------------|---------------|---------------|
|13.8           |1596695        |1922525        |1148778        |438631         |
|---------------|---------------|---------------|---------------|---------------|
|15.3           |1545509        |1886615        |1133133        |431864         |
|---------------|---------------|---------------|---------------|---------------|
|RSD/%          |10             |7              |8              |8              |
|---------------|---------------|---------------|---------------|---------------|
|Conclusion: The RSD of the peak area response of dimethyl sulfate in the       |
|control solution is 10%, not more than 10%; The RSD of the peak area           |
|response of diethyl sulfate was 7%, less than 10%; The RSD of the peak area    |
|response of diisopropyl sulfate was 8%, less than 10%; The RSD of the peak     |
|area response of disec-butyl sulfate was 8%, not more than 10%, indicating     |
|that the stability of the impurities in the control solution met the           |
|requirements, that is, stable within 15.3 h.                                   |
---------------------------------------------------------------------------------

Stability test results of 100% labeled test product solution 



















-------------------------------------------------------
|Time point|Impurity peak area response value         |
|(h)       |                                          |
|          |------------------------------------------|
|          |Dimethyl|Diethyl |Diisopropyl|Di-sec-butyl|
|          |sulfate |sulfate |sulfate    |sulfate     |
|----------|--------|--------|-----------|------------|
|0         |2086277 |2331842 |1461126    |571654      |
|----------|--------|--------|-----------|------------|
|1.5       |2012763 |2227395 |1374888    |525995      |
|----------|--------|--------|-----------|------------|
|3.0       |1942224 |2187200 |1347851    |519604      |
|----------|--------|--------|-----------|------------|
|4.6       |1871331 |2157936 |1331608    |516497      |
|----------|--------|--------|-----------|------------|
|6.1       |1835089 |2160943 |1321617    |512831      |
|----------|--------|--------|-----------|------------|
|7.7       |1745523 |2107728 |1280936    |494456      |
|----------|--------|--------|-----------|------------|
|9.2       |1765301 |2068140 |1260113    |487783      |
|----------|--------|--------|-----------|------------|
|10.7      |1696135 |2023748 |1223767    |473809      |
|----------|--------|--------|-----------|------------|
|12.3      |1646900 |1993164 |1201867    |462912      |
-------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 399 of 542 





Page 400
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

---------------------------------------------------------------------------------
|13.8           |1599533        |1951026        |1178292        |448921         |
|---------------|---------------|---------------|---------------|---------------|
|15.3           |1546866        |1931126        |1163169        |448232         |
|---------------|---------------|---------------|---------------|---------------|
|RSD/%          |10             |6              |8              |8              |
|---------------|---------------|---------------|---------------|---------------|
|Conclusion: The RSD of peak area response of dimethyl sulfate in 100%          |
|standard test solution is 10%, not more than 10%; The RSD of the peak area     |
|response of diethyl sulfate was 6%, less than 10%; The RSD of the peak area    |
|response of diisopropyl sulfate was 8%, less than 10%; The RSD of the peak     |
|area response of disec-butylsulfate was 8%, not more than 10%, indicating      |
|that the stability of impurities in 100% standard test solution met the        |
|requirements, that is, stable within 15.3 h.                                   |
---------------------------------------------------------------------------------



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 400 of 542 





Page 401
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**III. Summary of Method Validation** 



Summary of the results of the verification of the method of genotoxic impurities in the finished product 






























------------------------------------------------------------------------------------------------------------------------
|Project     |Acceptable criteria        |Verification result                                                          |
|------------|---------------------------|-----------------------------------------------------------------------------|
|System      |The signal-to-noise ratio  |The SNR of dimethyl sulfate, diethyl sulfate, diisopropyl sulfate and        |
|suitabil    |of                         |disec-butyl                                                                  |
|ity         |each impurity peak in the  |sulfate in the sensitivity solution were 110.87, 179.58, 54.31 and 43.75,    |
|            |sensitivity solution should|respectively, and were NLT 10. The RSD of the retention time of dimethyl     |
|            |NLT                        |sulfate,                                                                     |
|            |10; The RSD of the         |diethyl sulfate, diisopropyl sulfate and di-sec-butylsulfate in the          |
|            |retention                  |irradiation                                                                  |
|            |time of each impurity in   |solution were 0.05%, 0%, 0% and 0.021%, respectively, and were not greater   |
|            |the                        |than 1%.                                                                     |
|            |luminous solution NMT 1%,  |The RSD of the peak area of dimethyl sulfate, diethyl sulfate, diisopropyl   |
|            |and                        |sulfate                                                                      |
|            |the RSD of the peak area   |and di-sec-butylsulfate in the irradiation solution were 2.9%, 2.5%, 3.0% and|
|            |response value NMT 10%.    |6%,                                                                          |
|            |                           |respectively, all of which were less than 10%, indicating that the system    |
|            |                           |applicability of the method for the detection of dimethyl sulfate, diethyl   |
|            |                           |sulfate,                                                                     |
|            |                           |diisopropyl sulfate and di-sec-butylsulfate met the requirements.            |
|------------|---------------------------|-----------------------------------------------------------------------------|
|Specific    |The retention time of each |The retention time of each impurity in the specific mixed solution and the   |
|ity         |impurity in the specific   |reference solution is consistent with the retention time of each impurity    |
|            |mixed                      |localization solution. Dimethyl sulfate, diethyl sulfate, diisopropyl sulfate|
|            |solution and the control   |and                                                                          |
|            |solution should be         |disec-butyl sulfate were not detected in the blank solution, indicating that |
|            |consistent                 |the                                                                          |
|            |with the retention time in |specificity of the method met the requirements.                              |
|            |the                        |                                                                             |
|            |impurity localization      |                                                                             |
|            |solution.                  |                                                                             |
|            |The peak area response     |                                                                             |
|            |value of                   |                                                                             |
|            |dimethyl sulfate, diethyl  |                                                                             |
|            |sulfate, diisopropyl       |                                                                             |
|            |sulfate and                |                                                                             |
|            |disec-butyl sulfate in the |                                                                             |
|            |blank                      |                                                                             |
|            |solution NMT 20% of the    |                                                                             |
|            |average                    |                                                                             |
|            |value of the peak area     |                                                                             |
|            |response                   |                                                                             |
|            |of each impurity in the    |                                                                             |
|            |mass                       |                                                                             |
|            |spectrum of 6 limited      |                                                                             |
|            |quantification solutions.  |                                                                             |
|------------|---------------------------|-----------------------------------------------------------------------------|
|Limits of   |It is required that the SNR|Impurities       |Detection Limits      |Limit of          |                 |
|quantifi    |of                         |                 |                      |quantitation      |                 |
|cation and  |each impurity in the 6     |                 |                      |                  |                 |
|detectio    |limited                    |                 |                      |                  |                 |
|            |quantitation solutions     |                 |                      |                  |                 |
|            |should                     |                 |                      |                  |                 |
|            |NLT 10, the RSD of the     |                 |                      |                  |                 |
|            |retention                  |                 |                      |                  |                 |
|            |time of each impurity      |                 |                      |                  |                 |
|            |should not                 |                 |                      |                  |                 |
|            |be more than 1.0%, and the |                 |                      |                  |                 |
|            |RSD                        |                 |                      |                  |                 |
|            |of the peak                |                 |                      |                  |                 |
|            |                           |                 |----------------------|------------------|                 |
|            |                           |                 |Concentration         |Concentration (equivalent to        |
|            |                           |                 |(equivalent to        |the test product solution           |
|            |                           |                 |the percentage of     |concentration percentage)           |
|            |                           |                 |solution              |                                    |
|            |                           |                 |concentration of the  |                                    |
|            |                           |                 |test                  |                                    |
|            |                           |                 |product)              |                                    |
|            |                           |-----------------|----------------------|------------------------------------|
|            |                           |Dimethyl         |4.4806ng/ml (2.2ppm)  |14.9352ng/ml (7.5ppm)               |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 401 of 542 





Page 402
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 
























---------------------------------------------------------
|Impurities   |Dimethyl|Diethyl|Diisopropyl|Di-sec-butyl|
|             |sulfate |sulfate|sulfate    |sulfate     |
|-------------|--------|-------|-----------|------------|
|Repeatability|10%, n=6|4%, n=6|5%, n=6    |6%, n=6     |
---------------------------------------------------------








































-------------------------------------------------------------------------------------------------------------------------
|n       |area response |sulfate        |                                   |                                  |       | 
|        |value of each |               |                                   |                                  |       | 
|        |impurity      |               |                                   |                                  |       | 
|        |should not be |               |                                   |                                  |       | 
|        |more than     |               |                                   |                                  |       | 
|        |10%. The      |               |                                   |                                  |       | 
|        |signal-to-noise|               |                                   |                                  |       |
|        |ratio         |               |                                   |                                  |       | 
|        |of every      |               |                                   |                                  |       | 
|        |impurity in   |               |                                   |                                  |       | 
|        |the mass      |               |                                   |                                  |       | 
|        |spectrogram of|               |                                   |                                  |       | 
|        |the detection |               |                                   |                                  |       | 
|        |limited       |               |                                   |                                  |       | 
|        |solution      |               |                                   |                                  |       | 
|        |should be NLT |               |                                   |                                  |       | 
|        |3.            |               |                                   |                                  |       | 
|        |              |---------------|-----------------------------------|----------------------------------|       | 
|        |              |Diethyl        |4.6094ng/ml (2.3ppm)               |15.3648ng/ml (7.7ppm)             |       | 
|        |              |sulfate        |                                   |                                  |       | 
|        |              |---------------|-----------------------------------|----------------------------------|       | 
|        |              |Diisopropyl    |4.5425ng/ml (2.3ppm)               |15.1417ng/ml (7.6ppm)             |       | 
|        |              |sulfate        |                                   |                                  |       | 
|        |              |---------------|-----------------------------------|----------------------------------|       | 
|        |              |Di-sec-butyl   |4.6091ng/ml (2.3ppm)               |15.3638ng/ml (7.7ppm)             |       | 
|        |              |sulfate        |                                   |                                  |       | 
|--------|--------------|---------------|-----------------------------------|----------------------------------|-------| 
|Linearit|The regression|       |Impurities     |Concentration (equivalent to the    |Linear equation  |               | 
|y       |coefficient R |       |               |percentage of solution concentration|                 |               | 
|vs.     |of            |       |               |of                                  |                 |               | 
|Range   |the obtained  |       |               |the test product)                   |                 |               | 
|        |linear graph  |       |               |                                    |                 |               | 
|        |should        |       |               |                                    |                 |               | 
|        |be NLT 0.990, |       |               |                                    |                 |               | 
|        |and the       |       |               |                                    |                 |               | 
|        |Y-intercept   |       |               |                                    |                 |               | 
|        |should be less|       |               |                                    |                 |               | 
|        |than          |       |               |                                    |                 |               | 
|        |25% of the    |       |               |                                    |                 |               | 
|        |100% response |       |               |                                    |                 |               | 
|        |value.        |       |               |                                    |                 |               | 
|        |              |       |---------------|------------------------------------|-----------------|               | 
|        |              |       |Dimethyl       |14.9352ng/ml~298.7040ng/ml          |y=13215x-26946   |       |       | 
|        |              |       |sulfate        |(7.5ppm~149.4ppm)                   |                 |       |       | 
|        |              |       |---------------|------------------------------------|-----------------|       |-------| 
|        |              |       |Diethyl        |15.3648ng/ml to 307.2960ng/ml       |y=16542x-91014   |       |       | 
|        |              |       |sulfate        |(7.7ppm to                          |                 |       |       | 
|        |              |       |               |153.6ppm)                           |                 |       |       | 
|        |              |       |---------------|------------------------------------|-----------------|       |-------| 
|        |              |       |Diisopropyl    |15.1417ng/ml to 302.8340ng/ml       |y=11126x-84402   |       |       | 
|        |              |       |sulfate        |(7.6ppm to                          |                 |       |       | 
|        |              |       |               |151.4ppm)                           |                 |       |       | 
|        |              |       |---------------|------------------------------------|-----------------|       |-------| 
|        |              |       |Disec-butyl    |15.3638ng/ml to 307.2754ng/ml       |Y = 4616.2 x -   |       |       | 
|        |              |       |sulfate        |(7.7ppm to                          |41084            |       |       | 
|        |              |       |               |153.6ppm)                           |                 |       |       | 
|--------|--------------|-------|---------------|------------------------------------|-----------------|       |-------| 
|Repeata |The RSD of the|Impurities Dimethyl sulfate Diethyl sulfate Diisopropyl sulfate Di-sec-butyl  |       |       | 
|bility  |content of    |sulfate Repeatability 10%, n=6 4%, n=6 5%, n=6 6%, n=6                        |       |       | 
|        |dimethyl      |                                                                              |       |       | 
|        |sulfate,      |                                                                              |       |       | 
|        |diethyl       |                                                                              |       |       | 
|        |sulfate,      |                                                                              |       |       | 
|        |diisopropyl   |                                                                              |       |       | 
|        |sulfate and   |                                                                              |       |       | 
|        |disec-butyl   |                                                                              |       |       | 
|        |sulfate in the|                                                                              |       |       | 
|        |solution of 6 |                                                                              |       |       | 
|        |repeatable    |                                                                              |       |       | 
|        |test          |                                                                              |       |       | 
|        |products      |                                                                              |       |       | 
|        |should NMT    |                                                                              |       |       | 
|        |20%.          |                                                                              |       |       | 
|--------|--------------|------------------------------------------------------------------------------|-------|-------| 
|Accura  |It is required|       |Impurities     |        |Marking  |Average          |        |RSD     |               | 
|cy      |that the      |       |               |        |condition|recovery rate    |        |        |               | 
|        |recovery      |       |               |        |         |                 |        |        |               | 
|        |rate of each  |       |               |        |         |                 |        |        |               | 
|        |impurity in   |       |               |        |         |                 |        |        |               | 
|        |the           |       |               |        |         |                 |        |        |               | 
|        |solution of   |       |               |        |         |                 |        |        |               | 
|        |each added    |       |               |        |         |                 |        |        |               | 
|        |standard      |       |               |        |         |                 |        |        |               | 
|        |test product  |       |               |        |         |                 |        |        |               | 
|        |should be     |       |               |        |         |                 |        |        |               | 
|        |between       |       |               |        |         |                 |        |        |               | 
|        |80.0% and     |       |               |        |         |                 |        |        |               | 
|        |120.0%, and   |       |               |        |         |                 |        |        |               | 
|        |the RSD of    |       |               |        |         |                 |        |        |               | 
|        |each impurity |       |               |        |         |                 |        |        |               | 
|        |recovery rate |       |               |        |         |                 |        |        |               | 
|        |NMT           |       |               |        |         |                 |        |        |               | 
|        |15%.          |       |               |        |         |                 |        |        |               | 
|        |              |       |---------------|--------|---------|-----------------|--------|--------|               | 
|        |              |       |Dimethyl       |        |Added    |96.33%, n=9      |        |2.4%, n=9       |       | 
|        |              |       |sulfate        |        |0.2317ng |                 |        |                |       | 
|        |              |       |               |        |to       |                 |        |                |       | 
|        |              |       |               |        |1.1584ng |                 |        |                |       | 
|        |              |       |---------------|--------|---------|-----------------|--------|----------------|-------| 
|        |              |       |Diethyl        |        |Added    |100.96%, n=9     |        |7%, n=9         |       | 
|        |              |       |sulfate        |        |0.2333ng |                 |        |                |       | 
|        |              |       |               |        |to       |                 |        |                |       | 
|        |              |       |               |        |1.1665ng |                 |        |                |       | 
|        |              |       |---------------|--------|---------|-----------------|--------|----------------|-------| 
|        |              |       |Diisopropyl    |        |Added    |103.00%, n=9     |        |6%, n=9         |       | 
|        |              |       |sulfate        |        |0.2210ng |                 |        |                |       | 
|        |              |       |               |        |to       |                 |        |                |       | 
|        |              |       |               |        |1.1051ng |                 |        |                |       | 
|        |              |       |---------------|--------|---------|-----------------|--------|----------------|-------| 
|        |              |       |Di-sec-butyl   |        |Added    |98.57%, n=9      |        |7%, n=9         |       | 
|        |              |       |sulfate        |        |0.2306ng |                 |        |                |       | 
|        |              |       |               |        |to       |                 |        |                |       | 
|        |              |       |               |        |1.1530ng |                 |        |                |       | 
|--------|--------------|-------|---------------|--------|---------|-----------------|--------|----------------|-------| 
|Durabil |Under         |The initial column temperature was 50℃±5℃, the flow rate of carrier gas was|       |       |    
|        |different     |                                                                              |       |       | 
|        |conditions of |                                                                              |       |       | 
-------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 402 of 542 





Page 403
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















------------------------------------------------------------------------------------------------------------------------
|ity           |the same chromatographic      |1.5ml/min±0.1ml/min, and the inlet temperature was 250℃±5℃. The     |    
|              |parameters, the               |results were as                                                         |
|              |signal-to-noise               |follows: System applicability: Under different chromatographic          |
|              |ratio of each impurity peak in|conditions, the                                                         |
|              |the sensitivity solution      |signal-to-noise ratio of dimethyl sulfate, diethyl sulfate, diisopropyl |
|              |should                        |sulfate and                                                             |
|              |NLT 10, and the RSD of each   |disec-butyl sulfate in the sensitivity solution were all greater than   |
|              |impurity content in the       |10, and the                                                             |
|              |durability test product NMT   |system applicability met the requirements. Test product solution: under |
|              |20%.                          |different                                                               |
|              |                              |chromatographic conditions, the RSDS of dimethyl sulfate, diethyl       |
|              |                              |sulfate,                                                                |
|              |                              |diisopropyl sulfate and di-sec-butylsulfate in the durability test      |
|              |                              |product solution                                                        |
|              |                              |were not more than 20%, which met the verification requirements.        |
|--------------|------------------------------|------------------------------------------------------------------------|
|Stabilit y    |Each solution is placed at    |The RSDS of the peak area response of dimethyl sulfate, diethyl sulfate,|
|of solutio    |room                          |diisopropyl sulfate and disec-butylsulfate were 9%, 5%, 6% and 5%,      |
|n             |temperature, and the          |respectively,                                                           |
|              |sensitivity solution, the     |within 15.3h after the sensitivity solution was placed at room          |
|              |reference solution and the    |temperature, and                                                        |
|              |100%                          |were all less than 10%. The verification requirements were met,         |
|              |labeled test product solution |indicating that the                                                     |
|              |are injected at different     |sensitive solution was stable within 15.3h at room temperature. The RSD |
|              |times. The RSD of the peak    |of the peak                                                             |
|              |area                          |area response of dimethyl sulfate, diethyl sulfate, diisopropyl sulfate |
|              |response value of each        |and                                                                     |
|              |impurity                      |disec-butyl sulfate were 10%, 7%, 8% and 8%, respectively, within 15.3h |
|              |in the sensitivity solution,  |when the                                                                |
|              |the reference solution and the|control solution was placed at room temperature. The verification       |
|              |100% labeled test product     |requirements were                                                       |
|              |solution NMT 10%.             |met, indicating that the control solution was stable within 15.3h at    |
|              |                              |room                                                                    |
|              |                              |temperature. The RSD of peak area response of dimethyl sulfate, diethyl |
|              |                              |sulfate,                                                                |
|              |                              |diisopropyl sulfate and disec-butyl sulfate were 10%, 6%, 8% and 8%,    |
|              |                              |respectively,                                                           |
|              |                              |and none of them were greater than 10%, after 100% standard test        |
|              |                              |solution was                                                            |
|              |                              |placed at room temperature for 15.3h. It met the verification           |
|              |                              |requirements,                                                           |
|              |                              |indicating that the 100% labeled test solution was stable within 15.3h  |
|              |                              |at room                                                                 |
|              |                              |temperature. The above solutions do not need to be used in the new      |
|              |                              |preparation.                                                            |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 403 of 542 





Page 404
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4.3.5 Method Validation of assay in Finerenone** 



**I. Analytical Procedures** 



Please refer to the analytical procedures of assay in Finerenone in _section_ 



_3.2.S.4.2_ . 



**II. Validation Results and Discussion** 



**a. Selection of Detection Wavelength** 



 **Acceptance Criteria** 



The selection of detection wavelength is through the ultraviolet scanning of 



the principal component at 200nm ~ 400nm wavelength, and the principal 



component is required to have a large absorption at 251nm. 



 **Solution Preparation** 



Solvent acetonitrile: water (30:70, v/v) 



Blank solution: solvent. 



Reference solution: Accurately weigh YA2304 about 10mg of reference 



product, place it in a 25ml bottle, add an appropriate amount of solvent to 



dissolve by ultrasound, dilute it with solvent to scale, and shake well; 



Accurately measure 1ml of the above solution, place it in a 20ml measuring 



bottle, dilute it with solvent to the scale, shake well, and then obtain. (About 



0.02mg/ml) 



 **Injection procedure** 



After the chromatographic system is balanced, take blank solution and 



reference solution to inject 1 needle each, and record the chromatogram. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 404 of 542 





Page 405
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



 **Measurement resultss** 



















--------------------------------------------------------------------------------
|Name of          |Test             |Retention time   |Whether there is a large|
|solution         |substance        |(min)            |absorption at 251nm     |
|-----------------|-----------------|-----------------|------------------------|
|Reference        |Finerenone       |9.833            |is                      |
|solution         |                 |                 |                        |
|-----------------|-----------------|-----------------|------------------------|
|Reference        |                                                            |
|solution         |                                                            |
|wavelength       |                                                            |
|scan             |                                                            |
|-----------------|                                                            |
|Conclusion: The principal component has greater absorption at 251nm.          |
--------------------------------------------------------------------------------

**(4.2) System applicability** 



 **Acceptance Criteria** 



The blank solution should be free from interference; The relative standard 



deviation of the main peak area should NMT 2%, the relative standard 



deviation of the main peak retention time should NMT 2.0%, the theoretical 



plate number should NLT 3000 according to the phenalidone peak, and the 



trailing factor NMT 1.5. 



 **Solution preparation** 



Blank solution: solvent. 



Reference solution: Prepare it by the same method as the reference solution 



under "4.1 wavelength selection". (Approx. 0.02mg/ml) 



 **Injection procedure** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 405 of 542 





Page 406
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



After the chromatographic system was balanced, the blank solution was 



injected with 1 needle, the control solution was injected with 6 needles again, 



and the chromatogram was recorded. 



 **Measurement resultss** 



















--------------------------------------------------------------------------------------
|Investigation |Control solution was injected                              |RSD      |
|parameters    |                                                           |         |
|              |-----------------------------------------------------------|         |
|              |1        |2        |3        |4        |5        |6        |         |
|--------------|---------|---------|---------|---------|---------|---------|---------|
|Retention time|9.852    |9.848    |9.850    |9.863    |9.862    |9.861    |0.07%    |
|(min)         |         |         |         |         |         |         |         |
|--------------|---------|---------|---------|---------|---------|---------|---------|
|Main peak area|362915   |362748   |362771   |365085   |364069   |364169   |0.27%    |
|--------------|---------|---------|---------|---------|---------|---------|---------|
|Main peak     |1.18     |1.17     |1.18     |1.18     |1.18     |1.18     |/        |
|trailing      |         |         |         |         |         |         |         |
|factor        |         |         |         |         |         |         |         |
|--------------|---------|---------|---------|---------|---------|---------|---------|
|Main peak     |76308    |76957    |77076    |77267    |77520    |77334    |/        |
|theoretical   |         |         |         |         |         |         |         |
|plate number  |         |         |         |         |         |         |         |
|--------------|         |         |         |         |         |         |         |
|Conclusion: the blank solution has no interference; The RSD of the main             |
|peak retention time was 0.07% (required not to exceed 2.0%), the RSD of the         |
|peak area was 0.27% (required not to exceed 2.0%), and the theoretical              |
|plate number of the peak of finalidone was NLT 76308 (NLT 3000). The                |
|trailing factor was in the range of 1.17~1.18 (the requirement NMT 1.5).            |
|All above meet the requirements, indicating that the method has good                |
|applicability in the system.                                                        |
--------------------------------------------------------------------------------------

**(4.3) Linearity and range** 



 **Acceptance Criteria** 



In the concentration range equivalent to 60%~140% of the control solution, a 



relatively uniform selection of 5 concentration points, with the concentration 



as the horizontal coordinate and the peak area as the vertical coordinate as 



the linear regression curve, the correlation coefficient (R) of the regression 



curve is NLT 0.998, the RSD of the response factor should NMT 2.0%. The 



absolute value of Y-axis intercept accounts for less than 2% of 100% 



response value. 



 **Solution preparation** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 406 of 542 





Page 407
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Blank solution: solvent. 



YA2304 reference product reserve liquid: Accurately weigh YA2304 reference 



product about 10mg, place in 25ml measuring bottle, add appropriate 



amount of solvent to dissolve by ultrasound, dilute with solvent to scale, 



shake well, and then get. (About 0.4mg/ml) 



Linear solution ① : Accurately measure 0.6ml of YA2304 reference product 



reserve liquid, place it in a 20ml measuring bottle, dilute it with solvent to the 



scale, shake well, and obtain. (about 12μg/ml) 



Linear solution ② : Accurately measure 0.8ml of YA2304 reference product 



reserve liquid, place it in 20ml measuring bottle, dilute it with solvent to the 



scale, shake well, and then obtain. (about 16μg/ml) 



Linear solution ③ : Accurately measure YA2304 reference product reserve 



liquid 1.0ml, place it in a 20ml measuring bottle, dilute it with solvent to the 



scale, shake well, and then obtain. (About 20μg/ml) 



Linear solution ④ : precisely measure 1.2ml of YA2304 reference product 



reserve liquid, place it in a 20ml measuring bottle, dilute it with solvent to the 



scale, shake well, and get. (about 24μg/ml) 



Linear solution ⑤ : Accurately measure 1.4ml of YA2304 reference product 



reserve liquid, place it in 20ml measuring bottle, dilute it with solvent to the 



scale, shake well, and get. (about 28μg/ml) 



 **Injection procedure** 



After the chromatographic system was balanced, the blank solution was 



injected with 1 needle, and the 5 linear solutions were injected with 1 needle 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 407 of 542 





Page 408
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



each from low concentration to high concentration, and the chromatogram 



was recorded. 



 **Measurement resultss** 



Results of linear and range tests 



























----------------------------------------------------------------
|Name of solution|Equivalent to|Concentratio|Peak area|Response|
|                |the          |n (μg/ml)  |         |factor  | 
|                |percentage of|            |         |        |
|                |the          |            |         |        |
|                |concentration|            |         |        |
|                |of the       |            |         |        |
|                |control      |            |         |        |
|                |solution     |            |         |        |
|----------------|-------------|------------|---------|--------|
|Linear solution |61.79%       |12.3576     |208458   |16869   |
|①              |             |            |         |        | 
|----------------|-------------|------------|---------|--------|
|Linear solution |82.38%       |16.4768     |275246   |16705   |
|②              |             |            |         |        | 
|----------------|-------------|------------|---------|--------|
|Linear solution |102.98%      |20.5960     |345639   |16782   |
|③              |             |            |         |        | 
|----------------|-------------|------------|---------|--------|
|Linear solution |123.58%      |24.7152     |416368   |16847   |
|④              |             |            |         |        | 
|----------------|-------------|------------|---------|--------|
|Linear solution |144.17%      |28.8344     |484119   |16790   |
|⑤              |             |            |         |        | 
|----------------|-------------|------------|---------|--------|
|Response factor |0.4%                                         |
|RSD             |                                             |
|----------------|---------------------------------------------|
|Linear graph    |                                             |
|----------------|---------------------------------------------|
|Linear equations|y=16810x-256                                 |
|----------------|---------------------------------------------|
|Slope           |16810                                        |
|----------------|---------------------------------------------|
|Correlation     |0.99995                                      |
|coefficient r   |                                             |
|----------------|---------------------------------------------|
|Absolute value  |0.076%                                       |
|of Y-axis       |                                             |
|intercept as a  |                                             |
|percentage of   |                                             |
|100% response   |                                             |
----------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 408 of 542 





Page 409
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

-----------------------------------------------------------------------------
|value                                |                                     |
|-------------------------------------|-------------------------------------|
|Conclusion: When Finerenone was in the concentration range of              |
|12.3576μg/ml~28.8344μg/ml, the linear equation was y=16810x-256, the     |  
|correlation coefficient r was 0.99995 (NLT 0.998), and the RSD of the      |
|response factor was 0.4% (NMT 2.0%). The absolute value of Y-axis intercept|
|as a percentage of 100% response value is 0.076% (no more than 2.0%        |
|required). All of the above meet the requirements, indicating that under   |
|this method, when Finerenone is in the concentration range of 12.3576μg/ml| 
|to 28.8344μg/ml, the linear relationship between peak area and            | 
|concentration is good.                                                     |
-----------------------------------------------------------------------------



**(4.4) Accuracy** 



 **Brief Description** 



Add YA2304 reference in the range of 80% to 120% reference solution 



concentration to the solvent; The recovery rate is required to be between 98% 



and 101%, and the RSD of recovery rate NMT 2.0%. 



 **Solution preparation** 



Blank solution: solvent 



Reference solution: Prepare it by the same method as the reference solution 



under "4.1 wavelength selection". 2 copies were prepared in parallel, in which 



the control solution ② was prepared by sharing the control product reserve 



liquid under "4.3 linearity and range". (Approx. 0.02mg/ml) 



80% recovery solution: precision weigh YA2304 reference product about 8mg, 



put it in 25ml bottle, add appropriate amount of solvent to dissolve by 



ultrasound, dilute with solvent to scale, shake well; Accurately measure 1ml 



of the above solution, place it in a 20ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. Prepare 3 servings in 



parallel (about 0.016mg/ml) 



100% recovery solution: accurately weigh YA2304 reference product about 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 409 of 542 





Page 410
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



10mg, put it in 25ml bottle, add appropriate amount of solvent to dissolve by 



ultrasound, dilute it with solvent to scale, shake well; Accurately measure 



1ml of the above solution, place it in a 20ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. Prepare 3 servings in 



parallel (about 0.02mg/ml) 



120% recovery solution: accurately weigh YA2304 reference product about 



12mg, place it in 25ml bottle, add appropriate amount of solvent to dissolve 



by ultrasound, dilute it with solvent to scale, shake well; Accurately measure 



1ml of the above solution, place it in a 20ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then obtain. Prepare 3 servings in 



parallel (about 0.024mg/ml) 



 **Injection procedure** 



After the chromatographic system was balanced, the blank solution was 



injected with 1 needle, the control solution (1) was injected with 6 needles, 



the control solution (2) was injected with 2 needles, the 9 recovery solutions 



were injected with 1 needle each, and the chromatogram was recorded. 



 **Measurement resultss** 



























---------------------------------------------------------------
|Name of solution|Amount to|Measured|Recovery|Average |RSD    |
|                |add      |quantity|rate    |recovery|       |
|                |(μg/ml) |(μg/ml)|        |rate    |       |  
|----------------|---------|--------|--------|--------|-------|
|80% recovery    |16.0417  |16.1074 |100.4%  |99.9%   |0.6%   |
|solution -1     |         |        |        |        |       |
|----------------|---------|--------|--------|        |       |
|80% recovery    |16.0038  |15.9873 |99.9%   |        |       |
|solution -2     |         |        |        |        |       |
|----------------|---------|--------|--------|        |       |
|80% recovery    |16.0597  |16.0472 |99.9%   |        |       |
|solution -3     |         |        |        |        |       |
|----------------|---------|--------|--------|        |       |
|100% recovery   |20.7416  |20.7942 |100.3%  |        |       |
|solution -1     |         |        |        |        |       |
|----------------|---------|--------|--------|        |       |
|100% recovery   |20.6977  |20.6882 |100.0%  |        |       |
---------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 410 of 542 





Page 411
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

--------------------------------------------------------------------------------
|solution -2  |            |            |            |            |            |
|-------------|------------|------------|------------|            |            |
|100% recovery|20.6897     |20.7189     |100.1%      |            |            |
|solution -3  |            |            |            |            |            |
|-------------|------------|------------|------------|            |            |
|120% recovery|24.3747     |24.2658     |99.6%       |            |            |
|solution -1  |            |            |            |            |            |
|-------------|------------|------------|------------|            |            |
|120% recovery|24.2889     |23.9431     |98.6%       |            |            |
|solution -2  |            |            |            |            |            |
|-------------|------------|------------|------------|            |            |
|120% recovery|24.4963     |24.5611     |100.3%      |            |            |
|solution -3  |            |            |            |            |            |
|-------------|------------|------------|------------|------------|------------|
|Conclusion: 16.0038μg/ml~24.4963μg/ml of YA2304 was added into the solvent. |  
|The recoveries were 98.6%~100.4% (the requirement was 98%~101%), and the      |
|RSD of the recovery was 0.6% (the requirement was not more than 2.0%). All    |
|the above met the verification requirements, indicating the accuracy of the   |
|method was good.                                                              |
--------------------------------------------------------------------------------



**(4.5) Precision** 



Precision refers to the proximity between the results obtained by multiple 



sampling of the same uniform test product under specified test conditions, 



and its precision is judged by examining repeatability and intermediate 



precision. 



**(4.5.1) Repeatability** 



 **Acceptance Criteria** 



The analyst A prepared 6 repeatable sample solutions on the date A, 



measured by instrument A, requiring the first reference solution to be 



continuously sampled for 6 times, the relative standard deviation of the main 



peak area should NMT 2%, the relative standard deviation of the main peak 



retention time should NMT 2.0%, and the theoretical plate number should 



NLT 3000 calculated according to the peak of Finerenone. The trailing factor 



NMT 1.5; The RSD of principal component in 6 repeatable test product 



solutions NMT 1.0%. 



 **Solution preparation** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 411 of 542 





Page 412
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Blank solution: solvent 



Reference solution: Prepare it by the same method as the reference solution 



under "4.1 wavelength selection". Prepare 2 parts in parallel. (Approx. 



0.02mg/ml) 



Repeatable test product solution: accurately weigh about 10mg of this 



product, place it in 25ml measuring bottle, add appropriate amount of 



solvent and ultrasonic to dissolve, dilute it with solvent to scale, shake well; 



Accurately measure 1ml of the above solution, place it in a 20ml measuring 



bottle, dilute it with solvent to the scale, shake well, and then get. Prepare 6 



parts in parallel. (Approx. 0.02mg/ml) 



 **Injection procedure** 



After the chromatographic system was balanced, the blank solution was 



injected with 1 needle, the control solution (1) was injected with 6 needles, 



the control solution (2) was injected with 2 needles, each of the 6 repetitive 



test solutions was injected with 1 needle, and the chromatogram was 



recorded. 



 **Measurement results** 



Results of repeatability - system suitability test 


















------------------------------------------------------------------------
|Investigation |Control solution was injected                  |RSD    |
|parameters    |                                               |       |
|              |-----------------------------------------------|       |
|              |1      |2      |3      |4      |5      |6      |       |
|--------------|-------|-------|-------|-------|-------|-------|-------|
|Retention time|9.882  |9.884  |9.883  |9.886  |9.883  |9.885  |0.015 %|
|(min)         |       |       |       |       |       |       |       |
|--------------|-------|-------|-------|-------|-------|-------|-------|
|Main peak area|340753 |340305 |340824 |341335 |340663 |340895 |0.10%  |
|--------------|-------|-------|-------|-------|-------|-------|-------|
|Main peak     |1.18   |1.19   |1.18   |1.19   |1.19   |1.19   |/      |
|trailing      |       |       |       |       |       |       |       |
|factor        |       |       |       |       |       |       |       |
|--------------|-------|-------|-------|-------|-------|-------|-------|
|Main peak     |79832  |79779  |80060  |79587  |79934  |79660  |/      |
|theoretical   |       |       |       |       |       |       |       |
|plate         |       |       |       |       |       |       |       |
------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 412 of 542 





Page 413
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

---------------------------------------------------------------------------------
|number   |         |         |         |         |         |         |         |
|---------|---------|---------|---------|---------|---------|---------|---------|
|Conclusion: the blank solution has no interference; The RSD of the main        |
|peak retention time was 0.015% (required not to exceed 2.0%), the RSD of       |
|the peak area was 0.10% (required not to exceed 2.0%), and the theoretical     |
|plate number of the peak of finalidone was NLT 79587 (NLT 3000). The           |
|trailing factor is in the range of 1.18~1.19 (the requirement NMT 1.5). The    |
|above all meet the verification requirements, indicating that the              |
|suitability of the system meets the requirements.                              |
---------------------------------------------------------------------------------



Repeatability test results 































-----------------------------------------------------------------------------------------
|Investigati|Solution name                                                    |RSD      |
|on items   |                                                                 |         |
|           |-----------------------------------------------------------------|         |
|           |Repetiti  |Repetiti  |Repetiti  |Repetiti  |Repetiti  |Repetiti  |         |
|           |ve test   |ve test   |ve test   |ve test   |ve test   |ve test   |         |
|           |product   |product   |product   |product   |product   |product   |         |
|           |solution 1|solution 2|solution 3|solution 4|solution 5|solution 6|         |
|-----------|----------|----------|----------|----------|----------|----------|---------|
|Principal  |99.1%     |99.3%     |98.9%     |100.0%    |99.7%     |99.3%     |0.5%     |
|component  |          |          |          |          |          |          |         |
|content    |          |          |          |          |          |          |         |
|-----------|----------|----------|----------|----------|----------|----------|---------|
|Conclusion: The RSD of principal component in 6 repeatable samples was 0.5%            |
|(the requirement NMT 1.0%), which met the verification requirements,                   |
|indicating that the method had good repeatability.                                     |
-----------------------------------------------------------------------------------------

**(4.5.2) Intermediate precision** 



 **sketch** 



6 intermediate precision test product solutions were prepared by Analyst B 



on date B. The relative standard deviation of the main peak area should NMT 



2%, the relative standard deviation of the main peak retention time should 



NMT 2.0%, the theoretical plate number should NLT 3000, and the trailing 



factor NMT 1.5. The RSD of principal component in 6 intermediate precision 



test product solutions NMT 1.0%. 



For the results of 12 tests of repeatability and intermediate precision, the 



RSD of principal component content NMT 2.0%. 



 **Solution preparation** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 413 of 542 





Page 414
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Blank solution: thinner 



Reference solution: Prepare it by the same method as the reference solution 



under "4.1 wavelength selection". 2 copies were prepared in parallel, in which 



the control solution (1) shared the control solution under "4.1 wavelength 



selection". (Approx. 0.02mg/ml) 



Intermediate precision test product solution: accurately weigh about 10mg of 



this product, place it in a 25ml measuring bottle, add an appropriate amount 



of diluent to dissolve by ultrasound, dilute it with diluent to the scale, and 



shake well; Precision measure 1ml of the above solution, place it in a 20ml 



measuring bottle, dilute it with diluent to the scale, shake well, and then get. 



Prepare 6 parts in parallel. (Approx. 0.02mg/ml) 



 **Injection procedure** 



After the chromatographic system is balanced, take blank solution into 1 



needle, control solution 1 into 6 needles, control solution 2 into 2 needles, 6 



intermediate precision test solution 1 needle each, record the chromatogram. 



 **Measurement results** 



Results of intermediate precision - system suitability test 



















-------------------------------------------------------------------------------
|Investigation |Control solution was injected                        |RSD     |
|parameters    |                                                     |        |
|              |-----------------------------------------------------|        |
|              |1       |2       |3       |4       |5       |6       |        |
|--------------|--------|--------|--------|--------|--------|--------|--------|
|Retention time|9.809   |9.798   |9.788   |9.785   |9.796   |9.795   |0.09%   |
|(min)         |        |        |        |        |        |        |        |
|--------------|--------|--------|--------|--------|--------|--------|--------|
|Main peak area|344187  |345304  |345625  |345620  |345536  |345986  |0.19%   |
|--------------|--------|--------|--------|--------|--------|--------|--------|
|Main peak     |1.23    |1.23    |1.23    |1.23    |1.23    |1.22    |/       |
|trailing      |        |        |        |        |        |        |        |
|factor        |        |        |        |        |        |        |        |
|--------------|--------|--------|--------|--------|--------|--------|--------|
|Main peak     |50253   |48230   |48071   |47066   |48322   |48600   |/       |
|theoretical   |        |        |        |        |        |        |        |
|plate number  |        |        |        |        |        |        |        |
|--------------|        |        |        |        |        |        |        |
|Conclusion: the blank solution has no interference; The RSD of the main      |
|peak                                                                         |
-------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 414 of 542 





Page 415
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



retention time was 0.09% (required not to exceed 2.0%), the RSD of the peak area was 



0.19% (required not to exceed 2.0%), and the theoretical plate number of the peak of 



finalidone was NLT 47066 (NLT 3000). The trailing factor was in the range of 



1.22~1.23 (the requirement NMT 1.5). The above all meet the verification 



requirements, indicating that the suitability of the system meets the requirements. 



Precision test results 






















---------------------------------------------------------------------------------------
|Investigatio|Repetitive test product solution                     |RSD (n=6)|RSD (n=1|
|n items     |                                                     |         |2)      |
|            |-----------------------------------------------------|         |        |
|            |1       |2       |3       |4       |5       |6       |         |        |
|------------|--------|--------|--------|--------|--------|--------|---------|        |
|Principal   |99.1%   |99.3%   |98.9%   |100.0 % |99.7%   |99.3%   |0.5%     |        |
|component   |        |        |        |        |        |        |         |        |
|content     |        |        |        |        |        |        |         |        |
|------------|--------|        |        |        |        |        |---------|--------|
|Items to    |Intermediate precision test product solution         |RSD (n=6)|0.4%    |
|examine     |                                                     |         |        |
|            |-----------------------------------------------------|         |        |
|            |1       |2       |3       |4       |5       |6       |         |        |
|------------|--------|--------|--------|--------|--------|--------|---------|        |
|Principal   |99.5%   |99.0%   |99.7%   |99.4%   |99.5%   |98.8%   |0.4%     |        |
|component   |        |        |        |        |        |        |         |        |
|content     |        |        |        |        |        |        |         |        |
|------------|        |        |        |        |        |        |         |        |
|Conclusion: The RSD of principal component in 6 intermediate precision test          |
|solutions was 0.4% (the requirement NMT 1.0%), which met the verification            |
|requirements, indicating that the intermediate precision of the method was           |
|good. The RSD of principal component in 12 repetitive sample solutions and           |
|intermediate precision sample solutions was 0.4% (the requirement NMT                |
|2.0%), which met the verification requirements, indicating that the method           |
|was of good precision.                                                               |
---------------------------------------------------------------------------------------

**(4.6) Stability of the solution** 



 **Acceptance Criteria** 



Each solution is placed under the 5℃ injector, the control solution and the 



test product solution are injected at different time points, and the theoretical 



plate number in the control solution is required to be NLT 3000 according to 



the peak of Finerenone, and the tail factor NMT 1.5; The RSD of the main 



peak-peak area between the control solution and the test solution NMT 2.0%, 



and no new impurities interfering with the detection of principal components 



should be added. 



 **Solution preparation** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 415 of 542 





Page 416
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Blank solution: solvent. 



Reference solution: Share the reference solution under "4.2 System 



Suitability". (Approx. 0.02mg/ml) 



Test product solution: accurately weigh about 10mg of this product, put it in 



25ml measuring bottle, add appropriate amount of solvent to dissolve by 



ultrasound, dilute it with solvent to scale, shake well; Accurately measure 



1ml of the above solution, place it in a 20ml measuring bottle, dilute it with 



solvent to the scale, shake well, and then get. (About 0.02mg/ml) 



 **Injection procedure** 



After the chromatographic system was balanced, the control solution placed 



in the 5℃ injector was injected at 0h, 2h, 4h, 6h, 12h, 24h, 39h, 54h and 75h, 



and the chromatogram was recorded. (Chromatograms of reference solution 



0h and 2h share the chromatograms of reference solution 1 and 5 with 



repeated injection of 6 needles under "4.2 System Suitability", respectively) 



After the chromatographic system was balanced, the test solution placed in 



the 5℃ injector was injected at 0h, 2h, 4h, 10h, 22h, 37h, 52h and 73h 



respectively, and the chromatogram was recorded. 



 **Results of Determination** 






















---------------------------------------------------------------
|Reference solution                         |Test product     |
|                                           |solution         |
|-------------------------------------------|-----------------|
|Inspection|Main peak|Main peak|Main peak   |Survey |Main peak|
|time      |area     |trailing |theoretical |time   |area     |
|          |         |factor   |plate number|       |         |
|----------|---------|---------|------------|-------|---------|
|0h        |362915   |1.18     |76308       |0h     |346965   |
|----------|---------|---------|------------|-------|---------|
|2h        |364069   |1.18     |77520       |2h     |347156   |
|----------|---------|---------|------------|-------|---------|
|4h        |364017   |1.18     |76537       |4h     |348093   |
|----------|---------|---------|------------|-------|---------|
|6h        |364517   |1.18     |77200       |10h    |351717   |
|----------|---------|---------|------------|-------|---------|
|12h       |365302   |1.18     |77107       |22h    |355761   |
|----------|---------|---------|------------|-------|---------|
|24h       |366661   |1.18     |79369       |37h    |347277   |
---------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 416 of 542 





Page 417
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 

-------------------------------------------------------------------------------
|39h         |363491      |1.19        |79861       |52h         |350903      |
|------------|------------|------------|------------|------------|------------|
|54h         |365063      |1.19        |81912       |73h         |360143      |
|------------|------------|------------|------------|------------|------------|
|75h         |369263      |1.20        |82877       |/           |/           |
|------------|------------|------------|------------|------------|------------|
|RSD         |0.6%        |/           |/           |/           |1.4%        |
|------------|------------|------------|------------|------------|------------|
|Verdict: ①The control solution was placed under the sample injector at      | 
|5℃for 75h, the peak area RSD of the main peak area was 0.6% (required not   | 
|to exceed 2.0%), the theoretical plate number of the peak of finalidone was  |
|NLT 76308 (NLT 3000), and the trailing factor was in the range of 1.18~1.20  |
|(required not to exceed 1.5). And no impurities interfering with the         |
|detection of Finerenone content were produced, indicating that the           |
|reference solution was stable within 75h after being placed under the        |
|5℃injector. ②The sample solution was placed under the 5℃injector for 73h, |   
|the RSD of the main peak area was 1.4% (required not to exceed 2.0%), and    |
|no impurities interfered with the detection of fineridone content,           |
|indicating that the sample solution was stable within 73h under the          |
|5℃injector.                                                                 | 
-------------------------------------------------------------------------------



**(4.7) Durability** 



 **Brief Description** 



Durability refers to the determination conditions have a small change, the 



Measurement resultss are not affected by the degree of tolerance, by 



examining a single factor to change the chromatographic conditions (change 



column temperature, wavelength, flow rate, different columns) and normal 



chromatographic conditions to test the content of the test product solution to 



achieve. In the chromatogram obtained from the reference product solution, 



the number of theoretical plates should NLT 3000 according to the 



phenalidone peak, and the trailing factor NMT 1.5. Single factor change 



chromatographic conditions and normal chromatographic conditions under 



the test sample solution, the RSD of the principal component content should 



NMT 2.0%. 



Table 3.2.S.4.3.7-10 Changes in chromatographic conditions for durability 



test 



Chromatogra Standard conditions Variable Values 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 417 of 542 





Page 418
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 












-----------------------------------------------------------------------
|phic       |                           |                             |
|Parameters |                           |                             |
|-----------|---------------------------|-----------------------------|
|Column     |20 ℃                      |22℃, 18℃                   |   
|temperature|                           |                             |
|-----------|---------------------------|-----------------------------|
|Wavelength |251 nm                     |249 nm, 253 nm               |
|-----------|---------------------------|-----------------------------|
|Flow rate  |1.0 ml/min                 |0.95ml/min, 1.05 ml/min      |
|-----------|---------------------------|-----------------------------|
|Chromatogra|YMC Trairt C18 (3μm, 4.6mm|YMC Trairt C18 (3μm, 4.6mm x|  
|phic column|x 150mm) (serial number:   |150mm) (serial number:       |
|           |129ZB00034; Serial number: |117EB10004; Serial number:   |
|           |ZJC18-35)                  |CXC18-05)                    |
-----------------------------------------------------------------------

 **Solution preparation** 



Blank solution: solvent. 



Reference solution: Prepare it by the same method as the reference solution 



under "4.1 wavelength selection". 2 copies were prepared in parallel, in which 



the reference solution under "4.5.2 intermediate precision" was shared for 



durability of different chromatographic columns, and the rest were shared 



under "4.5.1 repeatability". (Approx. 0.02mg/ml) 



Test product solution: Prepare the test product solution under "4.3 specific 



properties" by the same method. Two samples were prepared in parallel, in 



which, except for the intermediate precision test solution ① and ② under 



"4.5.2 Intermediate precision" for durability of different chromatocolumns, 



the rest were shared with the repetitive test solution ① and ② under "4.5.1 



repeatability". (Approx. 0.02mg/ml) 



 **Injection procedure** 



Under the conditions of different durability (normal conditions, column 



temperature, flow rate, wavelength, different column), after the 



chromatographic system was balanced, the blank solution was injected with 



1 needle, 2 control solution and 2 test solution were injected with 2 needles 



respectively, and the chromatogram was recorded. 



 **Measurement resultss** 




Inspe 



ction 




Parame 



ter 




Reference solution 



① 




Control solution ② 




Test product 



solution 




Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 418 of 542 





Page 419
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 














































-----------------------------------------------------------------------------------
|condi     |values   |Main peak|Main peak|Main peak|Main peak|Principal |RSD of   |
|tions     |         |trailing |theoretic|trailing |theoretic|compone nt|content  |
|          |         |factor   |al plate |factor   |al plate |content   |         |
|          |         |         |number   |         |number   |          |         |
|----------|         |---------|---------|---------|---------|----------|---------|
|Normal              |1.18     |80373    |1.19     |80074    |99.5%     |0.23%    |
|conditions          |         |         |         |         |          |         |
|                    |---------|---------|---------|---------|          |         |
|          |         |1.18     |80414    |1.19     |80543    |          |         |
|----------|---------|---------|---------|---------|---------|----------|         |
|Wave lengt|249nm    |1.16     |73280    |1.17     |74216    |99.9%     |         |
|h         |         |         |         |         |         |          |         |
|          |         |---------|---------|---------|---------|          |         |
|          |         |1.17     |74786    |1.17     |75205    |          |         |
|          |---------|---------|---------|---------|---------|----------|         |
|          |253nm    |1.17     |73925    |1.17     |73825    |99.8%     |         |
|          |         |---------|---------|---------|---------|          |         |
|          |         |1.17     |74339    |1.17     |74802    |          |         |
|----------|---------|---------|---------|---------|---------|----------|         |
|Colu mn   |18 ℃    |1.20     |80421    |1.20     |80180    |99.5%     |         | 
|temp eratu|         |         |         |         |         |          |         |
|re        |         |         |         |         |         |          |         |
|          |         |---------|---------|---------|---------|          |         |
|          |         |1.19     |79968    |1.20     |80426    |          |         |
|          |---------|---------|---------|---------|---------|----------|         |
|          |22 ℃    |1.19     |84752    |1.19     |84360    |99.6%     |         | 
|          |         |---------|---------|---------|---------|          |         |
|          |         |1.18     |83317    |1.19     |84331    |          |         |
|----------|---------|---------|---------|---------|---------|----------|         |
|Flow rate |0.95     |1.21     |88884    |1.21     |88706    |100.0%    |         |
|          |ml/min   |         |         |         |         |          |         |
|          |         |---------|---------|---------|---------|          |         |
|          |         |1.21     |88534    |1.21     |89418    |          |         |
|          |---------|---------|---------|---------|---------|----------|         |
|          |1.05     |1.18     |78257    |1.18     |78226    |99.9%     |         |
|          |ml/min   |         |         |         |         |          |         |
|          |         |---------|---------|---------|---------|          |         |
|          |         |1.19     |78526    |1.19     |78432    |          |         |
|----------|---------|---------|---------|---------|---------|----------|         |
|Column 2            |1.18     |84401    |1.18     |84466    |99.4%     |         |
|                    |---------|---------|---------|---------|          |         |
|          |         |1.18     |85388    |1.18     |84993    |          |         |
|----------|---------|---------|---------|---------|---------|----------|         |
|Conclusion: Under the conditions of column temperature, wavelength, flow         |
|rate, different chromatographic columns and normal conditions, the               |
|theoretical plate number calculated by the peak of fenelidone is NLT 73280       |
|(NLT 3000), and the trailing factor is in the range of 1.16~1.21 (NMT 1.5).      |
|Under the condition of single factor change of color, the sample solution        |
|was tested under normal chromatographic conditions, and the RSD of               |
|principal component was 0.23% (not more than 2.0%). The above are in line        |
|with the verification requirements, indicating that the method has good          |
|durability.                                                                      |
-----------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 419 of 542 





Page 420
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**III. Summary of Method Validation** 



Summaries of Method Validation of Assay in Finerenone 












------------------------------------------------------------------------------------------------------------------------
|Item             |Acceptable criteria                  |Verification of results                                       |
|-----------------|-------------------------------------|--------------------------------------------------------------|
|Wavelength       |The principal component has large    |The principal component has greater absorption at 251nm. In   |
|selection        |absorption at 251nm wavelength       |the                                                           |
|                 |                                     |control solution, the retention time of Finerenone was        |
|                 |                                     |9.833min, and                                                 |
|                 |                                     |the spectral diagram of the control solution was as follows:  |
|-----------------|-------------------------------------|--------------------------------------------------------------|
|System           |The blank solution should be free of |The blank solution has no interference; The RSD of the main   |
|applicability    |interference; The relative standard  |peak                                                          |
|                 |deviation of the main peak area      |retention time was 0.07% (required not to exceed 2.0%), the   |
|                 |should                               |RSD of the                                                    |
|                 |NMT 2%, the relative standard        |peak area was 0.27% (required not to exceed 2.0%), and the    |
|                 |deviation                            |theoretical                                                   |
|                 |of the main peak retention time      |plate number of the peak of fenalidone was NLT 76308 (required|
|                 |should                               |NLT                                                           |
|                 |NMT 2.0%, the theoretical plate      |3000). The trailing factor was in the range of 1.17~1.18 (the |
|                 |number                               |requirement NMT 1.5). All above meet the requirements,        |
|                 |should NLT 3000 according to the     |indicating that                                               |
|                 |phenalidone peak, and the            |the method has good applicability in the system.              |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 420 of 542 





Page 421
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















-------------------------------------------------------------
|Impuriti|Concentration (equivalent to the  |Linear equation|
|es      |percentage of solution            |               |
|        |concentration of the test product)|               |
|--------|----------------------------------|---------------|
|YA2304  |12.3576μg/ml~28.8344μg/ml       |y=16810x-256   |  
|        |(61.79%~144.17%)                  |               |
-------------------------------------------------------------


















--------------------------------------------------------
|Impurities|Marking condition     |Average   |RSD      |
|          |                      |recovery  |         |
|          |                      |rate      |         |
|----------|----------------------|----------|---------|
|YA2304    |Added 16.0038μg/ml to|99.9%, n=9|0.6%, n=9| 
|          |24.4963μg/ml         |          |         | 
--------------------------------------------------------



------------------------------------------------------------------------------------------------------------------------
|           |trailing factor NMT 1.5.   |                                                                 |            |
|-----------|---------------------------|-----------------------------------------------------------------|            |
|Linearity  |In the concentration range |Impuriti es Concentration (equivalent to the percentage of solution           |
|and range  |equivalent to              |concentration of the test product) Linear equation YA2304                     |
|           |60%~140% of the control    |12.3576μg/ml~28.8344μg/ml (61.79%~144.17%) y=16810x-256                     |  
|           |solution, 5                |                                                                              |
|           |concentration points were  |                                                                              |
|           |evenly                     |                                                                              |
|           |selected, and the          |                                                                              |
|           |concentration was taken    |                                                                              |
|           |as the horizontal          |                                                                              |
|           |coordinate and the peak    |                                                                              |
|           |area was taken as the      |                                                                              |
|           |vertical coordinate        |                                                                              |
|           |as the linear regression   |                                                                              |
|           |curve. The                 |                                                                              |
|           |correlation coefficient (R)|                                                                              |
|           |of the                     |                                                                              |
|           |regression curve was NLT   |                                                                              |
|           |0.998, and the             |                                                                              |
|           |RSD of the response factor |                                                                              |
|           |should NMT                 |                                                                              |
|           |2.0%. The absolute value of|                                                                              |
|           |Y-axis                     |                                                                              |
|           |intercept accounts for less|                                                                              |
|           |than 2% of                 |                                                                              |
|           |100% response value.       |                                                                              |
|-----------|---------------------------|------------------------------------------------------------------------------|
|Accuracy   |Add YA2304 reference in the|Impurities Marking condition Average recovery rate RSD YA2304 Added           |
|           |range of 80%               |16.0038μg/ml to 24.4963μg/ml 99.9%, n=9 0.6%, n=9                           |  
|           |reference solution         |                                                                              |
|           |concentration to 120%      |                                                                              |
|           |reference solution         |                                                                              |
|           |concentration to the       |                                                                              |
|           |thinner; The recovery rate |                                                                              |
|           |is required to             |                                                                              |
|           |be between 98% and 101%,   |                                                                              |
|           |and the RSD of             |                                                                              |
|           |recovery rate NMT 2.0%.    |                                                                              |
|-----------|---------------------------|------------------------------------------------------------------------------|
|Precision  |Repeatability and          |Principal Component Repeatability Intermediate precision Precisi              |
|           |intermediate precision:    |YA2304 0.5%, n=6 0.4%, n=6 0.4%, n                                            |
|           |the RSD of principal       |                                                                              |
|           |component in 6             |                                                                              |
|           |repeatability (or          |                                                                              |
|           |intermediate precision)    |                                                                              |
|           |test product solution NMT  |                                                                              |
|           |1.0%.                      |                                                                              |
|           |Precision: For the results |                                                                              |
|           |of 12                      |                                                                              |
|           |repeatability and          |                                                                              |
|           |intermediate precision     |                                                                              |
|           |tests, the RSD of          |                                                                              |
|           |                           |                                                                              |
|           |                           |            |Principal   |Repeatability|Intermediate|Precisi     |            |
|           |                           |            |Component   |             |precision   |            |            |
|           |                           |            |------------|-------------|------------|------------|------------|
|           |                           |            |YA2304      |0.5%, n=6    |0.4%, n=6   |0.4%, n     |=           |
|           |                           |            |------------|-------------|------------|------------|------------|
|           |                           |            |            |             |            |            |            |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 421 of 542 





Page 422
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 












------------------------------------------------------------------------------------------------------------------------
|              |principal component content NMT 2.0%. |                                                                |
|--------------|--------------------------------------|----------------------------------------------------------------|
|Solution      |Each solution was placed in the sample|The control product solution: Placed under the 5℃injector for  | 
|stability     |injector at 5℃, the control solution |75h, the                                                        | 
|              |and                                   |peak area RSD of the main peak area is 0.6% (required not to    |
|              |the test product solution were        |exceed                                                          |
|              |injected                              |2.0%), the theoretical plate number of the peak of finalidone is|
|              |at different times, and the           |NLT                                                             |
|              |theoretical                           |76308 (required NLT 3000), and the trailing factor is in the    |
|              |plate number in the control solution  |range of                                                        |
|              |was                                   |1.18~1.20 (required not to exceed 1.5). And no impurities       |
|              |required to be NLT 3000 according to  |interfered                                                      |
|              |the                                   |with the detection of Finerenone content, indicating that the   |
|              |peak of Finerenone, and the tail      |control                                                         |
|              |factor                                |solution was stable within 75h after being placed under the     |
|              |NMT 1.5; The RSD of the main peak-peak|5℃sampler.                                                     | 
|              |area between the control solution and |Test solution: The RSD of main peak area was 1.4% (required not |
|              |the                                   |to                                                              |
|              |test solution NMT 2.0%, and no new    |exceed 2.0%) within 73h after being placed under the            |
|              |impurities interfering with the       |5℃injector, and                                                | 
|              |detection                             |no impurities interfered with the detection of Finerenone       |
|              |of principal components should be     |content,                                                        |
|              |added.                                |indicating that the test solution was stable within 73h after   |
|              |                                      |being                                                           |
|              |                                      |placed under the 5℃injector. The above solutions do not need   | 
|              |                                      |new                                                             |
|              |                                      |preparation for temporary use.                                  |
|--------------|--------------------------------------|----------------------------------------------------------------|
|Durability    |Under the conditions of single factor |The column temperature was 20℃±2℃, the wavelength was        |   
|              |change column temperature, wavelength,|251nm±2nm, the                                                 | 
|              |flow rate, different chromatographic  |flow rate was 1.0ml/min±0.05ml/min, and the chromatographic    | 
|              |columns and normal chromatographic    |column                                                          |
|              |conditions, the theoretical plate     |with different batch NO.s was investigated as follows: System   |
|              |number                                |applicability: In the chromatogram obtained from the control    |
|              |calculated according to the peak of   |product                                                         |
|              |Finerenone should NLT 3000, and the   |solution, the theoretical plate number calculated by the peak of|
|              |trailing factor NMT 1.5. Under single |Finerenone was NLT 73280 (required NLT 3000), and the trailing  |
|              |factor change chromatographic         |factor                                                          |
|              |conditions                            |was in the range of 1.16~1.21 (required not to exceed 1.5). The |
|              |and normal chromatographic conditions,|suitability of the system met the verification requirements.    |
|              |the RSD of the principal component    |Test                                                            |
|              |content should NMT 2.0%.              |product solution: The test product solution was tested under    |
|              |                                      |normal                                                          |
|              |                                      |chromatographic conditions under single factor color change     |
|              |                                      |condition,                                                      |
|              |                                      |and the RSD of principal component was 0.23% (no more than 2.0% |
|              |                                      |required); The                                                  |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 422 of 542 





Page 423
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



above are in line with the verification requirements. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 423 of 542 





Page 424
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4.4** **Batch Analyses** 



**Analytical Data of Three Consecutive Batches** 



Analytical data of three commercial scale batches (Batch No.: 231201, 240101 



and 240102) are summarized in _3.2.S.4.4 Table 1_ . All batches were fully tested 



according to the analytical procedures in _section 3.2.S.4.2_ . 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 424 of 542 





Page 425
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.4.4-1 Batch Analysis Results of Finerenone 















----------------------------------------------------------------------------------------------------
|Batch No.                                   |Batch No.: 231201|Batch No.: 240101|Batch No.: 240102|
|--------------------------------------------|-----------------|-----------------|-----------------|
|Batch size                                  |11.085kg         |9.925kg          |10.215kg         |
|--------------------------------------------|-----------------|-----------------|-----------------|
|Date of manufacture                         |Jan. 06, 2024    |Jan. 19, 2024    |Jan. 30, 2024    |
|--------------------------------------------|-----------------|-----------------|-----------------|
|Site of manufacture                         |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.    |
|--------------------------------------------|-----------------------------------------------------|
|Items         |Specifications               |Results          |Results          |Results          |
|--------------|-----------------------------|-----------------|-----------------|-----------------|
|Characters    |white to yellow powder       |white powder     |white powder     |white powder     |
|              |-----------------------------|-----------------|-----------------|-----------------|
|              |Solubility: dissolved in     |Complies         |Complies         |Complies         |
|              |methanol, slightly soluble in|                 |                 |                 |
|              |ethanol, acetonitrile and    |                 |                 |                 |
|              |acetone, slightly soluble in |                 |                 |                 |
|              |isopropyl alcohol, and almost|                 |                 |                 |
|              |insoluble in water           |                 |                 |                 |
|--------------|-----------------------------|-----------------|-----------------|-----------------|
|Identification|IR: The infrared light       |Complies         |Complies         |Complies         |
|              |absorption pattern of this   |                 |                 |                 |
|              |product should be consistent |                 |                 |                 |
|              |with that of the control     |                 |                 |                 |
|              |product                      |                 |                 |                 |
|              |-----------------------------|-----------------|-----------------|-----------------|
|              |HPLC: In the chromatogram    |Complies         |Complies         |Complies         |
|              |recorded under the enantiomer|                 |                 |                 |
|              |determination, the retention |                 |                 |                 |
|              |time of the main peak of the |                 |                 |                 |
|              |test solution should be      |                 |                 |                 |
|              |consistent with the retention|                 |                 |                 |
|              |time of the main peak of the |                 |                 |                 |
|              |system suitability solution  |                 |                 |                 |
|--------------|-----------------------------|-----------------|-----------------|-----------------|
|Related       |YA2304-10: NMT 0.10%         |Not detected     |Not detected     |Not detected     |
|substances I  |                             |                 |                 |                 |
|              |-----------------------------|-----------------|-----------------|-----------------|
|              |YA2304-12: NMT 0.15%         |Not detected     |Not detected     |Not detected     |
|              |-----------------------------|-----------------|-----------------|-----------------|
|              |YA2304-14: NMT 0.15%         |Not detected     |Not detected     |Not detected     |
----------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 425 of 542 





Page 426
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 









-----------------------------------------------------------------------------------
|           |YA2304-15: NMT 0.15%          |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |YA2304-16: NMT 0.15%          |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |YA2304-17: NMT 0.15%          |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |YA2304-18: NMT 0.15%          |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |YA2304-19: NMT 0.15%          |< 0.05%     |< 0.05%     |< 0.05%     |
|           |------------------------------|------------|------------|------------|
|           |Other single impurities: NMT  |< 0.05%     |< 0.05%     |< 0.05%     |
|           |0.1 0%                        |            |            |            |
|           |------------------------------|------------|------------|------------|
|           |Total impurity: NMT 1.0%      |< 0.05%     |< 0.05%     |< 0.05%     |
|-----------|------------------------------|------------|------------|------------|
|enantiomers|YA2304-20: NMT 0.15%          |0.03%       |0.03%       |0.02%       |
|-----------|------------------------------|------------|------------|------------|
|Residual   |Ethanol NMT 0.5%              |0.1%        |0.2%        |0.1%        |
|solvents   |                              |            |            |            |
|           |------------------------------|------------|------------|------------|
|           |Isopropyl alcohol NMT 0.5%    |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |Ethyl acetate NMT 0.5%        |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |Secondary butanol NMT 0.5%    |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |Tetrahydrofuran NMT 0.072%    |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |Toluene NMT 0.089%            |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |N-methylpyrrolidone NMT 0.053%|Not detected|Not detected|Not detected|
|-----------|------------------------------|------------|------------|------------|
|genotoxic  |Dimethyl sulfate NMT 75ppm    |Not detected|Not detected|Not detected|
|impurities |                              |            |            |            |
|           |------------------------------|------------|------------|------------|
|           |Diethyl sulfate NMT 75ppm     |Not detected|Not detected|Not detected|
|           |------------------------------|------------|------------|------------|
|           |Diisopropyl sulfate NMT 75ppm |Not detected|Not detected|Not detected|
-----------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 426 of 542 





Page 427
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 












-------------------------------------------------------------------------------------
|            |Disec-butyl sulfate NMT 75ppm  |Not detected|Not detected|Not detected|
|            |-------------------------------|------------|------------|------------|
|            |Sum of genotoxic impurities NMT|Not detected|Not detected|Not detected|
|            |250ppm                         |            |            |            |
|------------|-------------------------------|------------|------------|------------|
|Water       |NMT 0.5%                       |0.05%       |0.04%       |0.2%        |
|------------|-------------------------------|------------|------------|------------|
|Residue on  |NMT 0.1%                       |Complies    |Complies    |Complies    |
|ignition    |                               |            |            |            |
|------------|-------------------------------|------------|------------|------------|
|Heavy metals|NMT 10ppm                      |Complies    |Complies    |Complies    |
|------------|-------------------------------|------------|------------|------------|
|Microbial   |TAMC: NMT 103CFU/g             |< 10 CFU/g  |< 10 CFU/g  |<10 CFU/g   |
|limits      |                               |            |            |            |
|            |-------------------------------|------------|------------|------------|
|            |TYMC: NMT 102CFU/g             |< 10 CFU/g  |< 10 CFU/g  |<10 CFU/g   |
|            |-------------------------------|------------|------------|------------|
|            |Absence of Escherichia coli    |Not detected|Not detected|Not detected|
|            |(1g)                           |            |            |            |
|------------|-------------------------------|------------|------------|------------|
|Assay       |98.0% to 102.0% (anhydrous     |99.8%       |99.8%       |99.7%       |
|            |substance).                    |            |            |            |
-------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 427 of 542 





Page 428
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**Batch Determination** 



The Batch No. of commercial production of APIs can be divided into two cases: 



Batch No. of intermediates and Batch No. of the final drug substance (API). 



1) Batch No. composition of intermediate: product code + year + month + serial 



number (D+YY+MM+ZZ). For example, the Batch No. of an intermediate is 



D220901, where D is the product code, 22 is the year, 09 is the month, 01 is the 



serial number, indicating the first batch of intermediate of a specific API in 



September 2022. 



2) Batch No. composition of the final drug substance (API): year + month + 



product code + serial number (YYYY+MM+X+ZZ), in which the year is 4 digits, the 



month is 2 digits, and the product code is 1 or 2 letters (2 letters are W+ the other 



letter). For example, the Batch No. of an API is 202209D01, in which 2022 is the 



year; 09 is the month; D is the product code; 01 is the serial number, representing 



the first batch of a specific API in September 2022. 



Batch No. composition of API manufactured from trial production in technology 



transfer stage and process validation: 6 digits. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 428 of 542 





Page 429
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**Certificate of Analysis (COA) of three Commercial Scale Batches** 



COA of Finerenone (Batch No.: 231201) 



COA of Finerenone (Batch No.: 240101) 



COA of Finerenone (Batch No.: 240102) 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 429 of 542 





Page 430
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.4.5** **Justification of Specification** 



The specification of Finerenone was established by the applicant according to 



the Quality Guidelines and Multidisciplinary Guidelines of ICH. The analytical 



procedures of all of the tests (Characters, Identification, Related substances, 



Residual solvents, Loss and Dry, Residue on ignition, Heavy metals, Microbial 



limits and Assay) were established by the applicant and the test methods have 



been well validated. 



**Appearance** 



A qualitative test performed to know the colour of the API. White to yellow 



powder by visual inspection. 



**Solubility** 



Solubility is a basic phenomenon and commonly evaluated parameter which 



helps in pre-formulation studies and to know the dissolution of the API in 



different solvents. dissolved in methanol, slightly soluble in ethanol, 



acetonitrile and acetone, slightly soluble in isopropyl alcohol, and almost 



insoluble in water. 



**Infrared Absorption Spectrophotometry** 



This is a specific test for identification of drug substances by IR using 



validated method. The IR spectra of the substance to be examined should 



comply with that of the Finerenone CRS. Examine by _Standard operating_ 



_procedure of infrared absorption spectrophotometry_ . 



**High Performance Liquid Chromatography** 



In the chromatogram recorded under the enantiomer determination, the 



retention time of the main peak of the test solution should be consistent with 



the retention time of the main peak of the system suitability solution. _(See_ 



_Enantiomer)._ 



**Related substances** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 430 of 542 





Page 431
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The _related substances_ of Finerenone was established by the applicant 



according to the _[ICH Q3A(R2): Impurities in New Drug Substances](https://www.cde.org.cn/ichWeb/guideIch/downloadAtt/1/fb4a4ec406cecd99722d2f7c4455d2a1)_ . The 



threshold of Specified Impurity including all of the Impurity (YA2304-14, 



YA2304-15, YA2304-19): NMT 0.15%., YA2304-10: NMT 0.10%; Unspecified 



Impurity was established by the Identified threshold : NMT 0.10%. 



**Enantiomers** 



The _Enantiomers_ of Finerenone was established by the applicant according to 



the _[ICH Q3A(R2): Impurities in New Drug Substances](https://www.cde.org.cn/ichWeb/guideIch/downloadAtt/1/fb4a4ec406cecd99722d2f7c4455d2a1)_ . The threshold of 



Specified Impurity including all of the YA2304-20: NMT 0.15%. 



**Residual solvents** 



The _residual solvents_ of Finerenone was established by the applicant 



according to the _[ICH Q3C(R8) Impurities: Guideline for Residual Solvents](https://www.cde.org.cn/ichWeb/guideIch/downloadAtt/1/1245a501be703877657ab15986adbc16)_ . 



Ethanol NMT 0.5 %; Tetrahydrofuran NMT 0.072%; Toluene NMT 0.089%; 



N-methylpyrrolidone NMT 0.053%. 



**Water** 



NMT 0.5%. Examine in accordance with Standard operating procedure of 



Water by the Karl Fischer determination. 



**Residue on ignition** 



NMT 0.1%. Examine by _Standard operating procedure of residue on ignition_ 



_determination_ . 



**Heavy metals** 



NMT 10ppm. Examine by _Standard operating procedure of heavy metals_ 



_determination_ . 



**Microbial Limits** 



The drug substance Finerenone is a non-sterile API. The applicant established 



microbial limits test in the Finerenone specification according to chapter 



_Microbiological examination of non-sterile products microbial enumeration tests_ 



and _Microbiological examination of non-sterile products control bacteria tests_ : 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 431 of 542 





Page 432
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



   - TAMC is NMT 10 [3] CFU/g; 



   - TYMC is NMT 10 [2] CFU/g; 



_- E.coli_ is absent in each 1 g of sample. 



**Assay** 



A quantitative test performed to know the actual content of API and the 



acceptance criteria has calculated based on the content specified and 



unspecified impurities controlled. It contains NLT 98.0% and NMT 102.0% of 



C21H22N4O3, calculated on the anhydrous substance basis. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 432 of 542 





Page 433
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.5** **Reference Standards or Materials** 



**I. Reference Standards used for Testing Finerenone** 



In-house working standards has been established. Their basic information is 



as below. 



Table 3.2.S.5-1 Reference Standards used for Testing of Finerenone 






























-----------------------------------------------------------
|No.    |Name of  |Category|Batch No. |Content|Source of  |
|       |reference|        |          |(%)    |reference  |
|       |standard |        |          |       |standard   |
|-------|---------|--------|----------|-------|-----------|
|1      |YA2304-10|Working |DTA304    |99.77% |Purchased*1|
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|2      |YA2304-12|Working |23081801-C|99.0%  |Selfmade   |
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|3      |YA2304-14|Working |23082301-C|99.6%  |Selfmade   |
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|4      |YA2304-15|Working |23082903-C|99.3%  |Selfmade   |
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|5      |YA2304-16|Working |23082201-C|93.7%  |Selfmade   |
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|6      |YA2304-17|Working |DMW857    |99.30% |Purchased*1|
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|7      |YA2304-18|Working |23082802-C|98.9%  |Selfmade   |
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|8      |YA2304-19|Working |23080701-A|99.4%  |Selfmade   |
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|9      |YA2304-20|Working |23080401-A|99.2%  |Selfmade   |
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|10     |YA2304-52|Working |24022801-C|90.8%  |Selfmade   |
|       |         |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|11     |Dimethyl |Working |C15128674 |99.759%|Purchased*2|
|       |sulfate  |standard|          |       |           |
|-------|---------|--------|----------|-------|-----------|
|12     |Diethyl  |Working |C14721434 |99.024%|Purchased*2|
|       |sulfate  |standard|          |       |           |
-----------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 433 of 542 





Page 434
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 












--------------------------------------------------------------
|13     |Diisopropyl |Working |DLX318    |97%    |Purchased*1|
|       |sulfate     |standard|          |       |           |
|-------|------------|--------|----------|-------|-----------|
|14     |Di-sec-butyl|Working |23110207-H|99.7%  |Selfmade   |
|       |sulfate     |standard|          |       |           |
|-------|------------|--------|----------|-------|-----------|
|15     |YA2304      |Working |23091802-D|99.7%  |Selfmade   |
|       |(Finerenone)|standard|          |       |           |
--------------------------------------------------------------

*1: Reference standard of YA2304-10, YA2304-17, Diisopropyl sulfate was 
purchased from Shanghai Bidd Pharmaceutical Technology Co., LTD. 



*2: Reference standard of Dimethyl sulfate, Diethyl sulfatewas purchased 



from Shanghai McLean Biochemical Technology Co., LTD. 



The in-house prepared Finerenone (batch No. 23091802-D) is employed as 



working standard. It has been fully characterized in terms of chemical 



structure and purity. Its content value has been assigned by the applicant 



according to Finerenone working standard. 



**II. Description and Establishment of Working Standards** 



YA2304-10 working standard (batch No. DTA304), YA2304-17 working 



standard (batch No. DMW857), Dimethyl sulfate working standard (batch No. 



C15128674), Diethyl sulfate working standard (batch No. C14721434), 



Diisopropyl sulfate working standard (batch No. DLX318) was purchased 



from other companies. 



The description (preparation, specification and analytical procedures) of 



Finerenone(YA2304) working standard, YA2304-12 working standard, 



YA2304-14 working standard, YA2304-15 working standard, YA2304-16 



working standard, YA2304-18 working standard, YA2304-19 working 



standard, YA2304-20 working standard, YA2304-52 working standard and 



Di-sec-butyl sulfate working standard are as follows. 



**(1) YA2304-10 working standard** 



The YA2304-10 reference product used in this application was derived fr 



om Shanghai BidD Medical Technology Co., LTD. It was named D-dibenz 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 434 of 542 





Page 435
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



oyl tartaric acid on the physical label and (2S,3S)-2, 3-BIS (beznoyloxy)s 



uccinic acid on the manufacturer's report. The reference product on the 



invoice is called (2S,3S)-2, 3-bis (benzoyloxy) succinic acid. The applicant 



has confirmed its chemical structure and the content is 99.77% accordi 



ng to the report form provided by the manufacturer. 



Sample lot No.: DTA304 



Structural formula: 



Molecular formula: C18H14O 



Molecular weight: 358.3 



**(1.1) Structural analysis of YA2304-10 reference** 



The chemical structure of the reference product was confirmed by the 



applicant by means of [1] H NMR, [13] C NMR, mass spectrometry and specific curl. 



1H NMR, specific curl and mass spectrometry were provided by Shanghai 



Bider Medical Technology Co., LTD.,and 13C NMR was commissioned by 



Changsha Kangpeng Pharmaceutical Co., LTD. The relevant test results and 



structural analysis are detailed as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 435 of 542 





Page 436
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-2 and Table 3.2.S.5-3. 



Table 3.2.S.5-2 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 






















--------------------------------------------------------------
|Peak No.|Delta ppm|Peak   |Coupling|Proton |Attribution     |
|        |         |pattern|constant|numbe r|                |
|        |         |       |(J)     |       |                |
|--------|---------|-------|--------|-------|----------------|
|1       |5.95     |s      |/       |2H     |2, 4 - CH       |
|--------|---------|-------|--------|-------|----------------|
|2       |7.62     |t      |/       |4H     |21,23,14,16 - CH|
|--------|---------|-------|--------|-------|----------------|
|3       |7.73     |d      |7.4     |2H     |15, 22 - CH     |
|--------|---------|-------|--------|-------|----------------|
|4       |8.06     |d      |7.3     |4H     |13,17,20,24 - CH|
|--------|---------|-------|--------|-------|----------------|
|5       |13.97    |s      |/       |2H     |9, 7 - OH       |
--------------------------------------------------------------

Table 3.2.S.5-3 [13] CNMR chemical shift value and correlation spectrum (from 



high field to low field) of the tested sample 




Peak 




Peak Number of 

Delta ppm 
No. carbon 




Attribution 
carbon 




Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 436 of 542 





Page 437
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



1 

-----------------------------------------
|       |       |atoms  |               |
|-------|-------|-------|---------------|
|1      |71.973 |2      |2, 4 - C       |
|-------|-------|-------|---------------|
|2      |128.954|2      |12-3 C         |
|-------|-------|-------|---------------|
|3      |129.517|4      |14,16,21,23 - C|
|-------|-------|-------|---------------|
|4      |129.901|4      |13,17,22,24 - C|
|-------|-------|-------|---------------|
|5      |134.591|2      |15, 22 - C     |
|-------|-------|-------|---------------|
|6      |165.176|2      |11-16 C        |
|-------|-------|-------|---------------|
|7      |167.686|2      |3, 5 - C       |
-----------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 14 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 18 carbon atoms, and the carbon 



displacement of each group could be reasonably assigned. The NMR data 



were in good agreement with the target compound. 



**b, Mass spectrometry (MS)** 



Testing instrument: LC-MS (Manufacturer's spectrum) 



Analytical method: / 



Test data: 



Table 3.2.S.5-4 MS data of the tested sample 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|357.1            |[M-H]-           |Molecular ion peak in|
|                 |                 |negative ion mode    |
-----------------------------------------------------------



In the negative ion mode, the mass charge ratio m/z is 357.1 peak, which is 



attributed to the molecular ion peak in the negative ion mode, consistent with 



the molecular weight of the target molecule 358.3. 



**c, specific curl** 



Test data: 



Table 3.2.S.5-5 Specific curl of the tested sample 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 437 of 542 





Page 438
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Specific Curl 



116.129 (C=1.31 ETOH) 



The relative rotation value of the control substance is +116.129°, which can 



confirm that the optical rotation configuration is right-handed structure, 



which is consistent with the target molecule. 



**(2) YA2304-12 working standard** 



The reference product YA2304-12 used in this study was self-made by T 



iandi Hengyi Pharmaceutical Co., LTD. It was named 4-(4-aminoformyl-2 



-methoxyphenyl) -5-ethoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyl-3-for 



mamide on the physical label and the reference product report. The appl 



icant confirmed its chemical structure and content calibration, and the c 



ontent was calculated according to 99.0%. 



Sample lot No.: 23081801-C 



Structural formula: 



Molecular formula: C21H24O4N 



Molecular weight: 396.45 



**(2.1) Preparation method of YA2304-12** 



Add YA2304-8(4.2g), potassium carbonate (2.2g) and DMSO(20 mL) into a 



250 mL flask, slowly add 30% hydrogen peroxide (6 mL) under agitation, stir 



at room temperature for 0.5 h, add water (60 mL) into the reaction system, 



stir for 0.5 h, and filter. Rinse with water (100 mL) and dry at 50 ℃ to obtain 



YA2304-12, white solid (4.3 g). 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 438 of 542 





Page 439
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**(2.2) Structural analysis of YA2304-12 reference** 



The chemical structure of the reference product was confirmed by [1] the 



applicant by means of H NMR, [13] C NMR and mass spectrometry. The mass 



spectrometry was tested by the applicant by himself, [1] and the H NMR and [13] C 



NMR were tested by Changsha Kangpeng Pharmaceutical Co., LTD. The 



relevant test results and structural analysis are detailed as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Reference material: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 439 of 542 





Page 440
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-6 and Table 3.2.S.5-7. 



Table 3.2.S.5-6 [1] H NMR chemical shift value and correlation spectrum (from 



high field to low field) of the tested sample 






















--------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attributio|
|        |           |pattern|constant (J)|number |n         |
|--------|-----------|-------|------------|-------|----------|
|1       |1.063-1.098|t      |6.8         |3H     |27-CH3    |
|--------|-----------|-------|------------|-------|----------|
|2       |2.137      |s      |/           |3H     |28-CH3    |
|--------|-----------|-------|------------|-------|----------|
|3       |2.249      |s      |/           |3H     |22-CH3    |
|--------|-----------|-------|------------|-------|----------|
|4       |3.841      |s      |/           |3H     |24-CH3    |
|--------|-----------|-------|------------|-------|----------|
|5       |4.000-4.041|m      |6.8         |2H     |26-CH2    |
|--------|-----------|-------|------------|-------|----------|
|6       |5.326      |s      |/           |1H     |9-CH      |
|--------|-----------|-------|------------|-------|----------|
|7       |6.672      |bs     |/           |2H     |20-NH2    |
|--------|-----------|-------|------------|-------|----------|
|8       |7.048-7.068|d      |8.0         |1H     |4-CH      |
|--------|-----------|-------|------------|-------|----------|
|9       |7.278      |s      |/           |2H     |8-NH2     |
|--------|-----------|-------|------------|-------|----------|
|10      |7.289-7.313|dd     |7.6, 1.4    |1H     |5-CH      |
|--------|-----------|-------|------------|-------|----------|
|11      |7.371-7.377|d      |1.3         |1H     |1-CH      |
|--------|-----------|-------|------------|-------|----------|
|12      |7.553      |s      |/           |1H     |16-CH     |
|--------|-----------|-------|------------|-------|----------|
|13      |7.709      |s      |/           |1H     |12-NH     |
|--------|-----------|-------|------------|-------|----------|
|14      |7.865      |s      |/           |2H     |8-NH2     |
--------------------------------------------------------------

Table 3.2.S.5-7 [13] C NMR chemical shift values and correlation spectra (from 



high field to low field) of the tested sample 



Number of 
Peak No. Delta ppm Attribution 

carbon atoms 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 440 of 542 





Page 441
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



1 

----------------------------------------
|1      |14.198  |1      |28-bit carbon|
|-------|--------|-------|-------------|
|2      |14.795  |1      |27-bit carbon|
|-------|--------|-------|-------------|
|3      |18.769  |1      |22-place     |
|       |        |       |carbon       |
|-------|--------|-------|-------------|
|4      |31.950  |1      |9-bit carbons|
|-------|--------|-------|-------------|
|5      |56.170  |1      |24-bit carbon|
|-------|--------|-------|-------------|
|6      |60.989  |1      |26-bit carbon|
|-------|--------|-------|-------------|
|7      |104.515 |1      |14-bit carbon|
|-------|--------|-------|-------------|
|8      |105.682 |1      |10-bit carbon|
|-------|--------|-------|-------------|
|9      |110.334 |1      |3-place      |
|       |        |       |carbons      |
|-------|--------|-------|-------------|
|10     |111.895 |1      |15-place     |
|       |        |       |carbon       |
|-------|--------|-------|-------------|
|11     |120.433 |1      |1 bit carbon |
|-------|--------|-------|-------------|
|12     |130.041 |1      |5-bit carbon |
|-------|--------|-------|-------------|
|13     |133.912 |1      |4-place      |
|       |        |       |carbons      |
|-------|--------|-------|-------------|
|14     |139.612 |1      |6-place      |
|       |        |       |carbons      |
|-------|--------|-------|-------------|
|15     |139.784 |1      |11-bit carbon|
|-------|--------|-------|-------------|
|16     |144.399,|1      |13-place     |
|       |        |       |carbon       |
|-------|--------|-------|-------------|
|17     |144.441 |1      |16-bit carbon|
|-------|--------|-------|-------------|
|18     |155.225 |1      |2-bit carbons|
|-------|--------|-------|-------------|
|19     |159.845 |1      |18-bit carbon|
|-------|--------|-------|-------------|
|20     |168.212 |1      |19-carbon    |
|-------|--------|-------|-------------|
|21     |170.093 |1      |7-bit carbons|
----------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 24 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 21 carbon atoms, and the carbon 



displacement of each group could be reasonably assigned. The NMR data 



were in good agreement with the target compounds. 



**b, Mass spectrometry (MS)** 



Detection instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 441 of 542 





Page 442
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Analytical method: Chinese Pharmacopoeia 2020 Edition of the four General 



Rules 0512 and 0431 



Test data: 



Table 3.2.S.5-8 MS data of the tested sample 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|395.19           |[M-H]-           |Molecular ion peak in|
|                 |                 |negative ion mode    |
-----------------------------------------------------------



In the negative ion mode, the mass-charge ratio m/z is 395.19 peak, which is 



attributed to the molecular ion peak in the negative ion mode, which is 



consistent with the molecular weight of the target molecule 396.45. 



**(2.3) Content calibration** 



**Properties** 



This product should be white to white powder. 



**Purity** 



Determination according to high performance liquid chromatography 



(General Rule 0512 of the Fourth part of Chinese Pharmacopoeia, 2020 



Edition). 



Chromatographic conditions: octadecylsilane bonded silica gel was used as 



filler (XBridge Shield RP18, 150×4.6mm, 3.5μm or equivalent column 



performance); A Welch Ghost-Buster Column (4.6×50mm, or equivalent 



ghost-buster column) was installed after the mixer of the pump and before the 



sampler. 0.03% phosphoric acid solution was used as mobile phase A and 



acetonitrile as mobile phase B; Gradient elution is performed according to the 



following table; Column temperature is 25℃; The detection wavelength was 



251nm; The flow rate was 1.0mL per minute; The injection volume was 5µl. 




Mobile 
Time /min 

phase A/% 




Mobile 



phase B/% 




0 95 5 



16.5 50 50 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 442 of 542 





Page 443
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



17 20 80 



22 20 80 



22.5 95 5 



35 95 5 



Solvent 30% acetonitrile 



Take an appropriate amount of this product from the test product solution, 



weigh it accurately, dissolve and dilute it with solvent to make a solution 



containing YA2304-12 about 0.25mg per 1ml. 



Method 5μl of the test solution was accurately measured and injected into the 



liquid chromatograph, and the chromatogram was recorded. The main peak 



purity should NLT 95.0% according to area normalization method. 



The content is calculated according to the purity. 



**(3) YA2304-14 working standard** 



The reference product YA2304-14 used in this study was self-made by T 



iandi Hengyi Pharmaceutical Co., LTD. It was named 4-(4-cyano-2-metho 



xyphenyl) -5-methoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyl-3-formami 



de on the physical label and the reference product report. The applicant 



confirmed its chemical structure and content calibration, and the conte 



nt was calculated according to 99.6%. 



Sample lot No.: 23082301-C 



Structural formula: 



Molecular formula: C20H20O3N 



Molecular weight: 364.40 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 443 of 542 





Page 444
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**(3.1) Preparation method of YA2304-14** 



Add YA2304-16 (2.0g) and tetrahydrofuran (12mL) into 250 mL flask, stir and 



add CDI (1.2g) in batches, stir for 1 hour, add DMAP (0.07g), and heat up to 



50 ℃. After 2.5 h of agitation, hamethyldisilazane (3.9 g) was added to the 



reaction system, the temperature was raised to reflux reaction for 3 h, and the 



temperature was lowered to 0 ~ 10 ℃. Tetrahydrofuran (1.2 g) and water (1.0 



g) were added to the reaction system, and the temperature was raised to 50 ℃ 



for 20 minutes, and the temperature was lowered to 0 ~ 10 ℃ for 30 minutes, 



and then filtered. Washed with water (30 mL) and dried at 50 ℃, YA2304-14, 



white solid (0.8 g) was obtained. 



**(3.2) Structural analysis of YA2304-14 reference** 



The chemical structure of the reference product was confirmed by the 



applicant through [1] HNMR, [13] CNMR and mass spectrometry, among which the 



mass spectrometry was tested by the applicant himself, and the [1] H NMR and 



13C NMR commissioned Changsha Kangpeng Pharmaceutical Co., LTD for 



testing. the relevant test results and structural analysis are detailed as 



follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 444 of 542 





Page 445
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data of hydrocarbon spectra and the analytical results are sho 



wn in Table 3.2.S.5-9 and Table 3.2.S.5-10. 



Table 3.2.S.5-9 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 






















--------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attributio|
|        |           |pattern|constant (J)|number |n         |
|--------|-----------|-------|------------|-------|----------|
|1       |2.141      |s      |/           |3H     |27-CH3    |
|--------|-----------|-------|------------|-------|----------|
|2       |2.188      |s      |/           |3H     |22-CH3    |
|--------|-----------|-------|------------|-------|----------|
|3       |3.616      |s      |/           |3H     |26-CH3    |
|--------|-----------|-------|------------|-------|----------|
|4       |3.824      |s      |/           |3H     |24-CH3    |
|--------|-----------|-------|------------|-------|----------|
|5       |5.406      |s      |/           |1H     |9-CH      |
|--------|-----------|-------|------------|-------|----------|
|6       |6.730-6.828|bs     |/           |2H     |20-NH2    |
|--------|-----------|-------|------------|-------|----------|
|7       |7.098-7.117|d      |7.6         |1H     |4-CH      |
|--------|-----------|-------|------------|-------|----------|
|8       |7.269-7.292|dd     |7.6, 1.2    |1H     |5-CH      |
|--------|-----------|-------|------------|-------|----------|
|9       |7.400-7.403|d      |1.2         |1H     |1-CH      |
|--------|-----------|-------|------------|-------|----------|
|10      |7.597      |s      |/           |1H     |16-CH     |
|--------|-----------|-------|------------|-------|----------|
|11      |7.738      |s      |/           |1H     |12-NH     |
--------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 445 of 542 





Page 446
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.5-10 [13] C NMR chemical shift values and correlation spectra (from 



high field to low field) of the tested sample 



1 

---------------------------------------------------
|Peak No.    |Delta ppm|Number of   |Attribution  |
|            |         |carbon atoms|             |
|------------|---------|------------|-------------|
|1           |14.199   |1           |27-place     |
|            |         |            |carbon       |
|------------|---------|------------|-------------|
|2           |18.398   |1           |22-place     |
|            |         |            |carbon       |
|------------|---------|------------|-------------|
|Solvent Peak|25.581   |/           |THF          |
|------------|---------|------------|-------------|
|3           |32.977   |1           |9-bit carbon |
|------------|---------|------------|-------------|
|4           |53.267   |1           |24-place     |
|            |         |            |carbon       |
|------------|---------|------------|-------------|
|5           |56.789   |1           |26-bit carbon|
|------------|---------|------------|-------------|
|Solvent peak|67.482   |/           |THF          |
|------------|---------|------------|-------------|
|6           |103.281  |1           |14-bit carbon|
|------------|---------|------------|-------------|
|7           |105.921  |1           |10-bit carbon|
|------------|---------|------------|-------------|
|8           |110.056  |1           |3-place      |
|            |         |            |carbons      |
|------------|---------|------------|-------------|
|9           |112.209  |1           |15-place     |
|            |         |            |carbon       |
|------------|---------|------------|-------------|
|10          |115.155  |1           |1 bit carbon |
|------------|---------|------------|-------------|
|11          |119.383  |1           |7-bit carbon |
|------------|---------|------------|-------------|
|12          |125.343  |1           |5-bit carbons|
|------------|---------|------------|-------------|
|13          |130.958  |1           |4-place      |
|            |         |            |carbons      |
|------------|---------|------------|-------------|
|14          |138.328  |1           |11-bit carbon|
|------------|---------|------------|-------------|
|15          |141.802  |1           |6-bit carbons|
|------------|---------|------------|-------------|
|16          |144.545  |1           |13-place     |
|            |         |            |carbon       |
|------------|---------|------------|-------------|
|17          |144.926  |1           |16-bit carbon|
|------------|---------|------------|-------------|
|18          |156.284  |1           |2-bit carbons|
|------------|---------|------------|-------------|
|19          |160.130  |1           |18-bit carbon|
|------------|---------|------------|-------------|
|20          |170.327  |1           |19-carbon    |
---------------------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 20 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 20 carbon atoms, and the carbon 



displacement of each group could be reasonably assigned. The NMR data 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 446 of 542 





Page 447
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



were in good agreement with the target compound. 



**b, Mass spectrometry (MS)** 



Detection instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Analytical method: Chinese Pharmacopoeia 2020 Edition of the four General 



Rules 0512 and 0431 



Test data: 



Table 3.2.S.5-11 MS data of the tested sample 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|365.26           |[M+H]+           |Molecular ion peak in|
|                 |                 |positive ion mode    |
-----------------------------------------------------------



In the positive ion mode, the mass charge ratio m/z was detected to be 365.26, 



which was attributed to the molecular ion peak in the positive ion mode, 



consistent with the molecular weight of the target molecule 364.40. 



**(3.3) Content calibration** 



**Properties** 



This product should be white to white powder. 



**purity** 



Determination according to high performance liquid chromatography 



(General Rule 0512 of the Fourth part of Chinese Pharmacopoeia, 2020 



Edition). 



Chromatographic conditions: octadecylsilane bonded silica gel was used as 



filler (XBridge Shield RP18, 150*4.6mm, 3.5μm or equivalent performance 



column); Welch Ghost-Buster Column (4.6×50mm, or equivalent 



ghost-buster column) was installed after the mixer of the pump and before the 



sampler. 0.03% phosphoric acid solution was used as mobile phase A and 



acetonitrile as mobile phase B; Gradient elution is performed according to the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 447 of 542 





Page 448
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



following table; Column temperature is 25℃; The detection wavelength was 



251nm; The flow rate was 1.0mL per minute; The injection volume was 5µl. 




Mobile 
Time /min 

phase A/% 




Mobile 



phase B/% 




0 95 5 



16.5 50 50 



17 20 80 



22 20 80 



22.5 95 5 



35 95 5 



Solvent 70% acetonitrile 



Take an appropriate amount of this product from the test product solution, 



weigh it accurately, dissolve and dilute it with solvent to make a solution 



containing YA2304-14 about 0.25mg per 1ml. 



Method 5μl of the test solution was accurately measured and injected into the 



liquid chromatograph, and the chromatogram was recorded. The main peak 



purity should NLT 95.0% according to area normalization method. 



The content is calculated according to the purity. 



**(4) YA2304-15 working standard** 



The reference product YA2304-15 used in this study was derived from T 



iandi Hengyi Pharmaceutical Co., LTD. It was named 4-(4-cyano-2-metho 



xyphenyl) -5-isopropoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyl-3-forma 



mide on the physical label and the reference product report. The applica 



nt confirmed its chemical structure and content calibration, and the con 



tent was calculated according to 99.3%. 



Sample lot No.: 23082903-C 



Structural formula: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 448 of 542 





Page 449
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Molecular formula: C22H24O3N 



Molecular weight: 392.46 



**(4.1) Preparation method of YA2304-15** 



Add YA2304-18(2.0g) and tetrahydrofuran (21mL) into 250 mL flask, add CDI 



(2.0g) in batches under agitation, add DMAP (0.11g) after 1 hour of agitation, 



heat up to 50℃, add hexamethyldisilazane (6.3g) into the reaction system 



after 2.5 h of agitation. Heating up to reflux reaction for 3 h, cooling down to 



0~10℃, adding tetrahydrofuran (1.2 g) and water (1.0 g) to the reaction 



system, stirring at 80 ℃ for 2 h, cooling down to 0~10℃ for 30 minutes, 



filtering, washing with water (30 mL), drying at 50 ℃, YA2304-15 was 



obtained. White solid (2.6g). 



**(4.2) Structural analysis of YA2304-15 reference** 



The chemical structure of the reference product was confirmed by [1] the 



applicant by means of HNMR, [13] CNMR and mass spectrometry, among which 



the mass spectrometry was tested by the applicant himself, [1] HNMR and [13] 



CNMR commissioned Changsha Kangpeng Pharmaceutical Co., LTD for 



testing. The relevant test atlas and contract for testing are detailed in section 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 449 of 542 





Page 450
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



3.2.R.7.S, and the relevant test results and structural analysis are detailed as 



follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-12 and Table 3.2.S.5-13. 



Table 3.2.S.5-12 HN [1] MR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 






















--------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attributio|
|        |           |pattern|constant (J)|number |n         |
|--------|-----------|-------|------------|-------|----------|
|1       |0.733-0.748|t      |6           |3H     |27-CH3    |
|--------|-----------|-------|------------|-------|----------|
|2       |1.178-1.193|t      |6           |3H     |29-CH3    |
--------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 450 of 542 





Page 451
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 

------------------------------------------------------
|3      |2.124      |s      |/       |3H     |28-CH3 |
|-------|-----------|-------|--------|-------|-------|
|4      |2.203      |s      |/       |3H     |22-CH3 |
|-------|-----------|-------|--------|-------|-------|
|Solvent|3.583-3.616|m      |/       |/      |THF    |
|peak   |           |       |        |       |       |
|-------|-----------|-------|--------|-------|-------|
|5      |3.835      |s      |/       |3H     |24-CH3 |
|-------|-----------|-------|--------|-------|-------|
|6      |4.956-4.987|m      |/       |1H     |26-CH  |
|-------|-----------|-------|--------|-------|-------|
|7      |5.361      |s      |/       |1H     |9-CH   |
|-------|-----------|-------|--------|-------|-------|
|8      |6.773-6.705|bs     |/       |2H     |20-NH2 |
|-------|-----------|-------|--------|-------|-------|
|9      |7.168-7.188|d      |8.0     |1H     |4-CH   |
|-------|-----------|-------|--------|-------|-------|
|10     |7.274-7.297|dd     |8.0, 1.2|1H     |5-CH   |
|-------|-----------|-------|--------|-------|-------|
|11     |7.370-7.373|d      |1.2     |1H     |1-CH   |
|-------|-----------|-------|--------|-------|-------|
|12     |7.557      |s      |/       |1H     |16-CH  |
|-------|-----------|-------|--------|-------|-------|
|13     |7.675      |s      |/       |1H     |12-NH  |
------------------------------------------------------



Table 3.2.S.5-13 CN [13] MR chemical shift values and correlation spectra (from 



high field to low field) of the tested sample 













----------------------------------------------------
|Peak sequence|Delta ppm|Number of   |Attribution  |
|number       |         |carbon atoms|             |
|-------------|---------|------------|-------------|
|1            |14.182   |1           |28-bit carbon|
|-------------|---------|------------|-------------|
|2            |18.556   |1           |22-place     |
|             |         |            |carbon       |
|-------------|---------|------------|-------------|
|3            |21.708   |1           |27-place     |
|             |         |            |carbon       |
|-------------|---------|------------|-------------|
|4            |22.365   |1           |29-place     |
|             |         |            |carbon       |
|-------------|---------|------------|-------------|
|Solvent Peak |25.586   |/           |THF          |
|-------------|---------|------------|-------------|
|5            |32.442   |1           |9-bit carbon |
|-------------|---------|------------|-------------|
|6            |56.405   |1           |24-place     |
|             |         |            |carbon       |
|-------------|---------|------------|-------------|
|7            |67.002   |1           |26-bit carbon|
|-------------|---------|------------|-------------|
|Solvent Peak |67.478   |/           |THF          |
|-------------|---------|------------|-------------|
|8            |104.245  |1           |14-bit carbon|
|-------------|---------|------------|-------------|
|9            |105.756  |1           |10-carbon    |
|-------------|---------|------------|-------------|
|10           |109.875  |1           |3-place      |
|             |         |            |carbons      |
|-------------|---------|------------|-------------|
|11           |111.510  |1           |15-place     |
|             |         |            |carbon       |
----------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 451 of 542 





Page 452
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



1 

---------------------------------------
|12     |114.313|1      |1 bit carbon |
|-------|-------|-------|-------------|
|13     |119.462|1      |7-bit carbon |
|-------|-------|-------|-------------|
|14     |125.154|1      |5-bit carbons|
|-------|-------|-------|-------------|
|15     |131.563|1      |4-place      |
|       |       |       |carbons      |
|-------|-------|-------|-------------|
|16     |138.558|1      |11-bit carbon|
|-------|-------|-------|-------------|
|17     |142.476|1      |6-bit carbons|
|-------|-------|-------|-------------|
|18     |144.662|1      |13-place     |
|       |       |       |carbon       |
|-------|-------|-------|-------------|
|19     |144.726|1      |16-bit carbon|
|-------|-------|-------|-------------|
|20     |156.101|1      |2-bit carbons|
|-------|-------|-------|-------------|
|21     |159.440|1      |18-bit carbon|
|-------|-------|-------|-------------|
|22     |170.174|1      |19-bit carbon|
---------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 24 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 22 carbon atoms, and the carbon 



displacement of each group could be reasonably attributed, and the NMR 



data were consistent with the target compound. 



**b, Mass spectrometry (MS)** 



Test instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Analytical method: Chinese Pharmacopoeia 2020 Edition of the four General 



Rules 0512 and 0431 



Test data: 



Table 3.2.S.5-14 MS data of the tested sample 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|393.29           |[M+H]+           |Molecular ion peak in|
|                 |                 |positive ion mode    |
-----------------------------------------------------------



In the positive ion mode, the mass-charge ratio m/z is 393.29 peak, which is 



attributed to the molecular ion peak in the positive ion mode, consistent with 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 452 of 542 





Page 453
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



the molecular weight of the target molecule 392.46. 



**(4.3) Content calibration** 



**Properties** 



This product should be white to white powder. 



**Purity** 



Determination according to high performance liquid chromatography 



(General Rule 0512 of the Fourth part of Chinese Pharmacopoeia, 2020 



Edition). 



Chromatographic conditions: octadecylsilane bonded silica gel was used as 



filler (XBridge Shield RP18, 150×4.6mm, 3.5μm or equivalent performance 



column); A Welch Ghost-Buster Column (4.6×50mm, or equivalent 



ghost-buster column) was installed after the mixer of the pump and before the 



sampler. 0.03% phosphoric acid solution was used as mobile phase A and 



acetonitrile as mobile phase B; Gradient elution is performed according to the 



following table; Column temperature is 25℃; The detection wavelength was 



251nm; The flow rate was 1.0mL per minute; The injection volume was 5µl. 




Mobile 
Time /min 

phase A/% 




Mobile 



phase B/% 




0 95 5 



16.5 50 50 



17 20 80 



22 20 80 



22.5 95 5 



35 95 5 



Solvent 70% acetonitrile 



Take an appropriate amount of this product from the test product solution, 



weigh it accurately, dissolve and dilute it with solvent to make a solution 



containing YA2304-15 about 0.25mg per 1ml. 



The test solution of 5μl was accurately measured and injected into the liquid 



chromatograph, and the chromatogram was recorded. The main peak purity 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 453 of 542 





Page 454
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



was NLT 95.0% according to the area normalization method. 



The content is calculated according to the purity. 



**(5) YA2304-16 working standard** 



The reference product YA2304-16 used in this study was derived from T 



iandi Hengyi Pharmaceutical Co., LTD. It was named 4-(4-cyano-2-metho 



xyphenyl) -5-methoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyl-3-carboxyl 



ic acid on the physical label and the reference product report. The appli 



cant confirmed its chemical structure and content calibration, and the c 



ontent was calculated according to 93.7%. 



Sample lot No.: 23082201-C 



Structural formula: 



Molecular formula: C20H19O4N 



Molecular weight: 365.39 



**(5.1) Preparation method of YA2304-16** 



Add YA2304-50(4.8g), tetrahydrofuran (60 mL) and water (30 mL) into 250 



mL flask, stir and cool to 0~5 ℃, slowly add 7.3% NaOH aq.(12.5 g) into the 



reaction system, and react at 0~5 ℃ for 3 h. Sodium acetate (0.9 g) and 



toluene (50 mL) were added into the reaction system, and the solution was 



divided after stirring at 0 ~ 5 ℃ for 20 minutes. The lower aqueous phase was 



treated with 10% NaOH aq. Adjust the pH to 6.5~7.0, stir at 0~5 ℃ for 30 



minutes, filter, rinse with water (100 mL), dry at 50 ℃, YA2304-16, light 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 454 of 542 





Page 455
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



yellow solid (3.2 g) was obtained. 



**(5.2) Structural analysis of YA2304-16 reference** 



The chemical structure of the reference product was confirmed by the 



applicant by means of [1] H NMR, [13] C NMR and mass spectrometry. The mass 



spectrometry was tested by the applicant by himself, and the [1] H NMR and [13] C 



NMR were tested by Changsha Kangpeng Pharmaceutical Co., LTD. The 



relevant test results and structural analysis are detailed as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Reference material: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 455 of 542 





Page 456
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-15 and Table 3.2.S.5-16. 



Table 3.2.S.5-15 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 






















--------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attributio|
|        |           |pattern|constant (J)|number |n         |
|--------|-----------|-------|------------|-------|----------|
|1       |2.160      |s      |/           |3H     |27-CH3    |
|--------|-----------|-------|------------|-------|----------|
|2       |2.504      |s      |/           |3H     |22-CH3    |
|--------|-----------|-------|------------|-------|----------|
|3       |3.650      |s      |/           |3H     |24-CH3    |
|--------|-----------|-------|------------|-------|----------|
|4       |3.766      |s      |/           |3H     |26-CH3    |
|--------|-----------|-------|------------|-------|----------|
|5       |5.370      |s      |/           |1H     |9-CH      |
|--------|-----------|-------|------------|-------|----------|
|6       |7.248-7.262|t      |/           |2H     |4, 5 - CH |
|--------|-----------|-------|------------|-------|----------|
|7       |7.340-7.343|d      |/           |1H     |1-CH      |
|--------|-----------|-------|------------|-------|----------|
|8       |7.606      |s      |/           |1H     |16-CH     |
|--------|-----------|-------|------------|-------|----------|
|9       |8.202      |s      |/           |1H     |12-NH     |
|--------|-----------|-------|------------|-------|----------|
|10      |11.481     |s      |/           |1H     |20-COOH   |
--------------------------------------------------------------

Table 3.2.S.5-16 [13] C NMR chemical shift values and correlation spectra (from 



high field to low field) of the tested sample 

-----------------------------------------------
|Peak No.|Delta ppm|Number of   |Attribution  |
|        |         |carbon atoms|             |
|--------|---------|------------|-------------|
|1       |14.174   |1           |27-place     |
|        |         |            |carbon       |
|--------|---------|------------|-------------|
|2       |19.272   |1           |Twenty-two   |
|        |         |            |carbon       |
|--------|---------|------------|-------------|
|3       |34.223   |1           |9-bit carbons|
-----------------------------------------------



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 456 of 542 





Page 457
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



1 

----------------------------------------
|4      |56.352 |1      |24-place      |
|       |       |       |carbon        |
|-------|-------|-------|--------------|
|5      |56.453 |1      |26-bit carbon |
|-------|-------|-------|--------------|
|6      |100.037|1      |14-bit carbon |
|-------|-------|-------|--------------|
|7      |103.771|1      |10-bit carbon |
|-------|-------|-------|--------------|
|8      |110.034|1      |3-place       |
|       |       |       |carbons       |
|-------|-------|-------|--------------|
|9      |112.438|1      |15-place      |
|       |       |       |carbon        |
|-------|-------|-------|--------------|
|10     |115.416|1      |1 bit carbon  |
|-------|-------|-------|--------------|
|11     |119.430|1      |7-bit carbon  |
|-------|-------|-------|--------------|
|12     |124.497|2      |4, 5-place    |
|       |       |       |carbon        |
|-------|-------|-------|--------------|
|13     |141.344|1      |6-place carbon|
|-------|-------|-------|--------------|
|14     |144.232|2      |13,16 carbon  |
|-------|-------|-------|--------------|
|15     |147.519|1      |11-bit carbon |
|-------|-------|-------|--------------|
|16     |157.660|1      |2-bit carbons |
|-------|-------|-------|--------------|
|17     |160.155|1      |18-bit carbon |
|-------|-------|-------|--------------|
|18     |168.962|1      |19-carbon     |
----------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 19 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 20 carbon atoms, and the carbon 



displacement of each group could be reasonably assigned. The NMR data 



were in good agreement with the target compound. 



**b, Mass spectrometry (MS)** 



Detection instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Analytical method: Chinese Pharmacopoeia 2020 Edition of the four General 



Rules 0512 and 0431 



Test data: 



Table 3.2.S.5-17 MS data of the tested sample 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 457 of 542 





Page 458
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|366.26           |[M+H]+           |Molecular ion peak in|
|                 |                 |positive ion mode    |
-----------------------------------------------------------



In the positive ion mode, the detected mass-charge ratio m/z is 366.26 peak, 



which is attributed to the molecular ion peak in the positive ion mode, 



consistent with the molecular weight of the target molecule 365.39. 



**(5.3) Content calibration** 



**Properties** 



This product should be like white to yellow powder. 



**purity** 



Determination according to high performance liquid chromatography 



(General Rule 0512 of the Fourth part of Chinese Pharmacopoeia, 2020 



Edition). 



Chromatographic conditions: octadecylsilane bonded silica gel was used as 



filler (XBridge Shield RP18, 150×4.6mm, 3.5μm or equivalent performance 



column); 20mM ammonium acetate solution (pH8.1) (weigh ammonium 



acetate about 1.54g, dissolve in 1000ml pure water, adjust the pH to 8.1 with 



ammonia water) was used as mobile phase A, acetonitrile was used as mobile 



phase B; Gradient elution was performed according to the following table; 



Column temperature is 25℃; The detection wavelength was 251nm; The flow 



rate was 1.0mL per minute; The injection volume was 5µl. 




Mobile 
Time /min 

phase A/% 




Mobile 



phase B/% 




0 95 5 



16.5 50 50 



17 20 80 



22 20 80 



22.5 95 5 



35 95 5 



Solvent acetonitrile 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 458 of 542 





Page 459
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Sample solution take appropriate amount of this product, weigh it accurately, 



dissolve and dilute it with solvent to make a solution containing YA2304-16 



about 0.25mg per 1ml. 



Method 5μl of the test solution was accurately measured and injected into the 



liquid chromatograph, and the chromatogram was recorded. The main peak 



purity should NLT 90.0% according to area normalization method. 



The content is calculated according to the purity. 



**(6) YA2304-17 working standard** 



The control product YA2304-17 used in this application is from Shangha 



i Bide Pharmaceutical Technology Co., LTD., which is named Benzoic aci 



d on the physical label, which is named Benzoic acid on the manufactu 



rer's photo report list, and the control product name is Benzoic acid on 



the invoice. The applicant has confirmed its chemical structure, and acc 



ording to the report provided by the manufacturer, the content is calcul 



ated by 99.30%. 



Sample lot No.: DMW857 



Structural formula: 



Molecular formula: C7H6O 



Molecular weight: 122.12 



**(6.1) Structural analysis of YA2304-17 reference** 



The chemical structure of the reference product was confirmed by [1] the 



applicant by means of H NMR, [13] CNMR and mass spectrometry, among which 



the mass spectrometry was tested by the applicant himself, 1H NMR was 



provided by Shanghai Bider Medical Technology Co., LTD., and 13C NMR 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 459 of 542 





Page 460
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



commissioned Changsha Kangpeng Medical Co., LTD to test. The relevant 



test results and structural analysis are detailed as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-18 and Table 3.2.S.5-19. 



Table 3.2.S.5-18 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 






















---------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling     |Proton |Attributio|
|        |           |pattern|constant (J) |number |n         |
|--------|-----------|-------|-------------|-------|----------|
|1       |5.74 ~ 7.39|m      |/            |2H     |1, 3 - CH |
|--------|-----------|-------|-------------|-------|----------|
|2       |7.71 ~ 7.54|m      |/            |1H     |2-CH      |
|--------|-----------|-------|-------------|-------|----------|
|3       |7.94       |ddd    |7.4, 2.9, 1.6|2H     |4, 6 - CH |
|--------|-----------|-------|-------------|-------|----------|
|4       |12.94      |s      |0.8Hz        |1H     |9-OH      |
---------------------------------------------------------------

Table 3.2.S.5-19 [13] C NMR chemical shift values and correlation spectra of the 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 460 of 542 





Page 461
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



tested sample (from high field to low field) 










1 

----------------------------------------------
|Peak No.|Delta ppm|Number of   |Attribution |
|        |         |carbon atoms|            |
|--------|---------|------------|------------|
|1       |128.992  |2           |1, 3-place C|
|--------|---------|------------|------------|
|2       |129.727  |2           |4,6 C's     |
|--------|---------|------------|------------|
|3       |131.222  |1           |5 digit C's |
|--------|---------|------------|------------|
|4       |133.286  |1           |2-bit C     |
|--------|---------|------------|------------|
|5       |167.796  |1           |7-bit C     |
----------------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 6 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 7 carbon atoms, and the carbon 



displacement of each group could be reasonably assigned. The NMR data 



were in good agreement with the target compound. 



**b, Mass spectrometry (MS)** 



Detection instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Analytical method: Chinese Pharmacopoeia 2020 Edition of the four General 



Rules 0512 and 0431 



Test data: 



Table 3.2.S.5-20 MS data of the tested sample 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|121.08           |[M-H]-           |Molecular ion peak in|
|                 |                 |negative ion mode    |
-----------------------------------------------------------



In the negative ion mode, the mass-charge ratio m/z was detected as 121.08 



peak, which was attributed to the molecular ion peak in the negative ion 



mode, consistent with the molecular weight of the target molecule 122.12. 



**(7) YA2304-18 working standard** 



The reference product YA2304-18 used in this study was derived from T 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 461 of 542 





Page 462
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



iandi Hengyi Pharmaceutical Co., LTD. It was named 4-(4-cyano-2-metho 



xyphenyl) -5-isopropoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyl-3-carbo 



xylic acid on the physical label and the reference product report. The ap 



plicant confirmed its chemical structure and content calibration, and the 



content was calculated according to 98.9%. 



Sample lot No.: 23082802-C 



Structural formula: 



Molecular formula: C22H23O4N 



Molecular weight: 393.44 



**(7.1) Preparation method of YA2304-18** 



Add YA2304-51(6.0 g), tetrahydrofuran (36 mL) and water (18 mL) into 250 



mL flask, stir and cool to 0~5℃, slowly add 7.3% NaOH aq.(14.7 g) into the 



reaction system, and react at 0~5℃ for 3 h. Sodium acetate (1.1g) and toluene 



(45 mL) were added into the reaction system, stirring at 0~5 ℃ for 20 minutes 



before separating the solution, and the lower aqueous phase was treated with 



10% NaOH aq. Adjust the pH to 6.5~7.0, stir at 0~5 ℃ for 30 minutes, filter, 



rinse with water (100 mL), dry at 50 ℃, YA2304-18, white solid (4.5 g) was 



obtained. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 462 of 542 





Page 463
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**(7.2) Structural analysis of YA2304-18 reference** 



The chemical structure of the reference product was confirmed by [1] the 



applicant by means of H NMR, [13] C NMR and mass spectrometry. The mass 



spectrometry was tested by the applicant by himself, [1] and the H NMR and [13] C 



NMR were tested by Changsha Kangpeng Pharmaceutical Co., LTD. For 



details about the relevant test graphs and contract, see section 3.2.R.7.S. The 



relevant test results and structural analysis are detailed as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 463 of 542 





Page 464
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-21 and Table 3.2.S.5-22. 



Table 3.2.S.5-21 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 






















--------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attributio|
|        |           |pattern|constant (J)|number |n         |
|--------|-----------|-------|------------|-------|----------|
|1       |0.829-0.845|d      |6.4         |3H     |27-CH3    |
|--------|-----------|-------|------------|-------|----------|
|2       |1.209-1.224|d      |6.4         |3H     |29-CH3    |
|--------|-----------|-------|------------|-------|----------|
|3       |2.144      |s      |/           |3H     |28-CH3    |
|--------|-----------|-------|------------|-------|----------|
|4       |2.383      |s      |/           |3H     |22-CH3    |
|--------|-----------|-------|------------|-------|----------|
|5       |3.727      |s      |/           |3H     |24-CH3    |
|--------|-----------|-------|------------|-------|----------|
|6       |4.968-5.029|m      |/           |1H     |26-CH     |
|--------|-----------|-------|------------|-------|----------|
|7       |5.307      |s      |/           |1H     |9-CH      |
|--------|-----------|-------|------------|-------|----------|
|8       |7.275-7.313|d      |/           |3H     |1, four,  |
|        |           |       |            |       |five - CH |
|--------|-----------|-------|------------|-------|----------|
|9       |7.570      |s      |/           |1H     |16-CH     |
|--------|-----------|-------|------------|-------|----------|
|10      |8.119      |s      |/           |1H     |12-NH     |
|--------|-----------|-------|------------|-------|----------|
|11      |11.429     |s      |/           |1H     |20-COOH   |
--------------------------------------------------------------

Table 3.2.S.5-22 [13] C NMR chemical shift value and correlation spectrum 



(from high field to low field) of the tested sample 

-----------------------------------------------
|Peak No.|Delta ppm|Number of   |Attribution  |
|        |         |carbon atoms|             |
|--------|---------|------------|-------------|
|1       |14.141   |1           |28-bit carbon|
|--------|---------|------------|-------------|
|2       |19.361   |1           |22-place     |
|        |         |            |carbon       |
-----------------------------------------------



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 464 of 542 





Page 465
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



1 

---------------------------------------
|3      |21.817 |1      |27-place     |
|       |       |       |carbon       |
|-------|-------|-------|-------------|
|4      |22.400 |1      |26-place     |
|       |       |       |carbon       |
|-------|-------|-------|-------------|
|5      |34.719 |1      |9-bit carbons|
|-------|-------|-------|-------------|
|6      |56.188 |1      |24-place     |
|       |       |       |carbon       |
|-------|-------|-------|-------------|
|7      |67.091 |1      |26-bit carbon|
|-------|-------|-------|-------------|
|8      |99.901 |1      |10-bit carbon|
|-------|-------|-------|-------------|
|9      |104.274|2      |3,14 carbon  |
|-------|-------|-------|-------------|
|10     |109.867|1      |15-position  |
|       |       |       |carbon       |
|-------|-------|-------|-------------|
|11     |111.681|1      |1 bit carbon |
|-------|-------|-------|-------------|
|12     |119.520|1      |7-bit carbon |
|-------|-------|-------|-------------|
|13     |124.126|1      |5-bit carbons|
|-------|-------|-------|-------------|
|14     |132.412|1      |4-place      |
|       |       |       |carbons      |
|-------|-------|-------|-------------|
|15     |141.553|1      |6-place      |
|       |       |       |carbons      |
|-------|-------|-------|-------------|
|16     |144.164|1      |13-place     |
|       |       |       |carbon       |
|-------|-------|-------|-------------|
|17     |144.836|1      |16-bit carbon|
|-------|-------|-------|-------------|
|18     |147.451|1      |11 bit carbon|
|-------|-------|-------|-------------|
|19     |157.793|1      |2-bit carbons|
|-------|-------|-------|-------------|
|20     |159.446|1      |18-bit carbon|
|-------|-------|-------|-------------|
|21     |169.063|1      |19-bit carbon|
---------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 23 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 22 carbon atoms, and the carbon 



displacement of each group could be reasonably assigned. The NMR data 



were in good agreement with the target compound. 



**b, Mass spectrometry (MS)** 



Detection instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Analysis methods: General Rules 0512 and 0431 of the fourth edition of 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 465 of 542 





Page 466
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Chinese Pharmacopoeia (2020 edition) 



Test data: 



Table 3.2.S.5-23 MS data of the tested sample 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|394.31           |[M+H]+           |Molecular ion peak in|
|                 |                 |positive ion mode    |
-----------------------------------------------------------



In the positive ion mode, the mass-charge ratio m/z is 394.31 peak, which is 



attributed to the molecular ion peak in the positive ion mode, consistent with 



the molecular weight of the target molecule 393.44. 



**(7.3) Content calibration** 



**Properties** 



This product should be white to white powder. 



**Purity** 



Determination according to high performance liquid chromatography 



(General Rule 0512 of the Fourth part of Chinese Pharmacopoeia, 2020 



Edition). 



Chromatographic conditions: octadecylsilane bonded silica gel was used as 



filler (XBridge Shield RP18, 150×4.6mm, 3.5μm or equivalent performance 



column); 20mM ammonium acetate solution (pH 8.1) (weigh ammonium 



acetate about 1.54g, dissolve in 1000ml pure water, adjust the pH to 8.1 with 



ammonia water) was used as mobile phase A, acetonitrile was used as mobile 



phase B; Gradient elution was performed according to the following table; 



Column temperature is 25℃; The detection wavelength was 251nm; The flow 



rate was 1.0mL per minute; The injection volume was 5µl. 




Mobile 
Time /min 

phase A/% 




Mobile 



phase B/% 




0 95 5 



16.5 50 50 



17 20 80 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 466 of 542 





Page 467
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



22 20 80 



22.5 95 5 



35 95 5 



Solvent acetonitrile 



Sample solution take appropriate amount of this product, weigh it accurately, 



dissolve and dilute it with solvent to make a solution containing YA2304-18 



about 0.25mg per 1ml. 



Method 5μl of the test solution was accurately measured and injected into the 



liquid chromatograph, and the chromatogram was recorded. The main peak 



purity should NLT 95.0% according to area normalization method. 



The content is calculated according to the purity. 



**(8) YA2304-19 working standard** 



The reference product YA2304-19 used in this study was from Tiandi He 



ngyi Pharmaceutical Co., LTD. It was named 4-(4-cyano-2-methoxyphenyl) 



-5-ethoxy-2, 8-dimethyl-1, 6-naphthyl-3-formamide on the physical label 



and the reference product report. The applicant confirmed its chemical 



structure and content calibration, and the content was calculated accord 



ing to 99.4%. 



Sample lot No.: 23080701-A 



Structural formula: 



Molecular formula: C21H20O3N 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 467 of 542 





Page 468
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Molecular weight: 376.42 



**(8.1) Preparation method of YA2304-19** 



Add YA2304-7(20.0g), CDI (12.0g) and tetrahydrofuran (100 mL) into 250 mL 



flask, stir to dissolve, control the temperature by 15~20℃, add DMAP (0.64g), 



stir for 10 minutes, rise to 50 ℃ and react for 2 h, add hamethyldisilazane 



(37.4g), stir for 10 minutes. Overnight reaction at 60℃ until the reaction of 



raw material is complete. Drop to 0~5℃, add water (10.4 g) and 



tetrahydrofuran (16.0 g) mixed liquid crystallization, temperature rise reflux 



stirring for 3 h beating, temperature drop to 0~5℃ stirring for 2 h after 



filtration, mother liquor concentrated to dry, column purification (EA/ 



n-heptane =1/1), concentration, recrystallization (EA/ n-heptane =1/5), 



vacuum drying, Yellow granular solid YA2304-19 was obtained. 



**(8.2) Structural analysis of YA2304-19 reference** 



The chemical structure of the reference product was confirmed by [1] the 



applicant by means of H NMR, [13] C NMR and mass spectrometry. The mass 



spectrometry was tested by the applicant by himself, [1] and the H NMR and [13] C 



NMR were tested by Changsha Kangpeng Pharmaceutical Co., LTD. The 



relevant test results and structural analysis are detailed as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 468 of 542 





Page 469
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Solvent: DMSO; 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-24 and Table 3.2.S.5-25. 



Table 3.2.S.5-24 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 






















--------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attributio|
|        |           |pattern|constant (J)|number |n         |
|--------|-----------|-------|------------|-------|----------|
|1       |0.702-0.737|t      |/           |3H     |27-CH3    |
|--------|-----------|-------|------------|-------|----------|
|2       |2.508      |s      |/           |3H     |28-CH3    |
|--------|-----------|-------|------------|-------|----------|
|3       |2.719      |s      |/           |3H     |22-CH3    |
|--------|-----------|-------|------------|-------|----------|
|4       |3.669      |s      |/           |3H     |24-CH3    |
|--------|-----------|-------|------------|-------|----------|
|5       |3.945-4.049|m      |/           |2H     |26-CH2    |
|--------|-----------|-------|------------|-------|----------|
|6       |7.318-7.338|d      |/           |1H     |4-CH      |
|--------|-----------|-------|------------|-------|----------|
|7       |7.461-7.465|d      |/           |1H     |5-CH      |
|--------|-----------|-------|------------|-------|----------|
|8       |7.524-7.527|d      |/           |2H     |20-NH2    |
|--------|-----------|-------|------------|-------|----------|
|9       |7.735      |s      |/           |1H     |16-CH     |
|--------|-----------|-------|------------|-------|----------|
|10      |8.041-8.043|d      |/           |1H     |1-CH      |
--------------------------------------------------------------

Table 3.2.S.5-25 [13] C NMR chemical shift value and correlation spectrum 



(from high field to low field) of the tested sample 



Peak No. Delta ppm Number of ownership 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 469 of 542 





Page 470
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



1 

---------------------------------------------
|       |       |carbon atoms|              |
|-------|-------|------------|--------------|
|1      |13.585 |1           |28-bit carbon |
|-------|-------|------------|--------------|
|2      |14.761 |1           |27-bit carbon |
|-------|-------|------------|--------------|
|3      |24.055 |1           |22-place      |
|       |       |            |carbon        |
|-------|-------|------------|--------------|
|4      |56.565 |1           |24-place      |
|       |       |            |carbon        |
|-------|-------|------------|--------------|
|5      |61.687 |1           |26-bit carbon |
|-------|-------|------------|--------------|
|6      |111.026|1           |14-bit carbon |
|-------|-------|------------|--------------|
|7      |111.838|1           |10-bit carbon |
|-------|-------|------------|--------------|
|8      |113.883|1           |7-bit carbons |
|-------|-------|------------|--------------|
|9      |119.443|1           |15-bit carbon |
|-------|-------|------------|--------------|
|10     |122.968|1           |1 bit carbon  |
|-------|-------|------------|--------------|
|11     |124.052|1           |6-place carbon|
|-------|-------|------------|--------------|
|12     |130.463|1           |5-bit carbon  |
|-------|-------|------------|--------------|
|13     |133.312|1           |4-place       |
|       |       |            |carbons       |
|-------|-------|------------|--------------|
|14     |133.765|1           |11-bit carbon |
|-------|-------|------------|--------------|
|15     |139.899|1           |3-bit carbons |
|-------|-------|------------|--------------|
|16     |142.589|1           |13-bit carbon |
|-------|-------|------------|--------------|
|17     |151.139|1           |16-bit carbon |
|-------|-------|------------|--------------|
|18     |157.750|1           |2-bit carbons |
|-------|-------|------------|--------------|
|19     |158.515|1           |18-bit carbon |
|-------|-------|------------|--------------|
|20     |159.484|1           |9-bit carbons |
|-------|-------|------------|--------------|
|21     |168.540|1           |19-place      |
|       |       |            |carbon        |
---------------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 20 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 21 carbon atoms, and the carbon 



displacement of each group could be reasonably assigned. The NMR data 



were in good agreement with the target compounds. 



**b, Mass spectrometry (MS)** 



Detection instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Analytical method: Chinese Pharmacopoeia 2020 Edition of the four General 



Rules 0512 and 0431 



Test data: 



Table 3.2.S.5-26 MS data of the tested sample 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 470 of 542 





Page 471
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|377.26           |[M+H]+           |Molecular ion peak in|
|                 |                 |positive ion mode    |
-----------------------------------------------------------



In the positive ion mode, the mass-charge ratio m/z is detected to be 377.26 



peak, which is attributed to the molecular ion peak in the positive ion mode, 



consistent with the molecular weight of the target molecule 376.42. 



**(8.3) Content calibration** 



**Properties** 



This product should be like white to yellow powder. 



**Purity** 



Determination according to high performance liquid chromatography 



(General Rule 0512 of the Fourth part of Chinese Pharmacopoeia, 2020 



Edition). 



Chromatographic conditions: octadecylsilane bonded silica gel was used as 



filler (XBridge Shield RP18, 150×4.6mm, 3.5μm or equivalent performance 



column); A Welch Ghost-Buster Column (4.6×50mm, or equivalent 



ghost-buster column) was installed after the mixer of the pump and before the 



sampler. 0.03% phosphoric acid solution was used as mobile phase A and 



acetonitrile as mobile phase B; Gradient elution is performed according to the 



following table; Column temperature is 25℃; The detection wavelength was 



251nm; The flow rate was 1.0mL per minute; The injection volume was 5µl. 




Mobile 
Time /min 

phase A/% 




Mobile 



phase B/% 




0 95 5 



16.5 50 50 



17 20 80 



22 20 80 



22.5 95 5 



35 95 5 



Solvent 70% acetonitrile 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 471 of 542 





Page 472
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Take an appropriate amount of this product from the test product solution, 



weigh it accurately, dissolve and dilute it with solvent to make a solution 



containing YA2304-19 about 0.25mg per 1ml. 



Method 5μl of the test solution was accurately measured and injected into the 



liquid chromatograph, and the chromatogram was recorded. The main peak 



purity should NLT 95.0% according to area normalization method. 



The content is calculated according to the purity. 



**(9) YA2304-20 working standard** 



The reference product YA2304-20 used in this study was derived from T 



iandi Hengyi Pharmaceutical Co., LTD. It was named (4R)-4-(4-cyano-2- 



methoxyphenyl) -5-ethoxy-2, 8-dimethyl-1, 4-dihydro-1, 6-naphthyl-3-for 



mamide on the physical label and the reference product report. The appl 



icant confirmed its chemical structure and content calibration, and the c 



ontent was calculated according to 99.2%. 



Sample lot No.: 23080401-A 



Structural formula: 



Molecular formula: C21H22O3N 



Molecular weight: 378.43 



**(9.1) Preparation method of YA2304-20** 



Take YA2304-9 mother liquor (600ml, obtained by combining multiple 



batches of small experiments), control the temperature by 15~20℃, add 9% 



potassium phosphate solution to pH>7.5, and add water (200ml). Water bath 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 472 of 542 





Page 473
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



temperature control 50℃, decompression concentration until no large 



fraction, a large number of white solid precipitation. Heat preservation 



20~25℃, filtration, wet product added with ethanol (300ml), reflux 



dissolution at high temperature, filtration, concentration under reduced 



pressure to about 110g, reflux at high temperature for 1 hour, cooling to 



0~5℃, crystallization for 2 h, filtration, vacuum drying at 50℃, YA2304-20 



(13.0g) was obtained. 



**(9.2) Structural analysis of YA2304-20 reference product** 



The chemical structure of the reference product was confirmed by [1] the 



applicant by means of H NMR, [13] C NMR, mass spectrometry and chiral liquid 



chromatography. The mass spectrometry and chiral liquid chromatography 



were tested by the applicant by himself, [1] and the H NMR and [13] C NMR were 



tested by Changsha Kangpeng Pharmaceutical Co., LTD. The relevant 



detection spectra and contract for commissioned testing are detailed in 



section 3.2.R.7.S. The relevant test results and structural analysis are listed 



as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Reference: TMS ( [1] H spectrum); 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 473 of 542 





Page 474
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of hydrocarbon atoms in the structure (non-systematic nam 



ing, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-27 and Table 3.2.S.5-28 



Table 3.2.S.5-27 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 






















--------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attributio|
|        |           |pattern|constant (J)|number |n         |
|--------|-----------|-------|------------|-------|----------|
|1       |1.038-1.073|t      |7.2         |3H     |27-CH3    |
|--------|-----------|-------|------------|-------|----------|
|2       |2.128      |s      |/           |3H     |28-CH3    |
|--------|-----------|-------|------------|-------|----------|
|3       |2.207      |s      |/           |3H     |22-CH3    |
|--------|-----------|-------|------------|-------|----------|
|4       |3.836      |s      |/           |3H     |24-CH3    |
|--------|-----------|-------|------------|-------|----------|
|5       |4.010-4.034|m      |7.2         |2H     |26-CH2    |
|--------|-----------|-------|------------|-------|----------|
|6       |5.396      |s      |/           |1H     |9-CH      |
|--------|-----------|-------|------------|-------|----------|
|7       |6.710-6.785|bs     |/           |2H     |20-NH2    |
|--------|-----------|-------|------------|-------|----------|
|8       |7.160-7.180|d      |7.6         |1H     |4-CH      |
|--------|-----------|-------|------------|-------|----------|
|9       |7.275-7.298|dd     |7.6, 1.4    |1H     |5-CH      |
|--------|-----------|-------|------------|-------|----------|
|10      |7.377-7.380|d      |1.3         |1H     |1-CH      |
|--------|-----------|-------|------------|-------|----------|
|11      |7.561      |s      |/           |1H     |16-CH     |
|--------|-----------|-------|------------|-------|----------|
|12      |7.706      |s      |/           |1H     |12-NH     |
--------------------------------------------------------------

Table 3.2.S.5-28 [13] C NMR chemical shift value and correlation spectrum 



(from high field to low field) of the tested sample 

-----------------------------------------------
|Peak No.|Delta ppm|Number of   |Attribution  |
|        |         |carbon atoms|             |
|--------|---------|------------|-------------|
|1       |14.196   |1           |28-bit carbon|
-----------------------------------------------



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 474 of 542 





Page 475
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



1 

---------------------------------------
|2      |14.734 |1      |27-bit carbon|
|-------|-------|-------|-------------|
|3      |18.521 |1      |22-place     |
|       |       |       |carbon       |
|-------|-------|-------|-------------|
|4      |32.868 |1      |9-bit carbons|
|-------|-------|-------|-------------|
|5      |56.505 |1      |24-place     |
|       |       |       |carbon       |
|-------|-------|-------|-------------|
|6      |61.006 |1      |26-bit carbon|
|-------|-------|-------|-------------|
|7      |103.643|1      |14-bit carbon|
|-------|-------|-------|-------------|
|8      |105.771|1      |10-bit carbon|
|-------|-------|-------|-------------|
|9      |109.986|1      |2-place      |
|       |       |       |carbons      |
|-------|-------|-------|-------------|
|10     |111.911|1      |15-place     |
|       |       |       |carbon       |
|-------|-------|-------|-------------|
|11     |114.583|1      |1 bit carbon |
|-------|-------|-------|-------------|
|12     |119.432|1      |7-bit carbon |
|-------|-------|-------|-------------|
|13     |125.223|1      |5-bit carbons|
|-------|-------|-------|-------------|
|14     |131.366|1      |4-site carbon|
|-------|-------|-------|-------------|
|15     |138.643|1      |11-bit carbon|
|-------|-------|-------|-------------|
|16     |142.151|1      |7-bit carbons|
|-------|-------|-------|-------------|
|17     |144.669|2      |13,16 carbon |
|-------|-------|-------|-------------|
|18     |156.137|1      |3-bit carbon |
|-------|-------|-------|-------------|
|19     |159.846|1      |18-bit carbon|
|-------|-------|-------|-------------|
|20     |170.202|1      |19-bit carbon|
---------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 22 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 21 carbon atoms, and the carbon 



displacement of each group could be reasonably assigned. The NMR data 



were in good agreement with the target compounds. 



**b, Mass spectrometry (MS)** 



Detection instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Analytical method: Chinese Pharmacopoeia 2020 Edition of the four General 



Rules 0512 and 0431 



Test data: 



Table 3.2.S.5-29 MS data of the tested sample 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|379.28           |[M+H]+           |Molecular ion peak in|
|                 |                 |positive ion mode    |
-----------------------------------------------------------



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 475 of 542 





Page 476
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



In the positive ion mode, the detected mass-charge ratio m/z is 379.28 peak, 



which is attributed to the molecular ion peak in the positive ion mode, 



consistent with the molecular weight of the target molecule 378.43. 



**c. Chiral liquid chromatography** 



Testing instrument: Waters Acquity Arc 



Analytical methods: General Rule 0512 of the fourth part of Chinese 



Pharmacopoeia (2020 Edition) 



Test data: 



Table 3.2.S.5-30 Retention time of the tested sample 

------------------------------------------------------------
|Sample                               |Retention time (min)|
|-------------------------------------|--------------------|
|YA2304-20 Reference product (lot No.:|24.858              |
|23080401-A)                          |                    |
|-------------------------------------|--------------------|
|Control Product YA2304 (lot No.:     |20.240              |
|23091802-D)                          |                    |
------------------------------------------------------------



According to the results under 3.2.S.4.3.3 Specific attribute of product 



enantiomer methodology verification, the retention time of the main peak in 



the control product solution (YA2304-20 positioning solution) was 24.858min, 



and the retention time of the main peak in YA2304 positioning solution was 



20.240min. The separation degree between YA2304 peaks and YA2304-20 



peaks in the system suitability solution was 3.0. 



**d. Configuration confirmation** 



According to the structural analysis of the compound, Finerenone contains a 



chiral center, and Finerenone C9 is in the S configuration. According to the 



preparation process of YA2304, Finerenone is salted out with the resolution 



agent during the resolution step and separated after filtration, while the 



enantiomer YA2304-20 is dissolved in the filtrate. YA2304-20 reference 



product was prepared by caustic collection of filtrate and then refined. 



Finerenone has been proved by single crystal diffraction that C9 has an S 



configuration (see section 3.2.S.3.1 Structure and Physical and Chemical 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 476 of 542 





Page 477
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Properties for details). Based on the confirmed planar structure and the 



principle that the retention time of enantiomers is different under chiral 



chromatography conditions, the results detected by the chiral liquid 



chromatography above are as follows: It can be confirmed that the reference 



product YA2304-20 is the enantiomer of fenelidone. 



**(9.3) Content calibration** 



**Properties** 



This product should be white to white powder. 



**Moisture** 



Take about 0.1g~0.2g of this product, according to the water determination 



method (" Chinese Pharmacopoeia "2020 edition of the fourth part of the 



general rule 0832 coulometric titration method) determination, water content 



shall not exceed 2.0%. 



**Purity** 



Determination according to high performance liquid chromatography 



(General Rule 0512 of the Fourth part of Chinese Pharmacopoeia, 2020 



Edition). 



Solvent acetonitrile-water (30:70) 



Take an appropriate amount of this product from the test product solution, 



dissolve it with a solvent and dilute it into a solution containing about 0.5mg 



per 1ml. 



System suitability reserve liquid precision measure 0.6ml of test product 



solution, place it in 10ml measuring bottle, dilute it with solvent to scale, 



shake well, and then obtain. 



Precision weigh the system suitability solution YA2304 reference product 



about 20mg, put it into a 20ml measuring bottle, then accurately add the 



system suitability reserve solution 1.0ml, dissolve it with solvent and dilute it 



to the scale, shake well, and then obtain. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 477 of 542 





Page 478
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Chromatographic conditions with silica gel surface covalently bonded 



cellulose - III - (3, 5-dichlorophenyl carbamate) as filler column (CHIRALPAK 



IC, 250×4.6mm, 5μm or equivalent performance); With 20mM ammonium 



acetate buffer (pH adjusted to 3.1 with phosphoric acid) -acetonitrile (70:30) 



as mobile phase, iso-degree elution was performed for 40min; The flow rate 



was 1.0ml per minute. Column temperature was 40℃; The detection 



wavelength was 251nm; Injection volume 5µl. 



System suitability requirements In the system suitability solution 



chromatogram, the separation degree of YA2304 peaks and YA2304-20 peaks 



should be greater than 1.5. 



The test product solution and the system suitability solution were precisely 



measured and injected into the chromatograph respectively to record the 



chromatogram. According to the area normalization method, the main peak 



purity should NLT 95.0%. 



The content is measured by purity x (1- moisture). 



**(10) YA2304-52 working standard** 



The reference product YA2304-52 used in this study was derived from T 



iandi Hengyi Pharmaceutical Co., LTD. It was named D-monobenzoyl tar 



taric acid on the physical label and the reference product report. The ap 



plicant confirmed its chemical structure and content calibration, and the 



content was calculated according to 90.8%. 



Sample lot No.: 24022801-C 



Structural formula: 



Molecular formula: C11H10O 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 478 of 542 





Page 479
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Molecular weight: 254.19 



**(10.1) Preparation method of YA2304-52** 



YA2304-10-Lf1126185589 (5.0g), sodium hydroxide (1.6g), methanol 



(20ml), and water (20ml) were added to the reaction bottle at 45℃ for 2h, then 



lowered to room temperature for filtration, and the pH of the filtrate was 



adjusted to about 7. The chromatography was prepared by reversed-phase 



column under medium pressure and purified, and fractions were collected. 



Freeze-dried 0.72g white solid, YA2304-52. 



**(10.2) Structural analysis of YA2304-52 reference** 



The chemical structure of the reference product was confirmed by the 



applicant through [1] H NMR, [13] C NMR, mass spectrometry, specific curl and 



other testing means. 1H NMR and 13C NMR commissioned Changsha 



Kangpeng Pharmaceutical Co., LTD for testing. The relevant test atlas and 



commissioned test contract are detailed in section 3.2.R.7.S. The relevant test 



results and structural analysis are detailed as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Reference: TMS ( [1] H spectrum); 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 479 of 542 





Page 480
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-31 and Table 3.2.S.5-32 



Table 3.2.S.5-31 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 



















---------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attribution|
|        |           |pattern|constant (J)|number |           |
|--------|-----------|-------|------------|-------|-----------|
|1       |4.251      |s      |/           |1H     |17-OH      |
|--------|-----------|-------|------------|-------|-----------|
|2       |4.520-4.525|d      |/           |1H     |4-CH       |
|--------|-----------|-------|------------|-------|-----------|
|3       |5.329-5.335|d      |/           |1H     |3-CH       |
|--------|-----------|-------|------------|-------|-----------|
|4       |7.449-7.488|t      |7.6         |2H     |13, 15 -   |
|        |           |       |            |       |CH         |
|--------|-----------|-------|------------|-------|-----------|
|5       |7.596-7.633|t      |7.6         |1H     |14-CH      |
|--------|-----------|-------|------------|-------|-----------|
|6       |7.977-7.998|t      |7.6         |2H     |, 12 dec - |
|        |           |       |            |       |CH         |
---------------------------------------------------------------

Table 3.2.S.5-32 [13] C NMR chemical shift value and correlation spectrum 



(from high field to low field) of the tested sample 

--------------------------------------------
|Peak No.|Delta ppm|Carbon atom|Attribution|
|        |         |number     |           |
|--------|---------|-----------|-----------|
|1       |73.791   |1          |4 digit C  |
|--------|---------|-----------|-----------|
|2       |77.398   |1          |3-bit C    |
|--------|---------|-----------|-----------|
|3       |128.666  |2          |13,15 C's  |
|--------|---------|-----------|-----------|
|4       |129.110  |1          |11 bit C's |
|--------|---------|-----------|-----------|
|5       |129.701  |2          |12,16 C's  |
|--------|---------|-----------|-----------|
|6       |133.891  |1          |14 bit C   |
|--------|---------|-----------|-----------|
|7       |168.029  |1          |9 digit C's|
--------------------------------------------



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 480 of 542 





Page 481
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



1 

-------------------------------------
|8      |177.157|1      |5 digit C's|
|-------|-------|-------|-----------|
|9      |178.400|1      |2-bit C    |
-------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 8 hydrogen protons, 2 carboxyl hydrogen 



did not peak, and the hydrogen displacement of each group could be 



reasonably attributed. [13] C-NMR(DMSO- _d6_ , 100Hz) showed 11 carbon atoms, 



and the carbon displacement of each group could be reasonably assigned. 



The NMR data were in good agreement with the target compound. 



**b, Mass spectrometry (MS)** 



Testing instrument: Waters Acquity Arc-QDA liquid chromatography-mass 



spectrometry 



Analytical methods: General Rules 0512 and 0431 of the Fourth part of 



Chinese Pharmacopoeia (2020 Edition) 



Test data: 



Table 3.2.S.5-33 MS data of the tested sample 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|253.17           |[M-H]-           |Molecular ion peak in|
|                 |                 |negative ion mode    |
-----------------------------------------------------------



In the negative ion mode, the mass-charge ratio m/z is 253.17 peak, which is 



attributed to the molecular ion peak in the negative ion mode, which is 



consistent with the molecular weight of the target molecule 254.19. 



**c. Confirmation of configuration** 



Combined with the analysis of the preparation process of the reference 



product, the two chiral centers in YA2304-52 were introduced from the raw 



material YA2304-10 used in its preparation, and the two chiral centers were 



not affected in the subsequent ester hydrolysis reaction when the hydroxyl 



group was replaced and left. The molecular configuration of the reference 



product YA2304-52 and the raw material YA2304-10 is the same. The specific 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 481 of 542 





Page 482
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



rotation of raw material YA2304-10 (batch NO.: Lf1126185589) is 114.1°, 



that is, the configuration should be (2S,3S). Combined with the preparation 



technology, it can be confirmed that the reference product YA2304-52 is the 



configuration of (2S,3S), that is, the absolute configuration expressed in the 



structural formula by classical chemical correlation method. 



**(10.3) Content calibration** 



**Properties** 



This product should be like white powder. 



**Purity** 



Determination according to high performance liquid chromatography 



(General Rule 0512 of the Fourth part of Chinese Pharmacopoeia, 2020 



Edition). 



Chromatographic conditions: Philomon Comixsil RP-100 (4.6mm×250mm, 



5μm) or equivalent performance column); 0.1% sulfuric acid solution as 



mobile phase A, acetonitrile as mobile phase B; Gradient elution is performed 



according to the following table; The flow rate is 1.0ml per minute; Column 



temperature was 30℃; Sample plate temperature is 5℃; The detection 



wavelength was 210nm; And the injection volume was 20µl. 



Time (min.) Mobile phase A (%) Mobile phase B (%) 



0 86 14 



8.5 86 14 



20 35 65 



23 35 65 



25 20 80 



27 20 80 



28 86 14 



40 86 14 



Solvent 50% acetonitrile 



Take an appropriate amount of this product from the test product solution, 



weigh it accurately, dissolve and dilute it with solvent to make a solution 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 482 of 542 





Page 483
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



containing YA2304-52 about 2mg per 1ml. 



The test product solution was accurately measured 20μl and injected into the 



liquid chromatograph, and the chromatogram was recorded. The main peak 



purity should NLT 90.0% according to area normalization method. 



The content is calculated according to the purity. 



**(11) Dimethyl sulfate working standard** 



The reference product of Dimethyl sulfate used in this application comes from 



Shanghai McLean Biochemical Technology Co., LTD. It is named Dimethyl 



sulfate on the physical label, Dimethyl sulfate on the manufacturer's report, 



and Dimethyl sulfate on the invoice. The chemical structure of Dimethyl 



sulfate was confirmed by the applicant, and the content was 99.759% 



according to the manufacturer's report. 



Sample lot No.: C15128674 



Structural formula: 



Molecular formula: C2H6O4S 



Molecular weight: 126.13 



**(11.1) Structure analysis of dimethyl sulfate reference** 



The chemical structure of the reference product was confirmed by [1] the 



applicant by means of H NMR, [13] C NMR and mass spectrometry. The mass 



spectrometry was tested by the applicant by himself, [1] and the H NMR and [13] C 



NMR were tested by Changsha Kangpeng Pharmaceutical Co., LTD. The 



relevant detection graphs and the contract for entrusted testing are detailed 



in section 3.2.R.7.S. The relevant test results and structural analysis are 



detailed as follows: 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 483 of 542 





Page 484
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: CDCl3; 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-35 and Table 3.2.S.5-36 



Table 3.2. [1] H NMR chemical shift value and correlation spectrum (from high 



field to low field) of the tested sample S.5-35 













---------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attribution|
|        |           |pattern|constant (J)|number |           |
|--------|-----------|-------|------------|-------|-----------|
|1       |3.914-3.915|d      |0.6         |6H     |6, 7 - CH  |
---------------------------------------------------------------

Table 3.2.S.5-36 [13] C NMR chemical shift value and correlation spectrum 



(from high field to low field) of the tested sample 



1 

----------------------------------------------
|Peak No.|Delta ppm|Number of   |Attribution |
|        |         |carbon atoms|            |
|--------|---------|------------|------------|
|1       |58.654   |2           |6, 7-place C|
----------------------------------------------
H-NMR(CDCl3, 400Hz) shows 6 hydrogen protons, and the hydrogen 



displacement of each group can be reasonably attributed; [13] C-NMR(CDCl3, 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 484 of 542 





Page 485
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



100Hz) showed 2 carbon atoms, and the carbon displacement of each group 



could be reasonably assigned. The NMR data corresponded well with the 



target compound. 



**b, Mass spectrometry (MS)** 



Testing instrument: Agilent 8890-7010B gas chromatogram-mass 



spectrometry 



Analytical methods: 0521 and 0431 of the Four General Rules of Chinese 



Pharmacopoeia (2020 Edition) 



The results were consistent with dimethyl sulfate in the standard spectrum 



library. 



**(12) diethyl sulfate working standard** 



The reference product of Diethyl sulfate used in this study came from S 



hanghai McLean Biochemical Technology Co., LTD. It was named as Diet 



hyl sulfate on the physical label, Diethyl sulfate on the manufacturer's r 



eport and Diethyl sulfate on the invoice. The chemical structure of the p 



roduct was confirmed by the applicant and its content was 99.024% acc 



ording to the manufacturer's report. 



Sample lot No.: C14721434 



Structural formula: 



Molecular formula: C4H10O4S 



Molecular weight: 154.18 



**(12.1) Structure analysis of diethyl sulfate reference** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 485 of 542 





Page 486
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The chemical structure of the reference product was confirmed by [1] the 



applicant by means of H NMR, [13] C NMR and mass spectrometry. The mass 



spectrometry was tested by the applicant by himself, [1] and the H NMR and [13] C 



NMR were tested by Changsha Kangpeng Pharmaceutical Co., LTD. For 



details about the relevant detection graphs and contract, see section 



3.2.R.7.S. The relevant test results and structural analysis are detailed as 



follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: CDCl3; 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-37 and Table 3.2.S.5-38. 



Table 3.2.S.5-37 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 



Peak Delta ppm Peak Coupling Proton Attributio 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 486 of 542 





Page 487
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 

------------------------------------------------------------
|No.    |           |pattern|constant (J)|number |n        |
|-------|-----------|-------|------------|-------|---------|
|1      |1.366-1.401|t      |7.2         |6H     |8 or 9 - |
|       |           |       |            |       |CH       |
|-------|-----------|-------|------------|-------|---------|
|2      |4.265-4.318|q      |7.1         |4H     |6, 7 - CH|
------------------------------------------------------------



Table 3.2.S.5-38 [13] C NMR chemical shift value and correlation spectrum 



(from high field to low field) of the tested sample 



1 

------------------------------------------------
|Peak No.|Delta ppm|Number of   |Attribution   |
|        |         |carbon atoms|              |
|--------|---------|------------|--------------|
|1       |14.470   |2           |8, 9-place C  |
|--------|---------|------------|--------------|
|2       |69.426   |2           |Six, seven C's|
------------------------------------------------
H-NMR(CDCl3, 400Hz) showed 10 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. [13] C-NMR(CDCl3, 



100Hz) showed 4 carbon atoms, and the carbon displacement of each group 



could be reasonably assigned. The NMR data corresponded well with the 



target compound. 



**b, Mass spectrometry (MS)** 



Testing instrument: Agilent 8890-7010B gas chromatogram-mass 



spectrometry 



Analytical methods: 0521 and 0431 of the Four General Rules of Chinese 



Pharmacopoeia (2020 Edition) 



Detection result: It was consistent with diethyl sulfate in standard spectrum 



library. 



**(13) diisopropyl sulfate working standard** 



The reference product of Diisopropyl Sulfate used in this research applic 



ation came from Shanghai Bidd Pharmaceutical Technology Co., LTD. It 



was named diisopropyl sulfate on the physical label, diisopropyl sulfate 



on the manufacturer's report, and diisopropyl sulfate on the invoice. The 



chemical structure of the product was confirmed by the applicant. Acco 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 487 of 542 





Page 488
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



rding to the report provided by the manufacturer, the content was 97%. 



Sample lot No.: DLX318 



Structural formula: 



Molecular formula: C6H14O4S 



Molecular weight: 182.23 



**(13.1) Structure analysis of diisopropyl sulfate reference** 



The chemical structure of the reference product was confirmed by the 



applicant through [1] H NMR, [13] C NMR and mass spectrometry, among which 



the mass spectrometry was tested by the applicant himself, [1] H NMR was 



provided by Shanghai Bider Medical Technology Co., LTD., [13] and C NMR was 



tested by Changsha Kangpeng Medical Co., LTD. The relevant detection 



spectra and the contract for commissioning are detailed in section 3.2.R.7.S, 



and the relevant test results and structural analysis are detailed as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: CDCl3; 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 488 of 542 





Page 489
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-39 and Table 3.2.S.5-40. 



Table 3.2.S.5-39 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 













----------------------------------------------------------------
|Peak No.|Delta ppm|Peak   |Coupling    |Proton |ownership     |
|        |         |pattern|constant (J)|number |              |
|--------|---------|-------|------------|-------|--------------|
|1       |1.43-1.44|d      |/           |12H    |8,9,10,11 - CH|
|--------|---------|-------|------------|-------|--------------|
|2       |4.86-4.93|dt     |/           |2H     |6, 7 - CH     |
----------------------------------------------------------------

Table 3.2.S.5-40 [13] C NMR chemical shift values and correlation spectra (from 



high field to low field) of the tested sample 

-------------------------------------------------
|Peak No.|Delta ppm|Number of   |Attribution    |
|        |         |carbon atoms|               |
|--------|---------|------------|---------------|
|1       |22.518   |4           |8,9,10,11 digit|
|        |         |            |C's            |
|--------|---------|------------|---------------|
|2       |79.885   |2           |6,7 C's        |
-------------------------------------------------



1 
H-NMR(CDCl3, 400Hz) showed 14 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. [13] C-NMR(CDCl3, 



100Hz) showed 6 carbon atoms, and the carbon displacement of each group 



could be reasonably assigned. The NMR data corresponded well with the 



target compound. 



**b, Mass spectrometry (MS)** 



Testing instrument: Agilent 8890-7010B gas chromatogram-mass 



spectrometry 



Analytical methods: 0521 and 0431 of the Four General Rules of Chinese 



Pharmacopoeia (2020 Edition) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 489 of 542 





Page 490
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Test data: 



Table 3.2.S.5-41 MS data of the tested sample 

--------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note        |
|(m/z)            |                 |                  |
|-----------------|-----------------|------------------|
|183.0000         |[M]+             |Molecular ion peak|
|-----------------|-----------------|------------------|
|167.1000         |[M-CH3]+         |Fragment ion peak |
|-----------------|-----------------|------------------|
|138.9000         |[M-CHCH3CH3]+    |Fragment ion peak |
--------------------------------------------------------



The molecular weight of the target is 182.23, and the molecular ion peak of 



the mass-charge ratio of 183.0000 was detected, which is consistent with the 



target molecule. The mass-charge ratio of 167.1000 and 138.9000 was 



detected, which is attributed to the molecular fragment peak after cracking off 



a methyl group and a propyl group, which is consistent with the target 



molecule. 



**(14) disec-butylsulfate working standard** 



The reference product of sec-butyl sulfate used in the process of this st 



udy was from Tiandi Hengyi Pharmaceutical Co., LTD. It was named as 



sec-butyl sulfate on the physical label and the reference product report. 



The applicant confirmed its chemical structure and content calibration, 



and the content was calculated according to 99.7%. 



Sample lot No.: 23110207-H 



Structural formula: 



Molecular formula: C8H18O4S 



Molecular weight: 210.29 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 490 of 542 





Page 491
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**(14.1) Preparation method of disec-butyl sulfate** 



Boric acid (30 g), secondary butanol (360 g) and toluene (200 ml) were added 



into the reaction bottle, and the reaction was continued for 1 h after the reflux 



water separation reaction to anhydrous formation at 135℃. Control the 



temperature below 55℃ and concentrate under pressure (until the 



concentration weighs 100 g), add dichloromethane (100 ml) to dissolve, cool 



down to 0℃, drop concentrated sulfuric acid (55 g), after dripping, keep warm 



at 25~30℃ for 24 h, add dichloromethane, filter, wash organic layer three 



times, wash saturated salt water once, dry anhydrous sodium sulfate. 



Control the temperature below 50℃ vacuum concentration without distillate, 



light yellow oil that is di-sec-butylsulfate. 



**(14.2) Analysis of the structure of disec-butylsulfate reference** 



The chemical structure of the reference product was confirmed by the 



applicant through [1] H NMR, [13] C NMR, mass spectrometry and other detection 



means. The mass spectrometry was tested by the applicant, and the [1] H NMR 



and [13] C NMR were tested by Changsha Kangpeng Pharmaceutical Co., LTD., 



the relevant detection spectrum and the contract for entrusted testing are 



detailed in section 3.2.R.7.S. The relevant test results and structural analysis 



are as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: CDCl3; 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 491 of 542 





Page 492
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-42 and Table 3.2.S.5-43 



Table 3.2.S.5-42 [1] H NMR chemical shift value and correlation spectrum of the 



tested sample (from high field to low field) 






















--------------------------------------------------------------
|Peak No.|Delta ppm  |Peak   |Coupling    |Proton |Attributio|
|        |           |pattern|constant (J)|number |n         |
|--------|-----------|-------|------------|-------|----------|
|1       |0.963-1.000|t      |7.2         |6H     |9, 13 - CH|
|--------|-----------|-------|------------|-------|----------|
|2       |1.412-1.428|d      |6.4         |6H     |7, 11 - CH|
|--------|-----------|-------|------------|-------|----------|
|3       |1.679-1.781|m      |/           |4H     |8, 12 - CH|
|--------|-----------|-------|------------|-------|----------|
|4       |4.695-4.742|m      |/           |2H     |6, 10 - CH|
--------------------------------------------------------------

Table 3.2.S.5-43 [13] C NMR chemical shift value and correlation spectrum 



(from high field to low field) of the tested sample 

---------------------------------------------
|Peak No.|Delta ppm|Number of   |Attribution|
|        |         |carbon atoms|           |
|--------|---------|------------|-----------|
|1       |9.175    |1           |9 Place C  |
|--------|---------|------------|-----------|
|2       |9.194    |1           |13 bit C   |
|--------|---------|------------|-----------|
|3       |19.820   |1           |7 digit C's|
|--------|---------|------------|-----------|
|4       |19.839   |1           |11 bit C   |
|--------|---------|------------|-----------|
|5       |29.239   |1           |8-bit C    |
---------------------------------------------



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 492 of 542 





Page 493
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 

----------------------------------
|6      |29.291 |1      |12 bit C|
|-------|-------|-------|--------|
|7      |84.508 |2      |6,10 C's|
----------------------------------



1 
H-NMR(CDCl3, 400Hz) showed 18 hydrogen protons, and the hydrogen 



displacement of each group could be reasonably attributed. [13] C-NMR(CDCl3, 



100Hz) showed 8 carbon atoms, and the carbon displacement of each group 



could be reasonably assigned. The NMR data corresponded well with the 



target compound. 



**b, Mass spectrometry (MS)** 



Testing instrument: Agilent 8890-7010B gas chromatogram-mass 



spectrometry 



Analytical methods: 0521 and 0431 of the Four General Rules of Chinese 



Pharmacopoeia (2020 Edition) 



Test data: 



Table 3.2.S.5-44 MS data of the tested sample 

-------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Remarks          |
|(m/z)            |                 |                 |
|-----------------|-----------------|-----------------|
|194.9987         |[M-CH3]+         |Fragment ion peak|
|-----------------|-----------------|                 |
|180.9999         |[M-C2H5]+        |                 |
|-----------------|-----------------|                 |
|152.9994         |[M-CHCH2CH3CH3]+ |                 |
|-----------------|-----------------|                 |
|57.1996          |-CHCH2CH3CH3+    |                 |
-------------------------------------------------------



The molecular weight of the target was 210.29, and the detected 



mass-to-charge ratio was 194.9987, 180.9999 and 152.9994, which belonged 



to the molecular fragment peak after splitting one methyl group, one ethyl 



group and one butyl group. The mass-to-charge ratio of 57.1996 was the 



butyl fragment peak, which was consistent with the target molecule. 



**(14.3) Content calibration** 



**Properties** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 493 of 542 





Page 494
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



This product should be light yellow oily liquid. 



**Moisture** 



Take about 0.1~0.3g of this product, according to the water determination 



method (" Chinese Pharmacopoeia "2020 edition of the fourth part of the 



general rule 0832 Coulometric titration method) determination, water content 



should not exceed 1.0%. 



**Purity** 



Determination by gas chromatography (General Rule 0521 of the Fourth part 



of Chinese Pharmacopoeia, 2020 Edition). 



The capillary column with 100% dimethylpolysiloxane (DB-1, 30m×0.32mm, 



1μm or similar polarity) as fixed liquid was used as the chromatographic 



column; The initial column temperature was 50℃ for 3min, and then it was 



heated up to 135℃ at the rate of 10℃/min for 9min, and then heated up to 



230℃ at the rate of 20℃/min for 14.5min. Inlet temperature: 150 ° C; The 



detector is FID detector, the temperature is 250℃; (Recommended carrier gas 



nitrogen, carrier gas flow rate of 3.0ml/min; The air flow rate is 300ml/min; 



Hydrogen flow rate is 30ml/min; The injection volume is 1μl and the shunt 



ratio is 5:1) 



Solvent acetonitrile 



Preparation of test product solution: Take about 70mg of this product, weigh 



it accurately, put it in a 10ml measuring bottle, add acetonitrile to dissolve, 



dilute with acetonitrile to the scale, shake well, as test product solution. 



Determination method: Precisely measure the above test product solution 1µl, 



inject it into the liquid chromatograph, record the chromatogram, according 



to the area normalization method, the main peak purity shall NLT 95.0%. 



The content is measured by purity × (1-moisture). 



**(15) YA2304 working standard** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 494 of 542 





Page 495
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The reference product YA2304 used in this study was derived from Tian 



di Hengyi Pharmaceutical Co., LTD. It was named Finerenone on the ph 



ysical label and the reference product report. The chemical structure of 



YA2304 was confirmed by the applicant and its content was calibrated. 



The content was 99.7%. 



Sample lot No.: 23091802-D 



Structural formula: 



Molecular formula: C21H22O3N 



Molecular weight: 378.43 



**(15.1) Preparation method of YA2304** 



YA2304-cp (613g) and ethanol (9.81kg) were added to the reactor, and the 



system was heated to 70-80℃ and stirred to dissolve, and then filtered while 



hot. Most of the ethanol was concentrated under pressure at 55℃ and the 



total volume of residual distillate was about 4L. The system was stirred at 



30-40℃ for about 15 h. The temperature was lowered to 0-5℃ and stirred for 



2.0 h. The filter cake was washed with 0-5℃ ethanol (1.5kg), and the filter 



cake was vacuum-dried at 55℃ to obtain white solid (534.8g). 



**(15.2) Structural analysis of YA2304** 



The chemical structure of the reference product was confirmed by [1] the 



applicant by means of H NMR, [13] C NMR, mass spectrometry and chiral liquid 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 495 of 542 





Page 496
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



chromatography. The mass spectrometry and chiral liquid chromatography 



were tested by the applicant by himself, [1] and the H NMR and [13] C NMR were 



tested by Changsha Kangpeng Pharmaceutical Co., LTD. The relevant test 



results and structural analysis are listed as follows: 



**a. Nuclear Magnetic Resonance (NMR)** 



Instrument model: Bruker Avance AV 400 superconducting pulse Fourier 



transform nuclear magnetic resonance spectrometer 



Test conditions: 



Solvent: DMSO; 



Reference: TMS ( [1] H spectrum); 



Resonance frequency of hydrogen spectrum: 400MHz 



Resonant frequency of carbon spectrum: 100MHz 



The number of the hydrocarbon atom in the structure (non-systematic n 



aming, only used for hydrocarbon magnetic spectrum analysis) 



The test data and analytical results of hydrocarbon spectra are shown i 



n Table 3.2.S.5-45 and Table 3.2.S.5-46. 



Table 3.2.S.5-45 [1] H NMR chemical shift value and correlation spectrum (from 



high field to low field) of the tested sample 



Peak Delta ppm Peak Coupling Proton Attributio 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 496 of 542 





Page 497
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 

----------------------------------------------------------
|No.    |           |pattern|constant (J)|number |n      |
|-------|-----------|-------|------------|-------|-------|
|1      |1.038-1.073|t      |7.2         |3H     |27-CH3 |
|-------|-----------|-------|------------|-------|-------|
|2      |2.128      |s      |/           |3H     |28-CH3 |
|-------|-----------|-------|------------|-------|-------|
|3      |2.204      |s      |/           |3H     |22-CH3 |
|-------|-----------|-------|------------|-------|-------|
|4      |3.835      |s      |/           |3H     |24-CH3 |
|-------|-----------|-------|------------|-------|-------|
|5      |4.010-4.034|qd     |7.2         |2H     |26-CH2 |
|-------|-----------|-------|------------|-------|-------|
|6      |5.394      |s      |/           |1H     |9-CH   |
|-------|-----------|-------|------------|-------|-------|
|7      |6.707-6.783|bs     |/           |2H     |20-NH2 |
|-------|-----------|-------|------------|-------|-------|
|8      |7.158-7.178|d      |8.0         |1H     |4-CH   |
|-------|-----------|-------|------------|-------|-------|
|9      |7.276-7.299|dd     |8.0, 1.2    |1H     |5-CH   |
|-------|-----------|-------|------------|-------|-------|
|10     |7.377-7.380|d      |1.2         |1H     |1-CH   |
|-------|-----------|-------|------------|-------|-------|
|11     |7.560-7.561|s      |0.4         |1H     |16-CH  |
|-------|-----------|-------|------------|-------|-------|
|12     |7.705      |s      |/           |1H     |12-NH  |
----------------------------------------------------------



Table 3.2.S.5-46 [13] C NMR chemical shift value and correlation spectrum 



(from high field to low field) of the tested sample 



1 

------------------------------------------------
|Peak No.|Delta ppm|Number of   |Attribution   |
|        |         |carbon atoms|              |
|--------|---------|------------|--------------|
|1       |14.202   |1           |28-bit carbon |
|--------|---------|------------|--------------|
|2       |14.739   |1           |27-bit carbon |
|--------|---------|------------|--------------|
|3       |18.521   |1           |Twenty-two    |
|        |         |            |carbon        |
|--------|---------|------------|--------------|
|4       |32.872   |1           |9-bit carbons |
|--------|---------|------------|--------------|
|5       |56.509   |1           |24-place      |
|        |         |            |carbon        |
|--------|---------|------------|--------------|
|6       |61.005   |1           |26-bit carbon |
|--------|---------|------------|--------------|
|7       |103.640  |1           |14-bit carbon |
|--------|---------|------------|--------------|
|8       |105.784  |1           |10-bit carbon |
|--------|---------|------------|--------------|
|9       |109.983  |1           |2-place       |
|        |         |            |carbons       |
|--------|---------|------------|--------------|
|10      |111.909  |1           |15-place      |
|        |         |            |carbon        |
|--------|---------|------------|--------------|
|11      |114.588  |1           |1 bit carbon  |
|--------|---------|------------|--------------|
|12      |119.434  |1           |6-place carbon|
|--------|---------|------------|--------------|
|13      |125.223  |1           |5-bit carbon  |
|--------|---------|------------|--------------|
|14      |131.363  |1           |4-place       |
|        |         |            |carbons       |
|--------|---------|------------|--------------|
|15      |138.616  |1           |11-bit carbon |
|--------|---------|------------|--------------|
|16      |142.150  |1           |7-bit carbons |
|--------|---------|------------|--------------|
|17      |144.646  |1           |13-bit carbon |
|--------|---------|------------|--------------|
|18      |144.674  |1           |16-bit carbon |
|--------|---------|------------|--------------|
|19      |156.138  |1           |3-site carbon |
|--------|---------|------------|--------------|
|20      |159.843  |1           |18-bit carbon |
|--------|---------|------------|--------------|
|21      |170.190  |1           |19-bit carbon |
------------------------------------------------
H-NMR(DMSO-d6, 400Hz) showed 22 hydrogen protons, and the hydrogen 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 497 of 542 





Page 498
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



displacement of each group could be reasonably attributed. 



13C-NMR(DMSO- _d6_ , 100Hz) showed 21 carbon atoms, and the carbon 



displacement of each group could be reasonably assigned. The NMR data 



were in good agreement with the target compounds. 



**b, Mass spectrometry (MS)** 



Detection instrument: Vanquish-TSQ QUANTIS liquid chromatography-mass 



spectrometry 



Analytical method: Chinese Pharmacopoeia 2020 Edition of the four General 



Rules 0512 and 0431 



Test data: See Table 3.2.S.5-47 



Table 3.2.S.5-47 MS data of the tested sample 

-----------------------------------------------------------
|Mass-charge ratio|Corresponding ion|Spare note           |
|(m/z)            |                 |                     |
|-----------------|-----------------|---------------------|
|379.27           |[M+H]+           |Molecular ion peak in|
|                 |                 |positive ion mode    |
-----------------------------------------------------------



In the positive ion mode, the mass-charge ratio m/z is detected as 379.27 



peak, which is attributed to the molecular ion peak in the positive ion mode, 



consistent with the molecular weight of the target molecule 378.43. 



**c. Chiral liquid chromatography** 



Testing instrument: Waters Acquity Arc 



Analytical methods: General Rule 0512 of the fourth part of Chinese 



Pharmacopoeia (2020 Edition) 



Test data: 



Table 3.2.S.5-48 Retention time of the tested sample 

------------------------------------------------------------
|Sample                               |Retention time (min)|
|-------------------------------------|--------------------|
|YA2304-20 Reference product (lot No.:|24.858              |
|23080401-A)                          |                    |
|-------------------------------------|--------------------|
|Control Product YA2304 (lot No.:     |20.240              |
|23091802-D)                          |                    |
------------------------------------------------------------



According to the results under 3.2.S.4.3.3 Specific attribute of product 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 498 of 542 





Page 499
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



enantiomer methodology verification, the retention time of the main peak in 



the control product solution (YA2304-20 positioning solution) was 24.858min, 



and the retention time of the main peak in YA2304 positioning solution was 



20.240min. The separation degree between YA2304 peaks and YA2304-20 



peaks in the system suitability solution was 3.0. 



**d. Configuration confirmation** 



There is a chiral center in the molecular structure of fineridone, and C9 in the 



structure of Fineridone is S configuration. The applicant has carried out 



single crystal diffraction detection on the sample of Fineridone prepared by 



registered process (lot No.: 231101), and confirmed that its three-dimensional 



structure is consistent with the theory. The preparation process of the 



reference product in this batch is consistent with the registered process, so its 



configuration can be confirmed as S configuration. 



**(15.3) Content calibration** 



**Properties** 



This product should be white to yellow powder. 



**Moisture** 



Take about 0.1g~0.2g of this product, according to the water determination 



method (" Chinese Pharmacopoeia "2020 edition of the fourth part of the 



general rule 0832 Coulometric titration method) determination, water content 



should not exceed 0.5%. 



**Incandescent residue** 



Take about 1.0g of this product, according to the method of incandescent 



residue inspection (" Chinese Pharmacopoeia "2020 edition of the fourth part 



of the General Rule 0841) determination, residual residue shall not exceed 



0.1%. 



**Purity** 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 499 of 542 





Page 500
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Determination according to high performance liquid chromatography 



(General Rule 0512 of the Fourth part of Chinese Pharmacopoeia, 2020 



Edition). 



Chromatographic conditions: octadecylsilane bonded silica gel was used as 



filler (XBridge Shield RP18, 150*4.6mm, 3.5μm or equivalent performance 



column); Welch Ghost-Buster Column (4.6×50mm, or equivalent 



ghost-buster column) was installed after the mixer of the pump and before the 



sampler. 0.03% phosphoric acid solution was used as mobile phase A and 



acetonitrile as mobile phase B; Gradient elution is performed according to the 



following table; Column temperature is 25℃; The detection wavelength was 



251nm; The flow rate was 1.0mL per minute; The injection volume was 5µl. 




Mobile 
Time /min 

phase A/% 




Mobile 



phase B/% 




0 95 5 



16.5 50 50 



17 20 80 



22 20 80 



22.5 95 5 



35 95 5 



Solvent 30% acetonitrile 



Appropriate amount of this product is taken from the test product solution, 



accurately weighed, dissolved and diluted with solvent to make a solution 



containing Finerenone of about 0.25mg per 1ml. 



The main peak purity was NLT 99.0% according to area normalization method. 



5μl of test solution was injected into liquid chromatograph. 



The content is measured by purity × (1- moisture - incandescent residue). 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 500 of 542 





Page 501
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.6** **Container Closure System** 



**I. Description of Container Closure System** 



The container closure system of Finerenone manufactured by Hinye 



Pharmaceutical Co., Ltd. consists of pharmaceutical grade low-density 



polyethylene (LDPE) bag as primary packaging and cardboard drum as 



secondary packaging. 



The packaging procedure is as follows: 



**Primary packaging:** The drug substance is weighed and packed with 



double-layered pharmaceutical grade low-density polyethylene (LDPE) bag 



according to the package size. Lock and seal with cable tie, and transfer to the 



outside packaging room through the transfer window. 



**Secondary packaging:** Put it into cardboard drum as one bag per drum, and 



seal. Fill in packaging label, and affix it to the outside of the drum. 



**Package size:** 0.5 kg/drum, 1.0 kg/drum, 2.0 kg/drum, 3.0 kg/drum, 5.0 



kg/drum, 10.0 kg/drum. 



**II. Specification of Packaging Materials** 



**Primary Packaging Material** 



The specification and analytical method of pharmaceutical grade low-density 



polyethylene (LDPE) bag established by the applicant is as follows: 



Table 3.2.S.6-1 Acceptance Criteria of pharmaceutical grade low-density 



polyethylene (LDPE) bag 









-----------------------------------------------------
|Test item |Acceptance criteria                     |
|----------|----------------------------------------|
|Appearance|The surface should be smooth, uniform in|
|          |color, and free of holes, foreign       |
|          |matters, odors, and conglutination. The |
|          |heat-sealed part of the bag should be   |
|          |flat and free of defects.               |
-----------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 501 of 542 





Page 502
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 






















--------------------------------------------------------------------------
|Test item                      |Acceptance criteria                     |
|-------------------------------|----------------------------------------|
|Size                           |Length: 1100 ± 5mm; Width: 810 ± 5mm; |  
|-------------------------------|----------------------------------------|
|Test      |density             |0.910～0.935g/cm3                       | 
|          |--------------------|----------------------------------------|
|          |Residue on ignition |NMT 0.1%                                |
|----------|--------------------|----------------------------------------|
|Extractabl|Easy oxide          |The difference between the titration    |
|es Test   |                    |volumes is NMT 1.5 mL.                  |
|          |--------------------|----------------------------------------|
|          |Heavy metals        |NMT 1ppm.                               |
|          |--------------------|----------------------------------------|
|          |Non-volati|Water    |The residue of the water extract is NMT |
|          |le        |         |30.0 mg comparing to the blank solution.|
|          |substance |         |                                        |
|          |s         |         |                                        |
|          |          |---------|----------------------------------------|
|          |          |65%      |The residue of the 65% ethanol extract  |
|          |          |Ethanol  |is NMT 30.0 mg comparing to the blank   |
|          |          |         |solution.                               |
|          |          |---------|----------------------------------------|
|          |          |n-Hexa ne|The residue of the n-hexane extract is  |
|          |          |         |NMT 30.0 mg comparing to the blank      |
|          |          |         |solution.                               |
|----------|----------|         |----------------------------------------|
|Microbial |Total aerobic       |NMT 1000 CFU/100 cm2.                   |
|limit     |microbial count     |                                        |
|          |(TAMC)              |                                        |
|          |--------------------|----------------------------------------|
|          |Total yeasts and    |NMT 100 CFU/100 cm2.                    |
|          |moulds count (TYMC) |                                        |
|          |--------------------|----------------------------------------|
|          |Escherichia coli    |Absence of Escherichia coli             |
--------------------------------------------------------------------------

**Test Methods for pharmaceutical grade low-density polyethylene (LDPE)** 



**bag** 



**Appearance** 



Take an appropriate amount of sample, and look directly at it in a bright 



environment with natural light. The surface should be smooth, uniform in 



color, and free of holes, foreign matters, odors, and conglutination. The 



heat-sealed part of the bag should be flat and free of defects. Except for 



“NB046” which is black, all other parts should be transparent. 



**Size** 



Take an appropriate amount of sample and measure the length and width 



with a ruler, which should comply with the acceptance criteria. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 502 of 542 





Page 503
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Length: 1100 ± 5mm; Width: 810 ± 5mm. 



**Test** 



**Density** 



The sample should be placed in an environment with a temperature of 



(23±2)℃ and a relative humidity of (50±5)% for more than 4h, and then 



perform the test under these conditions. Weigh accurately about 2g of sample, 



immerse it with anhydrous ethanol. (The density of the immersion liquid is 



generally less than the density of the sample. When the material density is 



greater than 1, use water as immersion liquid. When the material density is 



less than 1, use anhydrous ethanol). 



Take an appropriate amount of the sample, place it on the balance, weigh 



accurately and record the mass in the air (a). Then place the sample in a 



certain amount of immersion liquid anhydrous ethanol with a known density 



(ρx), weigh accurately and record the mass (b). The upper end of the sample 



should NLT 10 mm from the liquid surface, and air bubbles should not 



adhere to the surface of the sample. The density of the sample is calculated by 



the following formula. The density should be 0.910～0.935 g/cm3. 



_a_   _x_ 
  
_a_  _b_ 



**Residue on ignition:** 



NMT 0.10 %, using 1.0 g.Examine by _Determination of Residue on Ignition._ 



**Extractables Test** 



Test solution: unless otherwise specified, take an appropriate amount of 



sample, and take three pieces of the sample with an inner surface area of 



about 600 cm [2] each (divided into small pieces of 3 cm in length and 0.3 cm in 



width), place these small pieces in three conical flasks with stoppers, 



respectively, add 200 mL of water (70℃ ± 2℃), 65% ethanol (70℃ ± 2℃), 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 503 of 542 





Page 504
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



n-hexane (58℃ ± 2℃), respectively. After soaking for 2h, take it out, let it cool 



to room temperature, and compensate to original volume using the same 



solvent, and use the obtained solutions as the test solutions (water-extracting 



solution, ethanol-extracting solution, and _n_ -hexane extracting solution). 



Prepare each blank solution in same manner using the same batch of water, 



65% ethanol, and _n_ -hexane respectively. 



**Heavy metals** 



Measure accurately 20 mL of the water-extracting solution, add 2 mL of 



acetate buffer solution (pH 3.5). Perform the test according to the "Operating 



Procedures for the Test of Heavy Metals" (Method 1). The heavy metals is NMT 



1 ppm. 



**Easy oxide** 



Precisely measure 20ml of the water-extracting solution, add 20ml of 



0.002mol/L potassium permanganate titration solution and 1ml of dilute 



sulfuric acid, boil for 3min, and cool rapidly. Add 0.1 g of potassium iodide, 



allow to stand protected from light for 5min, and titrate with 0.01 mol/L 



sodium thiosulfate titration solution. When the titration is near the end point, 



add 5 drops of starch indicator solution, continue to titrate until it becomes 



colorless. Perform a blank titration using 20 mL of the bank solution, The 



difference between the titration volumes is NMT 1.5 mL. 



**Non-volatile substances** 



Measure 100 mL of water-extracting solution, 65% ethanol-extracting 



solutioN, N-hexane extracting solution and the respective blank solution. 



Place them in an evaporating dish that has been dried to a constant weight, 



evaporate in a water bath, then dry at 105℃ for 2h, and weigh the residue 



accurately after cooling. 



The residue of the water extract is NMT 30.0 mg comparing to the blank 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 504 of 542 





Page 505
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



solution. The residue of the 65% ethanol extract is NMT 30.0 mg comparing to 



the blank solution. The residue of the n-hexane extract is NMT 30.0 mg 



comparing to the blank solution. 



**Microbial limits** 



Take the sample and press it on the inner surface with a sterilized metal plate 



with hole area of 20 cm [2] . Slightly moisten the sterile cotton swab with 0.9% 



sterile sodium chloride solution. Use a cotton swab to wipe the hole area of 



the plate 5 times, then use another cotton swab to wipe 5 times. That is to 



say,wipe each hole area with 2 cotton swabs 10 times totally. Wipe 5 hole 



areas with a total area of 100 cm [2] . 



Cut each cotton swab immediately after being used, and put it into an conical 



flask (or large test tube) containing 30 mL of 0.9% sterile sodium chloride 



solution. Put all the cotton swabs into the conical flask (or large test tube), 



shake immediately for 1min to get the sample solution. 



Perform the test with sample solution according to _Operating Procedures for_ 



_the Test of Microbial Limit_ . The acceptance criteria of total aerobic microbial 



count (TAMC) and total yeasts and moulds count (TYMC) are 1000 cfu/100 



cm [2] and 100 cfu/100 cm [2] , respectively. _Escherichia coli_ is not observed. 



The copy of typical COA of pharmaceutical grade low-density polyethylene 



(LDPE) bag analyzed by Hinye Pharmaceutical Co., Ltd. and corresponding 



translation are annexed. 



3.2.S.6 Annex 1 COA of pharmaceutical grade low-density polyethylene 



(LDPE) bag analyzed by Hinye Pharmaceutical Co., Ltd.(Batch No. ) 



3.2.S.6 Annex 2 English translation of COA of pharmaceutical grade 



low-density polyethylene (LDPE) bag analyzed by Hinye Pharmaceutical Co., 



Ltd.(Batch No. ) 



3.2.S.6 Annex 3 COA of pharmaceutical grade low-density polyethylene 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 505 of 542 





Page 506
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



(LDPE) bag analyzed by Hinye Pharmaceutical Co., Ltd.(Batch No. ) 



3.2.S.6 Annex 4 English translation of COA of pharmaceutical grade 



low-density polyethylene (LDPE) bag analyzed by QHinye Pharmaceutical Co., 



Ltd.(Batch No. ) 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 506 of 542 





Page 507
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**Secondary Packaging Material** 



The specification and analytical method of cardboard drum established by the 



applicant is as follows: 



Table 3.2.S.6-2 Acceptance Criteria of Cardboard Drum 















-----------------------------------------------------------------------------
|Test item       |Acceptance criteria                                       |
|----------------|----------------------------------------------------------|
|Appeara|Surfac e|The surface is smooth, clean and free from pollution      |
|nce    |        |and other abnormal conditions.                            |
|       |--------|----------------------------------------------------------|
|       |Size    |Inner diameter × height: (310 mm ± 5 mm) × (410 mm ± 5|    
|       |        |mm)                                                       |
|       |        |----------------------------------------------------------|
|       |        |Inner diameter × height: (450 mm ± 5 mm) × (500 mm ± 5|    
|       |        |mm)                                                       |
|-------|--------|----------------------------------------------------------|
|Material and    |The sidewall is convolutely yellow paperboard. The        |
|construction    |cover and bottom are wood boards locking into sidewall    |
|                |with a stainless steel hoop.                              |
-----------------------------------------------------------------------------

**Test Methods for Cardboard Drum** 



**Appearance** 



**Surface** 



Visual inspection. The surface is smooth, clean and free from pollution and 



other abnormal conditions. 



**Size** 



Measure the inner diameter and height of the cardboard with rule. The size 



should comply with the requirements below: 

---------------------------------------------
|Material code|Inner diameter|Inner height  |
|-------------|--------------|--------------|
|WB081        |310 mm ± 5 mm|410 mm ± 5 mm|  
|-------------|--------------|--------------|
|WB465        |450 mm ± 5 mm|500 mm ± 5 mm|  
---------------------------------------------



**Material** 



Visual inspection. The sidewall is convolutely yellow paperboard. The cover 



and bottom are wood boards locking into sidewall with a stainless steel hoop. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 507 of 542 





Page 508
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



The copy of typical COA of cardboard drum analyzed by Hinye 



Pharmaceutical Co., Ltd. and corresponding translation are annexed. 



_3.2.S.6 Annex 5_ _COA of cardboard drum analyzed by Hinye Pharmaceutical_ 



_Co., Ltd._ 



_3.2.S.6 Annex 6_ _English translation of COA of cardboard drum analyzed by_ 



_Hinye Pharmaceutical Co., Ltd._ 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 508 of 542 





Page 509
**Drug Master File of Finerenone** 
Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**III. Annexes: COAs** 



3.2.S.6 Annex 1 COA of pharmaceutical grade low-density polyethylene 



(LDPE) bag analyzed by Hinye Pharmaceutical Co., Ltd. (Batch No. ) 



3.2.S.6 Annex 2 English translation of COA of pharmaceutical grade 



low-density polyethylene (LDPE) bag analyzed by Hinye Pharmaceutical Co., 



Ltd.(Batch No. ) 



3.2.S.6 Annex 3 COA of pharmaceutical grade low-density polyethylene 



(LDPE) bag analyzed by Hinye Pharmaceutical Co., Ltd.(Batch No. ) 



3.2.S.6 Annex 4 English translation of COA of pharmaceutical grade 



low-density polyethylene (LDPE) bag analyzed by Hinye Pharmaceutical Co., 



Ltd.(Batch No. ) 



3.2.S.6 Annex 5 COA of cardboard drum analyzed by Hinye Pharmaceutical 



Co., Ltd.(Batch No. ) 



3.2.S.6 Annex 6 English translation of COA of cardboard drum analyzed by 



Hinye Pharmaceutical Co., Ltd. (Batch No. 1 ) 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 509 of 542 





Page 510
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.7 Stability** 



**3.2.S.7.1** **Stability Summary and Conclusions** 



**Batch Tested** 



Long-term and accelerated stability studies were carried out on three 



validation batches (batch No. 231201, 240101 and 240102, batch size: 10 



kg). 



Stress testing was carried out on one Commercial scale batch (batch No. 



240101). It included the effect of high temperature (60 ℃), high humidity 



(92.5% RH, 25℃) and illumination (visible light: 4500±500 LX; near 



ultraviolet: 90±5 μW/cm [2] , 25℃) on Finerenone without packaging. 



The stability batch information and studies conducted are summarized in 



Table 3.2.S.7.1-1. 



**Stability Protocol of Long-term Stability** 



Storage condition: 30℃±2℃/65%RH±5%RH. 



Packaging: double-layered pharmaceutical grade low-density polyethylene 



(LDPE) bag. 



Study period: 4 years for the three validation batches (batch No. 231201, 



240101 and 240102). 



Test points: 0, 3, 6, 9, 12, 18, 24, 36, 48 months for the validation batches 



(batch No. 231201, 240101 and 240102) as needed. 



**Stability Protocol of Accelerated Stability** 



Storage condition: 40℃±2℃/75%RH±5%RH 



Packaging: double-layered pharmaceutical grade low-density polyethylene 



(LDPE) bag. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 510 of 542 





Page 511
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Study period: 6 months. 



Test points: 0, 3, 6 months for the validation batches (batch No.: 231201, 



240101 and 240102). 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 511 of 542 





Page 512
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 
















--------------------------------------------------------------------------------------------------------------------
|Batch No.              |Validation batches                                                                        |
|                       |------------------------------------------------------------------------------------------|
|                       |231201                    |240101                         |240102                         |
|-----------------------|--------------------------|-------------------------------|-------------------------------|
|Batch size             |10 kg                     |10 kg                          |10 kg                          |
|-----------------------|--------------------------|-------------------------------|-------------------------------|
|Manufacturing date     |Jan. 2024                 |Jan. 2024                      |Jan. 2024                      |
|-----------------------|--------------------------|-------------------------------|-------------------------------|
|Stability studies      |Stress test, Long-term,   |Long-term, accelerated         |Long-term, accelerated         |
|                       |accelerated               |                               |                               |
|-----------------------|--------------------------|-------------------------------|-------------------------------|
|starting time          |Sept. 12, 2022            |Sept. 12, 2022                 |Sept. 12, 2022                 |
|-----------------------|--------------------------|-------------------------------|-------------------------------|
|Testing frequency (time|Stress test: 0, 5, 15, 30D|Long-term: 0, 3, 6, 9, 12, 18, |, Long-term: 0, 3, 6, 9, 12,   |
|points)                |Long-term: 0, 3, 6, 9, 12,|24, 36 48 M; Accelerated: 0, 3,|18, 24, 36 48, 60M;            |
|                       |18, 24, 36, 48,60M;       |6 M.                           |Accelerated: 0, 3, 6 M.        |
|                       |Accelerated: 0, 3, 6 M.   |                               |                               |
|-----------------------|--------------------------|-------------------------------|-------------------------------|
|Status                 |Long-term: Ongoing        |Long-term: Ongoing Accelerated:|Long-term: Ongoing Accelerated:|
|                       |Accelerated: Completed    |Completed                      |Completed                      |
|-----------------------|--------------------------|-------------------------------|-------------------------------|
|Completed time points* |Long-term: 0, 3, 6 M;     |Long-term: 0, 3, 6 M;          |Long-term: 0, 3, 6 M;          |
|                       |Accelerated: 0, 3, 6 M.   |Accelerated: 0, 3, 6 M.        |Accelerated: 0, 3, 6 M.        |
--------------------------------------------------------------------------------------------------------------------


- Stability data available are presented in section 3.2.S.7.3 




Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 512 of 542 





Page 513
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**Stability Specification and Analytical Method** 



The test items are listed in the table below. Process validation batch in the 



long-term stability study, The tests of particle size, microbial limits, XRD at 3, 



9 and 18 months are omitted. The tests of Genotoxic impurities at 3, 9, 12 



and 18 months are omitted. The stability specification is described in the 



table below. The analytical methods are referred to section 3.2.S.4.2. 



Validation of these analytical methods is described in section 3.2.S.4.3. 































-----------------------------------------------------------------------
|Test Items           |Acceptance Criteria                            |
|---------------------|-----------------------------------------------|
|Characters|Appearance|White to yellow powder                         |
|----------|----------|-----------------------------------------------|
|Tests     |Particle  |Basically consistent with the results of 0     |
|          |size      |month                                          |
|          |----------|-----------------------------------------------|
|          |Related   |YA2304-10 NMT 0.10%； YA2304-12 NMT 0.15%；    |  
|          |substances|YA2304-14 NMT 0.15%； YA2304-15 NMT 0.15%；    |  
|          |          |YA2304-16 NMT 0.15%； YA2304-17 NMT 0.15%；    |  
|          |          |YA2304-18 NMT 0.15%； YA2304-19 NMT 0.15%；    |  
|          |          |Individual unspecified impurity NMT 0.10%；    | 
|          |          |Total impurities NMT 1.0%                      |
|          |----------|-----------------------------------------------|
|          |Enantiomer|YA2304-20 NMT 0.15%                            |
|          |s         |                                               |
|          |----------|-----------------------------------------------|
|          |Genotoxic |Dimethyl sulfate NMT 75ppm; Diethyl sulfate NMT|
|          |impurities|75ppm; Diisopropyl sulfate NMT 75ppm;          |
|          |          |Disec-butyl sulfate NMT 75ppm; The sum of      |
|          |          |genotoxic impurities NMT 250ppm                |
|          |----------|-----------------------------------------------|
|          |Water     |NMT 0.5%                                       |
|          |----------|-----------------------------------------------|
|          |Microbial |TAMC: NMT 103CFU/g TYMC: NMT 102CFU/g Absence  |
|          |limits    |of Escherichia coli (1g)                       |
|----------|          |-----------------------------------------------|
|Assay                |98.0% to 102.0% (anhydrous substance).         |
|---------------------|-----------------------------------------------|
|Crystal form(XRD)    |Basically consistent with the results of 0     |
|                     |month                                          |
-----------------------------------------------------------------------

**Stability Study Conclusions, Proposed Storage Conditions and Re-test** 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 513 of 542 





Page 514
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**Period** 



The results of characters, related substances, loss on drying, assay, and 



hygroscopic weight gain of batch 240101 are qualified at condition of high 



temperature (60℃), high humidity (92.5% RH, 25℃) and photolysis (visible 



light: 4500 ± 500 LX; near ultraviolet: 90±5 μW/cm [2] , 25℃) in 30 days. The 



Finerenone drug substance has a good stability under high temperature, high 



humidity and photolysis. 



Currently 6 months of three validation batches (batch No. 231201、240101 



and 240102) has been completed. All data presented at accelerated condition 



40℃±2℃/75%RH±5%RH (6 months) and long–term condition 30℃±2℃ / 



65%RH±5%RH (6 months) met the acceptance criteria, and there is no 



significant change. 



There is no significant change at accelerated condition within 6 months. The 



data of long-term stability already conducted for 6 months met the 



acceptance criteria. No change trends are observed. The applicant request a 



retest period of 24 months for Finerenone packed in double-layered 



pharmaceutical grade low-density polyethylene (LDPE) bag. The storage 



condition is sealed storage. 



**3.2.S.7.2** **Post-approval Stability Protocol and Stability Commitment** 



We, Hinye Pharmaceutical Co., Ltd., hereby make the commitment that the 



long-term stability studies on validation batches (batch No.: 231201, 240101 



and 240102)will be continued throughout the protocol period of 4 years, 



which covers the proposed re-test period. All the stability data obtained on 



these batches will be supplied to authority. 



**Stability Protocol of Long-term Stability** 



Storage condition: 30℃±2℃ / 75%RH±5%RH. 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 514 of 542 





Page 515
**Drug Master File of Finerenone** 


Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Packaging: double-layered pharmaceutical grade low-density polyethylene 



(LDPE) bag. 



Study period: 4 years for the validation batches (batch No.: 231201, 240101 



and 240102). 



Test points: 0, 3, 6, 9, 12, 18, 24, 36 and 48 months as needed. 



Test items: Appearance, related substances, Genotoxic impurities, Water, 



microbial limits, assay, particle size distribution, crystal form. The 



acceptance criteria and test points for each item are listed in the table below. 



Analytical method: the same as the procedures described in section 3.2.S.4.2 



_Analytical Procedures_ . 



Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 515 of 542 





Page 516
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.7.2-1 Stability Specification and Test Points of Post-approval Stability Study 






















-------------------------------------------------------------------------------------------------------------------------------------
|Storage condition                                          |30°C±2°C / 65%RH±5%RH                                              |    
|-----------------------------------------------------------|-----------------------------------------------------------------------|
|Packaging                                                  |double-layered pharmaceutical grade low-density                        |
|                                                           |polyethylene (LDPE) bag                                                |
|-----------------------------------------------------------|-----------------------------------------------------------------------|
|Items             |Specifications                          |Time points (months)                                                   |
|                  |----------------------------------------|-----------------------------------------------------------------------|
|                  |                                        |0      |3      |6      |9      |12     |18     |24     |36     |48     |
|------------------|----------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|Appearance        |White to yellow powder                  |√     |√     |√     |√     |√     |√     |√     |√     |√     |         
|------------------|----------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|Related substances|YA2304-10 NMT 0.10%； YA2304-12 NMT     |√     |√     |√     |√     |√     |√     |√     |√     |√     |          
|                  |0.15%； YA2304-14 NMT 0.15%； YA2304-15 |       |       |       |       |       |       |       |       |       |  
|                  |NMT 0.15%； YA2304-16 NMT 0.15%；       |       |       |       |       |       |       |       |       |       |  
|                  |YA2304-17 NMT 0.15%； YA2304-18 NMT     |       |       |       |       |       |       |       |       |       | 
|                  |0.15%； YA2304-19 NMT 0.15%； Individual|       |       |       |       |       |       |       |       |       |  
|                  |unspecified impurity NMT 0.10%； Total  |       |       |       |       |       |       |       |       |       | 
|                  |impurities NMT 1.0%                     |       |       |       |       |       |       |       |       |       |
|------------------|----------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|Enantiomers       |YA2304-20 NMT 0.15%                     |√     |√     |√     |√     |√     |√     |√     |√     |√     |         
-------------------------------------------------------------------------------------------------------------------------------------

Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 516 of 542 





Page 517
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 




























----------------------------------------------------------------------------------------------------------------------------------
|Storage condition                                       |30°C±2°C / 65%RH±5%RH                                              |    
|--------------------------------------------------------|-----------------------------------------------------------------------|
|Packaging                                               |double-layered pharmaceutical grade low-density                        |
|                                                        |polyethylene (LDPE) bag                                                |
|--------------------------------------------------------|-----------------------------------------------------------------------|
|Items            |Specifications                        |Time points (months)                                                   |
|                 |--------------------------------------|-----------------------------------------------------------------------|
|                 |                                      |0      |3      |6      |9      |12     |18     |24     |36     |48     |
|-----------------|--------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|Genotoxic        |Dimethyl sulfate NMT 75ppm; Diethyl   |√     |×     |√     |×     |×     |×     |√     |√     |√     |         
|impurities       |sulfate NMT 75ppm; Diisopropyl sulfate|       |       |       |       |       |       |       |       |       |
|                 |NMT 75ppm; Disec-butyl sulfate NMT    |       |       |       |       |       |       |       |       |       |
|                 |75ppm; The sum of genotoxic impurities|       |       |       |       |       |       |       |       |       |
|                 |NMT 250ppm                            |       |       |       |       |       |       |       |       |       |
|-----------------|--------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|Water            |NMT 0.5%                              |√     |√     |√     |√     |√     |√     |√     |√     |√     |         
|-----------------|--------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|Microbial limits |TAMC: NMT 103CFU/g; TYMC: NMT         |√     |×     |√     |×     |√     |×     |√     |√     |√     |         
|                 |102CFU/g; Absence of Escherichia coli |       |       |       |       |       |       |       |       |       |
|                 |(1g)                                  |       |       |       |       |       |       |       |       |       |
|-----------------|--------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|Assay            |98.0% to 102.0% (Anhydrous substance).|√     |√     |√     |√     |√     |√     |√     |√     |√     |         
|-----------------|--------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|Particle size    |Basically consistent with the results |√     |×     |√     |×     |√     |×     |√     |√     |√     |         
|                 |of 0 month                            |       |       |       |       |       |       |       |       |       |
|-----------------|--------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
|Crystal form(XRD)|Basically consistent with the results |√     |×     |√     |×     |√     |×     |√     |√     |√     |         
|                 |of 0 month                            |       |       |       |       |       |       |       |       |       |
----------------------------------------------------------------------------------------------------------------------------------

Note: the cell marked with √indicates that the item will be tested at the corresponding time point; while the cell marked with 



× indicates that the item will be omitted. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 517 of 542 





Page 518
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**3.2.S.7.3** **Stability Data** 



The stability results for the three validation batches (batch No. 231201, 



240101 and 240102, batch size: 10 kg) are detailed below. 



- long term stability studies: 3.2.S.7.3 _Table 1, Table 2, Table 3._ 



- accelerated stability studies: _3.2.S.7.3_ _Table 4, Table 5, Table 6._ 



Stress testing was carried out on one batch of Finerenone (batch No. 240101). 



It included the effect of high temperature (60℃), high humidity (92.5%RH, 



25℃) and illumination (visible light: 4500 ± 500 LX; near ultraviolet: 90±5 



μW/cm [2] , 25℃). 



- high temperature: _3.2.S.7.3 Table 7_ ; 



- high humidity: _3.2.S.7.3 Table 8_ ; 



- photostability: _3.2.S.7.3 Table 9_ . 



Please note: 



- “Not Detected” is abbreviated as ‘ND’; 



- “NMT” is abbreviated as ‘NMT’. 



- “Not Test” is abbreviated as ‘--’. 



Finerenone 
Confidential Hinye Pharmaceutical Co., Ltd. 



Page 518 of 542 





Page 519
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**Long term stability studies** 



Table 3.2.S.7.3-1 Long-term Stability Data of Finerenone (Batch No. 231201) 
















-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                         |231201                              |Batch size             |10 kg                                  |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Primary package                   |double-layered pharmaceutical       |Storage condition      |30℃±2℃/ 65%RH±5%RH                 |    
|                                  |grade low-density polyethylene      |                       |                                       |
|                                  |(LDPE) bag                          |                       |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                |Jan. 06, 2024                       |Stability starting     |Feb. 04, 2024                          |
|                                  |                                    |date                   |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                   |
|----------------------------------|----------------------------------------------------------------------------------------------------|
|Items    |Specifications          |Time points (Months)                                                                                |
|         |------------------------|----------------------------------------------------------------------------------------------------|
|         |                        |0           |3           |6                 |9      |12             |18     |24     |36     |48     |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Appearanc|White to yellow powder. |white powder|white powder|white powder      |       |               |       |       |       |       |
|e        |                        |            |            |                  |       |               |       |       |       |       |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Related  |YA2304-10 NMT 0.10%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|substance|                        |            |            |                  |       |               |       |       |       |       |
|s        |                        |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-12 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-14 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-15 NMT 0.15%；   |ND          |＜0.05%     |ND                |       |               |       |       |       |       |  
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-16 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-17 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-18 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-19 NMT 0.15%；   |＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |    
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Other single impurities:|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|         |NM T 0.10%              |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Total impurity: NMT 1.0%|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 519 of 542 





Page 520
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 































---------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                           |231201                          |Batch size             |10 kg                                  |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Primary package                     |double-layered pharmaceutical   |Storage condition      |30℃±2℃/ 65%RH±5%RH                 |    
|                                    |grade low-density polyethylene  |                       |                                       |
|                                    |(LDPE) bag                      |                       |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                  |Jan. 06, 2024                   |Stability starting     |Feb. 04, 2024                          |
|                                    |                                |date                   |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                  |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                               |
|------------------------------------|------------------------------------------------------------------------------------------------|
|Items     |Specifications           |Time points (Months)                                                                            |
|          |-------------------------|------------------------------------------------------------------------------------------------|
|          |                         |0         |3         |6                 |9      |12             |18     |24     |36     |48     |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|enantiome |YA2304-20: NMT 0.15%     |0.03%     |0.03%     |0.04%             |       |               |       |       |       |       |
|rs        |                         |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|genotoxic |Dimethyl sulfate NMT 75pp|ND        |/         |ND                |       |               |       |       |       |       |
|impurities|m                        |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diethyl sulfate NMT 75ppm|ND        |/         |ND                |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diisopropyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Disec-butyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Sum of genotoxic         |ND        |/         |ND                |       |               |       |       |       |       |
|          |impurities NMT 250ppm    |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Water     |NMT 0.5%                 |0.05%     |0.1%      |0.05%             |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Microbial |TAMC: NMT 103CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|limits    |                         |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |TYMC: NMT 102CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Absence of Escherichia   |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |coli (1g)                |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Assay     |98.0% to 102.0%          |99.8%     |100.2%    |100.7%            |       |               |       |       |       |       |
|          |(anhydrous substance).   |          |          |                  |       |               |       |       |       |       |
---------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 520 of 542 





Page 521
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                          |231201                             |Batch size             |10 kg                                  |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Primary package                    |double-layered pharmaceutical      |Storage condition      |30℃±2℃/ 65%RH±5%RH                 |    
|                                   |grade low-density polyethylene     |                       |                                       |
|                                   |(LDPE) bag                         |                       |                                       |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                 |Jan. 06, 2024                      |Stability starting     |Feb. 04, 2024                          |
|                                   |                                   |date                   |                                       |
|-----------------------------------|-----------------------------------|                       |                                       |
|Manufacturing site                 |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                  |
|-----------------------------------|---------------------------------------------------------------------------------------------------|
|Items    |Specifications           |Time points (Months)                                                                               |
|         |                         |---------------------------------------------------------------------------------------------------|
|         |                         |0            |3         |6                 |9      |12             |18     |24     |36     |48     |
|---------|-------------------------|-------------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Crystal  |Basically consistent with|Complies     |/         |Complies          |       |               |       |       |       |       |
|form XRD |the results of 0 month   |             |          |                  |       |               |       |       |       |       |
|---------|-------------------------|-------------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Particle |Basically consistent with|D90: 7.712μm|/         |D90: 6.163μm     |       |               |       |       |       |       |  
|size     |the results of 0 month   |             |          |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 521 of 542 





Page 522
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.7.3-2 Long-term Stability Data of Finerenone (Batch No. 240101) 










-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                         |240101                              |Batch size             |10 kg                                  |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Primary package                   |double-layered pharmaceutical       |Storage condition      |30℃±2℃/ 65%RH±5%RH                 |    
|                                  |grade low-density polyethylene      |                       |                                       |
|                                  |(LDPE) bag                          |                       |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                |Jan. 19, 2024                       |Stability starting     |Feb. 04, 2024                          |
|                                  |                                    |date                   |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                   |
|----------------------------------|----------------------------------------------------------------------------------------------------|
|Items    |Specifications          |Time points (Months)                                                                                |
|         |------------------------|----------------------------------------------------------------------------------------------------|
|         |                        |0           |3           |6                 |9      |12             |18     |24     |36     |48     |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Appearanc|White to yellow powder. |white powder|white powder|white powder      |       |               |       |       |       |       |
|e        |                        |            |            |                  |       |               |       |       |       |       |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Related  |YA2304-10 NMT 0.10%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|substance|                        |            |            |                  |       |               |       |       |       |       |
|s        |                        |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-12 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-14 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-15 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-16 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-17 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-18 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-19 NMT 0.15%；   |＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |    
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Other single impurities:|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|         |N MT 0.10%              |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Total impurity: NMT 1.0%|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|enantiome|YA2304-20: NMT 0.15%    |0.03%       |0.04%       |0.04%             |       |               |       |       |       |       |
|rs       |                        |            |            |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 522 of 542 





Page 523
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 







































---------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                           |240101                          |Batch size             |10 kg                                  |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Primary package                     |double-layered pharmaceutical   |Storage condition      |30℃±2℃/ 65%RH±5%RH                 |    
|                                    |grade low-density polyethylene  |                       |                                       |
|                                    |(LDPE) bag                      |                       |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                  |Jan. 19, 2024                   |Stability starting     |Feb. 04, 2024                          |
|                                    |                                |date                   |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                  |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                               |
|------------------------------------|------------------------------------------------------------------------------------------------|
|Items     |Specifications           |Time points (Months)                                                                            |
|          |-------------------------|------------------------------------------------------------------------------------------------|
|          |                         |0         |3         |6                 |9      |12             |18     |24     |36     |48     |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|genotoxic |Dimethyl sulfate NMT 75pp|ND        |/         |ND                |       |               |       |       |       |       |
|impurities|m                        |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diethyl sulfate NMT 75ppm|ND        |/         |ND                |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diisopropyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Disec-butyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Sum of genotoxic         |ND        |/         |ND                |       |               |       |       |       |       |
|          |impurities NMT 250ppm    |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Water     |NMT 0.5%                 |0.04%     |0.1%      |0.04%             |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Microbial |TAMC: NMT 103CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|limits    |                         |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |TYMC: NMT 102CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Absence of Escherichia   |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |coli (1g)                |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Assay     |98.0% to 102.0%          |99.8%     |100.5%    |99.5%             |       |               |       |       |       |       |
|          |(anhydrous substance).   |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Crystal   |Basically consistent with|Complies  |/         |Complies          |       |               |       |       |       |       |
|form XRD  |the results of 0 month   |          |          |                  |       |               |       |       |       |       |
---------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 523 of 542 





Page 524
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                          |240101                             |Batch size             |10 kg                                  |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Primary package                    |double-layered pharmaceutical      |Storage condition      |30℃±2℃/ 65%RH±5%RH                 |    
|                                   |grade low-density polyethylene     |                       |                                       |
|                                   |(LDPE) bag                         |                       |                                       |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                 |Jan. 19, 2024                      |Stability starting     |Feb. 04, 2024                          |
|                                   |                                   |date                   |                                       |
|-----------------------------------|-----------------------------------|                       |                                       |
|Manufacturing site                 |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                  |
|-----------------------------------|---------------------------------------------------------------------------------------------------|
|Items    |Specifications           |Time points (Months)                                                                               |
|         |                         |---------------------------------------------------------------------------------------------------|
|         |                         |0            |3         |6                 |9      |12             |18     |24     |36     |48     |
|---------|-------------------------|-------------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Particle |Basically consistent with|D90: 7.833μm|/         |D90: 7.500μm     |       |               |       |       |       |       |  
|size     |the results of 0 month   |             |          |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 524 of 542 





Page 525
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.7.3-3 Long-term Stability Data of Finerenone (Batch No. 240102) 










-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                         |240102                              |Batch size             |10 kg                                  |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Primary package                   |double-layered pharmaceutical       |Storage condition      |30℃±2℃/ 65%RH±5%RH                 |    
|                                  |grade low-density polyethylene      |                       |                                       |
|                                  |(LDPE) bag                          |                       |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                |Jan. 30, 2024                       |Stability starting     |Feb. 04, 2024                          |
|                                  |                                    |date                   |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                   |
|----------------------------------|----------------------------------------------------------------------------------------------------|
|Items    |Specifications          |Time points (Months)                                                                                |
|         |------------------------|----------------------------------------------------------------------------------------------------|
|         |                        |0           |3           |6                 |9      |12             |18     |24     |36     |48     |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Appearanc|White to yellow powder. |white powder|white powder|white powder      |       |               |       |       |       |       |
|e        |                        |            |            |                  |       |               |       |       |       |       |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Related  |YA2304-10 NMT 0.10%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|substance|                        |            |            |                  |       |               |       |       |       |       |
|s        |                        |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-12 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-14 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-15 NMT 0.15%；   |＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |    
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-16 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-17 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-18 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-19 NMT 0.15%；   |＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |    
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Other single impurities:|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|         |N MT 0.10%              |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Total impurity: NMT 1.0%|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|enantiome|YA2304-20: NMT 0.15%    |0.02%       |0.01%       |0.02%             |       |               |       |       |       |       |
|rs       |                        |            |            |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 525 of 542 





Page 526
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 







































---------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                           |240102                          |Batch size             |10 kg                                  |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Primary package                     |double-layered pharmaceutical   |Storage condition      |30℃±2℃/ 65%RH±5%RH                 |    
|                                    |grade low-density polyethylene  |                       |                                       |
|                                    |(LDPE) bag                      |                       |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                  |Jan. 30, 2024                   |Stability starting     |Feb. 04, 2024                          |
|                                    |                                |date                   |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                  |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                               |
|------------------------------------|------------------------------------------------------------------------------------------------|
|Items     |Specifications           |Time points (Months)                                                                            |
|          |-------------------------|------------------------------------------------------------------------------------------------|
|          |                         |0         |3         |6                 |9      |12             |18     |24     |36     |48     |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|genotoxic |Dimethyl sulfate NMT 75pp|ND        |/         |ND                |       |               |       |       |       |       |
|impurities|m                        |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diethyl sulfate NMT 75ppm|ND        |/         |ND                |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diisopropyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Disec-butyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Sum of genotoxic         |ND        |/         |ND                |       |               |       |       |       |       |
|          |impurities NMT 250ppm    |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Water     |NMT 0.5%                 |0.2%      |0.1%      |0.1%              |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Microbial |TAMC: NMT 103CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|limits    |                         |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |TYMC: NMT 102CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Absence of Escherichia   |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |coli (1g)                |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Assay     |98.0% to 102.0%          |99.7%     |100.7%    |99.5%             |       |               |       |       |       |       |
|          |(anhydrous substance).   |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Crystal   |Basically consistent with|Complies  |/         |Complies          |       |               |       |       |       |       |
|form XRD  |the results of 0 month   |          |          |                  |       |               |       |       |       |       |
---------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 526 of 542 





Page 527
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                          |240102                             |Batch size             |10 kg                                  |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Primary package                    |double-layered pharmaceutical      |Storage condition      |30℃±2℃/ 65%RH±5%RH                 |    
|                                   |grade low-density polyethylene     |                       |                                       |
|                                   |(LDPE) bag                         |                       |                                       |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                 |Jan. 30, 2024                      |Stability starting     |Feb. 04, 2024                          |
|                                   |                                   |date                   |                                       |
|-----------------------------------|-----------------------------------|                       |                                       |
|Manufacturing site                 |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                  |
|-----------------------------------|---------------------------------------------------------------------------------------------------|
|Items    |Specifications           |Time points (Months)                                                                               |
|         |                         |---------------------------------------------------------------------------------------------------|
|         |                         |0            |3         |6                 |9      |12             |18     |24     |36     |48     |
|---------|-------------------------|-------------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Particle |Basically consistent with|D90: 8.027μm|/         |D90: 7.559μm     |       |               |       |       |       |       |  
|size     |the results of 0 month   |             |          |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 527 of 542 





Page 528
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**Accelerated stability studies** 



Table 3.2.S.7.3-4 Accelerated Stability Data of Finerenone (Batch No. 231201) 










-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                         |231201                              |Batch size             |10 kg                                  |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Primary package                   |double-layered pharmaceutical       |Storage condition      |40℃±2℃/ 75%RH±5%RH                 |    
|                                  |grade low-density polyethylene      |                       |                                       |
|                                  |(LDPE) bag                          |                       |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                |Jan. 06, 2024                       |Stability starting     |Feb. 04, 2024                          |
|                                  |                                    |date                   |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                   |
|----------------------------------|----------------------------------------------------------------------------------------------------|
|Items    |Specifications          |Time points (Months)                                                                                |
|         |------------------------|----------------------------------------------------------------------------------------------------|
|         |                        |0           |3           |6                 |9      |12             |18     |24     |36     |48     |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Appearanc|White to yellow powder. |white powder|white powder|white powder      |       |               |       |       |       |       |
|e        |                        |            |            |                  |       |               |       |       |       |       |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Related  |YA2304-10 NMT 0.10%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|substance|                        |            |            |                  |       |               |       |       |       |       |
|s        |                        |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-12 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-14 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-15 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-16 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-17 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-18 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-19 NMT 0.15%；   |＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |    
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Other single impurities:|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|         |N MT 0.10%              |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Total impurity: NMT 1.0%|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 528 of 542 





Page 529
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 































---------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                           |231201                          |Batch size             |10 kg                                  |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Primary package                     |double-layered pharmaceutical   |Storage condition      |40℃±2℃/ 75%RH±5%RH                 |    
|                                    |grade low-density polyethylene  |                       |                                       |
|                                    |(LDPE) bag                      |                       |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                  |Jan. 06, 2024                   |Stability starting     |Feb. 04, 2024                          |
|                                    |                                |date                   |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                  |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                               |
|------------------------------------|------------------------------------------------------------------------------------------------|
|Items     |Specifications           |Time points (Months)                                                                            |
|          |-------------------------|------------------------------------------------------------------------------------------------|
|          |                         |0         |3         |6                 |9      |12             |18     |24     |36     |48     |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|enantiome |YA2304-20: NMT 0.15%     |0.03%     |0.03%     |0.04%             |       |               |       |       |       |       |
|rs        |                         |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|genotoxic |Dimethyl sulfate NMT 75pp|ND        |/         |ND                |       |               |       |       |       |       |
|impurities|m                        |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diethyl sulfate NMT 75ppm|ND        |/         |ND                |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diisopropyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Disec-butyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Sum of genotoxic         |ND        |/         |ND                |       |               |       |       |       |       |
|          |impurities NMT 250ppm    |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Water     |NMT 0.5%                 |0.05%     |0.1%      |0.04%             |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Microbial |TAMC: NMT 103CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|limits    |                         |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |TYMC: NMT 102CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Absence of Escherichia   |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |coli (1g)                |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Assay     |98.0% to 102.0%          |99.8%     |100.8%    |99.8%             |       |               |       |       |       |       |
|          |(anhydrous substance).   |          |          |                  |       |               |       |       |       |       |
---------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 529 of 542 





Page 530
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                          |231201                             |Batch size             |10 kg                                  |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Primary package                    |double-layered pharmaceutical      |Storage condition      |40℃±2℃/ 75%RH±5%RH                 |    
|                                   |grade low-density polyethylene     |                       |                                       |
|                                   |(LDPE) bag                         |                       |                                       |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                 |Jan. 06, 2024                      |Stability starting     |Feb. 04, 2024                          |
|                                   |                                   |date                   |                                       |
|-----------------------------------|-----------------------------------|                       |                                       |
|Manufacturing site                 |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                  |
|-----------------------------------|---------------------------------------------------------------------------------------------------|
|Items    |Specifications           |Time points (Months)                                                                               |
|         |                         |---------------------------------------------------------------------------------------------------|
|         |                         |0            |3         |6                 |9      |12             |18     |24     |36     |48     |
|---------|-------------------------|-------------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Crystal  |Basically consistent with|Complies     |/         |Complies          |       |               |       |       |       |       |
|form XRD |the results of 0 month   |             |          |                  |       |               |       |       |       |       |
|---------|-------------------------|-------------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Particle |Basically consistent with|D90: 7.712μm|/         |D90: 6.235μm     |       |               |       |       |       |       |  
|size     |the results of 0 month   |             |          |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 530 of 542 





Page 531
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.7.3-5 Accelerated Stability Data of Finerenone (Batch No. 240101) 










-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                         |240101                              |Batch size             |10 kg                                  |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Primary package                   |double-layered pharmaceutical       |Storage condition      |40℃±2℃/ 75%RH±5%RH                 |    
|                                  |grade low-density polyethylene      |                       |                                       |
|                                  |(LDPE) bag                          |                       |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                |Jan. 19, 2024                       |Stability starting     |Feb. 04, 2024                          |
|                                  |                                    |date                   |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                   |
|----------------------------------|----------------------------------------------------------------------------------------------------|
|Items    |Specifications          |Time points (Months)                                                                                |
|         |------------------------|----------------------------------------------------------------------------------------------------|
|         |                        |0           |3           |6                 |9      |12             |18     |24     |36     |48     |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Appearanc|White to yellow powder. |white powder|white powder|white powder      |       |               |       |       |       |       |
|e        |                        |            |            |                  |       |               |       |       |       |       |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Related  |YA2304-10 NMT 0.10%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|substance|                        |            |            |                  |       |               |       |       |       |       |
|s        |                        |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-12 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-14 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-15 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-16 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-17 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-18 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-19 NMT 0.15%；   |＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |    
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Other single impurities:|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|         |N MT 0.10%              |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Total impurity: NMT 1.0%|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|enantiome|YA2304-20: NMT 0.15%    |0.03%       |0.03%       |0.05%             |       |               |       |       |       |       |
|rs       |                        |            |            |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 531 of 542 





Page 532
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 







































---------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                           |240101                          |Batch size             |10 kg                                  |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Primary package                     |double-layered pharmaceutical   |Storage condition      |40℃±2℃/ 75%RH±5%RH                 |    
|                                    |grade low-density polyethylene  |                       |                                       |
|                                    |(LDPE) bag                      |                       |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                  |Jan. 19, 2024                   |Stability starting     |Feb. 04, 2024                          |
|                                    |                                |date                   |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                  |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                               |
|------------------------------------|------------------------------------------------------------------------------------------------|
|Items     |Specifications           |Time points (Months)                                                                            |
|          |-------------------------|------------------------------------------------------------------------------------------------|
|          |                         |0         |3         |6                 |9      |12             |18     |24     |36     |48     |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|genotoxic |Dimethyl sulfate NMT 75pp|ND        |/         |ND                |       |               |       |       |       |       |
|impurities|m                        |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diethyl sulfate NMT 75ppm|ND        |/         |ND                |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diisopropyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Disec-butyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Sum of genotoxic         |ND        |/         |ND                |       |               |       |       |       |       |
|          |impurities NMT 250ppm    |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Water     |NMT 0.5%                 |0.05%     |0.1%      |0.04%             |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Microbial |TAMC: NMT 103CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|limits    |                         |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |TYMC: NMT 102CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Absence of Escherichia   |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |coli (1g)                |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Assay     |98.0% to 102.0%          |99.8%     |100.6%    |99.6%             |       |               |       |       |       |       |
|          |(anhydrous substance).   |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Crystal   |Basically consistent with|Complies  |/         |Complies          |       |               |       |       |       |       |
|form XRD  |the results of 0 month   |          |          |                  |       |               |       |       |       |       |
---------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 532 of 542 





Page 533
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                          |240101                             |Batch size             |10 kg                                  |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Primary package                    |double-layered pharmaceutical      |Storage condition      |40℃±2℃/ 75%RH±5%RH                 |    
|                                   |grade low-density polyethylene     |                       |                                       |
|                                   |(LDPE) bag                         |                       |                                       |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                 |Jan. 19, 2024                      |Stability starting     |Feb. 04, 2024                          |
|                                   |                                   |date                   |                                       |
|-----------------------------------|-----------------------------------|                       |                                       |
|Manufacturing site                 |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                  |
|-----------------------------------|---------------------------------------------------------------------------------------------------|
|Items    |Specifications           |Time points (Months)                                                                               |
|         |                         |---------------------------------------------------------------------------------------------------|
|         |                         |0            |3         |6                 |9      |12             |18     |24     |36     |48     |
|---------|-------------------------|-------------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Particle |Basically consistent with|D90: 7.833μm|/         |D90: 7.227μm     |       |               |       |       |       |       |  
|size     |the results of 0 month   |             |          |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 533 of 542 





Page 534
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.7.3-6 Accelerated Stability Data of Finerenone (Batch No. 240102) 










-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                         |240102                              |Batch size             |10 kg                                  |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Primary package                   |double-layered pharmaceutical       |Storage condition      |40℃±2℃/ 75%RH±5%RH                 |    
|                                  |grade low-density polyethylene      |                       |                                       |
|                                  |(LDPE) bag                          |                       |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                |Jan. 30, 2024                       |Stability starting     |Feb. 04, 2024                          |
|                                  |                                    |date                   |                                       |
|----------------------------------|------------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                   |
|----------------------------------|----------------------------------------------------------------------------------------------------|
|Items    |Specifications          |Time points (Months)                                                                                |
|         |------------------------|----------------------------------------------------------------------------------------------------|
|         |                        |0           |3           |6                 |9      |12             |18     |24     |36     |48     |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Appearanc|White to yellow powder. |white powder|white powder|white powder      |       |               |       |       |       |       |
|e        |                        |            |            |                  |       |               |       |       |       |       |
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|Related  |YA2304-10 NMT 0.10%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|substance|                        |            |            |                  |       |               |       |       |       |       |
|s        |                        |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-12 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-14 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-15 NMT 0.15%；   |＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |    
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-16 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-17 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-18 NMT 0.15%；   |ND          |ND          |ND                |       |               |       |       |       |       | 
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |YA2304-19 NMT 0.15%；   |＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |    
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Other single impurities:|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|         |N MT 0.10%              |            |            |                  |       |               |       |       |       |       |
|         |------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|         |Total impurity: NMT 1.0%|＜0.05%     |＜0.05%     |＜0.05%           |       |               |       |       |       |       |   
|---------|------------------------|------------|------------|------------------|-------|---------------|-------|-------|-------|-------|
|enantiome|YA2304-20: NMT 0.15%    |0.02%       |0.01%       |0.02%             |       |               |       |       |       |       |
|rs       |                        |            |            |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 534 of 542 





Page 535
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 







































---------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                           |240102                          |Batch size             |10 kg                                  |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Primary package                     |double-layered pharmaceutical   |Storage condition      |40℃±2℃/ 75%RH±5%RH                 |    
|                                    |grade low-density polyethylene  |                       |                                       |
|                                    |(LDPE) bag                      |                       |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                  |Jan. 30, 2024                   |Stability starting     |Feb. 04, 2024                          |
|                                    |                                |date                   |                                       |
|------------------------------------|--------------------------------|-----------------------|---------------------------------------|
|Manufacturing site                  |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                               |
|------------------------------------|------------------------------------------------------------------------------------------------|
|Items     |Specifications           |Time points (Months)                                                                            |
|          |-------------------------|------------------------------------------------------------------------------------------------|
|          |                         |0         |3         |6                 |9      |12             |18     |24     |36     |48     |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|genotoxic |Dimethyl sulfate NMT 75pp|ND        |/         |ND                |       |               |       |       |       |       |
|impurities|m                        |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diethyl sulfate NMT 75ppm|ND        |/         |ND                |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Diisopropyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Disec-butyl sulfate NMT  |ND        |/         |ND                |       |               |       |       |       |       |
|          |75 ppm                   |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Sum of genotoxic         |ND        |/         |ND                |       |               |       |       |       |       |
|          |impurities NMT 250ppm    |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Water     |NMT 0.5%                 |0.2%      |0.1%      |0.05%             |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Microbial |TAMC: NMT 103CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|limits    |                         |          |          |                  |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |TYMC: NMT 102CFU/g       |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|          |Absence of Escherichia   |Complies  |/         |Complies          |       |               |       |       |       |       |
|          |coli (1g)                |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Assay     |98.0% to 102.0%          |99.7%     |100.7%    |101.1%            |       |               |       |       |       |       |
|          |(anhydrous substance).   |          |          |                  |       |               |       |       |       |       |
|----------|-------------------------|----------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Crystal   |Basically consistent with|Complies  |/         |Complies          |       |               |       |       |       |       |
|form XRD  |the results of 0 month   |          |          |                  |       |               |       |       |       |       |
---------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 535 of 542 





Page 536
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 















-----------------------------------------------------------------------------------------------------------------------------------------
|Batch No.                          |240102                             |Batch size             |10 kg                                  |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Primary package                    |double-layered pharmaceutical      |Storage condition      |40℃±2℃/ 75%RH±5%RH                 |    
|                                   |grade low-density polyethylene     |                       |                                       |
|                                   |(LDPE) bag                         |                       |                                       |
|-----------------------------------|-----------------------------------|-----------------------|---------------------------------------|
|Manufacturing date                 |Jan. 30, 2024                      |Stability starting     |Feb. 04, 2024                          |
|                                   |                                   |date                   |                                       |
|-----------------------------------|-----------------------------------|                       |                                       |
|Manufacturing site                 |API (II) Workshop, Hinye Pharmaceutical Co., Ltd.                                                  |
|-----------------------------------|---------------------------------------------------------------------------------------------------|
|Items    |Specifications           |Time points (Months)                                                                               |
|         |                         |---------------------------------------------------------------------------------------------------|
|         |                         |0            |3         |6                 |9      |12             |18     |24     |36     |48     |
|---------|-------------------------|-------------|----------|------------------|-------|---------------|-------|-------|-------|-------|
|Particle |Basically consistent with|D90: 8.027μm|/         |D90: 7.246μm     |       |               |       |       |       |       |  
|size     |the results of 0 month   |             |          |                  |       |               |       |       |       |       |
-----------------------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 536 of 542 





Page 537
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



**Stress testing** 



Table 3.2.S.7.3-7 High Temperature Stress Test Data of Finerenone (Batch No. 231201) 



















------------------------------------------------------------------------------------------------------------------------
|Batch No.                      |240101                  |Batch size              |           |10 kg                   |
|-------------------------------|------------------------|------------------------|-----------|------------------------|
|Manufacturing date             |Jan. 06, 2024           |Stability starting date |           |Feb. 26, 2024           |
|-------------------------------|------------------------|------------------------|-----------|------------------------|
|Degradation condition          |High temperature 60℃: place appropriate amount of substance without package into a   | 
|                               |container                                                                             |
|                               |evenly, the thickness of substance is 3 ~ 5 mm. Store the culture dish into constant  |
|                               |temperature oven at 60℃.                                                             | 
|-------------------------------|                                                                                      |
|Items             |Specifications           |Time points                                                              |
|                  |                         |-------------------------------------------------------------------------|
|                  |            |            |0d                     |5d          |15d                    |30d         |
|------------------|------------|------------|-----------------------|------------|-----------------------|------------|
|Appearance        |White to yellow powder.  |White powder           |Off White   |Yellowish powder       |Yellowish   |
|                  |                         |                       |powder      |                       |powder      |
|------------------|-------------------------|-----------------------|------------|-----------------------|------------|
|Related substances|YA2304-10 NMT 0.10%；    |ND                     |ND          |ND                     |ND          | 
|                  |-------------------------|-----------------------|------------|-----------------------|------------|
|                  |YA2304-12 NMT 0.15%；    |ND                     |＜0.05%     |＜0.05%                |＜0.05%     |    
|                  |-------------------------|-----------------------|------------|-----------------------|------------|
|                  |YA2304-14 NMT 0.15%；    |ND                     |＜0.05%     |＜0.05%                |＜0.05%     |    
|                  |-------------------------|-----------------------|------------|-----------------------|------------|
|                  |YA2304-15 NMT 0.15%；    |ND                     |ND          |ND                     |ND          | 
|                  |-------------------------|-----------------------|------------|-----------------------|------------|
|                  |YA2304-16 NMT 0.15%；    |ND                     |ND          |ND                     |0.05%       | 
|                  |-------------------------|-----------------------|------------|-----------------------|------------|
|                  |YA2304-17 NMT 0.15%；    |ND                     |ND          |ND                     |ND          | 
|                  |-------------------------|-----------------------|------------|-----------------------|------------|
|                  |YA2304-18 NMT 0.15%；    |ND                     |ND          |ND                     |＜0.05%     |  
|                  |-------------------------|-----------------------|------------|-----------------------|------------|
|                  |YA2304-19 NMT 0.15%；    |＜0.05%                |＜0.05%     |0.07%                  |0.11%       |   
|                  |-------------------------|-----------------------|------------|-----------------------|------------|
|                  |Other single impurities: |＜0.05%                |＜0.05%     |＜0.05%                |0.06%       |   
|                  |NMT                      |                       |            |                       |            |
|                  |0.10%                    |                       |            |                       |            |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 537 of 542 





Page 538
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 


















------------------------------------------------------------------------------------------------------------------------
|Batch No.                  |240101                   |Batch size               |            |10 kg                    |
|---------------------------|-------------------------|-------------------------|------------|-------------------------|
|Manufacturing date         |Jan. 06, 2024            |Stability starting date  |            |Feb. 26, 2024            |
|---------------------------|-------------------------|-------------------------|------------|-------------------------|
|Degradation condition      |High temperature 60℃: place appropriate amount of substance without package into a       | 
|                           |container                                                                                 |
|                           |evenly, the thickness of substance is 3 ~ 5 mm. Store the culture dish into constant      |
|                           |temperature oven at 60℃.                                                                 | 
|---------------------------|                                                                                          |
|Items      |Specifications              |Time points                                                                  |
|           |                            |-----------------------------------------------------------------------------|
|           |               |            |0d                       |5d          |15d                      |30d         |
|-----------|---------------|------------|-------------------------|------------|-------------------------|------------|
|           |Total impurity: NMT 1.0%    |＜0.05%                  |＜0.05%     |0.11%                    |0.22%       |  
|-----------|----------------------------|-------------------------|------------|-------------------------|------------|
|Enantiomers|YA2304-20: NMT 0.15%        |0.03%                    |ND          |ND                       |ND          |
|-----------|----------------------------|-------------------------|------------|-------------------------|------------|
|Water      |NMT 0.5%                    |0.05%                    |0.03%       |0.05%                    |0.06%       |
|-----------|----------------------------|-------------------------|------------|-------------------------|------------|
|Assay      |98.0% to 102.0% (anhydrous  |99.8%                    |100.2%      |99.9%                    |99.9%       |
|           |substance).                 |                         |            |                         |            |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 538 of 542 





Page 539
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.7.3-8 High Humidity Stress Test Data of Finerenone (Batch No. 231201) 

























------------------------------------------------------------------------------------------------------------------------
|Batch No.                        |231201                  |Batch size             |           |10 kg                  |
|---------------------------------|------------------------|-----------------------|-----------|-----------------------|
|Manufacturing date               |Jan. 06, 2024           |Stability starting date|           |Feb. 24, 2024          |
|---------------------------------|------------------------|-----------------------|-----------|-----------------------|
|Degradation condition            |High humidity 92.5%RH: place appropriate amount of substance without package into a |
|                                 |container                                                                           |
|                                 |evenly, the thickness of substance is 3 ~ 5 mm. Store the culture dish at condition |
|                                 |92.5%RH,                                                                            |
|                                 |25℃.                                                                               | 
|---------------------------------|                                                                                    |
|Items               |Specifications           |Time points                                                            |
|                    |                         |-----------------------------------------------------------------------|
|                    |            |            |0d                     |5d         |15d                    |30d        |
|--------------------|------------|------------|-----------------------|-----------|-----------------------|-----------|
|Appearance          |White to yellow powder.  |White powder           |White      |White powder           |White      |
|                    |                         |                       |powder     |                       |powder     |
|--------------------|-------------------------|-----------------------|-----------|-----------------------|-----------|
|Related substances  |YA2304-10 NMT 0.10%；    |ND                     |ND         |ND                     |ND         | 
|                    |-------------------------|-----------------------|-----------|-----------------------|-----------|
|                    |YA2304-12 NMT 0.15%；    |ND                     |＜0.05%    |＜0.05%                |＜0.05%    |    
|                    |-------------------------|-----------------------|-----------|-----------------------|-----------|
|                    |YA2304-14 NMT 0.15%；    |ND                     |ND         |＜0.05%                |ND         |  
|                    |-------------------------|-----------------------|-----------|-----------------------|-----------|
|                    |YA2304-15 NMT 0.15%；    |ND                     |＜0.05%    |＜0.05%                |＜0.05%    |    
|                    |-------------------------|-----------------------|-----------|-----------------------|-----------|
|                    |YA2304-16 NMT 0.15%；    |ND                     |ND         |ND                     |ND         | 
|                    |-------------------------|-----------------------|-----------|-----------------------|-----------|
|                    |YA2304-17 NMT 0.15%；    |ND                     |ND         |ND                     |ND         | 
|                    |-------------------------|-----------------------|-----------|-----------------------|-----------|
|                    |YA2304-18 NMT 0.15%；    |ND                     |ND         |ND                     |ND         | 
|                    |-------------------------|-----------------------|-----------|-----------------------|-----------|
|                    |YA2304-19 NMT 0.15%；    |＜0.05%                |＜0.05%    |＜0.05%                |＜0.05%    |     
|                    |-------------------------|-----------------------|-----------|-----------------------|-----------|
|                    |Other single impurities: |＜0.05%                |＜0.05%    |＜0.05%                |＜0.05%    |    
|                    |NMT                      |                       |           |                       |           |
|                    |0.10%                    |                       |           |                       |           |
|                    |-------------------------|-----------------------|-----------|-----------------------|-----------|
|                    |Total impurity: NMT 1.0% |＜0.05%                |＜0.05%    |＜0.05%                |＜0.05%    |    
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 539 of 542 





Page 540
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 






















------------------------------------------------------------------------------------------------------------------------
|Batch No.                  |231201                   |Batch size               |            |10 kg                    |
|---------------------------|-------------------------|-------------------------|------------|-------------------------|
|Manufacturing date         |Jan. 06, 2024            |Stability starting date  |            |Feb. 24, 2024            |
|---------------------------|-------------------------|-------------------------|------------|-------------------------|
|Degradation condition      |High humidity 92.5%RH: place appropriate amount of substance without package into a       |
|                           |container                                                                                 |
|                           |evenly, the thickness of substance is 3 ~ 5 mm. Store the culture dish at condition       |
|                           |92.5%RH,                                                                                  |
|                           |25℃.                                                                                     | 
|---------------------------|                                                                                          |
|Items         |Specifications           |Time points                                                                  |
|              |                         |-----------------------------------------------------------------------------|
|              |            |            |0d                       |5d          |15d                      |30d         |
|--------------|------------|------------|-------------------------|------------|-------------------------|------------|
|Enantiomers   |YA2304-20: NMT 0.15%     |0.03%                    |0.02%       |0.02%                    |0.02%       |
|--------------|-------------------------|-------------------------|------------|-------------------------|------------|
|Water         |NMT 0.5%                 |0.05%                    |0.03%       |0.03%                    |0.03%       |
|--------------|-------------------------|-------------------------|------------|-------------------------|------------|
|Assay         |98.0% to 102.0%          |99.8%                    |100.0%      |100.3%                   |100.0%      |
|              |(anhydrous               |                         |            |                         |            |
|              |substance).              |                         |            |                         |            |
|--------------|-------------------------|-------------------------|------------|-------------------------|------------|
|Hygroscopic   |NMT 5%                   |/                        |0.04%       |0.02%                    |0.05%       |
|gain          |                         |                         |            |                         |            |
|(%)           |                         |                         |            |                         |            |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 540 of 542 





Page 541
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 



Table 3.2.S.7.3-9 Photostability Data of Finerenone (Batch No. 231201) 



















------------------------------------------------------------------------------------------------------------------------
|Batch No.             |231201                        |Batch size                 |             |10 kg                 |
|----------------------|------------------------------|---------------------------|-------------|----------------------|
|Manufacturing date    |Jan. 04, 2024                 |Stability starting date    |             |Feb. 24, 2024         |
|----------------------|------------------------------|---------------------------|-------------|----------------------|
|Degradation condition |Illumination (visible light: 4500 ± 500 LX; near ultraviolet: 90±5    |         |            |  
|                      |μW/cm2, 25℃): place                                                   |         |            |  
|                      |appropriate amount of substance without package into a container evenly,|         |            |
|                      |the thickness of                                                        |         |            |
|                      |substance is 3 ~ 5 mm. Store the culture dish at condition: visible     |         |            |
|                      |light: 4500 ± 500 LX; near                                             |         |            | 
|                      |ultraviolet: 90±5 μW/cm2, 25℃.                                       |         |            |   
|----------------------|                                                                        |---------|------------|
|Items     |Specifications              |Time points                                            |         |            |
|          |                            |-------------------------------------------------------|---------|------------|
|          |           |                |0d                         |5d           |15d                    |30d         |
|----------|-----------|----------------|---------------------------|-------------|-----------------------|------------|
|Appearance|White to yellow powder.     |White powder               |Off White    |Yellowish powder       |Yellowish   |
|          |                            |                           |powder       |                       |powder      |
|----------|----------------------------|---------------------------|-------------|-----------------------|------------|
|Related   |YA2304-10 NMT 0.10%；       |ND                         |ND           |ND                     |ND          | 
|substances|                            |                           |             |                       |            |
|          |----------------------------|---------------------------|-------------|-----------------------|------------|
|          |YA2304-12 NMT 0.15%；       |ND                         |＜0.05%      |＜0.05%                |＜0.05%     |    
|          |----------------------------|---------------------------|-------------|-----------------------|------------|
|          |YA2304-14 NMT 0.15%；       |ND                         |＜0.05%      |＜0.05%                |＜0.05%     |    
|          |----------------------------|---------------------------|-------------|-----------------------|------------|
|          |YA2304-15 NMT 0.15%；       |ND                         |＜0.05%      |＜0.05%                |＜0.05%     |    
|          |----------------------------|---------------------------|-------------|-----------------------|------------|
|          |YA2304-16 NMT 0.15%；       |ND                         |＜0.05%      |＜0.05%                |＜0.05%     |    
|          |----------------------------|---------------------------|-------------|-----------------------|------------|
|          |YA2304-17 NMT 0.15%；       |ND                         |ND           |ND                     |ND          | 
|          |----------------------------|---------------------------|-------------|-----------------------|------------|
|          |YA2304-18 NMT 0.15%；       |ND                         |ND           |ND                     |ND          | 
|          |----------------------------|---------------------------|-------------|-----------------------|------------|
|          |YA2304-19 NMT 0.15%；       |＜0.05%                    |0.06%        |0.14%                  |0.12%       |  
|          |----------------------------|---------------------------|-------------|-----------------------|------------|
|          |Other single impurities:    |＜0.05%                    |0.08%        |0.12%                  |0.11%       | 
|          |NMT 0.10%                   |                           |             |                       |            |
------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 541 of 542 





Page 542
**Drug Master File of Finerenone** 



Document: YA2304-Quality Version: 001 Date:Sep. 2024 










-------------------------------------------------------------------------------------------------------------------------
|Batch No.             |231201                           |Batch size                 |             |10 kg              | 
|----------------------|---------------------------------|---------------------------|-------------|-------------------| 
|Manufacturing date    |Jan. 04, 2024                    |Stability starting date    |             |Feb. 24, 2024      | 
|----------------------|---------------------------------|---------------------------|-------------|-------------------| 
|Degradation condition |Illumination (visible light: 4500 ± 500 LX; near ultraviolet: 90±5       |         |         |   
|                      |μW/cm2, 25℃): place                                                      |         |         |   
|                      |appropriate amount of substance without package into a container evenly,   |         |         | 
|                      |the thickness of                                                           |         |         | 
|                      |substance is 3 ~ 5 mm. Store the culture dish at condition: visible light: |         |         | 
|                      |4500 ± 500 LX; near                                                       |         |         |  
|                      |ultraviolet: 90±5 μW/cm2, 25℃.                                          |         |         |    
|----------------------|                                                                           |---------|---------| 
|Items     |Specifications                 |Time points                                            |         |         | 
|          |                               |-------------------------------------------------------|---------|---------| 
|          |           |                   |0d                         |5d           |15d                    |30d      | 
|----------|-----------|-------------------|---------------------------|-------------|-----------------------|---------| 
|          |Total impurity: NMT 1.0%       |＜0.05%                    |0.14%        |0.30%                  |0.22%    |  
|----------|-------------------------------|---------------------------|-------------|-----------------------|---------| 
|Enantiomers|YA2304-20: NMT 0.15%           |0.03%                      |ND           |ND                     |ND       |
|----------|-------------------------------|---------------------------|-------------|-----------------------|---------| 
|Water     |NMT 0.5%                       |0.05%                      |0.04%        |0.07%                  |0.08%    | 
|----------|-------------------------------|---------------------------|-------------|-----------------------|---------| 
|Assay     |98.0% to 102.0%                |99.8%                      |99.7%        |99.1%                  |100.0%   | 
|          |(anhydrous substance).         |                           |             |                       |         | 
-------------------------------------------------------------------------------------------------------------------------

Finerenone Confidential Hinye Pharmaceutical Co., Ltd. 



Page 542 of 542 



